PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huang, C; Rajfur, Z; Borchers, C; Schaller, MD; Jacobson, K				Huang, C; Rajfur, Z; Borchers, C; Schaller, MD; Jacobson, K			JNK phosphorylates paxillin and regulates cell migration	NATURE			English	Article							JUN NH2-TERMINAL KINASE; FOCAL ADHESION KINASE; N-TERMINAL KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ACTIVATION; FIBRONECTIN; SERINE; MORPHOGENESIS	The c-Jun amino-terminal kinase (JNK) is generally thought to be involved in inflammation, proliferation and apoptosis(1,2). Accordingly, its substrates are transcription factors and antiapoptotic proteins(2). However, JNK has also been shown to be required for Drosophila dorsal closure(3,4), and MAP kinase/ERK kinase kinase 1, an upstream kinase in the JNK pathway, has been shown to be essential for cell migration(5,6). Both results imply that JNK is important in cell migration. Here we show that JNK1 is required for the rapid movement of both fish keratocytes and rat bladder tumour epithelial cells (NBT-II). Moreover, JNK1 phosphorylates serine 178 on paxillin, a focal adhesion adaptor, both in vitro and in intact cells. NBT-II cells expressing the Ser 178 --> Ala mutant of paxillin (Pax(S178A)) formed focal adhesions and exhibited the limited movement associated with such contacts in both single-cell-migration and wound-healing assays. In contrast, cells expressing wild-type paxillin moved rapidly and retained close contacts as the predominant adhesion. Expression of Pax(S178A) also inhibited the migration of two other cell lines. Thus, phosphorylation of paxillin by JNK seems essential for maintaining the labile adhesions required for rapid cell migration.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jacobson, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	frap@med.unc.edu	BORCHERS, Christoph/U-5964-2019; Rajfur, Zenon/H-2506-2013	Rajfur, Zenon/0000-0003-1265-6480				Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hauck CR, 2001, CANCER RES, V61, P7079; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; ILLC D, 1995, NATURE, V377, P539; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Lee J, 1997, J CELL SCI, V110, P2833; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Uyen HD, 2002, J CELL SCI, V115, P3073; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	30	398	416	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					219	223		10.1038/nature01745	http://dx.doi.org/10.1038/nature01745			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853963				2022-12-28	WOS:000184032700048
J	Talwalkar, JA; Lindor, KD				Talwalkar, JA; Lindor, KD			Primary biliary cirrhosis	LANCET			English	Review							URSODEOXYCHOLIC-ACID THERAPY; PLACEBO-CONTROLLED TRIAL; CHOLESTATIC LIVER-DISEASE; PYRUVATE-DEHYDROGENASE COMPLEX; RANDOMIZED CONTROLLED TRIALS; DOUBLE-BLIND; EPITHELIAL-CELLS; NATURAL-HISTORY; BONE LOSS; CLASS-II	Primary biliary cirrhosis is a chronic cholestatic liver disease of adults. This disorder is characterised histologically by chronic non-suppurative destruction of interlobular bile ducts leading to advanced fibrosis, cirrhosis, and liver failure. The precise aetiopathogenesis of primary biliary cirrhosis remains unknown, although dysregulation of the immune system and genetic susceptibility both seem to be important. Affected patients are typically middle-aged women with abnormal serum concentrations of alkaline phosphatase. Presence of antimitochondrial antibody in serum is almost diagnostic of the disorder. Identification of primary biliary cirrhosis is important, because effective treatment with ursodeoxycholic acid has been shown to halt disease progression and improve survival without need for liver transplantation. However, therapeutic options for disease-related complications-including fatigue and metabolic bone disease-remain unavailable. Mathematical models have been developed that accurately predict the natural history of primary biliary cirrhosis in individuals. Despite advances in understanding of the disease, it remains one of the major indications for liver transplantation worldwide.	Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Lindor, KD (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.							Abdulkarim AS, 2002, GASTROENTEROLOGY, V122, pA641; Almasio PL, 2000, ALIMENT PHARM THERAP, V14, P1645, DOI 10.1046/j.1365-2036.2000.00869.x; Angulo P, 1999, J HEPATOL, V30, P830, DOI 10.1016/S0168-8278(99)80136-6; Angulo P, 2000, HEPATOLOGY, V31, P318, DOI 10.1002/hep.510310209; Angulo P, 1999, LIVER, V19, P115, DOI 10.1111/j.1478-3231.1999.tb00020.x; Angulo P, 1999, Clin Liver Dis, V3, P529, DOI 10.1016/S1089-3261(05)70084-2; Angulo P, 2000, HEPATOLOGY, V32, P897, DOI 10.1053/jhep.2000.18663; ARRIA AM, 1990, AM J CLIN NUTR, V52, P383, DOI 10.1093/ajcn/52.2.383; BACH N, 1994, J HEPATOL, V20, P698, DOI 10.1016/S0168-8278(05)80137-0; BALAN V, 1994, MAYO CLIN PROC, V69, P923, DOI 10.1016/S0025-6196(12)61815-1; BEGOVICH AB, 1994, TISSUE ANTIGENS, V43, P71, DOI 10.1111/j.1399-0039.1994.tb02303.x; Bergasa NV, 2000, BEST PRACT RES CL GA, V14, P643, DOI 10.1053/bega.2000.0109; BERGASA NV, 1995, ANN INTERN MED, V123, P161, DOI 10.7326/0003-4819-123-3-199508010-00001; Bergasa NV, 1998, HEPATOLOGY, V27, P679, DOI 10.1002/hep.510270307; BERNSTEIN RM, 1982, ANN RHEUM DIS, V41, P612, DOI 10.1136/ard.41.6.612; BLOOMER JR, 1975, ANN INTERN MED, V82, P310, DOI 10.7326/0003-4819-82-3-310; Brot C, 1999, EUR J CLIN NUTR, V53, P920, DOI 10.1038/sj.ejcn.1600870; BURROUGHS AK, 1992, NATURE, V358, P377, DOI 10.1038/358377a0; Cauch-Dudek K, 1998, GUT, V43, P705, DOI 10.1136/gut.43.5.705; CHRISTENSEN E, 1980, GASTROENTEROLOGY, V78, P236; CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; COMBES B, 1995, HEPATOLOGY, V22, P759, DOI 10.1016/0270-9139(95)90294-5; COMPSTON JE, 1986, GUT, V27, P1073, DOI 10.1136/gut.27.9.1073; CRIPPIN JS, 1992, HEPATOLOGY, V15, P858, DOI 10.1002/hep.1840150518; CRIPPIN JS, 1994, AM J GASTROENTEROL, V89, P47; CROWE J, 1980, GASTROENTEROLOGY, V78, P1005; DATTA DV, 1966, GASTROENTEROLOGY, V50, P323; DICKSON ER, 1985, NEW ENGL J MED, V312, P1011, DOI 10.1056/NEJM198504183121602; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; EASTELL R, 1991, HEPATOLOGY, V14, P296, DOI 10.1002/hep.1840140215; Floreani A, 1997, J CLIN GASTROENTEROL, V24, P239, DOI 10.1097/00004836-199706000-00012; Garcia RFL, 2001, HEPATOLOGY, V33, P22, DOI 10.1053/jhep.2001.20894; Gershwin M E, 1992, Prog Liver Dis, V10, P47; Gershwin ME, 2000, IMMUNOL REV, V174, P210, DOI 10.1034/j.1600-0528.2002.017402.x; Goldblatt J, 2002, GASTROENTEROLOGY, V122, P1235, DOI 10.1053/gast.2002.32993; GonzalezKoch A, 1997, J HEPATOL, V27, P143, DOI 10.1016/S0168-8278(97)80294-2; GOODMAN ZD, 1995, DIGEST DIS SCI, V40, P1232, DOI 10.1007/BF02065530; GORDON SC, 1995, GASTROENTEROLOGY, V108, P1802, DOI 10.1016/0016-5085(95)90143-4; GORES GJ, 1989, GASTROENTEROLOGY, V96, P1552, DOI 10.1016/0016-5085(89)90526-X; GORES GJ, 1987, HEPATOLOGY, V7, P889, DOI 10.1002/hep.1840070516; GOUDIE BM, 1985, BRIT MED J, V291, P1597, DOI 10.1136/bmj.291.6509.1597; Goulis J, 1999, LANCET, V354, P1053, DOI 10.1016/S0140-6736(98)11293-X; GREGORY WL, 1994, ATHEROSCLEROSIS, V105, P43, DOI 10.1016/0021-9150(94)90006-X; GUANABENS N, 1992, J HEPATOL, V15, P345, DOI 10.1016/0168-8278(92)90066-X; HASHIMOTO E, 1993, MAYO CLIN PROC, V68, P1049, DOI 10.1016/S0025-6196(12)60897-0; Haydon GH, 2000, GUT, V47, P586, DOI 10.1136/gut.47.4.586; HEATHCOTE EJ, 1994, HEPATOLOGY, V19, P1149, DOI 10.1002/hep.1840190512; Hendrickse MT, 1999, GASTROENTEROLOGY, V117, P400, DOI 10.1053/gast.1999.0029900400; HEUMAN DM, 1994, GASTROENTEROLOGY, V106, P1333, DOI 10.1016/0016-5085(94)90027-2; HILLAIRE S, 1994, GASTROENTEROLOGY, V107, P781, DOI 10.1016/0016-5085(94)90127-9; HOOFNAGLE JH, 1986, GASTROENTEROLOGY, V91, P1327, DOI 10.1016/0016-5085(86)90183-6; Howel D, 2000, HEPATOLOGY, V31, P1055, DOI 10.1053/he.2000.7050; INOUE K, 1995, LIVER, V15, P70; Jones DEJ, 1999, J HEPATOL, V30, P402, DOI 10.1016/S0168-8278(99)80097-X; Jones EA, 1997, HEPATOLOGY, V25, P492; Jones EA, 2002, HEPATOLOGY, V35, P258, DOI 10.1053/jhep.2002.31607; JOPLIN R, 1992, LANCET, V339, P93, DOI 10.1016/0140-6736(92)91001-O; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; Kim WR, 1999, HEPATOLOGY, V30, P395, DOI 10.1002/hep.510300210; Kim WR, 1998, HEPATOLOGY, V28, P33, DOI 10.1002/hep.510280106; Kim WR, 1997, HEPATOLOGY, V26, P22; Kim WR, 2000, GASTROENTEROLOGY, V119, P1631, DOI 10.1053/gast.2000.20197; KUNIHARA T, 2000, AM J GASTROENTEROL, V95, P2990; LANSPA SJ, 1985, HEPATOLOGY, V5, P837, DOI 10.1002/hep.1840050522; Leuschner M, 1999, GASTROENTEROLOGY, V117, P918, DOI 10.1016/S0016-5085(99)70351-3; Leuschner M, 1996, J HEPATOL, V25, P49, DOI 10.1016/S0168-8278(96)80327-8; Leuschner M, 2000, GUT, V46, P121, DOI 10.1136/gut.46.1.121; LIM AG, 1994, HEPATOLOGY, V20, P882, DOI 10.1002/hep.1840200416; Lindor KD, 2000, J HEPATOL, V33, P878, DOI 10.1016/S0168-8278(00)80118-X; Lindor KD, 1997, MAYO CLIN PROC, V72, P1137, DOI 10.4065/72.12.1137; LINDOR KD, 1995, HEPATOLOGY, V22, P1158; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; Long SA, 2001, J IMMUNOL, V167, P2956, DOI 10.4049/jimmunol.167.5.2956; Longo M, 2002, GUT, V51, P265, DOI 10.1136/gut.51.2.265; LOOF L, 1994, HEPATOLOGY, V20, P101, DOI 10.1016/0270-9139(94)90140-6; Ludwig J, 2000, BEST PRACT RES CL GA, V14, P601, DOI 10.1053/bega.2000.0106; LUDWIG J, 1978, VIRCHOWS ARCH A, V379, P103, DOI 10.1007/BF00432479; Mason Andrew, 2002, Curr Gastroenterol Rep, V4, P45, DOI 10.1007/s11894-002-0037-8; MCCORMICK PA, 1994, J HEPATOL, V21, P496, DOI 10.1016/S0168-8278(94)80092-8; Menon KVN, 2001, J HEPATOL, V35, P316, DOI 10.1016/S0168-8278(01)00144-1; Metcalf JV, 1997, INT J EPIDEMIOL, V26, P830, DOI 10.1093/ije/26.4.830; MILLER KB, 1983, AM J MED, V75, P75, DOI 10.1016/0002-9343(83)91170-1; MITCHISON HC, 1986, HEPATOLOGY, V6, P1279, DOI 10.1002/hep.1840060609; MITCHISON HC, 1992, J HEPATOL, V15, P336, DOI 10.1016/0168-8278(92)90065-W; MITCHISON HC, 1989, HEPATOLOGY, V10, P420, DOI 10.1002/hep.1840100405; MITCHISON HC, 1993, J HEPATOL, V17, P227; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P1518; MURTAUGH PA, 1994, HEPATOLOGY, V20, P126, DOI 10.1016/0270-9139(94)90144-9; Neuman M, 2002, J GASTROEN HEPATOL, V17, P196, DOI 10.1046/j.1440-1746.2002.02672.x; NIERI S, 1985, J CLIN GASTROENTEROL, V7, P434, DOI 10.1097/00004836-198510000-00014; Nijhawan PK, 1999, HEPATOLOGY, V29, P1396, DOI 10.1002/hep.510290511; Nilsson I, 2000, GUT, V46, P410, DOI 10.1136/gut.46.3.410; Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI200110716; PARES A, 1981, GASTROENTEROLOGY, V80, P681; Pares A, 2000, J HEPATOL, V32, P561, DOI 10.1016/S0168-8278(00)80216-0; Parikh-Patel A, 2002, ANN EPIDEMIOL, V12, P264, DOI 10.1016/S1047-2797(01)00277-0; Parikh-Patel A, 2001, HEPATOLOGY, V33, P16, DOI 10.1053/jhep.2001.21165; Pasha T, 1999, HEPATOLOGY, V29, P21, DOI 10.1002/hep.510290116; Phillips JR, 2001, AM J GASTROENTEROL, V96, P2745, DOI 10.1111/j.1572-0241.2001.04134.x; Poupon RE, 1999, HEPATOLOGY, V29, P1668, DOI 10.1002/hep.510290603; Poupon RE, 2000, J HEPATOL, V32, P685, DOI 10.1016/S0168-8278(00)80232-9; Poupon RE, 1996, HEPATOLOGY, V24, P1098; Poupon RE, 1997, GASTROENTEROLOGY, V113, P884, DOI 10.1016/S0016-5085(97)70183-5; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; POUPON RE, 1993, HEPATOLOGY, V17, P599, DOI 10.1002/hep.1840170412; Prince MI, 2000, J HEPATOL, V32, P368, DOI 10.1016/S0168-8278(00)80385-2; Prince MI, 2002, GUT, V50, P436, DOI 10.1136/gut.50.3.436; Prince MI, 2001, HEPATOLOGY, V34, P1083, DOI 10.1053/jhep.2001.29760; Rodrigues CMP, 2000, J HEPATOL, V32, P135, DOI 10.1016/S0168-8278(00)80200-7; RUBEL LR, 1984, HEPATOLOGY, V4, P671, DOI 10.1002/hep.1840040418; Sadamoto T, 1998, LANCET, V352, P1595, DOI 10.1016/S0140-6736(05)61042-2; SCHEUER PJ, 1965, AM J PATHOL, V46, P387; SHAPIRO JM, 1979, GUT, V20, P137, DOI 10.1136/gut.20.2.137; SHERLOCK S, 1973, NEW ENGL J MED, V289, P674, DOI 10.1056/NEJM197309272891306; SPIVEY JR, 1992, AM J GASTROENTEROL, V87, pA1307; Springer J, 1999, AM J GASTROENTEROL, V94, P47; Springer JE, 2000, GASTROENTEROLOGY, V118, P145, DOI 10.1016/S0016-5085(00)70423-9; SWAIN MG, 1995, HEPATOLOGY, V22, P1560, DOI 10.1002/hep.1840220532; Talwalkar J, 2001, HEPATOLOGY, V34, p372A; Talwalkar JA, 2002, AM J GASTROENTEROL, V97, P1191; TALWALKAR JA, 2003, IN PRESS CLIN GASTRO; Trauner M, 2001, CURR OPIN GASTROEN, V17, P242, DOI 10.1097/00001574-200105000-00007; TSIANOS EV, 1990, HEPATOLOGY, V11, P730, DOI 10.1002/hep.1840110504; TSUNEYAMA K, 1995, HEPATOLOGY, V21, P1031, DOI 10.1016/0270-9139(95)90251-1; TURNER IB, 1994, ALIMENT PHARM THERAP, V8, P337; UNDERHILL J, 1992, HEPATOLOGY, V16, P1404, DOI 10.1002/hep.1840160616; *US SCI REG TRANSP, 2000, 1999 ANN REP US SCI; VANDEWATER J, 1991, J IMMUNOL, V146, P89; VANDEWATER J, 1993, J CLIN INVEST, V91, P2653, DOI 10.1172/JCI116504; WALKER JG, 1965, LANCET, V1, P827; WALT RP, 1988, BRIT MED J, V296, P607, DOI 10.1136/bmj.296.6622.607; WATSON RGP, 1995, GUT, V36, P927, DOI 10.1136/gut.36.6.927; WIESNER RH, 1990, NEW ENGL J MED, V322, P1419, DOI 10.1056/NEJM199005173222003; WITTSULLIVAN H, 1990, HEPATOLOGY, V12, P98, DOI 10.1002/hep.1840120116; Wolfhagen FHJ, 1998, J HEPATOL, V29, P736, DOI 10.1016/S0168-8278(98)80254-7; YOSHIKAWA M, 1992, HEPATOLOGY, V16, P358, DOI 10.1002/hep.1840160213; Zein CO, 2003, CLIN GASTROENTEROL H, V1, P89, DOI 10.1053/cgh.2003.50014	140	246	277	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					53	61		10.1016/S0140-6736(03)13808-1	http://dx.doi.org/10.1016/S0140-6736(03)13808-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853201				2022-12-28	WOS:000184056900024
J	Traversa, G; Bianchi, C; Da Cas, R; Abraha, I; Menniti-Ippolito, F; Venegoni, M				Traversa, G; Bianchi, C; Da Cas, R; Abraha, I; Menniti-Ippolito, F; Venegoni, M			Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To estimate the risk of acute hepatotoxicity associated with nimesulide compared with other non-steroidal anti-inflammatory drugs. Design Retrospective cohort and nested case-control study. Setting Umbria region, Italy. Participants 400 000 current, recent, and past users (almost 2 million prescriptions) of non-steroidal anti-inflammatory drugs between I January 1997 and 31 December 2001. Main outcome measures Admissions to hospital for acute non-viral hepatitis and incidence of all hepatopathies and liver injury among users of nimesulide and other non-steroidal anti-inflammatory drugs. Results Cur-rent use of non-steroidal anti-inflammatory drugs was associated with a 1.4 (95% confidence interval 1.0 to 2.1) increased risk of hepatopathy compared with past use. In current users of nimesulide the rate ratio for all heparopathies and more severe liver injury was 1.3 (0.7 to 2.3) and 1.9 (1.1 to 3.8), respectively. Conclusion The risk of liver injury in patients taking nimesulide and other non-steroidal anti-inflammatory drugs is small.	Natl Inst Hlth, Dept Epidemiol, I-00161 Rome, Italy; Reg Hlth Author Umbria Reg, I-06124 Perugia, Italy; Fatebenefratelli Hosp, Dept Internal Med, I-20121 Milan, Italy	Istituto Superiore di Sanita (ISS)	Traversa, G (corresponding author), Natl Inst Hlth, Dept Epidemiol, Regina Elena 299, I-00161 Rome, Italy.	giuseppe.traversa@iss.it	Abraha, Iosief/K-4327-2018; Venegoni, Mauro/H-3416-2019	Abraha, Iosief/0000-0002-5440-775X; Venegoni, Mauro/0000-0002-5462-5327				BENICHOU C, 1990, J HEPATOL, V11, P272; Conforti A, 2001, DRUG SAFETY, V24, P1081, DOI 10.2165/00002018-200124140-00006; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; DANAN G, 1994, ADVERSE DRUG REACTIO; Hernandez-Diaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; Macia MA, 2002, CLIN PHARMACOL THER, V72, P596, DOI 10.1067/mcp.2002.128869; Menniti-Ippolito F, 1998, EUR J CLIN PHARMACOL, V54, P393, DOI 10.1007/s002280050481; RODRIGUEZ LAG, 1992, BRIT MED J, V305, P865, DOI 10.1136/bmj.305.6858.865; Rodriguez LAG, 1998, ARCH INTERN MED, V158, P33, DOI 10.1001/archinte.158.1.33; RODRIQUEZ LAG, 1994, ARCH INTERN MED, V154, P311, DOI 10.1001/archinte.1994.00420030117012; TRAVERSA G, 1995, EPIDEMIOLOGY, V6, P49, DOI 10.1097/00001648-199501000-00010; Walker AM, 1997, ARTHRITIS RHEUM, V40, P201, DOI 10.1002/art.1780400204	13	130	163	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2003	327	7405					18	22		10.1136/bmj.327.7405.18	http://dx.doi.org/10.1136/bmj.327.7405.18			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842950	Bronze, Green Published			2022-12-28	WOS:000184062700017
J	Ruthazer, ES; Akerman, CJ; Cline, HT				Ruthazer, ES; Akerman, CJ; Cline, HT			Control of axon branch dynamics by correlated activity in vivo	SCIENCE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; NMDA RECEPTOR; VISUAL-CORTEX; SYNAPSE ELIMINATION; RETINOTECTAL AXONS; RANA-PIPIENS; TIME-LAPSE; PROJECTION; MAP; ZEBRAFISH	To determine how patterned visual activity regulates the development of axonal projections, we collected in vivo time-lapse images of retinal axons from albino Xenopus tadpoles in which binocular innervation of the optic tectum was induced. Axons added branch tips with nearly equal probability in all territories, but eliminated them preferentially from territory dominated by the opposite eye. This selective branch elimination was abolished by blockade of N-methyl-D-aspartate receptors. These results describe a correlation-based mechanism by which visual experience directly governs axon branch dynamics that contribute to the development of topographic maps.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Cline, HT (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Ruthazer, Edward S/P-5935-2014; Ruthazer, Edward/H-4782-2019	Ruthazer, Edward S/0000-0003-0452-3151; Ruthazer, Edward/0000-0003-0452-3151	NATIONAL EYE INSTITUTE [F32EY006963] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY006963-03] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Antonini A, 1996, J COMP NEUROL, V369, P64; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BOSS VC, 1984, J NEUROSCI, V4, P2891; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1991, TRENDS NEUROSCI, V14, P104, DOI 10.1016/0166-2236(91)90071-2; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; Cohen-Cory S, 1999, J NEUROSCI, V19, P9996; CONSTANTINEPATON M, 1978, SCIENCE, V202, P639, DOI 10.1126/science.309179; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Dawson AJ, 2001, J COMP NEUROL, V434, P40, DOI 10.1002/cne.1163; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; GAZE RM, 1979, J EMBRYOL EXP MORPH, V53, P103; Gnuegge L, 2001, J NEUROSCI, V21, P3542, DOI 10.1523/JNEUROSCI.21-10-03542.2001; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KAETHNER RJ, 1992, J NEUROSCI, V12, P3257, DOI 10.1523/JNEUROSCI.12-08-03257.1992; KATZ LC, 1996, SCIENCE, V274, P1132; Lichtman JW, 2000, NEURON, V25, P269, DOI 10.1016/S0896-6273(00)80893-4; MEYER RL, 1982, SCIENCE, V218, P589, DOI 10.1126/science.7123262; OLSON MD, 1991, J COMP NEUROL, V303, P412, DOI 10.1002/cne.903030307; OROURKE NA, 1994, NEURON, V12, P921, DOI 10.1016/0896-6273(94)90343-3; Rajan I, 1999, J NEUROBIOL, V38, P357, DOI 10.1002/(SICI)1097-4695(19990215)38:3<357::AID-NEU5>3.0.CO;2-#; REH TA, 1984, J NEUROSCI, V4, P442; REH TA, 1985, J NEUROSCI, V5, P1132; Rittenhouse CD, 1999, NATURE, V397, P347, DOI 10.1038/16922; Schmidt JT, 2000, J NEUROBIOL, V42, P303, DOI 10.1002/(SICI)1097-4695(20000215)42:3<303::AID-NEU2>3.3.CO;2-1; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRAZNICKY C, 1979, J EMBRYOL EXP MORPH, V50, P111; Walsh MK, 2003, NEURON, V37, P67, DOI 10.1016/S0896-6273(02)01142-X; Witte S, 1996, J NEUROBIOL, V31, P219, DOI 10.1002/(SICI)1097-4695(199610)31:2<219::AID-NEU7>3.0.CO;2-E; Yates PA, 2001, J NEUROSCI, V21, P8548, DOI 10.1523/JNEUROSCI.21-21-08548.2001	33	188	191	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					66	70		10.1126/science.1082545	http://dx.doi.org/10.1126/science.1082545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843386				2022-12-28	WOS:000183914700032
J	Jayne, D; Rasmussen, N; Andrassy, K; Bacon, P; Tervaert, JWC; Dadoniene, J; Ekstrand, A; Gaskin, G; Gregorini, G; de Groot, K; Gross, W; Hagen, EC; Mirapeix, E; Pettersson, E; Siegert, C; Sinico, A; Tesar, V; Westman, K; Pusey, C				Jayne, D; Rasmussen, N; Andrassy, K; Bacon, P; Tervaert, JWC; Dadoniene, J; Ekstrand, A; Gaskin, G; Gregorini, G; de Groot, K; Gross, W; Hagen, EC; Mirapeix, E; Pettersson, E; Siegert, C; Sinico, A; Tesar, V; Westman, K; Pusey, C		European Vasculitis Study Grp	A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANCA-ASSOCIATED VASCULITIS; SYSTEMIC NECROTIZING VASCULITIS; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; PULSE CYCLOPHOSPHAMIDE; RENAL INVOLVEMENT; ANTIBODY TITER; DAMAGE INDEX; GLOMERULONEPHRITIS; RELAPSE	BACKGROUND: The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. METHODS: We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. RESULTS: Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03). CONCLUSIONS: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.	Addenbrookes Hosp, Dept Med, Cambridge CB1 2QQ, England; Rigshosp, DK-2100 Copenhagen, Denmark; Univ Heidelberg, Heidelberg, Germany; Univ Birmingham, Birmingham, W Midlands, England; Univ Maastricht, Maastricht, Netherlands; Vilnius State Univ, Vilnius, Lithuania; Univ Helsinki, Helsinki, Finland; Univ London Imperial Coll Sci Technol & Med, London, England; Spedali Civil Brescia, I-25125 Brescia, Italy; Hannover Med Sch, D-3000 Hannover, Germany; Univ Luebeck, Dept Rheumatol, Lubeck, Germany; Rheumaklin Bad Bramstedt, Lubeck, Germany; Eemland Hosp, Amersfoort, Netherlands; Hosp Clin Barcelona, Barcelona, Spain; Huddinge Univ Hosp, Stockholm, Sweden; Leiden Univ, Med Ctr, Leiden, Netherlands; Osped San Carlos Borromeo, Milan, Italy; Charles Univ, Prague, Czech Republic; Lund Univ, Lund, Sweden	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Rigshospitalet; University of Copenhagen; Ruprecht Karls University Heidelberg; University of Birmingham; Maastricht University; Vilnius University; University of Helsinki; Imperial College London; Hospital Spedali Civili Brescia; Hannover Medical School; University of Lubeck; University of Barcelona; Hospital Clinic de Barcelona; Karolinska Institutet; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; San Carlo Borromeo Hospital; Charles University Prague; Lund University	Jayne, D (corresponding author), Addenbrookes Hosp, Dept Med, Box 157, Cambridge CB1 2QQ, England.		tervaert, jan willem cohen/AAB-1111-2019; sinico, renato alberto/I-6777-2012; Tesar, Vladimir/A-4485-2008; Tesar, Vladimir/O-2312-2017	sinico, renato alberto/0000-0002-9470-218X; Tesar, Vladimir/0000-0001-6982-0689; Murray, Philip/0000-0001-8491-3795; Jayne, David/0000-0002-1712-0637; Westman, Kerstin/0000-0002-2930-998X				Adu D, 1997, QJM-MON J ASSOC PHYS, V90, P401, DOI 10.1093/qjmed/90.6.401; BACON PA, 1995, CLIN EXP RHEUMATOL, V13, P275; Bajema IM, 1999, KIDNEY INT, V56, P1751, DOI 10.1046/j.1523-1755.1999.00758.x; Brooks CJ, 1996, CLIN EXP IMMUNOL, V106, P273, DOI 10.1046/j.1365-2249.1996.d01-835.x; de Groot K, 2001, NEPHROL DIAL TRANSPL, V16, P2018, DOI 10.1093/ndt/16.10.2018; deGroot K, 1996, ARTHRITIS RHEUM, V39, P2052, DOI 10.1002/art.1780391215; DEOLIVIERA J, 1995, AM J KIDNEY DIS, V25, P380, DOI 10.1016/0272-6386(95)90098-5; Exley AR, 1998, BRIT J RHEUMATOL, V37, P57; Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FALK RJ, 1990, ANN INTERN MED, V113, P656, DOI 10.7326/0003-4819-113-9-656; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Gaskin Gill, 1999, Journal of the American Society of Nephrology, V10, p101A; Guillevin L, 1997, ARTHRITIS RHEUM, V40, P2187, DOI 10.1002/art.1780401213; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Harper L, 2000, J PATHOL, V190, P349, DOI 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A; Haubitz M, 1998, NEPHROL DIAL TRANSPL, V13, P2074, DOI 10.1093/ndt/13.8.2074; Haubitz M, 1998, ARTHRITIS RHEUM, V41, P1835, DOI 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q; Hauer H. A., 1998, Clinical and Experimental Immunology, V112, P28; Hauer HA, 2002, KIDNEY INT, V61, P80, DOI 10.1046/j.1523-1755.2002.00089.x; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; Jayne D, 2000, RHEUMATOLOGY, V39, P585, DOI 10.1093/rheumatology/39.6.585; JAYNE DRW, 1995, QJM-MON J ASSOC PHYS, V88, P127; Jayne DRW, 1997, MAYO CLIN PROC, V72, P737; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JENNETTE JC, 1989, AM J PATHOL, V135, P921; King WJ, 1998, CLIN EXP IMMUNOL, V112, P539; LUQMANI RA, 1994, Q J MED, V87, P671; Luqmani RA, 1997, BAILLIERE CLIN RHEUM, V11, P423, DOI 10.1016/S0950-3579(97)80052-0; Nowack R, 1999, J AM SOC NEPHROL, V10, P1965; PUSEY CD, 1991, KIDNEY INT, V40, P757, DOI 10.1038/ki.1991.272; Reinhold-Keller E, 2000, ARTHRITIS RHEUM, V43, P1021, DOI 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J; ReinholdKeller E, 2000, ARTHRITIS RHEUM, V43, P2379; REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622; Savige J, 1999, AM J CLIN PATHOL, V111, P507; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stone JH, 2001, ARTHRITIS RHEUM, V44, P1149, DOI 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.3.CO;2-6; SZPIRT WM, 1996, INT J ARTIF ORGANS, V10, P501; TERVAERT JWC, 1990, LANCET, V336, P709; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Westman KWA, 1998, J AM SOC NEPHROL, V9, P842; WILK A, 1993, MANUAL BIOL MARKER A, V9, P1; 1995, CLIN EXP IMMUNOL S1, V101, P29	46	954	1012	1	37	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					36	44		10.1056/NEJMoa020286	http://dx.doi.org/10.1056/NEJMoa020286			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840090				2022-12-28	WOS:000183896100006
J	Rodenhuis, S; Bontenbal, M; Beex, LVAM; Wagstaff, J; Richel, DJ; Nooij, MA; Voest, EE; Hupperets, P; van Tinteren, H; Peterse, HL; TenVergert, EM; de Vries, EGE				Rodenhuis, S; Bontenbal, M; Beex, LVAM; Wagstaff, J; Richel, DJ; Nooij, MA; Voest, EE; Hupperets, P; van Tinteren, H; Peterse, HL; TenVergert, EM; de Vries, EGE		Netherlands Working Party Autologo	High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT THERAPY; HER-2/NEU OVEREXPRESSION; PROGNOSTIC FACTOR; STAGE-II; SUPPORT; CYCLOPHOSPHAMIDE; TRANSPLANTATION; CARBOPLATIN; EXPRESSION; C-ERBB-2	BACKGROUND: The use of high-dose adjuvant chemotherapy for high-risk primary breast cancer is controversial. We studied its efficacy in patients with 4 to 9 or 10 or more tumor-positive axillary lymph nodes. METHODS: Patients younger than 56 years of age who had undergone surgery for breast cancer and who had no distant metastases were eligible if they had at least four tumor-positive axillary lymph nodes. Patients in the conventional-dose group received fluorouracil, epirubicin, and cyclophosphamide (FEC) every three weeks for five courses, followed by radiotherapy and tamoxifen. The high-dose treatment was identical, except that high-dose chemotherapy (6 g of cyclophosphamide per square meter of body-surface area, 480 mg of thiotepa per square meter, and 1600 mg of carboplatin per square meter) with autologous peripheral-blood hematopoietic progenitor-cell transplantation replaced the fifth course of FEC. RESULTS: Of the 885 patients, 442 were assigned to the high-dose group and 443 to the conventional-dose group. After a median follow-up of 57 months, the actuarial 5-year relapse-free survival rates were 59 percent in the conventional-dose group and 65 percent in the high-dose group (hazard ratio for relapse in the high-dose group, 0.83; 95 percent confidence interval, 0.66 to 1.03; P=0.09). In the group with 10 or more positive nodes, the relapse-free survival rates were 51 percent in the conventional-dose group and 61 percent in the high-dose group (P=0.05 by the log-rank test; hazard ratio for relapse, 0.71; 95 percent confidence interval, 0.50 to 1.00). CONCLUSIONS: High-dose alkylating therapy improves relapse-free survival among patients with stage II or III breast cancer and 10 or more positive axillary lymph nodes. This benefit may be confined to patients with HER-2/neu-negative tumors.	Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands; Erasmus Med Ctr, Dr Daniel den Hoed Canc Ctr, Rotterdam, Netherlands; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; Univ Hosp Maastricht, Maastricht, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Med Ctr Enschede, Enschede, Netherlands; Univ Med Ctr Leiden, Leiden, Netherlands; Univ Med Ctr Utrecht, Utrecht, Netherlands; Univ Groningen Hosp, Groningen, Netherlands	Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Radboud University Nijmegen; Vrije Universiteit Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Utrecht University; Utrecht University Medical Center; University of Groningen	Rodenhuis, S (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Wagstaff, John/0000-0002-1140-5981; de Vries, Elisabeth/0000-0002-8949-7425; van Tinteren, Harm/0000-0002-4626-8702				Bewick M, 2001, BONE MARROW TRANSPL, V27, P847, DOI 10.1038/sj.bmt.1703005; Bitran JD, 1996, CLIN CANCER RES, V2, P1509; Clarke M, 1998, LANCET, V351, P1451; de Vries EGE, 1998, J CLIN ONCOL, V16, P809, DOI 10.1200/JCO.1998.16.2.809; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Hensel M, 2002, INT J CANCER, V100, P290, DOI 10.1002/ijc.10478; Kim YS, 2001, CLIN CANCER RES, V7, P4008; Lohrisch C, 2001, Clin Breast Cancer, V2, P129, DOI 10.3816/CBC.2001.n.017; MUSS HB, 1994, NEW ENGL J MED, V331, P211; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nieto Y, 2000, J CLIN ONCOL, V18, P2070, DOI 10.1200/JCO.2000.18.10.2070; Nieto Y, 2002, J CLIN ONCOL, V20, P707, DOI 10.1200/JCO.20.3.707; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PETERS W, 1999, P AN M AM SOC CLIN, V18, pA1; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; Rodenhuis S, 2000, Oncologist, V5, P369, DOI 10.1634/theoncologist.5-5-369; RODENHUIS S, 1992, ANN ONCOL, V3, P855, DOI 10.1093/oxfordjournals.annonc.a058111; RODENHUIS S, 2000, P AN M AM SOC CLIN, V19, P74; Schneeweiss A, 2001, BIOL BLOOD MARROW TR, V7, P332, DOI 10.1016/S1083-8791(01)80004-5; Somlo G, 2002, BRIT J CANCER, V87, P281, DOI 10.1038/sj.bjc.6600450; Tallman MS, 2003, NEW ENGL J MED, V349, P17, DOI 10.1056/NEJMoa030684; VANDERWALL E, 1995, BRIT J CANCER, V71, P857, DOI 10.1038/bjc.1995.165; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Yamauchi H, 2001, J CLIN ONCOL, V19, P2334, DOI 10.1200/JCO.2001.19.8.2334	26	199	210	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					7	16		10.1056/NEJMoa022794	http://dx.doi.org/10.1056/NEJMoa022794			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840087	Green Published			2022-12-28	WOS:000183896100003
J	Whitehouse, PJ				Whitehouse, PJ			Lessons and responses in Alzheimer disease research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION; TRIAL		Case Western Reserve Univ, Cleveland, OH 44106 USA	Case Western Reserve University	Whitehouse, PJ (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.							Bishop GM, 2002, NATURE, V416, P677, DOI 10.1038/416677d; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Ernst RL, 1997, ALZ DIS ASSOC DIS, V11, P135; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Kodish E, 1996, ACAD MED, V71, P1287, DOI 10.1097/00001888-199612000-00009; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SUMMERS WK, 1986, NEW ENGL J MED, V315, P1241, DOI 10.1056/NEJM198611133152001; Whitehouse P. J., 1999, J AM GERIATR SOC, V47, P1; Whitehouse PJ, 2000, CONCEPTS ALZHEIMER D; PARKINSON STUDY GROU	12	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					115	115		10.1001/jama.290.1.115	http://dx.doi.org/10.1001/jama.290.1.115			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837723	Bronze			2022-12-28	WOS:000183868600031
J	Pizzolato, JF; Saltz, LB				Pizzolato, JF; Saltz, LB			The camptothecins	LANCET			English	Article							CELL LUNG-CANCER; PHASE-II TRIAL; METASTATIC COLORECTAL-CANCER; DNA TOPOISOMERASE-I; ADVANCED PANCREATIC-CANCER; ADVANCED SOLID TUMORS; PREVIOUSLY UNTREATED PATIENTS; COOPERATIVE-ONCOLOGY-GROUP; CONTINUOUS-INFUSION; RANDOMIZED TRIAL	Supported by detailed understanding of their mechanism of action, and facilitated by chemical manipulations that have amplified their solubility, the camptothecins have advanced to the forefront of several areas of therapeutic and developmental chemotherapy. Additive and synergistic laboratory interactions with other cytotoxic drugs have been exploited to allow development of camptothecin-based multidrug regimens, which are showing important activity in several malignancies. Topotecan and irinotecan are already in widespread use in clinical practice, and newer agents with promising preclinical activity are in various stages of clinical assessment. As knowledge of molecular and biochemical mechanisms of action and resistance continues to expand, newer and better camptothecin-based strategies for treatment of malignant disease are likely to evolve.	Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Saltz, LB (corresponding author), Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA.	saltzl@mskcc.org		Saltz, Leonard/0000-0001-8353-4670				ABIGERGES D, 1994, J NATL CANCER I, V86, P446, DOI 10.1093/jnci/86.6.446; ABOUALFA GK, P AM SOC CLIN ONC 20; Ardizzoni A, 1997, J CLIN ONCOL, V15, P2090, DOI 10.1200/JCO.1997.15.5.2090; BAUMER P, 1992, GUT, V33, P753, DOI 10.1136/gut.33.6.753; Beran M, 1998, SEMIN HEMATOL, V35, P26; BLANKE CD, P AM SOC CLIN ONC 20; Boku N, 1999, J CLIN ONCOL, V17, P319, DOI 10.1200/JCO.1999.17.1.319; Bookman MA, 2002, SEMIN ONCOL, V29, P20, DOI 10.1053/sonc.2002.31592; CHABOT GG, 1995, ANN ONCOL, V6, P141, DOI 10.1093/oxfordjournals.annonc.a059109; Clarke-Pearson DL, 2001, J CLIN ONCOL, V19, P3967, DOI 10.1200/JCO.2001.19.19.3967; Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709; Creemers GJ, 1995, ANN ONCOL, V6, P844, DOI 10.1093/oxfordjournals.annonc.a059328; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; DADAMO D, P AM SOC CLIN ONC 20; Date H, 2002, BRIT J CANCER, V86, P530, DOI 10.1038/sj.bjc.6600117; de Jonge MJA, 1999, J CLIN ONCOL, V17, P2219, DOI 10.1200/JCO.1999.17.7.2219; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ellerhorst JA, 2002, ANTI-CANCER DRUG, V13, P169, DOI 10.1097/00001813-200202000-00009; FRIEDMAN HS, 1994, CANCER CHEMOTH PHARM, V34, P171; Fukuda M, 1996, CANCER RES, V56, P789; Gerrits CJH, 1998, EUR J CANCER, V34, P1030, DOI 10.1016/S0959-8049(97)10173-3; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; Gore M, 2002, EUR J CANCER, V38, P57, DOI 10.1016/S0959-8049(01)00188-5; Gupta E, 1997, CANCER CHEMOTH PHARM, V39, P440, DOI 10.1007/s002800050595; GUPTA E, 1994, CANCER RES, V54, P3723; HENNIN KC, P AM SOC CLIN ONC 19; HOCHSTER H, 1994, J CLIN ONCOL, V12, P553, DOI 10.1200/JCO.1994.12.3.553; HOUGHTON PJ, 1992, CANCER CHEMOTH PHARM, V31, P229, DOI 10.1007/BF00685553; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huinink WTB, 1997, J CLIN ONCOL, V15, P2183, DOI 10.1200/JCO.1997.15.6.2183; HUSAIN I, 1994, CANCER RES, V54, P539; Ilson DH, 2002, ONCOLOGY-NY, V16, P11; Ilson DH, 1999, J CLIN ONCOL, V17, P3270, DOI 10.1200/JCO.1999.17.10.3270; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; KANEDA N, 1990, CANCER RES, V50, P1721; KANO Y, 1992, INT J CANCER, V50, P604, DOI 10.1002/ijc.2910500420; Kawai T, 2001, DIABETES RES CLIN PR, V51, P1, DOI 10.1016/S0168-8227(00)00201-1; KAWATO Y, 1991, CANCER CHEMOTH PHARM, V28, P192, DOI 10.1007/BF00685508; Kehrer DFS, 2001, CLIN CANCER RES, V7, P1136; Kindler HL, 1998, AM J CLIN ONCOL-CANC, V21, P438, DOI 10.1097/00000421-199810000-00003; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; LI LH, 1972, CANCER RES, V32, P2643; Lima CMSR, 2002, J CLIN ONCOL, V20, P1182, DOI 10.1200/JCO.20.5.1182; Macdonald JS, 1997, INVEST NEW DRUG, V15, P357, DOI 10.1023/A:1005941603420; Mainwaring PN, 1997, BRIT J CANCER, V76, P1636, DOI 10.1038/bjc.1997.609; MASUDA N, P AM SOC CLIN ONC 19; MASUMOTO N, 1995, ANTICANCER RES, V15, P405; MOERTEL CG, 1972, CANCER CHEMOTH REP 1, V56, P95; MROSS K, P AM SOC CLIN ONC 20; NEGORO S, 1991, J NATL CANCER I, V83, P1164, DOI 10.1093/jnci/83.16.1164; NIHO S, P AM SOC CLIN ONC 19; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; OHE Y, 1992, J NATL CANCER I, V84, P972, DOI 10.1093/jnci/84.12.972; OREILLY E, P AM SOC CLIN ONC 20; PARNES HL, 1995, ONCOL REP, V2, P1131; Pazdur R, 1997, J CLIN ONCOL, V15, P2905, DOI 10.1200/JCO.1997.15.8.2905; PEREZ EA, P AM SOC CLIN ONC 20; Pitot HC, 2000, CANCER-AM CANCER SOC, V89, P1699, DOI 10.1002/1097-0142(20001015)89:8<1699::AID-CNCR8>3.0.CO;2-T; PRATESI G, 1995, BRIT J CANCER, V71, P525, DOI 10.1038/bjc.1995.104; Raymond E, 2002, EUR J CANCER, V38, P1348, DOI 10.1016/S0959-8049(02)00070-9; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; ROWINSKY EK, 1994, CANCER RES, V54, P427; Rowinsky EK, 2000, J CLIN ONCOL, V18, P3151, DOI 10.1200/JCO.2000.18.17.3151; ROYCE M, P AM SOC CLIN ONC 20; Saliba F, 1998, J CLIN ONCOL, V16, P2745, DOI 10.1200/JCO.1998.16.8.2745; SALTZ L, 1993, J NATL CANCER I, V85, P1499, DOI 10.1093/jnci/85.18.1499; Saltz LB, 1997, CANCER-AM CANCER SOC, V80, P1727, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1727::AID-CNCR5>3.0.CO;2-B; Saltz LB, 1996, J CLIN ONCOL, V14, P2959, DOI 10.1200/JCO.1996.14.11.2959; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Saltz LB, 1998, J CLIN ONCOL, V16, P3858, DOI 10.1200/JCO.1998.16.12.3858; Saltz LB, 1997, AM J CLIN ONCOL-CANC, V20, P621, DOI 10.1097/00000421-199712000-00018; Sane AT, 1999, CANCER RES, V59, P3565; Schiller JH, 2001, J CLIN ONCOL, V19, P2114, DOI 10.1200/JCO.2001.19.8.2114; Schiller JH, 1996, J CLIN ONCOL, V14, P2345, DOI 10.1200/JCO.1996.14.8.2345; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; Sharma S, 2001, CLIN CANCER RES, V7, P3963; SHIMADA Y, 1993, J CLIN ONCOL, V11, P909, DOI 10.1200/JCO.1993.11.5.909; Simpson AB, 2002, ANN ONCOL, V13, P399, DOI 10.1093/annonc/mdf041; Siu LL, 1998, J CLIN ONCOL, V16, P1122, DOI 10.1200/JCO.1998.16.3.1122; SIU LL, P AM SOC CLIN ONC 20; Stehlin JS, 1999, INT J ONCOL, V14, P821; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; Verschraegen CF, 1999, ANTI-CANCER DRUG, V10, P375, DOI 10.1097/00001813-199904000-00005; VERWEIJ J, 1993, ANN ONCOL, V4, P673, DOI 10.1093/oxfordjournals.annonc.a058623; Vokes EE, 2001, INVEST NEW DRUG, V19, P329, DOI 10.1023/A:1010674113243; von Pawel J, 2001, J CLIN ONCOL, V19, P1743, DOI 10.1200/JCO.2001.19.6.1743; WAGENER DJT, 1995, ANN ONCOL, V6, P129, DOI 10.1093/oxfordjournals.annonc.a059107; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; Wasserman E, 1997, ANN ONCOL, V8, P1049, DOI 10.1023/A:1008261821434	92	329	348	1	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2235	2242		10.1016/S0140-6736(03)13780-4	http://dx.doi.org/10.1016/S0140-6736(03)13780-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842380				2022-12-28	WOS:000183815600028
J	Ubach, C; Scott, A; French, F; Awramenko, M; Needham, G				Ubach, C; Scott, A; French, F; Awramenko, M; Needham, G			What do hospital consultants value about their jobs? A discrete choice experiment	BRITISH MEDICAL JOURNAL			English	Article							CONJOINT-ANALYSIS; HEALTH-CARE; PREFERENCES	Objective To examine the strength of hospital consultants' preferences for various aspects of their work. Design Questionnaire survey including a discrete choice experiment. Setting NHS Scotland. Participants 2923 hospital consultants in Scotland. Main outcome measures Monetary valuations or prices for each job characteristic, based on consultants' willingness to pay and willingness to accept extra income for a change in each job characteristic, calculated from regression coefficients. Results The response rate was 61% (1793 respondents). Being on call was the most important attribute, as consultants would need to be compensated up to 918 000 (30% of their average net income) (P < 0.001) for a high on-call workload. Compensation of up to 19700 (16% of their net income) (P < 0.001) would be required for consultants to forgo opportunities to undertake non-NHS work. Consultants would be willing to accept pound7000 (12% of net income) (P < 0.001) in compensation for fair rather than good working relationships with staff, and &POUND;6500 (11% of net income) (P < 0.001) to compensate them for a shortage of staff. The least important characteristic was hours of work, with pound562 per year (0.9% of their net income) (P < 0.001) required to induce consultants to work one extra hour per week. These preferences also varied among specific subgroups of consultants. Conclusions Important information on consultants' strength of preferences for characteristics of their job should be used to help to address recruitment and, retention problems. Consultants would require increased payment to cover more intensive on-call commitments. Other aspects of working conditions would require smaller increases.	Univ Aberdeen, Inst Appl Hlth Sci, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland; NHS Educ Scotland, Aberdeen AB25 2ZP, Scotland	University of Aberdeen; NHS Education for Scotland	Scott, A (corresponding author), Univ Aberdeen, Inst Appl Hlth Sci, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland.		Scott, Anthony/E-6636-2010	Scott, Anthony/0000-0002-2851-5378				BLAIR M, 2002, REV BODY DOCTORS DEN; BRADLEY M, 1991, USERS MANUAL SPEED V; Carlsson F, 2003, HEALTH ECON, V12, P281, DOI 10.1002/hec.729; Department of Health (2001c), 2001, NHS PLAN PROP NEW AP; Greene W. H., 1993, ECONOMETRIC ANAL; Lloyd AJ, 2003, HEALTH ECON, V12, P393, DOI 10.1002/hec.772; Pearmain D, 1991, STATED PREFERENCE TE; PROPPER C, 1995, J HUM RESOUR, V30, P677, DOI 10.2307/146227; Ratcliffe J, 2000, INT J TECHNOL ASSESS, V16, P270, DOI 10.1017/S0266462300161227; Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530; RYAN M, 2002, ADV HLTH EC; Scott A, 2002, J ECON PSYCHOL, V23, P383, DOI 10.1016/S0167-4870(02)00082-X; Scott A, 2001, J HEALTH ECON, V20, P329, DOI 10.1016/S0167-6296(00)00083-7; Skjoldborg US, 2003, HEALTH ECON, V12, P479, DOI 10.1002/hec.742; Zwerina K., 1996, GEN METHOD CONSTRUCT	15	58	59	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1432	1435		10.1136/bmj.326.7404.1432	http://dx.doi.org/10.1136/bmj.326.7404.1432			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	697FP	12829556	Green Published, Bronze			2022-12-28	WOS:000183931800018
J	Bryden, HL; McDonagh, EL; King, BA				Bryden, HL; McDonagh, EL; King, BA			Changes in ocean water mass properties: Oscillations or trends?	SCIENCE			English	Article							ANTHROPOGENIC CLIMATE-CHANGE; ANTARCTIC MODE WATER; NORTH-ATLANTIC OCEAN; INDIAN-OCEAN; DECADAL CHANGES; INTERMEDIATE WATERS; 32-DEGREES-S; SECTION; PACIFIC	A new transindian hydrographic section across 32 degreesS reveals that thermocline mode waters have become saltier and colder since 1987. This change almost entirely reverses the observed freshening of mode waters from the 1960s to 1987 that has been interpreted to be the result of anthropogenic climate change on the basis of coupled climate models. Here, we compare five hydrographic sections from 1936, 1965, 1987, 1995, and 2002 to show that upper thermocline waters (10 degreesC to 17 degreesC) changed little from 1936 to 1965, freshened from 1965 to 1987, and since 1987 have become saltier. These results demonstrate substantial oscillations in mode-water properties.	Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England	NERC National Oceanography Centre; University of Southampton	Bryden, HL (corresponding author), Southampton Oceanog Ctr, Empress Dock, Southampton SO14 3ZH, Hants, England.			McDonagh, Elaine/0000-0002-8813-4585; Bryden, Harry/0000-0002-8216-6359				Arbic BK, 2001, J CLIMATE, V14, P4091, DOI 10.1175/1520-0442(2001)014<4091:CWOAIW>2.0.CO;2; Banks H, 2002, J CLIMATE, V15, P879, DOI 10.1175/1520-0442(2002)015<0879:WTLFAC>2.0.CO;2; Banks H, 2002, J PHYS OCEANOGR, V32, P2816, DOI 10.1175/1520-0485(2002)032<2816:CTIOSM>2.0.CO;2; Banks HT, 2000, GEOPHYS RES LETT, V27, P2961, DOI 10.1029/2000GL011601; Banks HT, 2003, J CLIMATE, V16, P156, DOI 10.1175/1520-0442(2003)016<0156:COOTAS>2.0.CO;2; Belkin IM, 1996, J GEOPHYS RES-OCEANS, V101, P3675, DOI 10.1029/95JC02750; BENSON BB, 1980, J SOLUTION CHEM, V9, P895, DOI 10.1007/BF00646402; Bindoff NL, 2000, J PHYS OCEANOGR, V30, P1207, DOI 10.1175/1520-0485(2000)030<1207:DCAAIO>2.0.CO;2; Bryden HL, 1996, J CLIMATE, V9, P3162, DOI 10.1175/1520-0442(1996)009<3162:DCIWMC>2.0.CO;2; Deacon G. E. R., 1937, DISCOVERY REP, V15, P1, DOI DOI 10.1016/0198-0149(82)90058-9; DONOHUE KA, 2003, DEEP SEA RES 2, V50, P1983; JENKINS WJ, 1976, DEEP-SEA RES, V23, P481, DOI 10.1016/0011-7471(76)90860-3; Johnson GC, 1997, J CLIMATE, V10, P306, DOI 10.1175/1520-0442(1997)010<0306:SPOWMC>2.0.CO;2; McCartney M. S., 1979, VOYAGE DISCOVERY G D, P103; PARRILLA G, 1994, NATURE, V369, P48, DOI 10.1038/369048a0; Rintoul SR, 2002, J PHYS OCEANOGR, V32, P1308, DOI 10.1175/1520-0485(2002)032<1308:ETDLAS>2.0.CO;2; Talley LD, 1997, GEOPHYS RES LETT, V24, P2789, DOI 10.1029/97GL02657; TOOLE JM, 1993, DEEP-SEA RES PT I, V40, P1973, DOI 10.1016/0967-0637(93)90042-2; TOOLE JM, 1985, DEEP-SEA RES, V32, P917, DOI 10.1016/0198-0149(85)90036-6; Wong APS, 1999, NATURE, V400, P440, DOI 10.1038/22733	20	71	72	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2086	2088		10.1126/science.1083980	http://dx.doi.org/10.1126/science.1083980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829781				2022-12-28	WOS:000183774900044
J	Sullenberger, LE; Rohrer, MJ				Sullenberger, LE; Rohrer, MJ			Shot to the heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Walter Reed Army Med Ctr, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Sullenberger, LE (corresponding author), Walter Reed Army Med Ctr, Washington, DC 20307 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2634	2634		10.1056/NEJMicm020844	http://dx.doi.org/10.1056/NEJMicm020844			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826638				2022-12-28	WOS:000183726400007
J	Rose, D; Wykes, T; Leese, M; Bindman, J; Fleischmann, P				Rose, D; Wykes, T; Leese, M; Bindman, J; Fleischmann, P			Patients' perspectives on electroconvulsive therapy: systematic review	BRITISH MEDICAL JOURNAL			English	Article							ECT; ATTITUDES; SATISFACTION	Objective To ascertain patients' views on the benefits of and possible memory loss from electroconvulsive therapy. Design Descriptive systematic review. Data sources Psychinfo, Medline, Web of Science, and Social Science Citation Index databases, and bibliographies. Study selection Articles with patients' views after treatment with electroconvulsive therapy. Data extraction 26 studies carried out by clinicians and nine reports of work undertaken by patients or with the collaboration of patients were, identified; 16 studies investigated the perceived benefit of electroconvulsive therapy and seven met criteria for investigating memory loss. Data synthesis The studies showed heterogeneity. The methods used were associated with levels of perceived benefit. At least one third of patients reported persistent memory loss. Conclusions The current statement for patients from the Royal College of Psychiatrists that over 80% of patients are satisfied with electroconvulsive therapy and that memory loss is not clinically important is unfounded.	Inst Psychiat, Serv User Res Enterprise, London SE5 8AF, England; Inst Psychiat, Dept Psychol, London SE5 8AF, England; Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London	Rose, D (corresponding author), Inst Psychiat, Serv User Res Enterprise, PO34,De Crespigny Pk, London SE5 8AF, England.		Rose, Diana S/D-1387-2010; Leese, Morven N/E-4195-2010; Rose, Diana/HGE-8574-2022; Wykes, Til/B-3812-2011; Wykes, Til/AAE-9718-2022; Wykes, Til H M/B-7894-2008; Wykes, Til/AFE-8438-2022	Rose, Diana S/0000-0002-6393-6389; Wykes, Til/0000-0002-5881-8003; Wykes, Til/0000-0002-5881-8003; Wykes, Til/0000-0002-5881-8003				APERIA B, 1986, ACTA PSYCHIAT SCAND, V73, P271, DOI 10.1111/j.1600-0447.1986.tb02685.x; BENBOW SM, 1988, CONVULSIVE THER, V4, P146; Bernstein HJ, 1998, PSYCHIAT ANN, V28, P524, DOI 10.3928/0048-5713-19980901-10; Department of Health, 1999, EL THER SURV COV PER; FREEMAN C, 1986, PSYCHOPHARMACOL BULL, V22, P487; Freeman C.P. L., 1986, Convuls Ther, V2, P31; FREEMAN CPL, 1980, BRIT J PSYCHIAT, V137, P17, DOI 10.1192/bjp.137.1.17; FREEMAN CPL, 1980, BRIT J PSYCHIAT, V137, P8, DOI 10.1192/bjp.137.1.8; FREEMAN G, 1986, PSYCHOPHARMACOL B, V22, P487; Goodman JA, 1999, MAYO CLIN PROC, V74, P967; HUGHES J, 1981, J ROY SOC MED, V74, P283, DOI 10.1177/014107688107400409; KENNEDY SH, 1996, CAN J PSYCHIAT, V4, P609; KERR RA, 1982, AUST NZ J PSYCHIAT, V16, P43, DOI 10.3109/00048678209159469; Kidder L. H., 1986, RES METHODS SOCIAL R, V5th; *MAN DEPR FELL, 2002, LIST OUR MEMB; *MENT HLTH FDN, 1997, KNOW OUR OWN MINDS; Pedler M., 2000, SHOCK TREATMENT SURV; PETTINATI HM, 1994, PSYCHOPHARMACOL BULL, V30, P471; POLOWCZYK D, 1993, HOSP COMMUNITY PSYCH, V44, P589; Riordan D. M., 1993, PSYCHIAT B, V17, P531; ROGERS A, 1993, SOCIOL HEALTH ILL, V15, P612, DOI 10.1111/1467-9566.ep11433593; Royal College of Psychiatrists, 1995, FACT SHEET ECT; SQUIRE LR, 1983, BRIT J PSYCHIAT, V142, P1, DOI 10.1192/bjp.142.1.1; SZUBA MP, 1991, CONVULSIVE THER, V7, P175; UK ECT Review Group, 2003, LANCET, V354, P1369; United Kingdom Advocacy Network, 1995, ECT SURV NAT EXP; Wheeldon TJ, 1999, PSYCHOL MED, V29, P221, DOI 10.1017/S0033291798007193; 1999, QUESTIONNAIRE RESULT	28	280	285	1	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1363	1365		10.1136/bmj.326.7403.1363	http://dx.doi.org/10.1136/bmj.326.7403.1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	694CN	12816822	Green Published, Bronze			2022-12-28	WOS:000183756400020
J	Schwartz, CE; Wright, CI; Shin, LM; Kagan, J; Rauch, SL				Schwartz, CE; Wright, CI; Shin, LM; Kagan, J; Rauch, SL			Inhibited and uninhibited infants "grown up": Adult amygdalar response to novelty	SCIENCE			English	Article							BEHAVIORAL-INHIBITION; SOCIAL PHOBIA; TEMPERAMENT; ASSOCIATION; ACTIVATION; CHILDREN; ANXIETY; FACES	Infants with an inhibited temperament tend to develop into children who avoid people, objects, and situations that are novel or unfamiliar, whereas uninhibited children spontaneously approach novel persons, objects, and situations. Behavioral and physiological features of these two temperamental categories are moderately stable from infancy into early adolescence and have been hypothesized to be due, in part, to variation in amygdalar responses to novelty. We found that adults who had been categorized in the second year of life as inhibited, compared with those previously categorized as uninhibited, showed greater functional MRI signal response within the amygdala to novel versus familiar faces.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Dev Psychopathol Res Grp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Psychiat Neuroimaging Res Program, Charlestown, MA 02129 USA; MGH, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA; MGH, Nucl Magnet Resonance Ctr, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Dept Neurol, Brigham Behav Neurol Grp, Boston, MA 02115 USA; Tufts Univ, Dept Psychol, Medford, MA 02155 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Tufts University; Harvard University	Schwartz, CE (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Dev Psychopathol Res Grp, 13th St,Bldg 149,CNY-9, Charlestown, MA 02129 USA.	carl_schwartz@hms.harvard.edu						Biederman J, 2001, AM J PSYCHIAT, V158, P1673, DOI 10.1176/appi.ajp.158.10.1673; Birbaumer N, 1998, NEUROREPORT, V9, P1223, DOI 10.1097/00001756-199804200-00048; Calkins SD, 1996, CHILD DEV, V67, P523, DOI 10.2307/1131830; CHESS S, 1960, AM J PSYCHIAT, V117, P434, DOI 10.1176/ajp.117.5.434; COLL CG, 1984, CHILD DEV, V55, P1005, DOI 10.2307/1130152; Davidson RJ, 2000, MED RAD DIA IMG, P487; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; HIRSHFELD DR, 1992, J AM ACAD CHILD PSY, V31, P103, DOI 10.1097/00004583-199201000-00016; KAGAN J, 1987, CHILD DEV, V58, P1459, DOI 10.1111/j.1467-8624.1987.tb03858.x; Kagan J, 1998, CHILD DEV, V69, P1483, DOI 10.1111/j.1467-8624.1998.tb06171.x; KAGAN J, 1984, CHILD DEV, V55, P2212, DOI 10.1111/j.1467-8624.1984.tb03916.x; KAGAN J, 1988, SCIENCE, V240, P167, DOI 10.1126/science.3353713; Kagan J, 1999, DEV PSYCHOPATHOL, V11, P209, DOI 10.1017/S0954579499002023; Kagan J., 1994, GALENS PROPHECY; MATHENY A, 1990, DEV BEHAV GENETICS N, P25; Pfeifer M, 2002, CHILD DEV, V73, P1474, DOI 10.1111/1467-8624.00484; ROBINSON JL, 1992, DEV PSYCHOL, V28, P1030, DOI 10.1037/0012-1649.28.6.1030; ROSENBAUM JF, 1988, ARCH GEN PSYCHIAT, V45, P463; Rubin KH, 1997, CHILD DEV, V68, P467, DOI 10.2307/1131672; Schneider F, 1999, BIOL PSYCHIAT, V45, P863, DOI 10.1016/S0006-3223(98)00269-8; Schwartz CE, 1996, J ANXIETY DISORD, V10, P89, DOI 10.1016/0887-6185(96)87623-7; Schwartz CE, 1999, J AM ACAD CHILD PSY, V38, P1008, DOI 10.1097/00004583-199908000-00017; Schwartz CE, 1996, DEV PSYCHOPATHOL, V8, P527, DOI 10.1017/S0954579400007252; Stein MB, 2002, ARCH GEN PSYCHIAT, V59, P1027, DOI 10.1001/archpsyc.59.11.1027; Tillfors M, 2001, AM J PSYCHIAT, V158, P1220, DOI 10.1176/appi.ajp.158.8.1220; Veit R, 2002, NEUROSCI LETT, V328, P233, DOI 10.1016/S0304-3940(02)00519-0; Wright CI, 2001, NEUROREPORT, V12, P379, DOI 10.1097/00001756-200102120-00039	27	377	382	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1952	1953		10.1126/science.1083703	http://dx.doi.org/10.1126/science.1083703			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	691RN	12817151	Green Submitted			2022-12-28	WOS:000183619400049
J	Krupke, R; Hennrich, F; von Lohneysen, H; Kappes, MM				Krupke, R; Hennrich, F; von Lohneysen, H; Kappes, MM			Separation of metallic from semiconducting single-walled carbon nanotubes	SCIENCE			English	Article							TRANSPORT	We have developed a method to separate metallic from semiconducting single-walled carbon nanotubes from suspension using alternating current dielectrophoresis. Our method takes advantage of the difference of the relative dielectric constants of the two species with respect to the solvent, resulting in an opposite movement of metallic and semiconducting tubes along the electric field gradient. Metallic tubes are attracted toward a microelectrode array, leaving semiconducting tubes in the solvent. Proof of the effectiveness of separation is given by a comparative Raman spectroscopy study on the dielectrophoretically deposited tubes and on a reference sample.	Forschungszentrum Karlsruhe, Inst Nanotechnol, D-76021 Karlsruhe, Germany; Univ Karlsruhe, Inst Phys Chem, D-76128 Karlsruhe, Germany; Forschungszentrum Karlsruhe, Inst Festkorperphys, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Krupke, R (corresponding author), Forschungszentrum Karlsruhe, Inst Nanotechnol, D-76021 Karlsruhe, Germany.	ralph.krupke@int.fzk.de; frank.hennrich@int.fzk.de	Loehneysen, Hilbert/W-2490-2019; Hennrich, Frank/U-5733-2019; Kappes, Manfred/G-7142-2017; Krupke, Ralph/G-8786-2013	Kappes, Manfred/0000-0002-1199-1730; Krupke, Ralph/0000-0001-8427-8592				Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; BENEDICT LX, 1995, PHYS REV B, V52, P8541, DOI 10.1103/PhysRevB.52.8541; Chen XQ, 2001, APPL PHYS LETT, V78, P3714, DOI 10.1063/1.1377627; Derycke V, 2002, APPL PHYS LETT, V80, P2773, DOI 10.1063/1.1467702; Diehl MR, 2002, ANGEW CHEM INT EDIT, V41, P353, DOI 10.1002/1521-3773(20020118)41:2<353::AID-ANIE353>3.0.CO;2-Y; Ding JW, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.073401; Dresselhaus MS, 2002, CARBON, V40, P2043, DOI 10.1016/S0008-6223(02)00066-0; Gommans HH, 2000, J APPL PHYS, V88, P2509, DOI 10.1063/1.1287128; Hughes MP, 2002, ELECTROPHORESIS, V23, P2569, DOI 10.1002/1522-2683(200208)23:16<2569::AID-ELPS2569>3.0.CO;2-M; Jones T. B., 1995, ELECTROMECHANICS PAR; Krupke R, 2003, APPL PHYS A-MATER, V76, P397, DOI 10.1007/s00339-002-1592-4; McEuen PL, 2000, PHYS WORLD, V13, P31; Nagahara LA, 2002, APPL PHYS LETT, V80, P3826, DOI 10.1063/1.1481237; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Pichler T, 1998, PHYS REV LETT, V80, P4729, DOI 10.1103/PhysRevLett.80.4729; Pohl H., 1978, DIELECTROPHORESIS; Sauvajol JL, 2002, CARBON, V40, P1697, DOI 10.1016/S0008-6223(02)00010-6; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Wind SJ, 2002, APPL PHYS LETT, V80, P3817, DOI 10.1063/1.1480877; Yamamoto K, 1998, J PHYS D APPL PHYS, V31, pL34, DOI 10.1088/0022-3727/31/8/002; Yao Z, 2000, PHYS REV LETT, V84, P2941, DOI 10.1103/PhysRevLett.84.2941	22	1385	1470	10	445	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	2003	301	5631					344	347		10.1126/science.1086534	http://dx.doi.org/10.1126/science.1086534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12829788				2022-12-28	WOS:000184207300036
J	Murphy, CT; McCarroll, SA; Bargmann, CI; Fraser, A; Kamath, RS; Ahringer, J; Li, H; Kenyon, C				Murphy, CT; McCarroll, SA; Bargmann, CI; Fraser, A; Kamath, RS; Ahringer, J; Li, H; Kenyon, C			Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans	NATURE			English	Article							SUPEROXIDE-DISMUTASE; INSULIN-RECEPTOR; COMPUTATIONAL ANALYSIS; REGULATES LONGEVITY; STRESS RESISTANCE; OXIDATIVE STRESS; EXPRESSION; MEMBER; IDENTIFICATION; FAMILY	Ageing is a fundamental, unsolved mystery in biology. DAF-16, a FOXO-family transcription factor, influences the rate of ageing of Caenorhabditis elegans in response to insulin/insulin-like growth factor 1 (IGF-I) signalling. Using DNA microarray analysis, we have found that DAF-16 affects expression of a set of genes during early adulthood, the time at which this pathway is known to control ageing. Here we find that many of these genes influence the ageing process. The insulin/IGF-I pathway functions cell non-autonomously to regulate lifespan, and our findings suggest that it signals other cells, at least in part, by feedback regulation of an insulin/IGF-I homologue. Furthermore, our findings suggest that the insulin/IGF-I pathway ultimately exerts its effect on lifespan by upregulating a wide variety of genes, including cellular stress-response, antimicrobial and metabolic genes, and by downregulating specific life-shortening genes.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Cambridge; University of Cambridge	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu	McCarroll, Steven A/A-8433-2009	Kenyon, Cynthia/0000-0003-3446-2636; Ahringer, Julie/0000-0002-7074-4051; Fraser, Andrew/0000-0001-9939-6014; McCarroll, Steven/0000-0002-6954-8184; Murphy, Coleen/0000-0002-8257-984X; Bargmann, Cornelia/0000-0002-8484-0618	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Banyai L, 1998, BBA-PROTEIN STRUCT M, V1429, P259, DOI 10.1016/S0167-4838(98)00237-4; Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bussemaker HJ, 2000, P NATL ACAD SCI USA, V97, P10096, DOI 10.1073/pnas.180265397; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DAVIS WL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P276, DOI 10.1016/0167-4889(90)90133-X; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Gems D, 1998, GENETICS, V150, P129; Gregoire FM, 1998, BIOCHEM BIOPH RES CO, V249, P385, DOI 10.1006/bbrc.1998.9164; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Herndon LA, 2000, RES PRO CEL, V29, P113; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Kawano T, 2000, BIOCHEM BIOPH RES CO, V273, P431, DOI 10.1006/bbrc.2000.2971; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ookuma S, 2003, CURR BIOL, V13, P427, DOI 10.1016/S0960-9822(03)00108-8; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Riddle DL, 1997, C ELEGANS, P739; Ried K, 1998, HUM MOL GENET, V7, P1771, DOI 10.1093/hmg/7.11.1771; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sun JT, 2002, GENETICS, V161, P661; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Taub J, 2003, NATURE, V421, P764, DOI 10.1038/nature01425; Tissenbaum HA, 1998, GENETICS, V148, P703; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Wang J, 2003, DEVELOPMENT, V130, P1621, DOI 10.1242/dev.00363; Wolkow Catherine A., 2000, Science (Washington D C), V290, P147, DOI 10.1126/science.290.5489.147; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384	52	1597	1719	10	224	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	2003	424	6946					277	284		10.1038/nature01789	http://dx.doi.org/10.1038/nature01789			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	701RZ	12845331				2022-12-28	WOS:000184183900032
J	Haake, M; Buch, M; Schoellner, C; Goebel, F; Vogel, M; Mueller, I; Hausdorf, J; Zamzow, K; Schade-Brittinger, C; Mueller, HH				Haake, M; Buch, M; Schoellner, C; Goebel, F; Vogel, M; Mueller, I; Hausdorf, J; Zamzow, K; Schade-Brittinger, C; Mueller, HH			Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial	BRITISH MEDICAL JOURNAL			English	Article							PAINFUL HEEL; ESWT	Objective To determine the effectiveness of extracorporeal shock wave therapy compared with placebo in the treatment of chronic plantar fascilitis. Design Randomised, blinded, multicentre trial with parallel group design. Setting Nine hospitals and one outpatient clinic in Germany. Participants 272 patients with chronic plantar fasciitis recalcitrant to conservative therapy for at least six months: 135 patients were allocated extracorporeal shock wave therapy and 137 were allocated placebo. Main outcome measures Primary end point was the success rate 12 weeks after intervention based on the Roles and Maudsley score. Secondary end points encompassed subjective pain ratings and walking ability up to a year after the last intervention. Results The primary end point could be assessed in 94% (n=257) of patients. The success rate 12 weeks after intervention was 34% (n=46) in the. extracorporeal shock wave therapy group and 30% (n=41) in the placebo group (95% confidence interval - 8.0% to 15.1%). No difference was found in the secondary end points. Few side effects were reported. Conclusions Extracorporeal shock wave therapy is ineffective in the treatment of chronic plantar fasciitis.	Univ Regensburg, Orthopad Klin, D-93077 Bad Abbach, Germany; Orthopad Klin Kassel, D-43131 Kassel, Germany; Univ Mainz, Orthopad Klin, D-55131 Mainz, Germany; Univ Halle Wittenberg, Orthopad Klin, D-06097 Halle Saale, Germany; Rehbergklin St Andreasberg, D-37444 St Andreasberg, Germany; Univ Kiel, Orthopad Klin, D-24105 Kiel, Germany; Univ Munich, Orthopad Klin, D-81377 Munich, Germany; Univ Marburg, Koordinierungszentrum Klin Studien, D-35033 Marburg, Germany	University of Regensburg; Klinikum Kassel; Johannes Gutenberg University of Mainz; Martin Luther University Halle Wittenberg; University of Kiel; Schleswig Holstein University Hospital; University of Munich; Philipps University Marburg	Haake, M (corresponding author), Univ Regensburg, Orthopad Klin, D-93077 Bad Abbach, Germany.							Alvarez R, 2002, FOOT ANKLE INT, V23, P197, DOI 10.1177/107110070202300302; Beckman KD, 2002, CLIN ORTHOP RELAT R, P267; Boddeker IR, 2001, CLIN RHEUMATOL, V20, P324, DOI 10.1007/PL00011207; Buch M, 2002, ORTHOPADE, V31, P637, DOI 10.1007/s00132-002-0323-z; Buchbinder R, 2002, JAMA-J AM MED ASSOC, V288, P1364, DOI 10.1001/jama.288.11.1364; CHAUSSY C, 1976, UROL RES, V181, P352; Crawford F., 2000, COCHRANE DB SYST REV, V3; Dahmen G.P., 1992, EXTR ORTHOP, V11, P25; DAVIS PF, 1994, FOOT ANKLE INT, V15, P531, DOI 10.1177/107110079401501002; DEMAIO M, 1993, ORTHOPEDICS, V16, P1153; Gill, 1997, J Am Acad Orthop Surg, V5, P109; GRANZ B, 1992, J STONE DIS, V4, P123; Hammer DS, 2002, FOOT ANKLE INT, V23, P309, DOI 10.1177/107110070202300403; Krischek O, 1998, Z ORTHOP GRENZGEB, V136, P169, DOI 10.1055/s-2008-1051301; KUHNS JG, 1949, J BONE JOINT SURG AM, V31-A, P541, DOI 10.2106/00004623-194931030-00010; Ogden JA, 2001, CLIN ORTHOP RELAT R, P47, DOI 10.1097/00003086-200106000-00007; ROLES N C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P499; Rompe JD, 1996, ARCH ORTHOP TRAUM SU, V115, P75, DOI 10.1007/BF00573445; Rompe JD, 2002, J BONE JOINT SURG AM, V84A, P335, DOI 10.2106/00004623-200203000-00001; Rompe JD, 1996, FOOT ANKLE SURG, V2, P215, DOI DOI 10.1016/S1268-7731(96)80004-X; SCHEPSIS AA, 1991, CLIN ORTHOP RELAT R, P185; Wang CJ, 2000, J FORMOS MED ASSOC, V99, P580; Weil Lowell Scott Jr, 2002, J Foot Ankle Surg, V41, P166	23	134	136	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					75	77		10.1136/bmj.327.7406.75	http://dx.doi.org/10.1136/bmj.327.7406.75			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855524	Bronze, Green Published			2022-12-28	WOS:000184229400017
J	Castrillon, DH; Miao, LL; Kollipara, R; Horner, JW; DePinho, RA				Castrillon, DH; Miao, LL; Kollipara, R; Horner, JW; DePinho, RA			Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; MOUSE; GROWTH; FAILURE; IDENTIFICATION; OOCYTES; PATHWAY; AGE-1; GENES; FKHR	Foxo transcription factors have been implicated in diverse biological processes, including metabolism, cellular stress responses, and aging. Here, we show that Foxo3a(-/-) female mice exhibit a distinctive ovarian phenotype of global follicular activation leading to oocyte death, early depletion of functional ovarian follicles, and secondary infertility. Foxo3a thus functions at the earliest stages of follicular growth as a suppressor of follicular activation. In addition to providing a molecular entry point for studying the regulation of follicular growth, these results raise the possibility that accelerated follicular initiation plays a role in premature ovarian failure, a common cause of infertility and premature aging in women.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Womens & Perinatal Pathol Div, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X	PHS HHS [K08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anasti JN, 1998, FERTIL STERIL, V70, P1, DOI 10.1016/S0015-0282(98)00099-5; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; COULAM CB, 1986, OBSTET GYNECOL, V67, P604; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; DORMAN JB, 1995, GENETICS, V141, P1399; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; Eppig JJ, 1996, BIOL REPROD, V54, P197, DOI 10.1095/biolreprod54.1.197; Fortune JE, 2000, MOL CELL ENDOCRINOL, V163, P53, DOI 10.1016/S0303-7207(99)00240-3; FRASER IS, 1988, FERTIL STERIL, V50, P747; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gems D, 1998, GENETICS, V150, P129; Kaestner KH, 2000, GENE DEV, V14, P142; LINTERNMOORE S, 1979, BIOL REPROD, V20, P773, DOI 10.1095/biolreprod20.4.773; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PETERS H, 1975, J REPROD FERTIL, V45, P559, DOI 10.1530/jrf.0.0450559; Prueitt RL, 2001, NAT GENET, V27, P132, DOI 10.1038/84735; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5	23	655	687	2	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					215	218		10.1126/science.1086336	http://dx.doi.org/10.1126/science.1086336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855809				2022-12-28	WOS:000184056200044
J	Buston, P				Buston, P			Social hierarchies: Size and growth modification in clownfish	NATURE			English	Article									Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA	Cornell University	Buston, P (corresponding author), Univ Calif Santa Barbara, Natl Ctr Ecol Anal & Synth, Santa Barbara, CA 93101 USA.							Allen G. R, 1972, ANEMONEFISHES THEIR; Balshine-Earn S, 1998, BEHAV ECOL, V9, P432, DOI 10.1093/beheco/9.5.432; BUSTON PM, UNPUB P R SOC LOND B; BUSTON PM, IN PRESS BEHAV ECOL; Elliott JK, 2001, MAR BIOL, V138, P23, DOI 10.1007/s002270000441; Field J, 1999, BEHAV ECOL SOCIOBIOL, V45, P378, DOI 10.1007/s002650050574; FRICKE HW, 1979, Z TIERPSYCHOL, V50, P313; Kokko H, 1999, P ROY SOC B-BIOL SCI, V266, P571, DOI 10.1098/rspb.1999.0674; REEVE HK, 1992, NATURE, V358, P147, DOI 10.1038/358147a0; [No title captured]	10	236	239	0	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					145	146		10.1038/424145a	http://dx.doi.org/10.1038/424145a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853944				2022-12-28	WOS:000184032700029
J	Cleland, JGF; Pennell, DJ; Ray, SG; Coats, AJ; Macfarlane, PW; Murray, GD; Mule, JD; Vered, Z; Lahiri, A				Cleland, JGF; Pennell, DJ; Ray, SG; Coats, AJ; Macfarlane, PW; Murray, GD; Mule, JD; Vered, Z; Lahiri, A		CHRISTMAS Investigators	Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial	LANCET			English	Article							REVERSIBLE ISCHEMIA TRIAL; LEFT-VENTRICULAR FUNCTION; CORONARY-ARTERY DISEASE; CHRONIC HIBERNATION; SUCCESS CHRISTMAS; REVASCULARIZATION; METOPROLOL; CARDIOMYOPATHY; METAANALYSIS; IMPROVEMENT	Background The improvement in left-ventricular ejection fraction (LVEF) in response to beta blockers is heterogeneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations in the myocardial substrate underlying left-ventricular dysfunction. We investigated whether improvement in LVEF was associated with the volume of hibernating myocardium (viable myocardium with contractile failure). Methods We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction. We enrolled 489 patients, of whom 387 were randomised. Patients were designated hibernators or non-hibernators according to the volume of hibernating myocardium. The primary endpoint was change in LVEF, measured by radionuclide ventriculography, in hibernators versus non-hibernators, on carvedilol compared with placebo. Analysis was by intention to treat. Results 82 patients dropped out of the study because of adverse events, withdrawal of consent, or failure to complete the investigation. Thus, 305 (79%) were analysed. LVEF was unchanged with placebo (mean change -0.4 [SE 0.9] and -0.4 [0.8] for non-hibernators and hibernators, respectively) but increased with carvedilol (2.5 [0.9] and 32 [0.8], respectively; p<0.0001 compared with baseline). Mean placebo-subtracted change in LVEF was 32% (95% CI 1.8-4.7; p=0.0001) overall, and 2.9% (0.7-5.1; p=0.011) and 3.6% (1.7-5.4; p=0.0002) in non-hibernators and hibernators, respectively. Effect of hibernator status on response of LVEF to carvedilol was not significant (0.7 [-2.2 to 3.5]; p=0.644). However, patients with more myocardium affected by hibernation or by hibernation and ischaemia had a greater increase in LVEF on carvedilol (p=0.0002 and p=0.009, respectively). Interpretation Some of the effect of carvedilol on LVEF might be mediated by improved function of hibernating or ischaemic myocardium, or both. Medical treatment might be an important adjunct or alternative to revascularisation for patients with hibernating myocardium.	Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU16 5JQ, Yorks, England; Royal Brompton Hosp, London SW3 6LY, England; Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Osped Pieve Cadore, Pieve Di Cadore, Italy; Assaf Harofeh Hosp, Zerifin, Israel; Northwick Pk Hosp & Clin Res Ctr, Harrow HA1 3UJ, Middx, England	University of Hull; Royal Brompton Hospital; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Glasgow; University of Edinburgh; ULSS 1 Dolomiti; Ospedale di Pieve di Cadore; Shamir Medical Center (Assaf Harofeh); Imperial College London	Cleland, JGF (corresponding author), Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU16 5JQ, Yorks, England.		Cleland, John G./AAZ-4185-2020; Coats, Andrew J Stewart/E-4451-2012	Cleland, John G./0000-0002-1471-7016; Coats, Andrew J Stewart/0000-0002-2771-4260; Pennell, Dudley/0000-0001-5523-1314; Murray, Gordon/0000-0001-9866-4734				Allman KC, 2002, J AM COLL CARDIOL, V39, P1151, DOI 10.1016/S0735-1097(02)01726-6; Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; Bristow MR, 1998, LANCET, V352, P8; Canty JM, 2000, J NUCL CARDIOL, V7, P509, DOI 10.1067/mnc.2000.109683; Chen CG, 1997, J AM COLL CARDIOL, V30, P1407, DOI 10.1016/S0735-1097(97)00309-4; Cleland JGF, 1999, EUR J HEART FAIL, V1, P191, DOI 10.1016/S1388-9842(99)00024-0; Cleland JGF, 2003, EUR J HEART FAIL, V5, P295, DOI 10.1016/S1388-9842(03)00056-4; Cleland JGF, 2002, EUR J HEART FAIL, V4, P243, DOI 10.1016/S1388-9842(02)00039-9; Cleland JGF, 1996, EUR HEART J, V17, P1629; Cleland JGF, 1999, EUR J HEART FAIL, V1, P41, DOI 10.1016/S1388-9842(99)00009-4; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; FEUERSTEIN GZ, 1995, EUR HEART J, V16, P38, DOI 10.1093/eurheartj/16.suppl_F.38; FISHER ML, 1994, J AM COLL CARDIOL, V23, P943, DOI 10.1016/0735-1097(94)90641-6; HALL SA, 1995, J AM COLL CARDIOL, V25, P1154, DOI 10.1016/0735-1097(94)00543-Y; Hjalmarson A, 1999, LANCET, V353, P2001; Kaprielian RR, 1998, CIRCULATION, V97, P651, DOI 10.1161/01.CIR.97.7.651; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Lechat P, 1999, LANCET, V353, P9; Medrano R, 1996, CIRCULATION, V94, P1010, DOI 10.1161/01.CIR.94.5.1010; O'Keefe JH, 2000, J NUCL CARDIOL, V7, P3, DOI 10.1067/mnc.2000.102678; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 2001, AM HEART J, V141, P899, DOI 10.1067/mhj.2001.115584; Pennell DJ, 2000, INT J CARDIOL, V72, P265, DOI 10.1016/S0167-5273(99)00198-9; Schwarz ER, 1998, J AM COLL CARDIOL, V31, P1018, DOI 10.1016/S0735-1097(98)00041-2; UNVERFERTH DV, 1983, AM HEART J, V105, P176, DOI 10.1016/0002-8703(83)90305-8; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426	26	201	210	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					14	21		10.1016/S0140-6736(03)13801-9	http://dx.doi.org/10.1016/S0140-6736(03)13801-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853194				2022-12-28	WOS:000184056900008
J	Munker, C; Pfander, JA; Weyer, S; Buchl, A; Kleine, T; Mezger, K				Munker, C; Pfander, JA; Weyer, S; Buchl, A; Kleine, T; Mezger, K			Evolution of planetary cores and the earth-moon system from Nb/Ta systematics	SCIENCE			English	Article							OCEANIC BASALTS; SOLAR-SYSTEM; MANTLE; ORIGIN; ZR/HF; FRACTIONATION; NIOBIUM; IMPACT; NB; DIFFERENTIATION	It has been assumed that Nb and Ta are not fractionated during differentiation processes on terrestrial planets and that both elements are lithophile. High-precision measurements of Nb/Ta and Zr/Hf reveal that Nb is moderately siderophile at high pressures. Nb/Ta values in the bulk silicate Earth (14.0 +/- 0.3) and the Moon (17.0 +/- 0.8) are below the chondritic ratio of 19.9 +/- 0.6, in contrast to Mars and asteroids. The lunar Nb/Ta constrains the mass fraction of impactor material in the Moon to less than 65%. Moreover, the Moon-forming impact can be linked in time with the final core-mantle equilibration on Earth 4.533 billion years ago.	Univ Munster, Inst Mineral, D-48149 Munster, Germany; Max Planck Inst Chem, D-55020 Mainz, Germany	University of Munster; Max Planck Society	Munker, C (corresponding author), Univ Munster, Inst Mineral, Corrensstr 24, D-48149 Munster, Germany.	muenker@nwz.uni-muenster.de	Kleine, Thorsten/S-2792-2017; Mezger, Klaus/D-9502-2011; Munker, Carsten/O-7606-2015; Weyer, Stefan/AAA-8827-2020	Kleine, Thorsten/0000-0003-4657-5961; Mezger, Klaus/0000-0002-2443-8539; Munker, Carsten/0000-0001-6406-559X				Barth MG, 2000, CHEM GEOL, V165, P197, DOI 10.1016/S0009-2541(99)00173-4; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Cameron AGW, 2001, METEORIT PLANET SCI, V36, P9, DOI 10.1111/j.1945-5100.2001.tb01806.x; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; David K, 2000, EARTH PLANET SC LETT, V178, P285, DOI 10.1016/S0012-821X(00)00088-1; El Goresy A, 2001, EARTH PLANET SC LETT, V192, P485, DOI 10.1016/S0012-821X(01)00480-0; HART SR, 1993, CONTRIB MINERAL PETR, V113, P1, DOI 10.1007/BF00320827; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; JOCHUM KP, 1986, GEOCHIM COSMOCHIM AC, V50, P1173, DOI 10.1016/0016-7037(86)90400-X; Jochum KP, 2000, METEORIT PLANET SCI, V35, P229, DOI 10.1111/j.1945-5100.2000.tb01771.x; Jochum KP, 2002, GEOCHIM COSMOCHIM AC, V66, pA368; JOCHUM KP, 1996, EOS S, V77, P785; Jones J. H., 2000, ORIGIN EARTH MOON, P197, DOI DOI 10.1016/0016-7037(83)90024-8.; Kamber BS, 2000, CHEM GEOL, V166, P241, DOI 10.1016/S0009-2541(99)00218-1; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; Lee DC, 2002, EARTH PLANET SC LETT, V198, P267, DOI 10.1016/S0012-821X(02)00533-2; Munker C, 1998, CHEM GEOL, V144, P23, DOI 10.1016/S0009-2541(97)00105-8; Munker C, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2001GC000183; MUNKER C, 2001, EOS S, V82, P1173; Niu YL, 1997, EARTH PLANET SC LETT, V148, P471, DOI 10.1016/S0012-821X(97)00048-4; Pfander JA, 2002, GEOCHIM COSMOCHIM AC, V66, pA597; Rudnick RL, 2000, SCIENCE, V287, P278, DOI 10.1126/science.287.5451.278; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Stolz AJ, 1996, GEOLOGY, V24, P587, DOI 10.1130/0091-7613(1996)024<0587:FAMREI>2.3.CO;2; van Westrenen W, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000133; Wade J, 2001, NATURE, V409, P75, DOI 10.1038/35051064; WANKE H, 1975, P LUNAR PLANET SCI C, V6, P1313; Weyer S, 2003, EARTH PLANET SC LETT, V205, P309, DOI 10.1016/S0012-821X(02)01059-2; Weyer S, 2002, CHEM GEOL, V187, P295, DOI 10.1016/S0009-2541(02)00129-8; Yi W, 2000, J GEOPHYS RES-SOL EA, V105, P18927, DOI 10.1029/2000JB900152; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995	33	321	350	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					84	87		10.1126/science.1084662	http://dx.doi.org/10.1126/science.1084662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843390				2022-12-28	WOS:000183914700037
J	Kim, J; Chung, YD; Park, DY; Choi, SK; Shin, DW; Soh, H; Lee, HW; Son, W; Yim, J; Park, CS; Kernan, MJ; Kim, C				Kim, J; Chung, YD; Park, DY; Choi, SK; Shin, DW; Soh, H; Lee, HW; Son, W; Yim, J; Park, CS; Kernan, MJ; Kim, C			A TRPV family ion channel required for hearing in Drosophila	NATURE			English	Article							REGULATORY FACTOR-X; CAPSAICIN-RECEPTOR; MECHANOSENSORY TRANSDUCTION; HEAT; EXPRESSION; MECHANISMS; ACTIVATION; ELEGANS; PROTEIN; GENOME	The many types of insect ear share a common sensory element, the chordotonal organ, in which sound-induced antennal or tympanal vibrations are transmitted to ciliated sensory neurons and transduced to receptor potentials(1,2). However, the molecular identity of the transducing ion channels in chordotonal neurons, or in any auditory system, is still unknown(3,4). Drosophila that are mutant for NOMPC, a transient receptor potential (TRP) superfamily ion channel, lack receptor potentials and currents in tactile bristles(5,6) but retain most of the antennal sound-evoked response(7), suggesting that a different channel is the primary transducer in chordotonal organs. Here we describe the Drosophila Nanchung (Nan) protein, an ion channel subunit similar to vanilloid-receptor-related (TRPV) channels of the TRP superfamily. Nan mediates hypo-osmotically activated calcium influx and cation currents in cultured cells. It is expressed in vivo exclusively in chordotonal neurons and is localized to their sensory cilia. Antennal sound-evoked potentials are completely absent in mutants lacking Nan, showing that it is an essential component of the chordotonal mechanotransducer.	Hanwha Chem Co R&D Ctr, Dept Genet, Taejon 305345, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 305764, South Korea; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; K JIST, Dept Life Sci, Gwangju 500712, South Korea; Seoul Natl Univ, Natl Creat Res Inst Genet Reprogramming, Seoul 151742, South Korea	Chungnam National University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Gwangju Institute of Science & Technology (GIST); Seoul National University (SNU)	Kim, C (corresponding author), Hanwha Chem Co R&D Ctr, Dept Genet, Taejon 305345, South Korea.		Kim, Janghwan/B-4522-2009	Park, Chul-Seung/0000-0003-0209-1412; Kernan, Maurice/0000-0002-1546-6159; Son, Wonseok/0000-0003-1623-1236	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002780] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC002780] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; BRAND AH, 1993, DEVELOPMENT, V118, P401; Caldwell JC, 2002, J NEUROBIOL, V53, P172, DOI 10.1002/neu.10126; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung YD, 2001, NEURON, V29, P415, DOI 10.1016/S0896-6273(01)00215-X; Colbert HA, 1997, J NEUROSCI, V17, P8259; Dubruille R, 2002, DEVELOPMENT, V129, P5487, DOI 10.1242/dev.00148; Eberl DF, 1999, CURR OPIN NEUROBIOL, V9, P389, DOI 10.1016/S0959-4388(99)80058-0; Eberl DF, 2000, J NEUROSCI, V20, P5981, DOI 10.1523/JNEUROSCI.20-16-05981.2000; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Strassmaier M, 2002, CURR OPIN NEUROBIOL, V12, P380, DOI 10.1016/S0959-4388(02)00344-6; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Vandaele C, 2001, MECH DEVELOP, V103, P159, DOI 10.1016/S0925-4773(01)00340-9; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200; Yager DD, 1999, MICROSC RES TECHNIQ, V47, P380, DOI 10.1002/(SICI)1097-0029(19991215)47:6<380::AID-JEMT3>3.0.CO;2-P	27	281	303	4	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					81	84		10.1038/nature01733	http://dx.doi.org/10.1038/nature01733			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12819662				2022-12-28	WOS:000183912800044
J	Ferguson, TB; Peterson, ED; Coombs, LP; Eiken, MC; Carey, ML; Grover, FL; DeLong, ER				Ferguson, TB; Peterson, ED; Coombs, LP; Eiken, MC; Carey, ML; Grover, FL; DeLong, ER		Soc Thoracic Surg Natl Cardiac Dat	Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BETA-BLOCKER USE; NEW-YORK-STATE; COOPERATIVE CARDIOVASCULAR PROJECT; STS NATIONAL DATABASE; CARDIAC-SURGERY; HEALTH-CARE; OPERATIVE MORTALITY; HOSPITAL MORTALITY; IMPROVING QUALITY	Context A rigorous evaluation of continuous quality improvement (CQI) in medical practice has not been carried out on a national scale. Objective To test whether low-intensity CQI interventions can be used to speed the, national adoption of 2 coronary artery bypass graft (CABG) surgery process-of-care measures: preoperative beta-blockade therapy and internal mammary artery (IMA) grafting in patients 75 years or older. Design, Setting, and Participants Three hundred fifty-nine academic and nonacademic hospitals (treating 267917 patients using CABG surgery) participating in the Society of Thoracic Surgeons National Cardiac Database between January 2000 and July 2002 were randomized to a control arm or to 1 of 2 groups that used CQI interventions designed to increase use of the process-of-care measures. Intervention Each intervention group received measure-specific information, including a call to action to a physician leader; educational products; and periodic longitudinal, nationally benchmarked, site-specific feedback. Main Outcome Measure Differential incorporation of the targeted care processes into practice at the intervention sites vs the control sites, assessed by measuring preintervention (January-December 2000)/postintervention (January 2001 -July 2002) site differences and by using a hierarchical patient-level analysis. Results From January 2000 to July 2002, use of both process measures increased nationally (beta-blockade, 60.0%-65.6%; IMA grafting, 76.2%-82.8%). Use of beta-blockade increased significantly more at beta-blockade intervention sites (7.3% [SD, 12.8%]) vs control sites (3.6% [SD, 11.5%]) in the preintervention/ postintervention (P=.04) and hierarchical analyses (P<.001). Use of IMA grafting also tended to increase at IMA intervention sites (8.7% [SD, 17.5%]) vs control sites (5.4% [SD,15.8%]) (P=.20 and P=.11 for preintervention/postintervention and hierarchical analyses, respectively). Both interventions tended to have more impact at lower-volume CABG sites (for interaction: P=.04 for &beta;-blockade; P=.02 for IMA grafting). Conclusions A multifaceted, physician-led, low-intensity CQI effort can improve the adoption of care processes into national practice within the context of a medical specialty society infrastructure.	Louisiana State Univ, Hlth Sci Ctr, Dept Surg, New Orleans, LA 70119 USA; Louisiana State Univ, Hlth Sci Ctr, Cardiovasc Outcomes Res Grp, New Orleans, LA 70119 USA; Duke Univ, Duke Clin Res Inst, Durham, NC USA; Soc Thorac Surg, Chicago, IL USA; Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80262 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Duke University; Society of Thoracic Surgeons; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ferguson, TB (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Surg, 3535 Bienville St,Suite E-325, New Orleans, LA 70119 USA.		Peterson, Eric David/ABF-5033-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010403] Funding Source: NIH RePORTER; AHRQ HHS [R0-1 HS 10403] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; BOERSMA E, 2001, JAMA-J AM MED ASSOC, V285, P1965; Bradley EH, 2001, JAMA-J AM MED ASSOC, V285, P2604, DOI 10.1001/jama.285.20.2604; Cameron A, 1996, NEW ENGL J MED, V334, P216, DOI 10.1056/NEJM199601253340402; Chassin MR, 2002, HEALTH AFFAIR, V21, P40, DOI 10.1377/hlthaff.21.4.40; CLARK RE, 1994, ANN THORAC SURG, V57, P20, DOI 10.1016/0003-4975(94)90359-X; Codman EA, 1917, STUDY HOSP EFFICIENC; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; EDWARDS FH, 1994, ANN THORAC SURG, V57, P27, DOI 10.1016/0003-4975(94)90360-3; Ferguson TB, 2002, JAMA-J AM MED ASSOC, V287, P2221, DOI 10.1001/jama.287.17.2221; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Ferguson TB, 2002, J THORAC CARDIOV SUR, V123, P869, DOI 10.1067/mtc.2002.121679; Ferguson TB, 2000, ANN THORAC SURG, V69, P680, DOI 10.1016/S0003-4975(99)01538-6; GARDNER TJ, 1990, ANN THORAC SURG, V49, P188, DOI 10.1016/0003-4975(90)90137-U; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; Goldberg H I, 1998, Jt Comm J Qual Improv, V24, P130; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Grover FL, 2001, ANN SURG, V234, P464, DOI 10.1097/00000658-200110000-00006; GROVER FL, 1994, ANN THORAC SURG, V57, P559, DOI 10.1016/0003-4975(94)90546-0; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Holman WL, 2001, JAMA-J AM MED ASSOC, V285, P3003, DOI 10.1001/jama.285.23.3003; Hsia DC, 2003, JAMA-J AM MED ASSOC, V289, P354, DOI 10.1001/jama.289.3.354; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Juran J. M., 1995, MANAGERIAL BREAKTHRO; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Leavitt BJ, 2001, CIRCULATION, V103, P507, DOI 10.1161/01.CIR.103.4.507; LITTELL RC, 1996, SAS SYSTEM MIXED MOD, P426; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Mehta RH, 2002, JAMA-J AM MED ASSOC, V287, P1269, DOI 10.1001/jama.287.10.1269; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Peterson ED, 2002, ANN THORAC SURG, V74, P464, DOI 10.1016/S0003-4975(02)03694-9; Phillips KA, 2000, JAMA-J AM MED ASSOC, V284, P2748, DOI 10.1001/jama.284.21.2748; Sharma SK, 2000, CIRCULATION, V102, P166, DOI 10.1161/01.CIR.102.2.166; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Shroyer ALW, 1999, ANN THORAC SURG, V67, P1205, DOI 10.1016/S0003-4975(99)00206-4; *SOC THOR SURG, 2002, STS NCD EX SUMM; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Weightman WM, 1999, ANESTH ANALG, V88, P286, DOI 10.1097/00000539-199902000-00011; WELKE K, IN PRESS ANN THORAC	48	141	141	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					49	56		10.1001/jama.290.1.49	http://dx.doi.org/10.1001/jama.290.1.49			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837711	Bronze			2022-12-28	WOS:000183868600019
J	Boulanger, MJ; Chow, DC; Brevnova, EE; Garcia, KC				Boulanger, MJ; Chow, DC; Brevnova, EE; Garcia, KC			Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex	SCIENCE			English	Article							PROXIMAL EXTRACELLULAR DOMAINS; RECEPTOR COMPLEXES; CRYSTAL-STRUCTURE; GP130; ACTIVATION; CYTOKINES; DISTINCT; PROGRAM; FAMILY; SITES	Interleukin-6 (IL-6) is an immunoregulatory cytokine that activates a cell-surface signaling assembly composed of IL-6, the IL-6 alpha-receptor (IL-6Ralpha), and the shared signaling receptor gp130. The 3.65 angstrom - resolution structure of the extracellular signaling complex reveals a hexameric, interlocking assembly mediated by a total of 10 symmetry-related, thermodynamically coupled interfaces. Assembly of the hexameric complex occurs sequentially: IL-6 is. rst engaged by IL-6Ralpha and then presented to gp130 in the proper geometry to facilitate a cooperative transition into the high-affinity, signaling-competent hexamer. The quaternary structures of other IL-6/IL-12 family signaling complexes are likely constructed by means of a similar topological blueprint.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild D319,299 Campus Dr, Stanford, CA 94305 USA.	kcgarcia@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051321] Funding Source: NIH RePORTER; NIAID NIH HHS [AI51321] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; Benigni F, 1996, BLOOD, V87, P1851, DOI 10.1182/blood.V87.5.1851.bloodjournal8751851; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Chow DC, 2002, BBA-MOL CELL RES, V1592, P225, DOI 10.1016/S0167-4889(02)00317-8; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Chow DC, 2001, BIOCHEMISTRY-US, V40, P7593, DOI 10.1021/bi010192q; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Grotzinger J, 1997, PROTEINS, V27, P96; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Timmermann A, 2002, EUR J BIOCHEM, V269, P2716, DOI 10.1046/j.1432-1033.2002.02941.x; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; WARD LD, 1994, J BIOL CHEM, V269, P23286	22	444	491	4	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2101	2104		10.1126/science.1083901	http://dx.doi.org/10.1126/science.1083901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829785				2022-12-28	WOS:000183774900049
J	Chlebowski, RT; Hendrix, SL; Langer, RD; Stefanick, ML; Gass, M; Lane, D; Rodabough, RJ; Gilligan, MA; Cyr, MG; Thomson, CA; Khandekar, J; Petrovitch, H; McTiernan, A				Chlebowski, RT; Hendrix, SL; Langer, RD; Stefanick, ML; Gass, M; Lane, D; Rodabough, RJ; Gilligan, MA; Cyr, MG; Thomson, CA; Khandekar, J; Petrovitch, H; McTiernan, A		WHI Investigators	Influence of estrogen plus progestin on breast, cancer and mammography in healthy postmenopausal women - The Women's Health Initiative Randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; RISK REDUCTION; TAMOXIFEN; CARCINOMA; BENEFITS; DENSITY; TERM	Context The Women's Health Initiative trial of combined estrogen plus progestin was stopped early when overall health risks, including invasive breast cancer, exceeded benefits. Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography. Objective To determine the relationship among estrogen plus progestin use, breast cancer characteristics, and mammography recommendations. Design, Setting, and Participants Following a comprehensive breast cancer risk assessment, 16608 postmenopausal women aged 50 to 79 years with an intact uterus were randomly assigned to receive combined conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) or placebo from 1993 to 1998 at 40 clinical centers. Screening mammography and clinical breast examinations were performed at baseline and yearly thereafter. Main Outcome Measures Breast cancer number and characteristics, and frequency of abnormal mammograms by estrogen plus progestin exposure. Results In intent-to-treat analyses, estrogen plus progestin increased total (245 vs 185 cases; hazard ratio [HR], 1.24; weighted P<001) and invasive (199 vs 150 cases; HR, 1.24; weighted P=.003) breast cancers compared with placebo. The invasive breast cancers diagnosed in the estrogen plus progestin group were similar in histology and grade but were larger (mean [SD], 1.7 cm [1.11 vs 1.5 cm [0.9], respectively; P=.04) and were at more advanced stage (regional/metastatic 25.4% vs 16.0%, respectively; P=.04) compared with those diagnosed in the placebo group. After 1 year, the percentage of women with abnormal mammograms was substantially greater in the estrogen plus progestin group (716 [9.4%] of 7656) compared with placebo group (398 [5.4%] of 7310; P<001), a pattern which continued for the study duration. Conclusions Relatively short-term combined estrogen plus progestin use increases incident breast cancers, which are diagnosed at a more advanced stage compared with placebo use, and also substantially increases the percentage of women with abnormal mammograms. These results suggest estrogen plus progestin may stimulate breast cancer growth and hinder breast cancer diagnosis.	Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; Wayne State Univ, Detroit, MI USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Stanford Univ, Dept Med, Palo Alto, CA 94304 USA; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Brown Med Sch, Dept Med, Providence, RI USA; Univ Arizona, Tucson, AZ USA; Evanston NW Healthcare, Dept Med, Evanston, IL USA; Univ Hawaii, John A Burns Sch Med, Dept Geriatr & Med, Honolulu, HI 96822 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Wayne State University; University of California System; University of California San Diego; Stanford University; University System of Ohio; University of Cincinnati; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Fred Hutchinson Cancer Center; Medical College of Wisconsin; Brown University; University of Arizona; NorthShore University Health System; University of Hawaii System	Chlebowski, RT (corresponding author), Harbor UCLA Res & Educ Inst, 1124 W Carson St,Bldg J-3, Torrance, CA 90502 USA.							*AM COLL OBST GYN, 2002, INT J GYNECOL OBSTET, V76, P333; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; Barton MB, 2001, J GEN INTERN MED, V16, P150, DOI 10.1111/j.1525-1497.2001.00329.x; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Chlebowski RT, 2002, J CLIN ONCOL, V20, P3328, DOI 10.1200/JCO.2002.06.029; Chlebowski RT, 2003, JNCI-J NATL CANCER I, V95, P4, DOI 10.1093/jnci/95.1.4; Chlebowski RT, 2002, ANNU REV MED, V53, P519, DOI 10.1146/annurev.med.53.082901.103925; Cobleigh MA, 1999, JAMA-J AM MED ASSOC, V281, P1528, DOI 10.1001/jama.281.16.1528; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Daling JR, 2002, CANCER-AM CANCER SOC, V95, P2455, DOI 10.1002/cncr.10984; Delgado RC, 2001, MATURITAS, V38, P147, DOI 10.1016/S0378-5122(00)00213-9; Gail MH, 1999, J NATL CANCER I, V91, P1829, DOI 10.1093/jnci/91.21.1829; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; GORDON NP, 1993, J NATL CANCER I, V85, P566, DOI 10.1093/jnci/85.7.566; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; LeBlanc ES, 1999, J WOMEN HEALTH GEN-B, V8, P815, DOI 10.1089/152460999319138; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; Lower EE, 1999, BREAST CANCER RES TR, V58, P205, DOI 10.1023/A:1006315607241; Manjer J, 2001, INT J CANCER, V92, P919, DOI 10.1002/ijc.1279; Marsden J, 2002, LANCET ONCOL, V3, P303, DOI 10.1016/S1470-2045(02)00732-5; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Pilon D, 2001, OBSTET GYNECOL, V97, P97, DOI 10.1016/S0029-7844(00)01104-2; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sacchini V, 2002, ANN SURG ONCOL, V9, P266, DOI 10.1245/aso.2002.9.3.266; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Thurfjell E, 2002, NEW ENGL J MED, V347, P866, DOI 10.1056/NEJMp020093; Whiteman MK, 2001, J WOMEN HEALTH GEN-B, V10, P571, DOI 10.1089/15246090152543157	38	1373	1435	0	78	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3243	3253		10.1001/jama.289.24.3243	http://dx.doi.org/10.1001/jama.289.24.3243			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824205	Bronze			2022-12-28	WOS:000183704600017
J	Smith, SM				Smith, SM			10-minute consultation - Newly diagnosed type 2 diabetes mellitus	BRITISH MEDICAL JOURNAL			English	Article									Natl Childrens Hosp, Adelaide & Meath Hosp, Trinity Coll, Ctr Hlth Sci,Dept Community Hlth & Gen Practice, Dublin 24, Ireland	Trinity College Dublin	Smith, SM (corresponding author), Natl Childrens Hosp, Adelaide & Meath Hosp, Trinity Coll, Ctr Hlth Sci,Dept Community Hlth & Gen Practice, Dublin 24, Ireland.		Smith, Susan/D-1872-2012	Smith, Susan/0000-0001-6027-2727					0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1371	1371		10.1136/bmj.326.7403.1371	http://dx.doi.org/10.1136/bmj.326.7403.1371			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816825	Green Published, Bronze			2022-12-28	WOS:000183756400023
J	Terzano, C; Petroianni, A				Terzano, C; Petroianni, A			Clarithromycin and pulmonary infiltration with eosinophilia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DISEASE; HYPERSENSITIVITY; PATIENT		Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Resp Dis Unit, Rome, Italy	Sapienza University Rome	Terzano, C (corresponding author), Via Ugo Bartolomei 18, I-00136 Rome, Italy.	cterzano@tin.it		TERZANO, CLAUDIO/0000-0002-9851-7731				ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; Amayasu H, 2000, ANN ALLERG ASTHMA IM, V84, P594, DOI 10.1016/S1081-1206(10)62409-X; Camus P, 2001, EUR RESPIR J, V18, p93S; Demoly P, 2000, PRESSE MED, V29, P321; GIRARD JP, 1967, AM J MED, V42, P441, DOI 10.1016/0002-9343(67)90272-0; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Kranke B, 1997, LANCET, V350, P1551, DOI 10.1016/S0140-6736(05)63984-0; LOPEZ M, 1992, IMMUNOL ALLERGY CLIN, V12, P349; MEGURO H, 1989, Japanese Journal of Antibiotics, V42, P255; Oermann CM, 2000, J PEDIATR-US, V136, P351, DOI 10.1067/mpd.2000.103350; Ozkan M, 2001, CLEV CLIN J MED, V68, P782, DOI 10.3949/ccjm.68.9.782; POE RH, 1980, CHEST, V77, P449, DOI 10.1378/chest.77.3.449; REEDER WH, 1952, ANN INTERN MED, V36, P1217, DOI 10.7326/0003-4819-36-5-1217; Robinson J, 1999, ANN ALLERG ASTHMA IM, V82, P144, DOI 10.1016/S1081-1206(10)62588-4; ROSENOW EC, 1992, CHEST, V102, P239, DOI 10.1378/chest.102.1.239; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SPRY CJF, 1980, CLIN HAEMATOL, V9, P521; Uno K, 1995, Arerugi, V44, P1401; YONEMARU M, 1992, CHEST, V102, P1907, DOI 10.1378/chest.102.6.1907; Zalewska-Kaszubska J, 2001, PHARMACOL RES, V44, P451, DOI 10.1006/phrs.2001.0884	20	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2003	326	7403					1377	1378		10.1136/bmj.326.7403.1377	http://dx.doi.org/10.1136/bmj.326.7403.1377			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816827	Green Published			2022-12-28	WOS:000183756400025
J	George, WD; Houghton, J; Austoker, J; Bishop, H; Cuzick, J; Fentiman, IS; Forbes, JF; Foster, E; Ellis, I; Leinster, S; Spittle, M; Joslin, C; Stewart, H; Baum, M; Campbell, R; Elston, C; Stroner, P; Taylor, I; Teasdale, C; Cooke, T; MacPherson, K; Priestman, T; Sloane, J; Houghton, J; Williams, N; Riley, D; Moritz, S; Wells, U; Bellenger, K; Coles, E; Chan, J; Foster, E; Stroner, P; MacDonald, C; Douglas, A; Campbell, R; Forbes, JF; Wilson, A; Hornery, S; Lindsay, D				George, WD; Houghton, J; Austoker, J; Bishop, H; Cuzick, J; Fentiman, IS; Forbes, JF; Foster, E; Ellis, I; Leinster, S; Spittle, M; Joslin, C; Stewart, H; Baum, M; Campbell, R; Elston, C; Stroner, P; Taylor, I; Teasdale, C; Cooke, T; MacPherson, K; Priestman, T; Sloane, J; Houghton, J; Williams, N; Riley, D; Moritz, S; Wells, U; Bellenger, K; Coles, E; Chan, J; Foster, E; Stroner, P; MacDonald, C; Douglas, A; Campbell, R; Forbes, JF; Wilson, A; Hornery, S; Lindsay, D		UKCCCR; DCIS Working Party	Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial	LANCET			English	Article							SURGICAL ADJUVANT BREAST; STAGE-I; CANCER; CONSERVATION; MASTECTOMY; LUMPECTOMY; THERAPY; B-17	Background As a consequence of mammographic breast screening programmes, ductal carcinoma in situ is diagnosed with increasing frequency. Mastectomy for localised ductal carcinoma in situ is thought to be an overtreatment by many physicians, but there is much controversy as to whether complete local excision alone is sufficient. We aimed to assess the effectiveness of adjuvant radiotherapy and tamoxifen. Methods We used a 2X2 factorial design in a randomised controlled trial. Between May, 1990, and August, 1998, 1701 patients recruited from screening programmes were randomised to both treatments in combination or singly, or to none, or to either one (eg, radiotherapy) with an elective decision to give or to withhold the other (ie, in this case tamoxifen). Patients had complete surgical excision of the lesion confirmed by specimen radiography and histology. Patients have been followed up at least once a year. Median follow-up was 52.6 (range 2.4-118.3) months. Our primary endpoint was the incidence of ipsilateral invasive disease. Findings lpsilateral invasive disease was not reduced by tamoxifen but recurrence of overall ductal carcinoma in situ was decreased (hazard ratio 0.68 [0.49-0.96]; p=0.03). Radiotherapy reduced the incidence of ipsilateral invasive disease (0.45 [0.24-0.85]; p=0.01) and ipsilateral ductal carcinoma in situ (0.36 [0.19-0.66]; p=0.0004), but there was no effect on the occurrence of contralateral disease. There was no evidence of interaction between radiotherapy and tamoxifen. Interpretation Radiotherapy can be recommended for patients with ductal carcinoma in situ treated by complete local excision; however, there is little evidence for the use of tamoxifen in these women.	Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; UCL, London, England; Univ Oxford, Inst Hlth Sci, Oxford OX1 2JD, England; Royal Bolton Hosp, Bolton, England; Imperial Canc Res Fund, London WC2A 3PX, England; Guys Hosp, London SE1 9RT, England; Mater Misericordiae Univ Hosp, Newcastle, NSW, Australia; Scottish Canc Therapy Network Cent Off, Edinburgh, Midlothian, Scotland; City Hosp Nottingham, Nottingham, England; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; Middlesex Hosp, London, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; New Cross Hosp, Wolverhampton, W Midlands, England; Royal Liverpool Infirm, Liverpool, Merseyside, England	University of Glasgow; University of London; University College London; University of Oxford; Royal Bolton Hospital; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University College Dublin; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of East Anglia; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; New Cross Hospital	Houghton, J (corresponding author), Royal Free & Univ Coll Med Sch, Dept Surg, Clin Trials Grp, Charles Bell House, London W1W 7EJ, England.	j.houghton@ctg.ucl.ac.uk	Duggan, Catherine/F-9414-2015; Fentiman, Ian/AAB-9886-2020; Fentiman, Ian S/I-7644-2019; WILLIAMS, Norman/C-2002-2008	Duggan, Catherine/0000-0001-7369-4021; WILLIAMS, Norman/0000-0001-6496-312X				ANDERSON TJ, 1991, BRIT J CANCER, V64, P108, DOI 10.1038/bjc.1991.251; CUZICK J, 1985, LANCET, V2, P282; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; FORNANDER T, 1989, LANCET, V2, P1070; JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402; Julien JP, 2000, LANCET, V355, P528, DOI 10.1016/S0140-6736(99)06341-2; Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1995, EUR J CANCER, V31A, P1574, DOI 10.1016/0959-8049(95)00271-J	12	452	479	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					95	102		10.1016/S0140-6736(03)13859-7	http://dx.doi.org/10.1016/S0140-6736(03)13859-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867108				2022-12-28	WOS:000184089200007
J	Nordentoft, M; Wandall-Holm, N				Nordentoft, M; Wandall-Holm, N			10 year follow up study of mortality among users of hostels for homeless people in Copenhagen	BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-CITY; CHILDHOOD EXPERIENCES; MEN; ADULTS; INDIVIDUALS; DISORDERS; SHELTERS; OUTCOMES	Objectives To investigate mortality among users of hostels for homeless people in Copenhagen, and to identify predictors of death such as conditions during upbringing, mental illness, and misuse of alcohol and drugs. Design Register based follow up study. Setting Two hostels for homeless people in Copenhagen, Denmark Participants 579 people who stayed in one hostel in Copenhagen in 199 1, and a representative sample of 185 people who stayed in the original hostel and one other in Copenhagen. Main outcome measure Cause specific mortality. Results The age and sex standardised mortality ratio for both sexes was 3.8 (95% confidence interval 3.5 to 4.1); 2.8 (2.6 to 3.1) for men and 5.6 (4.3 to 6.9) for women. The age and sex standardised mortality ratio for suicide for both sexes was 6.0 (3.9 to 8.1), for death from natural causes 2.6 (2.3 to 2.9), for unintentional injuries 14.6 (11.4 to 17.8), and for unknown cause of death 62.9 (52.7 to 73.2). Mortality was comparatively higher in the younger age groups. It was also significantly higher among homeless people who had stayed in a hostel more than once and stayed fewer than 11 days, compared with the rest of the study group. Risk factors for early death were premature death of the father and misuse of alcohol and sedatives. Conclusion Homeless people staying in hostels, particularly young women, are more likely to die early than the general population. Other predictors of early death include adverse experiences in childhood, such as death of the father, and misuse of alcohol and sedatives.	Bispebjerg Hosp, Dept Psychiat, DK-2400 Copenhagen NV, Denmark	University of Copenhagen; Bispebjerg Hospital	Nordentoft, M (corresponding author), Bispebjerg Hosp, Dept Psychiat, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.		Nordentoft, Merete/AAH-3253-2019	Nordentoft, Merete/0000-0003-4895-7023				ALSTROM CH, 1975, BRIT J ADDICT, V70, P245; *AM PSYCH ASS, 1987, AM PSYCH ASS DIAGN C; Armitage P., 1987, STAT METHODS MED RES; Barrow S M, 1991, New Dir Ment Health Serv, P29; Barrow SM, 1999, AM J PUBLIC HEALTH, V89, P529, DOI 10.2105/AJPH.89.4.529; BRANDT P, 1987, NORD PSYKIATR TIDSSK, V41, P295; *DUNDH, 2002, DOD 1999; FEITEL B, 1992, HOSP COMMUNITY PSYCH, V43, P155; HANSEN EJ, 1986, WELFARDSUNDERSOGELSE; HANSEN EJ, 1986, VELFAERDSUNDERSOGELS; HANSEN EJ, 1988, DATAMATERIALE DDA 10; Herman DB, 1997, AM J PUBLIC HEALTH, V87, P249, DOI 10.2105/AJPH.87.2.249; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; Hwang SW, 2000, JAMA-J AM MED ASSOC, V283, P2152, DOI 10.1001/jama.283.16.2152; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; KOMMUNE SKK, 1997, KOBENHAVNS STAT ARBO; Martens W H, 2001, Public Health Rev, V29, P13; Shern DL, 2000, AM J PUBLIC HEALTH, V90, P1873, DOI 10.2105/AJPH.90.12.1873; Shern DL, 1997, PSYCHIATR SERV, V48, P239; *SUNDH, 2002, DODS 1999; SUSSER E, 1989, ARCH GEN PSYCHIAT, V46, P845; SUSSER E, 1987, AM J PSYCHIAT, V144, P1599; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	24	110	112	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					81	83		10.1136/bmj.327.7406.81	http://dx.doi.org/10.1136/bmj.327.7406.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855527	Bronze, Green Published			2022-12-28	WOS:000184229400020
J	Greenberg, EP				Greenberg, EP			Tiny teamwork	NATURE			English	Editorial Material									Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Greenberg, EP (corresponding author), Univ Iowa, Carver Coll Med, Iowa City, IA 52242 USA.			Greenberg, Everett/0000-0001-9474-8041				Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x	4	69	75	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					134	134		10.1038/424134a	http://dx.doi.org/10.1038/424134a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853935	Bronze			2022-12-28	WOS:000184032700022
J	Jonsson, S; Segall, P; Pedersen, R; Bjornsson, G				Jonsson, S; Segall, P; Pedersen, R; Bjornsson, G			Post-earthquake ground movements correlated to pore-pressure transients	NATURE			English	Article							HECTOR-MINE-EARTHQUAKE; ICELAND SEISMIC ZONE; JUNE 2000/; DEFORMATION; VISCOSITY; BENEATH; RUPTURE; FLOW	Large earthquakes alter the stress in the surrounding crust, leading to triggered earthquakes and aftershocks(1-3). A number of time-dependent processes, including afterslip, pore-fluid flow and viscous relaxation of the lower crust and upper mantle, further modify the stress and pore pressure near the fault, and hence the tendency for triggered earthquakes(4,5). It has proved difficult, however, to distinguish between these processes on the basis of direct field observations, despite considerable effort(6). Here we present a unique combination of measurements consisting of satellite radar interferograms(7) and water-level changes in geothermal wells following two magnitude-6.5 earthquakes in the south Iceland seismic zone. The deformation recorded in the interferograms cannot be explained by either afterslip or viscoelastic relaxation, but is consistent with rebound of a porous elastic material in the first 1-2 months following the earthquakes. This interpretation is confirmed by direct measurements which show rapid (1-2-month) recovery of the earthquake-induced water-level changes. In contrast, the duration of the aftershock sequence is projected to be similar to3.5 years, suggesting that pore-fluid flow does not control aftershock duration. But because the surface strains are dominated by pore-pressure changes in the shallow crust, we cannot rule out a longer pore-pressure transient at the depth of the aftershocks. The aftershock duration is consistent with models of seismicity rate variations based on rate- and state-dependent friction laws.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Stanford Univ, Dept Geophys, Stanford, CA 94305 USA; Nord Volcanol Inst, IS-108 Reykjavik, Iceland; Natl Energy Author, IS-108 Reykjavik, Iceland	Harvard University; Stanford University; University of Iceland	Jonsson, S (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.		Jonsson, Sigurjon/G-4353-2015; Pedersen, Rikke/C-8584-2013	Jonsson, Sigurjon/0000-0001-5378-7079; 				Arnadottir T, 2001, GEOPHYS RES LETT, V28, P4031, DOI 10.1029/2001GL013332; BJORNSSON G, 2001, P 26 WORKSH GEOTH RE, P327; Burgmann R, 2002, B SEISMOL SOC AM, V92, P126, DOI 10.1785/0120000833; CLIFTON A, 2000, AUT M 2000 ABSTR, P1; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Dziewonski AM, 2001, PHYS EARTH PLANET IN, V123, P1, DOI 10.1016/S0031-9201(00)00200-4; EINARSSON P, 1991, TECTONOPHYSICS, V189, P261, DOI 10.1016/0040-1951(91)90501-I; Einarsson P., 1982, J KULL, V32; EINARSSON P, 1981, M EWING SERIES, V4, P141; Freed AM, 2001, NATURE, V411, P180, DOI 10.1038/35075548; HARRIS RA, 1995, NATURE, V375, P221, DOI 10.1038/375221a0; Hofton MA, 1996, J GEOPHYS RES-SOL EA, V101, P25403, DOI 10.1029/96JB02466; NUR A, 1972, SCIENCE, V175, P885, DOI 10.1126/science.175.4024.885; Pedersen R, 2001, GEOPHYS RES LETT, V28, P3341, DOI 10.1029/2001GL013235; PEDERSEN R, IN PRESS EARTH PLANE; Peltzer G, 1998, J GEOPHYS RES-SOL EA, V103, P30131, DOI 10.1029/98JB02302; Pollitz FF, 2001, SCIENCE, V293, P1814, DOI 10.1126/science.1061361; Pollitz FF, 1996, J GEOPHYS RES-SOL EA, V101, P17771, DOI 10.1029/96JB01074; RICE JR, 1976, REV GEOPHYS, V14, P227, DOI 10.1029/RG014i002p00227; Roeloffs E, 1996, ADV GEOPHYS, V37, P135, DOI 10.1016/S0065-2687(08)60270-8; SEGALL P, 1992, PURE APPL GEOPHYS, V139, P535, DOI 10.1007/BF00879950; SIGMUNDSSON F, 1991, GEOPHYS RES LETT, V18, P1131, DOI 10.1029/91GL01342; SIGMUNDSSON F, 1992, GEOPHYS RES LETT, V19, P2123, DOI 10.1029/92GL02209; Toda S, 2002, NATURE, V419, P58, DOI 10.1038/nature00997; Wang H. F., 2001, THEORY LINEAR POROEL; ZEBKER HA, 1994, J GEOPHYS RES-SOL EA, V99, P19617, DOI 10.1029/94JB01179	28	375	404	3	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					179	183		10.1038/nature01776	http://dx.doi.org/10.1038/nature01776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853953				2022-12-28	WOS:000184032700038
J	Joron, M; Brakefield, PM				Joron, M; Brakefield, PM			Captivity masks inbreeding effects on male mating success in butterflies	NATURE			English	Article							BICYCLUS-ANYNANA; CONSERVATION BIOLOGY; EXTINCTION RISK; SONG SPARROWS; DEPRESSION; POPULATIONS; DROSOPHILA; FITNESS; METAPOPULATION; SATYRIDAE	Small isolated populations are frequently genetically less diverse than core populations, resulting in higher homozygosity that can hamper their long-term survival(1-4). The decrease in fitness of organisms owing to matings between relatives is well known from captive and laboratory animals. Such inbreeding can have strongly deleterious effects on life-history traits and survival(5-11), and can be critical to the success of population conservation(2,4,12). Because pedigrees are hard to follow in the wild, most field studies have used marker loci to establish that fitness declines with increasing homozygosity(1,13,14). Very few have experimentally explored the effects of inbreeding in the wild(15), or compared observations in the laboratory with field conditions(8,9). Here, using a technique involving the transfer of marker dusts during copulation, we show that a small decrease in mating success of captive inbred male butterflies in cages is greatly accentuated in conditions with unconstrained flight. Our results have important implications for conservation and for studies of sexual selection because they show that the behaviours underlying patterns of mating can be profoundly influenced by a history of inbreeding or by any restraining experimental conditions.	Leiden Univ, Inst Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Joron, M (corresponding author), UCL, Galton Lab, 4 Stephenson Way, London NW1 2HE, England.	m.joron@ucl.ac.uk; brakefield@rulsfb.leidenuniv.nl	Joron, Mathieu/C-9178-2009	Joron, Mathieu/0000-0003-1043-4147				Armbruster P, 2000, P ROY SOC B-BIOL SCI, V267, P1939, DOI 10.1098/rspb.2000.1233; Bijlsma R, 2000, J EVOLUTION BIOL, V13, P502, DOI 10.1046/j.1420-9101.2000.00177.x; Brakefield PM, 2001, J EVOLUTION BIOL, V14, P148, DOI 10.1046/j.1420-9101.2001.00248.x; BRAKEFIELD PM, 1991, ECOL ENTOMOL, V16, P291, DOI 10.1111/j.1365-2311.1991.tb00220.x; Breuker CJ, 2002, P ROY SOC B-BIOL SCI, V269, P1233, DOI 10.1098/rspb.2002.2005; Coulson TN, 1998, J ANIM ECOL, V67, P434, DOI 10.1046/j.1365-2656.1998.00205.x; DeRose MA, 1999, EVOLUTION, V53, P1288, DOI 10.2307/2640831; Ebert D, 2002, SCIENCE, V295, P485, DOI 10.1126/science.1067485; Hanski I., 1996, METAPOPULATION BIOL; Hedrick PW, 2000, ANNU REV ECOL SYST, V31, P139, DOI 10.1146/annurev.ecolsys.31.1.139; Hoglund J, 2002, P ROY SOC B-BIOL SCI, V269, P711, DOI 10.1098/rspb.2001.1937; JIMENEZ JA, 1994, SCIENCE, V266, P271, DOI 10.1126/science.7939661; KELLER LF, 1994, NATURE, V372, P356, DOI 10.1038/372356a0; Keller LF, 2002, TRENDS ECOL EVOL, V17, P230, DOI 10.1016/S0169-5347(02)02489-8; Lynch M., 1998, GENETICS ANAL QUANTI; Madsen T, 1999, NATURE, V402, P34, DOI 10.1038/46941; Marr AB, 2002, EVOLUTION, V56, P131; Meagher S, 2000, P NATL ACAD SCI USA, V97, P3324, DOI 10.1073/pnas.060284797; MEFFERT LM, 1991, EVOLUTION, V45, P293, DOI 10.1111/j.1558-5646.1991.tb04404.x; MILLER PS, 1993, GENETICA, V88, P29, DOI 10.1007/BF02424449; MILLER PS, 1993, ZOO BIOL, V12, P333, DOI 10.1002/zoo.1430120404; Nieminen M, 2001, AM NAT, V157, P237, DOI 10.1086/318630; Roff DA, 2001, EVOLUTION, V55, P111, DOI 10.1111/j.0014-3820.2001.tb01277.x; Saccheri I, 1998, NATURE, V392, P491, DOI 10.1038/33136; Saccheri IJ, 1996, EVOLUTION, V50, P2000, DOI 10.1111/j.1558-5646.1996.tb03587.x; Saccheri IJ, 2002, P ROY SOC B-BIOL SCI, V269, P1073, DOI 10.1098/rspb.2002.1963; SMITH J. M., 1956, JOUR GENETICS, V54, P261, DOI 10.1007/BF02982781; Sokal R.R., 2012, BIOMETRY; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; van Oosterhout C, 2000, EVOLUTION, V54, P218, DOI 10.1554/0014-3820(2000)054[0218:IDAGLI]2.0.CO;2	30	129	130	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					191	194		10.1038/nature01713	http://dx.doi.org/10.1038/nature01713			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853956				2022-12-28	WOS:000184032700041
J	Miller-Butterworth, CM; Jacobs, DS; Harley, EH				Miller-Butterworth, CM; Jacobs, DS; Harley, EH			Strong population substructure is correlated with morphology and ecology in a migratory bat	NATURE			English	Article							LONG-FINGERED BAT; MITOCHONDRIAL-DNA; MINIOPTERUS-SCHREIBERSII; GENETIC-STRUCTURE; MICROSATELLITE DATA; PHILOPATRY; DISPERSAL; MTDNA	Examining patterns of inter-population genetic diversity can provide valuable information about both historical and current evolutionary processes affecting a species. Population genetic studies of flying and migratory species such as bats and birds have traditionally shown minimal population substructure, characterized by high levels of gene flow between populations(1,2). In general, strongly substructured mammalian populations either are separated by non-traversable barriers or belong to terrestrial species with low dispersal abilities(3). Species with female philopatry ( the tendency to remain in or consistently return to the natal territory) might show strong substructure when examined with maternally inherited mitochondrial DNA, but this substructure generally disappears when biparentally inherited markers are used, owing to male-mediated gene flow(4). Male-biased dispersal is considered typical for mammals(5), and philopatry in both sexes is rare. Here we show strong population substructure in a migratory bat species, and philopatry in both sexes, as indicated by concordance of nuclear and mtDNA findings. Furthermore, the genetic structure correlates with local biomes and differentiation in wing morphology. There is therefore a close correlation of genetic and morphological differentiation in sympatric subspecific populations of this mammalian species.	Univ Cape Town, Dept Zool, ZA-7701 Rondebosch, South Africa; Univ Cape Town, Div Chem Pathol, Wildlife Genet Unit, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town	Miller-Butterworth, CM (corresponding author), NCI, Lab Genom Divers, POB B, Frederick, MD 21702 USA.	cbutterworth@mail.ncifcrf.gov	Miller-Butterworth, Cassandra/H-5994-2013; Jacobs, David Steve/L-9118-2013	Jacobs, David Steve/0000-0002-3243-8571				AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; [Anonymous], 1997, VEGETATION SO AFRICA; AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.es.18.110187.002421; BALL RM, 1988, P NATL ACAD SCI USA, V85, P1558, DOI 10.1073/pnas.85.5.1558; BERNARD RTF, 1994, J ZOOL, V232, P485, DOI 10.1111/j.1469-7998.1994.tb01589.x; Burland TM, 1999, P ROY SOC B-BIOL SCI, V266, P975, DOI 10.1098/rspb.1999.0732; Cardinal BR, 2000, AUST J ZOOL, V48, P1, DOI 10.1071/ZO99067; FENTON MB, 1990, CAN J ZOOL, V68, P411, DOI 10.1139/z90-061; Goodman SJ, 1997, MOL ECOL, V6, P881, DOI 10.1046/j.1365-294X.1997.00260.x; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HARLEY EH, 2000, BAT RES NEWS, V41, P99; Kerth G, 2000, MOL ECOL, V9, P793, DOI 10.1046/j.1365-294x.2000.00934.x; MCCRACKEN GF, 1994, J MAMMAL, V75, P500, DOI 10.2307/1382574; Miller-Butterworth CM, 2002, MOL ECOL NOTES, V2, P139, DOI 10.1046/j.1471-8286.2002.00170.x; Moore SS, 1998, ANIM GENET, V29, P33, DOI 10.1046/j.1365-2052.1998.00234.x; NORBERG U M, 1987, Philosophical Transactions of the Royal Society of London B Biological Sciences, V316, P335, DOI 10.1098/rstb.1987.0030; NORMAN JA, 1994, MOL ECOL, V3, P363, DOI 10.1111/j.1365-294X.1994.tb00076.x; Paetkau D, 1997, GENETICS, V147, P1943; Palmeirim JM, 1995, SYM ZOOL S, P219; Petit E, 1999, P ROY SOC B-BIOL SCI, V266, P1717, DOI 10.1098/rspb.1999.0837; Racey Paul A., 2000, P363, DOI 10.1016/B978-012195670-7/50010-2; RAUTENBACH IL, 1988, KOEDOE, V31, P77; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; SAUNDERS MB, 1992, ECOLOGY, V73, P1335, DOI 10.2307/1940680; THOMPSON MJA, 1992, J ZOOL, V228, P673, DOI 10.1111/j.1469-7998.1992.tb04466.x; Van der Merwe M., 1973, Mammalia, V37, P379, DOI 10.1515/mamm.1973.37.3.379; WILKINSON GS, 1985, BEHAV ECOL SOCIOBIOL, V17, P123; WILKINSON GS, 1991, GENETICS, V128, P607; Wilmer Jessica Worthington, 1996, Bat Research News, V37, P1; Worthington Wilmer J., 1994, Proceedings of the Royal Society of London Series B Biological Sciences, V257, P193	30	96	98	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					187	191		10.1038/nature01742	http://dx.doi.org/10.1038/nature01742			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853955				2022-12-28	WOS:000184032700040
J	Dana, J; Loewenstein, G				Dana, J; Loewenstein, G			A social science perspective on gifts to physicians from industry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHARMACEUTICAL SALES REPRESENTATIVES; ATTITUDES; HOUSESTAFF; RESIDENTS; FAIRNESS; FACULTY		Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Dana, J (corresponding author), Carnegie Mellon Univ, Dept Social & Decis Sci, 208 Porter hall, Pittsburgh, PA 15213 USA.		Loewenstein, George/G-7616-2014	Loewenstein, George/0000-0003-2790-0474				American Medical Student Association, AMSA POL PHARM PROM; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Babcock L, 1997, J ECON PERSPECT, V11, P109, DOI 10.1257/jep.11.1.109; Babcock L, 1995, AM ECON REV, V85, P1337; Babcock L, 1996, Q J ECON, V111, P1, DOI 10.2307/2946655; Babcock L, 1997, LAW SOCIAL INQUIRY, V22, P401; BOWER AD, 1987, J FAM PRACTICE, V24, P612; Cain D, 2003, DIRT COMING CLEAN PE; Caudill TS, 1996, ARCH FAM MED, V5, P201, DOI 10.1001/archfami.5.4.201; Gibbons RV, 1998, J GEN INTERN MED, V13, P151, DOI 10.1046/j.1525-1497.1998.00048.x; HUME AL, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039018; LEXCHIN J, 1993, CAN MED ASSOC J, V149, P1401; Loewenstein G., 1992, J LEGAL STUD, V12, P135; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; Messick D. M., 1983, EQUITY THEORY PSYCHO; MESSICK DM, 1979, J EXP SOC PSYCHOL, V15, P418, DOI 10.1016/0022-1031(79)90047-7; *NAT I HLTH CAR MA, 2003, CHANG PATT PHARM INN; *OFF INSP GEN HLTH, 2003, OIG COMPL PROGR GUID; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; PALMISANO P, 1980, J MED EDUC, V55, P453; *PHARM RES MAN AM, 2003, PHRMA COD INT HEALTH; *PHARM RES MAN AM, PHRMA COD INT HEALTH; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P442; Spingarn RW, 1996, ACAD MED, V71, P86, DOI 10.1097/00001888-199601000-00022; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	27	390	401	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					252	255		10.1001/jama.290.2.252	http://dx.doi.org/10.1001/jama.290.2.252			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	698GH	12851281				2022-12-28	WOS:000183989800031
J	Checchi, F; Elder, G; Schafer, M; Drouhin, E; Legros, D				Checchi, F; Elder, G; Schafer, M; Drouhin, E; Legros, D			Consequences of armed conflict for an ethnic Karen population	LANCET			English	Editorial Material									Epictr, F-75011 Paris, France; Med Sans Frontieres, F-75011 Paris, France	Doctors Without Borders	Checchi, F (corresponding author), Epictr, 8 Rue St Sabin, F-75011 Paris, France.			Checchi, Francesco/0000-0001-9030-5382				Lanjouw S, 2000, DISASTERS, V24, P228, DOI 10.1111/1467-7717.00144; Petersen HD, 2000, DAN MED BULL, V47, P359; *REF INT, 2002, B BURM INT DISPL NO	3	12	12	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					74	75		10.1016/S0140-6736(03)13813-5	http://dx.doi.org/10.1016/S0140-6736(03)13813-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699KW	12854585				2022-12-28	WOS:000184056900028
J	Molina-Heredia, FP; Wastl, J; Navarro, JA; Bendall, DS; Hervas, M; Howe, CJ; De la Rosa, MA				Molina-Heredia, FP; Wastl, J; Navarro, JA; Bendall, DS; Hervas, M; Howe, CJ; De la Rosa, MA			A new function for an old cytochrome?	NATURE			English	Article							PHOTOSYSTEM-I; PLASTOCYANIN; C(6); MECHANISMS		Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Ctr Isla Cartuja, Seville 41092, Spain; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University of Cambridge	Molina-Heredia, FP (corresponding author), Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.		Hervas, Manuel/K-9279-2014; navarro, jose a/B-6354-2015; De la Rosa, Miguel/B-2545-2014; Molina-Heredia, Fernando P./F-7877-2015; Wastl, Juergen/C-6876-2016	Hervas, Manuel/0000-0003-4523-8891; navarro, jose a/0000-0002-0536-6074; De la Rosa, Miguel/0000-0003-1187-5737; Molina-Heredia, Fernando P./0000-0002-3637-0519; Wastl, Juergen/0000-0001-7757-8001				De la Rosa MA, 2002, BIOELECTROCHEMISTRY, V55, P41, DOI 10.1016/S1567-5394(01)00136-0; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; Metzger SU, 1995, PHOTOSYNTHESIS LIGHT, V2, P823; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; Wastl J, 2002, TRENDS PLANT SCI, V7, P244, DOI 10.1016/S1360-1385(02)02280-X	7	61	66	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					33	34		10.1038/424033b	http://dx.doi.org/10.1038/424033b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840749				2022-12-28	WOS:000183912800030
J	Schaal, B; Coureaud, G; Langlois, D; Ginies, C; Semon, E; Perrier, G				Schaal, B; Coureaud, G; Langlois, D; Ginies, C; Semon, E; Perrier, G			Chemical and behavioural characterization of the rabbit mammary pheromone	NATURE			English	Article							NEWBORN RABBITS; OLFACTION; ODORS; RATS; PUP	Mammals owe part of their evolutionary success to the harmonious exchanges of information, energy and immunity between females and their offspring. This functional reciprocity is vital for the survival and normal development of infants, and for the inclusive fitness of parents(1,2). It is best seen in the intense exchanges taking place around the mother's offering of, and the infant's quest for, milk. All mammalian females have evolved behavioural and sensory methods of stimulating and guiding their inexperienced newborns to their mammae, whereas newborns have coevolved means to respond to them efficiently(3). Among these cues, maternal odours have repeatedly been shown to be involved(4-6), but the chemical identity and pheromonal nature of these cues have not been definitively characterized until now. Here we focus on the nature of an odour signal emitted by the female rabbit to which newborn pups respond by attraction and oral grasping, and provide a complete chemical and behavioural description of a pheromone of mammary origin in a mammalian species.	Ctr Europeen Sci Gout, CNRS, Fre 2328, F-21000 Dijon, France; INRA, Unite Mixte Rech Aromes, F-21000 Dijon, France; Etab Natl Enseignement Super Agr, F-21000 Dijon, France	Institut Agro; AgroSup Dijon; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; INRAE	Schaal, B (corresponding author), Ctr Europeen Sci Gout, CNRS, Fre 2328, F-21000 Dijon, France.	schaal@cesg.cnrs.fr	Coureaud, Gérard/N-9108-2017; Coureaud, Gérard/ABF-1205-2020	Coureaud, Gérard/0000-0001-6754-3884; Coureaud, Gérard/0000-0001-6754-3884				ABBOTT N, 1993, J AGR FOOD CHEM, V41, P1698, DOI 10.1021/jf00034a034; BEAUCHAMP GK, 1976, OLFACTION BEHAV MAMM, P143; BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; Clutton-Brock T. H., 1991, EVOLUTION PARENTAL C; Coureaud G, 2002, DEV PSYCHOBIOL, V40, P372, DOI 10.1002/dev.10038; Coureaud G, 2001, ANIM BEHAV, V61, P153, DOI 10.1006/anbe.2000.1563; Coureaud G, 2000, DEV PSYCHOBIOL, V36, P271, DOI 10.1002/(SICI)1098-2302(200005)36:4<271::AID-DEV2>3.0.CO;2-3; Coureaud G, 2000, REPROD NUTR DEV, V40, P19, DOI 10.1051/rnd:2000117; COUREAUD G, 2001, THESIS U PARIS 13; GALEF BG, 1988, PHYSIOL BEHAV, V42, P119, DOI 10.1016/0031-9384(88)90285-5; GOODRICH BS, 1981, J CHEM ECOL, V7, P817, DOI 10.1007/BF00992380; HUDSON R, 1983, BEHAVIOUR, V85, P260, DOI 10.1163/156853983X00255; Johnson BA, 2000, J COMP NEUROL, V426, P330, DOI 10.1002/1096-9861(20001016)426:2<330::AID-CNE12>3.0.CO;2-5; JOHNSTON RE, 2000, NEUROBIOLOGY TASTE S, P101; KEIL W, 1990, PHYSIOL BEHAV, V47, P525, DOI 10.1016/0031-9384(90)90120-S; LEBAS F, 1970, ANN ZOOTECH, V19, P223, DOI 10.1051/animres:19700207; LEON M, 1971, PHYSIOL BEHAV, V7, P265, DOI 10.1016/0031-9384(71)90296-4; Macfarlane A, 1975, Ciba Found Symp, P103; MORROWTESCH J, 1990, PHYSIOL BEHAV, V47, P1, DOI 10.1016/0031-9384(90)90034-2; Pedersen P. E., 1981, DEV PERCEPTION PSYCH, P359; Rosenblatt J. S., 1996, ADV STUD BEHAV, V715; ROSENBLATT JS, 1983, DEV PSYCHOBIOL, V16, P347, DOI 10.1002/dev.420160502; Sam M, 2001, NATURE, V412, P142, DOI 10.1038/35084137; SCHLEY P, 1981, KLEINTIERPRAXIS, V26, P261; SCHLEY P, 1976, THESIS U GIESEN; TEICHER MH, 1977, SCIENCE, V198, P635, DOI 10.1126/science.918660; Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857; ZARROW MX, 1965, SCIENCE, V150, P1835, DOI 10.1126/science.150.3705.1835; Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506; [No title captured]	30	258	272	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					68	72		10.1038/nature01739	http://dx.doi.org/10.1038/nature01739			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840760				2022-12-28	WOS:000183912800041
J	Stuart, FM; Lass-Evans, S; Fitton, JG; Ellam, RM				Stuart, FM; Lass-Evans, S; Fitton, JG; Ellam, RM			High He-3/He-4 ratios in picritic basalts from Baffin Island and the role of a mixed reservoir in mantle plumes	NATURE			English	Article							NORTHWEST ICELAND; WEST GREENLAND; NOBLE-GASES; BAY LAVAS; HELIUM; CONSTRAINTS; EARTH; LEAD; SYSTEMATICS; COMPONENT	The high He-3/He-4 ratio of volcanic rocks thought to be derived from mantle plumes is taken as evidence for the existence of a mantle reservoir that has remained largely undegassed since the Earth's accretion(1-3). The helium isotope composition of this reservoir places constraints on the origin of volatiles within the Earth and on the evolution and structure of the Earth's mantle. Here we show that olivine phenocrysts in picritic basalts presumably derived from the proto-Iceland plume at Baffin Island, Canada, have the highest magmatic He-3/He-4 ratios yet recorded. A strong correlation between He-3/He-4 and Sr-87/Sr-86, Nd-143/Nd-144 and trace element ratios demonstrate that the He-3-rich end-member is present in basalts that are derived from large-volume melts of depleted upper-mantle rocks. This reservoir is consistent with the recharging of depleted upper-mantle rocks by small volumes of primordial volatile-rich lower-mantle material at a thermal boundary layer between convectively isolated reservoirs. The highest He-3/He-4 basalts from Hawaii and Iceland plot on the observed mixing trend. This indicates that a He-3-recharged depleted mantle (HRDM) reservoir may be the principal source of high He-3/He-4 in mantle plumes, and may explain why the helium concentration of the 'plume' component in ocean island basalts is lower than that predicted for a two-layer, steady-state model of mantle structure.	Scottish Univ Environm Res Ctr, Isotope Geosci Unit, E Kilbride G75 0QF, Lanark, Scotland; Univ Edinburgh, Sch Geosci, Edinburgh EH9 3JW, Midlothian, Scotland	Scottish Universities Research & Reactor Center; University of Edinburgh	Stuart, FM (corresponding author), Scottish Univ Environm Res Ctr, Isotope Geosci Unit, E Kilbride G75 0QF, Lanark, Scotland.		Stuart, Finlay/E-7417-2010; Ellam, Rob M/B-7878-2009	Ellam, Rob M/0000-0001-8159-4864				Anderson DL, 1998, P NATL ACAD SCI USA, V95, P9087, DOI 10.1073/pnas.95.16.9087; DEPAOLO DJ, 1976, GEOPHYS RES LETT, V3, P743, DOI 10.1029/GL003i012p00743; Dixon ET, 2000, EARTH PLANET SC LETT, V180, P309, DOI 10.1016/S0012-821X(00)00164-3; Eiler JM, 1998, GEOCHIM COSMOCHIM AC, V62, P1977, DOI 10.1016/S0016-7037(98)00113-6; Fitton J.G., 1998, P OCEAN DRILLING PRO, V152, P331, DOI DOI 10.2973/0DP.PR0C.SR.152.233.1998; Fitton JG, 1997, EARTH PLANET SC LETT, V153, P197, DOI 10.1016/S0012-821X(97)00170-2; FRANCIS D, 1985, CONTRIB MINERAL PETR, V89, P144, DOI 10.1007/BF00379449; Graham DW, 1998, EARTH PLANET SC LETT, V160, P241, DOI 10.1016/S0012-821X(98)00083-1; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; Hardarson BS, 1997, EARTH PLANET SC LETT, V153, P181, DOI 10.1016/S0012-821X(97)00145-3; HAURI EH, 1994, J GEOPHYS RES-SOL EA, V99, P24275, DOI 10.1029/94JB01257; Hilton DR, 2000, EARTH PLANET SC LETT, V183, P43, DOI 10.1016/S0012-821X(00)00253-3; Hilton DR, 1999, EARTH PLANET SC LETT, V173, P53, DOI 10.1016/S0012-821X(99)00215-0; HONDA M, 1993, GEOCHIM COSMOCHIM AC, V57, P859, DOI 10.1016/0016-7037(93)90174-U; KURZ MD, 1982, NATURE, V297, P43, DOI 10.1038/297043a0; KURZ MD, 1986, NATURE, V320, P435, DOI 10.1038/320435a0; Marty B, 1996, EARTH PLANET SC LETT, V144, P223, DOI 10.1016/0012-821X(96)00158-6; MARTY B, 1993, CHEM GEOL, V106, P1, DOI 10.1016/0009-2541(93)90162-C; MCKENZIE D, 1995, J PETROL, V36, P133, DOI 10.1093/petrology/36.1.133; Olive V, 2001, GEOSTANDARD NEWSLETT, V25, P219, DOI 10.1111/j.1751-908X.2001.tb00597.x; Pedersen AK, 2002, GEOL SOC SPEC PUBL, V197, P157, DOI 10.1144/GSL.SP.2002.197.01.07; Porcelli D, 2002, REV MINERAL GEOCHEM, V47, P411, DOI 10.2138/rmg.2002.47.11; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; Prestvik T, 2001, EARTH PLANET SC LETT, V190, P211, DOI 10.1016/S0012-821X(01)00390-9; ROBILLARD I, 1992, CONTRIB MINERAL PETR, V112, P230, DOI 10.1007/BF00310457; Saunders A.D., 1997, GEOPHYS MONOGRAPH SE, P45, DOI 10.1029/GM100p0045; Stuart FM, 2000, EARTH PLANET SC LETT, V177, P273, DOI 10.1016/S0012-821X(00)00050-9; STUART FM, 1994, EARTH PLANET SC LETT, V122, P245, DOI 10.1016/0012-821X(94)90064-7; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Whitehouse MJ, 1998, PRECAMBRIAN RES, V91, P365, DOI 10.1016/S0301-9268(98)00058-8	30	231	234	4	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					57	59		10.1038/nature01711	http://dx.doi.org/10.1038/nature01711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840756	Green Accepted, Green Published			2022-12-28	WOS:000183912800037
J	Iribarne, A				Iribarne, A			Orphan diseases and adoptive initiatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEGLECTED DISEASES; DRUGS		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Iribarne, A (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Davies D M, 1983, Lancet, V1, P290; FRANCISCO A, 2002, LANCET, V360, P1102; Kettler HE, 2001, B WORLD HEALTH ORGAN, V79, P742; Lavandeira A, 2002, HAEMOPHILIA, V8, P194, DOI 10.1046/j.1365-2516.2002.00643.x; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Schieppati A, 2001, LANCET, V358, P1638, DOI 10.1016/S0140-6736(01)06658-2; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; *US DEP HHS, 1989, PUBL US DEP HLTH HUM; Wheeler C, 2001, B WORLD HEALTH ORGAN, V79, P728	9	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					116	116		10.1001/jama.290.1.116	http://dx.doi.org/10.1001/jama.290.1.116			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837724	Bronze			2022-12-28	WOS:000183868600032
J	Barkal, R; Gopher, A; Lauritzen, SE; Frumkin, A				Barkal, R; Gopher, A; Lauritzen, SE; Frumkin, A			Uranium series dates from Qesem Cave, Israel, and the end of the Lower Palaeolithic	NATURE			English	Article							ARCHAEOLOGICAL SITES; CARMEL; RECORD	Israel is part of a geographical 'out of Africa' corridor for human dispersals. An important event in these dispersals was the possible arrival of anatomically modern humans in the Levant during the late Middle Pleistocene(1-3). In the Levant the Lower Palaeolithic ends with the Acheulo-Yabrudian complex, characterized by technological developments(4,5), including the introduction of technological innovations such as the systematic production of blades and the disappearance of hand-axes. These reflect new human perceptions and capabilities in lithic technology and tool function(6). Qesem Cave, discovered in 2000, has a rich, well-preserved Acheulo-Yabrudian deposit holding great promise for providing new insights into the period. Here we report the dates of this deposit obtained by uranium isotopic series on associated speleothems and their implications. The results shed light on the temporal range of the Acheulo-Yabrudian and the end of the Lower Palaeolithic, suggesting a long cultural phase between the Lower Palaeolithic Acheulian and the Middle Palaeolithic Mousterian phases, starting before 382 kyr ago and ending at about 200 kyr ago.	Tel Aviv Univ, Dept Archaeol, IL-69978 Tel Aviv, Israel; Univ Bergen, Dept Geosci, N-5007 Bergen, Norway; Hebrew Univ Jerusalem, Dept Geog, IL-91905 Jerusalem, Israel	Tel Aviv University; University of Bergen; Hebrew University of Jerusalem	Barkal, R (corresponding author), Tel Aviv Univ, Dept Archaeol, IL-69978 Tel Aviv, Israel.	barkaran@post.tau.ac.il	Barkai, Ran/L-6495-2019	BARKAI, RAN/0000-0002-8125-8788				BARYOSEF O, 1994, J WORLD PREHIST, V8, P211, DOI 10.1007/BF02221050; BARYOSEF O, 1994, INTERD CONT, P23; Frumkin A, 1999, QUATERNARY RES, V51, P317, DOI 10.1006/qres.1998.2031; FRUMKIN A, 1996, NAHAL QANAH CAVE, P139; Garrod D.A.E., 1937, STONE AGE MOUNT CARM, VI; Garrod DAE, 1956, QUATERNARIA, V3, P39; Gisis I., 1974, PALEORIENT, V2, P175; GRUN R, 1991, J HUM EVOL, V20, P231, DOI 10.1016/0047-2484(91)90074-6; Jelinek A. J., 1990, EMERGENCE MODERN HUM, P81; Kaufman A, 1998, EARTH PLANET SC LETT, V156, P141, DOI 10.1016/S0012-821X(98)00002-8; Lauritzen SE, 1999, HOLOCENE, V9, P659, DOI 10.1191/095968399667823929; LAURITZEN SE, 1997, TIMS AGE 4U2U PROGRA; Mercier N, 2000, CR ACAD SCI II A, V330, P731, DOI 10.1016/S1251-8050(00)00193-2; PETRE FT, 1927, RES PREHISTORIC GALI; Porat N, 2002, J HUM EVOL, V43, P107, DOI 10.1006/jhev.2002.0562; Rink WJ, 2003, J ARCHAEOL SCI, V30, P195, DOI 10.1006/jasc.2002.0831; Ronen A., 2000, BAR INT SERIES, V850, P97; RONEN A, 2000, RECHERCHE HOMME PREH, V95, P209; RUST A, 1950, HOHLENFUNDE YABRUD S; SCHWARCZ HP, 1980, ISRAEL J EARTH SCI, V29, P157; SCHWARCZ HP, 1980, ARCHAEOMETRY, V22, P3, DOI 10.1111/j.1475-4754.1980.tb00263.x; SOHN SG, 1993, AM J PHYS ANTHROPOL, V91, P325, DOI 10.1002/ajpa.1330910307; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; VANDERMEERSCH B, 1989, HUMAN REVOLUTION, P155; VISHNYATSKY LB, 1994, ANTIQUITY, V68, P134, DOI 10.1017/S0003598X00046287; Weinstein-Evron M, 1999, S AFR J SCI, V95, P186; YARYOSEF O, 1998, NEANDERTALS MODERN H, P39; Zeitoun V, 2001, CR ACAD SCI II A, V332, P521, DOI 10.1016/S1251-8050(01)01568-3; [No title captured]	29	113	115	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					977	979		10.1038/nature01718	http://dx.doi.org/10.1038/nature01718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	694BL	12827199				2022-12-28	WOS:000183753900047
J	Woodcock, A; Forster, L; Matthews, E; Martin, J; Letley, L; Vickers, M; Britton, J; Strachan, D; Howarth, P; Altmann, D; Frost, C; Custovic, A				Woodcock, A; Forster, L; Matthews, E; Martin, J; Letley, L; Vickers, M; Britton, J; Strachan, D; Howarth, P; Altmann, D; Frost, C; Custovic, A		Med Res Council Gen Practice Res	Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED STEROIDS; CONTROLLED TRIAL; OCCUPATIONAL ASTHMA; INDOOR ALLERGENS; AVOIDANCE; CHILDREN; ENCASEMENT; REDUCTION; MATTRESS	Background: The effectiveness of avoidance of house-dust-mite allergen (Dermatophagoides pteronyssinus 1 [Der p1]) in the management of asthma is uncertain. Methods: We conducted a double-blind, randomized, placebo-controlled study of allergen-impermeable bed covers involving 1122 adults with asthma. The primary outcomes were the mean morning peak expiratory flow rate over a four-week period during the run-in phase and at six months and the proportion of patients who discontinued inhaled corticosteroid therapy as part of a phased-reduction program during months 7 through 12. Der p1 was measured in mattress dust in a 10 percent random subsample of homes at entry and at 6 and 12 months. Results: The prevalence of sensitivity to dust-mite allergen was 65.4 percent in the group supplied with allergen-impermeable bed covers (active-intervention group) and 65.1 percent in the control group supplied with non-impermeable bed covers. The concentration of Der p1 in mattress dust was significantly lower in the active-intervention group at 6 months (geometric mean, 0.58 mug per gram vs. 1.71 mug per gram in the control group; P=0.01) but not at 12 months (1.05 mug per gram vs. 1.64 mug per gram; P=0.74). The mean morning peak expiratory flow rate improved significantly in both groups (from 410.7 to 419.1 liters per minute in the active-intervention group, P<0.001 for the change; and from 417.8 to 427.4 liters per minute in the control group, P<0.001 for the change). After adjustment for base-line differences (by analysis of covariance), there was no significant difference between the groups in the peak expiratory flow rate at six months (difference in means, active-intervention group vs. control group, -1.6 liters per minute [95 percent confidence interval, -5.9 to 2.7] among all patients [P=0.46] and -1.5 liters per minute [95 percent confidence interval, -6.9 to 3.9] among mite-sensitive patients [P=0.59]). There was no significant difference between the groups in the proportion in whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent in the active-intervention group and 17.1 percent in the control group) or in the mean reduction in steroid dose, either among all patients or among mite-sensitive patients. Conclusions: Allergen-impermeable covers, as a single intervention for the avoidance of exposure to dust-mite allergen, seem clinically ineffective in adults with asthma.	Univ Manchester, NW Lung Ctr, Wythenshawe Hosp, S Manchester Acad Grp, Manchester M23 9LT, Lancs, England; MRC, Gen Practice Res Framework, London, England; Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ Southampton, Gen Hosp, London, England; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; St Georges University London; University of Southampton; University of London; London School of Hygiene & Tropical Medicine	Woodcock, A (corresponding author), Univ Manchester, NW Lung Ctr, Wythenshawe Hosp, S Manchester Acad Grp, Manchester M23 9LT, Lancs, England.	ashley.a.woodcock@man.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Howarth, Peter/0000-0003-0619-7927; Woodcock, Ashley/0000-0002-5428-8578; Frost, Chris/0000-0003-0098-9915				BURR ML, 1976, LANCET, V1, P333; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2002, ANN ALLERG ASTHMA IM, V88, P432, DOI 10.1016/S1081-1206(10)62378-2; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V108, P685, DOI 10.1067/mai.2001.119569; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Green R, 2002, BRIT MED J, V324, P1131; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Paganelli R, 1998, ALLERGY, V53, P763; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323, DOI 10.1016/S0091-6749(99)70031-X; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Strachan DP, 1998, BRIT MED J, V317, P1096, DOI 10.1136/bmj.317.7166.1096; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; WONG CS, 1993, CLIN EXP ALLERGY, V23, P370, DOI 10.1111/j.1365-2222.1993.tb00341.x	25	208	219	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					225	236		10.1056/NEJMoa023175	http://dx.doi.org/10.1056/NEJMoa023175			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867606	Bronze, Green Accepted			2022-12-28	WOS:000184165700006
J	Levine, GN; Kem, MJ; Berger, PB; Brown, DL; Klein, LW; Kereiakes, DJ; Sanborn, TA; Jacobs, AK				Levine, GN; Kem, MJ; Berger, PB; Brown, DL; Klein, LW; Kereiakes, DJ; Sanborn, TA; Jacobs, AK		American Heart Assoc Diagnostic In	Management of patients undergoing percutaneous coronary revascularization	ANNALS OF INTERNAL MEDICINE			English	Review							PRACTICE GUIDELINES COMMITTEE; AMERICAN-HEART-ASSOCIATION; PERIPHERAL VASCULAR COMPLICATIONS; ACCESS SITE COMPLICATIONS; IODINATED CONTRAST-MEDIA; ACUTE-RENAL-FAILURE; RADIOCONTRAST-INDUCED NEPHROPATHY; FRENCH MULTICENTER REGISTRY; RANDOMIZED CONTROLLED-TRIAL; CREATINE-KINASE ELEVATION	While performance of percutaneous coronary intervention (PCl) remains the domain of specialized cardiologists, patients undergoing PCl are cared for by noninvasive cardiologists, internists, and primary care physicians. Therefore, patient care is optimized when the entire patient care team understands procedural risks and complications as well as optimum patient management before, during, and after PCl. Before PCl, patients with contrast dye allergies should be identified and pretreated with steroids and an H,-blocker. Hydration should be initiated and maintained before and after the procedure to minimize the risks for contrast nephropathy. Periprocedure, patients should be monitored clinically for evidence of ischemia. In patients with significant groin, flank, abdominal, or back pain, as well as those with decrease in hematocrit or unexplained hypotension, the diagnosis of groin or retroperitoneal hematoma should be considered and promptly evaluated. Groin tenderness, pulsatile mass, or bruit should prompt evaluation for possible femoral pseudoaneurysm or arteriovenous fistulae. After the procedure, all patients treated with coronary stents should receive aspirin plus clopidogrel. Patients who develop typical anginal symptoms between the 1st and 6th to 8th months after PCl are likely to have restenosis and can be evaluated by an imaging study or repeated catheterization.	Baylor Coll Med, Houston, TX 77030 USA; St Louis Univ, St Louis, MO 63103 USA; Beth Israel Deaconess Med Ctr, New York, NY 10003 USA; Rush Med Coll, Chicago, IL 60612 USA; Lindner Res Ctr, Cincinnati, OH USA; Ohio Heart Hlth Ctr, Cincinnati, OH USA; Evanston NW Healthcare, Evanston, IL USA; Boston Univ, Sch Med, Boston, MA 02215 USA	Baylor College of Medicine; Saint Louis University; Harvard University; Beth Israel Deaconess Medical Center; Rush University; NorthShore University Health System; Boston University	Levine, GN (corresponding author), Houston Vet Affairs Med Ctr, Cardiol Sect, 3C-330,111-B,2002 Holcombe Blvd, Houston, TX 77030 USA.	glevine@bcm.tmc.edu		Jacobs, Alice/0000-0002-2428-2458				ABDELMEGUID AE, 1995, CIRCULATION, V91, P2733, DOI 10.1161/01.CIR.91.11.2733; Abdelmeguid AE, 1996, AM HEART J, V131, P1097, DOI 10.1016/S0002-8703(96)90083-6; Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; Akkerhuis KM, 2001, JAMA-J AM MED ASSOC, V286, P78, DOI 10.1001/jama.286.1.78; Al Suwaidi J, 2000, JAMA-J AM MED ASSOC, V284, P1828, DOI 10.1001/jama.284.14.1828; Albiero R, 1997, CIRCULATION, V95, P1145; Allaqaband S, 2002, CATHETER CARDIO INTE, V57, P279, DOI 10.1002/ccd.10323; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Altmann DB, 1996, AM HEART J, V132, P503, DOI 10.1016/S0002-8703(96)90231-8; Angelini P, 2000, TEX HEART I J, V27, P337; Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; ASSAN R, 1977, DIABETOLOGIA, V13, P211, DOI 10.1007/BF01219702; Baim DS, 2000, AM J CARDIOL, V85, P864, DOI 10.1016/S0002-9149(99)00882-6; Baim DS, 2001, AM J CARDIOL, V87, P157, DOI 10.1016/S0002-9149(00)01308-4; BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Berger PB, 2002, CIRCULATION, V106, P2284, DOI 10.1161/01.CIR.0000035924.70846.20; Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624; BERTRAND ME, 1990, CIRCULATION, V82, P190; BHALLA HS, 1996, CIRCULATION S1, V94, P51; Bittl JA, 2001, AM HEART J, V142, P952, DOI 10.1067/mhj.2001.119374; Blankenship JC, 1998, AM J CARDIOL, V81, P36, DOI 10.1016/S0002-9149(97)00796-0; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; Briguori C, 2002, J AM COLL CARDIOL, V40, P298, DOI 10.1016/S0735-1097(02)01958-7; BROWN DL, 1993, AM J CARDIOL, V72, P1207, DOI 10.1016/0002-9149(93)90998-R; BROWN RS, 1990, J AM SOC NEPHROL, V1, P330; Buller CE, 1999, CIRCULATION, V100, P236, DOI 10.1161/01.CIR.100.3.236; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CALIFF RM, 1991, J AM COLL CARDIOL, V17, pB2; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; CAMENZIND E, 1994, J AM COLL CARDIOL, V24, P655, DOI 10.1016/0735-1097(94)90011-6; Carere RG, 1998, CATHETER CARDIO DIAG, V43, P124, DOI 10.1002/(SICI)1097-0304(199802)43:2<124::AID-CCD2>3.0.CO;2-C; Carere RG, 2000, AM HEART J, V139, P52, DOI 10.1016/S0002-8703(00)90308-9; CHENU PC, 1993, AM J CARDIOL, V72, P1209, DOI 10.1016/0002-9149(93)90999-S; Chesebro JH, 1989, CIRCULATION S2, V80, pII; Cutlip DE, 2001, CIRCULATION, V103, P1967; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Dangas G, 2001, AM J CARDIOL, V87, P470, DOI 10.1016/S0002-9149(00)01408-9; Dangas G, 2001, J AM COLL CARDIOL, V38, P638, DOI 10.1016/S0735-1097(01)01449-8; Diaz-Sandoval LJ, 2002, AM J CARDIOL, V89, P356, DOI 10.1016/S0002-9149(01)02243-3; Dieter RS, 2000, CLIN CARDIOL, V23, P808, DOI 10.1002/clc.4960231129; Eidt JF, 1999, AM J SURG, V178, P511, DOI 10.1016/S0002-9610(99)00246-9; EISENBERG RL, 1980, AM J MED, V68, P43, DOI 10.1016/0002-9343(80)90163-1; ELLIS SG, 1989, AM HEART J, V117, P777, DOI 10.1016/0002-8703(89)90612-1; Ellis SG, 2001, CIRCULATION, V104, P706; Fram DB, 2001, CATHETER CARDIO INTE, V53, P163, DOI 10.1002/ccd.1143; FRIEDMAN HZ, 1994, J AM COLL CARDIOL, V24, P1214, DOI 10.1016/0735-1097(94)90101-5; Fuchs S, 2002, CIRCULATION, V106, P86, DOI 10.1161/01.CIR.0000020678.16325.E0; Garachemani AR, 1998, AM HEART J, V136, P352, DOI 10.1053/hj.1998.v136.90240; Garzon P, 2001, CAN J CARDIOL, V17, P41; Gershlick AH, 2001, CIRCULATION, V104, P416; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; GOSS JE, 1995, CATHETER CARDIO DIAG, V34, P99, DOI 10.1002/ccd.1810340403; GREENBERGER PA, 1988, PROG CARDIOVASC DIS, V31, P239, DOI 10.1016/0033-0620(88)90017-5; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Grube E, 2002, J AM COLL CARDIOL, V39, p38A; Grube E, 2001, CIRCULATION, V104, P463; Gruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7; GRUNTZIG AR, 1979, NEW ENGL J MED, V301, P61, DOI 10.1056/NEJM197907123010201; Hanekamp CEE, 2000, J AM COLL CARDIOL, V35, p9A; Hanrath P, 1997, CIRCULATION, V96, P1445; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; Hasdai D, 1997, ARCH INTERN MED, V157, P677, DOI 10.1001/archinte.157.6.677; HERNANDEZ RA, 1992, J AM COLL CARDIOL, V19, P1402, DOI 10.1016/0735-1097(92)90594-D; Heupler FA, 1998, CATHETER CARDIO DIAG, V43, P121, DOI 10.1002/(SICI)1097-0304(199802)43:2<121::AID-CCD1>3.0.CO;2-C; HILDRETH EA, 1987, HOSP PRACT, V22, P77; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; Hoher M, 1999, J AM COLL CARDIOL, V34, P722, DOI 10.1016/S0735-1097(99)00254-5; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; Hongo RH, 2002, J AM COLL CARDIOL, V40, P231, DOI 10.1016/S0735-1097(02)01954-X; JOELSON JM, 1987, AM J CARDIOL, V60, P792, DOI 10.1016/0002-9149(87)91025-3; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; Jost C, 1998, J INVASIVE CARDIOL, V10, P477; Kanaparti PK, 2000, AM J CARDIOL, V86, P619, DOI 10.1016/S0002-9149(00)01039-0; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; KATZENSCHLAGER R, 1995, RADIOLOGY, V195, P463, DOI 10.1148/radiology.195.2.7724767; Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553; KENT KC, 1994, J VASC SURG, V20, P905, DOI 10.1016/0741-5214(94)90227-5; KERN MJ, 2003, CARDIAZ CARTHETERIZA, P1; King SB, 1998, J AM COLL CARDIOL, V31, P558, DOI 10.1016/S0735-1097(97)10523-X; Kini A, 1999, CATHETER CARDIO INTE, V48, P123, DOI 10.1002/(SICI)1522-726X(199910)48:2<123::AID-CCD1>3.0.CO;2-O; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; Klein LW, 1999, CATHETER CARDIO INTE, V48, P130, DOI 10.1002/(SICI)1522-726X(199910)48:2<130::AID-CCD2>3.0.CO;2-T; Kong DF, 1998, AM HEART J, V136, P183, DOI 10.1053/hj.1998.v136.90239; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; KOVAC JD, 1995, CIRCULATION S, V92, P347; Kranjec I, 2000, J INVASIVE CARDIOL, V12, P86; Krone RJ, 2001, J AM COLL CARDIOL, V38, P136, DOI 10.1016/S0735-1097(01)01312-2; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; Kurnik BRC, 1998, AM J KIDNEY DIS, V31, P674, DOI 10.1053/ajkd.1998.v31.pm9531185; KUSSMAUL WG, 1995, J AM COLL CARDIOL, V25, P1685, DOI 10.1016/0735-1097(95)00101-9; LAARMAN G, 1990, J AM COLL CARDIOL, V16, P578, DOI 10.1016/0735-1097(90)90346-Q; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; Laskey WK, 2001, AM J CARDIOL, V87, P964, DOI 10.1016/S0002-9149(01)01430-8; Laskey WK, 2000, CATHETER CARDIO INTE, V49, P19, DOI 10.1002/(SICI)1522-726X(200001)49:1<19::AID-CCD3>3.0.CO;2-Q; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; LEMBO NJ, 1990, AM J CARDIOL, V65, P422, DOI 10.1016/0002-9149(90)90804-A; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; LEVINE GN, 1995, CLIN CARDIOL, V18, P693, DOI 10.1002/clc.4960181203; LIEBERMAN P, 1986, CLIN REV ALLERG, V4, P229; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7; Lincoff AM, 2000, J AM COLL CARDIOL, V35, P1103, DOI 10.1016/S0735-1097(00)00554-4; Lip GYH, 1999, INT J CARDIOL, V70, P127, DOI 10.1016/S0167-5273(99)00063-7; Loubeyre C, 1999, CATHETER CARDIO INTE, V47, P441, DOI 10.1002/(SICI)1522-726X(199908)47:4<441::AID-CCD12>3.0.CO;2-S; MANSKE CL, 1990, AM J MED, V89, P615, DOI 10.1016/0002-9343(90)90180-L; McCartney MM, 1999, CLIN RADIOL, V54, P29, DOI 10.1016/S0009-9260(99)91236-9; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; McGrath PD, 1999, J AM COLL CARDIOL, V34, P674, DOI 10.1016/S0735-1097(99)00257-0; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Miller J. M., 1999, TXB INTERVENTIONAL C, P379; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; MOSCUCCI M, 1994, AM J CARDIOL, V74, P448, DOI 10.1016/0002-9149(94)90901-6; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; Murphy SW, 2000, J AM SOC NEPHROL, V11, P177, DOI 10.1681/ASN.V111177; NASSER TK, 1995, CLIN CARDIOL, V18, P609, DOI 10.1002/clc.4960181105; Nawaz S, 1998, CLIN RADIOL, V53, P342, DOI 10.1016/S0009-9260(98)80005-6; Ohman EM, 1997, JAMA-J AM MED ASSOC, V277, P495, DOI 10.1001/jama.277.6.495; Park SJ, 2003, NEW ENGL J MED, V348, P1537, DOI 10.1056/NEJMoa021007; Popma JJ, 2001, CHEST, V119, p321S, DOI 10.1378/chest.119.1_suppl.321S; PORTER GA, 1989, AM J CARDIOL, V64, pE22, DOI 10.1016/0002-9149(89)90730-3; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; Rankin JM, 1999, NEW ENGL J MED, V341, P1957, DOI 10.1056/NEJM199912233412602; RENSING BJ, 1993, CIRCULATION, V88, P975, DOI 10.1161/01.CIR.88.3.975; Resnic FS, 2001, AM J CARDIOL, V88, P493, DOI 10.1016/S0002-9149(01)01725-8; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Samal AK, 2002, CATHETER CARDIO INTE, V57, P12, DOI 10.1002/ccd.10179; SANBORN TA, 1993, J AM COLL CARDIOL, V22, P1273, DOI 10.1016/0735-1097(93)90529-A; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Schuhlen H, 2001, J AM COLL CARDIOL, V37, P2066, DOI 10.1016/S0735-1097(01)01285-2; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; Shah PB, 2001, CIRCULATION, V104, P706; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHELLOCK FG, 1999, GUIDE MR PROCEDURES; SHELLOCK FG, 2001, MRI SAFETY; Shubrooks SJ, 2001, AM HEART J, V142, P190, DOI 10.1067/mhj.2001.116077; Shyu KG, 2002, J AM COLL CARDIOL, V40, P1383, DOI 10.1016/S0735-1097(02)02308-2; SIMES PA, 1996, J AM COLL CARDIOL, V28, P1444; Simoons M. L., 1997, European Heart Journal, V18, P132; Simoons ML, 1997, LANCET, V349, P1429; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Sousa JE, 2001, CIRCULATION, V104, P2007, DOI 10.1161/hc4201.098056; Sprouse LR, 2001, J VASC SURG, V33, P688, DOI 10.1067/mva.2001.112324; SREERAM S, 1993, AM SURGEON, V59, P94; Stables RH, 2001, LANCET, V358, P520, DOI 10.1016/S0140-6736(01)05741-5; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Steinhubl SR, 1998, J AM COLL CARDIOL, V32, P1366, DOI 10.1016/S0735-1097(98)00376-3; Steinhubl SR, 2001, CIRCULATION, V103, P1403, DOI 10.1161/01.CIR.103.10.1403; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403; Stone GW, 2001, CIRCULATION, V104, P642, DOI 10.1161/hc3101.093902; Tcheng JE, 1997, LANCET, V349, P1422; Tcheng JE, 2000, LANCET, V356, P2037; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Toursarkissian B, 2001, Vasc Surg, V35, P203, DOI 10.1177/153857440103500307; Tumlin JA, 2002, AM HEART J, V143, P894, DOI 10.1067/mhj.2002.122118; Vlietstra RE, 1996, AM HEART J, V132, P1049, DOI 10.1016/S0002-8703(96)90021-6; WAKSMAN R, 1995, AM J CARDIOL, V75, P886, DOI 10.1016/S0002-9149(99)80681-X; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; WEINTRAUB WS, 1993, J AM COLL CARDIOL, V21, P6, DOI 10.1016/0735-1097(93)90711-9; Weintraub WS, 2001, AM J CARDIOL, V88, P497, DOI 10.1016/S0002-9149(01)01726-X; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32; WHITE CW, 1987, CIRCULATION, V76, P400; Wiley JM, 2002, CATHETER CARDIO INTE, V57, P257, DOI 10.1002/ccd.10307; Williams DO, 2000, CIRCULATION, V102, P2945; Wilson SH, 1999, AM J CARDIOL, V83, P1006, DOI 10.1016/S0002-9149(99)00005-3; WITTBRODT ET, 1994, ANN PHARMACOTHER, V28, P236, DOI 10.1177/106002809402800215; Yusuf S, 2001, NEW ENGL J MED, V345, P494; 1943, LANCET, P339; 2003, PHYSICIANS DESK REFE, P1079	181	62	64	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					123	136		10.7326/0003-4819-139-2-200307150-00012	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00012			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859162				2022-12-28	WOS:000184163100006
J	Hohnloser, SH; Ikeda, T; Bloomfield, DM; Dabbous, OH; Cohen, RJ				Hohnloser, SH; Ikeda, T; Bloomfield, DM; Dabbous, OH; Cohen, RJ			T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation	LANCET			English	Article							MYOCARDIAL-INFARCTION	In a trial of prophylactic implantation of a defibrillator, a mortality benefit was seen among patients with previous myocardial infarction and a left-ventricular ejection fraction of 0.30 or less. We identified 1.29 similar patients from two previously published clinical trials in which microvolt T-wave altemans testing was prospectively assessed. At 24 months of follow-up, no sudden cardiac death or cardiac arrest was seen among patients who tested T-wave alternans negative, compared with an event rate of 15.6% among the remaining patients. Testing of T-wave alternans seems to identify patients who are at low risk of ventricular tachyarrhythimic event and who may not benefit from defibrillator therapy.	MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02142 USA; Univ Frankfurt, D-6000 Frankfurt, Germany; Toho Univ, Tokyo, Japan; Columbia Univ, New York, NY USA; Univ Massachusetts, Worcester, MA 01605 USA	Harvard University; Massachusetts Institute of Technology (MIT); Goethe University Frankfurt; Toho University; Columbia University; University of Massachusetts System; University of Massachusetts Worcester	Cohen, RJ (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, Room E25-335A,45 Carleton St, Cambridge, MA 02142 USA.							Bloomfield DM, 2002, J CARDIOVASC ELECTR, V13, P502, DOI 10.1046/j.1540-8167.2002.00502.x; Ikeda T, 2002, AM J CARDIOL, V89, P79, DOI 10.1016/S0002-9149(01)02171-3; Klingenheben T, 2000, LANCET, V356, P651, DOI 10.1016/S0140-6736(00)02609-X; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474	4	124	128	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					125	126		10.1016/S0140-6736(03)13865-2	http://dx.doi.org/10.1016/S0140-6736(03)13865-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867114				2022-12-28	WOS:000184089200013
J	Krum, H; Gilbert, RE				Krum, H; Gilbert, RE			Demographics and concomitant disorders in heart failure	LANCET			English	Review							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING-ENZYME-INHIBITOR; CORONARY-ARTERY-DISEASE; POSITIVE AIRWAY PRESSURE; CLINICAL-TRIALS UPDATE; COLLEGE-OF-CARDIOLOGY; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; RANDOMIZED-TRIAL; RENAL-FUNCTION	Chronic heart failure is an increasingly common cause of premature death and poor quality of life. Community-based epidemiological studies have provided much-needed information on the demography of chronic heart failure, providing insight into its influence on public health. In most patients, chronic heart failure Is accompanied by a range of concomitant disorders that both contribute to the cause of the disease and have a key role in its progression and response to treatment. Information on the most common comorbidities in chronic heart failure-ischaemic heart disease, hypertension, and diabetes mellitus-is presented for prespecifled subgroups in the reports of many large-scale, multicentre trials; despite their limitations, these subanalyses provide guidance in therapeutic decision-making. Similarly, because chronic heart failure is commonly an endpoint in intervention trials of both hypertension and diabetes, such studies afford important information on the prevention of chronic heart failure in these common diseases.	Monash Univ, Alfred Hosp, Sch Med,NHMRC Ctr Clin Res Excellence Therape, Dept Prevent Med, Melbourne, Vic 3181, Australia; Monash Univ, Alfred Hosp, Sch Med,NHMRC Ctr Clin Res Excellence Therape, Dept Med, Melbourne, Vic 3181, Australia; Monash Univ, Alfred Hosp, Sch Med,NHMRC Ctr Clin Res Excellence Therape, Dept Epidemiol, Melbourne, Vic 3181, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; St Vincent's Hospital Melbourne; University of Melbourne	Krum, H (corresponding author), Monash Univ, Sch Med, Alfred Hosp, Clin Pharmacol Unit, Commercial Rd, Prahran, Vic 3181, Australia.	henry.krum@med.monash.edu.au						Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Agarwal AK, 2001, EUR J HEART FAIL, V3, P301, DOI 10.1016/S1388-9842(00)00149-5; Andreas S, 2000, SLEEP, V23, pS220; Bauersachs J, 2001, CIRCULATION, V104, P982, DOI 10.1161/hc3401.095946; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; BRAUNWALD E, 1986, J AM COLL CARDIOL, V8, P1467, DOI 10.1016/S0735-1097(86)80325-4; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; BRISTOW MR, 1996, CIRCULATION S, V94, P664; BROPHY JM, 1992, CAN J CARDIOL, V8, P495; Brown AM, 1998, EUR HEART J, V19, P1063, DOI 10.1053/euhj.1997.0859; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; CACCIATORE F, 1995, ARCH GERONTOL GERIAT, V20, P63; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; CEIA F, 2000, EUR HEART J SUPPL, V21, P291; Chae CU, 1999, JAMA-J AM MED ASSOC, V281, P634, DOI 10.1001/jama.281.7.634; Chen YT, 1999, AM J MED, V106, P605, DOI 10.1016/S0002-9343(99)00126-6; Clarke KW, 1995, J PUBLIC HEALTH MED, V17, P459; Cleland JGF, 1999, EUR J HEART FAIL, V1, P211, DOI 10.1016/S1388-9842(99)00039-2; Cleland JGF, 1997, CURR OPIN CARDIOL, V12, P276, DOI 10.1097/00001573-199705000-00009; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Coletta A, 2002, EUR J HEART FAIL, V4, P381, DOI 10.1016/S1388-9842(02)00040-5; Cowie MR, 1997, EUR HEART J, V18, P208; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; DICARLI MF, 1995, CIRCULATION, V92, P3436, DOI 10.1161/01.CIR.92.12.3436; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; Dries DL, 2001, J AM COLL CARDIOL, V38, P421, DOI 10.1016/S0735-1097(01)01408-5; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; EITZMAN D, 1992, J AM COLL CARDIOL, V20, P559, DOI 10.1016/0735-1097(92)90008-B; ELEFTERIADES JA, 1993, J AM COLL CARDIOL, V22, P1411, DOI 10.1016/0735-1097(93)90551-B; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Feenstra J, 1997, DRUG SAFETY, V17, P166, DOI 10.2165/00002018-199717030-00003; Floras JS, 1998, EUR HEART J, V19, P820; Ghali J K, 1997, J La State Med Soc, V149, P474; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; GILLUM RF, 1993, AM HEART J, V126, P1042, DOI 10.1016/0002-8703(93)90738-U; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Gustafsson I, 1999, J AM COLL CARDIOL, V34, P83, DOI 10.1016/S0735-1097(99)00146-1; Gustafsson I, 2001, DIABETES CARE, V24, P3, DOI 10.2337/diacare.24.1.3; Gustafsson I, 2000, EUR HEART J, V21, P1937, DOI 10.1053/euhj.2000.2244; HABER HL, 1991, NEW ENGL J MED, V324, P353, DOI 10.1056/NEJM199102073240601; Haldeman GA, 1999, AM HEART J, V137, P352, DOI 10.1053/hj.1999.v137.95495; Hampton JR, 1997, LANCET, V349, P971, DOI 10.1016/S0140-6736(96)10488-8; Harris CJ, 2001, CURR OPIN NEPHROL HY, V10, P603, DOI 10.1097/00041552-200109000-00009; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; Hillege HL, 2000, CIRCULATION, V102, P203, DOI 10.1161/01.CIR.102.2.203; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; HOES AW, 1998, EUR HEART J SUPPL, V19, P2; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Iribarren C, 2001, CIRCULATION, V103, P2668; Joglar JA, 2001, AM HEART J, V142, P498, DOI 10.1067/mhj.2001.117318; Kaneider NC, 2001, ATHEROSCLEROSIS, V158, P23, DOI 10.1016/S0021-9150(00)00764-4; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KATZ SD, 1995, PROG CARDIOVASC DIS, V38, P23, DOI 10.1016/S0033-0620(05)80012-X; Kjekshus J, 1997, J Card Fail, V3, P249, DOI 10.1016/S1071-9164(97)90022-1; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; Krum H, 2000, HEART, V84, P615, DOI 10.1136/heart.84.6.615; Krum H, 2002, J AM COLL CARDIOL, V39, P1567, DOI 10.1016/S0735-1097(02)01827-2; Krum H, 2001, MED J AUSTRALIA, V174, P439, DOI 10.5694/j.1326-5377.2001.tb143369.x; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lechat P, 1999, LANCET, V353, P9; Lechat P, 2001, CIRCULATION, V103, P1428, DOI 10.1161/01.CIR.103.10.1428; Levine TB, 2000, CIRCULATION, V101, P758, DOI 10.1161/01.CIR.101.7.758; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Louis A, 2001, EUR J HEART FAIL, V3, P381, DOI 10.1016/S1388-9842(01)00149-0; Lowe JM, 1998, MED J AUSTRALIA, V168, P115, DOI 10.5694/j.1326-5377.1998.tb126744.x; LUSCHER TF, 1992, HYPERTENSION, V19, P117, DOI 10.1161/01.HYP.19.2.117; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; MCMURRAY J, 1993, EUR HEART J, V14, P1158, DOI 10.1093/eurheartj/14.9.1158; MCMURRAY J, 1993, EUR HEART J, V14, P1493, DOI 10.1093/eurheartj/14.11.1493; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; Moller M, 2001, Congest Heart Fail, V7, P146, DOI 10.1111/j.1527-5299.2001.00243.x; Mortensen SA, 1997, MOL ASPECTS MED, V18, pS137; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; Mosterd A, 2002, HEART, V87, P75, DOI 10.1136/heart.87.1.75; Mosterd A, 2001, EUR HEART J, V22, P1318, DOI 10.1053/euhj.2000.2533; Murdoch DR, 1998, EUR HEART J, V19, P1829, DOI 10.1053/euhj.1998.1269; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; PEDERSEN TR, 1994, LANCET, V344, P1383; Perry G, 1997, NEW ENGL J MED, V336, P525; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pisetsky DS, 2001, JAMA-J AM MED ASSOC, V286, P2787, DOI 10.1001/jama.286.22.2787; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poirier P, 2001, DIABETES CARE, V24, P5, DOI 10.2337/diacare.24.1.5; Poole-Wilson P, 1998, EUR HEART J, V19, P481; RAGOSTA M, 1993, CIRCULATION, V87, P1630, DOI 10.1161/01.CIR.87.5.1630; RAHIMTOOLA SH, 1995, AM J CARDIOL, V75, pE16, DOI 10.1016/S0002-9149(99)80443-3; Rathore SS, 2002, NEW ENGL J MED, V347, P1403, DOI 10.1056/NEJMoa021266; Rauchhaus M, 2000, LANCET, V356, P930, DOI 10.1016/S0140-6736(00)02690-8; Rauchhaus M, 2000, CIRCULATION, V102, P3060; REMES J, 1992, EUR HEART J, V13, P588, DOI 10.1093/oxfordjournals.eurheartj.a060220; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rich MW, 1996, J AM GERIATR SOC, V44, P638, DOI 10.1111/j.1532-5415.1996.tb01824.x; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; RodriguezArtalejo F, 1997, EUR HEART J, V18, P1771; Rosenson RS, 1999, LANCET, V353, P983, DOI 10.1016/S0140-6736(98)05917-0; Ruggenenti P, 1997, LANCET, V349, P1857; Ruilope LM, 2001, J AM COLL CARDIOL, V38, P1782, DOI 10.1016/S0735-1097(01)01627-8; SALPETER SS, 2002, COCHRANE DB SYST REV, V2; SAUNDERS E, 1990, AM J MED, V88, pS21, DOI 10.1016/0002-9343(90)90006-Y; SCHALL RR, 1989, J AM COLL CARDIOL, V14, P1666; SEGAL R, 2000, EUR J HEART FAIL S2, V2, P96; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Senni M, 1999, ARCH INTERN MED, V159, P29, DOI 10.1001/archinte.159.1.29; Sever P, 2002, J RENIN-ANGIO-ALDO S, V3, P61, DOI 10.3317/jraas.2002.018; Shan K, 1997, CURR OPIN CARDIOL, V12, P218, DOI 10.1097/00001573-199705000-00002; Shibata MC, 2002, INT J CARDIOL, V86, P77, DOI 10.1016/S0167-5273(02)00321-2; Sica D A, 2001, J Clin Hypertens (Greenwich), V3, P244, DOI 10.1111/j.1524-6175.2001.00474.x; Silverberg DS, 2000, J AM COLL CARDIOL, V35, P1737, DOI 10.1016/S0735-1097(00)00613-6; Silverberg DS, 2001, J AM COLL CARDIOL, V37, P1775, DOI 10.1016/S0735-1097(01)01248-7; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Solang L, 1999, EUR HEART J, V20, P789, DOI 10.1053/euhj.1998.1472; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Standl E, 2000, DIABETOLOGIA, V43, P1455, DOI 10.1007/s001250051556; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stevenson WG, 1997, CURR OPIN CARDIOL, V12, P242, DOI 10.1097/00001573-199705000-00005; Stevenson WG, 1995, CARDIAC ELECTROPHYSI, Vsecond, P848; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; SUTTON GC, 1990, AM HEART J, V120, P1538, DOI 10.1016/0002-8703(90)90055-3; Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1; TARNOW L, 1994, DIABETES CARE, V17, P1247, DOI 10.2337/diacare.17.11.1247; Tavazzi L, 1997, EUR HEART J, V18, P1457; Teo K, 1996, ARCH INTERN MED, V156, P1669, DOI 10.1001/archinte.156.15.1669; Teo KK, 2002, LANCET, V360, P1037, DOI 10.1016/S0140-6736(02)11138-X; Tkacova R, 2000, J HYPERTENS, V18, P1257, DOI 10.1097/00004872-200018090-00012; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; YOUNG JB, 2001, J CARD FAILURE S, V7, P55; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145; 1998, MMWR MORB MORTAL WKL, V47, P633	162	108	111	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					147	158		10.1016/S0140-6736(03)13869-X	http://dx.doi.org/10.1016/S0140-6736(03)13869-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867118				2022-12-28	WOS:000184089200025
J	Hamilton, JTG; McRoberts, WC; Keppler, F; Kalin, RM; Harper, DB				Hamilton, JTG; McRoberts, WC; Keppler, F; Kalin, RM; Harper, DB			Chloride methylation by plant pectin: An efficient environmentally significant process	SCIENCE			English	Article							EMISSIONS; CHLOROMETHANE; HALOCARBONS; ATMOSPHERE; COMBUSTION; AFRICA; MATTER	Atmospheric chloromethane (CH3Cl) plays an important role in stratospheric ozone destruction, but many uncertainties exist regarding the strengths of its sources and sinks and particularly regarding the processes generating this naturally occurring gas. Evidence is presented here that CH3Cl is produced in many terrestrial environments by a common mechanism. Abiotic conversion of chloride to CH3Cl occurs readily in plant material, with the widespread plant component pectin acting as a methyl donor. Significant CH3Cl emissions from senescent and dead leaves were observed at ambient temperatures; those emissions rose dramatically when temperatures increased. This ubiquitous process acting in terrestrial ecosystems and during biomass burning could contribute the bulk of atmospheric CH3Cl.	Dept Agr & Rural Dev No Ireland, Belfast BT9 5PX, Antrim, North Ireland; Queens Univ Belfast, Belfast BT9 5PX, Antrim, North Ireland; Queens Univ Belfast, Questor Res Ctr, Belfast BT9 5AG, Antrim, North Ireland; Queens Univ Belfast, Environm Engn Res Ctr, Belfast BT9 5AG, Antrim, North Ireland	Queens University Belfast; Queens University Belfast; Queens University Belfast	Hamilton, JTG (corresponding author), Dept Agr & Rural Dev No Ireland, Newforge Lane, Belfast BT9 5PX, Antrim, North Ireland.		Kalin, Robert/E-8620-2011; Keppler, Frank/F-4401-2012	Kalin, Robert/0000-0003-3768-3848; Keppler, Frank/0000-0003-2766-8812				Andreae MO, 2001, GLOBAL BIOGEOCHEM CY, V15, P955, DOI 10.1029/2000GB001382; Andreae MO, 1996, J GEOPHYS RES-ATMOS, V101, P23603, DOI 10.1029/95JD01733; Attieh J, 2000, PLANT CELL ENVIRON, V23, P165, DOI 10.1046/j.1365-3040.2000.00541.x; Bowen H. J. M, 1979, ENV CHEM ELEMENTS; Dimmer CH, 2001, ATMOS ENVIRON, V35, P321, DOI 10.1016/S1352-2310(00)00151-5; EKLUND G, 1988, CHEMOSPHERE, V17, P575, DOI 10.1016/0045-6535(88)90032-X; FUNG I, 1993, BIOGEOCHEMISTRY OF GLOBAL CHANGE, P166; Hafren J, 2001, NORD PULP PAP RES J, V16, P284, DOI 10.3183/npprj-2001-16-04-p284-290; Harper DB, 1999, NEW PHYTOL, V142, P5, DOI 10.1046/j.1469-8137.1999.00382.x; Harper DB, 2003, HANDB ENVIRON CHEM, V3, P17; Harper DB, 2000, NAT PROD REP, V17, P337, DOI 10.1039/a809400d; Hu HN, 1996, J EXP BOT, V47, P227, DOI 10.1093/jxb/47.2.227; Keppler F, 2000, NATURE, V403, P298, DOI 10.1038/35002055; Khalil MAK, 1999, ATMOS ENVIRON, V33, P1305, DOI 10.1016/S1352-2310(98)00234-9; Lobert JM, 1999, J GEOPHYS RES-ATMOS, V104, P8373, DOI 10.1029/1998JD100077; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; Mellerowicz EJ, 2001, PLANT MOL BIOL, V47, P239, DOI 10.1023/A:1010699919325; MONTZKA SA, 2003, 47 WORLD MET ORG, pCH1; Moore RM, 1996, J GEOPHYS RES-OCEANS, V101, P28529, DOI 10.1029/96JC02915; Myneni SCB, 2002, SCIENCE, V295, P1039, DOI 10.1126/science.1067153; PALMER TY, 1976, NATURE, V263, P44, DOI 10.1038/263044a0; RASMUSSEN RA, 1980, J GEOPHYS RES-OCEANS, V85, P7350, DOI 10.1029/JC085iC12p07350; REINHARDT TE, 1995, ENVIRON SCI TECHNOL, V29, P825, DOI 10.1021/es00003a034; Rhew RC, 2000, NATURE, V403, P292, DOI 10.1038/35002043; RUDOLPH J, 1995, J ATMOS CHEM, V22, P67, DOI 10.1007/BF00708182; Saxena D, 1998, APPL ENVIRON MICROB, V64, P2831; Warneke C, 1999, GLOBAL BIOGEOCHEM CY, V13, P9, DOI 10.1029/98GB02428; Watling R, 1998, MYCOL RES, V102, P769, DOI 10.1017/S0953756298006157; Yokouchi Y, 2002, NATURE, V416, P163, DOI 10.1038/416163a	29	148	152	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					206	209		10.1126/science.1085036	http://dx.doi.org/10.1126/science.1085036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855805				2022-12-28	WOS:000184056200040
J	Rider, TH; Petrovick, MS; Nargi, FE; Harper, JD; Schwoebel, ED; Mathews, RH; Blanchard, DJ; Bortolin, LT; Young, AM; Chen, JZ; Hollis, MA				Rider, TH; Petrovick, MS; Nargi, FE; Harper, JD; Schwoebel, ED; Mathews, RH; Blanchard, DJ; Bortolin, LT; Young, AM; Chen, JZ; Hollis, MA			A B cell-based sensor for rapid identification of pathogens	SCIENCE			English	Article							PHOTOPROTEIN; BACTERIA; FOOD; SITE	We report the use of genetically engineered cells in a pathogen identification sensor. This sensor uses B lymphocytes that have been engineered to emit light within seconds of exposure to specific bacteria and viruses. We demonstrated rapid screening of relevant samples and identification of a variety of pathogens at very low levels. Because of its speed, sensitivity, and specificity, this pathogen identification technology could prove useful for medical diagnostics, biowarfare defense, food- and water-quality monitoring, and other applications.	MIT, Lincoln Lab, Lexington, MA 02420 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Rider, TH (corresponding author), MIT, Lincoln Lab, Lexington, MA 02420 USA.	thor@ll.mit.edu	Harper, James D/B-8701-2011	Harper, James/0000-0001-7895-8268				Ackers ML, 1998, J INFECT DIS, V177, P1588, DOI 10.1086/515323; Belgrader P, 1999, SCIENCE, V284, P449, DOI 10.1126/science.284.5413.449; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; CORMIER MJ, 1989, PHOTOCHEM PHOTOBIOL, V49, P509, DOI 10.1111/j.1751-1097.1989.tb09202.x; Hough AJ, 2002, J FOOD PROTECT, V65, P1329, DOI 10.4315/0362-028X-65.8.1329; Lindqvist R, 1997, INT J FOOD MICROBIOL, V37, P73, DOI 10.1016/S0168-1605(97)00054-8; Lucore LA, 2000, APPL ENVIRON MICROB, V66, P1769, DOI 10.1128/AEM.66.5.1769-1776.2000; PARIKH VS, 1991, J EXP MED, V174, P1103, DOI 10.1084/jem.174.5.1103; Pourahmadi F, 2000, CLIN CHEM, V46, P1511; ROEHRIG JT, 1985, VIROLOGY, V142, P347, DOI 10.1016/0042-6822(85)90343-5; Rowe CA, 1999, ANAL CHEM, V71, P3846, DOI 10.1021/ac981425v; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1978, P NATL ACAD SCI USA, V75, P2611, DOI 10.1073/pnas.75.6.2611; TSUJI FI, 1986, P NATL ACAD SCI USA, V83, P8107, DOI 10.1073/pnas.83.21.8107; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601	15	204	248	0	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					213	215		10.1126/science.1084920	http://dx.doi.org/10.1126/science.1084920			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855808				2022-12-28	WOS:000184056200043
J	Sage, J; Miller, AL; Perez-Mancera, PA; Wysocki, JM; Jacks, T				Sage, J; Miller, AL; Perez-Mancera, PA; Wysocki, JM; Jacks, T			Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry	NATURE			English	Article							TUMOR-SUPPRESSOR; G(1) CONTROL; RB; SENESCENCE; GROWTH; INACTIVATION; FIBROBLASTS; EXPRESSION; APOPTOSIS; SYSTEM	Cancer cells arise from normal cells through the acquisition of a series of mutations in oncogenes and tumour suppressor genes(1). Mouse models of human cancer often rely on germline alterations that activate or inactivate genes of interest. One limitation of this approach is that germline mutations might have effects other than somatic mutations, owing to developmental compensation(2,3). To model sporadic cancers associated with inactivation of the retinoblastoma (RB) tumour suppressor gene in humans, we have produced a conditional allele of the mouse Rb gene. We show here that acute loss of Rb in primary quiescent cells is sufficient for cell cycle entry and has phenotypic consequences different from germline loss of Rb function. This difference is explained in part by functional compensation by the Rb-related gene p107. We also show that acute loss of Rb in senescent cells leads to reversal of the cellular senescence programme. Thus, the use of conditional knockout strategies might refine our understanding of gene function and help to model human cancer more accurately.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Jacks, T (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tjacks@mit.edu						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Marino S, 2000, GENE DEV, V14, P994; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169	24	423	430	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					223	228		10.1038/nature01764	http://dx.doi.org/10.1038/nature01764			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853964				2022-12-28	WOS:000184032700049
J	Tice, JA; Ettinger, B; Ensrud, K; Wallace, R; Blackwell, T; Cummings, SR				Tice, JA; Ettinger, B; Ensrud, K; Wallace, R; Blackwell, T; Cummings, SR			Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) study - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; BREAST-CANCER; MENOPAUSAL SYMPTOMS; ESTROGEN/PROGESTIN REPLACEMENT; SOY PHYTOESTROGENS; ESTROGEN-RECEPTORS; DISEASE OUTCOMES; HORMONE-THERAPY; PLASMA; POPULATION	Context Clinical trials demonstrating increased risk of cardiovascular disease and breast cancer among women randomized to hormone replacement therapy have increased interest in other therapies for menopausal symptoms. Dietary supplements containing isoflavones are widely used as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting their efficacy. Objective To compare the efficacy and safety of 2 dietary supplements derived from red clover with placebo in symptomatic menopausal women. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of menopausal women, aged 45 to 60 years, who were experiencing at least 35 hot flashes per week. The study was conducted between November 1999 and March 2001 at 3 US medical centers and included women who were recently postmenopausal (mean [SDI, 3.3 [4.5] years since menopause) experiencing 8.1 hot flashes per day. Women were exluded if they were vegetarians, consumed soy products more than once per week, or took medications affecting isoflavone absorption. Intervention After a 2-week placebo run-in, 252 participants were randomly assigned to Promensil (82 mg of total isoflavones per day), Rimostil (57 mg of total isoflavones per day), or an identical placebo, and followed-up for 12 weeks. Main Outcome Measure The primary outcome measure was the change in frequency of hot flashes measured by participant daily diaries. Secondary outcome measures included changes in quality of life and adverse events. Results Of 252 participants, 246 (98%) completed the 12-week protocol. The reductions in mean daily hot flash count at 12 weeks were similar for the Promensil (5.1), Rimostil (5.4), and placebo (5.0) groups. In comparison with the placebo group, participants in the Promensil group (41%; 95% confidence interval [CI], 29%-51%; P=.03), but not in the Rimostil group (34%; 95% Cl, 22%-46%; P=.74) reduced hot flashes more rapidly. Quality-of-life improvements and adverse events were comparable in the 3 groups. Conclusion Although the study provides some evidence for a biological effect of Promensil, neither supplement had a clinically important effect on hot flashes or other symptoms of menopause.	Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Prevent Sci grp, San Francisco, CA 94143 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Dept Med, Div Gen Internal Med, Minneapolis, MN 55417 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Iowa, Dept Epidemiol, Prevent Intervent Ctr, Iowa City, IA USA	University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Kaiser Permanente; University of Iowa	Tice, JA (corresponding author), Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Prevent Sci grp, 1701 Divisadero St,Suite 554, San Francisco, CA 94143 USA.	jtice@medicine.ucsf.edu		Tice, Jeffrey/0000-0002-9857-2028; Ensrud, Kristine/0000-0002-9069-3036				ADLERCREUTZ H, 1990, SCAND J CLIN LAB INV, V50, P3, DOI 10.3109/00365519009085798; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; [Anonymous], 2000, Consum Rep, V65, P17; Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571; Barentsen R, 2001, MATURITAS, V38, P123, DOI 10.1016/S0378-5122(00)00212-7; BARNES S, 1994, J AGR FOOD CHEM, V42, P2466, DOI 10.1021/jf00047a019; BOULET MJ, 1994, MATURITAS, V19, P157, DOI 10.1016/0378-5122(94)90068-X; Brzezinski A, 1997, MENOPAUSE, V4, P89; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; Dalais F S, 1998, Climacteric, V1, P124, DOI 10.3109/13697139809085527; ERLIK Y, 1982, OBSTET GYNECOL, V59, P403; Freedman RR, 2002, MENOPAUSE, V9, P151, DOI 10.1097/00042192-200205000-00001; Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3; Gold EB, 2000, AM J EPIDEMIOL, V152, P463, DOI 10.1093/aje/152.5.463; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Greene JG, 1998, MATURITAS, V29, P25, DOI 10.1016/S0378-5122(98)00025-5; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Han KK, 2002, OBSTET GYNECOL, V99, P389, DOI 10.1016/S0029-7844(01)01744-6; Harris PF, 2002, J PAIN SYMPTOM MANAG, V23, P501, DOI 10.1016/S0885-3924(02)00395-0; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; HUTTON JD, 1978, LANCET, V1, P678; Jeri AR, 2002, FEMALE PATIENT, V27, P35; Kam IW, 2002, MENOPAUSE, V9, P72, DOI 10.1097/00042192-200201000-00011; King RA, 1998, AM J CLIN NUTR, V67, P867, DOI 10.1093/ajcn/67.5.867; Knight D C, 1999, Climacteric, V2, P79, DOI 10.3109/13697139909025570; Knight D C, 2001, Climacteric, V4, P13, DOI 10.1080/713605031; Kotsopoulos D, 2000, Climacteric, V3, P161, DOI 10.1080/13697130008500108; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LOCK M, 1991, LANCET, V337, P1270, DOI 10.1016/0140-6736(91)92931-Q; LOCK M, 1994, EXP GERONTOL, V29, P307, DOI 10.1016/0531-5565(94)90011-6; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860; MURKIES AL, 1995, MATURITAS, V21, P189, DOI 10.1016/0378-5122(95)00899-V; MURPHY PA, 1982, FOOD TECHNOL-CHICAGO, V36, P60; NACHTIGALL L, 1999, P 81 ANN M END SOC J; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scambia G, 2000, MENOPAUSE, V7, P105, DOI 10.1097/00042192-200007020-00006; Setchell KDR, 2001, J NUTR, V131, p1362S, DOI 10.1093/jn/131.4.1362S; Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280; St Germain A, 2001, MENOPAUSE, V8, P17, DOI 10.1097/00042192-200101000-00005; TANG GWK, 1994, MATURITAS, V19, P177, DOI 10.1016/0378-5122(94)90069-8; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; van de Weijer PHM, 2002, MATURITAS, V42, P187, DOI 10.1016/S0378-5122(02)00080-4; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; Washburn S, 1999, MENOPAUSE, V6, P7; Watanabe S, 1998, J NUTR, V128, P1710, DOI 10.1093/jn/128.10.1710; White J P, 2000, Clin Excell Nurse Pract, V4, P277; Whiteman MK, 2003, OBSTET GYNECOL, V101, P264, DOI 10.1016/S0029-7844(02)02593-0; Xu X, 1998, CANCER EPIDEM BIOMAR, V7, P1101	51	186	197	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					207	214		10.1001/jama.290.2.207	http://dx.doi.org/10.1001/jama.290.2.207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851275				2022-12-28	WOS:000183989800025
J	Sampson, JR; Dolwani, S; Jones, S; Eccles, D; Ellis, A; Evans, DG; Frayling, I; Jordan, S; Maher, ER; Mak, T; Maynard, J; Pigatto, F; Shaw, J; Cheadle, JP				Sampson, JR; Dolwani, S; Jones, S; Eccles, D; Ellis, A; Evans, DG; Frayling, I; Jordan, S; Maher, ER; Mak, T; Maynard, J; Pigatto, F; Shaw, J; Cheadle, JP			Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH	LANCET			English	Article								Familial, adenomatous polyposis (FAP) and attenuated FAP are autosomal dominant disorders characterised by multiple colorectal adenomas and cancers. Both are caused by inherited mutations in the APC gene, and management includes genetic testing, colonoscopic surveillance, and prophylactic surgery for the relatives of index cases. Among 614 families recorded in six regional registers of polyposis in the UK, we identified 111 with neither dominant transmission nor evidence of APC mutation. Molecular genetic analysis showed that 25 had biallelic mutations of the MYH gene. Since our data show that MYH polyposis can be transmitted as an autosomal recessive trait, a change in genetic counselling, testing, and surveillance Is needed.	Univ Wales Coll Med, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; Royal Liverpool Hosp, Dept Gastroenterol, Liverpool L7 8XP, Merseyside, England; St Marys Hosp, Acad Unit med Genet, Reg Genet Serv, Manchester M13 0JH, Lancs, England; Addenbrookes Hosp, Dept Med Genet, Genet Mol Lab, Cambridge, England; Univ Birmingham, Sect Med & Mol Genet, Birmingham, W Midlands, England; W Midlands Reg Genet Serv, Birmingham, W Midlands, England	Cardiff University; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Manchester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham	Sampson, JR (corresponding author), Univ Wales Coll Med, Inst Med Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Evans, D Gareth/AAB-4308-2022; MAHER, EAMONN R/A-9507-2008; Dolwani, Sunil/C-9187-2013; Dolwani, Sunil/G-9730-2012; Dolwani, Sunil/M-4241-2016; Jones, Sian/A-5050-2012; Eccles, Diana/K-6327-2019	Evans, D Gareth/0000-0002-8482-5784; MAHER, EAMONN R/0000-0002-6226-6918; Eccles, Diana/0000-0002-9935-3169; Frayling, Ian/0000-0002-3420-0794					0	317	332	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					39	41		10.1016/S0140-6736(03)13805-6	http://dx.doi.org/10.1016/S0140-6736(03)13805-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853198				2022-12-28	WOS:000184056900012
J	Skidmore, M				Skidmore, M			Medical assistance and refugee safety in contemporary conflicts	LANCET			English	Editorial Material									Australian Natl Univ, Ctr Cross Cultural Studies, Canberra, ACT 0200, Australia	Australian National University	Skidmore, M (corresponding author), Australian Natl Univ, Ctr Cross Cultural Studies, Canberra, ACT 0200, Australia.							BOWLES E, 1998, FORCED MIGR REV  AUG, P1; Checchi F, 2003, LANCET, V362, P74, DOI 10.1016/S0140-6736(03)13813-5; Shan Human Rights Foundation Shan Women's Action Network, 2002, LIC RAP BURM MIL REG; SKIDMORE M, 2003, VIOLENCE WOMEN ASIA, P90; Smith M., 1999, BURMA INSURGENCY POL; *UNHCR, 2002, UNHCR GLOB APP 2003	6	1	1	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					75	75		10.1016/S0140-6736(03)13814-7	http://dx.doi.org/10.1016/S0140-6736(03)13814-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12854586				2022-12-28	WOS:000184056900029
J	van Woensel, JBM; van Aalderen, WMC; Kimpen, JLL				van Woensel, JBM; van Aalderen, WMC; Kimpen, JLL			Viral lower respiratory tract infection in infants and young children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SYNCYTIAL VIRUS-INFECTION; HIGH-RISK INFANTS; ANTIBIOTIC-TREATMENT; DOUBLE-BLIND; BRONCHIOLITIS; INFLUENZA; BACTERIAL; HOSPITALIZATIONS; EFFICACY; DISEASE		Emma Childrens Hosp, Acad Med Ctr, Paediat Intens Care Unit G8ZW, NL-1100 DD Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Utrecht, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Wilhelmina Kinderziekenhuis	van Woensel, JBM (corresponding author), Emma Childrens Hosp, Acad Med Ctr, Paediat Intens Care Unit G8ZW, POB 22660, NL-1100 DD Amsterdam, Netherlands.	j.b.vanwoensel@amc.uva.nl						Abul-Ainine A, 2002, ARCH DIS CHILD, V86, P276, DOI 10.1136/adc.86.4.276; Adcock PM, 1998, ARCH PEDIAT ADOL MED, V152, P739; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Bont L, 2001, PEDIATR INFECT DIS J, V20, P277, DOI 10.1097/00006454-200103000-00012; Brooks AM, 1999, PEDIATRICS, V104, P463, DOI 10.1542/peds.104.3.463; Bulow SM, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e77; Clark SJ, 2000, ARCH DIS CHILD, V83, P313, DOI 10.1136/adc.83.4.313; Clements ML, 1996, J INFECT DIS, V173, P44, DOI 10.1093/infdis/173.1.44; CONDON VR, 1991, J THORAC IMAG, V6, P31, DOI 10.1097/00005382-199107000-00006; Couch RB, 2000, NEW ENGL J MED, V343, P1778, DOI 10.1056/NEJM200012143432407; Dobson JV, 1998, PEDIATRICS, V101, P361, DOI 10.1542/peds.101.3.361; FIELD CMB, 1966, BMJ-BRIT MED J, V1, P83, DOI 10.1136/bmj.1.5479.83; Flores G, 1997, PEDIATRICS, V100, P233, DOI 10.1542/peds.100.2.233; FRIIS B, 1984, ARCH DIS CHILD, V59, P1038, DOI 10.1136/adc.59.11.1038; GADOMSKI AM, 1994, PEDIATRICS, V93, P907; Garrison MM, 2000, PEDIATRICS, V105, pCP4, DOI 10.1542/peds.105.4.e44; Gavin PJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e9; Graham SM, 2002, BRIT MED BULL, V61, P133, DOI 10.1093/bmb/61.1.133; Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289; GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HALL CB, 1988, J PEDIATR-US, V113, P266; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; Henderson M, 2001, PEDIATR INFECT DIS J, V20, P214, DOI 10.1097/00006454-200102000-00019; HIETALA J, 1989, PEDIATR INFECT DIS J, V8, P683, DOI 10.1097/00006454-198910000-00004; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; HRUSKA JF, 1982, ANTIMICROB AGENTS CH, V21, P125, DOI 10.1128/AAC.21.1.125; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Jartti T, 2002, LANCET, V360, P1393, DOI 10.1016/S0140-6736(02)11391-2; KELLNER JD, 1998, BRONCHODILATOR THERA; Kimpen JLL, 1997, PEDIATR INFECT DIS J, V16, P479, DOI 10.1097/00006454-199705000-00004; Klassen TP, 1997, J PEDIATR-US, V130, P191, DOI 10.1016/S0022-3476(97)70342-1; Kneyber MCJ, 2002, PEDIATR INFECT DIS J, V21, P685, DOI 10.1097/00006454-200207000-00017; KORPPI M, 1989, PEDIATR INFECT DIS J, V8, P687, DOI 10.1097/00006454-198910000-00005; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350; MCCONNOCHIE KM, 1995, J PEDIATR-US, V126, P220, DOI 10.1016/S0022-3476(95)70548-1; Miedema CJ, 2001, PEDIATR INFECT DIS J, V20, P160, DOI 10.1097/00006454-200102000-00008; Muller-Pebody B, 2002, EPIDEMIOL INFECT, V129, P99, DOI 10.1017/S095026880200729X; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2001, PEDIATR INFECT DIS J, V20, P733, DOI 10.1097/00006454-200108000-00004; Nichol KL, 2003, VACCINE, V21, P2207, DOI 10.1016/S0264-410X(03)00029-X; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; Purcell K, 2002, ARCH PEDIAT ADOL MED, V156, P322, DOI 10.1001/archpedi.156.4.322; RODRIGUEZ WJ, 1994, J PEDIATR-US, V125, P129, DOI 10.1016/S0022-3476(94)70139-3; Roeckl-Wiedmann I, 2003, EUR J PEDIATR, V162, P237, DOI 10.1007/s00431-002-1106-6; Roosevelt G, 1996, LANCET, V348, P292, DOI 10.1016/S0140-6736(96)02285-4; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Simoes EAF, 2001, VACCINE, V20, P954, DOI 10.1016/S0264-410X(01)00388-7; Simoes EAF, 2002, RESP RES, V3, DOI 10.1186/rr187; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; van Woensel JBM, 2003, THORAX, V58, P383, DOI 10.1136/thorax.58.5.383; VINCENTE D, 2003, EMERG INFECT DIS, V9, P602; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Willson DF, 2001, PEDIATRICS, V108, P851, DOI 10.1542/peds.108.4.851; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X	63	69	79	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2003	327	7405					36	40C		10.1136/bmj.327.7405.36	http://dx.doi.org/10.1136/bmj.327.7405.36			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842956	Green Submitted, Green Published			2022-12-28	WOS:000184062700026
J	Cohn, BA; Cirillo, PM; Wolff, MS; Schwingi, PJ; Cohen, RD; Sholtz, RI; Ferrara, A; Christianson, RE; van den Berg, BJ; Siiteri, PK				Cohn, BA; Cirillo, PM; Wolff, MS; Schwingi, PJ; Cohen, RD; Sholtz, RI; Ferrara, A; Christianson, RE; van den Berg, BJ; Siiteri, PK			DDT and DDE exposure in mothers and time to pregnancy in daughters	LANCET			English	Article							ORGANOCHLORINES	Reproductive-tract anomalies after administration of the potent oestrogen, diethylstilboestrol, in pregnant women raised concerns about the reproductive effects of exposure to weakly oestrogenic environmental contaminants such as bis[4-chlorophenyl]-1,1,1-trichloroethane (p,p'-DDT) or its metabolites, such as bis[4-chlorophenyl]-1,1-dichloroethene (p,p'-DDE). We measured p,p'-DDT and p,p'-DDE in preserved maternal serum samples drawn 1-3 days after delivery between 1960 and 1963. We recorded time to pregnancy In 289 eldest daughters 28-31 years later. Daughters' probability of pregnancy fell by 32% per 10 mug/L p,p'-DDT in maternal serum (95% CI 11-48). By contrast, the probability of pregnancy increased 16% per 10 mug/L p,p'-DDE (6-27). The decreased fecundability associated with prenatal p,p'-DDT remains unexplained. We speculate that the antiandrogenic activity of p,p'-DDE may mitigate harmful androgen effects on the ovary during gestation or early life.	Inst Publ Hlth, Ctr Res Womens & Childrens Hlth, Berkeley, CA 94709 USA; Mt Sinai Sch Med, New York, NY USA; Univ N Carolina, Chapel Hill, NC USA; Kaiser Permanente, Div Res, Oakland, CA USA; Univ Calif San Francisco, Sch Med, Dept Obstet, San Francisco, CA USA; Univ Calif San Francisco, Sch Med, Dept Gynecol, San Francisco, CA USA; Univ Calif San Francisco, Sch Med, Dept Reprod Sci, San Francisco, CA USA	Public Health Institute; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cohn, BA (corresponding author), Inst Publ Hlth, Ctr Res Womens & Childrens Hlth, 1683 Shattuck Ave,Suite B, Berkeley, CA 94709 USA.				NICHD NIH HHS [N01 HD 63258] Funding Source: Medline; NIEHS NIH HHS [R01 ES08345] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD063258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008345] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott DH, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740001; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P47; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; Longnecker MP, 1999, ARCH ENVIRON HEALTH, V54, P110, DOI 10.1080/00039899909602244; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; SAXENA MC, 1981, ARCH TOXICOL, V48, P127, DOI 10.1007/BF00310482; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; WEINBERG CR, 1989, AM J EPIDEMIOL, V129, P1072, DOI 10.1093/oxfordjournals.aje.a115211	9	104	106	1	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2205	2206		10.1016/S0140-6736(03)13776-2	http://dx.doi.org/10.1016/S0140-6736(03)13776-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842376				2022-12-28	WOS:000183815600015
J	Redelmeier, DA; Tibshirani, RJ; Evans, L				Redelmeier, DA; Tibshirani, RJ; Evans, L			Traffic-law enforcement and risk of death from motor-vehicle crashes: case-crossover study	LANCET			English	Article							DRUNK DRIVERS; SAFETY	Background Driving offences and traffic deaths are common in countries with high rates of motor-vehicle use. We tested whether traffic convictions, because of their direct effect on the recipient, might be associated with a reduced risk of fatal motor-vehicle crashes. Methods We identified licensed drivers in Ontario, Canada, who had been involved in fatal crashes in the past 11 years. We used the case-crossover design to analyse the protective effect of recent convictions on individual drivers. Findings 8975 licensed drivers had fatal crashes during the study period. 21501 driving convictions were recorded for all drivers from the date of obtaining a full licence to the date of fatal crash, equivalent to about one conviction per driver every 5 years. The risk of a fatal crash in the month after a conviction was about 35% lower than in a comparable month with no conviction for the same driver (95% CI 20-45, p=0.0002). The benefit lessened substantially by 2 months and was not significant by 3-4 months. The benefit was not altered by age, previous convictions, and other personal characteristics; was greater for speeding violations with penalty points than speeding violations without points; was no different for crashes of differing severity; and was not seen in drivers whose licences were suspended. Interpretation Traffic-law enforcement effectively reduces the frequency of fatal motor-vehicle crashes in countries with high rates of motor-vehicle use. Inconsistent enforcement, therefore, may contribute to thousands of deaths each year worldwide.	Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Inst Clin Evaluat Sci Ontario, Toronto, ON, Canada; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Sci Serving Soc, Bloomfield Hills, MI USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Stanford University; Stanford University	Redelmeier, DA (corresponding author), Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Sunnybrook & Womens Coll Hlth Sci Ctr, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							AUSTIN RH, 1987, J TRAUMA, V27, P719, DOI 10.1097/00005373-198707000-00005; Blincoe LJ., 2002, EC IMPACT MOTOR VEHI; BOYLE J, 1998, DTNH2295C05096 NAT H; BREWER RD, 1994, NEW ENGL J MED, V331, P513, DOI 10.1056/NEJM199408253310806; Daigneault G, 2002, ACCIDENT ANAL PREV, V34, P257, DOI 10.1016/S0001-4575(01)00014-8; EVANS L, 1991, TRAFFIC SAFETY DRIVE, P311; EVANS L, IN PRESS AM J PUBLIC; FOLEY JP, 1987, ACCIDENT ANAL PREV, V19, P479, DOI 10.1016/0001-4575(87)90048-0; Graham John D., 1989, AUTO SAFETY ASSESSIN; *INS I HIGHW SAF, 2002, STATUS REPORT, V37, P2; Jonah B, 1999, ACCIDENT ANAL PREV, V31, P421, DOI 10.1016/S0001-4575(98)00081-5; Krug E., 1999, INJURY LEADING CAUSE; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; MCFARLAND RA, 1957, NEW ENGL J MED, V256, P792, DOI 10.1056/NEJM195704252561706; Min ST, 1998, CAN J PUBLIC HEALTH, V89, P157, DOI 10.1007/BF03404465; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; *ONT MIN TRANSP, 1994, ONT ROAD SAF ANN REP; Redelmeier DA, 1997, J CLIN EPIDEMIOL, V50, P1281, DOI 10.1016/S0895-4356(97)00196-0; REHM CG, 1993, ANN EMERG MED, V22, P1295, DOI 10.1016/S0196-0644(05)80110-6; Retting Richard A, 2003, Traffic Inj Prev, V4, P17, DOI 10.1080/15389580309858; SINEK J, 2002, WORLD WHEELS, V20, P4; SODERSTROM CA, 1977, NEW ENGL J MED, V297, P1356; Sorock G S, 2001, Inj Prev, V7 Suppl 1, pi38, DOI 10.1136/ip.7.suppl_1.i38; TREAT JR, 1980, HSRI RES REV     MAY; Tyler TR, 1997, AM J COMP LAW, V45, P871, DOI 10.2307/841024; Waller PF, 2002, ANNU REV PUBL HEALTH, V23, P93, DOI 10.1146/annurev.publhealth.23.100901.140522	26	78	78	2	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2177	2182		10.1016/S0140-6736(03)13770-1	http://dx.doi.org/10.1016/S0140-6736(03)13770-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	695DJ	12842370				2022-12-28	WOS:000183815600009
J	Chan, RC; Chan, A; Jeon, M; Wu, TF; Pasqualone, D; Rougvie, AE; Meyer, BJ				Chan, RC; Chan, A; Jeon, M; Wu, TF; Pasqualone, D; Rougvie, AE; Meyer, BJ			Chromosome cohesion is regulated by a clock gene paralogue TIM-1	NATURE			English	Article							SISTER-CHROMATID COHESION; CAENORHABDITIS-ELEGANS; C-ELEGANS; X-CHROMOSOME; DOSAGE COMPENSATION; MEIOTIC PROPHASE; PROTEIN; RECOMBINATION; CONDENSATION; DROSOPHILA	Faithful transmission of the genome requires that a protein complex called cohesin establishes and maintains the regulated linkage between replicated chromosomes before their segregation(1,2). Here we report the unforeseen participation of Caenorhabditis elegans TIM-1, a paralogue of the Drosophila clock protein TIMELESS, in the regulation of chromosome cohesion. Our biochemical experiments defined the C. elegans cohesin complex and revealed its physical association with TIM-1. Functional relevance of the interaction was demonstrated by aberrant mitotic chromosome behaviour, embryonic lethality and defective meiotic chromosome cohesion caused by the disruption of either TIM-1 or cohesin. TIM-1 depletion prevented the assembly of non-SMC ( structural maintenance of chromosome) cohesin subunits onto meiotic chromosomes; however, unexpectedly, a partial cohesin complex composed of SMC components still loaded. Further disruption of cohesin activity in meiosis by the simultaneous depletion of TIM-1 and an SMC subunit decreased homologous chromosome pairing before synapsis, revealing a new role for cohesin in metazoans. On the basis of comparisons between TIMELESS homologues in worms, flies and mice, we propose that chromosome cohesion, rather than circadian clock regulation, is the ancient and conserved function for TIMELESS-like proteins.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588; Chan, Raymond/0000-0003-3397-2351				Benna C, 2000, CURR BIOL, V10, pR512, DOI 10.1016/S0960-9822(00)00594-7; BROVERMAN SA, 1994, GENETICS, V136, P119; Chu DS, 2002, GENE DEV, V16, P796, DOI 10.1101/gad.972702; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; HODGKIN J, 1979, GENETICS, V91, P67; Howe M, 2001, J CELL BIOL, V153, P1227, DOI 10.1083/jcb.153.6.1227; HOWELL AM, 1987, GENET RES, V49, P207, DOI 10.1017/S0016672300027099; Jeon M, 1999, SCIENCE, V286, P1141, DOI 10.1126/science.286.5442.1141; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MacQueen AJ, 2002, GENE DEV, V16, P2428, DOI 10.1101/gad.1011602; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Panizza S, 2000, CURR BIOL, V10, P1557, DOI 10.1016/S0960-9822(00)00854-X; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; SCHEDL T, 1997, C ELEGANS, V2, P241; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Vodovar N, 2002, CURR BIOL, V12, pR610, DOI 10.1016/S0960-9822(02)01130-2; Williams JA, 2001, ANNU REV PHYSIOL, V63, P729, DOI 10.1146/annurev.physiol.63.1.729; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	29	128	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					1002	1009		10.1038/nature01697	http://dx.doi.org/10.1038/nature01697			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827206				2022-12-28	WOS:000183753900054
J	Maurer, BT				Maurer, BT			Eventide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3218	3218		10.1001/jama.289.24.3218	http://dx.doi.org/10.1001/jama.289.24.3218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824195	Bronze			2022-12-28	WOS:000183704600001
J	Daley, GQ				Daley, GQ			Cloning and stem cells - Handicapping the political and scientific debates	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Boston, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School	Daley, GQ (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.								0	13	13	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					211	212		10.1056/NEJMp030088	http://dx.doi.org/10.1056/NEJMp030088			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867604				2022-12-28	WOS:000184165700003
J	de la Chapelle, A				de la Chapelle, A			Microsatellite instability	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	de la Chapelle, A (corresponding author), Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA.								0	138	140	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					209	210		10.1056/NEJMp038099	http://dx.doi.org/10.1056/NEJMp038099			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867603				2022-12-28	WOS:000184165700002
J	Fowler, RA; Lapinsky, SE; Hallett, D; Detsky, AS; Sibbald, WJ; Slutsky, AS; Stewart, TE				Fowler, RA; Lapinsky, SE; Hallett, D; Detsky, AS; Sibbald, WJ; Slutsky, AS; Stewart, TE		Toronto SARS Critical Care Grp	Critically ill patients with severe acute respiratory syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MECHANICAL VENTILATION; HONG-KONG; OUTCOMES; OUTBREAK; SARS; INFLUENZA; MORTALITY; AIDS	Context Severe acute respiratory syndrome (SARS) is a newly recognized infectious disease capable of causing severe respiratory failure. Objective To determine the epidemiological features, course, and outcomes of patients with SARS-related critical illness. Design, Setting, and Patients Retrospective case series of 38 adult patients with SARS-related critical illness admitted to 13 intensive care units (ICUs) in the Toronto area between the onset of the outbreak and April 15, 2003. Data were collected daily during the first 7 days in the ICUs, and patients were followed up for 28 days. Main Outcome Measures The primary Outcome was mortality at 28 days alter ICU admission. Secondary outcomes included rate of SARS-related critical illness, number of tertiary care ICUs and staff placed under quarantine, and number of health care workers (HCWs) contracting SARS secondary to ICU-acquired transmission. Results Of 196 patients with SARS, 38 (19%) became critically ill, 7 (18%) of whom were HCWs. The median (interquartile range [IQR]) age of the 38 patients was 57.4 (39.0-69.6) years. The median (IQR) duration between initial symptoms and admission to the ICU was 8 (5-10) days. Twenty-nine (76%) required mechanical ventilation and 10 of these (34%) experienced barotrauma. Mortality at 28 days was 13 (34%) of 38 patients and for those requiring mechanical ventilation, mortality was 13 (45%) of 29.. Six patients (16%) remained mechanically ventilated at 28 days. Two of these patients had died by 8 weeks' follow-up. Patients who died were more often older, had preexisting diabetes mellitus,. and on admission to hospital were more likely to have bilateral radiographic infiltrates. Transmission of SARS in 6 study ICUs led to closure of 73 medical-surgical ICU beds. In 2 university ICUs, 164 HCWs were quarantined and 16 (10%) developed SARS. Conclusions Critical illness was common among patients with SARS. Affected patients had primarily single-organ respiratory failure, and half of mechanically ventilated patients died. The SARS outbreak greatly strained regional critical care resources.	Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lapinsky, SE (corresponding author), Mt Sinai Hosp, Suite 1825,600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Slutsky, Arthur/M-3325-2019; Lapinsky, Stephen/C-4624-2015; Slutsky, Arthur S/A-6013-2008	Lapinsky, Stephen/0000-0002-6930-0306; Slutsky, Arthur S/0000-0002-6063-3876				ANTINORI A, 1993, EUR J EPIDEMIOL, V9, P183, DOI 10.1007/BF00158789; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lapinsky SE, 2003, INTENS CARE MED, V29, P870, DOI 10.1007/s00134-003-1821-0; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Maunder R, 2003, CAN MED ASSOC J, V168, P1245; MCCLELLAN MD, 1991, CHEST, V100, P1224, DOI 10.1378/chest.100.5.1224; MONTANER JSG, 1992, CHEST, V102, P1823, DOI 10.1378/chest.102.6.1823; Oliveira EC, 2001, CHEST, V119, P1717, DOI 10.1378/chest.119.6.1717; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; QUIST J, 1995, CHEST, V108, P415, DOI 10.1378/chest.108.2.415; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; Stewart TE, 2002, AM J RESP CRIT CARE, V166, P1421, DOI 10.1164/rccm.2210002; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; World Health Organization, 2003, CAS DEF SURV SEV AC; World Health Organization, CUM NUMB REP PROB CA	22	228	237	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					367	373		10.1001/jama.290.3.367	http://dx.doi.org/10.1001/jama.290.3.367			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699WK	12865378				2022-12-28	WOS:000184078800031
J	Brandel, JP; Preece, M; Brown, P; Croes, E; Laplanche, JL; Agid, Y; Will, R; Alperovitch, A				Brandel, JP; Preece, M; Brown, P; Croes, E; Laplanche, JL; Agid, Y; Will, R; Alperovitch, A			Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK	LANCET			English	Article							CREUTZFELDT-JAKOB-DISEASE	Since homozygosity MM at codon 129 of the prion protein gene is a recognised risk factor in all forms of Creutzfeldt-Jakob disease (CJD), we studied the distribution of codon 129 polymorphism in patients in France and in the UK with CJD transmitted iatrogenically by human growth hormone. The overall frequencies of codon 1.29 genotypes in these patients differed from those in the population unaffected by CJD. An excess of VV homozygotes was noted among those with iatrogenic CJD compared with sporadic CJD cases. The proportion of MM genotype in UK patients was surprisingly low (4%) compared with that in French patients (62%). There is no evident explanation for this different distribution, which might be due to infection with different strains of prion in human growth hormone.	Salpetriere Hosp, Natl Reference Ctr Latrogen CJD, F-75651 Paris 13, France; Salpetriere Hosp, INSERM, U360, F-75651 Paris, France; Inst Child Hlth, London, England; NIH, Lab CNS Studies, Bethesda, MD 20892 USA; Erasmus Univ, Sch Med, Rotterdam, Netherlands; Lariboisiere Hosp, Cent Lab Biochem, Paris, France; Western Gen Hosp, CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; National Institutes of Health (NIH) - USA; Erasmus University Rotterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Edinburgh	Brandel, JP (corresponding author), Salpetriere Hosp, Natl Reference Ctr Latrogen CJD, F-75651 Paris 13, France.		LAPLANCHE, Jean-Louis/S-8707-2016	LAPLANCHE, Jean-Louis/0000-0003-2836-2903				Brown P, 2000, NEUROLOGY, V55, P1075, DOI 10.1212/WNL.55.8.1075; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; LAPLANCHE JL, 1994, NEUROLOGY, V44, P2347, DOI 10.1212/WNL.44.12.2347; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Swerdlow AJ, 2002, LANCET, V360, P273, DOI 10.1016/S0140-6736(02)09519-3	5	74	75	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					128	130		10.1016/S0140-6736(03)13867-6	http://dx.doi.org/10.1016/S0140-6736(03)13867-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867116				2022-12-28	WOS:000184089200015
J	Palanivelu, R; Brass, L; Edlund, AF; Preuss, D				Palanivelu, R; Brass, L; Edlund, AF; Preuss, D			Pollen tube growth and guidance is regulated by POP2, an Arabidopsis gene that controls GABA levels	CELL			English	Article							CELL-MOVEMENT; TIP GROWTH; GLUTAMATE; RECEPTORS; FEMALE; ACID; SIGNALS; IDENTIFICATION; FERTILIZATION; TRANSAMINASE	During angiosperm reproduction, pollen grains form a tube that navigates through female tissues to the micropyle, delivering sperm to the egg; the signals that mediate this process are poorly understood. Here, we describe a role for gamma-amino butyric acid (GABA) in pollen tube growth and guidance. In vitro, GABA stimulates pollen tube growth, although vast excesses are inhibitory. The Arabidopsis POP2 gene encodes a transaminase that degrades GABA and contributes to the formation of a gradient leading up to the micropyle. pop2 flowers accumulate GABA, and the growth of many pop2 pollen tubes is arrested, consistent with their in vitro GABA hypersensitivity. Some pop2 tubes continue to grow toward ovules, yet they are misguided, presumably because they target ectopic GABA on the ovule surface. Interestingly, wild-type tubes exhibit normal growth and guidance in pop2 pistils, perhaps by degrading excess GABA and sharpening the gradient leading to the micropyle.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Preuss, D (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA.	dpreuss@midway.uchicago.edu	Palanivelu, Ravishankar/AAE-6664-2020					Barker JL, 1998, PERSPECT DEV NEUROBI, V5, P305; Baum G, 1996, EMBO J, V15, P2988, DOI 10.1002/j.1460-2075.1996.tb00662.x; Behar TN, 2001, CEREB CORTEX, V11, P744, DOI 10.1093/cercor/11.8.744; BOWMAN JL, 1993, ARABIDOPSIS ATLAS MO, P135; Brenner ED, 2000, PLANT PHYSIOL, V124, P1615, DOI 10.1104/pp.124.4.1615; Brice NL, 2002, DIABETOLOGIA, V45, P242, DOI 10.1007/s00125-001-0750-0; CHAO CY, 1971, AM J BOT, V58, P649, DOI 10.2307/2441009; Christensen CA, 2002, PLANT CELL, V14, P2215, DOI 10.1105/tpc.002170; CHUNG ID, 1992, PLANT PHYSIOL, V99, P659, DOI 10.1104/pp.99.2.659; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; Gamel-Didelon K, 2002, NEUROENDOCRINOLOGY, V76, P170, DOI 10.1159/000064523; GIBSON KM, 1990, BIOMED ENVIRON MASS, V19, P89, DOI 10.1002/bms.1200190207; HANSEN GH, 1987, NEUROTROPHIC ACTIVIT, P109; Higashiyama T, 2001, SCIENCE, V293, P1480, DOI 10.1126/science.1062429; Huck N, 2003, DEVELOPMENT, V130, P2149, DOI 10.1242/dev.00458; Johnson MA, 2002, DEV CELL, V2, P273, DOI 10.1016/S1534-5807(02)00130-2; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; KATER SB, 1991, J NEUROSCI, V11, P891; Kathiresan A, 1998, PLANT GROWTH REGUL, V26, P131, DOI 10.1023/A:1006107815064; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; Lam HM, 1998, NATURE, V396, P125, DOI 10.1038/24066; Lasswell J, 2000, PLANT CELL, V12, P2395, DOI 10.1105/tpc.12.12.2395; Li H, 1999, PLANT CELL, V11, P1731, DOI 10.1105/tpc.11.9.1731; Lord E, 2000, TRENDS PLANT SCI, V5, P368, DOI 10.1016/S1360-1385(00)01744-1; Maitre M, 2000, ALCOHOL, V20, P277, DOI 10.1016/S0741-8329(99)00092-0; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; Medina-Kauwe LK, 1998, NEUROBIOL DIS, V5, P89, DOI 10.1006/nbdi.1998.0184; Mollet JC, 2000, PLANT CELL, V12, P1737, DOI 10.1105/tpc.12.9.1737; Neff MM, 1998, PLANT J, V14, P387, DOI 10.1046/j.1365-313X.1998.00124.x; Palanivelu R, 2000, TRENDS CELL BIOL, V10, P517, DOI 10.1016/S0962-8924(00)01849-3; Pinal CS, 1998, PERSPECT DEV NEUROBI, V5, P109; Prell J, 2002, MICROBIOL-SGM, V148, P615, DOI 10.1099/00221287-148-2-615; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Ray S, 1997, DEVELOPMENT, V124, P2489; Riffell JA, 2002, J EXP BIOL, V205, P1439; ROSENTHAL GA, 1994, BIOSYNTHESIS MOL REG, P245; Rotman N, 2003, CURR BIOL, V13, P432, DOI 10.1016/S0960-9822(03)00093-9; Satin LS, 1998, ENDOCRINE, V8, P213, DOI 10.1385/ENDO:8:3:213; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; Shimizu KK, 2000, DEVELOPMENT, V127, P4511; Van Cauwenberghe OR, 2002, CAN J BOT, V80, P933, DOI [10.1139/B02-087, 10.1139/b02-087]; Villanneva JM, 1999, GENE DEV, V13, P3160, DOI 10.1101/gad.13.23.3160; Wilhelmi LK, 1996, SCIENCE, V274, P1535, DOI 10.1126/science.274.5292.1535; Wolters-Arts M, 1998, NATURE, V392, P818, DOI 10.1038/33929; Wu HM, 2000, PLANT J, V22, P165, DOI 10.1046/j.1365-313x.2000.00731.x	47	391	423	2	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					47	59		10.1016/S0092-8674(03)00479-3	http://dx.doi.org/10.1016/S0092-8674(03)00479-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859897	Bronze			2022-12-28	WOS:000184219900005
J	Scully, MO; Zubairy, MS				Scully, MO; Zubairy, MS			Playing tricks with slow light	SCIENCE			English	Editorial Material							ELECTROMAGNETICALLY INDUCED TRANSPARENCY; QUANTUM COMMUNICATION; ATOMIC ENSEMBLES; ULTRASLOW		Texas A&M Univ, Dept Phys, College Stn, TX 77843 USA; Texas A&M Univ, Inst Quantum Studies, College Stn, TX 77843 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Princeton University	Scully, MO (corresponding author), Texas A&M Univ, Dept Phys, College Stn, TX 77843 USA.	scully@tamu.edu; zubairy@physics.tamu.edu						Bigelow MS, 2003, SCIENCE, V301, P200, DOI 10.1126/science.1084429; BOLLER KJ, 1991, PHYS REV LETT, V66, P2593, DOI 10.1103/PhysRevLett.66.2593; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Harris SE, 1997, PHYS TODAY, V50, P36, DOI 10.1063/1.881806; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; Kim YH, 2000, PHYS REV LETT, V84, P1, DOI 10.1103/PhysRevLett.84.1; KOCHAROVSKAYA O, 1992, PHYS REP, V219, P175, DOI 10.1016/0370-1573(92)90135-M; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; Matsko AB, 2001, ADV ATOM MOL OPT PHY, V46, P191, DOI 10.1016/S1049-250X(01)80064-1; Rostovtsev Y, 2002, OPT PHOTONICS NEWS, V13, P44, DOI 10.1364/OPN.13.6.000044; Scully M.O., 1997, QUANTUM OPT; Scully MO, 2002, P NATL ACAD SCI USA, V99, P10994, DOI 10.1073/pnas.172290899; Turukhin AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.023602; van der Wal CH, 2003, SCIENCE, V301, P196, DOI 10.1126/science.1085946	14	27	27	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					181	182		10.1126/science.1087097	http://dx.doi.org/10.1126/science.1087097			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855798				2022-12-28	WOS:000184056200031
J	Zhang, LI; Tan, AYY; Schreiner, CE; Merzenich, MM				Zhang, LI; Tan, AYY; Schreiner, CE; Merzenich, MM			Topography and synaptic shaping of direction selectivity in primary auditory cortex	NATURE			English	Article							RECEPTIVE-FIELDS; CORTICAL-NEURONS; UNIT RESPONSES; IN-VIVO; CAT; FREQUENCY; RAT; ORGANIZATION; INHIBITION; PATTERNS	The direction of frequency-modulated ( FM) sweeps is an important temporal cue in animal and human communication. FM direction-selective neurons are found in the primary auditory cortex (A1)(1,2), but their topography and the mechanisms underlying their selectivity remain largely unknown. Here we report that in the rat A1, direction selectivity is topographically ordered in parallel with characteristic frequency (CF): low CF neurons preferred upward sweeps, whereas high CF neurons preferred downward sweeps. The asymmetry of 'inhibitory sidebands', suppressive regions flanking the tonal receptive field (TRF) of the spike response, also co-varied with CF. In vivo whole-cell recordings showed that the direction selectivity already present in the synaptic inputs was enhanced by cortical synaptic inhibition, which suppressed the synaptic excitation of the nonpreferred direction more than that of the preferred. The excitatory and inhibitory synaptic TRFs had identical spectral tuning, but with inhibition delayed relative to excitation. The spectral asymmetry of the synaptic TRFs co-varied with CF, as had direction selectivity and sideband asymmetry, and thus suggested a synaptic mechanism for the shaping of FM direction selectivity and its topographic ordering.	Univ Calif San Francisco, Coleman Mem Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Zhang, LI (corresponding author), Univ Calif San Francisco, Coleman Mem Lab, San Francisco, CA 94143 USA.	lizhang@phy.ucsf.edu	Tan, Andrew/E-7752-2011	Tan, Andrew/0000-0002-4696-1347; Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260-08, R01 DC002260] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Anderson JS, 2000, J NEUROPHYSIOL, V84, P909, DOI 10.1152/jn.2000.84.2.909; Borg-Graham LJ, 1998, NATURE, V393, P369, DOI 10.1038/30735; BRITT R, 1976, J NEUROPHYSIOL, V39, P179, DOI 10.1152/jn.1976.39.1.179; Brosch M, 1997, J NEUROPHYSIOL, V77, P923, DOI 10.1152/jn.1997.77.2.923; CALFORD MB, 1995, J NEUROPHYSIOL, V73, P1876, DOI 10.1152/jn.1995.73.5.1876; CLOPTON BM, 1974, EXP NEUROL, V42, P532, DOI 10.1016/0014-4886(74)90076-4; De Ribaupierre F, 1972, Brain Res, V48, P185, DOI 10.1016/0006-8993(72)90178-3; deCharms RC, 1998, SCIENCE, V280, P1439, DOI 10.1126/science.280.5368.1439; Engert F, 2002, NATURE, V419, P470, DOI 10.1038/nature00988; Hirsch JA, 1998, J NEUROSCI, V18, P9517; Kowalski N, 1996, J NEUROPHYSIOL, V76, P3524, DOI 10.1152/jn.1996.76.5.3524; Margrie TW, 2002, PFLUG ARCH EUR J PHY, V444, P491, DOI 10.1007/s00424-002-0831-z; Mehta MR, 2000, NEURON, V25, P707, DOI 10.1016/S0896-6273(00)81072-7; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; MERZENICH MM, 1975, J NEUROPHYSIOL, V38, P231, DOI 10.1152/jn.1975.38.2.231; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882, DOI 10.1152/jn.1998.80.6.2882; Nelken I, 2000, EUR J NEUROSCI, V12, P549, DOI 10.1046/j.1460-9568.2000.00935.x; Ojima H, 2002, CEREB CORTEX, V12, P1079, DOI 10.1093/cercor/12.10.1079; Poon PWF, 2000, NEUROSCI LETT, V289, P9, DOI 10.1016/S0304-3940(00)01251-9; Rao RPN, 2000, ADV NEUR IN, V12, P164; Ricketts C, 1998, HEARING RES, V123, P27, DOI 10.1016/S0378-5955(98)00086-0; SALLY SL, 1988, J NEUROPHYSIOL, V59, P1627, DOI 10.1152/jn.1988.59.5.1627; Schnupp JWH, 2001, NATURE, V414, P200, DOI 10.1038/35102568; Schreiner CE, 2000, ANNU REV NEUROSCI, V23, P501, DOI 10.1146/annurev.neuro.23.1.501; SHAMMA SA, 1993, J NEUROPHYSIOL, V69, P367, DOI 10.1152/jn.1993.69.2.367; SUGA N, 1965, J PHYSIOL-LONDON, V181, P671, DOI 10.1113/jphysiol.1965.sp007791; VOLKOV IO, 1991, NEUROSCIENCE, V43, P307, DOI 10.1016/0306-4522(91)90295-Y; Zhang LI, 2001, NAT NEUROSCI, V4, P1123, DOI 10.1038/nn745; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665; Zhu JJ, 1999, J NEUROPHYSIOL, V81, P1171, DOI 10.1152/jn.1999.81.3.1171	30	298	302	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					201	205		10.1038/nature01796	http://dx.doi.org/10.1038/nature01796			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853959				2022-12-28	WOS:000184032700044
J	Gaeta, AL				Gaeta, AL			Collapsing light really shines	SCIENCE			English	Editorial Material							NONLINEAR DISPERSIVE MEDIA; TI-SAPPHIRE LASER; PULSES; AIR; BEAMS		Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14850 USA	Cornell University	Gaeta, AL (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14850 USA.		Gaeta, Alexander/AAE-2095-2019					ALFANO RR, 1989, SUPERCONTINUUM LASER, P13602; BESPALOV VI, 1966, JETP LETT-USSR, V3, P307; BRAUN A, 1995, OPT LETT, V20, P73, DOI 10.1364/OL.20.000073; CHIAO RY, 1964, PHYS REV LETT, V13, P479, DOI 10.1103/PhysRevLett.13.479; Diddams SA, 1998, OPT LETT, V23, P379, DOI 10.1364/OL.23.000379; Diels JC, 1997, SCI AM, V277, P50, DOI 10.1038/scientificamerican0897-50; Gaeta AL, 2000, PHYS REV LETT, V84, P3582, DOI 10.1103/PhysRevLett.84.3582; Mlejnek M, 1999, PHYS REV LETT, V83, P2938, DOI 10.1103/PhysRevLett.83.2938; Moll KD, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.203902; Rairoux P, 2000, APPL PHYS B-LASERS O, V71, P573, DOI 10.1007/s003400000375; Ranka JK, 1996, PHYS REV LETT, V77, P3783, DOI 10.1103/PhysRevLett.77.3783; ROTHENBERG JE, 1992, OPT LETT, V17, P583, DOI 10.1364/OL.17.000583; SILBERBERG Y, 1990, OPT LETT, V15, P1282, DOI 10.1364/OL.15.001282; SPENCE DE, 1991, OPT LETT, V16, P42, DOI 10.1364/OL.16.000042; Talebpour A, 1999, OPT COMMUN, V171, P285, DOI 10.1016/S0030-4018(99)00498-8; Tzortzakis S, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.213902; Tzortzakis S, 2001, PHYS REV LETT, V86, P5470, DOI 10.1103/PhysRevLett.86.5470; ZHAROVA NA, 1986, JETP LETT+, V44, P13	20	36	37	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					54	55		10.1126/science.1083629	http://dx.doi.org/10.1126/science.1083629			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843379				2022-12-28	WOS:000183914700025
J	He, JZ; Ritalahti, KM; Yang, KL; Koenigsberg, SS; Loffler, FE				He, JZ; Ritalahti, KM; Yang, KL; Koenigsberg, SS; Loffler, FE			Detoxification of vinyl chloride to ethene coupled to growth of an anaerobic bacterium	NATURE			English	Article							CHLOROETHENE-CONTAMINATED SITES; CIS-DICHLOROETHENE; REDUCTIVE DEHALOGENATION; TETRACHLOROETHENE; DECHLORINATION; DESULFUROMONAS; HYDROGEN; ACETATE	Tetrachloroethene (PCE) and trichloroethene (TCE) are ideal solvents for numerous applications, and their widespread use makes them prominent groundwater pollutants. Even more troubling, natural biotic and abiotic processes acting on these solvents lead to the accumulation of toxic intermediates (such as dichloroethenes) and carcinogenic intermediates (such as vinyl chloride)(1-4). Vinyl chloride was found in at least 496 of the 1,430 National Priorities List sites identified by the US Environmental Protection Agency, and its precursors PCE and TCE are present in at least 771 and 852 of these sites, respectively(5). Here we describe an unusual, strictly anaerobic bacterium that destroys dichloroethenes and vinyl chloride as part of its energy metabolism, generating environmentally benign products (biomass, ethene and inorganic chloride). This organism might be useful for cleaning contaminated subsurface environments and restoring drinking-water reservoirs.	Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Regenesis Bioremediat Prod, San Clemente, CA 92672 USA	University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology	Loffler, FE (corresponding author), Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA.		Loeffler, Frank E/M-8216-2013; Yang, Kun-Lin/C-2247-2011; Ritalahti, Kirsti M/B-4624-2010; He, Jianzhong/J-2704-2018	Yang, Kun-Lin/0000-0002-7958-9334; He, Jianzhong/0000-0003-1895-6628				Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063; Bunge M, 2003, NATURE, V421, P357, DOI 10.1038/nature01237; Coleman NV, 2002, APPL ENVIRON MICROB, V68, P6162, DOI 10.1128/AEM.68.12.6162-6171.2002; Coleman NV, 2002, APPL ENVIRON MICROB, V68, P2726, DOI 10.1128/AEM.68.6.2726-2730.2002; Cupples AM, 2003, APPL ENVIRON MICROB, V69, P953, DOI 10.1128/AEM.69.2.953-959.2003; Duhamel M, 2002, WATER RES, V36, P4193, DOI 10.1016/S0043-1354(02)00151-3; Gerhardt P, 1981, MANUAL METHODS GEN B; GRIBBLE GW, 1998, CHLORINATED COMPOUND, P972; He JZ, 2002, ENVIRON SCI TECHNOL, V36, P3945, DOI 10.1021/es025528d; He JZ, 2003, APPL ENVIRON MICROB, V69, P996, DOI 10.1128/AEM.69.2.996-1003.2003; Hendrickson ER, 2002, APPL ENVIRON MICROB, V68, P485, DOI 10.1128/AEM.68.2.485-495.2002; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Keppler F, 2002, ENVIRON SCI TECHNOL, V36, P2479, DOI 10.1021/es015611l; Kielhorn J, 2000, ENVIRON HEALTH PERSP, V108, P579, DOI 10.2307/3434875; Lendvay JM, 2003, ENVIRON SCI TECHNOL, V37, P1422, DOI 10.1021/es025985u; Loffler FE, 1999, APPL ENVIRON MICROB, V65, P4049; Loffler FE, 1997, APPL ENVIRON MICROB, V63, P4982, DOI 10.1128/AEM.63.12.4982-4985.1997; Loffler FE, 2003, DEHALOGENATION: MICROBIAL PROCESSES AND ENVIRONMENTAL APPLICATIONS, P53; Loffler FE, 2000, APPL ENVIRON MICROB, V66, P1369, DOI 10.1128/AEM.66.4.1369-1374.2000; MaymoGatell X, 1997, SCIENCE, V276, P1568, DOI 10.1126/science.276.5318.1568; MOHN WW, 1992, MICROBIOL REV, V56, P482, DOI 10.1128/MMBR.56.3.482-507.1992; Roberts AL, 1996, ENVIRON SCI TECHNOL, V30, P2654, DOI 10.1021/es9509644; Sung Y, 2003, APPL ENVIRON MICROB, V69, P2964, DOI 10.1128/AEM.69.5.2964-2974.2003; *US EPA, 1996, AG TOX SUBST DIS REG; VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001	25	387	403	14	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					62	65		10.1038/nature01717	http://dx.doi.org/10.1038/nature01717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840758				2022-12-28	WOS:000183912800039
J	Reimold, SC; Rutherford, JD				Reimold, SC; Rutherford, JD			Valvular heart disease in pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; EXERCISE HEMODYNAMICS; MITRAL REGURGITATION; WOMEN; MANAGEMENT; OUTCOMES; STENOSIS; COMPLICATIONS; ENDOCARDITIS; PREVENTION		Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Reimold, SC (corresponding author), Univ Texas, SW Med Ctr, Dallas, TX 75235 USA.							ALKASAB SM, 1990, AM J OBSTET GYNECOL, V163, P37, DOI 10.1016/S0002-9378(11)90661-9; ALLEN NM, 1993, CLIN PHARMACY, V12, P58; ASHCOM TL, 1995, CATHETER CARDIO DIAG, V35, P110, DOI 10.1002/ccd.1810350206; BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; Bastos Barbosa PJ, 2000, ARQ BRAS CARDIOL, V75, P220, DOI DOI 10.1590/S0066-782X2000000900003; Bernal J M, 1986, Obstet Gynecol Surv, V41, P1, DOI 10.1097/00006254-198601000-00001; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; BRADY K, 1989, CLIN OBSTET GYNECOL, V32, P21, DOI 10.1097/00003081-198903000-00006; BRIGGS GG, 1998, DRUGS PREGNANCY LACT, pR22; CAMPOS O, 1993, INT J CARDIOL, V40, P265, DOI 10.1016/0167-5273(93)90010-E; Carabello BA, 2002, CIRCULATION, V105, P1746, DOI 10.1161/01.CIR.0000015343.76143.13; Chan WS, 2000, ARCH INTERN MED, V160, P191, DOI 10.1001/archinte.160.2.191; Chan WS, 1999, HAEMOSTASIS, V29, P105; Chow T, 1998, AM J CARDIOL, V82, p58I, DOI 10.1016/S0002-9149(98)00473-1; CLARK SL, 1985, AM J OBSTET GYNECOL, V152, P984, DOI 10.1016/0002-9378(85)90544-7; CLARK SL, 1991, CRIT CARE CLIN, V7, P777, DOI 10.1016/S0749-0704(18)30280-X; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DEKABAN AS, 1968, J NUCL MED, V9, P471; Elkayam U, 1998, CARDIAC PROBLEMS PRE; ENRIQUEZSARANO M, 1995, CIRCULATION, V91, P1022, DOI 10.1161/01.CIR.91.4.1022; Fawzy ME, 2001, J HEART VALVE DIS, V10, P153; Ginsberg JS, 2001, CHEST, V119, p122S, DOI 10.1378/chest.119.1_suppl.122S; GOHLKEBARWOLF C, 1995, EUR HEART J, V16, P1320; Guyatt G, 2001, CHEST, V119, p3S, DOI 10.1378/chest.119.1_suppl.3S; Hameed A, 2001, J AM COLL CARDIOL, V37, P893, DOI 10.1016/S0735-1097(00)01198-0; JAMIESON WRE, 1995, ANN THORAC SURG, V60, pS282; Joglar JA, 1999, DRUG SAFETY, V20, P85, DOI 10.2165/00002018-199920010-00008; LAO TT, 1993, AM J OBSTET GYNECOL, V169, P540, DOI 10.1016/0002-9378(93)90616-Q; Laurent P, 2002, DRUGS, V62, P1314; MISHRA M, 1992, BRIT MED J, V304, P1413, DOI 10.1136/bmj.304.6839.1413; NIGHTINGALE SL, 1992, JAMA-J AM MED ASSOC, V267, P2445, DOI 10.1001/jama.267.18.2445; North RA, 1999, CIRCULATION, V99, P2669, DOI 10.1161/01.CIR.99.20.2669; Otto CM, 2001, NEW ENGL J MED, V345, P740, DOI 10.1056/NEJMcp003331; Parry AJ, 1996, ANN THORAC SURG, V61, P1865, DOI 10.1016/0003-4975(96)00150-6; Robin F, 1999, EUR J OBSTET GYN R B, V83, P171, DOI 10.1016/S0301-2115(99)00008-1; ROSENBLUM NG, 1983, AM J OBSTET GYNECOL, V146, P470, DOI 10.1016/0002-9378(83)90834-7; Sadler L, 2000, BRIT J OBSTET GYNAEC, V107, P245, DOI 10.1111/j.1471-0528.2000.tb11696.x; Salazar E, 1999, AM HEART J, V137, P714, DOI 10.1016/S0002-8703(99)70228-0; Sanson BJ, 1999, THROMB HAEMOSTASIS, V81, P668, DOI 10.1055/s-0037-1614550; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; Siu SC, 2002, CIRCULATION, V105, P2179, DOI 10.1161/01.CIR.0000015699.48605.08; STEPHEN SJ, 1992, J AM COLL CARDIOL, V19, P1276, DOI 10.1016/0735-1097(92)90335-K; STOLL BC, 1995, AM J CARDIOL, V75, P482, DOI 10.1016/S0002-9149(99)80585-2; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; SULLIVAN HJ, 1995, SURG CLIN N AM, V75, P59, DOI 10.1016/S0039-6109(16)46534-5; Tribouilloy CM, 1999, CIRCULATION, V99, P400, DOI 10.1161/01.CIR.99.3.400; vanOppen ACC, 1996, OBSTET GYNECOL, V88, P40, DOI 10.1016/0029-7844(96)00069-5; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003	48	86	95	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					52	59		10.1056/NEJMcp021265	http://dx.doi.org/10.1056/NEJMcp021265			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840093				2022-12-28	WOS:000183896100010
J	Sudo, H; Ito, M; Minami, A				Sudo, H; Ito, M; Minami, A			A moving middle finger	LANCET			English	Editorial Material							PAINFUL LEGS; TOES		Hokkaido Univ, Grad Sch Med, Dept Orthopaed Surg, Sapporo, Hokkaido, Japan	Hokkaido University	Sudo, H (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Orthopaed Surg, Sapporo, Hokkaido, Japan.		Sudo, Hideki/G-2748-2012					FUNAKAWA I, 1987, J NEUROL, V234, P342, DOI 10.1007/BF00314292; NATHAN PW, 1978, J NEUROL NEUROSUR PS, V41, P934, DOI 10.1136/jnnp.41.10.934; Okuda Y, 1998, PAIN, V78, P145, DOI 10.1016/S0304-3959(98)00129-8; VERHAGEN WIM, 1985, J NEUROL NEUROSUR PS, V48, P384, DOI 10.1136/jnnp.48.4.384	4	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2202	2202		10.1016/S0140-6736(03)13774-9	http://dx.doi.org/10.1016/S0140-6736(03)13774-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842374	Green Submitted			2022-12-28	WOS:000183815600013
J	Pfeilsticker, K; Lotter, A; Peters, C; Bosch, H				Pfeilsticker, K; Lotter, A; Peters, C; Bosch, H			Atmospheric detection of water dimers via near-infrared absorption	SCIENCE			English	Article							EQUILIBRIUM-CONSTANT; VAPOR CONTINUUM; SOLAR-RADIATION; SPECTROSCOPY; REGION; H2O; DIMERIZATION; CLUSTERS; CM(-1); LIQUID	Weakly bonded pairs of water molecules (H2O)(2), or water dimers (WDs), may play an important role in photochemistry and climate, but the overlap of most of its spectral features with the water monomer (WM) has made detection difficult. We report on WD absorption measurements by means of atmospheric long-path (18.34 kilometers) differential optical absorption spectroscopy of the near-infrared OH stretching mode 10>(f)\4>(b) overtone transition predicted to be located near 746 nanometers. Our observation is in reasonable agreement with the known thermochemistry, calculated and measured structure, and spectroscopy ( band strength, shape, and width) of the WD. The observation implies that the WD \0 >(f)\4>(b) band is located at 749.5 nanometers, with a full width at half maximum of similar to19.4 wave numbers, and that its band strength ranges between 1.23 x 10(-22) and 5.25 x 10(-22) centimeters per molecule.	Univ Heidelberg, Inst Umweltphys, INF 229, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Pfeilsticker, K (corresponding author), Univ Heidelberg, Inst Umweltphys, INF 229, D-69120 Heidelberg, Germany.		Lotter, Andre F./C-3477-2008; Boesch, Hartmut/G-6021-2012	Lotter, Andre F./0000-0002-2954-8809; Boesch, Hartmut/0000-0003-3944-9879				Aloisio S, 2000, J PHYS CHEM A, V104, P6597, DOI 10.1021/jp0006330; Chylek P, 1997, GEOPHYS RES LETT, V24, P2015, DOI 10.1029/97GL01949; Coheur PF, 2002, J QUANT SPECTROSC RA, V74, P493, DOI 10.1016/S0022-4073(01)00269-2; Cormier JG, 2002, J CHEM PHYS, V116, P1030, DOI 10.1063/1.1425825; CURTISS LA, 1979, J CHEM PHYS, V71, P2703, DOI 10.1063/1.438628; Daniel JS, 1999, J GEOPHYS RES-ATMOS, V104, P16785, DOI 10.1029/1999JD900220; DEVIR AD, 1994, OPT ENG, V33, P746, DOI 10.1117/12.159320; Goldman N, 2001, J PHYS CHEM A, V105, P515, DOI 10.1021/jp003567a; Hill C, 2000, J GEOPHYS RES-ATMOS, V105, P9421, DOI 10.1029/1999JD901153; Huisken F, 1996, J CHEM PHYS, V104, P17, DOI 10.1063/1.470871; Huneycutt AJ, 2003, SCIENCE, V299, P1329, DOI 10.1126/science.1082269; Jayne JT, 1997, J PHYS CHEM A, V101, P10000, DOI 10.1021/jp972549z; Keutsch FN, 2001, P NATL ACAD SCI USA, V98, P10533, DOI 10.1073/pnas.191266498; Loerting T, 2000, P NATL ACAD SCI USA, V97, P8874, DOI 10.1073/pnas.97.16.8874; Low GR, 1999, J CHEM PHYS, V110, P9104, DOI 10.1063/1.478832; Ma Q, 1999, J CHEM PHYS, V111, P5909, DOI 10.1063/1.479886; Platt U., 1994, CHEM ANAL SERIES, P27; Pruppacher H.R., 2011, MICROPHYSICS CLOUDS; PTASHNIK IV, COMMUNICATION; Schenter GK, 2002, J PHYS CHEM A, V106, P1557, DOI 10.1021/jp0129131; Schenter GK, 1999, PHYS REV LETT, V82, P3484, DOI 10.1103/PhysRevLett.82.3484; Schermaul R, 2001, J MOL SPECTROSC, V208, P32, DOI 10.1006/jmsp.2001.8373; SCHOFIELD DP, IN PRESS PHYS CHEM C; Vaida V, 2000, J PHYS CHEM A, V104, P5401, DOI 10.1021/jp000115p; Vaida V, 2001, Q J ROY METEOR SOC, V127, P1627, DOI 10.1002/qj.49712757509; VIGASIN AA, 1995, CHEM PHYS LETT, V242, P33, DOI 10.1016/0009-2614(95)00697-3	26	138	141	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2078	2080		10.1126/science.1082282	http://dx.doi.org/10.1126/science.1082282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829778				2022-12-28	WOS:000183774900041
J	Fahrner, KA; Ryu, WS; Berg, HC				Fahrner, KA; Ryu, WS; Berg, HC			Biomechanics: Bacterial flagellar switching under load	NATURE			English	Editorial Material							ESCHERICHIA-COLI; MOTOR; CHEMOTAXIS; ROTATION		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Rowland Inst, Cambridge, MA 02142 USA	Harvard University; Harvard University	Fahrner, KA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							BLOCK SM, 1983, J BACTERIOL, V154, P312, DOI 10.1128/JB.154.1.312-323.1983; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; Chen XB, 2000, BIOPHYS J, V78, P1036, DOI 10.1016/S0006-3495(00)76662-8; Chen XB, 2000, BIOPHYS J, V78, P2280, DOI 10.1016/S0006-3495(00)76774-9; HARSHEY RM, 1994, MOL MICROBIOL, V13, P389, DOI 10.1111/j.1365-2958.1994.tb00433.x; Kawagishi I, 1996, MOL MICROBIOL, V20, P693, DOI 10.1111/j.1365-2958.1996.tb02509.x; McCarter LL, 2001, MICROBIOL MOL BIOL R, V65, P445, DOI 10.1128/MMBR.65.3.445-462.2001; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; Prasad K, 1998, J MOL BIOL, V280, P821, DOI 10.1006/jmbi.1998.1922; Ryu WS, 2000, NATURE, V403, P444, DOI 10.1038/35000233; Scharf BE, 1998, P NATL ACAD SCI USA, V95, P201, DOI 10.1073/pnas.95.1.201	11	50	51	4	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					938	938		10.1038/423938a	http://dx.doi.org/10.1038/423938a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827190	Bronze			2022-12-28	WOS:000183753900037
J	Trichopoulou, A; Costacou, T; Bamia, C; Trichopoulos, D				Trichopoulou, A; Costacou, T; Bamia, C; Trichopoulos, D			Adherence to a Mediterranean diet and survival in a Greek population	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; ENERGY-INTAKE; SUBSEQUENT MORTALITY; EATING PATTERNS; RISK; COHORT; MEN; REPRODUCIBILITY; VALIDITY	BACKGROUND: Adherence to a Mediterranean diet may improve longevity, but relevant data are limited. METHODS: We conducted a population-based, prospective investigation involving 22,043 adults in Greece who completed an extensive, validated, food-frequency questionnaire at base line. Adherence to the traditional Mediterranean diet was assessed by a 10-point Mediterranean-diet scale that incorporated the salient characteristics of this diet (range of scores, 0 to 9, with higher scores indicating greater adherence). We used proportional-hazards regression to assess the relation between adherence to the Mediterranean diet and total mortality, as well as mortality due to coronary heart disease and mortality due to cancer, with adjustment for age, sex, body-mass index, physical-activity level, and other potential confounders. RESULTS: During a median of 44 months of follow-up, there were 275 deaths. A higher degree of adherence to the Mediterranean diet was associated with a reduction in total mortality (adjusted hazard ratio for death associated with a two-point increment in the Mediterranean-diet score, 0.75 [95 percent confidence interval, 0.64 to 0.87]). An inverse association with greater adherence to this diet was evident for both death due to coronary heart disease (adjusted hazard ratio, 0.67 [95 percent confidence interval, 0.47 to 0.94]) and death due to cancer (adjusted hazard ratio, 0.76 [95 percent confidence interval, 0.59 to 0.98]). Associations between individual food groups contributing to the Mediterranean-diet score and total mortality were generally not significant. CONCLUSIONS: Greater adherence to the traditional Mediterranean diet is associated with a significant reduction in total mortality.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Athens Medical School; National & Kapodistrian University of Athens; Harvard University; Harvard T.H. Chan School of Public Health	Trichopoulou, A (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 Mikras Asias St, GR-11527 Athens, Greece.	antonia@nut.uoa.gr	TRICHOPOULOU, ANTONIA/ABF-8727-2021	TRICHOPOULOU, ANTONIA/0000-0002-7204-6396				AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; CHATFIELD C, 1995, INTRO MULTIVARIATE A; COSTACOU T, IN PRESS EUR J CLIN; DELORGERIL, 1995, LANCET, V345, P738; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; FARCHI G, 1995, EUR J CLIN NUTR, V49, P408; Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857; GNARDELLIS C, 1995, EPIDEMIOLOGY, V6, P74, DOI 10.1097/00001648-199501000-00015; Hu FB, 2000, AM J CLIN NUTR, V72, P912; Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1; KANT AK, 1993, AM J CLIN NUTR, V57, P434, DOI 10.1093/ajcn/57.3.434; Kant AK, 2000, JAMA-J AM MED ASSOC, V283, P2109, DOI 10.1001/jama.283.16.2109; Katsouyanni K, 1997, INT J EPIDEMIOL, V26, pS118, DOI 10.1093/ije/26.suppl_1.S118; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Kouris-Blazos A, 1999, BRIT J NUTR, V82, P57, DOI 10.1017/S0007114599001129; Kumagai S, 1999, J Nutr Health Aging, V3, P29; Lasheras C, 2000, AM J CLIN NUTR, V71, P987; Michels KB, 2002, INT J EPIDEMIOL, V31, P847, DOI 10.1093/ije/31.4.847; NUBE M, 1987, J AM DIET ASSOC, V87, P171; Osler M, 1997, INT J EPIDEMIOL, V26, P155, DOI 10.1093/ije/26.1.155; Osler M, 2002, EUR J CLIN NUTR, V56, P568, DOI 10.1038/sj.ejcn.1601360; Osler M, 2001, BRIT J NUTR, V85, P219, DOI 10.1079/BJN2000240; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; SAS Institute, 1999, SAS STAT US GUID VER; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a; Terry P, 2001, AM J EPIDEMIOL, V154, P1143, DOI 10.1093/aje/154.12.1143; TOMASSON H, 1995, STAT MED, V14, P1331, DOI 10.1002/sim.4780141206; Trichopoulos D, 2001, BRIT J NUTR, V85, P133, DOI 10.1079/BJN2000282; Trichopoulou A, 2001, AM J CLIN NUTR, V74, P574; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2000, EPIDEMIOLOGY, V11, P333, DOI 10.1097/00001648-200005000-00018; TRICHOPOULOU A, 1992, COMPOSITION GREEK FO; TRICHOPOULOU A, IN PRESS COMPOSITION; *WHO, 1997 1999 WORLD HLTH; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT W, 1998, NUTR EPIDEMIOLOGY, P414; Willett W.C., 1998, SAUPTIKAPARVAN MAHAB, DOI [10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.003.11]; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; *WORLD CANC RES FU, 1997, FLOOD NUTR PREV CANC, P92; World Health Organization, 1977, INT CLASS DIS MAN IN	43	2807	2866	5	266	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2599	2608		10.1056/NEJMoa025039	http://dx.doi.org/10.1056/NEJMoa025039			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826634	Bronze			2022-12-28	WOS:000183726400003
J	Milani, A				Milani, A			Astronomy - Extraterrestrial material - Virtual or real hazards?	SCIENCE			English	Editorial Material							ASTEROIDS; EARTH; IMPACTS		Univ Pisa, Dipartimento Matemat, I-56127 Pisa, Italy	University of Pisa	Milani, A (corresponding author), Univ Pisa, Dipartimento Matemat, Via Buonarroti 2, I-56127 Pisa, Italy.							Beust H, 1996, ASTRON ASTROPHYS, V310, P181; CARUSI A, 1994, HAZARDS DUE COMETS A, P127; CHAPMAN CR, 1994, NATURE, V367, P33, DOI 10.1038/367033a0; Chesley SR, 2002, ICARUS, V159, P423, DOI 10.1006/icar.2002.6910; HARRIS AW, 2002, DIV PLAN SCI AM ASTR, V34; Milani A, 1999, ICARUS, V137, P269, DOI 10.1006/icar.1999.6045; Milani A, 1999, ASTRON ASTROPHYS, V346, pL65; MILANI A, 2003, ASTEROIDS, V3, P55; Morbidelli A, 2002, ICARUS, V158, P329, DOI 10.1006/icar.2002.6887; MORRISON D, 1994, HAZARDS DUE COMETS A, P59	11	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1882	1883		10.1126/science.1077708	http://dx.doi.org/10.1126/science.1077708			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817129				2022-12-28	WOS:000183619400023
J	Miralda-Escude, J				Miralda-Escude, J			The Dark Age of the universe	SCIENCE			English	Review							DIGITAL SKY SURVEY; HIGH-REDSHIFT; 1ST STARS; INTERGALACTIC MEDIUM; MOLECULAR-HYDROGEN; ALPHA FOREST; X-RAY; GALAXIES; REIONIZATION; ABSORPTION	The Dark Age is the period between the time when the cosmic microwave background was emitted and the time when the evolution of structure in the universe led to the gravitational collapse of objects, in which the first stars were formed. The period of reionization started with the ionizing light from the first stars, and it ended when all the atoms in the intergalactic medium had been reionized. The most distant sources of light known at present are galaxies and quasars at redshift z congruent to 6, and their spectra indicate that the end of reionization was occurring just at that time. The Cold Dark Matter theory for structure formation predicts that the first sources formed much earlier.	Ohio State Univ, Dept Astron, Columbus, OH 43210 USA; Inst Adv Study, Princeton, NJ 08540 USA; Inst Estudis Espacials Catalunya, ICREA, Barcelona, Spain	University System of Ohio; Ohio State University; Institute for Advanced Study - USA; ICREA; Institut d'Estudis Espacials de Catalunya (IEEC)	Miralda-Escude, J (corresponding author), Ohio State Univ, Dept Astron, 174 W 18th Ave, Columbus, OH 43210 USA.	jordi@astronomy.ohio-state.edu	Miralda-Escudé, Jordi/HHN-5448-2022	Miralda-Escude, Jordi/0000-0002-2316-8370	ICREA Funding Source: Custom	ICREA(ICREA)		Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Abel T, 1998, ASTROPHYS J, V508, P518, DOI 10.1086/306410; Abel T, 2000, ASTROPHYS J, V540, P39, DOI 10.1086/309295; Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; Allen SW, 1998, MON NOT R ASTRON SOC, V296, P392, DOI 10.1046/j.1365-8711.1998.01358.x; ARONS J, 1972, ASTROPHYS J, V177, P1, DOI 10.1086/151682; Barkana R, 2001, PHYS REP, V349, P126, DOI 10.1016/s0370-1573(01)00019-9; Becker RH, 2001, ASTRON J, V122, P2850, DOI 10.1086/324231; Begelman MC, 2003, SCIENCE, V300, P1898, DOI 10.1126/science.1085325; BENNETT C, IN PRESS ASTROPHYS J; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; BOND JR, 1991, ASTROPHYS J, V379, P440, DOI 10.1086/170520; Bromm V, 1999, ASTROPHYS J, V527, pL5, DOI 10.1086/312385; Bromm V, 2002, ASTROPHYS J, V575, P111, DOI 10.1086/341189; Bromm V, 2002, ASTROPHYS J, V564, P23, DOI 10.1086/323947; Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; Carilli CL, 2002, ASTROPHYS J, V577, P22, DOI 10.1086/342179; COUCHMAN HMP, 1986, MON NOT R ASTRON SOC, V221, P53, DOI 10.1093/mnras/221.1.53; EFSTATHIOU G, 1990, SUSSP PROC, V36, P361; Ettori S, 1999, MON NOT R ASTRON SOC, V305, P834, DOI 10.1046/j.1365-8711.1999.02460.x; FABER SM, 1979, ANNU REV ASTRON ASTR, V17, P135, DOI 10.1146/annurev.aa.17.090179.001031; Fan XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030; Fan XH, 2001, ASTRON J, V122, P2833, DOI 10.1086/324111; Fan XH, 2003, ASTRON J, V125, P1649, DOI 10.1086/368246; FIELD GB, 1959, ASTROPHYS J, V129, P551, DOI 10.1086/146654; Furlanetto SR, 2003, ASTROPHYS J, V588, P18, DOI 10.1086/374045; Furlanetto SR, 2002, ASTROPHYS J, V579, P1, DOI 10.1086/342757; Gnedin NY, 2000, ASTROPHYS J, V535, P530, DOI 10.1086/308876; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Haiman Z, 1996, ASTROPHYS J, V467, P522, DOI 10.1086/177628; Hu EM, 2002, ASTROPHYS J, V568, pL75, DOI 10.1086/340424; Iliev IT, 2002, ASTROPHYS J, V572, pL123, DOI 10.1086/341869; Kirshner RP, 2003, SCIENCE, V300, P1914, DOI 10.1126/science.1086879; Kodaira K, 2003, PUBL ASTRON SOC JPN, V55, pL17, DOI 10.1093/pasj/55.2.L17; LACEY C, 1993, MON NOT R ASTRON SOC, V262, P627, DOI 10.1093/mnras/262.3.627; LEPP S, 1984, ASTROPHYS J, V280, P465, DOI 10.1086/162013; Machacek ME, 2003, MON NOT R ASTRON SOC, V338, P273, DOI 10.1046/j.1365-8711.2003.06054.x; Mackey J, 2003, ASTROPHYS J, V586, P1, DOI 10.1086/367613; Madau P, 1997, ASTROPHYS J, V475, P429, DOI 10.1086/303549; McDonald P, 2001, ASTROPHYS J, V549, pL11, DOI 10.1086/319123; McKay TA, 2002, ASTROPHYS J, V571, pL85, DOI 10.1086/341364; Meszaros P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625; Miralda-Escude J, 1998, ASTROPHYS J, V501, P15, DOI 10.1086/305799; Oh SP, 2002, MON NOT R ASTRON SOC, V336, P1021, DOI 10.1046/j.1365-8711.2002.05859.x; Ostriker JP, 2003, SCIENCE, V300, P1909, DOI 10.1126/science.1085976; OSTRIKER JP, 1993, ANNU REV ASTRON ASTR, V31, P689; PALLA F, 1995, ASTROPHYS J, V451, P44, DOI 10.1086/176198; PEEBLES PJE, 1968, ASTROPHYS J, V154, P891, DOI 10.1086/149811; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; PRESS WH, 1974, ASTROPHYS J, V187, P425, DOI 10.1086/152650; Qian YZ, 2002, ASTROPHYS J, V567, P515, DOI 10.1086/338277; Rauch M, 1998, ANNU REV ASTRON ASTR, V36, P267, DOI 10.1146/annurev.astro.36.1.267; Ricotti M, 2002, ASTROPHYS J, V575, P33, DOI 10.1086/341255; Ricotti M, 2002, ASTROPHYS J, V575, P49, DOI 10.1086/341256; Ricotti M, 2001, ASTROPHYS J, V560, P580, DOI 10.1086/323051; Riess AG, 2001, ASTROPHYS J, V560, P49, DOI 10.1086/322348; SASLAW WC, 1967, NATURE, V216, P976, DOI 10.1038/216976a0; Schaerer D, 2002, ASTRON ASTROPHYS, V382, P28, DOI 10.1051/0004-6361:20011619; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; SCOTT D, 1990, MON NOT R ASTRON SOC, V247, P510; Stancil PC, 2002, ASTROPHYS J, V580, P29, DOI 10.1086/343070; Tegmark M, 1997, ASTROPHYS J, V474, P1, DOI 10.1086/303434; Tozzi P, 2000, ASTROPHYS J, V528, P597, DOI 10.1086/308196; Tumlinson J, 2000, ASTROPHYS J, V528, pL65, DOI 10.1086/312432; Venkatesan A, 2003, ASTROPHYS J, V584, P621, DOI 10.1086/345738; WHITE RL, IN PRESS ASTRON J; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WHYITHE S, IN PRESS ASTROPHYS J; WOUTHUYSEN SA, 1952, ASTRON J, V57, P31, DOI 10.1086/106661; YOSHIDA N, IN PRESS ASTROPHYS J; ZARITSKY D, 1994, ASTROPHYS J, V435, P599, DOI 10.1086/174840; ZHANG B, IN PRESS ASTROPHYS J	77	74	75	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1904	1909		10.1126/science.1085325	http://dx.doi.org/10.1126/science.1085325			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817139				2022-12-28	WOS:000183619400034
J	Goode, PS; Burgio, KL; Locher, JL; Roth, DL; Umlauf, MG; Richter, HE; Varner, RE; Lloyd, LK				Goode, PS; Burgio, KL; Locher, JL; Roth, DL; Umlauf, MG; Richter, HE; Varner, RE; Lloyd, LK			Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; OLDER WOMEN; VAGINAL CONES; BIOFEEDBACK; MANAGEMENT; BLIND	Context Pelvic floor electrical stimulation (PFES) has been shown to be effective for stress incontinence. However, its role in a multicomponent behavioral training program has not been defined. Objective To determine if PFES increases efficacy of behavioral training for community-dwelling women with stress incontinence. Design and Setting Prospective randomized controlled trial conducted from October 1, 1995, through May 1, 2001, at a university-based outpatient continence clinic in the United States. Patients Volunteer sample of 200 ambulatory, nondemented, community-dwelling women aged 40 to 78 years with stress or mixed incontinence with stress as the predominant pattern; stratified by race, type of incontinence (stress only vs mixed), and severity (frequency of episodes). Interventions Patients were randomly assigned to 8 weeks (4 visits) of behavioral training, 8 weeks (4 visits) of the behavioral training plus home PFES, or 8 weeks of self-administered behavioral treatment using a self-help booklet (control condition). Main Outcome Measures Primary outcome was percentage reduction in the number of incontinent episodes as documented in bladder diaries. Secondary outcomes were patient satisfaction and changes in quality of life. Results Intention-to-treat analysis showed that incontinence was reduced a mean of 68.6% with behavioral training, 71.9% with behavioral training plus PFES, and 52.5% with the self-help booklet (P=.005). In comparison with the self-help booklet, behavioral training (P=.02) and behavioral training plus PFES (P=.002) were significantly more effective, but they were not significantly different from each other (P=.60). The PFES group had significantly better patient self-perception of outcome (P<.001) and satisfaction with progress (P=.02). Significant improvements were seen across all 3 groups on the Incontinence Impact Questionnaire but with no between-group differences. Conclusions Treatment with PFES did not increase effectiveness of a comprehensive behavioral program for women with stress incontinence. A self-help booklet reduced incontinence and improved quality of life but not as much as the clinic-based programs.	Univ Alabama, Sch Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Alabama, Sch Nursing, Birmingham, AL USA; Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Geriatric Research Education & Clinical Center	Goode, PS (corresponding author), Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, 11G,700 19th St S, Birmingham, AL 35233 USA.		Umlauf, Mary Grace/A-5021-2015	Locher, Julie/0000-0002-2639-6459; Richter, Holly E/0000-0001-7741-5771	NIDDK NIH HHS [1R01DK49472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049472] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams P., 1990, INT UROGYNECOL J, V1, P45, DOI [10.1007/BF00373608, DOI 10.1007/BF00373608]; *AM MED ASS, 2001, BEH THER TREATM UR I, P12; Blowman C, 1991, PHYSIOTHERAPY, V77, P661; Bo K, 1999, BMJ-BRIT MED J, V318, P487, DOI 10.1136/bmj.318.7182.487; BURGIO KL, 1985, ANN INTERN MED, V103, P507, DOI 10.7326/0003-4819-103-4-507; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Burgio KL, 1989, STAYING DRY PRACTICA; CAPUTO RM, 1993, J REPROD MED, V38, P667; *DEP HHS, 2000, MED COV ISS MAN; Derogatis LR., 1994, SCL 90 R ADM SCORING; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; ERIKSEN BC, 1987, BRIT J UROL, V59, P45, DOI 10.1111/j.1464-410X.1987.tb04577.x; ERLANDSON BE, 1977, SCAND J UROL NEPHR S, V44, P49; Fall M, 1978, SCAND J UROL NEPHR S, V44, P41; FISCHER W, 1983, ACTA OBSTET GYN SCAN, V62, P579, DOI 10.3109/00016348309156252; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GODEC CJ, 1981, INVEST UROL, V18, P239; HAHN I, 1991, NEUROUROL URODYNAM, V10, P545, DOI 10.1002/nau.1930100604; HUFFMAN J W, 1952, Arch Phys Med Rehabil, V33, P674; KARRAM MM, 1988, OBSTET GYNECOL, V71, P807; KRALJ B, 1991, UROGYNECOLOGY URODYN, P508; Locher JL, 2001, J GERONTOL A-BIOL, V56, pM32, DOI 10.1093/gerona/56.1.M32; Montgomery E, 1983, Physiotherapy, V69, P112; MOORE T, 1967, BMJ-BRIT MED J, V3, P150, DOI 10.1136/bmj.3.5558.150; OLAH KS, 1990, AM J OBSTET GYNECOL, V162, P87, DOI 10.1016/0002-9378(90)90827-T; PLEVNIK S, 1977, MED BIOL ENG COMPUT, V15, P155, DOI 10.1007/BF02442959; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; SHUMAKER SA, 1994, QUAL LIFE RES, V3, P291, DOI 10.1007/BF00451721; Sung MS, 2000, J KOREAN MED SCI, V15, P303, DOI 10.3346/jkms.2000.15.3.303; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yamanishi T, 1997, J UROLOGY, V158, P2127, DOI 10.1016/S0022-5347(01)68176-X	32	118	127	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					345	352		10.1001/jama.290.3.345	http://dx.doi.org/10.1001/jama.290.3.345			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699WK	12865375	Bronze			2022-12-28	WOS:000184078800028
J	Lew, TWK; Kwek, TK; Tai, D; Earnest, A; Loo, S; Singh, K; Kwan, KM; Chan, Y; Yim, CF; Bek, SL; Kor, AC; Yap, WS; Chelliah, YR; Lai, YC; Goh, SK				Lew, TWK; Kwek, TK; Tai, D; Earnest, A; Loo, S; Singh, K; Kwan, KM; Chan, Y; Yim, CF; Bek, SL; Kor, AC; Yap, WS; Chelliah, YR; Lai, YC; Goh, SK			Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LUNG INJURY; CLINICAL-FEATURES; MORTALITY; SARS; OUTBREAK; OUTCOMES; CARE; ARDS	Context Severe acute respiratory syndrome (SARS) is an emerging infectious disease with a 25% incidence of progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and mortality exceeding 10%. Objective To describe the clinical spectrum and outcomes of ALI/ARDS in patients with SARS-related critical illness. Design, Setting, and Patients Retrospective case series of adult patients with probable SARS admitted to the intensive care unit (ICU) of a hospital in Singapore between March 6 and June 6, 2003. Main Outcome Measures The primary outcome measure was 28-day mortality after symptom onset. Results Of 199 patients hospitalized with SARS, 46 (23%) were admitted to the ICU, including 45 who fulfilled criteria for ALI/ARDS. Mortality at 28 days for the entire cohort was 20 (10.1%) of 199 and for ICU patients was 17 (37%) of 46. Intensive care unit mortality at 13 weeks was 24 (52.2%) of 46. Nineteen of 24 ICU deaths occurred late ( greater than or equal to7 days after ICU admission) and were attributed to complications related to severe ARDS, multiorgan failure, thromboembolic complications, or septicemic shock. ARDS was characterized by ease of derecruitment of alveoli and paucity of airway secretion, bronchospasm, or dynamic hyperinflation. Lower Acute Physiology and Chronic Health Evaluation if scores and higher baseline ratios of Pao(2) to fraction of inspired oxygen were associated with earlier recovery. Conclusions Critically ill patients with SARS and ALI/ARDS had characteristic clinical findings, high rates of complications; and high mortality. These findings may provide useful information for optimizing supportive care for SARS-related critical illness.	Tan Tock Seng Hosp, Dept Anaesthesiol, Singapore 308433, Singapore; Tan Tock Seng Hosp, Dept Gen Med, Med Intens Care Unit, Singapore, Singapore; Tan Tock Seng Hosp, Clin Res Unit, Singapore, Singapore; Tan Tock Seng Hosp, Dept Resp Med, Singapore, Singapore; Alexandra Hosp, Dept Anaesthesia, Singapore, Singapore	Tan Tock Seng Hospital; Tan Tock Seng Hospital; Tan Tock Seng Hospital; Tan Tock Seng Hospital	Lew, TWK (corresponding author), Tan Tock Seng Hosp, Dept Anaesthesiol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	thomas_lew@ttsh.com.sg	Earnest, Arul/L-4747-2013	Earnest, Arul/0000-0003-2693-5034				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; *CDCP, 2003, INF CONTR PREC AER G; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P405; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Ferring M, 1997, EUR RESPIR J, V10, P1297, DOI 10.1183/09031936.97.10061297; Hsu LY, 2003, EMERG INFECT DIS, V9, P713; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Lemanske RF, 2003, J PEDIATR-US, V142, pS3, DOI 10.1067/mpd.2003.19; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; Masur H, 2003, JAMA-J AM MED ASSOC, V289, P2861, DOI 10.1001/jama.289.21.JED30036; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Vincent JL, 2003, CRIT CARE MED, V31, pS296, DOI 10.1097/01.CCM.0000057906.89552.8F; *WHO, CAS DEF SURV SEV AC; World Health Organization, HOSP INF CONTR GUID; World Health Organization, 2003, CUM NUMB REP PROB CA	25	291	311	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					374	380		10.1001/jama.290.3.374	http://dx.doi.org/10.1001/jama.290.3.374			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699WK	12865379	Bronze			2022-12-28	WOS:000184078800032
J	Blundell, AG; Roe, S				Blundell, AG; Roe, S			Wegener's granulomatosis presenting as a pleural effusion	BRITISH MEDICAL JOURNAL			English	Review									City Hosp Nottingham, Nottingham Renal & Transplant Unit, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Blundell, AG (corresponding author), City Hosp Nottingham, Nottingham Renal & Transplant Unit, Hucknall Rd, Nottingham NG5 1PB, England.							ANDRASSY K, 1991, CLIN NEPHROL, V35, P139; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A; Mekhail TM, 2000, J RHEUMATOL, V27, P1237; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; RAO JK, 1995, ANN INTERN MED, V123, P925, DOI 10.7326/0003-4819-123-12-199512150-00005	6	8	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					95	96		10.1136/bmj.327.7406.95	http://dx.doi.org/10.1136/bmj.327.7406.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855530	Green Published			2022-12-28	WOS:000184229400024
J	Giasson, BI; Lee, VMY				Giasson, BI; Lee, VMY			Are ubiquitination pathways central to Parkinson's disease?	CELL			English	Review							ALPHA-SYNUCLEIN AGGREGATION; PROTEIN LIGASE; PROTEASOMAL FUNCTION; GENE; DEGRADATION; NEUROTOXICITY; SYNPHILIN-1; DROSOPHILA; PATHOLOGY; MUTATIONS	Parkinson's disease (PD) is the most common neurodegenerative movement disorder. The major motor disabilities of PD are associated with the extensive loss of dopaminergic neurons in the substantia nigra pars compacta. The physiological changes and biochemical pathways involved in the selective demise of these neurons are still unclear. Recent studies have demonstrated that alterations or reductions in ubiquitin-mediated proteasome function can be causal of at least some forms of parkinsonism, and multiple lines of evidence suggest that this mechanism of protein degradation may play an important role in the etiology of PD.	Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Lee, VMY (corresponding author), Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Dept Pathol, Philadelphia, PA 19104 USA.							Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Duda JE, 2002, ACTA NEUROPATHOL, V104, P7, DOI 10.1007/s00401-002-0563-3; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li K, 1997, J NEUROPATHOL EXP NE, V56, P125; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Mattila PM, 1998, ACTA NEUROPATHOL, V95, P576, DOI 10.1007/s004010050843; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	37	179	182	0	16	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 11	2003	114	1					1	8		10.1016/S0092-8674(03)00509-9	http://dx.doi.org/10.1016/S0092-8674(03)00509-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859888	Bronze			2022-12-28	WOS:000184219900001
J	Pickart, RS; Spall, MA; Ribergaard, MH; Moore, GWK; Milliff, RF				Pickart, RS; Spall, MA; Ribergaard, MH; Moore, GWK; Milliff, RF			Deep convection in the Irminger Sea forced by the Greenland tip jet	NATURE			English	Article							LABRADOR SEA; WATER; OCEAN	Open-ocean deep convection, one of the processes by which deep waters of the world's oceans are formed, is restricted to a small number of locations ( for example, the Mediterranean and Labrador seas). Recently, the southwest Irminger Sea has been suggested as an additional location for open-ocean deep convection. The deep water formed in the Irminger Sea has the characteristic temperature and salinity of the water mass that fills the mid-depth North Atlantic Ocean, which had been believed to be formed entirely in the Labrador basin. Here we show that the most likely cause of the convection in the Irminger Sea is a low-level atmospheric jet known as the Greenland tip jet, which forms periodically in the lee of Cape Farewell, Greenland, and is associated with elevated heat flux and strong wind stress curl. Using a history of tip-jet events derived from meteorological land station data and a regional oceanic numerical model, we demonstrate that deep convection can occur in this region when the North Atlantic Oscillation Index is high, which is consistent with observations. This mechanism of convection in the Irminger Sea differs significantly from those known to operate in the Labrador and Mediterranean seas.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Danish Meterol Inst, DK-2100 Copenhagen, Denmark; Univ Toronto, Toronto, ON M5S 1A1, Canada; NWRA, Colorado Res Associates Div, Boulder, CO 80301 USA	Woods Hole Oceanographic Institution; Danish Meteorological Institute DMI; University of Toronto; NorthWest Research Associates	Pickart, RS (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	rpickart@whoi.edu	Spall, Michael A/F-9001-2010; Moore, Kent/D-8518-2011; Milliff, Ralph F/C-4398-2013	Moore, Kent/0000-0002-3986-5605; MILLIFF, RALPH/0000-0003-3177-1206; Spall, Michael/0000-0003-1966-3122				BUMPKE K, 2002, J PHYS OCEANOGR, V32, P401; Cappelen J., 2001, OBSERVED CLIMATE GRE; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; DICKSON RR, 2003, T ICES S HYDR VAR IC; Doyle JD, 1999, TELLUS A, V51, P728, DOI 10.1034/j.1600-0870.1996.00014.x; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Joly A, 1999, Q J ROY METEOR SOC, V125, P3131, DOI 10.1002/qj.49712556103; Madec G, 1996, J PHYS OCEANOGR, V26, P1393, DOI 10.1175/1520-0485(1996)026<1393:LSPODW>2.0.CO;2; Marshall J, 1997, J GEOPHYS RES-OCEANS, V102, P5733, DOI 10.1029/96JC02776; Marshall J, 1998, B AM METEOROL SOC, V79, P2033, DOI 10.1175/1520-0477(1998)079<2033:TLSDCE>2.0.CO;2; Milliff RF, 2001, J ATMOS SCI, V58, P109, DOI 10.1175/1520-0469(2001)058<0109:TGDOTT>2.0.CO;2; Moore GWK, 2002, J CLIMATE, V15, P2020, DOI 10.1175/1520-0442(2002)015<2020:AAOTST>2.0.CO;2; NADERI FM, 1991, P IEEE, V79, P850, DOI 10.1109/5.90163; Nansen F., 1912, INT REV HYDROBIOL, V5, P1, DOI DOI 10.1002/IROH.19120050102; Nielsen J., 1928, GREENLAND DISCOVERY, VVolume I, P185; Pickart RS, 2003, DEEP-SEA RES PT I, V50, P23, DOI 10.1016/S0967-0637(02)00134-6; Pickart RS, 2002, J PHYS OCEANOGR, V32, P428, DOI 10.1175/1520-0485(2002)032<0428:HOTLSD>2.0.CO;2; Renfrew IA, 1999, B AM METEOROL SOC, V80, P605, DOI 10.1175/1520-0477(1999)080<0605:MFDAFP>2.0.CO;2; Renfrew IA, 2002, J PHYS OCEANOGR, V32, P383, DOI 10.1175/1520-0485(2002)032<0383:ACOSLA>2.0.CO;2; Rhein M, 2002, J PHYS OCEANOGR, V32, P648, DOI 10.1175/1520-0485(2002)032<0648:LSWPCI>2.0.CO;2; ROGERS JC, 1990, J CLIMATE, V3, P1364, DOI 10.1175/1520-0442(1990)003<1364:POLFMS>2.0.CO;2; Schott F, 1996, J PHYS OCEANOGR, V26, P505, DOI 10.1175/1520-0485(1996)026<0505:OODCIT>2.0.CO;2; Sy A, 1997, NATURE, V386, P675, DOI 10.1038/386675a0; WUST G, 1943, ANN HYDROGR MARIT ME, V4, P249	24	191	194	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					152	156		10.1038/nature01729	http://dx.doi.org/10.1038/nature01729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853947				2022-12-28	WOS:000184032700032
J	Sarwal, M; Chua, MS; Kambham, N; Hsieh, SC; Satterwhite, T; Masek, M; Salvatierra, O				Sarwal, M; Chua, MS; Kambham, N; Hsieh, SC; Satterwhite, T; Masek, M; Salvatierra, O			Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSPLANT RECIPIENTS; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; SCALE ANALYSIS; MESSENGER-RNA; GRANZYME-B; RISK; LYMPHOCYTES; ACTIVATION; DIAGNOSIS	BACKGROUND: The causes and clinical course of acute rejection vary, and it is not possible to predict graft outcome reliably on the basis of available clinical, pathological, and genetic markers. We hypothesized that previously unrecognized molecular heterogeneity might underlie some of the variability in the clinical course of acute renal allograft rejection and in its response to treatment. METHODS: We used DNA microarrays in a systematic study of gene-expression patterns in biopsy samples from normal and dysfunctional renal allografts. A combination of exploratory and supervised bioinformatic methods was used to analyze these profiles. RESULTS: We found consistent differences among the gene-expression patterns associated with acute rejection, nephrotoxic effects of drugs, chronic allograft nephropathy, and normal kidneys. The gene-expression patterns associated with acute rejection suggested at least three possible distinct subtypes of acute rejection that, although indistinguishable by light microscopy, were marked by differences in immune activation and cellular proliferation. Since the gene-expression patterns pointed to substantial variation in the composition of immune infiltrates, we used immunohistochemical staining to define these subtypes further. This analysis revealed a striking association between dense CD20+ B-cell infiltrates and both clinical glucocorticoid resistance (P=0.01) and graft loss (P<0.001). CONCLUSIONS: Systematic analysis of gene-expression patterns provides a window on the biology and pathogenesis of renal allograft rejection. Biopsy samples from patients with acute rejection that are indistinguishable on conventional histologic analysis reveal extensive differences in gene expression, which are associated with differences in immunologic and cellular features and clinical course. The presence of dense clusters of B cells in a biopsy sample was strongly associated with severe graft rejection, suggesting a pivotal role of infiltrating B cells in acute rejection.	Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Surg, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Sarwal, M (corresponding author), Stanford Univ, Dept Pediat, G320,300 Pasteur Dr, Stanford, CA 94305 USA.		Alizadeh, Ash A/C-5594-2009; Satterwhite, Thomas/AAC-7720-2019; Masek, Anna/P-1728-2019	Alizadeh, Ash A/0000-0002-5153-5625; Masek, Anna/0000-0003-3785-1995; Kambham, Neeraja/0000-0003-1136-3686; Chua, Mei-Sze/0000-0002-3282-4894	PHS HHS [NIH5P3-05, NIH3P3-05S1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Aranda JM, 2002, TRANSPLANTATION, V73, P907, DOI 10.1097/00007890-200203270-00013; BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; Brandle D, 1998, TRANSPLANTATION, V65, P1489; Charney DA, 1999, TRANSPLANTATION, V68, P791, DOI 10.1097/00007890-199909270-00011; Colvin RB, 1997, J AM SOC NEPHROL, V8, P1930; Diehn M, 2002, P NATL ACAD SCI USA, V99, P15245, DOI 10.1073/pnas.242581399; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Furness PN, 2001, KIDNEY INT, V60, P2429; Furness PN, 2001, KIDNEY INT, V60, P1998, DOI 10.1046/j.1523-1755.2001.00030.x; Guyot C, 1996, PEDIATR NEPHROL, V10, P723, DOI 10.1007/s004670050199; HANCOCK WW, 1984, IMMUNOL REV, V77, P61, DOI 10.1111/j.1600-065X.1984.tb00718.x; Humar A, 1999, TRANSPLANTATION, V68, P1200, DOI 10.1097/00007890-199910270-00023; Humar A, 2000, TRANSPLANTATION, V69, P2357, DOI 10.1097/00007890-200006150-00024; Jakt LM, 2001, GENOME RES, V11, P112, DOI 10.1101/gr.148301; KUMMER JA, 1995, KIDNEY INT, V47, P70, DOI 10.1038/ki.1995.8; Li BG, 2001, NEW ENGL J MED, V344, P947, DOI 10.1056/NEJM200103293441301; Madden RL, 2000, TRANSPLANT INT, V13, P344, DOI 10.1111/j.1432-2277.2000.tb01008.x; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; Meehan SM, 2001, HUM PATHOL, V32, P205, DOI 10.1053/hupa.2001.21574; Meier-Kriesche HU, 2000, TRANSPLANTATION, V70, P1098, DOI 10.1097/00007890-200010150-00018; Ogura Y, 2000, RADIOLOGY, V214, P795, DOI 10.1148/radiology.214.3.r00mr34795; Olyaei A J, 2001, Curr Opin Crit Care, V7, P384, DOI 10.1097/00075198-200112000-00003; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PLATT JL, 1982, J EXP MED, V155, P17, DOI 10.1084/jem.155.1.17; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; RANDHAWA PS, 1993, AM J SURG PATHOL, V17, P60, DOI 10.1097/00000478-199301000-00007; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; Shinn C, 1999, AM J KIDNEY DIS, V34, P304, DOI 10.1016/S0272-6386(99)70359-8; Strehlau J, 1997, P NATL ACAD SCI USA, V94, P695, DOI 10.1073/pnas.94.2.695; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tullius S G, 1998, Transpl Int, V11 Suppl 1, pS3, DOI 10.1007/s001470050414; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VONWILLEBRAND E, 1978, CELL IMMUNOL, V41, P358, DOI 10.1016/0008-8749(78)90233-2; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030	38	563	603	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					125	138		10.1056/NEJMoa035588	http://dx.doi.org/10.1056/NEJMoa035588			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853585				2022-12-28	WOS:000184024400005
J	Brussino, L; Bucca, C; Morello, M; Scappaticci, E; Mauro, M; Rolla, G				Brussino, L; Bucca, C; Morello, M; Scappaticci, E; Mauro, M; Rolla, G			Effect on dyspnoea and hypoxaemia of inhaled N-G-nitro-L-arginine methyl ester in hepatopulmonary syndrome	LANCET			English	Article							OXIDE	Hepatopulmonary syndrome-a complication of chronic liver disease-is characterised by hypoxaemia, which results from widespread intrapulmonary vascular dilatations. Amplified production of pulmonary nitric oxide is thought to be important in development of this disorder in patients with liver cirrhosis. Here, we report a 64-year-old man with hepatopulmonary syndrome associated with hepatitis-C-virus-related cirrhosis. We gave the patient nebulised N-G-nitro-L-arginine methyl ester (L-NAME), an Inhibitor of NO synthesis, which enhanced oxygenation (arterial oxygen pressure increased from 6.98 to 9.45 kPa). After L-NAME, the distance the patient could walk in 6 min rose by 92 m. Administration of L-NAME by aerosol might offer a new approach to treatment of hepatopulmonary syndrome.	Univ Turin, Osped Mauriziano Umberto 1, Allergol & Immunol Clin, I-10128 Turin, Italy; Osped Molinette, Dept Med & Chirurg, Turin, Italy; Italian Nitr Oxide Clin, Milan, Italy; Univ Turin, Dept Sci Biomed & Oncol Umana, Turin, Italy; Univ Turin, Osped Molinette, Div Cardiol, Turin, Italy	A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Mauritian Umberto I Hospital; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin	Rolla, G (corresponding author), Univ Turin, Osped Mauriziano Umberto 1, Allergol & Immunol Clin, Largo Turati 62, I-10128 Turin, Italy.		Rolla, Giovanni/C-9901-2009; Bucca, Caterina/C-9886-2009; brussino, luisa/J-2486-2012	Rolla, Giovanni/0000-0001-5997-7172; Bucca, Caterina/0000-0002-9941-9236; brussino, luisa/0000-0001-7249-7616				Krowka MJ, 2000, CHEST, V118, P615, DOI 10.1378/chest.118.3.615; Krowka MJ, 2000, LIVER TRANSPLANT, V6, pS31, DOI 10.1002/lt.500060508; Nunes H, 2001, AM J RESP CRIT CARE, V164, P879, DOI 10.1164/ajrccm.164.5.2009008; Rolla G, 1997, HEPATOLOGY, V26, P842, DOI 10.1002/hep.510260406; Schenk P, 2000, ANN INTERN MED, V133, P701, DOI 10.7326/0003-4819-133-9-200011070-00012	5	69	70	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					43	44		10.1016/S0140-6736(03)13807-X	http://dx.doi.org/10.1016/S0140-6736(03)13807-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853200				2022-12-28	WOS:000184056900014
J	Philipp, R; Grech, ED				Philipp, R; Grech, ED			ABC of interventional cardiology - Interventional pharmacotherapy	BRITISH MEDICAL JOURNAL			English	Review							PLATELET GLYCOPROTEIN IIB/IIIA; ACUTE CORONARY SYNDROMES; CONTROLLED TRIAL; EPTIFIBATIDE; INHIBITION		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Philipp, R (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; CHEW DP, 2002, PRACTICAL INTERVENTI, P207; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Tcheng JE, 2000, LANCET, V356, P2037; Topol E, 1998, NEW ENGL J MED, V339, P436	7	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					43	46		10.1136/bmj.327.7405.43	http://dx.doi.org/10.1136/bmj.327.7405.43			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842958	Green Published			2022-12-28	WOS:000184062700028
J	Erbe, RW; Salis, RJ				Erbe, RW; Salis, RJ			Severe methylenetetrahydrofolate reductase deficiency, methionine synthase, and nitrous oxide - A cautionary tale	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14260 USA; Univ Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Erbe, RW (corresponding author), Univ Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14260 USA.								0	14	16	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					5	6		10.1056/NEJMp030093	http://dx.doi.org/10.1056/NEJMp030093			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840086				2022-12-28	WOS:000183896100002
J	Matthias, S; Muller, F				Matthias, S; Muller, F			Asymmetric pores in a silicon membrane acting as massively parallel brownian ratchets	NATURE			English	Article							N-TYPE SILICON; MACROPOROUS SILICON; SEPARATION; PARTICLES; MOTION; ARRAY	The brownian motion of mesoscopic particles is ubiquitous and usually random. But in systems with periodic asymmetric barriers to movement, directed or 'rectified' motion can arise and may even modulate some biological processes(1). In man-made devices, brownian ratchets and variants based on optical or quantum effects have been exploited to induce directed motion(2-14), and the dependence of the amplitude of motion on particle size has led to the size-dependent separation of biomolecules(6,8,15). Here we demonstrate that the one-dimensional pores of a macroporous silicon membrane(16), etched to exhibit a periodic asymmetric variation in pore diameter, can act as massively parallel and multiply stacked brownian ratchets that are potentially suitable for large-scale particle separations. We show that applying a periodic pressure profile with a mean value of zero to a basin separated by such a membrane induces a periodic flow of water and suspended particles through the pores, resulting in a net motion of the particles from one side of the membrane to the other without moving the liquid itself. We find that the experimentally observed pressure dependence of the particle transport, including an inversion of the transport direction, agrees with calculations(17,18) of the transport properties in the type of ratchet devices used here.	Max Planck Inst Microstruct Phys, D-06120 Halle An Der Saale, Germany	Max Planck Society	Muller, F (corresponding author), Max Planck Inst Microstruct Phys, Weinberg 2, D-06120 Halle An Der Saale, Germany.	Frank.Mueller@mpi-halle.de						Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 2002, PHYS TODAY, V55, P33, DOI 10.1063/1.1535005; Cabodi M, 2002, ELECTROPHORESIS, V23, P3496, DOI 10.1002/1522-2683(200210)23:20<3496::AID-ELPS3496>3.0.CO;2-9; Derenyi I, 1998, PHYS REV E, V58, P7781, DOI 10.1103/PhysRevE.58.7781; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; Haenggi P., 1996, Nonlinear physics of complex systems. Current status and future trends, P294; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Kettner C, 2000, PHYS REV E, V61, P312, DOI 10.1103/PhysRevE.61.312; KETTNER C, 1999, Patent No. 199075641; Lehmann V, 1997, THIN SOLID FILMS, V297, P13, DOI 10.1016/S0040-6090(96)09478-3; LEHMANN V, 1990, J ELECTROCHEM SOC, V137, P653, DOI 10.1149/1.2086525; LEHMANN V, 1993, J ELECTROCHEM SOC, V140, P2836, DOI 10.1149/1.2220919; Linke H, 1999, SCIENCE, V286, P2314, DOI 10.1126/science.286.5448.2314; Linke H., 2002, APPL PHYS A, V75; Marquet C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.168301; Muller F, 2000, PHYS STATUS SOLIDI A, V182, P585, DOI 10.1002/1521-396X(200011)182:1<585::AID-PSSA585>3.0.CO;2-4; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Schilling J, 2001, APPL PHYS LETT, V78, P1180, DOI 10.1063/1.1351533; Switkes M, 1999, SCIENCE, V283, P1905, DOI 10.1126/science.283.5409.1905; Tong Q. Y., 1999, SEMICONDUCTOR WAFER, P53; van Oudenaarden A, 1999, SCIENCE, V285, P1046, DOI 10.1126/science.285.5430.1046; von Smoluchowski M, 1912, PHYS Z, V13, P1069	23	313	318	5	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					53	57		10.1038/nature01736	http://dx.doi.org/10.1038/nature01736			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840755				2022-12-28	WOS:000183912800036
J	Nunnari, G; Nigro, L; Palermo, F; Attanasio, M; Berger, A; Doerr, HW; Pomerantz, RJ; Cacopardo, B				Nunnari, G; Nigro, L; Palermo, F; Attanasio, M; Berger, A; Doerr, HW; Pomerantz, RJ; Cacopardo, B			Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-Helper 1 cytokine profile	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-G VIRUS; RNA; DISEASE; TYPE-1; CELLS	Background: Progression to AIDS is slower in persons infected with both HIV-1 and GB virus C (GBV-C), also known as hepatitis G virus. Objective: To compare clinical, virologic, and immunologic variables in HIV-1-seropositive patients with and without GBV-C co-infection. Design: Subanalysis of a prospective cohort study. Setting: Institute of Infectious Diseases, University of Catania, Catania, Italy. Patients: go asymptomatic HIV-1-seropositive patients. Measurements: GBV-C RNA level; plasma HIV-1 viral load; CD4(+) cell counts; and serum levels of interleukin (IL)-2, IL-4, IL-10, and IL-12. Results: At the start of the study, plasma GBV-C RNA was detected in 17 patients (21%). During follow-up, IL-2 and IL-12 levels decreased significantly (P = 0.005 and P = 0.01, respectively) and IL-4 and IL-10 levels increased significantly (P = 0.01 and P = 0.004, respectively) in the GBV-C-negative group but did not change substantially in the GBV-C-positive group. Each measured variable differed significantly between GBV-C-positive and GBV-C-negative groups during follow-up (P < 0.001 for IL-12, IL-4, and IL-10; P = 0.002 for IL-2). Conclusion: GB virus C may immunologically interfere with progression of HIV-1 infection to AIDS by maintaining an intact T-helper 1 cytokine profile.	Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Univ Catania, Catania, Italy; Univ Palermo, Palermo, Italy; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany	Jefferson University; University of Catania; University of Palermo; Goethe University Frankfurt	Nunnari, G (corresponding author), Thomas Jefferson Univ, Jefferson Alumni Hall,1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.	gnunnari@hotmail.com	Nunnari, Giuseppe/AAC-1928-2019; Attanasio, Massimo/A-6295-2016	Nunnari, Giuseppe/0000-0002-8113-8452; Attanasio, Massimo/0000-0003-2684-5530; cacopardo, bruno/0000-0002-7465-0714				Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Cacopardo B, 1998, J INFECTION, V36, P179, DOI 10.1016/S0163-4453(98)80010-8; Campo N, 2000, HEPATO-GASTROENTEROL, V47, P1385; Fogeda M, 1999, J VIROL, V73, P4052, DOI 10.1128/JVI.73.5.4052-4061.1999; HAND D, 1996, PRACTICAL LONGITUDIN; Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431; Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364; Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000; Yeo AET, 2000, ANN INTERN MED, V132, P959, DOI 10.7326/0003-4819-132-12-200006200-00006	16	75	82	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					26	30		10.7326/0003-4819-139-1-200307010-00009	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834315				2022-12-28	WOS:000183823200004
J	Hynes, RO				Hynes, RO			Metastatic potential: Generic predisposition of the primary tumor or rare, metastatic variants - or both?	CELL			English	Review							BREAST-CANCER; PROGRESSION; SIGNATURE; BIOLOGY; CELLS	Metastasis is a rare event. Does it arise from rare, variant, highly metastatic cells or does a primary tumor progress to a premalignant state from which metastases arise stochastically without further changes in gene expression? Arguments and evidence have been adduced to support either position. A paper in this month's Cancer Cell (Kang et al., 2003) and other arguments instead suggest models combining features of both.	MIT, Howard Hughes Med Inst, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA.							Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HART IR, 1981, BIOCHIM BIOPHYS ACTA, V651, P37, DOI 10.1016/0304-419X(81)90004-4; Kakiuchi S, 2003, MOL CANCER RES, V1, P485; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Porter D, 2003, MOL CANCER RES, V1, P362; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a	19	129	138	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					821	823		10.1016/S0092-8674(03)00468-9	http://dx.doi.org/10.1016/S0092-8674(03)00468-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837240	Bronze			2022-12-28	WOS:000183817900006
J	Ravichandran, KS				Ravichandran, KS			"Recruitment signals" from apoptotic cells: Invitation to a quiet meal	CELL			English	Review							C-ELEGANS; CRKII/DOCK180/RAC PATHWAY; CAENORHABDITIS-ELEGANS; PHAGOCYTOSIS; MIGRATION; ENGULFMENT; CLEARANCE; DEATH; PHOSPHATIDYLSERINE; ACTIVATION	An evolutionarily conserved machinery exists for engulfment of apoptotic cells from worm to mammals. New observations suggest that corpse clearance is tightly linked to apoptosis and that dying cells use both recruitment and eat-me signals for phagocyte attraction and recognition.	Univ Virginia, Carter Immunol Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Carter Immunol Ctr, Charlottesville, VA 22908 USA.							Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Horino K, 1998, LAB INVEST, V78, P603; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	20	122	128	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					817	820		10.1016/S0092-8674(03)00471-9	http://dx.doi.org/10.1016/S0092-8674(03)00471-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837239	Bronze			2022-12-28	WOS:000183817900005
J	McGlynn, EA; Asch, SM; Adams, J; Keesey, J; Hicks, J; DeCristofaro, A; Kerr, EA				McGlynn, EA; Asch, SM; Adams, J; Keesey, J; Hicks, J; DeCristofaro, A; Kerr, EA			The quality of health care delivered to adults in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELDERLY MEDICARE BENEFICIARIES; STANDARDIZED PATIENTS; UNDERUSE; APPROPRIATENESS; OUTCOMES; TRIALS; WOMEN	BACKGROUND: We have little systematic information about the extent to which standard processes involved in health care -- a key element of quality -- are delivered in the United States. METHODS: We telephoned a random sample of adults living in 12 metropolitan areas in the United States and asked them about selected health care experiences. We also received written consent to copy their medical records for the most recent two-year period and used this information to evaluate performance on 439 indicators of quality of care for 30 acute and chronic conditions as well as preventive care. We then constructed aggregate scores. RESULTS: Participants received 54.9 percent (95 percent confidence interval, 54.3 to 55.5) of recommended care. We found little difference among the proportion of recommended preventive care provided (54.9 percent), the proportion of recommended acute care provided (53.5 percent), and the proportion of recommended care provided for chronic conditions (56.1 percent). Among different medical functions, adherence to the processes involved in care ranged from 52.2 percent for screening to 58.5 percent for follow-up care. Quality varied substantially according to the particular medical condition, ranging from 78.7 percent of recommended care (95 percent confidence interval, 73.3 to 84.2) for senile cataract to 10.5 percent of recommended care (95 percent confidence interval, 6.8 to 14.6) for alcohol dependence. CONCLUSIONS: The deficits we have identified in adherence to recommended processes for basic care pose serious threats to the health of the American public. Strategies to reduce these deficits in care are warranted.	RAND Corp, Santa Monica, CA 90407 USA; Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; VA Ann Arbor Hlth Care Syst, VA Ctr Practice Management & Outcomes Res, Ann Arbor, MI USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	McGlynn, EA (corresponding author), RAND Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.	beth_mcglynn@rand.org	Greiver, Michelle/N-8764-2015; Young, Alexander/A-1523-2009; Wilkins, Thad/G-2541-2010	Greiver, Michelle/0000-0001-8957-0285; Young, Alexander/0000-0002-9367-9213; 				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Asch SM, 2000, JAMA-J AM MED ASSOC, V284, P2325, DOI 10.1001/jama.284.18.2325; Asch SM, 2001, ARCH INTERN MED, V161, P1329, DOI 10.1001/archinte.161.10.1329; Asch SM, 2001, J ACQ IMMUN DEF SYND, V28, P340, DOI 10.1097/00126334-200112010-00006; Asch SM, 2000, QUALITY CARE ONCOLOG; Berwick DM, 2003, MED CARE, V41, pI30; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; Brook R. H., 1994, AHCPR PUB, P59; CHERRY DK, 1999, ADV DATA VITAL HLTH, V322; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cunningham PJ, 2002, MED CARE RES REV, V59, P79, DOI 10.1177/107755870205900104; Draper DA, 2002, HEALTH AFFAIR, V21, P11, DOI 10.1377/hlthaff.21.1.11; Dresselhaus TR, 2002, J MED ETHICS, V28, P293, DOI 10.1136/jme.28.5.291; Efron B., 1994, MONOGRAPHS STAT APPL; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; HYMAN DJ, 2002, NEW ENGL J MED, V346, P544; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Jencks SF, 2000, JAMA-J AM MED ASSOC, V284, P1670, DOI 10.1001/jama.284.13.1670; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1984, DOI 10.1001/jama.264.15.1984; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; Kerr EA, 2000, QUALITY CARE CARDIOP; KERR EA, 2000, QUALITY CARE GEN MED; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luck J, 2002, BMJ-BRIT MED J, V325, P679, DOI 10.1136/bmj.325.7366.679; McGlynn E A, 1998, Jt Comm J Qual Improv, V24, P470; McGlynn EA, 2001, HEALTH AFFAIR, V20, P82, DOI 10.1377/hlthaff.20.3.82; McGlynn EA, 1999, WOMEN HEALTH ISS, V9, P184, DOI 10.1016/S1049-3867(99)00009-2; McGlynn EA, 2000, QUALITY CARE WOMEN; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Murata PJ, 1994, ARCH FAM MED, V3, P41; *NAT COMM QUAL ASS, 2002, STAT HLTH CAR QUAL; Nelson DE, 2002, JAMA-J AM MED ASSOC, V287, P2659, DOI 10.1001/jama.287.20.2659; PAYNE SMC, 1995, ARCH PEDIAT ADOL MED, V149, P162, DOI 10.1001/archpedi.1995.02170140044006; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STRUNK BC, 2001, TRACKING HLTH CARE C; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; Woolf SH, 1999, JAMA-J AM MED ASSOC, V282, P2358, DOI 10.1001/jama.282.24.2358	50	3441	3469	1	152	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2635	2645		10.1056/NEJMsa022615	http://dx.doi.org/10.1056/NEJMsa022615			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	693PN	12826639				2022-12-28	WOS:000183726400008
J	Su, HT; Hsu, RR; Chen, AB; Wang, YC; Hsiao, WS; Lai, WC; Lee, LC; Sato, M; Fukunishi, H				Su, HT; Hsu, RR; Chen, AB; Wang, YC; Hsiao, WS; Lai, WC; Lee, LC; Sato, M; Fukunishi, H			Gigantic jets between a thundercloud and the ionosphere	NATURE			English	Article							SPRITES94 AIRCRAFT CAMPAIGN; BLUE JETS; ELECTRICAL-DISCHARGE; THUNDERSTORM; IONIZATION; STARTERS; CIRCUIT	Transient luminous events in the atmosphere, such as lighting-induced sprites(1-8) and upwardly discharging blue jets(9-14), were discovered recently in the region between thunderclouds and the ionosphere. In the conventional picture, the main components of Earth's global electric circuit(15,16) include thunderstorms, the conducting ionosphere, the downward fair-weather currents and the conducting Earth. Thunderstorms serve as one of the generators that drive current upward from cloud tops to the ionosphere, where the electric potential is hundreds of kilovolts higher than Earth's surface. It has not been clear, however, whether all the important components of the global circuit have even been identified. Here we report observations of five gigantic jets that establish a direct link between a thundercloud (altitude similar to16 km) and the ionosphere at 90 km elevation. Extremely-low-frequency radio waves in four events were detected, while no cloud-to-ground lightning was observed to trigger these events. Our result indicates that the extremely-low-frequency waves were generated by negative cloud-to-ionosphere discharges, which would reduce the electrical potential between ionosphere and ground. Therefore, the conventional picture of the global electric circuit needs to be modified to include the contributions of gigantic jets and possibly sprites(17,18).	Natl Cheng Kung Univ, Dept Phys, Tainan 701, Taiwan; Natl Space Program Off, Hsinchu, Taiwan; Tohoku Univ, Dept Geophys, Sendai, Miyagi 9808578, Japan	National Cheng Kung University; Tohoku University	Su, HT (corresponding author), Natl Cheng Kung Univ, Dept Phys, Tainan 701, Taiwan.	htsu@phys.ncku.edu.tw	SATO, Mitsuteru/A-5254-2012; Lee, Lou-Chuang/I-2588-2013	Lee, Lou-Chuang/0000-0003-4012-991X				Bilitza D, 2001, RADIO SCI, V36, P261, DOI 10.1029/2000RS002432; BOECK WL, 1995, J GEOPHYS RES-ATMOS, V100, P1465, DOI 10.1029/94JD02432; Dowden RL, 2002, J ATMOS SOL-TERR PHY, V64, P817, DOI 10.1016/S1364-6826(02)00085-8; FRANZ RC, 1990, SCIENCE, V249, P48, DOI 10.1126/science.249.4964.48; Hardman SF, 2000, J GEOPHYS RES-ATMOS, V105, P4689, DOI 10.1029/1999JD900325; Hu WY, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014593; Huang E, 1999, J GEOPHYS RES-ATMOS, V104, P16943, DOI 10.1029/1999JD900139; Landau L.D., 1987, PHYS TODAY, V6; Lyons WA, 2003, B AM METEOROL SOC, V84, P445, DOI 10.1175/BAMS-84-4-445; Lyons WA, 1996, J GEOPHYS RES-ATMOS, V101, P29641, DOI 10.1029/96JD01866; MacGorman D. R., 1998, ELECT NATURE STORMS; Pasko VP, 1996, GEOPHYS RES LETT, V23, P649, DOI 10.1029/96GL00473; Pasko VP, 2002, NATURE, V416, P152, DOI 10.1038/416152a; ROBLE RG, 1991, J ATMOS TERR PHYS, V53, P831, DOI 10.1016/0021-9169(91)90097-Q; Rycroft MJ, 2000, J ATMOS SOL-TERR PHY, V62, P1563, DOI 10.1016/S1364-6826(00)00112-7; SATO M, 2002, EOS, V83, P103; SENTMAN DD, 1995, GEOPHYS RES LETT, V22, P1205, DOI 10.1029/95GL00583; SU HT, 2002, GEOPHYS RES LETT, V29; Takahashi Y, 2003, J ATMOS SOL-TERR PHY, V65, P551, DOI 10.1016/S1364-6826(02)00330-9; UMAN MA, 1987, LIGHTNING DISCHARGE; Wescott EM, 1996, GEOPHYS RES LETT, V23, P2153, DOI 10.1029/96GL01969; WESCOTT EM, 1995, GEOPHYS RES LETT, V22, P1209, DOI 10.1029/95GL00582; Wescott EM, 2001, J GEOPHYS RES-SPACE, V106, P21549, DOI 10.1029/2000JA000429; Wescott EM, 1998, J ATMOS SOL-TERR PHY, V60, P713, DOI 10.1016/S1364-6826(98)00018-2	24	163	170	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					974	976		10.1038/nature01759	http://dx.doi.org/10.1038/nature01759			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827198				2022-12-28	WOS:000183753900046
J	Garg, V; Kathiriyra, IS; Barnes, R; Schluterman, MK; King, IN; Butler, CA; Rothrock, CR; Eapen, RS; Hirayama-Yamada, K; Joo, K; Matsuoka, R; Cohen, JC; Srivastava, D				Garg, V; Kathiriyra, IS; Barnes, R; Schluterman, MK; King, IN; Butler, CA; Rothrock, CR; Eapen, RS; Hirayama-Yamada, K; Joo, K; Matsuoka, R; Cohen, JC; Srivastava, D			GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5	NATURE			English	Article								Congenital heart defects (CHDs) are the most common developmental anomaly and are the leading non-infectious cause of mortality in newborns(1). Only one causative gene, NKX2-5, has been identified through genetic linkage analysis of pedigrees with non-syndromic CHDs(2,3). Here, we show that isolated cardiac septal defects in a large pedigree were linked to chromosome 8p22-23. A heterozygous G296S missense mutation of GATA4, a transcription factor essential for heart formation(4-7), was found in all available affected family members but not in any control individuals. This mutation resulted in diminished DNA-binding affinity and transcriptional activity of Gata4. Furthermore, the Gata4 mutation abrogated a physical interaction between Gata4 and TBX5, a T-box protein responsible for a subset of syndromic cardiac septal defects(8,9). Conversely, interaction of Gata4 and TBX5 was disrupted by specific human TBX5 missense mutations that cause similar cardiac septal defects. In a second family, we identified a frame-shift mutation of GATA4 (E359del) that was transcriptionally inactive and segregated with cardiac septal defects. These results implicate GATA4 as a genetic cause of human cardiac septal defects, perhaps through its interaction with TBX5.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Tokyo Womens Med Univ, Grad Sch Med, Inst Adv Biomed Engn & Sci, Div Genom Med, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Heart Inst Japan, Tokyo 1628666, Japan; Kyusyu Kosei Nenkin Hosp, Dept Pediat, Fukuoka 8068501, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tokyo Women's Medical University; Tokyo Women's Medical University	Garg, V (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 6000 Harry Hines Blvd,Rm NA8-124, Dallas, TX 75390 USA.	Vidu.Garg@UTSouthwestern.edu; Deepak.Srivastava@UTSouthwestern.edu	Burdine, Marie Schluterman/GLU-1812-2022; Garg, Vidu/E-3101-2011; Garg, Vidu/D-8240-2012	Burdine, Marie Schluterman/0000-0002-3940-5748; Garg, Vidu/0000-0002-3778-5927	NHLBI NIH HHS [L40 HL078465-02, L40 HL078465] Funding Source: Medline; NICHD NIH HHS [K08 HD001382] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Basson CT, 1999, P NATL ACAD SCI USA, V96, P2919, DOI 10.1073/pnas.96.6.2919; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Cross SJ, 2000, J MED GENET, V37, P785, DOI 10.1136/jmg.37.10.785; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Gajewski K, 1999, DEVELOPMENT, V126, P5679; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Li QY, 1997, NAT GENET, V15, P21; McFadden DG, 2000, DEVELOPMENT, V127, P5331; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Yamagishi H, 2003, GENE DEV, V17, P269, DOI 10.1101/gad.1048903; Yang JF, 2000, AM J MED GENET, V92, P237, DOI 10.1002/(SICI)1096-8628(20000605)92:4<237::AID-AJMG2>3.0.CO;2-G	30	884	934	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 24	2003	424	6947					443	447		10.1038/nature01827	http://dx.doi.org/10.1038/nature01827			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704BT	12845333				2022-12-28	WOS:000184318400047
J	Thornton, H; Edwards, A; Baum, M				Thornton, H; Edwards, A; Baum, M			Women need better information about routine mammography	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; MORTALITY	Scientists continue to argue about the benefits of breast screening, but ultimately decisions about screening should be made by women themselves. To make this decision, however, women need to fully understand both the benefits and the potential harms.	Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Univ Coll Swansea, Swansea Clin Sch, Dept Primary Care, Swansea SA2 8PP, W Glam, Wales; UCL, Acad Dept Surg, London W1P 7PL, England	University of Leicester; Swansea University; University of London; University College London	Thornton, H (corresponding author), Saionara, Colchester CO5 7EA, Essex, England.	hazelcagct@aol.com						Austoker J, 1999, BMJ-BRIT MED J, V319, P722, DOI 10.1136/bmj.319.7212.722; Blanks RG, 2000, BRIT MED J, V321, P665, DOI 10.1136/bmj.321.7262.665; Coulter A., 2002, AUTONOMOUS PATIENT E; Davey C, 2003, MED SCI MONITOR, V8, pLE54; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; Edwards AGK, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004253.pub3; Gigerenzer G., 2002, RECKONING RISK; Gotzsche PC, 2003, ANN INTERN MED, V138, P769, DOI 10.7326/0003-4819-138-9-200305060-00021; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Mazur DJ, 2000, MED DECIS MAKING, V20, P132, DOI 10.1177/0272989X0002000117; *NHS BREAST SCREEN, 2001, FACTS; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OLSEN O, 2001, COCHRANE DB SYST REV, V1; Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; Rakovitch E, 2003, BREAST CANCER RES TR, V77, P285, DOI 10.1023/A:1021853302033; Slaytor EK, 1998, BRIT MED J, V317, P263, DOI 10.1136/bmj.317.7153.263; TABAR I, 2001, CANCER, V91, P1824; Tabar L, 2003, LANCET, V361, P1405, DOI 10.1016/S0140-6736(03)13143-1; Wragg JA, 2000, SOC SCI MED, V51, P453, DOI 10.1016/S0277-9536(99)00477-3; 2003, INDEPENDENT     0425, P10	21	69	69	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2003	327	7406					101	103		10.1136/bmj.327.7406.101	http://dx.doi.org/10.1136/bmj.327.7406.101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855532	Green Published			2022-12-28	WOS:000184229400026
J	Treasure, T; Utley, M; Bailey, A				Treasure, T; Utley, M; Bailey, A			Assessment of whether in-hospital mortality for lobectomy is a useful standard for the quality of lung cancer surgery: retrospective study	BRITISH MEDICAL JOURNAL			English	Article							VOLUME	Objectives To calculate in-hospital mortality after lobectonry for primary lung cancer in the United Kingdom; to explore the validity of using such data to assess the quality of UK thoracic surgeons; and to investigate the relation between in-hospital mortality and the number of procedures performed by surgeons. Design Retrospective study. Setting 36 departments dealing with thoracic surgery in UK hospitals. Participants 4028 patients who had undergone lobectomy for primary lung cancer by one of 102 surgeons. Main outcome measures In-hospital mortality in relation to individual surgeons, among all patients, and among each of five groups of patients defined by the number of operations performed by the surgeon. Results 103 patients (2.6%, 95% confidence interval 2.1% to 3.1%) died after surgery during the same hospital admission. No significant difference was found for in-hospital mortality between the five groups. Conclusions The number of procedures performed by a thoracic surgeon is not related to in-hospital mortality. Reporting data on in-hospital mortality after lobectomy for primary lung cancer is a poor tool for measuring a surgeon's performance.	Guys Hosp, Cardiothorac Unit, London SE1 9RT, England; UCL, Clin Operat Res Unit, London WC1E 6BT, England; Soc Cardiothorac Surg Great Britian & Ireland, London WC2APE, England	Guy's & St Thomas' NHS Foundation Trust; University of London; University College London	Treasure, T (corresponding author), Guys Hosp, Cardiothorac Unit, London SE1 9RT, England.	Torn.Treasure@gstt.sthames.nhs.uk		Utley, Martin/0000-0001-9928-1516				Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; ENGLISH TAH, 1984, BRIT MED J, V289, P1205, DOI 10.1136/bmj.289.6453.1205; Fine LG, 2003, BRIT MED J, V326, P25, DOI 10.1136/bmj.326.7379.25; Gawande A., 2002, NEW YORKER, V77, P52; Keogh B, 2002, NATL ADULT CARDIAC S; Partridge MR, 2002, BRIT MED J, V324, P376, DOI 10.1136/bmj.324.7334.376; Treasure T, 2002, THORAX, V57, P3, DOI 10.1136/thorax.57.1.3	8	41	41	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					73	75		10.1136/bmj.327.7406.73	http://dx.doi.org/10.1136/bmj.327.7406.73			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855523	Bronze, Green Published			2022-12-28	WOS:000184229400016
J	Celikel, R; McClintock, RA; Roberts, JR; Mendolicchio, GL; Ware, J; Varughese, KI; Ruggeri, ZM				Celikel, R; McClintock, RA; Roberts, JR; Mendolicchio, GL; Ware, J; Varughese, KI; Ruggeri, ZM			Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ib-alpha	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; VON-WILLEBRAND-FACTOR; PROCOAGULANT ACTIVITY; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; BINDING SITE; ACTIVATION; COMPLEX; IDENTIFICATION; RESIDUES	Thrombin bound to platelets contributes to stop bleeding and, in pathological conditions, may cause vascular thrombosis. We have determined the structure of platelet glycoprotein Ibalpha (GpIbalpha) bound to thrombin at 2.3 angstrom resolution and defined two sites in GpIbalpha that bind to exosite II and exosite I of two distinct alpha-thrombin molecules, respectively. GpIbalpha occupancy may be sequential, as the site binding to alpha-thrombin exosite I appears to be cryptic in the unoccupied receptor but exposed when a first thrombin molecule is bound through exosite II. These interactions may modulate alpha-thrombin function by mediating GpIbalpha clustering and cleavage of protease-activated receptors, which promote platelet activation, while limiting fibrinogen clotting through blockade of exosite I.	Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Div Expt Thrombosis & Hemostasis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Pathol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Varughese, KI (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Pathol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-48728, R01 HL042846, HL-31950, HL-55375, HL-42846] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, P01HL048728, P01HL031950, R01HL055375, R37HL042846] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BODE W, 1992, PROTEIN SCI, V1, P426; Bouton MC, 1998, THROMB HAEMOSTASIS, V80, P310, DOI 10.1055/s-0037-1615193; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; Marchese P, 1999, P NATL ACAD SCI USA, V96, P7837, DOI 10.1073/pnas.96.14.7837; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; MURATA M, 1991, J BIOL CHEM, V266, P15474; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; Tait AS, 2002, BLOOD, V99, P4422, DOI 10.1182/blood.V99.12.4422; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200	28	155	162	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					218	221		10.1126/science.1084183	http://dx.doi.org/10.1126/science.1084183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855810				2022-12-28	WOS:000184056200045
J	Day, M; Langston, R; Morris, RGM				Day, M; Langston, R; Morris, RGM			Glutamate-receptor-mediated encoding and retrieval of paired-associate learning	NATURE			English	Article							HIPPOCAMPAL CIRCUITRY; SYNAPTIC PLASTICITY; PLACE CELLS; MEMORY; POTENTIATION; TRANSMISSION; IMPAIRMENT; EXPERIENCE; SEQUENCES; AMNESIA	Paired-associate learning is often used to examine episodic memory in humans(1). Animal models include the recall of food-cache locations by scrub jays(2) and sequential memory(3,4). Here we report a model in which rats encode, during successive sample trials, two paired associates ( flavours of food and their spatial locations) and display better-than-chance recall of one item when cued by the other. In a first study, pairings of a particular foodstuff and its location were never repeated, so ensuring unique 'what-where' attributes. Blocking N-methyl-D-aspartate receptors in the hippocampus - crucial for the induction of certain forms of activity-dependent synaptic plasticity(5,6) impaired memory encoding but had no effect on recall. Inactivating hippocampal neural activity by blocking alpha-amino-3-hydroxy- 5-methyl-4-isoxazole propionic acid ( AMPA) receptors impaired both encoding and recall. In a second study, two paired associates were trained repeatedly over 8 weeks in new pairs, but blocking of hippocampal AMPA receptors did not affect their recall. Thus we conclude that unique what - where paired associates depend on encoding and retrieval within a hippocampal memory space(7,8), with consolidation of the memory traces representing repeated paired associates in circuits elsewhere.	Univ Edinburgh, Div Neurosci, Cognit Neurosci Lab, Edinburgh EH8 9JZ, Midlothian, Scotland; Univ Edinburgh, Ctr Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Morris, RGM (corresponding author), Univ Edinburgh, Div Neurosci, Cognit Neurosci Lab, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.	r.g.m.morris@ed.ac.uk	Morris, Richard G M/C-9982-2013	Langston, Rosamund/0000-0002-4668-3105				[Anonymous], 1983, CANADIAN PSYCHOL; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; COWAN WM, 2001, SYNAPSES; Eichenbaum H, 1999, NEURON, V23, P209, DOI 10.1016/S0896-6273(00)80773-4; Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305; Gardiner JM, 2001, EPISODIC MEMORY NEW, P11; Gilbert PE, 2002, BEHAV NEUROSCI, V116, P63, DOI 10.1037//0735-7044.116.1.63; Kesner RP, 2002, BEHAV NEUROSCI, V116, P286, DOI 10.1037//0735-7044.116.2.286; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MISHKIN M, 1975, J EXP PSYCHOL-ANIM B, V1, P326, DOI 10.1037/0097-7403.1.4.326; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Takahashi T, 2003, SCIENCE, V299, P1585, DOI 10.1126/science.1079886; Zeineh MM, 2003, SCIENCE, V299, P577, DOI 10.1126/science.1077775; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22	25	198	202	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					205	209		10.1038/nature01769	http://dx.doi.org/10.1038/nature01769			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853960	Green Published			2022-12-28	WOS:000184032700045
J	Grant, PM				Grant, PM			Hydrogen lifts off - with a heavy load - The dream of clean, usable energy needs to reflect practical reality.	NATURE			English	Editorial Material									Elect Power Res Inst, Palo Alto, CA 94303 USA	Electric Power Research Institute (EPRI)	Grant, PM (corresponding author), Elect Power Res Inst, POB 10412,3412 Hillview Ave, Palo Alto, CA 94303 USA.							Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Rhodes R, 2000, FOREIGN AFF, V79, P30, DOI 10.2307/20049612; RISTINEN RA, 1999, ENERGY ENV	3	80	86	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					129	130		10.1038/424129a	http://dx.doi.org/10.1038/424129a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	699AA	12853930				2022-12-28	WOS:000184032700018
J	Salomon, JA; Weinstein, MC; Hammitt, JK; Goldie, SJ				Salomon, JA; Weinstein, MC; Hammitt, JK; Goldie, SJ			Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERFERON-ALPHA-2B PLUS RIBAVIRIN; LIVER FIBROSIS PROGRESSION; TERM-FOLLOW-UP; INITIAL TREATMENT; VIRUS-INFECTION; NON-A; NON-B; COMBINATION THERAPY; NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA	Context Approximately 2.7 million US individuals are chronically infected with the hepatitis C virus (HCV). As public health campaigns are pursued, a growing number of treatment candidates are likely to have minimal evidence of liver damage. Objective To examine the clinical benefits and cost-effectiveness of newer treatments for chronic hepatitis C infection in a population of asymptomatic, HCV seropositive but otherwise healthy individuals. Design and Setting Cost-effectiveness analysis using a Markov model of the natural history of HCV infection and impact of treatment. We used an epidemiologic model to derive a range of natural history parameters that were empirically calibrated to provide a good fit to observed data on both prevalence of HCV seropositivity and time trends in outcomes related to HCV infection. Patients Cohorts of 40-year-old men and women with elevated levels of alanine aminotransferase, positive results on quantitative HCV RNA assays and serologic tests for antibody to HCV, and no histological evidence of fibrosis on liver biopsy. Interventions Monotherapy with standard or pegylated interferon alfa-2b; combination therapy with standard or pegylated interferon plus ribavirin. Main Outcome Measures Lifetime costs, life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Results The probability of patients with chronic HCV developing cirrhosis over a 30-year period ranged from 13% to 46% for men and from 1% to 29% for women. The incremental cost-effectiveness of combination therapy with pegylated interferon for men ranged from $26000 to $64000 per QALY for genotype 1 and from $10000 to $28000 per QALY for other genotypes; and for women ranged from $32000 to $90000 for genotype 1 and from $12000 to $42000 for other genotypes. Because the benefits of treatment were realized largely in the form of improvements in health-related quality of life, rather than prolonged survivorship, cost-effectiveness ratios expressed as dollars per year of life were substantially higher. Results were most sensitive to assumptions about the gains and decrements in health-related quality of life associated with treatment. Conclusions While newer treatment options for hepatitis C appear to be reasonably cost-effective on average, these results vary widely across different patient subgroups and depend critically on quality-of-life assumptions. As the pool of persons eligible for treatment for HCV infection expands to the more general population, it will be imperative for patients and their physicians to consider these assumptions in making individual-level treatment decisions.	Harvard Univ, Ctr Populat & Dev Studies, Cambridge, MA 02138 USA; WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva, Switzerland; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA	Harvard University; World Health Organization; Harvard University; Harvard T.H. Chan School of Public Health	Salomon, JA (corresponding author), Harvard Univ, Ctr Populat & Dev Studies, 9 Bow St, Cambridge, MA 02138 USA.	jsalomon@hsph.harvard.edu	Salomon, Joshua/S-1929-2019; Salomon, Joshua A/D-3898-2009	Salomon, Joshua/0000-0003-3929-5515; Salomon, Joshua A/0000-0003-3929-5515	OHS HRSA HHS [ST32HS00055-03] Funding Source: Medline	OHS HRSA HHS		Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117; [Anonymous], COMMUNICATION; Barbaro G, 2000, J HEPATOL, V33, P448, DOI 10.1016/S0168-8278(00)80281-0; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Buti M, 2000, J HEPATOL, V33, P651, DOI 10.1034/j.1600-0641.2000.033004651.x; Camma C, 1998, J HEPATOL, V28, P531, DOI 10.1016/S0168-8278(98)80274-2; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; CHRISTENSEN E, 1989, SCAND J GASTROENTERO, V24, P999, DOI 10.3109/00365528909089247; COLCHER MD, 1994, HEPATOLOGY, V20, P618; Cotler SJ, 2001, AM J GASTROENTEROL, V96, P2730, DOI 10.1111/j.1572-0241.2001.04132.x; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; Dore GJ, 2002, J GASTROEN HEPATOL, V17, P423, DOI 10.1046/j.1440-1746.2002.02730.x; Dusheiko G, 1997, HEPATOLOGY, V26, pS112, DOI 10.1002/hep.510260720; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; Edlin BR, 2002, HEPATOLOGY, V36, pS210, DOI 10.1053/jhep.2002.36809; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gold MR, 1996, COST EFFECTIVENESS H; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Kim WR, 1997, ANN INTERN MED, V127, P866, DOI 10.7326/0003-4819-127-10-199711150-00002; KIYOSAWA K, 1994, INTERVIROLOGY, V37, P101, DOI 10.1159/000150363; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; Kuehne FC, 2002, ARCH INTERN MED, V162, P2545, DOI 10.1001/archinte.162.22.2545; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Matsumura H, 2000, J VIRAL HEPATITIS, V7, P268; MATTSON L, 1993, LIVER, V13, P274; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; *MED EC, 2001, DRUG TOP RED BOOK; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; Okanoue T, 1999, J HEPATOL, V30, P653, DOI 10.1016/S0168-8278(99)80196-2; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; ROBERTS JM, 1993, GASTROENTEROL JPN, V28, P37, DOI 10.1007/BF02989202; Rodger AJ, 2000, HEPATOLOGY, V32, P582, DOI 10.1053/jhep.2000.9714; Russo MW, 2000, HEPATOLOGY, V31, P358, DOI 10.1002/hep.510310215; Sagmeister M, 2001, EUR J GASTROEN HEPAT, V13, P483, DOI 10.1097/00042737-200105000-00004; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; Salomon JA, 2002, AM J EPIDEMIOL, V156, P761, DOI 10.1093/aje/kwf100; Seeff LB, 2001, HEPATOLOGY, V33, P455, DOI 10.1053/jhep.2001.21905; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003; Seeff Leonard B., 1999, American Journal of Medicine, V107, p10S; Sennfalt K, 2001, SCAND J GASTROENTERO, V36, P870, DOI 10.1080/003655201750313414; Shiell A, 1999, MED J AUSTRALIA, V171, P189, DOI 10.5694/j.1326-5377.1999.tb123595.x; Shiratori Y, 2000, ANN INTERN MED, V132, P517, DOI 10.7326/0003-4819-132-7-200004040-00002; Sinha M, 2000, PEDIATR INFECT DIS J, V19, P23, DOI 10.1097/00006454-200001000-00006; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; Stein K, 2002, GUT, V50, P253, DOI 10.1136/gut.50.2.253; Stinnett AA, 1997, MED DECIS MAKING, V17, P483, DOI 10.1177/0272989X9701700414; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; Thomas DL, 2002, HEPATOLOGY, V36, pS201, DOI 10.1053/jhep.2002.36380; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; *US DEP HHS, 2001, HEP C EM THREAT PUBL; Wiese M, 2000, HEPATOLOGY, V32, P91, DOI 10.1053/jhep.2000.8169; Wong J B, 1999, Am J Med, V107, p74S; Wong JB, 2000, ANN INTERN MED, V133, P665, DOI 10.7326/0003-4819-133-9-200011070-00008; Wong JB, 2000, AM J MED, V108, P366, DOI 10.1016/S0002-9343(00)00303-X; Wong JB, 2000, AM J GASTROENTEROL, V95, P1524; Wong JB, 2002, ACTA GASTRO-ENT BELG, V65, P110; Wong JB, 1998, JAMA-J AM MED ASSOC, V280, P2088, DOI 10.1001/jama.280.24.2088; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; Younossi ZM, 1999, HEPATOLOGY, V30, P1318, DOI 10.1002/hep.510300518; Zaman A, 2000, AM J GASTROENTEROL, V95, P1323	78	192	198	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					228	237		10.1001/jama.290.2.228	http://dx.doi.org/10.1001/jama.290.2.228			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851278	Bronze			2022-12-28	WOS:000183989800028
J	Gardner, TS; di Bernardo, D; Lorenz, D; Collins, JJ				Gardner, TS; di Bernardo, D; Lorenz, D; Collins, JJ			Inferring genetic networks and identifying compound mode of action via expression profiling	SCIENCE			English	Article							TRANSCRIPTIONAL REGULATION; SIMULATION	The complexity of cellular gene, protein, and metabolite networks can hinder attempts to elucidate their structure and function. To address this problem, we used systematic transcriptional perturbations to construct a first-order model of regulatory interactions in a nine-gene subnetwork of the SOS pathway in Escherichia coli. The model correctly identified the major regulatory genes and the transcriptional targets of mitomycin C activity in the subnetwork. This approach, which is experimentally and computationally scalable, provides a framework for elucidating the functional properties of genetic networks and identifying molecular targets of pharmacological compounds.	Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; Telethon Inst Genet & Med, I-80131 Naples, Italy	Boston University; Boston University; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Collins, JJ (corresponding author), Boston Univ, Ctr Biodynam, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu	di Bernardo, Diego/AAF-5881-2021; di Bernardo, Diego/I-9440-2012	di Bernardo, Diego/0000-0002-1911-7407; di Bernardo, Diego/0000-0002-1911-7407; Lorenz, David/0000-0001-8732-3627	Telethon [TGM03P17, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Arkin A, 1997, SCIENCE, V277, P1275, DOI 10.1126/science.277.5330.1275; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Courcelle J, 2001, GENETICS, V158, P41; D'haeseleer P, 1999, Pac Symp Biocomput, P41; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; De Jong H, 2002, J COMPUT BIOL, V9, P67, DOI 10.1089/10665270252833208; de la Fuente A, 2002, TRENDS GENET, V18, P395, DOI 10.1016/S0168-9525(02)02692-6; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P56, DOI 10.1093/nar/30.1.56; Koch WH, 1998, CONT CANC RES, P107; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; Liang S, 1998, Pac Symp Biocomput, P18; Ljung L., 1999, SYSTEM IDENTIFICATIO; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; MONTGOMERY D. C., 2001, INTRO LINEAR REGRESS; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Tegner J, 2003, P NATL ACAD SCI USA, V100, P5944, DOI 10.1073/pnas.0933416100; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; VANSOMEREN EP, 2001, P 2 INT C SYST BIOL, P222; WALKER GC, 1996, CELLULAR MOL BIOL, P1400	27	842	877	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					102	105		10.1126/science.1081900	http://dx.doi.org/10.1126/science.1081900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843395				2022-12-28	WOS:000183914700043
J	Miranda, J; Chung, JY; Green, BL; Krupnick, J; Siddique, J; Revicki, DA; Belin, T				Miranda, J; Chung, JY; Green, BL; Krupnick, J; Siddique, J; Revicki, DA; Belin, T			Treating depression in predominantly low-income young minority women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; MENTAL-DISORDERS; UNITED-STATES; PSYCHOTHERAPY; GUIDELINES; QUALITY	Context Impoverished minority women experience a higher burden from depression than do white women because they are less likely to receive appropriate care. Little is known about the effectiveness of guideline-based care for depression with impoverished minority women, most of whom do not seek care. Objective To determine the impact of an intervention to deliver guideline-based care for depression compared with referral to community care with low-income and minority women. Design, Setting, and Participants A randomized controlled trial conducted in the Washington, DC, suburban area from March 1997 through May 2002 of 267 women. with current major depression, who attended county-run Women, Infants, and Children food subsidy programs and Title X family planning clinics. Outcomes Hamilton Depression Rating Scale measured monthly from baseline through 6 months; instrumental role functioning (Social Adjustment Scale) and social functioning (Short Form 36-Item Health Survey) measured at baseline and 3 and 6 months. Interventions Participants were randomly assigned to an antidepressant medication intervention (trial of paroxetine switched to buproprion, if lack of response) (n=88), a psychotherapy intervention (8 weeks of manual-guided cognitive behavior therapy) (n=90), or referral to community mental health services (n=89). Results Both the medication intervention (P<.001) and the psychotherapy intervention (P=.006) reduced depressive symptoms more than the community referral did. The medication intervention also resulted in improved instrumental role (P=.006) and social (P=.001) functioning. The psychotherapy intervention resulted in improved social functioning (P=.02). Women randomly assigned to receive medications were twice as likely (odds ratio, 2.04; 95% confidence interval, 0.98-4.27; P=.057) to achieve a Hamilton Depression Rating Scale score of 7 or less by month 6 as were those referred to community care. Conclusions Guideline-concordant care for major depression is effective for these ethnically diverse and impoverished patients. More women engaged in a sufficient duration of treatment with medications compared with psychotherapy, and outcome gains were more extensive and robust for medications.	Univ Calif Los Angeles, Inst Neuropsychiat, Hlth Serv Res Ctr, Los Angeles, CA 90024 USA; Georgetown Univ, Med Ctr, Dept Psychiat, Washington, DC 20007 USA; MEDTAP Int, Ctr Hlth Outcomes Res, Bethesda, MD USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; Georgetown University; University of California System; University of California Los Angeles	Miranda, J (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Hlth Serv Res Ctr, 10920 Wilshire Blvd,Suite 300, Los Angeles, CA 90024 USA.				NIMH NIH HHS [R01 MH56 864] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056864] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1997, COMP INT DIAGN INT C; Barret JE, 2001, J FAM PRACTICE, V50, P405; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beck C, 1997, NURS RES, V46, P126, DOI 10.1097/00006199-199705000-00002; DIMASCIO A, 1979, ARCH GEN PSYCHIAT, V36, P1450; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; First MB, 2001, STRUCTURED CLIN INTE; Goodman LA, 1998, J TRAUMA STRESS, V11, P521, DOI 10.1023/A:1024456713321; Guy W, 1976, ECDEU ASSESSMENT MAN, P217; Hollon S., 1992, APPLIED PREVENTIVE P, V1, P89, DOI DOI 10.1016/S0962-1849(05)80149-0; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Karasu T.B., 2000, PRACTICE GUIDELINE T, V2nd; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P86, DOI 10.1016/0163-8343(92)90033-7; Katon W, 2001, ARCH GEN PSYCHIAT, V58, P241, DOI 10.1001/archpsyc.58.3.241; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Klerman GL, 1984, INTERPERSONAL PSYCHO; LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878; MCHORNEY CA, 1992, MED CARE S, V30, P253; Miranda J, 2003, HEALTH SERV RES, V38, P613, DOI 10.1111/1475-6773.00136; Miranda J, 2003, PSYCHIAT SERV, V54, P219, DOI 10.1176/appi.ps.54.2.219; Munoz R. F., 1986, MANUAL TERAPIA GRUPO; Munoz RF, 1986, GROUP THERAPY COGNIT; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; OLFSON M, 1993, AM J PSYCHIAT, V150, P571; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; Rollman BL, 2001, ARCH INTERN MED, V161, P189, DOI 10.1001/archinte.161.2.189; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; RUSSELL M, 1979, AM J OBSTET GYNECOL, V134, P4, DOI 10.1016/0002-9378(79)90787-7; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Thase ME, 1996, J CONSULT CLIN PSYCH, V64, P646, DOI 10.1037/0022-006X.64.4.646; Thase Michael E., 1995, P1169; *US DEP HHS, 1993, AHRQ PUBL; *US DEP HHS, 2002, AHRQ PUBL; US Department of Health and Human Services, 2001, MENT HLTH CULT RAC E; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEISSMAN MM, 1974, DEPRESSED WOMAN STUD; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	43	399	399	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					57	65		10.1001/jama.290.1.57	http://dx.doi.org/10.1001/jama.290.1.57			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696CR	12837712	Bronze			2022-12-28	WOS:000183868600020
J	Agnelli, G; Prandoni, P; Becattini, C; Silingardi, M; Taliani, MR; Miccio, M; Imberti, D; Poggio, R; Ageno, W; Pogliani, E; Porro, F; Zonzin, P				Agnelli, G; Prandoni, P; Becattini, C; Silingardi, M; Taliani, MR; Miccio, M; Imberti, D; Poggio, R; Ageno, W; Pogliani, E; Porro, F; Zonzin, P		Optimal Duration Italian Trial Inv	Extended oral anticoagulant therapy after a first episode of pulmonary embolism	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; CLINICAL-COURSE; RISK	Background: The optimal duration of oral anticoagulant treatment after a first episode of pulmonary embolism remains uncertain. Objective: To evaluate the long-term clinical benefit of extending a 3-month course of oral anticoagulant therapy to 6 months (pulmonary embolism associated with temporary risk factors) or to 1 year (idiopathic pulmonary embolism) in patients with a first episode of pulmonary embolism. Design: Multicenter randomized study with independent, blinded assessment of the outcome events. Setting: 19 Italian hospitals. Patients: 326 patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding. Measurements: The primary study outcome was recurrence of symptomatic, objectively confirmed venous thromboembolism. Results: Among 165 patients assigned to extended anticoagulant therapy, 15 patients (9.1%) had a recurrence of venous thromboembolism (3.1% per patient-year; average follow-up, 34.9 months), as compared with 18 of 161 patients (11.2%) assigned to discontinue treatment (4.1% per patient-year; average follow-up, 32.7 months); the rate ratio was 0.81 (95% CI, 0.42 to 1.56). All but one of the recurrences occurred after anticoagulant treatment was discontinued. Nineteen recurrences (57.6%) were episodes of pulmonary embolism, two of which were fatal. Three major bleeding episodes were observed during extended anticoagulation (1.8%). Among patients with idiopathic venous thromboembolism, 11 of 90 patients assigned to extended anticoagulation and 11 of 91 patients assigned to discontinue treatment experienced a recurrence (relative risk, 0.99 [CI, 0.45 to 2.16]). Conclusion: Patients with pulmonary embolism have a substantial risk for recurrence after discontinuation of oral anticoagulation, regardless of treatment duration. Physicians should try to identify patients who are at high risk for recurrent venous thromboembolism and are therefore potential candidates for indefinite oral anticoagulant therapy.	Univ Perugia, Dipartimento Med Interna, Sez Med Interna & Cardiovasc, I-06123 Perugia, Italy; Univ Padua, Ist Clin Med 2, Padua, Italy; Arispedale S Maria, Reggio Emilia, Italy; Osped Maggiore Trieste, Trieste, Italy; Osped Galliera, Ctr Trombosi, Genoa, Italy; Osped Piacenza, Piacenza, Italy; Univ Milan, Osped San Gerardo, Monza, Italy; Univ Insubrai, Varese, Italy; Osped Maggiore, IRCCS, Milan, Italy; Osped S Maria Miseriocordia, Rovigo, Italy	University of Perugia; University of Padua; Ente Ospedaliero Ospedali Galliera; Ospedale di Piacenza; San Gerardo Hospital; University of Milan; University of Insubria; IRCCS Ca Granda Ospedale Maggiore Policlinico	Agnelli, G (corresponding author), Univ Perugia, Dipartimento Med Interna, Sez Med Interna & Cardiovasc, Via Enrio Dal Pozzo, I-06123 Perugia, Italy.	agnellig@unipg.it	Becattini, Cecilia/L-1739-2018; Imberti, Davide/AGB-5049-2022	Imberti, Davide/0000-0002-9284-6227; ageno, walter/0000-0002-1922-8879; Silingardi, Mauro/0000-0002-9518-8725; BECATTINI, Cecilia/0000-0002-8343-4888				Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Heit JA, 1999, ARCH INTERN MED, V159, P445, DOI 10.1001/archinte.159.5.445; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Lensing AWA, 1999, LANCET, V353, P479, DOI 10.1016/S0140-6736(98)04298-6; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Murin S, 2002, THROMB HAEMOSTASIS, V88, P407; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Pinede L, 2001, CIRCULATION, V103, P2453; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501	17	300	310	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					19	25		10.7326/0003-4819-139-1-200307010-00008	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834314				2022-12-28	WOS:000183823200003
J	Berger, A				Berger, A			How does it work? Positron emission tomography	BRITISH MEDICAL JOURNAL			English	Review																		VALK, 2002, POSITRON EMISSION TO	1	29	30	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1449	1449		10.1136/bmj.326.7404.1449	http://dx.doi.org/10.1136/bmj.326.7404.1449			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829560	Green Published			2022-12-28	WOS:000183931800022
J	Garrido, JJ; Giraud, P; Carlier, E; Fernandes, F; Moussif, A; Fache, MP; Debanne, D; Dargent, B				Garrido, JJ; Giraud, P; Carlier, E; Fernandes, F; Moussif, A; Fache, MP; Debanne, D; Dargent, B			A targeting motif involved in sodium channel clustering at the axonal initial segment	SCIENCE			English	Article							BETA-IV-SPECTRIN; POLARIZED NEURONS; ANKYRIN-G; RANVIER; NODES; LOCALIZATION; EXPRESSION; NA(V)1.6; DOMAINS; BARRIER	The sorting of sodium channels to axons and the formation of clusters are of primary importance for neuronal electrogenesis. Here, we showed that the cytoplasmic loop connecting domains II and III of the Na-v 1 subunit contains a determinant conferring compartmentalization in the axonal initial segment of rat hippocampal neurons. Expression of a soluble Na-v 1.2 II- III linker protein led to the disorganization of endogenous sodium channels. The motif was sufficient to redirect a somatodendritic potassium channel to the axonal initial segment, a process involving association with ankyrin G. Thus, this motif may play a fundamental role in controlling electrical excitability during development and plasticity.	Univ Mediterranee, Fac Med Secteur Nord, Inst Jean Roche, INSERM,U464, F-13916 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dargent, B (corresponding author), Univ Mediterranee, Fac Med Secteur Nord, Inst Jean Roche, INSERM,U464, Blvd P Dramard, F-13916 Marseille 20, France.		Garrido, Juan Jose/E-6782-2012; Debanne, Dominique/O-4673-2016	Garrido, Juan Jose/0000-0002-4499-4487; Debanne, Dominique/0000-0001-8581-5695				Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Alessandri-Haber N, 1999, J PHYSIOL-LONDON, V518, P203, DOI 10.1111/j.1469-7793.1999.0203r.x; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Boiko T, 2003, J NEUROSCI, V23, P2306; Bouzidi M, 2002, J BIOL CHEM, V277, P28996, DOI 10.1074/jbc.M201760200; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; DARGENT B, UNPUB; Fernandes F. M., UNPUB; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; Goldin AL, 1999, ANN NY ACAD SCI, V868, P38, DOI 10.1111/j.1749-6632.1999.tb11272.x; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; KOBAYASHI T, 1992, NATURE, V359, P647, DOI 10.1038/359647a0; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; LEMAILLET G, 2003, J BIOL CHEM; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Maier SKG, 2003, P NATL ACAD SCI USA, V100, P3507, DOI 10.1073/pnas.2627986100; MALHOTRA JD, 2002, J BIOL CHEM, V7, P7; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; WESTENBROEK RE, 1989, NEURON, V3, P695, DOI 10.1016/0896-6273(89)90238-9; Winckler B, 1999, NATURE, V397, P698, DOI 10.1038/17789; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhang X, 1998, J CELL BIOL, V142, P1571, DOI 10.1083/jcb.142.6.1571; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	31	271	302	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2091	2094		10.1126/science.1085167	http://dx.doi.org/10.1126/science.1085167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829783				2022-12-28	WOS:000183774900046
J	Hawley, RS				Hawley, RS			The human Y chromosome: Rumors of its death have been greatly exaggerated	CELL			English	Review							SEX	Recent papers by David Page and his collaborators present an intriguing new face to the human Y chromosome, including eight massive palindromic arrays, most of which contain multi-copy pairs of testis-specific genes. Sequence pairs within the arms of these palindromic sequences retain a high degree of similarity, suggesting that intrachromosomal gene conversion is frequent, perhaps providing a means of maintaining the integrity of individual members of the array.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	Stowers Institute for Medical Research; University of Kansas	Hawley, RS (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	rsh@stowers-institute.org		Hawley, R. Scott/0000-0002-6478-0494				Aitken RJ, 2002, NATURE, V415, P963, DOI 10.1038/415963a; Carvalho AB, 2001, P NATL ACAD SCI USA, V98, P13225, DOI 10.1073/pnas.231484998; DOVER GA, 1982, SCIENCE, V218, P1069, DOI 10.1126/science.7146895; Graves JAM, 2000, BIOL REPROD, V63, P667, DOI 10.1095/biolreprod63.3.667b; Kawaguchi TK, 2001, NAT GENET, V29, P279, DOI 10.1038/ng757; Lahn BT, 2001, NAT REV GENET, V2, P207, DOI 10.1038/35056058; Reijo RA, 2000, BIOL REPROD, V63, P1490, DOI 10.1095/biolreprod63.5.1490; Reugels AM, 2000, GENETICS, V154, P759; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Yen P, 2001, NAT GENET, V29, P243, DOI 10.1038/ng1101-243	11	13	14	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					825	828		10.1016/S0092-8674(03)00470-7	http://dx.doi.org/10.1016/S0092-8674(03)00470-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837241	Bronze			2022-12-28	WOS:000183817900007
J	Sreenarasimhaiah, J				Sreenarasimhaiah, J			Diagnosis and management of intestinal ischaemic disorders	BRITISH MEDICAL JOURNAL			English	Review							MESENTERIC VENOUS THROMBOSIS; ISCHEMIC COLITIS; MR-ANGIOGRAPHY; BOWEL; ARTERIES; DISEASE; THERAPY; CT		Univ Texas, SW Med Ctr, Dept Med, Div Digest & Liver Dis, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sreenarasimhaiah, J (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Digest & Liver Dis, 5323 Harry Hines Blvd,MC 8887, Dallas, TX 75390 USA.							ABDU RA, 1987, SURGERY, V101, P383; Boley S J, 1973, Surg Annu, V5, P355; Bradbury MS, 2002, J COMPUT ASSIST TOMO, V26, P392, DOI 10.1097/00004728-200205000-00014; Brandt LJ, 2000, GASTROENTEROLOGY, V118, P954, DOI 10.1016/S0016-5085(00)70183-1; Edwards MS, 2003, ANN VASC SURG, V17, P72, DOI 10.1007/s10016-001-0329-8; Endean ED, 2001, ANN SURG, V233, P801, DOI 10.1097/00000658-200106000-00010; Fitzgerald SF, 1993, SEMIN COLON RECTAL S, V4, P222; Gandhi SK, 1996, DIS COLON RECTUM, V39, P88, DOI 10.1007/BF02048275; Gilfeather M, 1997, RADIOGRAPHICS, V17, P423, DOI 10.1148/radiographics.17.2.9084082; Greenwald DA, 1998, J CLIN GASTROENTEROL, V27, P122, DOI 10.1097/00004836-199809000-00004; Greenwald DA, 2001, GASTROENTEROL CLIN N, V30, P445, DOI 10.1016/S0889-8553(05)70190-4; GUTTORMSON NL, 1989, DIS COLON RECTUM, V32, P469, DOI 10.1007/BF02554499; Ha HK, 2000, SEMIN ULTRASOUND CT, V21, P40, DOI 10.1016/S0887-2171(00)90012-X; HARNSBERGER JR, 1994, SEMIN COLON RECTAL S, V5, P2; HUNTER GC, 1988, MED CLIN N AM, V71, P1091; JOHNSTON KW, 1995, SURGERY, V118, P1; Kihara TK, 1999, ANN VASC SURG, V13, P37, DOI 10.1007/s100169900218; Kumar S, 2001, NEW ENGL J MED, V345, P1683, DOI 10.1056/NEJMra010076; Laissy JP, 2002, ABDOM IMAGING, V27, P488, DOI 10.1007/s00261-001-0063-2; Lefkovitz Z, 2002, MED CLIN N AM, V86, P1357, DOI 10.1016/S0025-7125(02)00080-9; LONGO WE, 1992, DIS COLON RECTUM, V35, P726, DOI 10.1007/BF02050319; Loomer DC, 1999, J VASC INTERV RADIOL, V10, P29, DOI 10.1016/S1051-0443(99)70005-9; Meaney JFM, 1997, J MAGN RESON IMAGING, V7, P171, DOI 10.1002/jmri.1880070126; Moawad J, 1997, ARCH SURG-CHICAGO, V132, P613; Moawad J, 1997, SURG CLIN N AM, V77, P357, DOI 10.1016/S0039-6109(05)70554-5; REINUS JF, 1990, GASTROENTEROL CLIN N, V19, P319; Rhee RY, 1997, SURG CLIN N AM, V77, P327, DOI 10.1016/S0039-6109(05)70552-1; RIVITZ SM, 1995, J VASC INTERV RADIOL, V6, P219, DOI 10.1016/S1051-0443(95)71098-3; ROOBOTTOM CA, 1993, AM J ROENTGENOL, V161, P985, DOI 10.2214/ajr.161.5.8273642; SAKAI L, 1980, AM J SURG, V140, P755, DOI 10.1016/0002-9610(80)90111-7; Sheehan SR., 2000, EMERY RADIOL, V7, P231; Simo G, 1997, RADIOLOGY, V204, P775, DOI 10.1148/radiology.204.3.9280258; SMERUD MJ, 1990, AM J ROENTGENOL, V154, P99, DOI 10.2214/ajr.154.1.2104734; Trompeter M, 2002, EUR RADIOL, V12, P1179, DOI 10.1007/s00330-001-1220-2	34	96	108	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1372	1376		10.1136/bmj.326.7403.1372	http://dx.doi.org/10.1136/bmj.326.7403.1372			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816826	Green Published			2022-12-28	WOS:000183756400024
J	Panda, S; Provencio, I; Tu, DC; Pires, SS; Rollag, MD; Castrucci, AM; Pletcher, MT; Sato, TK; Wiltshire, T; Andahazy, M; Kay, SA; Van Gelder, RN; Hogenesch, JB				Panda, S; Provencio, I; Tu, DC; Pires, SS; Rollag, MD; Castrucci, AM; Pletcher, MT; Sato, TK; Wiltshire, T; Andahazy, M; Kay, SA; Van Gelder, RN; Hogenesch, JB			Melanopsin is required for non-image-forming photic responses in blind mice	SCIENCE			English	Article							RETINAL GANGLION-CELLS; CIRCADIAN CLOCK; NON-CONE; NON-ROD; LIGHT; PHOTORECEPTORS; ENTRAINMENT; PINEAL; PHOTOSENSITIVITY; CRYPTOCHROMES	Although mice lacking rod and cone photoreceptors are blind, they retain many eye-mediated responses to light, possibly through photosensitive retinal ganglion cells. These cells express melanopsin, a photopigment that confers this photosensitivity. Mice lacking melanopsin still retain nonvisual photoreception, suggesting that rods and cones could operate in this capacity. We observed that mice with both outer-retinal degeneration and a deficiency in melanopsin exhibited complete loss of photoentrainment of the circadian oscillator, pupillary light responses, photic suppression of arylalkylamine-N-acetyltransferase transcript, and acute suppression of locomotor activity by light. This indicates the importance of both nonvisual and classical visual photoreceptor systems for nonvisual photic responses in mammals.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Sao Paulo, Dept Physiol, Biosci Inst, BR-05508900 Sao Paulo, Brazil	Novartis; Scripps Research Institute; Scripps Research Institute; Uniformed Services University of the Health Sciences - USA; Washington University (WUSTL); Washington University (WUSTL); Universidade de Sao Paulo	Hogenesch, JB (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John J Hopkins Dr, San Diego, CA 92121 USA.		Castrucci, Ana Maria L/C-3296-2014; Jansen, Heiko T./A-5770-2008; Van Gelder, Russell/ABB-4225-2021; Kay, Steve A/F-6025-2011; Panda, Satchidananda/J-6891-2012	Jansen, Heiko T./0000-0003-0178-396X; Van Gelder, Russell/0000-0001-5368-3659; Kay, Steve A/0000-0002-0402-2878; Castrucci, Ana Maria/0000-0002-2065-8198; Provencio, Ignacio/0000-0003-1175-920X	NEI NIH HHS [K08-EY00403, R01-EY14988] Funding Source: Medline; NIMH NIH HHS [MH51573, MH 62405] Funding Source: Medline; NATIONAL EYE INSTITUTE [K08EY000403, R01EY014988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062405, R01MH051573] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FARADJI H, 1980, BRAIN RES, V202, P41, DOI 10.1016/0006-8993(80)90642-3; Foster RG, 2002, PROG RETIN EYE RES, V21, P507, DOI 10.1016/S1350-9462(02)00036-8; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; Lucas RJ, 2003, SCIENCE, V299, P245, DOI 10.1126/science.1077293; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848; PANDA S, UNPUB; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Van Gelder RN, 2002, J NEUROGENET, V16, P181, DOI 10.1080/01677060215306; Van Gelder RN, 2003, SCIENCE, V299, P222, DOI 10.1126/science.1079536; Wee R, 2002, J NEUROSCI, V22, P10427	23	532	546	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 25	2003	301	5632					525	527		10.1126/science.1086179	http://dx.doi.org/10.1126/science.1086179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704LE	12829787				2022-12-28	WOS:000184340500045
J	Devinsky, O				Devinsky, O			A 48-year-old man with temporal lobe epilepsy and psychiatric illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIPPOCAMPAL NEURON LOSS; CLINICAL-FEATURES; RISK-FACTORS; DEPRESSION; IMPAIRMENT; PATTERNS; SURGERY; SUICIDE; MRI; EPIDEMIOLOGY		NYU, Sch Med, Epilepsy Ctr, New York, NY 10016 USA	New York University	Devinsky, O (corresponding author), NYU, Sch Med, Epilepsy Ctr, 403 E 34th St,Rivergate 4th Floor, New York, NY 10016 USA.	od4@nyu.edu		Devinsky, Orrin/0000-0003-0044-4632				AARTS JHP, 1984, BRAIN, V107, P293, DOI 10.1093/brain/107.1.293; Alper K, 2001, J NEUROPSYCH CLIN N, V13, P492, DOI 10.1176/appi.neuropsych.13.4.492; Annegers J. F., 2001, TREATMENT EPILEPSY P, V3, P131; [Anonymous], 1981, Epilepsia, V22, P489; Arroyo S, 2002, EPILEPSIA, V43, P437, DOI 10.1046/j.1528-1157.2002.38501.x; Begley CE, 2000, EPILEPSIA, V41, P342, DOI 10.1111/j.1528-1157.2000.tb00166.x; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Berg AT, 2000, NEUROLOGY, V54, P625, DOI 10.1212/WNL.54.3.625; BERG AT, 1997, EPILEPSY COMPREHENSI, P1891; Blake RV, 2000, BRAIN, V123, P472, DOI 10.1093/brain/123.3.472; Blume WT, 2001, CURR OPIN NEUROL, V14, P193, DOI 10.1097/00019052-200104000-00010; Briellmann RS, 2002, ANN NEUROL, V51, P641, DOI 10.1002/ana.10171; CAVAZZUTI GB, 1980, EPILEPSIA, V21, P43, DOI 10.1111/j.1528-1157.1980.tb04043.x; CHEE MWL, 1993, NEUROLOGY, V43, P2519, DOI 10.1212/WNL.43.12.2519; Cramer JA, 1998, EPILEPSIA, V39, P233, DOI 10.1111/j.1528-1157.1998.tb01364.x; Deckers CLP, 2002, EPILEPSY RES, V52, P43, DOI 10.1016/S0920-1211(02)00184-5; Devinsky O, 1999, NEUROLOGY, V53, pS13; DEVINSKY O, 1995, EPILEPSY RES, V20, P247, DOI 10.1016/0920-1211(94)00085-B; DEVINSKY O, 1986, AM J MED, V80, P195, DOI 10.1016/0002-9343(86)90009-4; Devinsky O, 1999, NEW ENGL J MED, V340, P1565, DOI 10.1056/NEJM199905203402008; Devinsky O, 1996, NEUROLOGY, V46, P1530, DOI 10.1212/WNL.46.6.1530; DEVINSKY O, 1993, NEUROL CLIN, V11, P127, DOI 10.1016/S0733-8619(18)30173-7; DEVINSKY O, 1994, CURRENT DIAGNOSIS NE, P18; DOSTOEVSKY FM, 1914, LETT FM DOST HIS FAM, P50; DUCHOWNY MS, 1997, EPILEPSY COMPREHENSI, P1677; EEGOLOFSSON O, 1971, NEUROPADIATRIE, V2, P375, DOI 10.1055/s-0028-1091791; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410; FLINT LA, 2002, 155 M AM PSYCH ASS M; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fried I, 1997, J NEUROPSYCH CLIN N, V9, P420; Frucht MM, 2000, EPILEPSIA, V41, P1534; Fukuchi T, 2002, EPILEPSY RES, V51, P233, DOI 10.1016/S0920-1211(02)00151-1; GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224; Geschwind N, 1980, J Clin Psychiatry, V41, P89; GESCHWIND N, 1974, TEMPORAL LOBE EPILEP; Getz K, 2002, AM J PSYCHIAT, V159, P644, DOI 10.1176/appi.ajp.159.4.644; Gilliam Frank, 2002, Epilepsy Behav, V3, P2, DOI 10.1016/S1525-5069(02)00503-0; Gowers WR, 1881, EPILEPSY OTHER CHRON; Gross A, 2000, J NEUROPSYCH CLIN N, V12, P458, DOI 10.1176/appi.neuropsych.12.4.458; Harden CL, 1999, EPILEPSIA, V40, P1402, DOI 10.1111/j.1528-1157.1999.tb02012.x; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; Hermann BP, 2002, PROG BRAIN RES, V135, P429; Herzog AG, 1997, EPILEPSIA, V38, P1082, DOI 10.1111/j.1528-1157.1997.tb01197.x; Jokeit H, 2002, PROG BRAIN RES, V135, P455; Kanner AM, 2002, NEUROLOGY, V58, pS27, DOI 10.1212/WNL.58.8_suppl_5.S27; Kotloski R, 2002, PROG BRAIN RES, V135, P95; KRUMHOLZ A, 1994, EPILEPSIA, V35, P668, DOI 10.1111/j.1528-1157.1994.tb02490.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lambert MV, 1999, EPILEPSIA, V40, pS21, DOI 10.1111/j.1528-1157.1999.tb00884.x; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; Liu RSN, 2002, ANN NEUROL, V52, P573, DOI 10.1002/ana.10338; LJUNGGREN B, 1982, NEUROSURGERY, V10, P733, DOI 10.1227/00006123-198206010-00009; Loring DW, 2001, EPILEPSIA, V42, P24, DOI 10.1046/j.1528-1157.2001.08008.x; MANFORD M, 1992, NEUROLOGY, V42, P1911; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Marson AG, 2001, EPILEPSY RES, V46, P259, DOI 10.1016/S0920-1211(01)00287-X; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; MATTHEWS WS, 1981, PSYCHOSOMATICS, V22, P515; Mattson R H, 1991, Adv Neurol, V55, P453; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MENDEZ MF, 1986, ARCH NEUROL-CHICAGO, V43, P766, DOI 10.1001/archneur.1986.00520080014012; Nilsson L, 2002, EPILEPSIA, V43, P644, DOI 10.1046/j.1528-1157.2002.40001.x; O'Brien TJ, 1999, ANN NEUROL, V45, P526, DOI 10.1002/1531-8249(199904)45:4<526::AID-ANA17>3.3.CO;2-E; Pacia SV, 1996, ANN NEUROL, V40, P724, DOI 10.1002/ana.410400508; Pfander M, 2002, EPILEPTIC DISORD, V4, P189; Pulliainen V, 2000, ACTA NEUROL SCAND, V101, P73, DOI 10.1034/j.1600-0404.2000.101002073.x; Quiske A, 2000, EPILEPSY RES, V39, P121, DOI 10.1016/S0920-1211(99)00117-5; RAMSAY RE, 1993, NON-EPILEPTIC SEIZURES, P47; Rush AJ, 2000, BIOL PSYCHIAT, V47, P276, DOI 10.1016/S0006-3223(99)00304-2; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; Salmenpera T, 2001, EPILEPSY RES, V46, P69, DOI 10.1016/S0920-1211(01)00258-3; Schachter SC, 2002, NEUROLOGY, V59, pS15, DOI 10.1212/WNL.59.6_suppl_4.S15; Schwarcz R, 2002, EPILEPSY RES, V50, P161, DOI 10.1016/S0920-1211(02)00077-3; Scicutella A, 2001, PSYCHIATRIC ISSUES IN EPILEPSY: A PRACTICAL GUIDE TO DIAGNOSIS AND TREATMENT, P95; Sirven JI, 1996, EPILEPSIA, V37, P450, DOI 10.1111/j.1528-1157.1996.tb00590.x; SLATER E, 1963, BRIT J PSYCHIAT, V109, P95, DOI 10.1192/bjp.109.458.95; Spencer SS, 1996, EPILEPSIA, V37, P807, DOI 10.1111/j.1528-1157.1996.tb00032.x; SPENCER SS, 1995, MAGN RESON IMAGING, V13, P1119, DOI 10.1016/0730-725X(95)02021-K; Tarulli A, 2001, EPILEPSIA, V42, P1468, DOI 10.1046/j.1528-1157.2001.10701.x; TRIMBLE MR, 1991, PSYCHOSES EPILEPSY, P124; UMBRICHT D, 1995, AM J PSYCHIAT, V152, P224; VICKREY BG, 1995, ANN NEUROL, V37, P158, DOI 10.1002/ana.410370205; WAXMAN SG, 1975, ARCH GEN PSYCHIAT, V32, P1580; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501; Wiebe S, 2000, CAN J NEUROL SCI, V27, pS6, DOI 10.1017/S0317167100000561; WILLIAMSON PD, 1993, ANN NEUROL, V34, P781, DOI 10.1002/ana.410340605; [No title captured]	90	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					381	392		10.1001/jama.290.3.381	http://dx.doi.org/10.1001/jama.290.3.381			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699WK	12865380				2022-12-28	WOS:000184078800033
J	Richmond, BJ; Liu, Z; Shidara, M				Richmond, BJ; Liu, Z; Shidara, M			Predicting future rewards	SCIENCE			English	Editorial Material							PREFRONTAL CORTEX; ANTERIOR CINGULATE; NEURONAL SIGNALS; SELECTION; MACAQUE; MOTOR		NIMH, Neuropsychol Lab, Bethesda, MD 20892 USA; AIST, Neurosci Res Inst, Syst Neurosci Grp, Tsukuba, Ibaraki, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institute of Advanced Industrial Science & Technology (AIST)	Richmond, BJ (corresponding author), NIMH, Neuropsychol Lab, Bldg 9, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002619, ZIAMH002619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; Glimcher PW, 2001, TRENDS NEUROSCI, V24, P654, DOI 10.1016/S0166-2236(00)01932-9; GOLDMANRAKIC PS, 2000, NEW COGNITIVE NEUROS; Hadland KA, 2003, J NEUROPHYSIOL, V89, P1161, DOI 10.1152/jn.00634.2002; Kobayashi S, 2002, J NEUROPHYSIOL, V87, P1488, DOI 10.1152/jn.00472.2001; Koechlin E, 2002, NEURON, V35, P371, DOI 10.1016/S0896-6273(02)00742-0; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; Liu Z, 2000, J NEUROPHYSIOL, V83, P1677, DOI 10.1152/jn.2000.83.3.1677; Matsumoto K, 2003, SCIENCE, V301, P229, DOI 10.1126/science.1084204; NASH JF, 1950, P NATL ACAD SCI USA, V36, P48, DOI 10.1073/pnas.36.1.48; Procyk E, 2001, EUR J NEUROSCI, V14, P1041, DOI 10.1046/j.0953-816x.2001.01738.x; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Shidara M, 1998, J NEUROSCI, V18, P2613; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; Watanabe M, 2002, J NEUROSCI, V22, P2391, DOI 10.1523/JNEUROSCI.22-06-02391.2002	18	24	26	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					179	180		10.1126/science.1087383	http://dx.doi.org/10.1126/science.1087383			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855797				2022-12-28	WOS:000184056200029
J	Skordalakes, E; Berger, JM				Skordalakes, E; Berger, JM			Structure of the Rho transcription terminator: Mechanism of mRNA recognition and helicase loading	CELL			English	Article							ESCHERICHIA-COLI RHO; RNP1-LIKE SEQUENCE MOTIF; TRP-T' TERMINATOR; DEPENDENT TERMINATION; CRYSTAL-STRUCTURE; BINDING DOMAIN; DNA HELICASE; PROTEIN-RHO; SHOCK PROTEIN; NMR STRUCTURE	In bacteria, one of the major transcriptional termination mechanisms requires a RNA/DNA helicase known as the Rho factor. We have determined two structures of Rho complexed with nucleic acid recognition site mimics in both free and nucleotide bound states to 3.0 Angstrom resolution. Both structures show that Rho forms a hexameric ring in which two RNA binding sites-a primary one responsible for target mRNA recognition and a secondary one required for mRNA translocation and unwinding-point toward the center of the ring. Rather than forming a closed ring, the Rho hexamer is split open, resembling a "lock washer" in its global architecture. The distance between subunits at the opening is sufficiently wide (12 Angstrom) to accommodate single-stranded RNA. This open configuration most likely resembles a state poised to load onto mRNA and suggests how related ring-shaped enzymes may be breached to bind nucleic acids.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Berger, JM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 239 Hildebrand Hall,3206, Berkeley, CA 94720 USA.	jmberger@uclink4.berkeley.edu	Skordalakes, Emmanuel/H-7071-2019	Skordalakes, Emmanuel/0000-0002-7600-2833				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALIFANO P, 1991, CELL, V64, P553; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; BROWN S, 1981, J BACTERIOL, V146, P422, DOI 10.1128/JB.146.1.422-425.1981; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; Burgess BR, 2001, J BIOL CHEM, V276, P17106, DOI 10.1074/jbc.M101856200; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P750, DOI 10.1107/S0907444997016247; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; ENGEL D, 1984, NUCLEIC ACIDS RES, V12, P7389, DOI 10.1093/nar/12.19.7389; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; LUSKY M, 1993, J BIOL CHEM, V268, P15795; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 2002, BBA-GENE STRUCT EXPR, V1577, P251, DOI 10.1016/S0167-4781(02)00456-6; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; RICHARDSON JP, 1996, CELLULAR MOL BIOL, P822; RICHARDSON LV, 1992, NUCLEIC ACIDS RES, V20, P5383, DOI 10.1093/nar/20.20.5383; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SHIGESADA K, 1980, NUCLEIC ACIDS RES, V8, P3355, DOI 10.1093/nar/8.15.3355; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; Stitt BL, 2001, BIOCHEMISTRY-US, V40, P2276, DOI 10.1021/bi002253a; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu H, 2000, BIOCHEMISTRY-US, V39, P12225, DOI 10.1021/bi0008938; Xu Y, 2002, J BIOL CHEM, V277, P30023, DOI 10.1074/jbc.M111009200; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810; Zhu AQ, 1998, BIOCHEMISTRY-US, V37, P11215, DOI 10.1021/bi972912s; Zhu AQ, 1998, BIOCHEMISTRY-US, V37, P11202, DOI 10.1021/bi9729110	81	194	198	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					135	146		10.1016/S0092-8674(03)00512-9	http://dx.doi.org/10.1016/S0092-8674(03)00512-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859904	Bronze			2022-12-28	WOS:000184219900012
J	Abraham, E; Reinhart, K; Opal, S; Demeyer, I; Doig, C; Rodriguez, AL; Beale, R; Svoboda, P; Laterre, PF; Simon, S; Light, B; Spapen, H; Stone, J; Seibert, A; Peckelsen, C; De Deyne, C; Postier, R; Pettila, V; Sprung, CL; Artigas, A; Percell, SR; Shu, V; Zwingelstein, C; Tobias, J; Poole, L; Stolzenbach, JC; Creasey, AA				Abraham, E; Reinhart, K; Opal, S; Demeyer, I; Doig, C; Rodriguez, AL; Beale, R; Svoboda, P; Laterre, PF; Simon, S; Light, B; Spapen, H; Stone, J; Seibert, A; Peckelsen, C; De Deyne, C; Postier, R; Pettila, V; Sprung, CL; Artigas, A; Percell, SR; Shu, V; Zwingelstein, C; Tobias, J; Poole, L; Stolzenbach, JC; Creasey, AA		OPTIMIST Trial Study Grp	Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED PROTEIN-C; BLOOD-COAGULATION; ESCHERICHIA-COLI; ANTITHROMBIN-III; SEPTIC SHOCK; SITE	Context The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation. Objectives To determine if administration of tifacogin (recombinant TFPI) provides mortality benefit in patients with severe sepsis and elevated international normalized ratio (INR) and to assess tifacogin safety in severe sepsis, including patients with low INR. Design and Setting A randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial conducted from March 21, 2000, through September 27, 2001, in 245 hospitals in 17 countries in North America, Europe, and Israel. Patients The primary efficacy population consisted of 1754 patients (greater than or equal to18 years) with severe sepsis and a high INR (greater than or equal to1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n=880) or placebo (arginine citrate buffer, n=874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo. Main Outcome Measure All-cause 28-day mortality. Results Overall mortality at 28 days in the tifacogin-treated group (n = 880) vs the placebo group (n=874) for high INR was 34.2% vs 33.9%, respectively (P=.88, Pearson &chi;(2) test; P=.75, logistic regression model). None of the protocol-specified secondary end points differed between the tifacogin vs placebo groups. An analysis on the first 722 patients demonstrated a mortality rate of 38.9% for placebo vs 29.1% for tifacogin (P=.006, Pearson &chi;(2) test). Tifacogin significantly attenuated prothrombin fragment 1.2 and thrombin:antithrombin complex levels (P<.001, 2-sample t test) in patients with high and low INR. Overall mortality was lower in the tifacogin response in patients with low INR (12%; n=83) vs placebo (22.9%; n=118) (P=.051, Pearson chi(2) Lest; P=.03, logistic regression model). There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR). Conclusions Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR. Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Jena, D-6900 Jena, Germany; Brown Med Sch, Div Infect Dis, Providence, RI USA; Onze Lieve Vrouw Hosp, Dept Intens Care, Aalst, Belgium; Univ Calgary, Dept Crit Care, Calgary, AB, Canada; Hosp Reg Univ Infanta Cristina, Intens Care Unit, Badajoz, Spain; St Thomas Hosp, Intens Care Res Off, London, England; Minist Hlth, Res Ctr Traumatol & Surg, Brno, Czech Republic; St Luc Univ Hosp, Intens Care Serv, Brussels, Belgium; Wellstar Cobb Med Ctr, SE Res Associates, Austell, GA USA; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Hosp, Intens Care Unit, Brussels, Belgium; Mem Hosp, Cumberland, MD USA; Mobile Diagnost Ctr Providence Pk, Mobile, AL USA; City Hosp Munich Harlaching, Munich, Germany; Oost Limburg Hosp, Genk, Belgium; Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK USA; Univ Helsinki, Cent Hosp, Helsinki, Finland; Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel; Corp Sanitaria Parc Tauli, Sabadell, Spain; Chiron Corp, Emeryville, CA 94608 USA; Pharmacia Corp, Skokie, IL USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Friedrich Schiller University of Jena; Brown University; University of Calgary; Guy's & St Thomas' NHS Foundation Trust; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Manitoba; Children's Hospital Research Institute of Manitoba; East Limburg Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Helsinki; Helsinki University Central Hospital; Hebrew University of Jerusalem; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Novartis; Pfizer	Abraham, E (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Campus Box C-272, Denver, CO 80262 USA.		Beale, Richard J/J-7831-2013; Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139; antonio, artigas/0000-0002-8029-1017				Abraham E, 2001, CRIT CARE MED, V29, P2081, DOI 10.1097/00003246-200111000-00007; Abraham E, 2000, CRIT CARE MED, V28, pS31, DOI 10.1097/00003246-200009001-00007; *ANT ADV COMM, 2001, FDA BRIEF DOC DROTR; BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; Bajaj MS, 2000, EUR RESPIR J, V15, P1069, DOI 10.1034/j.1399-3003.2000.01515.x; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BROZE GJ, 1995, BLOOD COAGUL FIBRIN, V6, pS7, DOI 10.1097/00001721-199506001-00002; BUZAN J, 1990, P NATL ACAD SCI USA, V87, P6934; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerota AJ, 1998, J INFECT DIS, V177, P668, DOI 10.1086/514246; CARR C, 1994, CIRC SHOCK, V44, P126; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; Creasey AA, 1999, SEPSIS, V3, P173; ENJYOJI K, 1995, BIOCHEMISTRY-US, V34, P5725, DOI 10.1021/bi00017a004; GUSTAFSON ME, 1994, PROTEIN EXPRES PURIF, V5, P233, DOI 10.1006/prep.1994.1036; Opal SM, 2000, CRIT CARE MED, V28, pS34, DOI 10.1097/00003246-200009001-00008; Shimura M, 1999, AM J HEMATOL, V60, P94, DOI 10.1002/(SICI)1096-8652(199902)60:2<94::AID-AJH2>3.0.CO;2-A; Siegel JP, 2002, NEW ENGL J MED, V347, P1030, DOI 10.1056/NEJMsb021512; THIJS LG, 1993, INTENS CARE MED, V19, P8; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Warren HS, 2002, NEW ENGL J MED, V347, P1027, DOI 10.1056/NEJMsb020574	21	658	741	3	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					238	247		10.1001/jama.290.2.238	http://dx.doi.org/10.1001/jama.290.2.238			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851279	Bronze			2022-12-28	WOS:000183989800029
J	Ruo, B; Rumsfeld, JS; Hlatky, MA; Liu, HY; Browner, WS; Whooley, MA				Ruo, B; Rumsfeld, JS; Hlatky, MA; Liu, HY; Browner, WS; Whooley, MA			Depressive symptoms and health-related quality of life - The heart and soul study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-RATED HEALTH; FUNCTIONAL STATUS; PRIMARY-CARE; PERCEIVED HEALTH; FOLLOW-UP; PRIME-MD; CORONARY; MORTALITY; DISEASE; ANGINA	Context Little is known regarding the extent to which patient-reported health status, including symptom burden, physical limitation, and quality of life, is determined by psychosocial vs physiological factors among patients with chronic disease. Objective To compare the contributions of depressive symptoms and measures of cardiac function to the health status of patients with coronary artery disease. Design, Setting, and Participants Cross-sectional study of 1024 adults with stable coronary artery disease recruited from outpatient clinics in the San Francisco Bay Area between September 2000 and December 2002. Main Measures Measurement of depressive symptoms using the Patient Health Questionnaire (PHQ); assessment of cardiac function by measuring left ventricular ejection fraction on echocardiography, exercise capacity on treadmill testing, and ischemia on stress echocardiography; and measurement of a range of health status outcomes, including symptom burden, physical limitation, and quality of life, using the Seattle Angina Questionnaire. Participants were also asked to rate their overall health as excellent, very good, good, fair, or poor. Results Of the 1024 participants, 201 (20%) had depressive symptoms (PHQ score :10). Participants with depressive symptoms were more likely than those without depressive symptoms to report at least mild symptom burden (60% vs 33%; P<.001), mild physical limitation (73% vs 40%; P<.001), mildly diminished quality of life (67% vs 31%; P<.001), and fair or poor overall health (66% vs 30%; P<.001). In multivariate analyses adjusting for measures of cardiac function and other patient characteristics, depressive symptoms were strongly associated with greater symptom burden (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.3-2.7; P=.002), greater physical limitation (OR, 3.1; 95% Cl, 2.1-4.6; P<.001), worse quality of life (OR, 3.1; 95% Cl, 2.2-4.6; P<.001), and worse overall health (OR, 2.0; 95% Cl, 1.3-2.9; P<.001). Although decreased exercise capacity was associated with worse health status, left ventricular ejection fraction and ischemia were not. Conclusions Among patients with coronary disease, depressive symptoms are strongly associated with patient-reported health status, including symptom burden, physical limitation, quality of life, and overall health. Conversely, 2 traditional measures of cardiac function-ejection fraction and ischemia-are not. Efforts to improve health status should include assessment and treatment of depressive symptoms.	Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Denver Vet Affairs Med Ctr, Cardiol & Hlth Serv Res, Denver, CO USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Stanford University; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Whooley, MA (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	whooley@itsa.ucsf.edu		Hlatky, Mark/0000-0003-4686-9441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079235] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL079235, R01 HL079235-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso J, 1997, EUR HEART J, V18, P414; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cossette S, 2001, PSYCHOSOM MED, V63, P257, DOI 10.1097/00006842-200103000-00009; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CUNNY KA, 1991, PSYCHOL REP, V69, P127, DOI 10.2466/PR0.69.5.127-130; DWOSH IL, 1983, NEW ENGL J MED, V308, P1124, DOI 10.1056/NEJM198305123081903; FISHER L, 1983, CIRCULATION, V68, P951; FRIMODTMOLLER PC, 1984, J UROLOGY, V132, P272, DOI 10.1016/S0022-5347(17)49587-5; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; GORKIN L, 1994, QUAL LIFE RES, V3, P111, DOI 10.1007/BF00435254; GUYATT G, 1991, CONTROL CLIN TRIALS, V12, pS81, DOI 10.1016/S0197-2456(05)80014-5; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; IDLER EL, 1990, AM J EPIDEMIOL, V131, P91, DOI 10.1093/oxfordjournals.aje.a115489; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; Mattera JA, 2000, AM HEART J, V140, P409, DOI 10.1067/mhj.2000.108518; Miller MD, 1996, AM J PSYCHIAT, V153, P1350; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NELSON CL, 1991, AM J CARDIOL, V68, P973, DOI 10.1016/0002-9149(91)90423-I; NERENZ DR, 1992, MED CARE, V30, pMS112, DOI 10.1097/00005650-199205001-00010; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; PETERSON WL, 1977, NEW ENGL J MED, V297, P341, DOI 10.1056/NEJM197708182970701; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; Pilote L, 2002, ARCH INTERN MED, V162, P553, DOI 10.1001/archinte.162.5.553; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; Rumsfeld JS, 2003, AM HEART J, V145, P493, DOI 10.1067/mhj.2003.177; Rumsfeld JS, 2002, CIRCULATION, V106, P5, DOI 10.1161/01.CIR.0000020805.31531.48; Rumsfeld JS, 2001, AM J CARDIOL, V88, P781, DOI 10.1016/S0002-9149(01)01852-5; Rumsfeld JS, 1999, JAMA-J AM MED ASSOC, V281, P1298, DOI 10.1001/jama.281.14.1298; Sauer WH, 2001, CIRCULATION, V104, P1894, DOI 10.1161/hc4101.097519; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SJOLAND H, 1995, INT J CARDIOL, V51, P221, DOI 10.1016/0167-5273(95)02424-U; Spertus JA, 2002, CIRCULATION, V106, P43, DOI 10.1161/01.CIR.0000020688.24874.90; SPERTUS JA, 1994, AM J CARDIOL, V74, P1240, DOI 10.1016/0002-9149(94)90555-X; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; Spertus JA, 2000, AM HEART J, V140, P105, DOI 10.1067/mhj.2000.106600; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sullivan MD, 2000, AM J CARDIOL, V86, P1135, DOI 10.1016/S0002-9149(00)01174-7; Sullivan MD, 1997, AM J MED, V103, P348, DOI 10.1016/S0002-9343(97)00167-8; Sullivan MD, 2001, PSYCHOSOM MED, V63, P248, DOI 10.1097/00006842-200103000-00008; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; WENGER NK, 1984, AM J CARDIOL, V54, P908, DOI 10.1016/S0002-9149(84)80232-5; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Whooley MA, 2000, NEW ENGL J MED, V343, P1942, DOI 10.1056/NEJM200012283432607; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; Ziegelstein RC, 2001, JAMA-J AM MED ASSOC, V286, P1621, DOI 10.1001/jama.286.13.1621	55	574	595	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					215	221		10.1001/jama.290.2.215	http://dx.doi.org/10.1001/jama.290.2.215			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	698GH	12851276	Green Accepted			2022-12-28	WOS:000183989800026
J	Wijnands, R; van der Klis, M; Homan, J; Chakrabarty, D; Markwardt, CB; Morgan, EH				Wijnands, R; van der Klis, M; Homan, J; Chakrabarty, D; Markwardt, CB; Morgan, EH			Quasi-periodic X-ray brightness fluctuations in an accreting millisecond pulsar	NATURE			English	Article							OSCILLATION PEAK SEPARATION; NEUTRON-STAR; DIFFERENCE-FREQUENCY; 4U 1636-53; BINARIES; SYSTEM; MODEL; PRECESSION; CONSTANT; FIELD	The relativistic plasma flows onto neutron stars that are accreting material from stellar companions can be used to probe strong-field gravity as well as the physical conditions in the supranuclear-density interiors of neutron stars. Plasma inhomogeneities orbiting a few kilometres above the stars are observable as X-ray brightness fluctuations on the millisecond dynamical timescale of the flows(1-3). Two frequencies in the kilohertz range dominate these fluctuations: the twin kilohertz quasi-periodic oscillations (kHz QPOs). Competing models for the origins of these oscillations (based on orbital motions) all predict that they should be related to the stellar spin frequency(4-10), but tests have been difficult because the spins were not unambiguously known. Here we report the detection of kHz QPOs from a pulsar whose spin frequency is known. Our measurements establish a clear link between kHz QPOs and stellar spin, but one not predicted by any current model. A new approach to understanding kHz QPOs is now required. We suggest that a resonance between the spin and general relativistic orbital and epicyclic frequencies could provide the observed relation between QPOs and spin.	Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Natl Inst Nucl & High Energy Phys, Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands; INAF, Osservatorio Astron Brera, I-23807 Merate LC, Italy; MIT, Ctr Space Res, Cambridge, MA 02139 USA; NASA, High Energy Astrophys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of St Andrews; University of Amsterdam; Istituto Nazionale Astrofisica (INAF); Massachusetts Institute of Technology (MIT); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Wijnands, R (corresponding author), Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland.			Wijnands, Rudi/0000-0002-3516-2152				ALPAR MA, 1985, NATURE, V316, P239, DOI 10.1038/316239a0; Campana S, 2000, ASTROPHYS J, V534, pL79, DOI 10.1086/312634; CHAKRABARTY D, NATURE; Cui W, 2000, ASTROPHYS J, V534, pL31, DOI 10.1086/312646; Jonker PG, 2000, ASTROPHYS J, V540, pL29, DOI 10.1086/312871; Jonker PG, 2002, MON NOT R ASTRON SOC, V336, pL1, DOI 10.1046/j.1365-8711.2002.05781.x; KLUZNIAK W, 2001, UNPUB ASTROPHYS J LE; Lamb FK, 2001, ASTROPHYS J, V554, P1210, DOI 10.1086/323148; LAMB FK, 1985, NATURE, V317, P681, DOI 10.1038/317681a0; MARKWARDT CB, 2002, 7993 IAU; Mendez M, 1998, ASTROPHYS J, V506, pL117, DOI 10.1086/311650; Mendez M, 1998, ASTROPHYS J, V505, pL23, DOI 10.1086/311600; Miller MC, 1998, ASTROPHYS J, V508, P791, DOI 10.1086/306408; Muno MP, 2002, ASTROPHYS J, V581, P550, DOI 10.1086/344152; Psaltis D, 2001, ASTROPHYS J, V555, P786, DOI 10.1086/323329; PSALTIS D, 2000, UNPUB ASTROPHYS J; SHIBAZAKI N, 1987, ASTROPHYS J, V318, P767, DOI 10.1086/165410; Stella L, 1999, PHYS REV LETT, V82, P17, DOI 10.1103/PhysRevLett.82.17; Stella L, 1998, ASTROPHYS J, V492, pL59, DOI 10.1086/311075; Stella L, 2001, AIP CONF PROC, V599, P365, DOI 10.1063/1.1434649; Strohmayer TE, 1996, ASTROPHYS J, V469, pL9, DOI 10.1086/310261; STROHMAYER TE, 2003, IN PRESS COMPACT STE; SVARTSMAN VF, 1971, SOV ASTRON, V15, P377; Titarchuk L, 1998, ASTROPHYS J, V499, P315, DOI 10.1086/305642; van der Klis M, 2000, ANNU REV ASTRON ASTR, V38, P717, DOI 10.1146/annurev.astro.38.1.717; VANDERKLIS M, 1985, NATURE, V316, P225, DOI 10.1038/316225a0; vanderKlis M, 1997, ASTROPHYS J, V481, pL97, DOI 10.1086/310656; VANDERKLIS M, 2002, XEUS STUDYING EVOLUT, P354; Wijnands R, 1998, NATURE, V394, P344, DOI 10.1038/28557	30	142	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					44	47		10.1038/nature01754	http://dx.doi.org/10.1038/nature01754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840752	Green Submitted			2022-12-28	WOS:000183912800033
J	Ahmadi, S; Muth-Selbach, U; Lauterbach, A; Lipfert, P; Neuhuber, WL; Zeilhofer, HU				Ahmadi, S; Muth-Selbach, U; Lauterbach, A; Lipfert, P; Neuhuber, WL; Zeilhofer, HU			Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; EXTRASYNAPTIC GLUTAMATE SPILLOVER; XENOPUS OOCYTES; D-SERINE; SITE; BRAIN; NEUROTRANSMITTER; TRANSMISSION; HIPPOCAMPUS; ACTIVATION	In the mammalian CNS, N-methyl-D-aspartate ( NMDA) receptors serve prominent roles in many physiological and pathophysiological processes including pain transmission. For full activation, NMDA receptors require the binding of glycine. It is not known whether the brain uses changes in extracellular glycine to modulate synaptic NMDA responses. Here, we show that synaptically released glycine facilitates NMDA receptor currents in the superficial dorsal horn, an area critically involved in pain processing. During high presynaptic activity, glycine released from inhibitory interneurons escapes the synaptic cleft and reaches nearby NMDA receptors by so-called spillover. In vivo, this process may contribute to the development of inflammatory hyperalgesia.	Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, D-91054 Erlangen, Germany; Univ Klinikum Dusseldorf, Anasthesiol Klin, D-40225 Dusseldorf, Germany; Univ Erlangen Nurnberg, Inst Anat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Erlangen Nuremberg	Zeilhofer, HU (corresponding author), Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, Fahrstr 17, D-91054 Erlangen, Germany.		Zeilhofer, Hanns Ulrich/A-4600-2008	Zeilhofer, Hanns Ulrich/0000-0001-6954-4629				Asztely F, 1997, NEURON, V18, P281, DOI 10.1016/S0896-6273(00)80268-8; Barbour B, 1997, TRENDS NEUROSCI, V20, P377; Berger AJ, 1998, J NEUROPHYSIOL, V80, P3336, DOI 10.1152/jn.1998.80.6.3336; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; DOUBELL TP, 1999, TXB PAIN, pCH6; Fern R, 1996, NEUROREPORT, V7, P1953, DOI 10.1097/00001756-199608120-00018; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; KISHIMOTO H, 1981, J NEUROCHEM, V37, P1015, DOI 10.1111/j.1471-4159.1981.tb04489.x; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kullmann DM, 2000, PROG BRAIN RES, V125, P339; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; LARSON AA, 1988, J NEUROSCI, V8, P3822; Lopez-Corcuera B, 2001, MOL MEMBR BIOL, V18, P13, DOI 10.1080/09687680120521; MCGALE EHF, 1977, J NEUROCHEM, V29, P291, DOI 10.1111/j.1471-4159.1977.tb09621.x; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Okuda-Ashitaka E, 1998, NATURE, V392, P286, DOI 10.1038/32660; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Supplisson S, 1997, J NEUROSCI, V17, P4580; Turecek R, 2001, NATURE, V411, P587, DOI 10.1038/35079084; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; Zeilhofer HU, 2000, J NEUROSCI, V20, P4922	26	108	110	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2094	2097		10.1126/science.1083970	http://dx.doi.org/10.1126/science.1083970			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829784	Green Accepted			2022-12-28	WOS:000183774900047
J	Gundersen, GG; Bretscher, A				Gundersen, GG; Bretscher, A			Microtubule asymmetry	SCIENCE			English	Editorial Material							ORIENTATION; SPINDLE; YEAST		Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Columbia University; Columbia University; Cornell University	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA.							Beach DL, 2000, CURR BIOL, V10, P1497, DOI 10.1016/S0960-9822(00)00837-X; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Hwang E, 2003, J CELL BIOL, V161, P483, DOI 10.1083/jcb.200302030; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Maekawa H, 2003, EMBO J, V22, P438, DOI 10.1093/emboj/cdg063; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pereira G, 2001, EMBO J, V20, P6359, DOI 10.1093/emboj/20.22.6359; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024	14	43	44	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2040	2041		10.1126/science.1084938	http://dx.doi.org/10.1126/science.1084938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829769				2022-12-28	WOS:000183774900029
J	Michael, PJ; Langmuir, CH; Dick, HJB; Snow, JE; Goldstein, SL; Graham, DW; Lehnert, K; Kurras, G; Jokat, W; Muhe, R; Edmonds, HN				Michael, PJ; Langmuir, CH; Dick, HJB; Snow, JE; Goldstein, SL; Graham, DW; Lehnert, K; Kurras, G; Jokat, W; Muhe, R; Edmonds, HN			Magmatic and amagmatic seafloor generation at the ultraslow-spreading Gakkel ridge, Arctic Ocean	NATURE			English	Article							MID-ATLANTIC RIDGE; EAST PACIFIC RISE; CRUSTAL THICKNESS; VOLCANIC ACTIVITY; MIDOCEAN RIDGES; MANTLE; MORB; GEOCHEMISTRY; CHEMISTRY; ISOTOPE	A high-resolution mapping and sampling study of the Gakkel ridge was accomplished during an international ice-breaker expedition to the high Arctic and North Pole in summer 2001. For this slowest-spreading endmember of the global mid-ocean-ridge system, predictions were that magmatism should progressively diminish as the spreading rate decreases along the ridge, and that hydrothermal activity should be rare. Instead, it was found that magmatic variations are irregular, and that hydrothermal activity is abundant. A 300-kilometre-long central amagmatic zone, where mantle peridotites are emplaced directly in the ridge axis, lies between abundant, continuous volcanism in the west, and large, widely spaced volcanic centres in the east. These observations demonstrate that the extent of mantle melting is not a simple function of spreading rate: mantle temperatures at depth or mantle chemistry ( or both) must vary significantly along-axis. Highly punctuated volcanism in the absence of ridge offsets suggests that first-order ridge segmentation is controlled by mantle processes of melting and melt segregation. The strong focusing of magmatic activity coupled with faulting may account for the unexpectedly high levels of hydrothermal activity observed.	Univ Tulsa, Dept Geosci, Tulsa, OK 74104 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Woods Hole Oceanog Inst, Dept Marine Geol & Geophys, Woods Hole, MA 02543 USA; Max Planck Inst Chem, D-55020 Mainz, Germany; Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany; Univ Kiel, Inst Geosci, D-24118 Kiel, Germany; Univ Texas, Inst Marine Sci, Port Aransas, TX 78373 USA	University of Tulsa; Harvard University; Woods Hole Oceanographic Institution; Max Planck Society; Columbia University; Oregon State University; University of Hawaii System; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; University of Kiel; University of Texas System	Michael, PJ (corresponding author), Univ Tulsa, Dept Geosci, 600 Coll Ave, Tulsa, OK 74104 USA.		Snow, Jonathan/E-5591-2011; Graham, David/C-3612-2014	Graham, David/0000-0002-7411-1905; Lehnert, Kerstin/0000-0001-7036-1977; Michael, Peter/0000-0003-2829-9502; Jokat, Wilfried/0000-0002-7793-5854				BACH W, 2002, GEOCHEM GEOPHYS GEOS, V3, DOI DOI 10.1029/2001GC000279; Baker ET, 1996, EARTH PLANET SC LETT, V142, P137, DOI 10.1016/0012-821X(96)00097-0; BAKER ET, 2001, GEOCHEM GEOPHYS GEOS, V2; BALLARD RD, 1977, GEOL SOC AM BULL, V88, P507, DOI 10.1130/0016-7606(1977)88<507:MATOTI>2.0.CO;2; BATIZA R, 1984, NATURE, V309, P440, DOI 10.1038/309440a0; BONATTI E, 1985, NATURE, V316, P33, DOI 10.1038/316033a0; BOWN JW, 1994, EARTH PLANET SC LETT, V121, P435, DOI 10.1016/0012-821X(94)90082-5; Brandon AD, 2000, EARTH PLANET SC LETT, V177, P319, DOI 10.1016/S0012-821X(00)00044-3; Coakley BJ, 1998, EARTH PLANET SC LETT, V162, P81, DOI 10.1016/S0012-821X(98)00158-7; COCHRAN JR, 2003, J GEOPHYS RES, V108; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; Dick H.B.J, 1989, GEOL SOC LOND SPEC P, V42, P71, DOI DOI 10.1144/GSL.SP.1989.042.01.06; DICK HJB, 1984, EARTH PLANET SC LETT, V69, P88, DOI 10.1016/0012-821X(84)90076-1; DICK HJB, 2001, EOS, V82, pS407; DRACHEV S, 1998, INT C ARCT MARG ICAM, P48; Edmonds HN, 2003, NATURE, V421, P252, DOI 10.1038/nature01351; Edwards MH, 2001, NATURE, V409, P808, DOI 10.1038/35057258; FEDEN RH, 1979, EARTH PLANET SC LETT, V44, P18, DOI 10.1016/0012-821X(79)90004-9; FOX PJ, 1984, TECTONOPHYSICS, V104, P205, DOI 10.1016/0040-1951(84)90124-0; German CR, 1998, EARTH PLANET SC LETT, V160, P327, DOI 10.1016/S0012-821X(98)00093-4; HANSON GN, 1977, J GEOL SOC LONDON, V134, P235, DOI DOI 10.1144/GSJGS.134.2.0235; Hellebrand E, 2002, CHEM GEOL, V182, P227, DOI 10.1016/S0009-2541(01)00291-1; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; HOLNESS MB, 1989, J GEOL, V97, P247, DOI 10.1086/629301; Jakobsson M., 2000, EOS T AM GEOPHYS UN, V81, P89, DOI [DOI 10.1029/00EO00059, DOI 10.1130/G32153.1]; Jokat W, 2003, NATURE, V423, P962, DOI 10.1038/nature01706; KARASIK AM, 1974, NAUCHNO ISSLEDOVATEL, P23; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; KONG LS, 1988, MAR GEOPHYS RES, V10, P59; KOVACKS LC, 1985, MAP CHART SERIES GEO; Langmuir C.H., 1992, AM GEOPHYS UNION GEO, V71, P183, DOI DOI 10.1029/GM071P0183; LANGMUIR CH, 1986, NATURE, V322, P422, DOI 10.1038/322422a0; LEHNERT K, 2000, GEOCHEM GEOPHYS GEOS, V1; LIN J, 1992, GEOPHYS RES LETT, V19, P13, DOI 10.1029/91GL03041; Mevel C., 1997, INTERRIDGE NEWS, V6, P25; Michael PJ, 1998, J GEOPHYS RES-SOL EA, V103, P18325, DOI 10.1029/98JB00791; MICHAEL PJ, 1985, EARTH PLANET SC LETT, V73, P91, DOI 10.1016/0012-821X(85)90037-8; Muhe R, 1997, EARTH PLANET SC LETT, V152, P1, DOI 10.1016/S0012-821X(97)00152-0; MUHE R, 1993, EARTH PLANET SC LETT, V120, P103, DOI 10.1016/0012-821X(93)90233-Y; MUHE RK, 1991, TECTONOPHYSICS, V190, P95, DOI 10.1016/0040-1951(91)90356-W; Muller C., 2000, EOS T AM GEOPHYS UN, V81, P265, DOI [10.1029/00EO00186, DOI 10.1029/00EO00186]; PHIPPSMORGAN J, 1993, J GEOPHYS RES, V98, P6283; PRINZHOFER A, 1989, EARTH PLANET SC LETT, V92, P189, DOI 10.1016/0012-821X(89)90046-0; REID I, 1981, MAR GEOPHYS RES, V5, P165; RITZMANN O, 2002, GEOPHYS J INT, V151, P1; Tolstoy M, 2001, GEOLOGY, V29, P1139, DOI 10.1130/0091-7613(2001)029<1139:SCOVAA>2.0.CO;2; VOGT PR, 1979, J GEOPHYS RES, V84, P1071, DOI 10.1029/JB084iB03p01071; VOGT PR, 1979, NORWEGIAN SEA S, P1; WHITEHEAD JA, 1984, NATURE, V312, P146, DOI 10.1038/312146a0	49	316	343	2	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					956	U1		10.1038/nature01704	http://dx.doi.org/10.1038/nature01704			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827193				2022-12-28	WOS:000183753900041
J	Parmar, MKB; Ledermann, JA; Colombo, N; du Bois, A; Delaloye, JF; Kristensen, GB; Wheeler, S; Swart, AM; Qian, W; Torri, V; Floriani, I; Jayson, G; Lamont, A; Trope, C; Lederman, JA; Parmar, MKB; Mangioni, C; Torri, V; Sandercock, J; Dubois, A				Parmar, MKB; Ledermann, JA; Colombo, N; du Bois, A; Delaloye, JF; Kristensen, GB; Wheeler, S; Swart, AM; Qian, W; Torri, V; Floriani, I; Jayson, G; Lamont, A; Trope, C; Lederman, JA; Parmar, MKB; Mangioni, C; Torri, V; Sandercock, J; Dubois, A		ICON Collaborators; AGO Collaborators	Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial	LANCET			English	Article							2ND-LINE THERAPY; STAGE-III; CISPLATIN; CYCLOPHOSPHAMIDE; CARBOPLATIN; CARCINOMA	Background Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment. Methods In parallel international, multicentre, randomised trials, between January, 1996, and March, 2002, 802 patients with platinum-sensitive ovarian cancer relapsing after 6 months of being treatment-free were enrolled from 119 hospitals in five countries. Patients were randomly assigned paclitaxel plus platinum chemotherapy or conventional platinum-based chemotherapy. Analysis was by intention to treat, except for toxic effects. Findings With a median follow-up of 42 months, 530 patients have died. Survival curves showed a difference in favour of paclitaxel plus platinum (hazard ratio 0.82 [95% Cl 0.69-0.97], p=0.02), corresponding to an absolute difference in 2-year survival of 7% between the paclitaxel and conventional treatment groups (57 vs 50% [95% Cl for difference 1-12]), and median survival of 5 months (29 vs 24 months [1-11). 717 patients developed progressive disease or died. The progress ion-free survival curves show a difference in favour of paclitaxel plus platinum (hazard ratio 0.76 [0.66-0.89], p=0.0004), corresponding to an absolute difference in 1-year progression-free survival of 10% (50 vs 40% [4-15]) and in median progress ion-free survival of 3 months (13 vs 10 months [1-5]). Interpretation Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.	MRC, Trials Unit, Canc Div, ICON Trial 4, London NW1 2DA, England	Medical Research Council Clinical Trials Unit	Parmar, MKB (corresponding author), MRC, Trials Unit, Canc Div, ICON Trial 4, 222 Euston Rd, London NW1 2DA, England.		Jayson, Gordon C/O-8224-2015; Colombo, Nicoletta/AAB-8319-2019; Torri, Valter/H-7550-2015	Jayson, Gordon C/0000-0002-8515-8944; Torri, Valter/0000-0001-9541-9354				Aabo K, 1998, BRIT J CANCER, V78, P1479, DOI 10.1038/bjc.1998.710; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; Cantu MG, 2002, J CLIN ONCOL, V20, P1232, DOI 10.1200/JCO.20.5.1232; Dizon DS, 2002, J CLIN ONCOL, V20, P1238, DOI 10.1200/JCO.20.5.1238; Fayers P, 2001, EORTC QLQ C30 SCORIN, P86; Girling D.J., 2003, CLIN TRIALS CANC; MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389; MARTIN AAG, 2003, P ASCO, V22; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Parmar MKB, 2002, LANCET, V360, P505; Parmar MKB, 1998, LANCET, V352, P1571; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Rose PG, 1998, J CLIN ONCOL, V16, P1494, DOI 10.1200/JCO.1998.16.4.1494; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; Van Warmerdam Laurence J. C., 1997, Seminars in Oncology, V24, P97	19	845	886	2	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2099	2106						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826431				2022-12-28	WOS:000183654200007
J	Chiu, CY; Weliky, M				Chiu, CY; Weliky, M			Synaptic modification by vision	SCIENCE			English	Editorial Material							VISUAL-CORTEX		Univ Rochester, Interdepartmental Program Neurosci, Rochester, NY 14627 USA; Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA	University of Rochester; University of Rochester	Chiu, CY (corresponding author), Univ Rochester, Interdepartmental Program Neurosci, 601 Elmwood Ave, Rochester, NY 14627 USA.			Chiu, Chiayu/0000-0001-5809-6306				Chiu CY, 2002, NEURON, V35, P1123, DOI 10.1016/S0896-6273(02)00867-X; Dudek SM, 1996, NEURON, V16, P1097, DOI 10.1016/S0896-6273(00)80136-1; Engert F, 2002, NATURE, V419, P470, DOI 10.1038/nature00988; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Schuett S, 2001, NEURON, V32, P325, DOI 10.1016/S0896-6273(01)00472-X; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665; Zhou Q, 2003, SCIENCE, V300, P1953, DOI 10.1126/science.1082212	10	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1890	1891		10.1126/science.1086934	http://dx.doi.org/10.1126/science.1086934			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817134				2022-12-28	WOS:000183619400029
J	Moffett, SE; Menon, AS; Meites, EM; Lowe, HJ				Moffett, SE; Menon, AS; Meites, EM; Lowe, HJ			Preparing doctors for bedside computing (vol 362, pg 86, 2003)	LANCET			English	Correction																		Moffett SE, 2003, LANCET, V362, P1860, DOI 10.1016/S0140-6736(03)13836-6	1	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 29	2003	362	9398					1860	1860		10.1016/S0140-6736(03)13836-6	http://dx.doi.org/10.1016/S0140-6736(03)13836-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748QQ	12853225				2022-12-28	WOS:000186872900045
J	Verburg, P; Hecky, RE; Kling, H				Verburg, P; Hecky, RE; Kling, H			Ecological consequences of a century of warming in Lake Tanganyika	SCIENCE			English	Article							PHYTOPLANKTON; RIVER	Deep tropical lakes are excellent climate monitors because annual mixing is shallow and flushing rates are low, allowing heat to accumulate during climatic warming. We describe effects of warming on Lake Tanganyika: A sharpened density gradient has slowed vertical mixing and reduced primary production. Increased warming rates during the coming century may continue to slow mixing and further reduce productivity in Lake Tanganyika and other deep tropical lakes.	Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada; Fisheries & Oceans Canada, Inst Freshwater, Algal Taxon & Ecol, Winnipeg, MB R3T 2N6, Canada	University of Waterloo; Fisheries & Oceans Canada	Verburg, P (corresponding author), Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada.	pverburg@scimail.uwaterloo.ca		verburg, piet/0000-0001-7574-9161				BEAUCHAMP R. S. A., 1939, INTERNAL REV GES HYDROBIOL U HYDROGR, V39, P316, DOI 10.1002/iroh.19390390303; Brooks J. L., 1950, Quarterly Review of Biology, V25, P131, DOI 10.1086/397539; CAPART A, 1952, I R SCI NAT BELG, V1, P3; COULTER GW, 1963, LIMNOL OCEANOGR, V8, P463, DOI 10.4319/lo.1963.8.4.0463; CRAIG H, 1974, LAKE TANGANYIKA GEOC, P1; Davies-Colley R. J, 1993, COLOUR CLARITY NATUR; DUBOIS J. T., 1958, HYDROBIOLOGIA, V10, P215, DOI 10.1007/BF00142188; EDMOND JM, 1993, LIMNOL OCEANOGR, V38, P725, DOI 10.4319/lo.1993.38.4.0725; Hecky R.E., 1991, P90; HECKY RE, 1981, LIMNOL OCEANOGR, V26, P548, DOI 10.4319/lo.1981.26.3.0548; Hutchinson G. E., 1957, TREATISE LIMNOLOGY, VI; Jarvinen M, 1999, HYDROBIOLOGIA, V407, P81, DOI 10.1023/A:1003706002126; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Kimbadi S, 1999, HYDROBIOLOGIA, V407, P75, DOI 10.1023/A:1003749817147; KUFFERATH J, 1952, MILIEU BIOCH, V1, P31; Magnuson JJ, 2000, SCIENCE, V289, P1743, DOI 10.1126/science.289.5485.1743; Millero FJ, 2000, AQUAT GEOCHEM, V6, P1, DOI 10.1023/A:1009626325650; PLISNIER PD, 1996, GCPRAF271FINTD56 FAO; Quayle WC, 2002, SCIENCE, V295, P645, DOI 10.1126/science.1064074; STAPPERS L, 1913, MISSION STAPPERS 191; Vandelannoote A, 1999, HYDROBIOLOGIA, V407, P65, DOI 10.1023/A:1003701901217; VANMEEL L, 1954, PHYTOPLANCTON, V4; Vollmer MK, 2002, ADV GLOB CHANGE RES, V12, P209	23	263	284	5	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	2003	301	5632					505	507		10.1126/science.1084846	http://dx.doi.org/10.1126/science.1084846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704LE	12829786				2022-12-28	WOS:000184340500039
J	Platts-Mills, TAE				Platts-Mills, TAE			Allergen avoidance in the treatment of asthma and rhinitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22903 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22903 USA.			Platts-Mills, Thomas/0000-0002-1263-329X					0	27	29	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					207	208		10.1056/NEJMp030082	http://dx.doi.org/10.1056/NEJMp030082			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867602				2022-12-28	WOS:000184165700001
J	Li, PKT; Chow, KM; Wong, TYH; Leung, CB; Szeto, CC				Li, PKT; Chow, KM; Wong, TYH; Leung, CB; Szeto, CC			Effects of an angiotensin-converting renal function in patients receiving enzyme inhibitor on residual peritoneal dialysis - A randomized, controlled study	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Nephrology	OCT 30-NOV 06, 2002	PHILADELPHIA, PA	Amer Soc Nephrol			CONTROLLED-TRIAL; ADEQUACY; MORTALITY; CAPD; PRESERVATION; PROGRESSION; CLEARANCES; MORBIDITY; CAPTOPRIL; RAMIPRIL	Background: Residual renal function is an important determinant of mortality and morbidity in patients receiving peritoneall dialysis. However, few studies have evaluated therapeutic approaches for preserving residual renal function after the initiation of dialysis. Objective: To test the hypothesis that the angiotensin-converting enzyme (ACE) inhibitor ramipril slows the decline in residual renal function in patients with end-stage renal failure treated with peritoneal dialysis. Design: Randomized, open-label, controlled trial. Setting: Single-center study in the dialysis unit of a university teaching hospital. Patients: 60 patients receiving peritoneal dialysis. Measurements: Patients were randomly assigned to ramipril (5 mg daily) or no treatment. The target blood pressure was 135/85 mm Hg or less. Rate of decline in residual glomerular filtration rate (GFR) and development of complete anuria were compared among groups. Results: Over 12 months, average residual GFR declined by 2.07 mUmin per 1.73 m(2) in the ramipril group versus 3.00 mL/min per 1.73 m(2) in the control group (P = 0.03). The difference between the average changes in residual GFR in the ramipril and control groups from baseline to 12 months was 0.93 mL/min per 1.73 m(2) (95% CI, 0.09 to 1.78 mL/min per 1.73 m(2)). At 12 months, 14 patients in the ramipril group and 22 in the control group developed anuria. With intention-to-treat multivariable analysis using the Cox model, it was estimated that at 3, 6, and 9 months, patients assigned to ramipril had a higher adjusted hazard of complete anuria than did patients assigned to no treatment. Of the 25 patients who still did not have complete anuria at 12 months, those assigned to ramipril had a better prognosis than did those assigned to no treatment (adjusted hazard ratio, 0.58 [CI, 0.36 to 0.94]). The rates of death from any cause, duration of hospitalization, and cardiovascular events did not differ significantly between groups. Conclusions: Although the trial was small and had a limited ability to exclude effects of potential confounding factors, the angiotensin-converting enzyme inhibitor ramipril may reduce the rate of decline of residual renal function in patients with end-stage renal failure treated with peritoneal dialysis.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Li, PKT (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	philipli@cuhk.edu.hk	Wong, Tien Yin/AAC-9724-2020; Szeto, Cheuk Chun/N-4954-2015; Li, Philip K. T./D-4051-2017; Ming, Chow Kai/Y-5568-2019	Wong, Tien Yin/0000-0002-8448-1264; Szeto, Cheuk Chun/0000-0002-8898-8505; Ming, Chow Kai/0000-0001-5310-5197				Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; BAUER JH, 1992, AM J KIDNEY DIS, V20, P443, DOI 10.1016/S0272-6386(12)70256-1; Blake P G, 1996, Perit Dial Int, V16 Suppl 1, pS143; Blake PG, 1996, PERITON DIALYSIS INT, V16, P243; CANCARINI GC, 1986, PERITON DIALYSIS INT, V6, P77; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Diaz-Buxo JA, 1999, AM J KIDNEY DIS, V33, P523, DOI 10.1016/S0272-6386(99)70190-3; Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6; Gokal R, 2000, PERITON DIALYSIS INT, V20, P386; Hiroshige K, 1996, PERITON DIALYSIS INT, V16, P307; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LI PK, 2000, HONG KONG J NEPHROLO, V2, P61; Li PKT, 2001, PERITON DIALYSIS INT, V21, pS378; Li PKT, 2001, PERITON DIALYSIS INT, V21, pS307; Maiorca R, 1995, NEPHROL DIAL TRANSPL, V10, P2295, DOI 10.1093/ndt/10.12.2295; Mathiesen ER, 1999, BRIT MED J, V319, P24, DOI 10.1136/bmj.319.7201.24; Medcalf JF, 2001, KIDNEY INT, V59, P1128, DOI 10.1046/j.1523-1755.2001.0590031128.x; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Nolph K D, 1992, ASAIO J, V38, pM139, DOI 10.1097/00002480-199207000-00004; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Stack AG, 2001, J AM SOC NEPHROL, V12, P1516, DOI 10.1681/ASN.V1271516; Szeto CC, 2000, KIDNEY INT, V58, P400, DOI 10.1046/j.1523-1755.2000.00179.x; Szeto CC, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341040; Szeto CC, 1999, AM J KIDNEY DIS, V34, P1056, DOI 10.1016/S0272-6386(99)70011-9; TATTERSALL JE, 1993, NEPHROL DIAL TRANSPL, V8, P535, DOI 10.1093/ndt/8.6.535; TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I; Van Biesen W, 2000, PERITON DIALYSIS INT, V20, P375; vanOlden RW, 1996, J AM SOC NEPHROL, V7, P745; Venkataraman V, 2000, PERITON DIALYSIS INT, V20, P392; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275	36	198	218	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					105	112		10.7326/0003-4819-139-2-200307150-00010	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	701HX	12859160				2022-12-28	WOS:000184163100004
J	MacCarthy, PA; Kearney, MT; Nolan, J; Lee, AJ; Prescott, RJ; Shah, AM; Brooksby, WP; Fox, KAA				MacCarthy, PA; Kearney, MT; Nolan, J; Lee, AJ; Prescott, RJ; Shah, AM; Brooksby, WP; Fox, KAA			Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							VARIABILITY		Guys Kings & St Thomass Sch Med, Dept Cardiol, London SE5 9PJ, England; N Staffordshire Cardiac Ctr, Stoke On Trent ST4 6QG, Staffs, England; Univ Edinburgh, Med Stat Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Pontefract Hosp, Pontefract WF8 1PL, England; Wakefield Hosp, Pontefract WF8 1PL, England; Univ Edinburgh, Dept Cardiol, Edinburgh EH8 9YL, Midlothian, Scotland	University of London; King's College London; University of Edinburgh; University of Edinburgh	Kearney, MT (corresponding author), Guys Kings & St Thomass Sch Med, Dept Cardiol, London SE5 9PJ, England.		Lee, Andrew/GVU-2817-2022; Fox, keith A A/I-3742-2013	Shah, Ajay/0000-0002-6547-0631; Fox, Keith/0000-0002-0140-2752				BIGGER JT, 1995, CIRCULATION, V91, P1936, DOI 10.1161/01.CIR.91.7.1936; Kearney MT, 2002, J AM COLL CARDIOL, V40, P1801, DOI 10.1016/S0735-1097(02)02490-7; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Nolan J, 1998, CIRCULATION, V98, P1510, DOI 10.1161/01.CIR.98.15.1510; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9	5	45	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					78	79		10.1136/bmj.327.7406.78	http://dx.doi.org/10.1136/bmj.327.7406.78			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855525	Bronze, Green Published			2022-12-28	WOS:000184229400018
J	Ringel, SP				Ringel, SP			Patients like Linda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					165	166		10.1001/jama.290.2.165	http://dx.doi.org/10.1001/jama.290.2.165			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851256				2022-12-28	WOS:000183989800001
J	Petersson, P; Waldenstrom, A; Fahraeus, C; Schouenborg, J				Petersson, P; Waldenstrom, A; Fahraeus, C; Schouenborg, J			Spontaneous muscle twitches during sleep guide spinal self-organization	NATURE			English	Article							NOCICEPTIVE WITHDRAWAL REFLEXES; SENSORIMOTOR TRANSFORMATION; DEVELOPMENTAL ADAPTATION; SUBSTANTIA-GELATINOSA; POSTNATAL-DEVELOPMENT; DORSAL-HORN; RAT; NEURONS; SYSTEM; NETWORK	During development, information about the three-dimensional shape and mechanical properties of the body is laid down in the synaptic connectivity of sensorimotor systems through unknown adaptive mechanisms. In spinal reflex systems, this enables the fast transformation of complex sensory information into adequate correction of movements. Here we use a computer simulation to show that an unsupervised correlation-based learning mechanism, using spontaneous muscle twitches, can account for the functional adaptation of the withdrawal reflex system. We also show that tactile feedback resulting from spontaneous muscle twitches during sleep(1-3) does indeed modify sensorimotor transformation in young rats in a predictable manner. The results indicate that these twitches, corresponding to human fetal movements(4), are important in spinal self-organization.	Lund Univ, Dept Physiol Sci, Sect Neurophysiol, S-22184 Lund, Sweden	Lund University	Petersson, P (corresponding author), Lund Univ, Dept Physiol Sci, Sect Neurophysiol, BMC F10, S-22184 Lund, Sweden.	per.petersson@mphy.lu.se	Petersson, Per/A-5740-2010; Petersson, Per/P-1878-2019	Petersson, Per/0000-0001-6697-0171; Petersson, Per/0000-0001-6697-0171; Schouenborg, Jens/0000-0002-2815-6918				BLUMBERG MS, 1994, BEHAV NEUROSCI, V108, P1196, DOI 10.1037/0735-7044.108.6.1196; Blumberg MS, 1996, DEV PSYCHOBIOL, V29, P1, DOI 10.1002/(SICI)1098-2302(199601)29:1<1::AID-DEV1>3.0.CO;2-Y; CERVERO F, 1980, BRAIN, V103, P717, DOI 10.1093/brain/103.4.717; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; DELISI L, 1932, RIV PATOL NERV MENT, V29, P481; FITZGERALD M, 1986, DEV BRAIN RES, V24, P261, DOI 10.1016/0165-3806(86)90194-X; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Fregnac Y, 1998, DAHLEM WORK, P113; Gardner R., 1975, ADV SLEEP RES, P67; HADDERSALGRA M, 1993, EARLY HUM DEV, V35, P63, DOI 10.1016/0378-3782(93)90140-P; Holmberg H, 1996, J PHYSIOL-LONDON, V493, P239, DOI 10.1113/jphysiol.1996.sp021379; Holmberg H, 1996, J PHYSIOL-LONDON, V495, P399, DOI 10.1113/jphysiol.1996.sp021602; Holmberg H, 1997, J NEUROSCI, V17, P2071; Johansson R., 1993, SYSTEM MODELING IDEN; Karlsson KAE, 2002, BEHAV NEUROSCI, V116, P912, DOI 10.1037//0735-7044.116.5.912; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Levinsson A, 2002, J NEUROSCI, V22, P8170; Levinsson A, 1999, J NEUROSCI, V19, P10397; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; Morisset V, 1998, EUR J NEUROSCI, V10, P3642, DOI 10.1046/j.1460-9568.1998.00370.x; Nakatsuka T, 2000, NEUROSCIENCE, V99, P549, DOI 10.1016/S0306-4522(00)00224-4; Nicolelis MAL, 1996, J NEUROPHYSIOL, V75, P2192, DOI 10.1152/jn.1996.75.5.2192; OJA E, 1982, J MATH BIOL, V15, P267, DOI 10.1007/BF00275687; Pouget A, 2000, NAT NEUROSCI, V3, P1192, DOI 10.1038/81469; ROSENBLATT F, 1958, PSYCHOL REV, V65, P386, DOI 10.1037/h0042519; SCHOUENBORG J, 1994, EXP BRAIN RES, V100, P170; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; WALDENSTROM A, 2002, IASP ABSTR, V1558, pP106; WALDENSTROM A, 2001, SOC NEUR ABSTR, V30, P1623	30	133	133	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					72	75		10.1038/nature01719	http://dx.doi.org/10.1038/nature01719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840761				2022-12-28	WOS:000183912800042
J	Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff , C; Woolf, SH; Westhoff, C				Berg, AO; Allan, JD; Frame, P; Homer, CJ; Johnson, MS; Klein, JD; Lieu, TA; Mulrow, CD; Orleans, CT; Peipert, JF; Pender, NJ; Siu, AL; Teutsch, SM; Westhoff , C; Woolf, SH; Westhoff, C			Routine vitamin supplementation to prevent cancer and cardiovascular disease: Recommendations and rationale	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-CAROTENE SUPPLEMENTATION; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; MULTIVITAMIN USE; COLON-CANCER; LUNG-CANCER; RISK; MORTALITY; ATHEROSCLEROSIS; ANTIOXIDANTS	This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on routine vitamin supplementation to prevent cancer and cardiovascular disease and the supporting scientific evidence. Part of the information on which this statement is based, including evidence tables and references, is available in the accompanying article on vitamins to prevent cardiovascular disease in this issue. More complete information can be found in the summaries of the evidence on vitamins to prevent cancer and vitamins to prevent cardiovascular disease, available on the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov). The summaries of the evidence on these topics and the recommendation statement are also available in print through subscription to the Guide to Clinical Preventive Services, Third Edition: Periodic Updates. A subscription costs $60 U.S. and can be ordered through the Agency for Healthcare Research and Quality Publications Clearinghouse (call 800-358-9295 or e-mail ahrqpubs@ahrq.gov).	Univ Washington, Seattle, WA 98195 USA; Univ Maryland, Baltimore, MD 21201 USA; Tri Cty Family Med, Cohocton, NY USA; Univ Rochester, Sch Med, Rochester, NY USA; Natl Initiat Childrens Healthcare Qual, Boston, MA USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Harvard Univ, Pilgrim Hlth Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA; Women & Infants Hosp Rhode Isl, Providence, RI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mt Sinai Sch Med, New York, NY USA; Merck & Co Inc, West Point, PA USA; Columbia Univ, New York, NY USA; Virginia Commonwealth Univ, Fairfax, VA USA	University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Baltimore; University of Rochester; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard University; Harvard Medical School; University of Texas System; University of Texas Health San Antonio; Robert Wood Johnson Foundation (RWJF); Women & Infants Hospital Rhode Island; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai; Merck & Company; Columbia University; Virginia Commonwealth University								Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM AC FAM PHYS, 2003, AAFP CLIN REC VIT; *AM CANC SOC, 2003, PREV EARL DET FOOD F; *AM HEART ASS, 2002, VIT MIN S AHA SCI PO; BOSTICK RM, 1993, CANCER RES, V53, P4230; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Cook NR, 1999, CANCER, V86, P1783, DOI 10.1002/(SICI)1097-0142(19991101)86:9&lt;1783::AID-CNCR21&gt;3.0.CO;2-N; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; Frieling UM, 2000, ARCH DERMATOL, V136, P179, DOI 10.1001/archderm.136.2.179; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P261; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; Morris CD, 2003, ANN INTERN MED, V139, P56, DOI 10.7326/0003-4819-139-1-200307010-00014; Muntwyler J, 2002, ARCH INTERN MED, V162, P1472, DOI 10.1001/archinte.162.13.1472; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pignone MP, 2003, AM J PREV MED, V24, P75, DOI 10.1016/S0749-3797(02)00580-9; [Preventive Services Task Force US US Preventive Services Task Force], 1996, GUID CLIN PREV SERV, P467; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Ritenbaugh C, ROUTINE VITAMIN SUPP; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHETTY P, 2002, ROUTINE VITAMIN SUPP; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Taylor BV, 2000, CAN FAM PHYSICIAN, V46, P2236; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Watkins ML, 2000, AM J EPIDEMIOL, V152, P149, DOI 10.1093/aje/152.2.149; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547; 2000, CAN TASK FORCE PREVE; 2002, US PHARMACOPEIA DIET	42	53	55	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					51	55		10.7326/0003-4819-139-1-200307010-00013	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834319				2022-12-28	WOS:000183823200008
J	Naleway, AL; Belongia, EA; Greenlee, RT; Kieke, BA; Chen, RT; Shay, DK				Naleway, AL; Belongia, EA; Greenlee, RT; Kieke, BA; Chen, RT; Shay, DK			Eczematous skin disease and recall of past diagnoses: Implications for smallpox vaccination	ANNALS OF INTERNAL MEDICINE			English	Article							ATOPIC-DERMATITIS; PREVALENCE; COMPLICATIONS; UK	Background: Persons with atopic dermatitis or eczema, regardless of disease severity or activity, may develop eczema vaccinatum if they or their close contacts receive the smallpox vaccine. According to current recommendations, a preexposure vaccination program should identify these persons and exclude them from participating. Objective: To determine the prevalence of diagnosed atopic dermatitis and eczema in a defined population and assess the sensitivity of screening questions to identify patients who have received these diagnoses. Design: Population-based prevalence survey and telephone interview. Setting: 14 ZIP code regions in Wisconsin. Patients: Persons given a diagnosis of atopic dermatitis or eczema in 2000 and 2001 were identified from a population-based cohort. Persons with a history of atopic dermatitis diagnosed since 1979 were eligible for the telephone survey. Measurements: Prevalence of diagnosed atopic dermatitis or eczema; proportions of respondents able to recall a past diagnosis of atopic dermatitis, eczema, or recurrent rash. Results: The prevalence of atopic dermatitis or eczema diagnosis in 2000 or 2001 was 0.8%. At least 2.4% of the cohort would be ineligible for smallpox vaccination because of active skin disease in themselves or household members. Among 94 adult respondents with atopic dermatitis, 55 (59%) correctly self-reported skin disease. Seventy-nine (60%) of 133 household contacts of adults with atopic dermatitis correctly reported the presence of skin disease in a household member. Parental recall of skin disease in children with atopic dermatitis was 70% (123 of 177). Conclusions: Identifying dermatologic contraindications to smallpox vaccination by relying only on a self-reported history of rash illnesses is likely to miss a substantial proportion of individuals who should not receive smallpox vaccine in a preexposure vaccination campaign.	Marshfield Med Res Fdn, Epidemiol Res Ctr, Marshfield, WI 54449 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Belongia, EA (corresponding author), Marshfield Med Res Fdn, Epidemiol Res Ctr, 1000 N Oak Ave,Mailstop ML2, Marshfield, WI 54449 USA.	belongia.edward@mcrf.mfldclin.edu		Belongia, Edward/0000-0001-7478-0415; Shay, David/0000-0001-9619-4820; Naleway, Allison/0000-0001-5747-4643	PHS HHS [200-95-0957] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM AC DERM, 2003, ECZ AT DERM; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bicknell WJ, 2002, NEW ENGL J MED, V347, P691; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; Breslow NE., 1987, STAT METHODS CANC RE, P81; *CDCP, 2003, SMALLP VACC REP STAT; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; *DEP DEF, 2003, SMALLP SAF SUMM; DeStefano F, 1996, J CLIN EPIDEMIOL, V49, P643, DOI 10.1016/0895-4356(96)00008-X; Ellis CN, 2002, J AM ACAD DERMATOL, V46, P361, DOI 10.1067/mjd.2002.120528; GOLDSTEIN JA, 1975, PEDIATRICS, V55, P342; GREENBERG M, 1948, AM J DIS CHILD, V76, P492; Hanifin JM., 1980, ACTA DERM-VENEREOL, V92, P44; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Herd RM, 1996, BRIT J DERMATOL, V135, P18; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kemper Alex R, 2002, Eff Clin Pract, V5, P84; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; Lane JM, 2002, NEW ENGL J MED, V347, P691; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; McNally NJ, 2000, BRIT J DERMATOL, V142, P712, DOI 10.1046/j.1365-2133.2000.03416.x; NEAME RL, 1995, BRIT J DERMATOL, V132, P772; Neff JM, 2002, JAMA-J AM MED ASSOC, V288, P1901, DOI 10.1001/jama.288.15.1901; WADDINGTON E, 1964, ANN REPORT T LONDON, V50, P22; Williams H, 2001, J AM ACAD DERMATOL, V45, pS33, DOI 10.1067/mjd.2001.117019; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; 2003, MMWR MORB MORTAL WKL, V52, P278; 2003, MMWR DISPATCH, V52, P1	33	33	35	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					1	7		10.7326/0003-4819-139-1-200307010-00006	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834312				2022-12-28	WOS:000183823200001
J	Law, MR; Wald, NJ; Morris, JK; Jordan, RE				Law, MR; Wald, NJ; Morris, JK; Jordan, RE			Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials	BRITISH MEDICAL JOURNAL			English	Article							DIURETIC-INDUCED HYPOKALEMIA; CONVERTING ENZYME-INHIBITOR; CORONARY HEART-DISEASE; HYPERTENSIVE PATIENTS; SYSTEMIC HYPERTENSION; THIAZIDE THERAPY; METAANALYSIS; POTASSIUM; STROKE; OUTCOMES	Objective To determine the average reduction in blood pressure, prevalence of adverse effects, and reduction in risk of stroke and ischaemic heart disease events produced by the five main categories of blood pressure lowering drugs according to dose, singly and in combination. Design Meta-analysis of 354 randomised double blind placebo controlled trials of thiazides, beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin 11 receptor antagonists, and calcium channel blockers in fixed dose. Subjects 40 000 treated patients and 16 000 patients given placebo. Main outcome measures Placebo adjusted reductions in systolic and diastolic blood pressure and prevalence of adverse effects, according to dose expressed as a multiple of the standard (recommended) doses of the drugs. Results All five categories of drug produced similar reductions in blood pressure. The average reduction was 9.1 turn Hg systolic and 5.5 mm Hg diastolic at standard dose and 7.1 turn Hg systolic and 4.4 mm Hg diastolic (20% lower) at half standard dose. The drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mm Hg higher blood pressure the reduction was 1.0 mm Hg systolic and 1.1 mm Hg diastolic greater. The blood pressure lowering effects of different categories of drugs were additive. Symptoms attributable to thiazides, P blockers, and calcium channel blockers were strongly dose related; symptoms caused by ACE inhibitors (mainly cough) were not dose related. Angiotensin 11 receptor antagonists caused no excess of symptoms. The prevalence of symptoms with two drugs in combination was less than additive. Adverse metabolic effects (such as changes in cholesterol or potassium) were negligible at half standard dose. Conclusions Combination low dose drug treatment increases efficacy and reduces adverse effects. From the average blood pressure in people who have strokes (150/90 turn Hg) three drugs at half standard dose are estimated to lower blood pressure by 20 turn Hg systolic and 11 mm Hg diastolic and thereby reduce the risk of stroke by 63% and ischaemic heart disease events by 46% at age 60-69.	Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, MR (corresponding author), Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.		Jordan, Rachel/ABG-1892-2021; Morris, Joan/AAT-9211-2020; Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021	Jordan, Rachel/0000-0002-0747-6883; Morris, Joan/0000-0002-7164-612X; 				AZIZI M, 1995, CIRCULATION, V92, P825, DOI 10.1161/01.CIR.92.4.825; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; FREIS ED, 1989, ARCH INTERN MED, V149, P2640, DOI 10.1001/archinte.149.12.2640; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; GREENBERG G, 1984, AM J MED, V76, P45, DOI 10.1016/0002-9343(84)90956-2; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Grimm RH, 1997, HYPERTENSION, V29, P8, DOI 10.1161/01.HYP.29.1.8; Grimm RH, 1996, JAMA-J AM MED ASSOC, V275, P1549, DOI 10.1001/jama.275.20.1549; Hansson L, 2000, ARCH INTERN MED, V160, P1654, DOI 10.1001/archinte.160.11.1654; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; KAPLAN NM, 1985, NEW ENGL J MED, V312, P746, DOI 10.1056/NEJM198503213121203; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Lawes CMM, 2003, J HYPERTENS, V21, P707, DOI 10.1097/01.hjh.0000052492.18130.07; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MURPHY MB, 1982, LANCET, V2, P1293; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; PAPADEMETRIOU V, 1988, ARCH INTERN MED, V148, P1272, DOI 10.1001/archinte.148.6.1272; PAPADEMETRIOU V, 1984, AM J CARDIOL, V54, P1015, DOI 10.1016/S0002-9149(84)80136-8; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; SEEDAT YK, 1989, J HYPERTENS, V7, P515, DOI 10.1097/00004872-198907000-00001; WILKINSON PR, 1975, LANCET, V1, P759; [No title captured]	28	852	895	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1427	1431		10.1136/bmj.326.7404.1427	http://dx.doi.org/10.1136/bmj.326.7404.1427			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829555	Bronze, Green Published			2022-12-28	WOS:000183931800017
J	Tautz, D				Tautz, D			Chordate evolution in a new light	CELL			English	Editorial Material							ORIGIN; SIMILARITIES	Gene expression studies in embryos often provide insights into evolutionary relationships across phyla. In this issue of Cell, Lowe et al. examine the patterning of the bilaterian nervous system by studying gene expression in a hemichordate, the acorn worm. Although these animals have an unstructured nervous system, they show surprisingly conserved gene expression domains, shedding new light on the evolution of the central nervous system and the phylogenetic placement of chordates.	Univ Cologne, Inst Genet, D-50931 Cologne, Germany	University of Cologne	Tautz, D (corresponding author), Univ Cologne, Inst Genet, Weyertal 121, D-50931 Cologne, Germany.		Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; Arendt D, 1997, MECH DEVELOP, V61, P7, DOI 10.1016/S0925-4773(96)00620-X; Bruce AEE, 1998, DEV BIOL, V201, P101, DOI 10.1006/dbio.1998.8968; BULLOCK TH, 1945, Q J MICROSC SCI, V86, P55; Dove H, 2003, DEVELOPMENT, V130, P2161, DOI 10.1242/dev.00442; Erwin DH, 2002, DEVELOPMENT, V129, P3021; Hirth F, 2003, DEVELOPMENT, V130, P2365, DOI 10.1242/dev.00438; KNIGHTJONES EW, 1952, PHILOS T ROY SOC B, V236, P315, DOI 10.1098/rstb.1952.0004; Lowe CJ, 2003, CELL, V113, P853, DOI 10.1016/S0092-8674(03)00469-0; Reichert H, 2001, PHILOS T R SOC B, V356, P1533, DOI 10.1098/rstb.2001.0972	10	3	3	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					812	813		10.1016/S0092-8674(03)00472-0	http://dx.doi.org/10.1016/S0092-8674(03)00472-0			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837236	Bronze			2022-12-28	WOS:000183817900002
J	Bunch, TJ; White, RD; Gersh, BJ; Meverden, RA; Hodge, DO; Ballman, KV; Hammill, SC; Shen, WK; Packer, DL				Bunch, TJ; White, RD; Gersh, BJ; Meverden, RA; Hodge, DO; Ballman, KV; Hammill, SC; Shen, WK; Packer, DL			Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-SERVICES SYSTEM; VENTRICULAR-FIBRILLATION; RAPID DEFIBRILLATION; HEALTH-STATUS; PRIMARY-CARE; SURVIVORS; LIFE; RESUSCITATION; TECHNICIANS; PARAMEDICS	BACKGROUND: Mortality after out-of-hospital cardiac arrest from ventricular fibrillation is high. Programs focusing on early defibrillation have improved the rate of survival to hospital discharge. We conducted a population-based analysis of the long-term outcome and quality of life of survivors. METHODS: All patients who had an out-of-hospital cardiac arrest between November 1990 and January 2001 who received early defibrillation for ventricular fibrillation in Olmsted County, Minnesota, were included. The survival rate was compared with that of an age-, sex-, and disease-matched (2:1) control population of residents who had not had an out-of-hospital cardiac arrest and with that of age- and sex-matched controls from the general U.S. population. The quality of life was assessed with use of the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) and compared with U.S. population norms. RESULTS: Of 200 patients who presented with an out-of-hospital cardiac arrest with ventricular fibrillation, 145 (72 percent) survived to hospital admission (7 died in the emergency department) and 79 (40 percent) were neurologically intact (good overall capability or moderate overall disability) at discharge. The mean (+/-SD) length of follow-up was 4.8+/-3.0 years. Nineteen patients died after discharge from the hospital. The expected five-year survival rate (79 percent) was identical to that among age-, sex-, and disease-matched controls (P=0.68) but lower than that among the age- and sex-matched U.S. population (86 percent, P=0.02). Fifty patients completed SF-36 surveys at the end of follow-up, and the majority had a nearly normal quality of life, with the exception of reduced vitality. CONCLUSIONS: Long-term survival among patients who have undergone rapid defibrillation after out-of-hospital cardiac arrest is similar to that among age-, sex-, and disease-matched patients who did not have out-of-hospital cardiac arrest. The quality of life among the majority of survivors is similar to that of the general population.	Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Div Biostat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	White, RD (corresponding author), Mayo Clin & Mayo Fdn, Dept Anesthesiol, 200 1St St SW, Rochester, MN 55905 USA.			Ballman, Karla/0000-0002-4492-0357				American Heart Association, 2000, 2001 HEART STROK STA; BERGNER L, 1985, AM J PUBLIC HEALTH, V75, P1321, DOI 10.2105/AJPH.75.11.1321; Bergner L, 1983, Am J Emerg Med, V1, P259, DOI 10.1016/0735-6757(83)90101-8; BERGNER L, 1984, AM J PUBLIC HEALTH, V74, P508, DOI 10.2105/AJPH.74.5.508; BERTINI G, 1990, Journal of Emergency Medicine, V8, P407, DOI 10.1016/0736-4679(90)90166-S; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Graves JR, 1997, RESUSCITATION, V35, P117; Herbst JH, 1999, PACE, V22, P915, DOI 10.1111/j.1540-8159.1999.tb06816.x; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; Hsu JWY, 1996, ANN EMERG MED, V28, P597, DOI 10.1016/S0196-0644(96)70080-X; JENNETT B, 1975, LANCET, V1, P480; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1708, DOI 10.1001/jama.270.14.1708; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; Kuilman M, 1999, RESUSCITATION, V41, P25, DOI 10.1016/S0300-9572(99)00016-7; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MYERBURG RJ, 1992, CIRCULATION, V85, P2; Nichol G, 1999, ACAD EMERG MED, V6, P95, DOI 10.1111/j.1553-2712.1999.tb01044.x; PARADIS NA, 1996, CARDIAC ARREST SCI P, P867; Smith HJ, 2000, HEART, V84, P390, DOI 10.1136/heart.84.4.390; Stratton S, 1998, ANN EMERG MED, V31, P471, DOI 10.1016/S0196-0644(98)70256-2; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; Sunnerhagen KS, 1996, RESUSCITATION, V31, P135, DOI 10.1016/0300-9572(95)00903-5; SWOR RA, 1995, ANN EMERG MED, V25, P780, DOI 10.1016/S0196-0644(95)70207-5; VALENZUELA TD, 1993, ANN EMERG MED, V22, P1678, DOI 10.1016/S0196-0644(05)81305-8; Ware JE, 1993, SF36 HLTH SURVEY MAN; White R D, 2001, Curr Opin Crit Care, V7, P145, DOI 10.1097/00075198-200106000-00002; White RD, 1996, ANN EMERG MED, V28, P480, DOI 10.1016/S0196-0644(96)70109-9; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X; White RD, 2001, RESUSCITATION, V49, P9, DOI 10.1016/S0300-9572(00)00338-5; 1994, JAMA, V271, P984; [No title captured]	35	270	278	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2626	2633		10.1056/NEJMoa023053	http://dx.doi.org/10.1056/NEJMoa023053			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826637				2022-12-28	WOS:000183726400006
J	Nishiyama, M; Hoshino, A; Tsai, L; Henley, JR; Goshima, Y; Tessier-Lavigne, M; Poo, MM; Hong, KS				Nishiyama, M; Hoshino, A; Tsai, L; Henley, JR; Goshima, Y; Tessier-Lavigne, M; Poo, MM; Hong, KS			Cyclic AMP/GMP-dependent modulation of Ca2+ channels sets the polarity of nerve growth-cone turning	NATURE			English	Article							ARACHIDONATE 12-LIPOXYGENASE; CALCIUM TRANSIENTS; CANINE BRAIN; NETRIN-1; GUIDANCE; CELLS; ACID; ORIENTATION; SPECIFICITY; ACTIVATION	Signalling by intracellular second messengers such as cyclic nucleotides and Ca2+ is known to regulate attractive and repulsive guidance of axons by extracellular factors(1,2). However, the mechanism of interaction among these second messengers in determining the polarity of the guidance response is largely unknown. Here, we report that the ratio of cyclic AMP to cyclic GMP activities sets the polarity of netrin-1-induced axon guidance: high ratios favour attraction, whereas low ratios favour repulsion. Whole-cell recordings of Ca2+ currents at Xenopus spinal neuron growth cones indicate that cyclic nucleotide signalling directly modulates the activity of L-type Ca2+ channels LCCs) in axonal growth cones. Furthermore, cGMP signalling activated by an arachidonate 12-lipoxygenase metabolite(3) suppresses LCC activity triggered by netrin-1, and is required for growth-cone repulsion mediated by the DCC-UNC5 receptor complex(4). By linking cAMP and cGMP signalling and modulation of Ca2+ channel activity in growth cones, these findings delineate an early membrane-associated event responsible for signal transduction during bi-directional axon guidance.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Div Neurobiol, Berkeley, CA 94720 USA; Yokohama City Univ, Sch Med, Dept Mol Pharmacol & Neurobiol, Yokohama, Kanagawa 2360004, Japan; Stanford Univ, Dept Biol Sci, Howard Hughes Med Inst, Stanford, CA 94305 USA	New York University; University of California System; University of California Berkeley; Yokohama City University; Howard Hughes Medical Institute; Stanford University	Hong, KS (corresponding author), NYU, Sch Med, Dept Biochem, New York, NY 10016 USA.		Henley, John/D-7171-2011	Henley, John/0000-0003-1846-5941				Baldridge WH, 2001, VISUAL NEUROSCI, V18, P849, DOI 10.1017/S0952523801186013; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BRUNE B, 1991, MOL PHARMACOL, V39, P671; Carabelli V, 2002, J PHYSIOL-LONDON, V541, P351, DOI 10.1113/jphysiol.2002.017749; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; Goshima Y, 1997, J NEUROBIOL, V33, P316, DOI 10.1002/(SICI)1097-4695(199709)33:3<316::AID-NEU9>3.0.CO;2-4; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAWKINS DJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P447, DOI 10.1016/0003-9861(89)90312-3; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Nishiyama M, 1998, EUR J PHARMACOL, V341, P57, DOI 10.1016/S0014-2999(97)01353-8; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Spitzer NC, 2000, BIOESSAYS, V22, P811; Tabti N., 1991, CULTURING NERVE CELL, P137	30	312	324	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					990	995		10.1038/nature01751	http://dx.doi.org/10.1038/nature01751			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827203				2022-12-28	WOS:000183753900051
J	Wijma, B; Schei, B; Swahnberg, K; Hilden, M; Offerdal, K; Pikarinen, U; Sidenius, K; Steingrimsdottir, T; Stourn, H; Halmesmaki, E				Wijma, B; Schei, B; Swahnberg, K; Hilden, M; Offerdal, K; Pikarinen, U; Sidenius, K; Steingrimsdottir, T; Stourn, H; Halmesmaki, E			Emotional, physical, and sexual abuse in patients visiting gynaecology clinics: a Nordic cross-sectional study	LANCET			English	Article							CHRONIC PELVIC PAIN; WOMEN; PREVALENCE; PREGNANCY; CHILDHOOD; HISTORY; VIOLENCE; COMMUNITY; SAMPLE	Background Abuse against women causes much suffering for individuals and is a major concern for society. We aimed to estimate the prevalence of three types of abuse in patients visiting gynaecology clinics in five Nordic countries, and to assess the frequency with which gynaecologists identify abuse victims. Methods We did a cross-sectional, multicentre study of women attending five departments of gynaecology in Denmark. Finland, Iceland, Norway, and Sweden. We recruited 4729 patients; 3641 (77%) responded and were included in the study. Participants completed a postal questionnaire (norvold abuse questionnaire) confidentially. Primary outcome measures were prevalences of emotional, physical, and sexual abuse, and whether abused patients had told their gynaecologist about these experiences. We assessed differences between countries with Pearson's chi(2) test. Findings The ranges across the five countries of lifetime prevalence were 38-66% for physical abuse, 19-37% for emotional abuse, and 17-33% for sexual abuse. Not all abused women reported current ill-effects from the abusive experience. Most women (92-98%) had not talked to their gynaecologist about their experiences of abuse at their latest clinic visit. Interpretation Despite prevalences of emotional, physical, and sexual abuse being high in patients visiting gynaecology clinics in the Nordic countries, most victims of abuse are not identified by their gynaecologists. This lack of discussion might increase the risk of abused patients not being treated according to their needs. Gynaecologists should always consider asking their patients about abuse.	Linkoping Univ, Fac Hlth Sci, Dept Mol & Clin Med, Div Womens Hlth, S-58185 Linkoping, Sweden; St Olav Hosp, Dept Gynaecol, Trondheim, Norway; Copenhagen Univ Hosp, Dept Obstet & Gynaecol, Glostrup, Denmark; Univ Copenhagen Hosp, Rigshosp, Ctr Victims Sexual Assault, DK-2100 Copenhagen, Denmark; Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland; Landspitalinn, Dept Gynaecol, Reykjavik, Iceland	Linkoping University; Norwegian University of Science & Technology (NTNU); University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital	Wijma, B (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Mol & Clin Med, Div Womens Hlth, S-58185 Linkoping, Sweden.							AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; [Anonymous], 1998, FAITH HOPE BATTERING; ARNOLD RP, 1990, BRIT MED J, V300, P705, DOI 10.1136/bmj.300.6726.705; Coid J, 2001, LANCET, V358, P450, DOI 10.1016/S0140-6736(01)05622-7; Cook DJ, 1996, CAN MED ASSOC J, V154, P1657; D'Avolio D, 2001, Health Care Women Int, V22, P349, DOI 10.1080/07399330152398891; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; Golding JM, 2000, J PSYCHOSOM OBST GYN, V21, P69, DOI 10.3109/01674820009075612; Gorey KM, 1997, CHILD ABUSE NEGLECT, V21, P391, DOI 10.1016/S0145-2134(96)00180-9; Heise L, 2002, INT J GYNECOL OBSTET, V78, pS5, DOI 10.1016/S0020-7292(02)00038-3; JEHU D, 1992, REPROD LIFE ADV RES; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; Mazza D, 1996, MED J AUSTRALIA, V164, P14, DOI 10.5694/j.1326-5377.1996.tb94101.x; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MOELLER TP, 1993, CHILD ABUSE NEGLECT, V17, P623, DOI 10.1016/0145-2134(93)90084-I; NORTON LB, 1995, OBSTET GYNECOL, V85, P321, DOI 10.1016/0029-7844(94)00429-H; PARKER B, 1993, NURS RES, V42, P173; PARSONS LH, 1995, AM J OBSTET GYNECOL, V173, P381, DOI 10.1016/0002-9378(95)90256-2; RAPKIN AJ, 1990, OBSTET GYNECOL, V76, P92; Rich D.J., 1997, J COLL STUD PSYCH, V11, P13, DOI [10.1300/J035v11n03_04, DOI 10.1300/J035V11N03_04]; SATIN AJ, 1992, AM J OBSTET GYNECOL, V167, P973, DOI 10.1016/S0002-9378(12)80022-6; SCHEI B, 1991, Scandinavian Journal of Primary Health Care, V9, P41, DOI 10.3109/02813439109026580; SCHEI B, 1990, SCAND J SOC MED, V18, P63, DOI 10.1177/140349489001800110; SCHEI B, 1990, ACTA OBSTET GYN SCAN, V69, P67, DOI 10.3109/00016349009021042; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; SMIKLE CB, 1995, J REPROD MED, V40, P347; SWAHNBERG K, IN PRESS EUR J PUBLI; SWAHNBERG K, IN PRESS ACTA OBSTET; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WALLING MK, 1994, OBSTET GYNECOL, V84, P193; WIJMA B, 2003, 2 LINK U FAC HLTH SC; Wijma K, 2000, J INTERPERS VIOLENCE, V15, P944, DOI 10.1177/088626000015009003; WILLIAMS LM, 1995, J CONSULT CLIN PSYCH, V63, P343; Yehuda R., 1999, RISK FACTORS POSTTRA	34	123	126	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2107	2113		10.1016/S0140-6736(03)13719-1	http://dx.doi.org/10.1016/S0140-6736(03)13719-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	692GY	12826432				2022-12-28	WOS:000183654200008
J	Rakitzis, TP; Samartzis, PC; Toomes, RL; Kitsopoulos, TN; Brown, A; Balint-Kurti, GG; Vasyutinskii, OS; Beswick, JA				Rakitzis, TP; Samartzis, PC; Toomes, RL; Kitsopoulos, TN; Brown, A; Balint-Kurti, GG; Vasyutinskii, OS; Beswick, JA			Spin-polarized hydrogen atoms from molecular photodissociation	SCIENCE			English	Article							ANGULAR-MOMENTUM DISTRIBUTIONS; PHOTOFRAGMENTATION; HCL; HF	The production of spin-polarized hydrogen atoms from the photodissociation of hydrogen chloride with circularly polarized 193-nanometer light is inferred from the measurement of the complete angular momentum distributions of ground state Cl(P-2(3/2)) and excited state Cl(P-2(1/2)) cofragments by slice imaging. The experimentally measured and ab initio predicted a(q)((k))(p) parameters, which describe the single-surface and multiple-surface-interference contributions to the angular momentum distributions, are in excellent agreement. For laser pulses longer than about 0.7 ns, the polarization of the electron and the proton are both 36%.	Univ Crete, Dept Phys, Iraklion, Greece; Univ Crete, Dept Chem, Iraklion, Greece; Fdn Res & Technol Hellas, Inst Elect Struct & Laser, Iraklion 71110, Greece; Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Cherry L Emerson Ctr Sci Computat, Atlanta, GA 30322 USA; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England; Russian Acad Sci, AF Ioffe Physicotech Inst, St Petersburg 194021, Russia; Univ Toulouse 3, Inst Rech Syst Atom & Mol Complexes, Lab Collis Agregats React, F-31062 Toulouse, France	University of Crete; University of Crete; Foundation for Research & Technology - Hellas (FORTH); Emory University; Emory University; University of Bristol; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Ioffe Physical Technical Institute; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Rakitzis, TP (corresponding author), Univ Crete, Dept Phys, Iraklion, Greece.	ptr@iesl.forth.gr	Kitsopoulos, Theofanis/A-8355-2014; Rakitzis, Peter/ABA-1640-2021; Vasyutinskiy, Oleg Svyatoslavovich/A-7641-2014; Rakitzis, T. Peter/C-5564-2011; Samartzis, Peter/H-4602-2012	Kitsopoulos, Theofanis/0000-0001-6228-1002; Vasyutinskiy, Oleg Svyatoslavovich/0000-0003-1669-824X; Rakitzis, T. Peter/0000-0002-0385-3936; Samartzis, Peter/0000-0001-8873-2326; Brown, Alex/0000-0002-5384-9222				Abraham R.J., 1988, INTRO NMR SPECTROSCO; ALEXANDER MH, 1993, J CHEM PHYS, V99, P1752, DOI 10.1063/1.465292; Balint-Kurti GG, 2002, J CHEM PHYS, V116, P10760, DOI 10.1063/1.1476937; BALINTKURTI GG, 1990, J CHEM SOC FARADAY T, V86, P1741, DOI 10.1039/ft9908601741; Bracker AS, 1998, PHYS REV LETT, V80, P1626, DOI 10.1103/PhysRevLett.80.1626; Bracker AS, 1999, J CHEM PHYS, V110, P6749, DOI 10.1063/1.478668; Brown A, 2000, J CHEM PHYS, V113, P1870, DOI 10.1063/1.482075; Gebhardt CR, 2001, REV SCI INSTRUM, V72, P3848, DOI 10.1063/1.1403010; KHUNDKAR LR, 1990, ANNU REV PHYS CHEM, V41, P15; Lambert HM, 1998, J CHEM PHYS, V108, P4460, DOI 10.1063/1.475857; Rakitzis TP, 2002, CHEM PHYS LETT, V364, P115, DOI 10.1016/S0009-2614(02)01324-6; Rakitzis TP, 1999, J CHEM PHYS, V110, P3341, DOI 10.1063/1.478200; Rakitzis TP, 1999, J CHEM PHYS, V110, P3351, DOI 10.1063/1.478201; Rakitzis TP, 1998, SCIENCE, V281, P1346, DOI 10.1126/science.281.5381.1346; RAKITZIS TP, UNPUB; REDSUN SG, 1990, PHYS REV A, V42, P1293, DOI 10.1103/PhysRevA.42.1293; ROTTKE H, 1986, PHYS REV A, V33, P736, DOI 10.1103/PhysRevA.33.736; Schinke R., 1993, PHOTODISSOCIATION DY; SLEBBELES LDA, 1994, J CHEM PHYS, V100, P3610; VANBRUNT RJ, 1968, J CHEM PHYS, V48, P4304, DOI 10.1063/1.1669773; VASYUTINSKII OS, 1981, ZH EKSP TEOR FIZ, V54, P855; ZAPFE K, 1995, REV SCI INSTRUM, V66, P28, DOI 10.1063/1.1146388; Zhang J, 1997, J CHEM PHYS, V107, P1403, DOI 10.1063/1.474494	23	73	76	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1936	1938		10.1126/science.1084809	http://dx.doi.org/10.1126/science.1084809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817146				2022-12-28	WOS:000183619400043
J	Sinervo, B; Clobert, J				Sinervo, B; Clobert, J			Morphs, dispersal behavior, genetic similarity, and the evolution of cooperation	SCIENCE			English	Article							ALTERNATIVE MALE; CORRELATIONAL SELECTION; KIN SELECTION; ALTRUISM; FITNESS; DRIVEN; CYCLES; GAME	Genetic similarity owing to kin relationship is often invoked to explain the evolution of social cooperation. In this study, male color morphs of side-blotched lizards settle nonrandomly with respect to genetic similarity. Blue morphs tend to settle in close proximity to other blue morphs with high genetic similarity. Blue neighbors have three times the average fitness of blue males lacking such neighbors. Conversely, genetically similar males depress fitness of the orange morph. Moreover, orange males are hyperdispersed with respect to genetic similarity. Pedigree and dispersal data show that genetically similar blue neighbors are not kin. Instead, conditions for the evolution of dispersal and cooperation are promoted by an emergent property of the morph locus that increases genetic similarity within morphs: genome-wide correlational selection links many traits to the morph locus, including settlement behavior.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; CNRS, UMR 7625, Ecol Lab, F-75252 Paris 05, France	University of California System; University of California Santa Cruz; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Sinervo, B (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Earth & Marine Sci Bldg,A316, Santa Cruz, CA 95064 USA.	sinervo@biology.ucsc.edu						AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Calsbeek R, 2002, OECOLOGIA, V132, P468, DOI 10.1007/s00442-002-0975-8; Dawkins Richard, 1976, SELFISH GENE; DOUGHTY P, 1994, J HERPETOL, V28, P485, DOI 10.2307/1564962; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hoglund J, 1999, P ROY SOC B-BIOL SCI, V266, P813; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Koella JC, 2000, P ROY SOC B-BIOL SCI, V267, P1979, DOI 10.1098/rspb.2000.1239; Kokko H, 1996, P ROY SOC B-BIOL SCI, V263, P919, DOI 10.1098/rspb.1996.0136; Komdeur J, 1999, TRENDS ECOL EVOL, V14, P237, DOI 10.1016/S0169-5347(98)01573-0; Le Galliard JF, 2003, EVOLUTION, V57, P1; Petrie M, 1999, NATURE, V401, P155, DOI 10.1038/43651; PFENNIG DW, 1993, NATURE, V362, P836, DOI 10.1038/362836a0; PFENNIG DW, 1993, ANIM BEHAV, V46, P87, DOI 10.1006/anbe.1993.1164; Rieseberg LH, 1996, SCIENCE, V272, P741, DOI 10.1126/science.272.5262.741; Riolo RL, 2001, NATURE, V414, P441, DOI 10.1038/35106555; SHERMAN PW, 1997, COOPERATIVE BREEDING, P267; Sinervo A, 2001, J HERED, V92, P198, DOI 10.1093/jhered/92.2.198; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Sinervo B, 2000, HORM BEHAV, V38, P222, DOI 10.1006/hbeh.2000.1622; Sinervo B, 2001, GENETICA, V112, P417, DOI 10.1023/A:1013360426789; Sinervo B, 2001, EVOLUTION, V55, P2040; Sinervo B, 2000, NATURE, V406, P985, DOI 10.1038/35023149; Sinervo B, 2000, ADAPTIVE GENETIC VARIATION IN THE WILD, P41; Svensson E, 2001, P NATL ACAD SCI USA, V98, P12561, DOI 10.1073/pnas.211071298; Svensson E, 2001, EVOLUTION, V55, P2053; WESTEBERHARD MJ, 1989, ANNU REV ECOL SYST, V20, P249, DOI 10.1146/annurev.es.20.110189.001341; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125; Zamudio KR, 2000, P NATL ACAD SCI USA, V97, P14427, DOI 10.1073/pnas.011544998	29	124	127	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1949	1951		10.1126/science.1083109	http://dx.doi.org/10.1126/science.1083109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817150				2022-12-28	WOS:000183619400048
J	Aspelmeyer, M; Bohm, HR; Gyatso, T; Jennewein, T; Kaltenbaek, R; Lindenthal, M; Molina-Terriza, G; Poppe, A; Resch, K; Taraba, M; Ursin, R; Walther, P; Zeilinger, A				Aspelmeyer, M; Bohm, HR; Gyatso, T; Jennewein, T; Kaltenbaek, R; Lindenthal, M; Molina-Terriza, G; Poppe, A; Resch, K; Taraba, M; Ursin, R; Walther, P; Zeilinger, A			Long-distance free-space distribution of quantum entanglement	SCIENCE			English	Article							KEY DISTRIBUTION; CRYPTOGRAPHY; VIOLATION; INEQUALITY; PHOTONS	We demonstrate the distribution of quantum entanglement via optical free-space links to independent receivers separated by 600 m, with no line of sight between each other. A Bell inequality between those receivers is violated by more than four standard deviations, confirming the quality of the entanglement. This outdoor experiment represents a step toward satellite-based distributed quantum entanglement.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria	University of Vienna	Aspelmeyer, M (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	markus.aspelmeyer@quantum.at; zeilingeroffice@quantum.at	Molina-Terriza, Gabriel/L-5687-2017; Ursin, Rupert/E-9548-2012; Terriza, Gabriel Molina/B-4761-2010; Aspelmeyer, Markus/C-4098-2017; Zeilinger, Anton/A-1170-2011; Walther, Philip/O-2993-2019; Walther, Philip/D-6346-2018; Kaltenbaek, Rainer/C-8141-2015	Molina-Terriza, Gabriel/0000-0002-7905-4938; Ursin, Rupert/0000-0002-9403-269X; Aspelmeyer, Markus/0000-0003-4499-7335; Walther, Philip/0000-0002-4964-817X; Walther, Philip/0000-0002-4964-817X; Kaltenbaek, Rainer/0000-0002-9991-9919				ASPELMEYER M, 1635802 EUR SPAC AG; Bell JS., 1964, PHYS, V1, P195, DOI [10.1103/PhysicsPhysiqueFizika.1.195, 10.1103/Physics-PhysiqueFizika.1.195, DOI 10.1103/PHYSICSPHYSIQUEFIZIKA.1.195]; BENNETT CH, 1992, PHYS REV LETT, V68, P557, DOI 10.1103/PhysRevLett.68.557; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Buttler WT, 1998, PHYS REV LETT, V81, P3283, DOI 10.1103/PhysRevLett.81.3283; EKERT AK, 1991, PHYS REV LETT, V67, P661, DOI 10.1103/PhysRevLett.67.661; Fuchs CA, 1997, PHYS REV A, V56, P1163, DOI 10.1103/PhysRevA.56.1163; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; Horvath H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001472; Hughes RJ, 2002, NEW J PHYS, V4, DOI 10.1088/1367-2630/4/1/343; Jennewein T, 2000, PHYS REV LETT, V84, P4729, DOI 10.1103/PhysRevLett.84.4729; Kurtsiefer C, 2002, NATURE, V419, P450, DOI 10.1038/419450a; Kurtsiefer C, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.023802; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Nordholt JE, 2002, PROC SPIE, V4635, P116, DOI 10.1117/12.464085; Rarity JG, 2002, NEW J PHYS, V4, DOI 10.1088/1367-2630/4/1/382; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; TAPSTER PR, 1994, PHYS REV LETT, V73, P1923, DOI 10.1103/PhysRevLett.73.1923; Tittel W, 1998, PHYS REV LETT, V81, P3563, DOI 10.1103/PhysRevLett.81.3563; Waks E, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.052310; Weihs G, 1998, PHYS REV LETT, V81, P5039, DOI 10.1103/PhysRevLett.81.5039; [No title captured]	23	165	178	4	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	2003	301	5633					621	623		10.1126/science.1085593	http://dx.doi.org/10.1126/science.1085593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	706UN	12817085				2022-12-28	WOS:000184473600032
J	Taylor, JRA; Kier, WM				Taylor, JRA; Kier, WM			Switching skeletons: Hydrostatic support in molting crabs	SCIENCE			English	Article							HOMARUS-AMERICANUS; CYCLE; CRUSTACEAN; LOBSTER; MUSCLE; BEHAVIOR	Skeletal support systems are essential for support, movement, muscular antagonism, and locomotion. Crustaceans shed their rigid exoskeleton at each molt yet are still capable of forceful movement. We hypothesize that the soft water-inflated body of newly molted crabs may rely on a hydrostatic skeleton, similar to that of worms and polyps. We measured internal hydrostatic pressure and the force exerted during claw adduction and observed a strong correlation between force and hydrostatic pressure, consistent with hydrostatic skeletal support. This alternation between the two basic skeletal types may be widespread among arthropods.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Taylor, JRA (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.							ADAMS ES, 1990, ANIM BEHAV, V39, P706, DOI 10.1016/S0003-3472(05)80382-3; Alexander R., 1983, ANIMAL MECH; CHAPMAN G, 1975, J EXP ZOOL, V194, P249, DOI 10.1002/jez.1401940118; CHAPMAN G, 1958, BIOL REV, V33, P338, DOI 10.1111/j.1469-185X.1958.tb01260.x; Clark R. B., 1964, DYNAMICS METAZOAN EV; CLARK RB, 1958, J EXP BIOL, V35, P731; CROMARTY SI, 1991, J EXP BIOL, V158, P565; Drach P., 1939, Ann Inst oceanogr Paris, V19, P103; GUTMANN WF, 1981, AM ZOOL, V21, P63; HARRIS JE, 1957, J EXP BIOL, V34, P116; Kelly DA, 1999, J EXP BIOL, V202, P253; LIPCIUS RN, 1982, MAR BIOL, V68, P241, DOI 10.1007/BF00409591; MYKLES DL, 1981, J ULTRA MOL STRUCT R, V75, P314, DOI 10.1016/S0022-5320(81)80088-3; MYKLES DL, 1980, J EXP BIOL, V84, P89; Olmsted JMD, 1923, J MORPHOL, V38, P279, DOI 10.1002/jmor.1050380203; Passano L., 1960, PHYSIOL CRUSTACEA, P473, DOI DOI 10.1016/B978-0-12-395628-6.50021-X; REAKA ML, 1975, J MORPHOL, V146, P55, DOI 10.1002/jmor.1051460104; Ryer CH, 1997, MAR ECOL PROG SER, V147, P77, DOI 10.3354/meps147077; Schmidt-Nielsen K., 1997, ANIMAL PHYSL; SHAFER GD, 1923, STANFORD U PUBL, V3, P303; SKINNER D M, 1985, P43; SKINNER DM, 1966, J EXP ZOOL, V163, P115, DOI 10.1002/jez.1401630202; SMITH KK, 1989, AM SCI, V77, P29; STEGER R, 1983, SCIENCE, V221, P558, DOI 10.1126/science.221.4610.558; TAMM GR, 1978, SCIENCE, V200, P79, DOI 10.1126/science.200.4337.79; TAYLOR JD, UNPUB; TRAVIS DF, 1954, BIOL BULL, V107, P433, DOI 10.2307/1538591; Trueman E. R., 1975, LOCOMOTION SOFT BODI; Wainwright S.A., 1982, MECH DESIGN ORGANISM; Wainwright SA., 1982, COMPANION ANIMAL PHY, P325	30	42	42	4	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					209	210		10.1126/science.1085987	http://dx.doi.org/10.1126/science.1085987			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855806				2022-12-28	WOS:000184056200041
J	Bick, RL				Bick, RL			Cancer-associated thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, SW Med Sch, Dallas Thrombosis Hemostasis Clin Ctr, Dallas, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bick, RL (corresponding author), Univ Texas, SW Med Sch, Dallas Thrombosis Hemostasis Clin Ctr, Dallas, TX 75230 USA.							Dolovich LR, 2000, ARCH INTERN MED, V160, P181, DOI 10.1001/archinte.160.2.181	1	216	228	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					109	111		10.1056/NEJMp030086	http://dx.doi.org/10.1056/NEJMp030086			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853582				2022-12-28	WOS:000184024400002
J	Gregg, JW; Jones, CG; Dawson, TE				Gregg, JW; Jones, CG; Dawson, TE			Urbanization effects on tree growth in the vicinity of New York City	NATURE			English	Article							ATMOSPHERIC DEPOSITION; RURAL GRADIENT; URBAN; OZONE; POPULUS; FORESTS; AREAS; CO2	Plants in urban ecosystems are exposed to many pollutants and higher temperatures, CO2 and nitrogen deposition than plants in rural areas(1-5). Although each factor has a detrimental or beneficial influence on plant growth(6), the net effect of all factors and the key driving variables are unknown. We grew the same cottonwood clone in urban and rural sites and found that urban plant biomass was double that of rural sites. Using soil transplants, nutrient budgets, chamber experiments and multiple regression analyses, we show that soils, temperature, CO2, nutrient deposition, urban air pollutants and microclimatic variables could not account for increased growth in the city. Rather, higher rural ozone (O-3) exposures reduced growth at rural sites. Urban precursors fuel the reactions of O-3 formation, but NOx scavenging reactions(7) resulted in lower cumulative urban O-3 exposures compared to agricultural and forested sites throughout the northeastern USA. Our study shows the overriding effect of O-3 despite a diversity of altered environmental factors, reveals 'footprints' of lower cumulative urban O-3 exposures amidst a background of higher regional exposures, and shows a greater adverse effect of urban pollutant emissions beyond the urban core.	Cornell Univ, Ithaca, NY 14853 USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA	Cornell University; Cary Institute of Ecosystem Studies	Gregg, JW (corresponding author), Cornell Univ, Ithaca, NY 14853 USA.		Jones, Clive G/I-4603-2014	Jones, Clive G/0000-0001-7630-7285				COLEMAN JS, 1988, OECOLOGIA, V76, P57, DOI 10.1007/BF00379600; *FED LAND MAN AIR, 2000, PHAS 1 REP; Freedman B., 1995, ENV ECOLOGY ECOLOGIC; GATZ DF, 1991, ATMOS ENVIRON B-URB, V25, P1, DOI 10.1016/0957-1272(91)90036-E; GOLDMAN MB, 1995, SOIL BIOL BIOCHEM, V27, P281, DOI 10.1016/0038-0717(94)00185-4; GREGG JW, 1999, THESIS CORNELL U; *I EC STUD, 2002, ENV MON PROGR; Idso CD, 2001, ATMOS ENVIRON, V35, P995, DOI 10.1016/S1352-2310(00)00412-X; ISAKSEN ISA, 1978, ENVIRON SCI TECHNOL, V12, P1279, DOI 10.1021/es60147a011; Jacovides CP, 1997, AGR FOREST METEOROL, V87, P91, DOI 10.1016/S0168-1923(97)00031-2; Jones H, 1996, PLANTS MICROCLIMATE; LEFOHN AS, 1987, JAPCA J AIR WASTE MA, V37, P595, DOI 10.1080/08940630.1987.10466247; Lovett GM, 2000, ENVIRON SCI TECHNOL, V34, P4294, DOI 10.1021/es001077q; LOVETT GM, 1993, CAN J FOREST RES, V23, P1603, DOI 10.1139/x93-200; MAGNUSSEN S, 1985, Forest Tree Improvement, P1; Mooney H.A., 1991, RESPONSE PLANTS MULT, DOI [10.1016/C2009-0-02664-6, DOI 10.1016/C2009-0-02664-6]; *NEW YORK STAT DEP, 1995, DAR951 NYS DEC; PETERSON JT, 1969, NAPCA PUB; Pickett STA, 2001, ANNU REV ECOL SYST, V32, P127, DOI 10.1146/annurev.ecolsys.32.081501.114012; Potvin C, 1988, FUNCT ECOL, V2, P123, DOI 10.2307/2389472; POUYAT RV, 1995, J ENVIRON QUAL, V24, P516, DOI 10.2134/jeq1995.00472425002400030019x; *US NAT RES COUNC, 1992, RETH OZ PROBL URB RE; *USDA FOR SERV, 1980, A134224C82 USDA FOR; *USDA FOR SERV FIA, 2002, FIELD METH PHAS 3 ME; Wait DA, 1999, OECOLOGIA, V121, P193, DOI 10.1007/s004420050921; Wait DA, 1996, TREE PHYSIOL, V16, P359; WEINSTEIN LH, 1990, USE NATIVE CULTIVATE, P117; Yun SC, 1999, NEW PHYTOL, V141, P411, DOI 10.1046/j.1469-8137.1999.00359.x; [No title captured]	29	275	309	20	260	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					183	187		10.1038/nature01728	http://dx.doi.org/10.1038/nature01728			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853954				2022-12-28	WOS:000184032700039
J	Levine, M; Tjian, R				Levine, M; Tjian, R			Transcription regulation and animal diversity	NATURE			English	Review							RNA-POLYMERASE-II; BETA-GLOBIN GENE; ENHANCER-PROMOTER SPECIFICITY; TBP-LIKE FACTOR; DROSOPHILA EMBRYO; DEVELOPMENTAL REGULATION; MEDIATOR COMPLEXES; NUCLEAR RECEPTORS; COFACTOR COMPLEX; BINDING-SITE	Whole-genome sequence assemblies are now available for seven different animals, including nematode worms, mice and humans. Comparative genome analyses reveal a surprising constancy in genetic content: vertebrate genomes have only about twice the number of genes that invertebrate genomes have, and the increase is primarily due to the duplication of existing genes rather than the invention of new ones. How, then, has evolutionary diversity arisen? Emerging evidence suggests that organismal complexity arises from progressively more elaborate regulation of gene expression.	Univ Calif Berkeley, Ctr Integrat Genom, Dept Mol & Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Tjian, R (corresponding author), Univ Calif Berkeley, Ctr Integrat Genom, Dept Mol & Cell Biol, Div Genet & Dev, 401 Barker Hall, Berkeley, CA 94720 USA.	mlevine@uclink4.berkeley.edu; jmlim@uclink4.berkeley.edu		Levine, Michael/0000-0001-7629-0081				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Aoyagi N, 2000, J CELL BIOL, V150, pF45, DOI 10.1083/jcb.150.2.F45; Baltimore D, 2001, NATURE, V409, P814, DOI 10.1038/35057267; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Calhoun VC, 2002, P NATL ACAD SCI USA, V99, P9243, DOI 10.1073/pnas.142291299; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; Davidson E. H., 2001, DEV EVOLUTION; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DiLeone RJ, 1998, GENETICS, V148, P401; DiMattia GE, 1997, DEV BIOL, V182, P180, DOI 10.1006/dbio.1996.8472; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Fujioka M, 1999, DEVELOPMENT, V126, P2527; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Halfon MS, 2002, GENOME RES, V12, P1019, DOI 10.1101/gr.228902; Harafuji N, 2002, P NATL ACAD SCI USA, V99, P6802, DOI 10.1073/pnas.052024999; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Merli C, 1996, GENE DEV, V10, P1260, DOI 10.1101/gad.10.10.1260; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ohtsuki S, 1998, GENE DEV, V12, P547, DOI 10.1101/gad.12.4.547; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; REBEIZ M, IN PRESS P NATL ACAD; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SMALE ST, IN PRESS ANN REV BIO; SMALL S, 1993, DEVELOPMENT, V119, P767; Struhl K, 1998, COLD SPRING HARB SYM, V63, P413, DOI 10.1101/sqb.1998.63.413; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Vesque C, 1996, EMBO J, V15, P5383, DOI 10.1002/j.1460-2075.1996.tb00922.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Wyrick JJ, 2002, CURR OPIN GENET DEV, V12, P130, DOI 10.1016/S0959-437X(02)00277-0; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	74	873	906	2	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					147	151		10.1038/nature01763	http://dx.doi.org/10.1038/nature01763			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853946				2022-12-28	WOS:000184032700031
J	Jose, J; Coatesworth, AP; Anthony, R; Reilly, PG				Jose, J; Coatesworth, AP; Anthony, R; Reilly, PG			Lesson of the week - Life threatening complications after partially treated mastoiditis	BRITISH MEDICAL JOURNAL			English	Review							LATERAL SINUS THROMBOSIS		Gen Infirm, Dept Otolaryngol, Leeds LS1 3EX, W Yorkshire, England; York Hosp, Dept Otolaryngol, York YO31 8HE, N Yorkshire, England	Leeds General Infirmary	Jose, J (corresponding author), 109 Ainsty Rd, Wetherby LS22 7FY, England.							BEZOLD F, 1881, DEUT MED WOCHENSCHR, V28, P381; GAFFNEY RJ, 1991, J LARYNGOL OTOL, V105, P765, DOI 10.1017/S0022215100117256; IRVING RM, 1991, J LARYNGOL OTOL, V105, P693, DOI 10.1017/S0022215100117050; Ludman H, 1997, SCOTTBROWNS OTOLARYN, V3, P1; Mygind H, 1910, ANN OTO RHINOL LARYN, V19, P259; OCONNELL JE, 1990, J LARYNGOL OTOL, V104, P949, DOI 10.1017/S0022215100114458; OYARZABAL MF, 1992, J LARYNGOL OTOL, V106, P535, DOI 10.1017/S0022215100120079; PALVA T, 1959, J Laryngol Otol, V73, P573, DOI 10.1017/S0022215100055742; PEARSON CR, 1994, J LARYNGOL OTOL, V108, P779, DOI 10.1017/S0022215100128105; Samaha M, 2001, J OTOLARYNGOL, V30, P250	10	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					41	42		10.1136/bmj.327.7405.41	http://dx.doi.org/10.1136/bmj.327.7405.41			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842957	Green Published			2022-12-28	WOS:000184062700027
J	Chew, MK; Laubichler, MD				Chew, MK; Laubichler, MD			Natural enemies - Metaphor or misconception?	SCIENCE			English	Editorial Material									Arizona State Univ, Sch Life Sci, Biol & Soc Program, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Laubichler, MD (corresponding author), Arizona State Univ, Sch Life Sci, Biol & Soc Program, Tempe, AZ 85287 USA.							Baumer A., 1990, NS BIOL; Huslin Anita, 2002, WASHINGTON POST 0723, pB03; Kevles D., 1985, NAME EUGENICS; Lakof G., 1980, METAPHORS WE LIVE; Lewontin R.C., 1984, NOT OUR GENES BIOL I; Paul Diane B., 1995, CONTROLLING HUMAN HE; Weindling P, 1989, HLTH RACE GERMAN POL; 1935, HORNADAYS AM NATURAL; 2002, NATURE, V418, P267; 2002, SCIENCE, V297, P2175	10	69	69	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					52	53		10.1126/science.1085274	http://dx.doi.org/10.1126/science.1085274			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12846231				2022-12-28	WOS:000183914700024
J	Merza, Z; Edwards, N; Walters, SJ; Newell-Price, J; Ross, RJM				Merza, Z; Edwards, N; Walters, SJ; Newell-Price, J; Ross, RJM			Patients with chronic pain and abnormal pituitary function require investigation	LANCET			English	Article							HEROIN-ADDICTION	Misuse of opioids is associated with abnormalities of pituitary function. Patients with chronic pain frequently complain of fatigue and undergo endocrine testing. To test whether oral opioid treatment causes abnormal pituitary function we prospectively assessed pituitary function in 37 patients with chronic pain who were receiving either oral opioid analgesia or non-opioid analgesia. Oral opioid treatment was not associated with abnormal pituitary function although a few patients had abnormal results mainly related to obesity. Our results suggest that patients with chronic pain who have abnormal endocrine results should have a complete assessment, since abnormal test results cannot be attributed to their analgesia.	Univ Sheffield, No Gen Hosp, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Sch Hlth & Related Res, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield; University of Sheffield	Ross, RJM (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England.		Ross, Richard/B-2672-2012	Ross, Richard/0000-0001-9222-9678; Walters, Stephen/0000-0001-9000-8126				Abs R, 2000, J CLIN ENDOCR METAB, V85, P2215, DOI 10.1210/jc.85.6.2215; BOLELLI G, 1979, TOXICOLOGY, V15, P19, DOI 10.1016/0300-483X(79)90016-7; CELANI MF, 1984, PHARMACOL RES COMMUN, V16, P1193, DOI 10.1016/S0031-6989(84)80084-3; Cleare AJ, 1999, LANCET, V353, P455, DOI 10.1016/S0140-6736(98)04074-4; CUSHMAN P, 1972, J CLIN ENDOCR METAB, V35, P352, DOI 10.1210/jcem-35-3-352	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2203	2204		10.1016/S0140-6736(03)13775-0	http://dx.doi.org/10.1016/S0140-6736(03)13775-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842375				2022-12-28	WOS:000183815600014
J	Johnson, CL; Constable, CG; Tauxe, L				Johnson, CL; Constable, CG; Tauxe, L			Mapping long-term changes in Earth's magnetic field	SCIENCE			English	Editorial Material							GEOMAGNETIC-FIELD; ODP SITE-983; PALEOINTENSITY; INTENSITY; KA		Univ Calif San Diego, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA; Univ Calif San Diego, Geosci Res Div, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Johnson, CL (corresponding author), Univ Calif San Diego, Inst Geophys & Planetary Phys, La Jolla, CA 92093 USA.		Constable, Catherine G/F-7784-2010	Constable, Catherine G/0000-0003-4534-4977				Channell JET, 1999, J GEOPHYS RES-SOL EA, V104, P22937, DOI 10.1029/1999JB900223; Constable CG, 2000, PHILOS T R SOC A, V358, P991, DOI 10.1098/rsta.2000.0570; Finlay CC, 2003, SCIENCE, V300, P2084, DOI 10.1126/science.1083324; GUBBINS D, 1993, NATURE, V365, P829, DOI 10.1038/365829a0; Guyodo Y, 2000, EARTH PLANET SC LETT, V184, P109, DOI 10.1016/S0012-821X(00)00313-7; Guyodo Y, 1999, NATURE, V399, P249, DOI 10.1038/20420; Hill MJ, 2002, GEOPHYS J INT, V151, P157, DOI 10.1046/j.1365-246X.2002.01745.x; Johnson CL, 1997, GEOPHYS J INT, V131, P643, DOI 10.1111/j.1365-246X.1997.tb06604.x; McMillan DG, 2002, EARTH PLANET SC LETT, V201, P509, DOI 10.1016/S0012-821X(02)00747-1; Stoner JS, 2002, QUATERNARY SCI REV, V21, P1141, DOI 10.1016/S0277-3791(01)00136-6; TAUXE L, 2003, GEOL GEOCHEM GEOSYST, V4; Thellier O., 1959, ANN GEOPHYS-ITALY, V15, P285; VALET JP, 1993, NATURE, V366, P234, DOI 10.1038/366234a0	13	15	16	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2044	2045		10.1126/science.1082007	http://dx.doi.org/10.1126/science.1082007			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829772				2022-12-28	WOS:000183774900032
J	Munk, W				Munk, W			Ocean freshening, sea level rising	SCIENCE			English	Editorial Material									Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Munk, W (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							ANTONOV JI, 2002, J GEOPHYS RES, V107; Cabanes C, 2001, SCIENCE, V294, P840, DOI 10.1126/science.1063556; CAZENAVE A, 2002, WOCE SAN ANT TX 21 N; Chambers DP, 2000, GEOPHYS RES LETT, V27, P3073, DOI 10.1029/2000GL011595; Douglas B.C., 2001, SEA LEVEL RISE HIST; Houghton J. T., 2001, CLIMATE CHANGE 2001; JOHANNESSEN OM, 2003, 218 NANS; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; MILLER L, 2003, EGS AGU EUG JOINT AS; Munk W, 2002, P NATL ACAD SCI USA, V99, P6550, DOI 10.1073/pnas.092704599; Nagurny A.P., 1999, METEOROL HYDROL, V3, P72; Wadhams P., 2000, ICE OCEAN, DOI [10.1201/9781482283082, DOI 10.1201/9781482283082]; [No title captured]	14	86	91	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2041	2043		10.1126/science.1085534	http://dx.doi.org/10.1126/science.1085534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829770				2022-12-28	WOS:000183774900030
J	Polesskaya, A; Seale, P; Rudnicki, MA				Polesskaya, A; Seale, P; Rudnicki, MA			Wnt signaling induces the myogenic specification of resident CD45(+) adult stem cells during muscle regeneration	CELL			English	Article							MURINE SKELETAL-MUSCLE; PARAXIAL MESODERM; PROGENITOR CELLS; SATELLITE CELLS; SONIC HEDGEHOG; BETA-CATENIN; IN-VITRO; EXPRESSION; MYOD; PATHWAY	The observation that CD45(+) stem cells injected into the circulation participate in muscle regeneration raised the question of whether CD45(+) stem cells resident in muscle play a physiological role during regeneration. We found that CD45(+) cells cultured from uninjured muscle were uniformly nonmyogenic. However, CD45(+) cells purified from regenerating muscle readily gave rise to determined myoblasts. The number of CD45(+) cells in muscle rapidly expanded following injury, and a high proportion entered the cell cycle. Investigation of candidate pathways involved in embryonic myogenesis revealed that Wnt signaling was sufficient to induce the myogenic specification of muscle-derived CD45(+) stem cells. Moreover, injection of the Wnt antagonists sFRP2/3 into regenerating muscle markedly reduced CD45(+) stem cell proliferation and myogenic specification. Our data therefore suggest that mobilization of resident CD45(+) stem cells is an important factor in regeneration after injury and highlight the Wnt pathway as a potential therapeutic target for degenerative neuromuscular disease.	Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	University of Ottawa; Ottawa Hospital Research Institute; McMaster University	Rudnicki, MA (corresponding author), Ottawa Hlth Res Inst, Program Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.			Rudnicki, Michael/0000-0002-3866-5249				Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Baranski M, 2000, DEV BIOL, V217, P25, DOI 10.1006/dbio.1999.9516; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; Borello U, 1999, DEVELOPMENT, V126, P4247; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Davies JA, 2002, EXP NEPHROL, V10, P102; Dell'Agnola C, 2002, EXP HEMATOL, V30, P905, DOI 10.1016/S0301-472X(02)00866-4; Dennis S, 1999, J CELL SCI, V112, P3815; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Heslop L, 2000, J CELL SCI, V113, P2299; Hirsinger E, 1997, DEVELOPMENT, V124, P4605; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Howell JC, 2002, EXP HEMATOL, V30, P915, DOI 10.1016/S0301-472X(02)00872-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kablar B, 1997, DEVELOPMENT, V124, P4729; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Labus Marie B., 1998, Wound Repair and Regeneration, V6, P58, DOI 10.1046/j.1524-475X.1998.60109.x; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Levin JM, 2001, J MUSCLE RES CELL M, V22, P361, DOI 10.1023/A:1013129209062; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Mahmud N, 2002, EXP HEMATOL, V30, P925, DOI 10.1016/S0301-472X(02)00863-9; Malik TH, 2000, BIOCHEM J, V349, P829, DOI 10.1042/bj3490829; Marcelle C, 1997, DEVELOPMENT, V124, P3955; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Pagel CN, 1999, J NEUROL SCI, V164, P103, DOI 10.1016/S0022-510X(99)00061-1; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1045>3.3.CO;2-3; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Reshef R, 1998, GENE DEV, V12, P290, DOI 10.1101/gad.12.3.290; Romero-Ramos M, 2002, J NEUROSCI RES, V69, P894, DOI 10.1002/jnr.10374; ROSENBLATT JD, 1995, IN VITRO CELL DEV-AN, V31, P773; Sasaki T, 2001, INT J BIOCHEM CELL B, V33, P1041, DOI 10.1016/S1357-2725(01)00075-9; Schmidt M, 2000, DEVELOPMENT, V127, P4105; SCHULTZ E, 1986, J MUSCLE RES CELL M, V7, P361, DOI 10.1007/BF01753657; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Vainio SJ, 2000, PEDIATR NEPHROL, V15, P151, DOI 10.1007/s004670000404; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; WAKEFORD S, 1991, MUSCLE NERVE, V14, P42, DOI 10.1002/mus.880140108; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhao P, 2002, J BIOL CHEM, V277, P30091, DOI 10.1074/jbc.M202668200	59	389	415	0	28	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					841	852		10.1016/S0092-8674(03)00437-9	http://dx.doi.org/10.1016/S0092-8674(03)00437-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837243	Bronze			2022-12-28	WOS:000183817900009
J	Jokat, W; Ritzmann, O; Schmidt-Aursch, MC; Drachev, S; Gauger, S; Snow, J				Jokat, W; Ritzmann, O; Schmidt-Aursch, MC; Drachev, S; Gauger, S; Snow, J			Geophysical evidence for reduced melt production on the Arctic ultraslow Gakkel mid-ocean ridge	NATURE			English	Article							CRUSTAL THICKNESS; SPREADING RATE; REFRACTION; INVERSION; BASIN	Most models of melt generation beneath mid-ocean ridges(1-3) predict significant reduction of melt production at ultraslow spreading rates ( full spreading rates < 20 mm yr(-1)) and consequently they predict thinned oceanic crust. The 1,800-km-long Arctic Gakkel mid-ocean ridge is an ideal location to test such models, as it is by far the slowest portion of the global mid-ocean-ridge spreading system, with a full spreading rate ranging from 6 to 13 mm yr(-1) ( refs 4, 5). Furthermore, in contrast to some other ridge systems, the spreading direction on the Gakkel ridge is not oblique and the rift valley is not offset by major transform faults. Here we present seismic evidence for the presence of exceptionally thin crust along the Gakkel ridge rift valley with crustal thicknesses varying between 1.9 and 3.3km ( compared to the more usual value of 7 km found on medium- to fast-spreading mid-ocean ridges). Almost 8,300 km of closely spaced aeromagnetic profiles across the rift valley show the presence of discrete volcanic centres along the ridge, which we interpret as evidence for strongly focused, three-dimensional magma supply. The traces of these eruptive centres can be followed to crustal ages of &SIM;25 Myr off-axis, implying that these magma production and transport systems have been stable over this timescale.	Alfred Wegener Inst Polar & Marine Res, D-27568 Bremerhaven, Germany; VNIIOkeangeol, St Petersburg 190121, Russia; Max Planck Inst Chem, D-55020 Mainz, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Max Planck Society	Jokat, W (corresponding author), Alfred Wegener Inst Polar & Marine Res, Columbusstr, D-27568 Bremerhaven, Germany.		Snow, Jonathan/E-5591-2011; Drachev, Sergey/M-2289-2018; Drachev, Sergey/AAB-6528-2019	Drachev, Sergey/0000-0002-4927-1819; Drachev, Sergey/0000-0002-4927-1819; Schmidt-Aursch, Mechita/0000-0002-2393-4514; Jokat, Wilfried/0000-0002-7793-5854				BOWN JW, 1994, EARTH PLANET SC LETT, V121, P435, DOI 10.1016/0012-821X(94)90082-5; Coakley BJ, 1998, EARTH PLANET SC LETT, V162, P81, DOI 10.1016/S0012-821X(98)00158-7; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; DUCKWORTH GL, 1985, TECTONOPHYSICS, V114, P55, DOI 10.1016/0040-1951(85)90007-1; JACKSON HR, 1982, J GEOPHYS RES, V87, P1773, DOI 10.1029/JB087iB03p01773; JACKSON HR, 1990, GEOLOGY N AM, V50, P153; Jakobsson M., 2000, EOS T AM GEOPHYS UN, V81, P89, DOI [DOI 10.1029/00EO00059, DOI 10.1130/G32153.1]; JOKAT W, 2002, REPORTS POLAR MARINE, V421, P165; KARASIK AM, 1974, NAUCHNO ISSLEDOVATEL, P23; Klingelhofer F, 2000, GEOPHYS J INT, V141, P509, DOI 10.1046/j.1365-246x.2000.00098.x; KRISTOFFERSEN Y, 1982, TECTONOPHYSICS, V82, P57, DOI 10.1016/0040-1951(82)90088-9; Michael PJ, 2003, NATURE, V423, P956, DOI 10.1038/nature01704; Muller MR, 1999, GEOLOGY, V27, P867, DOI 10.1130/0091-7613(1999)027<0867:SAMSAT>2.3.CO;2; REID I, 1981, MAR GEOPHYS RES, V5, P165; SU WS, 1994, J GEOPHYS RES-SOL EA, V99, P3215, DOI 10.1029/93JB02965; VOGT PR, 1979, J GEOPHYS RES, V84, P1071, DOI 10.1029/JB084iB03p01071; Weigelt E, 2001, GEOPHYS J INT, V145, P505, DOI 10.1046/j.1365-246X.2001.00398.x; White RS, 2001, J PETROL, V42, P1171, DOI 10.1093/petrology/42.6.1171; ZELT CA, 1992, GEOPHYS J INT, V108, P16, DOI 10.1111/j.1365-246X.1992.tb00836.x	19	132	139	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					962	965		10.1038/nature01706	http://dx.doi.org/10.1038/nature01706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827194				2022-12-28	WOS:000183753900042
J	Caulfield, M; Munroe, P; Pembroke, J; Samani, N; Dominiczak, A; Brown, M; Benjamin, N; Webster, J; Ratcliffe, P; O'Shea, S; Papp, J; Taylor, E; Dobson, R; Knight, J; Newhouse, S; Hooper, J; Lee, W; Brain, N; Clayton, D; Lathrop, GM; Farrall, M; Connell, J				Caulfield, M; Munroe, P; Pembroke, J; Samani, N; Dominiczak, A; Brown, M; Benjamin, N; Webster, J; Ratcliffe, P; O'Shea, S; Papp, J; Taylor, E; Dobson, R; Knight, J; Newhouse, S; Hooper, J; Lee, W; Brain, N; Clayton, D; Lathrop, GM; Farrall, M; Connell, J		MRC Brit Genetics Hypertension Stu	Genome-wide mapping of human loci for essential hypertension	LANCET			English	Article							SIB-PAIR LINKAGE; MATERNAL SUSCEPTIBILITY LOCUS; BLOOD-PRESSURE; COMPLEX TRAITS; SCANS; PREECLAMPSIA; CHROMOSOME-2	Background Blood pressure may contribute to 50% of the global cardiovascular disease epidemic. By understanding the genes predisposing to common disorders such as human essential hypertension we may gain insights into novel pathophysiological mechanisms and potential therapeutic targets. In the Medical Research Council BRItish Genetics of HyperTension (BRIGHT) study, we aim to identify these genetic factors by scanning the human genome for susceptibility genes for essential hypertension. We describe the results of a genome scan for hypertension in a large white European population. Methods We phenotyped 2010 affected sibling pairs drawn from 1599 severely hypertensive families, and completed a 10 centimorgan genome-wide scan. After rigorous quality control, we analysed the genotypic data by non-parametric linkage, which tests whether genes are shared in excess among the affected sibling pairs. Lod scores, calculated at regular points along each chromosome, were used to assess the support for linkage, Findings Linkage analysis identified a principle locus on chromosome 6q, with a lod score of 3.21 that attained genome-wide significance (p=0.042). The inclusion of three further loci with lod scores higher than 1.57 (2q, 5q, and 9q) also show genome-wide significance (p=0.017) when assessed under a locus-counting analysis. Interpretation These findings imply that human essential hypertension has an oligogenic element (a few genes may be involved in determination of the trait) possibly superimposed on more minor genetic effects, and that several genes may be tractable to a positional cloning strategy.	Queen Marys Sch Med, Barts & London, William Harvey Res Inst, Barts & London Genome Ctr, London EC1M 6BQ, England; Univ Leicester, Glenfield Hosp, Leicester, Leics, England; Univ Glasgow, Western Infirm, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Clin Med, Oxford, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford, England; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Ctr Natl Genotypage, Evry, France	University of London; Queen Mary University London; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Glasgow; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Aberdeen; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Wellcome Centre for Human Genetics; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Caulfield, M (corresponding author), Queen Marys Sch Med, Barts & London, William Harvey Res Inst, Barts & London Genome Ctr, Charterhouse Sq, London EC1M 6BQ, England.		Dominiczak, Anna F/P-9390-2017; Dobson, Richard j/C-9269-2011; Brown, Matthew A/E-5749-2010; Knight, Jo/F-4946-2011; Newhouse, Stephen J/C-9330-2011; Dominiczak, Anna F/D-2262-2009	Dominiczak, Anna F/0000-0003-4913-3608; Dobson, Richard j/0000-0003-4224-9245; Brown, Matthew A/0000-0003-0538-8211; Newhouse, Stephen J/0000-0002-1843-9842; Caulfield, Mark/0000-0001-9295-3594; Lee, Wai Kwong/0000-0001-8560-8063; Ratcliffe, Peter/0000-0002-2853-806X; Knight, Joanne/0000-0002-7148-1660; Munroe, Patricia/0000-0002-4176-2947				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069; Arngrimsson R, 1999, HUM MOL GENET, V8, P1799, DOI 10.1093/hmg/8.9.1799; Boehnke M, 1997, AM J HUM GENET, V61, P423, DOI 10.1086/514862; Cooper RS, 2002, HYPERTENSION, V40, P629, DOI 10.1161/01.HYP.0000035708.02789.39; HOLMANS P, 1993, AM J HUM GENET, V52, P362; Holmans P, 2002, HUM HERED, V53, P92, DOI 10.1159/000057987; HOLMANS P, 1995, AM J HUM GENET, V57, P1221; Hunt SC, 2002, HYPERTENSION, V40, P1, DOI 10.1161/01.HYP.0000022660.28915.B1; Jacob HJ, 2002, NAT REV GENET, V3, P33, DOI 10.1038/nrg702; Kardia SLR, 2003, AM J HYPERTENS, V16, P154, DOI 10.1016/S0895-7061(02)03249-1; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; Leal SM, 2000, AM J HUM GENET, V66, P567, DOI 10.1086/302748; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Luft FC, 2001, HYPERTENSION, V37, P350, DOI 10.1161/01.HYP.37.2.350; Moses EK, 2000, AM J HUM GENET, V67, P1581, DOI 10.1086/316888; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Perola M, 2000, J HYPERTENS, V18, P1579, DOI 10.1097/00004872-200018110-00008; Province MA, 2003, AM J HYPERTENS, V16, P144, DOI 10.1016/S0895-7061(02)03248-X; Ranade K, 2003, AM J HYPERTENS, V16, P158, DOI 10.1016/S0895-7061(02)03245-4; Rao DC, 2003, AM J HYPERTENS, V16, P148, DOI 10.1016/S0895-7061(02)03247-8; Rice JP, 1999, GENET EPIDEMIOL, V17, pS691; RISCH N, 1990, AM J HUM GENET, V46, P229; Samani NJ, 2003, AM J HYPERTENS, V16, P167, DOI 10.1016/S0895-7061(02)03244-2; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wiltshire S, 2002, AM J HUM GENET, V71, P1175, DOI 10.1086/342976; Zhu DL, 2001, J HYPERTENS, V19, P55, DOI 10.1097/00004872-200101000-00008	27	208	214	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2118	2123		10.1016/S0140-6736(03)13722-1	http://dx.doi.org/10.1016/S0140-6736(03)13722-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826435				2022-12-28	WOS:000183654200011
J	Francis, DP; Salukhe, TV				Francis, DP; Salukhe, TV			Who needs a defibrillator after myocardial infarction?	LANCET			English	Editorial Material							T-WAVE ALTERNANS		Natl Heart & Lung Inst, Heart Failure Unit, London SW3 6NP, England; St Marys Hosp, Dept Cardiol, London W2 1NY, England	Imperial College London; Imperial College London	Francis, DP (corresponding author), Natl Heart & Lung Inst, Heart Failure Unit, Royal Brompton Campus, London SW3 6NP, England.							Gold MR, 2000, J AM COLL CARDIOL, V36, P2247, DOI 10.1016/S0735-1097(00)01017-2; Ikeda T, 2002, AM J CARDIOL, V89, P79, DOI 10.1016/S0002-9149(01)02171-3; Klingenheben T, 2000, LANCET, V356, P651, DOI 10.1016/S0140-6736(00)02609-X; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; ROSENBAUM DS, 1994, NEW ENGL J MED, V330, P235, DOI 10.1056/NEJM199401273300402	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					91	92		10.1016/S0140-6736(03)13892-5	http://dx.doi.org/10.1016/S0140-6736(03)13892-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867104				2022-12-28	WOS:000184089200003
J	Xu, K; Evans, DB; Kawabata, K; Zeramdini, R; Klavus, J; Murray, CJL				Xu, K; Evans, DB; Kawabata, K; Zeramdini, R; Klavus, J; Murray, CJL			Household catastrophic health expenditure: a multicountry analysis	LANCET			English	Article							CARE EXPENDITURES; POLICY; POOR	Background Health policy makers have long been concerned with protecting people from the possibility that ill health will lead to catastrophic financial payments and subsequent impoverishment. Yet catastrophic expenditure is not rare. We investigated the extent of catastrophic health expenditure as a first step to developing appropriate policy responses. Methods We used a cross-country analysis design. Data from household surveys in 59 countries were used to explore, by regression analysis, variables associated with catastrophic health expenditure. We defined expenditure as being catastrophic if a household's financial contributions to the health system exceed 40% of income remaining after subsistence needs have been met. Findings The proportion of households facing catastrophic payments from out-of-pocket health expenses varied widely between countries. Catastrophic spending rates were highest in some countries in transition, and in certain Latin American countries. Three key preconditions for catastrophic payments were identified: the availability of health services requiring payment, low capacity to pay, and the lack of prepayment or health insurance. Interpretation People, particularly in poor households, can be protected from catastrophic health expenditures by reducing a health system's reliance on out-of-pocket payments and providing more financial risk protection. Increase in the availability of health services is critical to improving health in poor countries, but this approach could raise the proportion of households facing catastrophic expenditure; risk protection policies would be especially important in this situation.	WHO, EIP, CH-1211 Geneva 27, Switzerland	World Health Organization	Kawabata, K (corresponding author), WHO, EIP, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.				NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG17625-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANAND S, 1994, AM ECON REV, V84, P226; [Anonymous], WORLD HLTH REP 2002; ARHINTENKORANG D, MOBILIZING RESOURCES; BERKI SE, 1986, HEALTH AFFAIR, V5, P139; Bidani B, 1997, J ECONOMETRICS, V77, P125, DOI 10.1016/S0304-4076(95)01809-3; BOVBJERG RR, 2001, COVERING CATASTRO 66; Davison AC, 1997, BOOTSTRAP METHODS TH; Deaton A., 1980, EC CONSUMER BEHAV, DOI DOI 10.1017/CBO9780511805653; Filmer D, 2002, WORLD BANK RES OBSER, V17, P47, DOI 10.1093/wbro/17.1.47; Frenk J, 2002, B WORLD HEALTH ORGAN, V80, P88; Gilson L, 1997, HEALTH POLICY PLANN, V12, P273, DOI 10.1093/oxfordjournals.heapol.a018882; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Kuznets J, 1997, WHOSHSNHP955; MERLIS M, FAMILY OUT OF POCKET; MUSGROVE P, 2000, HLTH POLICY, V53, P61; NAJMAN JM, 1984, SOC SCI MED, V18, P949, DOI 10.1016/0277-9536(84)90265-X; Pannarunothai S, 1997, SOC SCI MED, V44, P1781, DOI 10.1016/S0277-9536(96)00287-0; Pradhan M, 2002, HEALTH ECON, V11, P431, DOI 10.1002/hec.689; Ranson MK, 2002, B WORLD HEALTH ORGAN, V80, P613; RICE T, 1990, HEALTH AFFAIR, V9, P75, DOI 10.1377/hlthaff.9.3.75; Russell S, 1997, INT J HEALTH SERV, V27, P359, DOI 10.2190/YHL2-F0EA-JW1M-DHEJ; Skarbinski J, 2002, JAMA-J AM MED ASSOC, V287, P1043, DOI 10.1001/jama.287.8.1043; TRAPNELL G, 1983, STRATEGIES INSURING; VISARIA P, 1980, 2 LIV STAND MEAS STU; Wagstaff A, 2002, B WORLD HEALTH ORGAN, V80, P97; WHO, 2001, WORLD HLTH REPORT 20; World Health Organization, 2000, WORLD HLTH REP 2000; WYSZEWIANSKI L, 1986, INQUIRY-J HEALTH CAR, V23, P382; WYSZEWIANSKI L, 1986, HEALTH SERV RES, V21, P617; XU K, IN PRESS HLTH SYSTEM	30	1227	1266	14	143	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					111	117		10.1016/S0140-6736(03)13861-5	http://dx.doi.org/10.1016/S0140-6736(03)13861-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699ZY	12867110				2022-12-28	WOS:000184089200009
J	Sorensen, JB; Nagy, G; Varoqueaux, F; Nehring, RB; Brose, N; Wilson, MC; Neher, E				Sorensen, JB; Nagy, G; Varoqueaux, F; Nehring, RB; Brose, N; Wilson, MC; Neher, E			Differential control of the releasable vesicle pools by SNAP-25 splice variants and SNAP-23	CELL			English	Article							SYNAPTOSOME-ASSOCIATED PROTEIN; TRANSMITTER RELEASE; CHROMAFFIN CELLS; MEMBRANE-FUSION; ISOFORMS; SYNAPTOTAGMIN; EXOCYTOSIS; EXPRESSION; BINDING; NEUROTRANSMITTER	The SNARE complex, consisting of synaptobrevin, syntaxin, and SNAP-25, is essential for calcium-triggered exocytosis in neurosecretory cells. Little is known, however, about how developmentally regulated isoforms and other cognate SNARE components regulate vesicular fusion. To address this question, we examined neuroexocytosis from chromaffin cells of Snap25 null mice rescued by the two splice variants SNAP-25a and SNAP-25b and the ubiquitously expressed homolog SNAP-23. In the absence of SNAP25, vesicle docking persisted, but primed vesicle pools were empty and fast calcium-triggered release abolished. Single vesicular fusion events showed normal characteristics, except for a shorter duration of the fusion pore. Overexpression of SNAP-25a, SNAP-25b, and SNAP-23 resulted in three distinct phenotypes; SNAP-25b induced larger primed vesicle pools than SNAP-25a, whereas SNAP-23 did not support a standing pool of primed vesicles. We conclude that three alternative SNARE components support exocytosis, but they differ in their ability to stabilize vesicles in the primed state.	Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ New Mexico, Ctr Hlth Sci, Dept Neurosci, Albuquerque, NM 87131 USA	Max Planck Society; Max Planck Society; University of New Mexico	Sorensen, JB (corresponding author), Max Planck Inst Biophys Chem, Am Fassberg 11, D-37077 Gottingen, Germany.	jsoeren@gwdg.de	Varoqueaux, Frederique/AAC-1834-2021; Neher, Erwin/A-2109-2013; Oka, Yoshitaka/C-9670-2010	Varoqueaux, Frederique/0000-0002-3614-3121; Oka, Yoshitaka/0000-0002-3482-3051; Sorensen, Jakob/0000-0001-5465-3769	NIMH NIH HHS [R01 MH048989, MH48989] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048989] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chieregatti E, 2002, TRAFFIC, V3, P496, DOI 10.1034/j.1600-0854.2002.30706.x; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Colliver TL, 2000, J NEUROCHEM, V74, P1086; Deitcher DL, 1998, J NEUROSCI, V18, P2028; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gil A, 2002, J BIOL CHEM, V277, P9904, DOI 10.1074/jbc.M110182200; Gonelle-Gispert C, 1999, BIOCHEM J, V339, P159, DOI 10.1042/0264-6021:3390159; Grant NJ, 1999, J NEUROCHEM, V72, P363, DOI 10.1046/j.1471-4159.1999.0720363.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hepp R, 2001, NEUROREPORT, V12, P673, DOI 10.1097/00001756-200103260-00011; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Koticha DK, 1999, J BIOL CHEM, V274, P9053, DOI 10.1074/jbc.274.13.9053; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Nagy G, 2002, J NEUROSCI, V22, P9278; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Puffer EB, 2001, BIOCHEMISTRY-US, V40, P9374, DOI 10.1021/bi010362z; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Scales SJ, 2001, SCIENCE, V294, P1015, DOI 10.1126/science.1066728; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Schulte A, 1996, ANAL CHEM, V68, P3054, DOI 10.1021/ac960210n; Shin OH, 2003, NEURON, V37, P99, DOI 10.1016/S0896-6273(02)01145-5; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2002, P NATL ACAD SCI USA, V99, P1627, DOI 10.1073/pnas.251673298; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Voets T, 2000, NEURON, V28, P537, DOI 10.1016/S0896-6273(00)00131-8; Voets T, 2001, P NATL ACAD SCI USA, V98, P11680, DOI 10.1073/pnas.201398798; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	41	265	275	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					75	86		10.1016/S0092-8674(03)00477-X	http://dx.doi.org/10.1016/S0092-8674(03)00477-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859899	Green Published, Bronze			2022-12-28	WOS:000184219900007
J	Dinse, HR; Ragert, P; Pleger, B; Schwenkreis, P; Tegenthoff, M				Dinse, HR; Ragert, P; Pleger, B; Schwenkreis, P; Tegenthoff, M			Pharmacological modulation of perceptual learning and associated cortical reorganization	SCIENCE			English	Article							LONG-TERM POTENTIATION; USE-DEPENDENT PLASTICITY; EVOKED-POTENTIALS; DENTATE GYRUS; D-AMPHETAMINE; CORTEX; HIPPOCAMPUS	The pharmacological basis of perceptual learning and associated cortical reorganizations remains elusive. We induced perceptual learning by Hebbian coactivation of the skin of the tip of the right index finger in humans. Under placebo, tactile two-point discrimination was improved on the coactivated but not on the left index finger. This augmentation was blocked by an N-methyl-D-aspartate-receptor blocker, but doubled by amphetamine. No drug effects were found on the left index finger. The individual amount of cortical reorganization as assessed by mapping of somatosensory evoked potentials was linearly correlated with the pharmacological modulation of discrimination thresholds, implying that perceptual learning and associated cortical changes are controlled by basic mechanisms known to mediate and modulate synaptic plasticity.	Ruhr Univ Bochum, Dept Theoret Biol, Inst Neuroinformat, D-44780 Bochum, Germany; Ruhr Univ Bochum, Dept Neurol, BG Kliniken Bergmannsheil, D-44789 Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Dinse, HR (corresponding author), Ruhr Univ Bochum, Dept Theoret Biol, Inst Neuroinformat, D-44780 Bochum, Germany.	hubert.dinse@neuroinformatik.ruhr-uni-bochum.de	Ragert, Patrick/AAI-7290-2020	dinse, hubert/0000-0001-9024-0451				ANGRIST B, 1987, BIOL PSYCHIAT, V22, P1357, DOI 10.1016/0006-3223(87)90070-9; Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; BAUMGARTNER C, 1991, EXP BRAIN RES, V87, P641; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLISS TVP, 1983, J PHYSIOL-LONDON, V334, P475, DOI 10.1113/jphysiol.1983.sp014507; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; Butefisch CM, 2000, P NATL ACAD SCI USA, V97, P3661, DOI 10.1073/pnas.050350297; DELANOY RL, 1983, PHARMACOL BIOCHEM BE, V18, P137, DOI 10.1016/0091-3057(83)90263-0; DIAMOND ME, 1993, P NATL ACAD SCI USA, V90, P2082, DOI 10.1073/pnas.90.5.2082; Dinse HR, 2002, PERCEPTUAL LEARNING, P19; DINSE HR, IN PRESS NEUROREPORT; DINSE HR, 2002, SOC NEUR ABSTR, V28; FOOTE SL, 1987, ANNU REV NEUROSCI, V10, P67, DOI 10.1146/annurev.ne.10.030187.000435; Godde B, 2000, J NEUROSCI, V20, P1597; Godde B, 1996, NEUROREPORT, V8, P281, DOI 10.1097/00001756-199612200-00056; Golding NL, 2002, NATURE, V418, P326, DOI 10.1038/nature00854; Kilgard MP, 2002, BIOL CYBERN, V87, P333, DOI 10.1007/s00422-002-0352-z; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; LACAILLE JC, 1985, BRAIN RES, V358, P210, DOI 10.1016/0006-8993(85)90965-5; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pleger B, 2001, P NATL ACAD SCI USA, V98, P12255, DOI 10.1073/pnas.191176298; PLEGER B, 2002, SOC NEUR ABSTR, V28; SCHERG M, 1993, PHYSIOL MEAS, V14, pA35, DOI 10.1088/0967-3334/14/4A/006; Tegenthoff M, 1999, EEG CL N SU, P188; Watanabe T, 2001, NATURE, V413, P844, DOI 10.1038/35101601	27	209	211	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					91	94		10.1126/science.1085423	http://dx.doi.org/10.1126/science.1085423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843392				2022-12-28	WOS:000183914700039
J	Leigh, GJ				Leigh, GJ			So that's how it's done - Maybe	SCIENCE			English	Editorial Material							MOLYBDENUM-IRON PROTEIN; CRYSTALLOGRAPHIC STRUCTURE; AZOTOBACTER-VINELANDII; FEMO-COFACTOR; NITROGENASE; MECHANISM; REDUCTION; FIXATION		Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England	University of Sussex	Leigh, GJ (corresponding author), Univ Sussex, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England.							Allen A. D., 1965, J CHEM SOC CHEM COMM, P621; Durrant MC, 2002, BIOCHEMISTRY-US, V41, P13934, DOI 10.1021/bi025623z; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gronberg KLC, 1998, J AM CHEM SOC, V120, P10613, DOI 10.1021/ja981832o; Henderson R. A., 2002, Nitrogen fixation at the millennium, P223, DOI 10.1016/B978-044450965-9/50009-4; HENDERSON RA, 1983, ADV INORG CHEM RAD, V27, P198; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LEIGH CJ, 2003, NITROGEN FIXATION MI, P299; LOWE DJ, 1984, BIOCHEM J, V224, P877, DOI 10.1042/bj2240877; Masepohl B., 2002, NITROGEN FIXATION MI, P191, DOI [10.1016/B978-044450965-9/50008-2, DOI 10.1016/B978-044450965-9/50008-2]; PICKETT CJ, 1986, J CHEM SOC DALTON, P1453, DOI 10.1039/dt9860001453; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; Yandulov DV, 2003, SCIENCE, V301, P76, DOI 10.1126/science.1085326	15	34	36	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					55	56		10.1126/science.1086678	http://dx.doi.org/10.1126/science.1086678			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843380				2022-12-28	WOS:000183914700026
J	Stillman, JH				Stillman, JH			Acclimation capacity underlies susceptibility to climate change	SCIENCE			English	Article							IMPACTS		Stanford Univ, Hopkins Marine Stn, Pacific Grove, CA 93950 USA	Stanford University	Stillman, JH (corresponding author), Stanford Univ, Hopkins Marine Stn, Oceanview Blvd, Pacific Grove, CA 93950 USA.			Stillman, Jonathon/0000-0002-4783-3830				Jensen MN, 2003, SCIENCE, V299, P38, DOI 10.1126/science.299.5603.38; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Sagarin RD, 1999, ECOL MONOGR, V69, P465, DOI 10.1890/0012-9615(1999)069[0465:CRCIAI]2.0.CO;2; Stillman JH, 2002, INTEGR COMP BIOL, V42, P790, DOI 10.1093/icb/42.4.790	5	578	587	5	229	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					65	65		10.1126/science.1083073	http://dx.doi.org/10.1126/science.1083073			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843385				2022-12-28	WOS:000183914700031
J	Yang, RT; Hernandez-Maldonado, AJ; Yang, FH				Yang, RT; Hernandez-Maldonado, AJ; Yang, FH			Desulfurization of transportation fuels with zeolites under ambient conditions	SCIENCE			English	Article							EFFECTIVE CORE POTENTIALS; PI-COMPLEXATION; ADSORPTION	Deep desulfurization of transportation fuels ( gasoline, diesel, and jet fuels) is being mandated by U. S. and foreign governments and is also needed for future fuel cell applications. However, it is extremely difficult and costly to achieve with current technology, which requires catalytic reactors operated at high pressure and temperature. We show that Cu+ and Ag+ zeolite Y can adsorb sulfur compounds from commercial fuels selectively and with high sulfur capacities (by pi complexation) at ambient temperature and pressure. Thus, the sulfur content was reduced from 430 to <0.2 parts per million by weight in a commercial diesel at a sorbent capacity of 34 cubic centimeters of clean diesel produced per gram of sorbent. This sulfur selectivity and capacity are orders of magnitude higher than those obtained by previously known sorbents.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Yang, RT (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.		Hernandez-Maldonado, Arturo J/I-6288-2012	Hernandez-Maldonado, Arturo J/0000-0001-9379-8987				ATES BC, 1979, CHEM CATALYTIC PROCE, pCH5; AVIDAN A, 2001, NAT PETR REF ASS ANN; HAY PJ, 1985, J CHEM PHYS, V82, P299, DOI [10.1063/1.448800, 10.1063/1.448799]; Hernandez-Maldonado AJ, 2003, IND ENG CHEM RES, V42, P123, DOI 10.1021/ie020728j; LARSEN SC, 1994, J PHYS CHEM-US, V98, P11533, DOI 10.1021/j100095a039; Ma XL, 2002, CATAL TODAY, V77, P107, DOI 10.1016/S0920-5861(02)00237-7; RUSSO TV, 1995, J PHYS CHEM-US, V99, P17085, DOI 10.1021/j100047a007; Takahashi A, 2002, IND ENG CHEM RES, V41, P2487, DOI 10.1021/ie0109657; *US DEP EN OFF TRA, 2001, FUEL CELLS TRNASP 20; YANG RT, 2003, ADSORBENTS FUNDAMENT, pCH10	10	826	930	15	439	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					79	81		10.1126/science.1085088	http://dx.doi.org/10.1126/science.1085088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843388				2022-12-28	WOS:000183914700035
J	Royer, DL; Osborne, CP; Beerling, DJ				Royer, DL; Osborne, CP; Beerling, DJ			Carbon loss by deciduous trees in a CO2-rich ancient polar environment	NATURE			English	Article							CLIMATE-CHANGE; FORESTS; ISLAND; FLORAS; CO2; VERTEBRATES; ANTARCTICA; VEGETATION; RESPONSES; TERTIARY	Fossils demonstrate that deciduous forests covered the polar regions for much of the past 250 million years(1) when the climate was warm and atmospheric CO2 high(2). But the evolutionary significance of their deciduous character has remained a matter of conjecture for almost a century(3). The leading hypothesis(1,4-7) argues that it was an adaptation to photoperiod, allowing the avoidance of carbon losses by respiration from a canopy of leaves unable to photosynthesize in the darkness of warm polar winters(8-11). Here we test this proposal with experiments using 'living fossil' tree species grown in a simulated polar climate with and without CO2 enrichment. We show that the quantity of carbon lost annually by shedding a deciduous canopy is significantly greater than that lost by evergreen trees through wintertime respiration and leaf litter production, irrespective of growth CO2 concentration. Scaling up our experimental observations indicates that the greater expense of being deciduous persists in mature forests, even up to latitudes of 83 degreesN, where the duration of the polar winter exceeds five months. We therefore reject the carbon-loss hypothesis as an explanation for the deciduous nature of polar forests.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Beerling, DJ (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.		Beerling, David J/C-2840-2009	Beerling, David J/0000-0003-1869-4314; Royer, Dana/0000-0003-0976-953X				AXELROD DI, 1966, EVOLUTION, V20, P1, DOI [10.2307/2406145, 10.1111/j.1558-5646.1966.tb03339.x]; Beerling DJ, 1998, PHILOS T R SOC B, V353, P131, DOI 10.1098/rstb.1998.0196; Beerling DJ, 2002, ANN BOT-LONDON, V89, P329, DOI 10.1093/aob/mcf045; CHANEY RW, 1947, ECOL MONOGR, V17, P139, DOI 10.2307/1943260; CREBER GT, 1985, PALAEOGEOGR PALAEOCL, V52, P35, DOI 10.1016/0031-0182(85)90030-6; Crowley TJ, 2001, SCIENCE, V292, P870, DOI 10.1126/science.1061664; Dutton AL, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000593; ESTES R, 1980, PALAEOGEOGR PALAEOCL, V30, P325, DOI 10.1016/0031-0182(80)90064-4; Falcon-Lang HJ, 2000, PALAEOGEOGR PALAEOCL, V160, P317, DOI 10.1016/S0031-0182(00)00079-1; Falcon-Lang HJ, 2001, GEOL MAG, V138, P39, DOI 10.1017/S0016756801004927; Givnish TJ, 2002, SILVA FENN, V36, P703, DOI 10.14214/sf.535; HICKEY LJ, 1984, DISCOVERY, V17, P17; MULLER MJ, 1981, SELECTED CLIMATIC DA; Osborne CP, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001467; Parrish JT, 1998, PALAIOS, V13, P149, DOI 10.2307/3515486; PARTON WJ, 1993, GLOBAL BIOGEOCHEM CY, V7, P785, DOI 10.1029/93GB02042; READ J, 1992, PALAEOGEOGR PALAEOCL, V99, P271, DOI 10.1016/0031-0182(92)90019-2; Reich PB, 1997, P NATL ACAD SCI USA, V94, P13730, DOI 10.1073/pnas.94.25.13730; SEWARD A.C., 1914, BR MUS NAT HIST GEOL, V1, P1; Sokal RR, 1995, BIOMETRY; SPICER RA, 1990, TRENDS ECOL EVOL, V5, P279, DOI 10.1016/0169-5347(90)90081-N; Tarduno JA, 1998, SCIENCE, V282, P2241, DOI 10.1126/science.282.5397.2241; Tjoelker MG, 2001, GLOBAL CHANGE BIOL, V7, P223, DOI 10.1046/j.1365-2486.2001.00397.x; Tripati A, 2001, PALAEOGEOGR PALAEOCL, V170, P101, DOI 10.1016/S0031-0182(01)00230-9; Upchurch G.R., 1990, ANTARCTIC J US, V24, P7; Valdes P.J., 1996, PALAEOCLIMATES, V2, P139, DOI DOI 10.1016/J.ECOLMODEL.2005.03.026; Villar R, 2001, NEW PHYTOL, V151, P213, DOI 10.1046/j.1469-8137.2001.00147.x; Wolfe J.A., 1985, GEOPHYS MONOGR SER, V32, P357, DOI DOI 10.1029/GM032P0357; WOLFE JA, 1987, PALEOBIOLOGY, V13, P215; Yin XW, 2002, GLOBAL CHANGE BIOL, V8, P631, DOI 10.1046/j.1365-2486.2002.00497.x	30	48	51	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					60	62		10.1038/nature01737	http://dx.doi.org/10.1038/nature01737			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840757	Green Accepted			2022-12-28	WOS:000183912800038
J	Nilsson, M; Johnsen, R; Ye, WM; Hveem, K; Lagergren, J				Nilsson, M; Johnsen, R; Ye, WM; Hveem, K; Lagergren, J			Obesity and estrogen as risk factors for gastroesophageal reflux symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOWER ESOPHAGEAL SPHINCTER; NITRIC-OXIDE SYNTHASE; BODY-MASS; GASTRIC CARDIA; DISEASE; PREVALENCE; POPULATION; WOMEN; ADENOCARCINOMAS; PERISTALSIS	Context Gastroesophageal reflux and obesity are both increasing in prevalence. The scientific evidence for an association between these conditions is sparse and contradictory. A difference between sexes concerning this relation has been proposed. Objective To evaluate the relation between body mass and gastroesophageal reflux symptoms and determine how this relation is influenced by female sex hormones. Design Population-based, cross-sectional, case-control study. Setting Two consecutive public health surveys within the county of Nord-Trondelag, Norway, conducted in 1984-1986 and 1995-1997. Participants Among 65363 adult participants in the second survey, 3113 individuals who reported severe heartburn or regurgitation during the last 12 months were defined as cases, whereas 39872 persons without reflux symptoms were defined as controls. Main Outcome Measure Risk of reflux, estimated using multivariate logistic regression, with odds ratios (ORs) and 95% confidence intervals (Cls) as measures of association. Results There was a dose-response association between increasing body mass index (BMI) and reflux symptoms in both sexes (P for trend <.001), with a significantly stronger association in women (P<.001). Compared with those with a BMI less than 25, the risk of reflux was increased significantly among severely obese (BMI >35) men (OR, 3.3; 95% Cl, 2.4-4.7) and women (OR, 6.3; 95% Cl, 4.9-8.0). The association between BMI and reflux symptoms was stronger among premenopausal women compared with postmenopausal women (P<.001), although use of postmenopausal hormone therapy increased the strength of the association (P<.001). Reduction in BMI was associated with decreased risk of reflux symptoms. Conclusions There is a significant association between body mass and symptoms of gastroesophageal reflux. The association is stronger among women, especially premenopausally, and use of hormone therapy strengthens the association, suggesting that estrogens may play an important role in the etiology of reflux disease.	Karolinska Inst, Karolinska Hosp, Dept Surg, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; Norwegian Univ Sci & Technol, Dept Community Med & Gen Practice, N-7034 Trondheim, Norway; Levanger Hosp, Dept Med, Levanger, Norway; HUNT Res Ctr, Verdal, Norway	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Norwegian University of Science & Technology (NTNU)	Nilsson, M (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Surg, SE-17176 Stockholm, Sweden.	magnus.nilsson@ks.se	Hveem, Kristian/AFV-4683-2022; Ye, Weimin/A-5939-2008	Nilsson, Magnus/0000-0002-6215-8132; Lagergren, Jesper/0000-0002-5143-5448				Bray George A., 1997, Human Reproduction (Oxford), V12, P26; CASTRO LDP, 1967, AM J OBSTET GYNECOL, V98, P1; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; DAY JP, 1990, GASTROENTEROL CLIN N, V19, P587; DEMAN JG, 1991, BRIT J PHARMACOL, V103, P1092; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Eloubeidi MA, 2000, AM J GASTROENTEROL, V95, P1881; GARROW JS, 1985, INT J OBESITY, V9, P147; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Hautanen A, 2000, INT J OBESITY, V24, pS64, DOI 10.1038/sj.ijo.0801281; HEY VMF, 1977, ANAESTHESIA, V32, P372, DOI 10.1111/j.1365-2044.1977.tb11643.x; Hirsch DP, 1998, GASTROENTEROLOGY, V115, P1374, DOI 10.1016/S0016-5085(98)70015-0; ISOLAURI J, 1995, ANN MED, V27, P67, DOI 10.3109/07853899509031939; *JOINT FAO WHO UNU, 1985, WHO TECHN REP SER, P724; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; Konturek JW, 1997, J PHYSIOL PHARMACOL, V48, P201; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P103, DOI 10.1136/jech.47.2.103; KUSZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; Lagergren J, 2000, GUT, V47, P26, DOI 10.1136/gut.47.1.26; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; LOCKE GR, 1994, MAYO CLIN PROC, V69, P539, DOI 10.1016/S0025-6196(12)62245-9; Locke GR, 1999, AM J MED, V106, P642, DOI 10.1016/S0002-9343(99)00121-7; Midthjell K, 1999, DIABETES CARE, V22, P1813, DOI 10.2337/diacare.22.11.1813; Nilsson M, 2002, SCAND J GASTROENTERO, V37, P626, DOI 10.1080/00365520212502; Nuedling S, 1999, CARDIOVASC RES, V43, P666, DOI 10.1016/S0008-6363(99)00093-0; Piccinini F, 2000, GYNECOL ENDOCRINOL, V14, P142, DOI 10.3109/09513590009167673; Revicki DA, 1998, QUAL LIFE RES, V7, P75; Rothacker DQ, 2000, J AM DIET ASSOC, V100, P784, DOI 10.1016/S0002-8223(00)00229-7; Ruhl CE, 1999, ANN EPIDEMIOL, V9, P424, DOI 10.1016/S1047-2797(99)00020-4; RUTH M, 1991, SCAND J GASTROENTERO, V26, P73, DOI 10.3109/00365529108996486; SIITERI PK, 1981, J ENDOCRINOL, V89, pP119; Ter RB, 1997, GASTROENTEROL CLIN N, V26, P549, DOI 10.1016/S0889-8553(05)70313-7; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; VANTHIEL DH, 1976, GASTROENTEROLOGY, V71, P232; VANTHIEL DH, 1977, GASTROENTEROLOGY, V72, P666; Xue SW, 1996, CAN J PHYSIOL PHARM, V74, P1249, DOI 10.1139/cjpp-74-11-1249; Ye WM, 2001, GASTROENTEROLOGY, V121, P1286, DOI 10.1053/gast.2001.29569; Zervou S, 1999, MOL HUM REPROD, V5, P1048, DOI 10.1093/molehr/5.11.1048	42	333	343	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					66	72		10.1001/jama.290.1.66	http://dx.doi.org/10.1001/jama.290.1.66			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837713	Bronze			2022-12-28	WOS:000183868600021
J	Schoen, RE; Pinsky, PF; Weissfeld, JL; Bresalier, RS; Church, T; Prorok, P; Gohagan, JK				Schoen, RE; Pinsky, PF; Weissfeld, JL; Bresalier, RS; Church, T; Prorok, P; Gohagan, JK		Prostate Lung Colorectal Ovarian C	Results of repeat sigmoidoscopy 3 years after a negative examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCREENING FLEXIBLE SIGMOIDOSCOPY; COLORECTAL-CANCER; ASYMPTOMATIC ADULTS; COLONOSCOPY; RISK; ADENOMAS; YIELD; SURVEILLANCE; PREVENTION; GUIDELINES	Context The necessary frequency of endoscopic colorectal cancer screening after a negative examination is uncertain. Objective To examine the yield of adenomas and cancer in the distal colon found by repeat flexible sigmoidoscopy (FSG) 3 years after a negative examination. Design, Setting, and Participants Participants were drawn from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a randomized, controlled community-based study of cancer screening. The mean (SD) age was 65.7 (4.0) years at study entry (1993-1995) and 61.6% were men. individuals underwent screening FSG at baseline and at 3 years as part of the protocol and were referred to their personal physicians for further evaluation of screen-detected abnormalities. Results from subsequent diagnostic evaluations were tracked in a standardized fashion. Of 11583 eligible for repeat screening FSG 3 years after an initial negative examination, 9317 (80.4%) returned. Main Outcome Measures Polyp or mass detection in distal colon at year 3 repeat FSG; incidence of adenoma or cancer in distal colon at year 3 examination; determination of reason for detection (increased depth of insertion or improved preparation at the year 3 examination or detection in a previously examined area). Results A total of 1292 returning participants (13.9%) had a polyp or mass detected by FSG 3 years after the initial examination. In the distal colon, 3.1% (292/ 9317) were found to have an adenoma or cancer. The incidence of advanced adenoma (n=72) or cancer (n=6) in the distal colon was 78 (0.8%)of 9317. Of individuals with advanced distal adenomas detected at the year 3 examination, 80.6% (58/72) had lesions found in a portion of the colon that had been adequately examined at the initial sigmoidoscopy. Conclusions Repeat FSG 3 years after a negative examination will detect advanced adenomas and distal colon cancer. Although the overall percentage with detected abnormalities is modest, these data raise concern about the impact of a prolonged screening interval after a negative examination.	Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; NCI, Div Canc Prevent, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Div Gastrointestinal Med & Nutr, Houston, TX 77030 USA; Univ Minnesota, Div Environm & Occupat Hlth, Minneapolis, MN USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; University of Minnesota System; University of Minnesota Twin Cities	Schoen, RE (corresponding author), Presbyterian Univ Hosp, Div Gastroenterol & Hepatol, Mezzanine Level,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA.	rschoen@pitt.edu	Church, Timothy/AAH-7017-2020	Church, Timothy/0000-0003-3292-5035; Bresalier, Robert/0000-0002-9740-281X	NCI NIH HHS [N01-CN2551] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkin WS, 2001, GASTROENTEROLOGY, V120, pA66; Bresalier RS, 2002, GASTROENTEROLOGY, V122, pA479; BRINT SL, 1993, AM J GASTROENTEROL, V88, P2019; COOPER GS, 1995, CANCER, V75, P775, DOI 10.1002/1097-0142(19950201)75:3<775::AID-CNCR2820750305>3.0.CO;2-D; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Fenlon HM, 1999, NEW ENGL J MED, V341, P1496, DOI 10.1056/NEJM199911113412003; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; KREVSKY B, 1994, AM J GASTROENTEROL, V89, P1165; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Marshall JR, 1996, GASTROENTEROLOGY, V111, P1411, DOI 10.1016/S0016-5085(96)70001-X; MAULE WF, 1994, NEW ENGL J MED, V330, P183, DOI 10.1056/NEJM199401203300307; MULLER AD, 1995, ARCH INTERN MED, V155, P1741, DOI 10.1001/archinte.155.16.1741; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; Pinsky PF, 2003, CLIN GASTROENTEROL H, V1, P103, DOI 10.1053/cgh.2003.50017; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; REX DK, 1994, GASTROENTEROLOGY, V106, P593, DOI 10.1016/0016-5085(94)90690-4; Rex DK, 1996, GASTROENTEROLOGY, V111, P1178, DOI 10.1053/gast.1996.v111.pm8898630; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; REX DK, 1990, FLEXIBLE SIGMOIDOSCO, P185; RIFF ER, 1990, CLEV CLIN J MED, V57, P131, DOI 10.3949/ccjm.57.2.131; Schoen RE, 2000, ARCH INTERN MED, V160, P1790, DOI 10.1001/archinte.160.12.1790; SCHOEN RE, IN PRESS AM J GASTRO; Schoenfeld P, 1999, GASTROENTEROLOGY, V117, P312, DOI 10.1053/gast.1999.0029900312; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Slattery ML, 1996, CANCER, V78, P1666, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1666::AID-CNCR5>3.0.CO;2-C; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; Smith RA, 2001, CA-CANCER J CLIN, V51, P150; SQUILLACE S, 1994, AM J GASTROENTEROL, V89, P1156; Stallings FL, 2000, CONTROL CLIN TRIALS, V21, p379S, DOI 10.1016/S0197-2456(00)00093-3; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; Weissfeld JL, 2002, CANCER, V94, P2569, DOI 10.1002/cncr.10538; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044	35	73	75	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					41	48		10.1001/jama.290.1.41	http://dx.doi.org/10.1001/jama.290.1.41			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837710	Bronze			2022-12-28	WOS:000183868600018
J	Cordonnier, C; Chevret, S; Legrand, M; Rafi, H; Dhedin, N; Lehmann, B; Bassompierre, F; Gluckman, E				Cordonnier, C; Chevret, S; Legrand, M; Rafi, H; Dhedin, N; Lehmann, B; Bassompierre, F; Gluckman, E		GREFIG Study Grp	Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW-TRANSPLANT; CYTOMEGALOVIRUS IMMUNE GLOBULIN; INTRAVENOUS IMMUNOGLOBULIN; VENOOCCLUSIVE DISEASE; FUNGAL-INFECTIONS; PREVENTION; GANCICLOVIR; HYPERIMMUNE; PROPHYLAXIS; EFFICACY	Background: The universal use of prophylactic immunoglobulin in stem-cell transplantation has not been supported by strong evidence of benefit. Results of most trials were reported before effective drugs for cytomegalovirus infection and disease were available, and no trial was placebo controlled. Objective: To assess the role and the close-effect relationship of immunoglobulin in the prophylaxis of complications after allogeneic stem-cell transplantation. Design: Multicenter randomized, double-blind, dose effect placebo-controlled study. Setting: 19 stem-cell transplantation centers in France. Patients: 200 patients who had allogeneic stem-cell transplantation from HLA-identical sibling donors between 1998 and 2000. Intervention: Immunoglobulin at doses of 50 mg/kg of body weight, 250 mg/kg, or 500 mg/kg weekly from day -7 to day 100 after transplantation or placebo. Measurements: Cumulative incidence of infection, graft-versus-host disease, veno-occlusive disease, interstitial pneumonia, and transplantation-related mortality at 6 months; overall survival at 2 years after transplantation. Results: Immunoglobulin had no benefit over placebo; 92% of patients in the pooled immunoglobulin group and 90% of patients in the placebo group had one or more infections (difference, 2 percentage points [95% CI, -8 to 12 percentage points]). Cumulative incidences of interstitial pneumonia, graft-versus-host disease, transplantation-related mortality, and overall survival were similar in patients receiving placebo and those receiving immunoglobulin; no dose-effect relationships were evident. Grade 3 (severe) veno-occlusive disease occurred more frequently as the immunoglobulin dose increased (P = 0.01). Conclusions: Use of prophylactic immunoglobulin in allogeneic recipients of stem-cell transplant from HLA-identical sibling donors is not recommended.	Hop Henri Mondor, Serv Hematol, F-94000 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Cordonnier, C (corresponding author), Hop Henri Mondor, Serv Hematol, 51 Av Marechal Lattre Tassigny, F-94000 Creteil, France.	carlcord@club-internet.fr		chevret, sylvie/0000-0001-6449-4730				AALEN O, 1978, ANN STAT, V6, P534, DOI 10.1214/aos/1176344198; Abdel-Mageed A, 1999, BONE MARROW TRANSPL, V23, P929, DOI 10.1038/sj.bmt.1701742; Akan H, 2001, BONE MARROW TRANSPL, V27, pS202; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; AUKRUST P, 1994, BLOOD, V84, P2136; BASS EB, 1993, BONE MARROW TRANSPL, V12, P273; Boeckh MJ, 1998, TRANSPLANT INFECTIONS, P215; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1991, J INFECT DIS, V164, P483, DOI 10.1093/infdis/164.3.483; CONDIE RM, 1984, AM J MED, V76, P134, DOI 10.1016/0002-9343(84)90332-2; EMANUEL D, 1992, BLOOD S, V80, pA217; Feinstein L C, 1999, Biol Blood Marrow Transplant, V5, P369, DOI 10.1016/S1083-8791(99)70013-3; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GRAY RJ, 2001, CMPRSK PACKAGE SERIA; GUGLIELMO BJ, 1994, BONE MARROW TRANSPL, V13, P499; HOLLER E, 1990, BLOOD, V75, P1011; Klaesson S, 1995, TRANSPLANTATION, V60, P1225; KLEIN JP, 1991, SCAND J STAT, V18, P333; KUBANEK B, 1985, TRANSPLANT P, V17, P468; LUNGMAN P, 1993, EXCERPTA MED INT C S, P233; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MEYERS JD, 1983, ANN INTERN MED, V98, P442, DOI 10.7326/0003-4819-98-4-442; Reusser P, 2002, BLOOD, V99, P1159, DOI 10.1182/blood.V99.4.1159; RINGDEN O, 1987, BONE MARROW TRANSPL, V2, P299; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SULLIVAN K, 2000, J CLIN ONCOL, V19, pA47; Sullivan K M, 1998, Biol Blood Marrow Transplant, V4, P20; Sullivan K M, 1996, Biol Blood Marrow Transplant, V2, P44; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; Winston DJ, 2001, BONE MARROW TRANSPL, V28, P187, DOI 10.1038/sj.bmt.1703109; WINSTON DJ, 1982, ANN INTERN MED, V97, P11, DOI 10.7326/0003-4819-97-1-11; WOLFF SN, 1993, ANN INTERN MED, V118, P937, DOI 10.7326/0003-4819-118-12-199306150-00004	40	91	92	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					8	18		10.7326/0003-4819-139-1-200307010-00007	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834313				2022-12-28	WOS:000183823200002
J	Fylkesnes, K; Fylkesnes, TK				Fylkesnes, K; Fylkesnes, TK			Informed consent as part and parcel of the scientific inquiry	LANCET			English	Editorial Material							TRIALS; VACCINE; HIV		Univ Bergen, Ctr Int Hlth, N-5021 Bergen, Norway; Arne Naess Ctr Ecol & Philosophy, Oslo, Norway	University of Bergen	Fylkesnes, K (corresponding author), Univ Bergen, Ctr Int Hlth, Armauer Hansen Bldg, N-5021 Bergen, Norway.							Coletti AS, 2003, JAIDS-J ACQ IMM DEF, V32, P161, DOI 10.1097/00126334-200302010-00008; Coulibaly-Traore D, 2003, PRESSE MED, V32, P343; Ferguson PR, 2003, BIOETHICS, V17, P101, DOI 10.1111/1467-8519.00324; Fitzgerald DW, 2002, LANCET, V360, P1301, DOI 10.1016/S0140-6736(02)11338-9; Kant I., 1949, CRITIQUE PRACTICAL R; Mariner WK, 2003, JAIDS-J ACQ IMM DEF, V32, P117, DOI 10.1097/00126334-200302010-00001; McGrath JW, 2001, J ACQ IMMUN DEF SYND, V27, P381, DOI 10.1097/00126334-200108010-00009; Ramjee G, 2000, AIDS, V14, P2553, DOI 10.1097/00002030-200011100-00018; Williams BF, 2003, LANCET, V361, P918, DOI 10.1016/S0140-6736(03)12773-0	9	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2171	2172		10.1016/S0140-6736(03)13785-3	http://dx.doi.org/10.1016/S0140-6736(03)13785-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842366				2022-12-28	WOS:000183815600005
J	Snider, L; Tapscott, SJ				Snider, L; Tapscott, SJ			Emerging parallels in the generation and regeneration of skeletal muscle	CELL			English	Editorial Material							SPECIFICATION	Previously, skeletal muscle regeneration appeared to be very different from embryonic specification of muscle, but in this issue of Cell, Polesskaya et al. show that Writ signaling induces myogenesis in adult muscle stem cells in a manner analogous to muscle induction in the somite.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Snider, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Tapscott, Stephen/0000-0002-0319-0968				Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Desplan C, 1997, CELL, V91, P861, DOI 10.1016/S0092-8674(00)80475-4; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	7	27	27	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					811	812		10.1016/S0092-8674(03)00474-4	http://dx.doi.org/10.1016/S0092-8674(03)00474-4			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837235	Bronze			2022-12-28	WOS:000183817900001
J	Berth-Jones, J; Damstra, RJ; Golsch, S; Livden, JK; Van Hooteghem, O; Allegra, F; Parker, CA				Berth-Jones, J; Damstra, RJ; Golsch, S; Livden, JK; Van Hooteghem, O; Allegra, F; Parker, CA			Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study	BRITISH MEDICAL JOURNAL			English	Article							CREAM 0.05-PERCENT; SUPPRESSION; CHILDREN; MODERATE; ECZEMA	Objective To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis. Design Randomised, double blind, parallel group study of 20 weeks' duration. Setting Dermatology outpatient clinics (6 countries, 39 centres). Participants Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare. Methods Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone propionate or its placebo base (emollient alone) twice weekly to the areas that were usually affected. Main outcome measure Time to relapse of atopic dermatitis during maintenance phase. Results 376 patients entered the stabilisation phase, and 295 continued into the maintenance phase. After 16 weeks in the maintenance phase, the disease remained under control in 133 patients (87 using fluticasone propionate twice weekly, 46 using emollient alone), 135 (40 fluticasone propionate, 95 emollient) had experienced a relapse, and 27 had discontinued. Median time to relapse was six weeks for emollient alone compared with more than 16 weeks for additional fluticasone propionate. Patients who applied fluticasone propionate cream twice weekly were 5.8 times less likely (95% confidence interval 3.1 to 10.8, P < 0.001) and patients using fluticasone propionate ointment 1.9 times less likely (1.2 to 3.2, P=0.010) to have a relapse than patients applying emollient alone. The groups showed no differences in adverse events. Conclusion After atopic dermatitis had been stabilised the addition of fluticasone propionate twice weekly to maintenance treatment with emollients significantly reduced the risk of relapse.	Walsgrave Gen Hosp, Univ Hosp Coventry & Warwickshire NHS Trust, Dept Dermatol, Coventry CV2 2DX, W Midlands, England; Ziekenhuis Nij Smellinghe, NL-9202 NN Drachten, Netherlands; Praxis Dr Golsch, D-80335 Munich, Germany; Hudpoliklinikken, N-5010 Bergen, Norway; Clin St Elizabeth, Dept Dermatol, B-5000 Namur, Belgium; Univ Parma, Inst Med & Surg Dermatol, I-43100 Parma, Italy; GlaxoSmithKline, Res & Dev, Clin Dev & Med Affairs, Greenford UB6 0HE, Middx, England	University of Warwick; University of Parma; GlaxoSmithKline	Berth-Jones, J (corresponding author), Walsgrave Gen Hosp, Univ Hosp Coventry & Warwickshire NHS Trust, Dept Dermatol, Coventry CV2 2DX, W Midlands, England.							*BRIT MED ASS ROYA, 2000, BRIT NAT FORM, P508; DYKES P, 1996, CLIN EXP DERMATOL, V21, P185; Fleischer AB, 1999, POSTGRAD MED, V106, P49, DOI 10.3810/pgm.1999.10.1.708; Friedlander SF, 2002, J AM ACAD DERMATOL, V46, P387, DOI 10.1067/mjd.2002.118337; Hanifin JM, 1999, J ALLERGY CLIN IMMUN, V104, pS123, DOI 10.1016/S0091-6749(99)70054-0; Hoare C, 2000, Health Technol Assess, V4, P1; KAIDBEY KH, 1974, J INVEST DERMATOL, V63, P292, DOI 10.1111/1523-1747.ep12680178; Spencer CM, 1997, BIODRUGS, V7, P318, DOI 10.2165/00063030-199707040-00006; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; Tschen EH, 1998, CLIN DRUG INVEST, V16, P111, DOI 10.2165/00044011-199816020-00003; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Westerhof W, 1999, ARCH DERMATOL, V135, P1061, DOI 10.1001/archderm.135.9.1061; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356	14	184	196	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1367	1370		10.1136/bmj.326.7403.1367	http://dx.doi.org/10.1136/bmj.326.7403.1367			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816824	Green Published			2022-12-28	WOS:000183756400022
J	Reimold, WU				Reimold, WU			Impact cratering comes of age	SCIENCE			English	Editorial Material									Univ Witwatersrand, Sch Geosci, Impact Cratering Res Grp, ZA-2050 Johannesburg, South Africa	University of Witwatersrand	Reimold, WU (corresponding author), Univ Witwatersrand, Sch Geosci, Impact Cratering Res Grp, ZA-2050 Johannesburg, South Africa.		Reimold, Wolf Uwe/AAI-6226-2021	Hauser, Natalia/0000-0002-6975-6186				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Baldwin RB, 1949, THE FACE OF THE MOON; Courtillot V., 2002, EVOLUTIONARY CATASTR; de Pater I., 2015, PLANETARY SCI; French B, 1998, TRACES CATASTROPHE; GIBSON RL, 2001, VREDEFORT IMPACT STR; Hess H.H., 1962, PETROLOGIC STUDIES V, P500, DOI [DOI 10.1130/PETROLOGIC.1962.599, 10.1130/PETROLOGIC.1962.599]; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; Milani A, 2003, SCIENCE, V300, P1882, DOI 10.1126/science.1077708; Montanari A., 2000, IMPACT STRATIGRAPHY; NICOLAYSEN LO, 1990, TECTONOPHYSICS, V171; PATRIDGE TC, 1999, INVESTIGATIONS ORIGI; TAYLOR SR, 2001, SOLAR SYSTEM EVOLUTI; Wegener A, 1915, ENTSTEHUNG KONTINENT; Wilson M., 1989, IGNEOUS PETROGENESIS, P342, DOI 10.1007/978-1-4020-6788-4	15	7	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1889	1890		10.1126/science.1080687	http://dx.doi.org/10.1126/science.1080687			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817133				2022-12-28	WOS:000183619400028
J	Gonzalez-Pastor, JE; Hobbs, EC; Losick, R				Gonzalez-Pastor, JE; Hobbs, EC; Losick, R			Cannibalism by sporulating bacteria	SCIENCE			English	Article							BACILLUS-SUBTILIS; ANTIBIOTICS; EXPRESSION; INITIATION; SIGMA(W); GROWTH; GENES	Spore formation by the bacterium Bacillus subtilis is an elaborate developmental process that is triggered by nutrient limitation. Here we report that cells that have entered the pathway to sporulate produce and export a killing factor and a signaling protein that act cooperatively to block sister cells from sporulating and to cause them to lyse. The sporulating cells feed on the nutrients thereby released, which allows them to keep growing rather than to complete morphogenesis. We propose that sporulation is a stress-response pathway of last resort and that B. subtilis delays a commitment to spore formation by cannibalizing its siblings.	Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Losick, R (corresponding author), Harvard Univ, Biol Labs, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.		González-Pastor, José/I-2118-2015	González-Pastor, José/0000-0002-7615-7042	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Branda SS, 2001, P NATL ACAD SCI USA, V98, P11621, DOI 10.1073/pnas.191384198; BROWN MRW, 1988, J ANTIMICROB CHEMOTH, V22, P777, DOI 10.1093/jac/22.6.777; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Cao M, 2002, MOL MICROBIOL, V45, P1267, DOI 10.1046/j.1365-2958.2002.03050.x; CHUNG JD, 1994, J BACTERIOL, V176, P1977, DOI 10.1128/jb.176.7.1977-1984.1994; COZENS RM, 1986, ANTIMICROB AGENTS CH, V29, P797, DOI 10.1128/AAC.29.5.797; Fawcett P, 2000, P NATL ACAD SCI USA, V97, P8063, DOI 10.1073/pnas.140209597; GONZALEZPASTOR JE, UNPUB; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lin D, 2001, J APPL MICROBIOL, V91, P1044, DOI 10.1046/j.1365-2672.2001.01475.x; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Piggot P. J., 2002, BACILLUS SUBTILIS IT, P473; PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Siezen RJ, 1996, ANTON LEEUW INT J G, V69, P171, DOI 10.1007/BF00399422; Sonenshein AL, 2000, PROKARYOTIC DEVELOPMENT, P133; Sonenshein AL, 2000, BACTERIAL STRESS RESPONSES, P199; Turner MS, 2000, J BACTERIOL, V182, P5202, DOI 10.1128/JB.182.18.5202-5210.2000; WIREMAN JW, 1975, SCIENCE, V189, P516, DOI 10.1126/science.806967; Zheng GL, 1999, J BACTERIOL, V181, P7346, DOI 10.1128/JB.181.23.7346-7355.1999	21	410	442	6	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 25	2003	301	5632					510	513		10.1126/science.1086462	http://dx.doi.org/10.1126/science.1086462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704LE	12817086				2022-12-28	WOS:000184340500041
J	Williams, PA; Cosme, J; Ward, A; Angova, HC; Vinkovic, DM; Jhoti, H				Williams, PA; Cosme, J; Ward, A; Angova, HC; Vinkovic, DM; Jhoti, H			Crystal structure of human cytochrome P4502C9 with bound warfarin	NATURE			English	Article								Cytochrome P450 proteins (CYP450s) are membrane-associated haem proteins that metabolize physiologically important compounds in many species of microorganisms, plants and animals. Mammalian CYP450s recognize and metabolize diverse xenobiotics such as drug molecules, environmental compounds and pollutants(1). Human CYP450 proteins CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are the major drug-metabolizing isoforms, and contribute to the oxidative metabolism of more than 90% of the drugs in current clinical use(2). Polymorphic variants have also been reported for some CYP450 isoforms, which has implications for the efficacy of drugs in individuals, and for the co-administration of drugs. The molecular basis of drug recognition by human CYP450s, however, has remained elusive. Here we describe the crystal structure of a human CYP450, CYP2C9, both unliganded and in complex with the anti-coagulant drug warfarin. The structure defines unanticipated interactions between CYP2C9 and warfarin, and reveals a new binding pocket. The binding mode of warfarin suggests that CYP2C9 may undergo an allosteric mechanism during its function. The newly discovered binding pocket also suggests that CYP2C9 may simultaneously accommodate multiple ligands during its biological function, and provides a possible molecular basis for understanding complex drug-drug interactions.	Astex Technol, Cambridge CB4 0QA, England		Jhoti, H (corresponding author), Astex Technol, 436 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0QA, England.	h.jhoti@astex-technology.com		Williams, Pamela/0000-0002-1257-2351				Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; de Groot MJ, 2002, J MED CHEM, V45, P1983, DOI 10.1021/jm0110791; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Haining RL, 1999, BIOCHEMISTRY-US, V38, P3285, DOI 10.1021/bi982161+; Hemeryck A, 1999, EUR J CLIN PHARMACOL, V54, P947, DOI 10.1007/s002280050580; Hlavica P, 2001, EUR J BIOCHEM, V268, P4817, DOI 10.1046/j.1432-1327.2001.02412.x; Hodgson J, 2001, NAT BIOTECHNOL, V19, P722, DOI 10.1038/90761; Hutzler JM, 2001, DRUG METAB DISPOS, V29, P1029; Hutzler JM, 2003, ARCH BIOCHEM BIOPHYS, V410, P16; Ibeanu GC, 1996, J BIOL CHEM, V271, P12496, DOI 10.1074/jbc.271.21.12496; Jones BC, 1996, DRUG METAB DISPOS, V24, P260; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Lewis DFV, 2000, BIOCHEM PHARMACOL, V60, P293, DOI 10.1016/S0006-2952(00)00335-X; Li H, 1996, BIOCHIMIE, V78, P695, DOI 10.1016/S0300-9084(97)82526-6; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; MANCY A, 1995, BIOCHEMISTRY-US, V34, P10365, DOI 10.1021/bi00033a007; Melet A, 2003, ARCH BIOCHEM BIOPHYS, V409, P80, DOI 10.1016/S0003-9861(02)00548-9; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p; MURSHUDOV GN, 1997, ACTA CRYSTALLOGR D, V50, P760; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NAVE C, 1995, RADIAT PHYS CHEM, V45, P483, DOI 10.1016/0969-806X(95)92800-E; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Ridderstrom M, 2000, BIOCHEM BIOPH RES CO, V270, P983, DOI 10.1006/bbrc.2000.2538; Schlichting I, 1997, FEBS LETT, V415, P253, DOI 10.1016/S0014-5793(97)01135-6; STRESSER DM, FLUOROMETRIC CYTOCHR; Takahashi H, 2001, CLIN PHARMACOKINET, V40, P587, DOI 10.2165/00003088-200140080-00003; Tang W, 2001, CURR DRUG METAB, V2, P185, DOI 10.2174/1389200013338658; Williams D, 2000, PERFORM RES, V5, P131	29	697	725	2	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 24	2003	424	6947					464	468		10.1038/nature01862	http://dx.doi.org/10.1038/nature01862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704BT	12861225				2022-12-28	WOS:000184318400052
J	McWilliams, R; Hoover-Fong, J; Hamosh, A; Beck, S; Beaty, T; Cutting, G				McWilliams, R; Hoover-Fong, J; Hamosh, A; Beck, S; Beaty, T; Cutting, G			Problematic variation in local institutional review of a multicenter genetic epidemiology study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INFORMED CONSENT; RESEARCH ETHICS; SYSTEM; TRIALS; BOARDS	Context Sequencing of the human genome provides an immense resource for studies correlating DNA variation and epidemiology. However, appropriately powered genetic epidemiology studies often require recruitment from multiple sites. Objectives To document the burden imposed by review of multicenter studies and. to determine the variability among local institutional review boards (IRBs) in the approval of a multicenter genetic epidemiology study. Design A PubMed search was performed to determine the frequency of citations of multicenter studies by 5-year intervals from 1974 through 2002. A 7-question survey was sent to all participating study centers to obtain information on frequency of IRB meetings, dates for submission and approval, use/nonuse of a specific consent form, type of review performed, types of consent forms required, preparation time, and number of changes requested by the IRB at each center. Centers also provided a copy of all consent forms they generated and IRB correspondence regarding the study, Setting and Participants Thirty-one of 42 cystic fibrosis care centers in this single US multicenter genetic epidemiology study of cystic fibrosis replied, yielding a 74% response rate. Main Outcome Measures Frequency of published research studies and consistency among IRBs. Results The number of all published single-center studies has increased 1.3-fold since 1985, while the number of published epidemiology and genetic epidemiology multicenter studies increased by 8- and 9-fold, respectively, during this same period. Evaluation of the risk of the same genetic epidemiology study by 31 IRBs ranged from minimal to high, resulting in 7 expedited reviews (23%) and 24 full reviews (77%). The number of consents required by the IRBs ranged from 1 to 4; 15 IRBs (48%) required 2 or more consents, while 10 (32%) did not require assent for children The most common concern (52%) of IRBs pertained to the genetic aspects of the study. Conclusions Review of a protocol for a multi center genetic epidemiology study by local IRBs was highly variable. Lack of uniformity in the review process creates uneven human subjects protection and incurs considerable inefficiency. The need for reform, such as the proposed centralized review, is underscored by the ever increasing rate of genetic discoveries facilitated by the Human Genome Project and the unprecedented opportunity to assess the relevance of genetic Variation to public health.	Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA; St Christophers Hosp Children, Philadelphia, PA 19133 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Drexel University	Cutting, G (corresponding author), Johns Hopkins Med Inst, McKusick Nathans Inst Genet Med, CMSC 1004,600 N Wolfe St, Baltimore, MD 21287 USA.			Hoover-Fong, Julie/0000-0002-1242-5626	NHLBI NIH HHS [HL68927] Funding Source: Medline; NIDDK NIH HHS [R01 DK44003] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044003] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; *AM ASS U PROF, 2000, PROT HUM BEINGS I RE; *AM COLL MED GEN S, 1995, STAT STOR US GEN MAT; *AM SOC HUM GEN AD, 1987, DNA BANK DNA AN POIN; American Hospital Directory, DAT AHA ANN SURV DAT; [Anonymous], 1998, CONS CDC RES REF DEV; Beskow LM, 2001, JAMA-J AM MED ASSOC, V286, P2315, DOI 10.1001/jama.286.18.2315; Boonstra H, 2000, GUTTMACHER REPORT PU; BROWN J, 2000, OEI019700197; Burman WJ, 2001, ANN INTERN MED, V134, P152, DOI 10.7326/0003-4819-134-2-200101160-00016; Christian MC, 2002, NEW ENGL J MED, V346, P1405, DOI 10.1056/NEJM200205023461814; *DEP HHS, 1991, PROT HUM SUBJ; *DEP HHS, 2001, HUM GEN PROJ; Durham ML, 2002, AM J LAW MED, V28, P491; Greely HT, 2001, PERSPECT BIOL MED, V44, P221, DOI 10.1353/pbm.2001.0026; GROB G, 2000, PROTECTING HUMAN SUB; *I MED COMM ASS SY, 2003, RESP RES SYST APPR P; Jamrozik K, 2000, J MED ETHICS, V26, P334, DOI 10.1136/jme.26.5.334; Lemmens T, 2001, IRB, V23, P1, DOI 10.2307/3563780; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MACFADYEN U, 2000, BRIT MED J, V320, P1182; MICETICH KC, 1994, CAMB Q HEALTHC ETHIC, V3, P506, DOI 10.1017/S0963180100005387; Morse MA, 2001, JAMA-J AM MED ASSOC, V285, P1201, DOI 10.1001/jama.285.9.1201; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1; *NAT HUM GEN RES I, I REV BOARD INV GU 2; *NAT I GEN MED SCI, MOD INF CONS FORM; *NAT I HLTH OFF EX, 2001, NIH EXTR AW STAT FOR; National Bioethics Advisory Committee, 1999, RES INV HUM BIOL MAT, V1; *OFF PROT RES RISK, 1993, I REV BOARD GUID HUM; Office for Protection from Research Risks, 1997, ISS CONS RES US STOR; Reilly PR, 1998, AM J HUM GENET, V63, P682, DOI 10.1086/302028; Sarraille William A, 2003, Healthc Financ Manage, V57, P46; *SAS I INC, 2001, SAS WIND REL 8 02 CO; Silverman H, 2001, CRIT CARE MED, V29, P235, DOI 10.1097/00003246-200102000-00002; Slater EE, 2002, NEW ENGL J MED, V346, P1402, DOI 10.1056/NEJM200205023461813; Stair TO, 2001, ACAD EMERG MED, V8, P636, DOI 10.1111/j.1553-2712.2001.tb00177.x; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828; Strass E, 1996, AM J HUM GENET, V59, P471; *US DEP HHS OFF IN, 1998, OEI019700193; Vastag B, 2001, JAMA-J AM MED ASSOC, V285, P721, DOI 10.1001/jama.285.6.721	40	153	155	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					360	366		10.1001/jama.290.3.360	http://dx.doi.org/10.1001/jama.290.3.360			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699WK	12865377	Bronze			2022-12-28	WOS:000184078800030
J	Hotary, KB; Allen, ED; Brooks, PC; Datta, NS; Long, MW; Weiss, SJ				Hotary, KB; Allen, ED; Brooks, PC; Datta, NS; Long, MW; Weiss, SJ			Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix	CELL			English	Article							TISSUE INHIBITOR; COLLAGEN MATRIX; CANCER-THERAPY; UP-REGULATION; ANGIOGENESIS; CELLS; PROLIFERATION; PROGRESSION; EXPRESSION; METASTASIS	Cancer cells are able to proliferate at accelerated rates within the confines of a three-dimensional (313) extracellular matrix (ECM) that is rich in type I collagen. The mechanisms used by tumor cells to circumvent endogenous antigrowth signals have yet to be clearly defined. We find that the matrix metalloproteinase, MT1-MMP, confers tumor cells with a distinct 3D growth advantage in vitro and in vivo. The replicative advantage conferred by MT1-MMP requires pericellular proteolysis of the ECM, as proliferation is fully suppressed when tumor cells are suspended in 3D gels of protease-resistant collagen. In the absence of proteolysis, tumor cells embedded in physiologically relevant ECM matrices are trapped in a compact, spherical configuration and unable to undergo changes in cell shape or cytoskeletal reorganization required for 3D growth. These observations identify MT1-MMP as a tumor-derived growth factor that regulates proliferation by controlling cell geometry within the confines of the 3D ECM.	Univ Michigan, Ctr Comprehens Canc, Div Mol Med & Genet, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Div Hemtol Oncol, Dept Pediat, Ann Arbor, MI 48109 USA; NYU, Sch Med, Dept Radiat Oncol, New York, NY 10016 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; New York University	Weiss, SJ (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Mol Med & Genet, Dept Internal Med, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA71699, CA88308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088308, R01CA071699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Brand K, 2000, CANCER RES, V60, P5723; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; Deryugina EI, 2002, CANCER RES, V62, P580; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feng XD, 1999, J INVEST DERMATOL, V113, P913, DOI 10.1046/j.1523-1747.1999.00786.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Ingber DE, 2003, P NATL ACAD SCI USA, V100, P1472, DOI 10.1073/pnas.0530201100; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; NISHIYAMA T, 1989, MATRIX, V9, P193, DOI 10.1016/S0934-8832(89)80050-2; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Petitclerc E, 1999, CANCER RES, V59, P2724; SELKI M, 2002, CURR OPIN CELL BIOL, V14, P624; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Walpita D, 2002, NAT REV MOL CELL BIO, V3, P137, DOI 10.1038/nrm727; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	37	560	583	0	33	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 11	2003	114	1					33	45		10.1016/S0092-8674(03)00513-0	http://dx.doi.org/10.1016/S0092-8674(03)00513-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859896	Bronze			2022-12-28	WOS:000184219900004
J	Sigurdsson, S; Richer, HB; Hansen, BM; Stairs, IH; Thorsett, SE				Sigurdsson, S; Richer, HB; Hansen, BM; Stairs, IH; Thorsett, SE			A young white dwarf companion to pulsar B1620-26: Evidence for early planet formation	SCIENCE			English	Article							SYSTEM PSR B1620-26; GLOBULAR-CLUSTER MESSIER-4; OPTICAL COUNTERPART; MILLISECOND PULSARS; TRIPLE SYSTEM; M4; SEQUENCE; SEARCH	The pulsar B1620-26 has two companions, one of stellar mass and one of planetary mass. We detected the stellar companion with the use of Hubble Space Telescope observations. The color and magnitude of the stellar companion indicate that it is an undermassive white dwarf (0.34 +/- 0.04 solar mass) of age 480 x 10(6) +/- 140 x 10(6) years. This places a constraint on the recent history of this triple system and supports a scenario in which the current configuration arose through a dynamical exchange interaction in the cluster core. This implies that planets may be relatively common in low-metallicity globular clusters and that planet formation is more widespread and has happened earlier than previously believed.	Penn State Univ, Dept Astron, Davey Lab 525, University Pk, PA 16802 USA; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of British Columbia; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Santa Cruz	Sigurdsson, S (corresponding author), Penn State Univ, Dept Astron, Davey Lab 525, University Pk, PA 16802 USA.			Sigurdsson, Steinn/0000-0002-8187-1144				BACKER DC, 1993, NATURE, V365, P817, DOI 10.1038/365817a0; BAILYN CD, 1994, ASTROPHYS J, V433, pL89, DOI 10.1086/187555; Bonnell IA, 2001, MON NOT R ASTRON SOC, V322, P859, DOI 10.1046/j.1365-8711.2001.04171.x; Camilo F, 1996, ASTROPHYS J, V469, P819, DOI 10.1086/177829; Davies MB, 2001, MON NOT R ASTRON SOC, V324, P612, DOI 10.1046/j.1365-8711.2001.04336.x; Ford EB, 2000, ASTROPHYS J, V528, P336, DOI 10.1086/308167; Gilliland RL, 2000, ASTROPHYS J, V545, pL47, DOI 10.1086/317334; Hansen BMS, 2002, ASTROPHYS J, V574, pL155, DOI 10.1086/342528; Hansen BMS, 2003, ASTROPHYS J, V586, P1364, DOI 10.1086/367827; Hansen BMS, 1998, MON NOT R ASTRON SOC, V294, P557, DOI 10.1046/j.1365-8711.1998.01232.x; Harris WE, 1996, ASTRON J, V112, P1487, DOI 10.1086/118116; Joshi KJ, 1997, ASTROPHYS J, V479, P948, DOI 10.1086/303916; KALIRAL JS, UNPUB; King IR, 1998, ASTROPHYS J, V492, pL37, DOI 10.1086/311082; KIPPENHAHN R, 1967, Z ASTROPHYS, V65, P251; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; LYNE AG, 1988, NATURE, V332, P45, DOI 10.1038/332045a0; MCKENNA J, 1988, NATURE, V336, P47; MICHEL FC, 1994, ASTROPHYS J, V432, P239, DOI 10.1086/174565; Murray N, 1998, SCIENCE, V279, P69, DOI 10.1126/science.279.5347.69; RASIO FA, 1994, ASTROPHYS J, V427, pL107, DOI 10.1086/187376; Richer HB, 1997, ASTROPHYS J, V484, P741, DOI 10.1086/304379; Richer HB, 2002, ASTROPHYS J, V574, pL151, DOI 10.1086/342527; Santos NC, 2001, ASTRON ASTROPHYS, V373, P1019, DOI 10.1051/0004-6361:20010648; Shearer A, 1996, ASTROPHYS J, V473, pL115, DOI 10.1086/310398; SIGURDSSON S, 1993, ASTROPHYS J, V415, pL43, DOI 10.1086/187028; SIGURDSSON S, 1995, ASTROPHYS J, V452, P323, DOI 10.1086/176304; SIGURDSSON S, 1992, ASTROPHYS J, V399, pL95, DOI 10.1086/186615; Thorsett SE, 1999, ASTROPHYS J, V523, P763, DOI 10.1086/307771; THORSETT SE, 1993, ASTROPHYS J, V412, pL33, DOI 10.1086/186933; van Kerkwijk MH, 2000, ASTROPHYS J, V530, pL37, DOI 10.1086/312478	31	167	168	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					193	196		10.1126/science.1086326	http://dx.doi.org/10.1126/science.1086326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855802	Green Submitted			2022-12-28	WOS:000184056200036
J	Chen, J; Larochelle, S; Li, XM; Suter, B				Chen, J; Larochelle, S; Li, XM; Suter, B			Xpd/Ercc2 regulates CAK activity and mitotic progression	NATURE			English	Article							CDK-ACTIVATING KINASE; RNA-POLYMERASE-II; CELL-CYCLE; IN-VIVO; TRANSCRIPTION; TFIIH; EMBRYOS; PHOSPHORYLATION; REPRESSION; MITOSIS	General transcription factor IIH (TFIIH) consists of nine subunits: cyclin-dependent kinase 7 (Cdk7), cyclin H and MAT1 ( forming the Cdk-activating-kinase or CAK complex), the two helicases Xpb/Hay and Xpd, and p34, p44, p52 and p62 (refs 1 - 3). As the kinase subunit of TFIIH, Cdk7 participates in basal transcription by phosphorylating the carboxy-terminal domain of the largest subunit of RNA polymerase II1,4,5. As part of CAK, Cdk7 also phosphorylates other Cdks, an essential step for their activation(6-9). Here we show that the Drosophila TFIIH component Xpd negatively regulates the cell cycle function of Cdk7, the CAK activity. Excess Xpd titrates CAK activity, resulting in decreased Cdk T-loop phosphorylation, mitotic defects and lethality, whereas a decrease in Xpd results in increased CAK activity and cell proliferation. Moreover, Xpd is downregulated at the beginning of mitosis when Cdk1, a cell cycle target of Cdk7, is most active. Downregulation of Xpd thus seems to contribute to the upregulation of mitotic CAK activity and to regulate mitotic progression positively. Simultaneously, the downregulation of Xpd might be a major mechanism of mitotic silencing of basal transcription.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Suter, B (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.		Larochelle, Stephane/D-3662-2012	Larochelle, Stephane/0000-0002-4594-4342				Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; Egly JM, 2001, FEBS LETT, V498, P124, DOI 10.1016/S0014-5793(01)02458-9; FISHER RP, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; Foe Victoria E., 1993, P149; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MALDONADOCODINA G, 1993, J CELL SCI, V105, P711; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Sandrock B, 2001, J BIOL CHEM, V276, P35328, DOI 10.1074/jbc.M105570200; Wallenfang MR, 2002, P NATL ACAD SCI USA, V99, P5527, DOI 10.1073/pnas.082618399	21	101	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					228	232		10.1038/nature01746	http://dx.doi.org/10.1038/nature01746			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853965				2022-12-28	WOS:000184032700050
J	Dancey, JE; Freidlin, B				Dancey, JE; Freidlin, B			Targeting epidermal growth factor receptor - are we missing the mark?	LANCET			English	Review							TYROSINE KINASE INHIBITOR; MONOCLONAL-ANTIBODY; CANCER; ZD1839; IRESSA	Context Aberrant signalling through the epidermal growth factor receptor (EGFR) is associated with neoplastic cell proliferation; migration; stromal invasion, resistance to apoptosis, and angiogenesis. The high frequency of abnormalities in EGFR signalling in human carcinomas and gliomas and laboratory studies showing that inhibition of EGFR can impair tumour growth means that EGFR is an attractive target for the development of cancer therapeutics. Among the classes of agents targeting EGFR in clinical development are monoclonal antibodies against the extracellular ligand-binding domain of the receptor, and small molecules that inhibit activation of the receptor tyrosine kinase. Although there are pharmacological and mechanistic differences between the two classes of inhibitor, preclinical studies suggest they both inhibit cell proliferation and have additive or synergistic cytotoxicity with standard therapies: Results from early clinical trials indicate that these agents are well tolerated and have antitumour activity. Starting point In May, 2003, the Australian Therapeutic Goods Administration and the US Food and Drug Administration. approved the EGFR inhibitor geftinib (ZD1839, Iressa) for, the. treatment of patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. The US approval was based on results of a phase 2 study of 216 patients with NSCLC; including 142 patients with refractory disease. In this subgroup, the response rate was about 10%. The approval of the drug was granted despite negative results from two randomised controlled trials in over 2000 previously untreated patients with NSCLC; which showed no benefit in survival, objective tumour response, or time to progression. when gefitinib was added to chemotherapy. Where next? Research is needed to identify and validate predictive factors that can be used to select patients with disease likely to respond to EGFR inhibitors, and to elucidate the mechanism of interaction of these agents with standard therapies and other molecularly targeted agents. Appropriately designed clinical trials are required to define the optimum dose; schedule; and sequence for these agents in combination with conventional therapies and other targeted agents.	NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dancey, JE (corresponding author), NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Execut Plaza N,6130 Execut Blvd, Bethesda, MD 20892 USA.	danceyj@ctep.nci.nih.gov						Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; CUNNINGHAM D, 2003, P AN M AM SOC CLIN, V22, P252; FUKUOKA M, 2002, P AN M AM SOC CLIN, V21, P1188; Giaccone G, 2002, ANN ONCOL, V13, P217, DOI 10.1093/annonc/mdf663; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; JOHNSON DH, 2002, ANN ONCOL, V13, P128; KRIS MG, 2002, P AN M AM SOC CLIN, V21, P1166; *ODAC ADV POS CHAL, 2002, CANC LETT, V28, P1; PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, P1235; Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739; Rowinsky E, 2000, DRUGS, V60, P41; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; *US FDA, 2003, CTR DRUG EV RES; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7	20	162	168	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2003	362	9377					62	64		10.1016/S0140-6736(03)13810-X	http://dx.doi.org/10.1016/S0140-6736(03)13810-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853203				2022-12-28	WOS:000184056900025
J	Nabel, EG				Nabel, EG			Cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACTIVATED PROTEIN-C; LEFT-VENTRICULAR HYPERTROPHY; CONVERTING ENZYME GENE; LONG-QT SYNDROME; INSERTION/DELETION POLYMORPHISM; BETA(2)-ADRENERGIC RECEPTOR; MYOCARDIAL-INFARCTION; DELETION POLYMORPHISM; FACTOR-V; CORONARY ATHEROSCLEROSIS		NHLBI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Nabel, EG (corresponding author), NHLBI, NIH, Bldg 10-8C103,10 Ctr Dr, Bethesda, MD 20892 USA.	enabel@nih.gov	Grace, Sherry L/H-1388-2013	Grace, Sherry L/0000-0001-7063-3610	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Ballantyne CM, 2000, J AM COLL CARDIOL, V36, P1572, DOI 10.1016/S0735-1097(00)00918-9; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Cargill M, 1999, NAT GENET, V23, P373, DOI 10.1038/15564; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Cockcroft JR, 2000, HYPERTENSION, V36, P371, DOI 10.1161/01.HYP.36.3.371; Cooper R, 2000, CIRCULATION, V102, P3137; De Stefano V, 2001, BRIT J HAEMATOL, V113, P630, DOI 10.1046/j.1365-2141.2001.02827.x; Dishy V, 2001, NEW ENGL J MED, V345, P1030, DOI 10.1056/NEJMoa010819; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Gerdes LU, 2000, CIRCULATION, V101, P1366, DOI 10.1161/01.CIR.101.12.1366; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; GREENGARD JS, 1994, NEW ENGL J MED, V331, P1559, DOI 10.1056/NEJM199412083312305; GRIFFIN JH, 1993, BLOOD, V82, P1989; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; Ho CY, 2000, CIRCULATION, V102, P1950, DOI 10.1161/01.CIR.102.16.1950; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Kane J, 2001, METAB MOL BASES INHE, P2717; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KOELEMAN BPC, 1994, BLOOD, V84, P1031; Kohno M, 1999, AM J MED, V106, P544, DOI 10.1016/S0002-9343(99)00067-4; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Liggett SB, 2000, AM J RESP CRIT CARE, V161, pS197, DOI 10.1164/ajrccm.161.supplement_2.a1q4-10; Marian AJ, 2000, J AM COLL CARDIOL, V35, P89, DOI 10.1016/S0735-1097(99)00535-5; Maron BJ, 1998, CIRCULATION, V98, P1460, DOI 10.1161/01.CIR.98.14.1460; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; McNamara DM, 2001, CIRCULATION, V103, P1644, DOI 10.1161/01.CIR.103.12.1644; MITSUUCHI Y, 1992, BIOCHEM BIOPH RES CO, V184, P1529; MITSUUCHI Y, 1992, BIOCHEM BIOPH RES CO, V182, P974, DOI 10.1016/0006-291X(92)91827-D; Mohlke KL, 2002, P NATL ACAD SCI USA, V99, P16928, DOI 10.1073/pnas.262661399; Myerson SG, 2001, CIRCULATION, V103, P226; *NAT HEART LUNG BL, 2003, NHLBI FACT BOOK FISC; *NAT HEART LUNG BL, 2002, NHLBI MORB MORT CHAR; *NHLBI PROGR GEN A, 2003, GEN CARD DEV AD REM; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; O'Toole L, 1998, J CARDIOVASC PHARM, V32, P988, DOI 10.1097/00005344-199812000-00017; Oliphant A, 2002, BIOTECHNIQUES, P56; Ortlepp JR, 2002, HEART, V87, P270, DOI 10.1136/heart.87.3.270; Osterop APRM, 1998, HYPERTENSION, V32, P825, DOI 10.1161/01.HYP.32.5.825; Pedro-Botet J, 2001, ATHEROSCLEROSIS, V158, P183, DOI 10.1016/S0021-9150(01)00410-5; Penno G, 1998, DIABETES, V47, P1507, DOI 10.2337/diabetes.47.9.1507; Perna A, 2000, KIDNEY INT, V57, P274, DOI 10.1046/j.1523-1755.2000.00818.x; Prasad A, 2000, CIRCULATION, V102, P35, DOI 10.1161/01.CIR.102.1.35; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Roberts R, 2001, CIRCULATION, V104, P2113, DOI 10.1161/hc4201.097429; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Sakaeda T, 2001, PHARMACEUT RES, V18, P1400, DOI 10.1023/A:1012244520615; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; SEIDMAN CE, 2001, METABOLIC MOL BASES, V4, P5433; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Stavroulakis GA, 2000, CARDIOVASC DRUG THER, V14, P427, DOI 10.1023/A:1007820401377; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Tan HL, 2001, NATURE, V409, P1043, DOI 10.1038/35059090; Tesson F, 1997, J MOL CELL CARDIOL, V29, P831, DOI 10.1006/jmcc.1996.0332; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270; Zohlnhofer D, 2001, MOL CELL, V7, P1059, DOI 10.1016/S1097-2765(01)00239-8; Zohlnhofer D, 2001, CIRCULATION, V103, P1396, DOI 10.1161/01.CIR.103.10.1396; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	92	276	301	4	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					60	72		10.1056/NEJMra035098	http://dx.doi.org/10.1056/NEJMra035098			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840094	Bronze			2022-12-28	WOS:000183896100011
J	Regal, CA; Ticknor, C; Bohn, JL; Jin, DS				Regal, CA; Ticknor, C; Bohn, JL; Jin, DS			Creation of ultracold molecules from a Fermi gas of atoms	NATURE			English	Article							BOSE-EINSTEIN CONDENSATE; FESHBACH RESONANCES; COLLISIONS; LASER	Following the realization of Bose-Einstein condensates in atomic gases, an experimental challenge is the production of molecular gases in the quantum regime. A promising approach is to create the molecular gas directly from an ultracold atomic gas; for example, bosonic atoms in a Bose-Einstein condensate have been coupled to electronic ground-state molecules through photoassociation(1) or a magnetic field Feshbach resonance(2). The availability of atomic Fermi gases offers the prospect of coupling fermionic atoms to bosonic molecules, thus altering the quantum statistics of the system. Such a coupling would be closely related to the pairing mechanism in a fermionic superfluid, predicted to occur near a Feshbach resonance(3,4). Here we report the creation and quantitative characterization of ultracold K-40(2) molecules. Starting with a quantum degenerate Fermi gas of atoms at a temperature of less than 150 nK, we scan the system over a Feshbach resonance to create adiabatically more than 250,000 trapped molecules; these can be converted back to atoms by reversing the scan. The small binding energy of the molecules is controlled by detuning the magnetic field away from the Feshbach resonance, and can be varied over a wide range. We directly detect these weakly bound molecules through their radio-frequency photodissociation spectra; these probe the molecular wavefunction, and yield binding energies that are consistent with theory.	Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Quantum Phys Div, Boulder, CO 80309 USA	National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA	Regal, CA (corresponding author), Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA.		Ticknor, Christopher/B-8651-2014	Ticknor, Christopher/0000-0001-9972-4524; REGAL, CINDY/0000-0002-0000-2140				Balakrishnan N, 1998, PHYS REV LETT, V80, P3224, DOI 10.1103/PhysRevLett.80.3224; BOURDEL T, MEASUREMENT INTERACT; Cornish SL, 2000, PHYS REV LETT, V85, P1795, DOI 10.1103/PhysRevLett.85.1795; DeMarco B, 1999, SCIENCE, V285, P1703, DOI 10.1126/science.285.5434.1703; Dieckmann K, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.203201; Donley EA, 2002, NATURE, V417, P529, DOI 10.1038/417529a; FESHBACH H, 1962, ANN PHYS-NEW YORK, V19, P287, DOI 10.1016/0003-4916(62)90221-X; Forrey RC, 1999, PHYS REV LETT, V82, P2657, DOI 10.1103/PhysRevLett.82.2657; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; Loftus T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173201; Mies FH, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.022721; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; O'Hara KM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.041401; Petrosyan KG, 1999, JETP LETT+, V70, P11, DOI 10.1134/1.568122; RATCLIFF LB, 1987, J MOL SPECTROSC, V122, P293, DOI 10.1016/0022-2852(87)90006-3; Regal CA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.053201; REGAL CA, IN PRESS PHYS REV LE; Soldan P, 2002, PHYS REV LETT, V89, DOI [10.1103/PhysRevLett.89.153201, 10.1103/PhysRevLett89.153201]; Stenger J, 1999, PHYS REV LETT, V82, P2422, DOI 10.1103/PhysRevLett.82.2422; STWALLEY WC, 1976, PHYS REV LETT, V37, P1628, DOI 10.1103/PhysRevLett.37.1628; TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PhysRevA.47.4114; Timmermans E, 1999, PHYS REP, V315, P199, DOI 10.1016/S0370-1573(99)00025-3; Timmermans E, 2001, PHYS LETT A, V285, P228, DOI 10.1016/S0375-9601(01)00346-2; Torma P, 2000, PHYS REV LETT, V85, P487, DOI 10.1103/PhysRevLett.85.487; Wynar R, 2000, SCIENCE, V287, P1016, DOI 10.1126/science.287.5455.1016; [No title captured]	27	634	648	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					47	50		10.1038/nature01738	http://dx.doi.org/10.1038/nature01738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840753	Green Submitted			2022-12-28	WOS:000183912800034
J	Takeda, S; Yamashita, A; Maeda, K; Maeda, Y				Takeda, S; Yamashita, A; Maeda, K; Maeda, Y			Structure of the core domain of human cardiac troponin in the Ca2+-saturated form	NATURE			English	Article							SKELETAL-MUSCLE TROPONIN; SUBFRAGMENT 1 ATPASE; THIN FILAMENT; ACTIN-TROPOMYOSIN; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; CENTRAL HELIX; T FRAGMENTS; 3 STATES; RABBIT	Troponin is essential in Ca2+ regulation of skeletal and cardiac muscle contraction. It consists of three subunits (TnT, TnC and TnI) and, together with tropomyosin, is located on the actin filament. Here we present crystal structures of the core domains (relative molecular mass of 46,000 and 52,000) of human cardiac troponin in the Ca2+-saturated form. Analysis of the four-molecule structures reveals that the core domain is further divided into structurally distinct subdomains that are connected by flexible linkers, making the entire molecule highly flexible. The alpha-helical coiled-coil formed between TnT and TnI is integrated in a rigid and asymmetric structure (about 80 Angstrom long), the IT arm, which bridges putative tropomyosin-anchoring regions. The structures of the troponin ternary complex imply that Ca2+ binding to the regulatory site of TnC removes the carboxy-terminal portion of TnI from actin, thereby altering the mobility and/or flexibility of troponin and tropomyosin on the actin filament.	SPring 8, RIKEN Harima Inst, Lab Struct Biochem, Sayo, Hyogo 6795148, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Japan Synchrotron Radiation Research Institute; RIKEN; Japan Science & Technology Agency (JST)	Takeda, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Cardiac Physiol, 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.		Yamashita, Atsuko/H-5566-2017	Yamashita, Atsuko/0000-0002-8001-4642				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BABU A, 1993, J BIOL CHEM, V268, P19232; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; FUJITABECKER S, 1993, J BIOCHEM, V114, P438, DOI 10.1093/oxfordjournals.jbchem.a124194; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; Geeves MA, 2000, BIOCHEMISTRY-US, V39, P9345, DOI 10.1021/bi0002232; Hai H, 2002, J BIOCHEM, V131, P407, DOI 10.1093/oxfordjournals.jbchem.a003116; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Li ZX, 2001, BIOPHYS J, V81, P321, DOI 10.1016/S0006-3495(01)75702-5; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; OHTSUKI I, 1988, J BIOCHEM-TOKYO, V103, P913, DOI 10.1093/oxfordjournals.jbchem.a122387; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; Ramakrishnan S, 1995, BIOCHEMISTRY-US, V34, P16789, DOI 10.1021/bi00051a029; ROUSSEL A, 1996, TURBO FRODO MANUAL; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; Takeda S, 1997, EUR J BIOCHEM, V246, P611, DOI 10.1111/j.1432-1033.1997.00611.x; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TANOKURA M, 1983, J BIOCHEM, V93, P331, DOI 10.1093/oxfordjournals.jbchem.a134185; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	50	612	624	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					35	41		10.1038/nature01780	http://dx.doi.org/10.1038/nature01780			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840750				2022-12-28	WOS:000183912800031
J	Cutts, FT; Fine, PEM				Cutts, FT; Fine, PEM			Caution - mortality ratios ahead	LANCET			English	Editorial Material							TITER MEASLES IMMUNIZATION		MRC Labs, Banjul, Gambia; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	Cutts, FT (corresponding author), MRC Labs, Banjul, Gambia.							AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; *EXP PROGR IMM, 1991, WEEKLY EPIDEMIOL REC, V66, P249; HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777; HALSEY NA, 1993, PEDIATR INFECT DIS J, V12, P462, DOI 10.1097/00006454-199306000-00002; HOLT EA, 1993, J INFECT DIS, V168, P1987; Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665	7	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2169	2170		10.1016/S0140-6736(03)13783-X	http://dx.doi.org/10.1016/S0140-6736(03)13783-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842364				2022-12-28	WOS:000183815600003
J	Peltola, H; Schmitt, J; Booy, R				Peltola, H; Schmitt, J; Booy, R			Pneumococcal conjugate vaccine for acute otitis media - yes or no?	LANCET			English	Editorial Material							EFFICACY		Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki 000290, Finland; Johannes Gutenberg Univ Mainz, Zentrum Pravent Padiatrie, D-6500 Mainz, Germany; Royal London Hosp, Queen Marys Sch Med & Dent, Acad Dept Child Hlth, London E1 1BB, England	University of Helsinki; Helsinki University Central Hospital; Johannes Gutenberg University of Mainz; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki 000290, Finland.	heikki.peltola@hus.fi	Booy, Robert/D-4188-2011					Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Dagan R, 2001, PEDIATR INFECT DIS J, V20, P951, DOI 10.1097/00006454-200110000-00008; Dagan R, 2000, PEDIATR INFECT DIS J, V19, pS79, DOI 10.1097/00006454-200005001-00012; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; KILPI T, 2002, 3 INT S PNEUM PNEUM, P110; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534; Vernacchio L, 1998, J PEDIATR-US, V133, P275, DOI 10.1016/S0022-3476(98)70235-5; Von Kries R, 2002, PEDIATR INFECT DIS J, V21, P1017, DOI 10.1097/00006454-200211000-00008	9	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2170	2171		10.1016/S0140-6736(03)13784-1	http://dx.doi.org/10.1016/S0140-6736(03)13784-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842365				2022-12-28	WOS:000183815600004
J	Mitchell, BS				Mitchell, BS			The proteasome - An emerging therapeutic target in cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHASE-I TRIAL; MALIGNANCIES		Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27514 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Mitchell, BS (corresponding author), Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27514 USA.							Aghajanian C, 2002, CLIN CANCER RES, V8, P2505; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133	2	82	93	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2597	2598		10.1056/NEJMp030092	http://dx.doi.org/10.1056/NEJMp030092			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826633				2022-12-28	WOS:000183726400002
J	Bedolla, G; Stemmerman, G				Bedolla, G; Stemmerman, G			Pulmonary small cell carcinocythaemia	LANCET			English	Editorial Material									Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bedolla, G (corresponding author), Univ Cincinnati, Med Ctr, Dept Pathol, Cincinnati, OH 45267 USA.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2113	2113		10.1016/S0140-6736(03)13720-8	http://dx.doi.org/10.1016/S0140-6736(03)13720-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826433	Bronze			2022-12-28	WOS:000183654200009
J	Brugha, R				Brugha, R			Antiretroviral treatment in developing countries: the peril of neglecting private providers	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Increased access to antiretroviral drugs is vital to maintain developing countries with high rates of HIV infection. But unless treatment is properly controlled, these drugs could rapidly become useless	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Brugha, R (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England.		Brugha, Ruairi/C-8420-2012	Brugha, Ruairi/0000-0003-0729-0197				Balambal R., 2001, Indian Journal of Tuberculosis, V48, P73; Benjarattanaporn P, 1997, AIDS, V11, pS87; Berman P, 2000, B WORLD HEALTH ORGAN, V78, P791; Brugha R, 1998, HEALTH POLICY PLANN, V13, P107, DOI 10.1093/heapol/13.2.107; Brugha Ruairi, 2002, HLTH POLICY GLOBALIS, P63; *BUS FIGHTS AIDS, MEMB PROF ABB LAB WO; EGROT M, 2002, P 14 INT AIDS C 7 12; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; International HIV Treatment Access Coalition, 2002, COMM ACT EXP ACC HIV; KAMAT VR, 1997, PRIVATE HLTH PROVIDE, P124; Nyazema N. Z., 2000, Central African Journal of Medicine, V46, P89; SAPLE DG, 2002, P 14 INT AIDS C 7 12; SEBULIME G, 2002, P 14 INT AIDS C 7 12; SMITH E, 2001, WORK PRIVATE SECTOR; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2002, SCAL ANT THER RES LT	16	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1382	1384		10.1136/bmj.326.7403.1382	http://dx.doi.org/10.1136/bmj.326.7403.1382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816829	Green Accepted, Green Published			2022-12-28	WOS:000183756400027
J	Grech, ED; Ramsdale, DR				Grech, ED; Ramsdale, DR			ABC of interventional cardiology - Acute coronary syndrome: ST infarction segment elevation myocardial infarction	BRITISH MEDICAL JOURNAL			English	Review							ANGIOPLASTY		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada; Ctr Cardiothorac, Liverpool, Merseyside, England	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; DEBOER MJ, 2002, PRACTICAL INTERVENTI, P189; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Lieu TA, 1997, J AM COLL CARDIOL, V30, P1741, DOI 10.1016/S0735-1097(97)00391-4; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404	7	14	16	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1379	1381		10.1136/bmj.326.7403.1379	http://dx.doi.org/10.1136/bmj.326.7403.1379			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816828	Green Published			2022-12-28	WOS:000183756400026
J	Melbourne, TI; Webb, FH				Melbourne, TI; Webb, FH			Slow but not quite silent	SCIENCE			English	Editorial Material							SOUTHWEST JAPAN; SUBDUCTION; METAMORPHISM; EARTHQUAKES; TREMOR		Cent Washington Univ, Dept Geol Sci, Ellensburg, WA 98926 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91125 USA	Central Washington University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Melbourne, TI (corresponding author), Cent Washington Univ, Dept Geol Sci, Ellensburg, WA 98926 USA.							AKI K, 1977, J VOLCANOL GEOTH RES, V2, P259, DOI 10.1016/0377-0273(77)90003-8; BEAVAN J, 1983, SCIENCE, V222, P322, DOI 10.1126/science.222.4621.322; Hirose H, 1999, GEOPHYS RES LETT, V26, P3237, DOI 10.1029/1999GL010999; HUENGES E, 1995, INT UN GEOD GEOPH 21, V21, P145; Julian B, 2002, SCIENCE, V296, P1625, DOI 10.1126/science.1072602; KAWASAKI I, 1995, J PHYS EARTH, V43, P105, DOI 10.4294/jpe1952.43.105; Miller MM, 2002, SCIENCE, V295, P2423, DOI 10.1126/science.1071193; Obara K, 2002, SCIENCE, V296, P1679, DOI 10.1126/science.1070378; Peacock SM, 1999, SCIENCE, V286, P937, DOI 10.1126/science.286.5441.937; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; WHITCOMB JH, 2000, SEISMOL RES LETT, V71, P251	11	33	34	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1886	1887		10.1126/science.1086163	http://dx.doi.org/10.1126/science.1086163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817131				2022-12-28	WOS:000183619400026
J	Sampaolesi, M; Torrente, Y; Innocenzi, A; Tonlorenzi, R; D'Antona, G; Pellegrino, MA; Barresi, R; Bresolin, N; De Angelis, MGC; Campbell, KP; Bottinelli, R; Cossu, G				Sampaolesi, M; Torrente, Y; Innocenzi, A; Tonlorenzi, R; D'Antona, G; Pellegrino, MA; Barresi, R; Bresolin, N; De Angelis, MGC; Campbell, KP; Bottinelli, R; Cossu, G			Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts	SCIENCE			English	Article							SKELETAL-MUSCLE FIBERS; MYOSIN HEAVY-CHAIN; STEM-CELLS; SHORTENING VELOCITY; MUSCULAR-DYSTROPHY; BONE-MARROW; ADENOASSOCIATED VIRUS; MDX MICE; MOUSE; TRANSPLANTATION	Preclinical or clinical trials for muscular dystrophies have met with modest success, mainly because of inefficient delivery of viral vectors or donor cells to dystrophic muscles. We report here that intra-arterial delivery of wildtype mesoangioblasts, a class of vessel-associated stem cells, corrects morphologically and functionally the dystrophic phenotype of virtually all downstream muscles in adult immunocompetent alpha-sarcoglycan (alpha-SG) null mice, a model organism for limb-girdle muscular dystrophy. When mesoangioblasts isolated from juvenile dystrophic mice and transduced with a lentiviral vector expressing alpha-SG were injected into the femoral artery of dystrophic mice, they reconstituted skeletal muscle in a manner similar to that seen in wild-type cells. The success of this protocol was mainly due to widespread distribution of donor stem cells through the capillary network, a distinct advantage of this strategy over previous approaches.	Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; Osped Maggiore Policlin, Ctr Dino Ferrari, IRCCS, Dept Neurol Sci, I-20122 Milan, Italy; Univ Pavia, Dept Expt Med, I-27100 Pavia, Italy; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol Biophys & Neurol, Iowa City, IA 52242 USA; IRCCS E Medea, I-23842 Bosisio Parini, Lecco, Italy; Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Inst Cell Biol & Tissue Engn, I-00128 Rome, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Pavia; Howard Hughes Medical Institute; University of Iowa; IRCCS Eugenio Medea; Sapienza University Rome	Cossu, G (corresponding author), Hosp San Raffaele, Stem Cell Res Inst, Via Olgettina 58, I-20132 Milan, Italy.	cossu.giulio@hsr.it	Tonlorenzi, Rossana/AAN-2241-2020; Barresi, Rita/AAB-9569-2022; Bottinelli, Roberto/AAC-1904-2020; canepari, Monica MC/D-7677-2015; Pellegrino, Maria Antonietta/AAC-4680-2022; Sampaolesi, Maurilio/H-6509-2013; TORRENTE, YVAN/A-2964-2015	Barresi, Rita/0000-0001-7351-959X; Bottinelli, Roberto/0000-0002-4960-7490; Pellegrino, Maria Antonietta/0000-0002-1653-1266; Sampaolesi, Maurilio/0000-0002-2422-3757; TORRENTE, YVAN/0000-0002-2705-3984; Campbell, Kevin/0000-0003-2066-5889; D'Antona, Giuseppe/0000-0002-0683-5565; Bresolin, Nereo/0000-0001-6694-3595; Tonlorenzi, Rossana/0000-0002-6060-8208	Telethon [463/BI, 1322] Funding Source: Medline	Telethon(Fondazione Telethon)		Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Bottinelli R, 2000, PROG BIOPHYS MOL BIO, V73, P195, DOI 10.1016/S0079-6107(00)00006-7; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Cossu G, 2000, J CLIN INVEST, V105, P1669, DOI 10.1172/JCI10376; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; DelloRusso C, 2002, P NATL ACAD SCI USA, V99, P12979, DOI 10.1073/pnas.202300099; Dressman D, 2002, HUM GENE THER, V13, P1631, DOI 10.1089/10430340260201725; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; MacGregor R R, 2001, Hum Gene Ther, V12, P2028; Minasi MG, 2002, DEVELOPMENT, V129, P2773; PALUMBO R, UNPUB; Pansarasa O, 2002, EUR J APPL PHYSIOL, V87, P550, DOI 10.1007/s00421-002-0668-3; Pellegrino MA, 2003, J PHYSIOL-LONDON, V546, P677, DOI 10.1113/jphysiol.2002.027375; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SAMPAOLESI M, UNPUB; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; Skuk D, 2002, CURR OPIN NEUROL, V15, P563, DOI 10.1097/00019052-200210000-00007; TAGLIAFICO E, UNPUB; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Weiss S, 2001, J BIOL CHEM, V276, P45902, DOI 10.1074/jbc.M107434200; Yuasa K, 2002, GENE THER, V9, P1576, DOI 10.1038/sj.gt.3301829	35	483	514	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	2003	301	5632					487	492		10.1126/science.1082254	http://dx.doi.org/10.1126/science.1082254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	704LE	12855815	Green Accepted			2022-12-28	WOS:000184340500034
J	Tasci, S; Ewig, S; Burghard, A; Luderitz, B				Tasci, S; Ewig, S; Burghard, A; Luderitz, B			Pneumocystis carinii pneumonia	LANCET			English	Editorial Material							TRANSMISSION		Univ Bonn, Dept Internal Med 2, Bochum, Germany; Augusta Hosp, Dept Pulm Med, Bochum, Germany	University of Bonn	Tasci, S (corresponding author), Univ Bonn, Dept Internal Med 2, Bochum, Germany.							Dumoulin A, 2000, EUR J CLIN MICROBIOL, V19, P671, DOI 10.1007/s100960000354; Kovacs JA, 2001, JAMA-J AM MED ASSOC, V286, P2450, DOI 10.1001/jama.286.19.2450; Morris A, 2002, MICROBES INFECT, V4, P95, DOI 10.1016/S1286-4579(01)01514-3; VOGEL P, 1993, J INFECT DIS, V168, P836, DOI 10.1093/infdis/168.4.836	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					124	124		10.1016/S0140-6736(03)13864-0	http://dx.doi.org/10.1016/S0140-6736(03)13864-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867113				2022-12-28	WOS:000184089200012
J	Cirac, JI; Zoller, P				Cirac, JI; Zoller, P			How to manipulate cold atoms	SCIENCE			English	Editorial Material							BOSE-EINSTEIN CONDENSATION; OPTICAL LATTICES		Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria	Max Planck Society; University of Innsbruck	Cirac, JI (corresponding author), Max Planck Inst Quantum Opt, D-85748 Garching, Germany.	ignacio.cirac@mpq.mpg.de; peter.zoller@uibk.ac.at	Cirac, J. Ignacio/A-9105-2017; Zoller, Peter/O-1639-2014	Cirac, J. Ignacio/0000-0003-3359-1743; Zoller, Peter/0000-0003-4014-1505				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Anglin JR, 2002, NATURE, V416, P211, DOI 10.1038/416211a; Brennen GK, 1999, PHYS REV LETT, V82, P1060, DOI 10.1103/PhysRevLett.82.1060; Greiner M, 2002, NATURE, V419, P51, DOI 10.1038/nature00968; Hofstetter W, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.220407; Jaksch D, 1999, PHYS REV LETT, V82, P1975, DOI 10.1103/PhysRevLett.82.1975; Jane E, 2003, QUANTUM INF COMPUT, V3, P15; Orzel C, 2001, SCIENCE, V291, P2386, DOI 10.1126/science.1058149; PHILLIPS WD, COMMUNICATION; Sachdev S., 2001, QUANTUM PHASE TRANSI	13	34	34	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					176	177		10.1126/science.1085130	http://dx.doi.org/10.1126/science.1085130			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855795				2022-12-28	WOS:000184056200027
J	Neumann, K				Neumann, K			New Guinea: A cradle of agriculture	SCIENCE			English	Editorial Material							DOMESTICATION; PLANT		Univ Frankfurt, D-60329 Frankfurt, Germany	Goethe University Frankfurt	Neumann, K (corresponding author), Univ Frankfurt, D-60329 Frankfurt, Germany.							Bayliss-Smith T.P., 1996, ORIGINS SPREAD AGR P, P499; BULMER S, 1975, J SOC OCEANISTES, V31, P7, DOI DOI 10.3406/JSO.1975.2688; Denham TP, 2003, SCIENCE, V301, P189, DOI 10.1126/science.1085255; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; Golson J., 1977, SUNDA SAHUL PREHISTO, P601; Haberle S., 1994, Tropical archaeobotany: applications and new developments. Derived from a thematic session of the Second World Archaeological Congress, held in Barquisimeto, Venezuela, September 1990., P172; HARLAN JR, 1971, SCIENCE, V174, P468, DOI 10.1126/science.174.4008.468; Lebot V, 1999, GENET RESOUR CROP EV, V46, P619, DOI 10.1023/A:1008748504038; NEUMANN K, IN PRESS AFRICAN ARC; Sauer Carl O., 1952, AGR ORIGINS DISPERSA; Smith B. D., 1998, EMERGENCE AGR; Vavilov NJ., 1992, ORIGIN GEOGRAPHY CUL	12	12	12	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					180	181		10.1126/science.1086677	http://dx.doi.org/10.1126/science.1086677			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12817087				2022-12-28	WOS:000184056200030
J	Park, S; Wolanin, PM; Yuzbashyan, EA; Silberzan, P; Stock, JB; Austin, RH				Park, S; Wolanin, PM; Yuzbashyan, EA; Silberzan, P; Stock, JB; Austin, RH			Motion to form a quorum	SCIENCE			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Inst Curie, F-75005 Paris, France	Princeton University; Princeton University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Stock, JB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Silberzan, Pascal/L-5934-2016; Park, Sungsu/L-1920-2013; Park, Sungsu/AAF-4792-2020	Silberzan, Pascal/0000-0002-8554-882X; Park, Sungsu/0000-0003-3062-1302	NHGRI NIH HHS [R01 HG001506] Funding Source: Medline; NIGMS NIH HHS [F32 GM064228] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM064228] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; Brenner MP, 1998, BIOPHYS J, V74, P1677, DOI 10.1016/S0006-3495(98)77880-4; BUDRENE EO, 1995, NATURE, V376, P49, DOI 10.1038/376049a0; CLARKE S, 1979, J BIOL CHEM, V254, P9695; McClaine JW, 2002, BIOTECHNOL BIOENG, V78, P179, DOI 10.1002/bit.10192; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Swift S, 2001, ADV MICROB PHYSIOL, V45, P199, DOI 10.1016/S0065-2911(01)45005-3	8	115	115	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					188	188		10.1126/science.1079805	http://dx.doi.org/10.1126/science.1079805			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855801				2022-12-28	WOS:000184056200034
J	Keeling, P; Hughes, D; Price, L; Shaw, S; Barton, A				Keeling, P; Hughes, D; Price, L; Shaw, S; Barton, A			Safety and feasibility of prehospital thrombolysis carried out by paramedics	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION		S Devon Healthcare Trust, Torquay TQ2 7AA, England; Peninsula Med Sch, Res & Dev Support Unit, Plymouth PL6 8BX, Devon, England; Univ Plymouth, Dept Math & Stat, Plymouth PL4 8AA, Devon, England	University of Plymouth; University of Plymouth	Keeling, P (corresponding author), S Devon Healthcare Trust, Lawes Bridge, Torquay TQ2 7AA, England.			barton, andy/0000-0003-2245-1446				Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; *DEP HLTH, 2001, NAT SERV FRAM COR HE; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; *NAT I CLIN EXC, 2002, GUID US DRUGS EARL T; *ROYAL COLL AMB LI, 2001, TECHN APPR PROC SER, V4	5	27	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					27	28		10.1136/bmj.327.7405.27	http://dx.doi.org/10.1136/bmj.327.7405.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842952	Bronze, Green Published			2022-12-28	WOS:000184062700022
J	Aaby, P; Jensen, H; Samb, B; Cisse, B; Sodemann, M; Jakobsen, M; Poulsen, A; Rodrigues, A; Lisse, IM; Simondon, F; Whittle, H				Aaby, P; Jensen, H; Samb, B; Cisse, B; Sodemann, M; Jakobsen, M; Poulsen, A; Rodrigues, A; Lisse, IM; Simondon, F; Whittle, H			Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies	LANCET			English	Article							EDMONSTON-ZAGREB; CHILD-MORTALITY; ROUTINE VACCINATIONS; IMMUNE-RESPONSES; GUINEA-BISSAU; IMMUNIZATION; SURVIVAL; TERM; MORBIDITY; COMMUNITY	Background Females given high-titre measles vaccine (HTMV) have high mortality; diphtheria-tetanus-pertussis (DTP) vaccination might be associated with increased female mortality. We aimed to assess whether IDTP or inactivated poliovirus (IPV) administered after HTMV was associated with increased female-male mortality ratio. Methods In three trials from West Africa, 2000 children were randomised to HTMV or control vaccine at 4-5 months of age; a second vaccination was given at age 9-10 months (standard measles vaccine). Children in high-titre groups were given IPV or DTP-IPV. Another 944 children received HTMV as routine vaccination in Senegal. Findings When we compared high-titre and control groups, no difference in mortality between the first and the second vaccination was noted. After the second vaccination, the female-male mortality ratio was 1.84 (95% CI 1.19-2.84) in children in the high-titre groups who received DTP-IPV or IPV, and 0.59 (0.34-1.04) in controls who received standard measles vaccine (p=0.007). Children who received HTMV but no additional DTP-IPV or IPV had a female-male mortality ratio of 0.83 (0.41-1.67). This ratio was 2.22 (1.04-4.71) for children who received DTP-IPV after routine HTMV and 1.00 (0.68-1.47) for those who did not. When we combined the results from all trials, the female-male mortality ratio was 1.93 (1.33-2.81) for those who received DTP or IPV after HTMV, and 0.96 (0.69-1.34) for those who did not (p=0.006). Interpretation A change in sequence of vaccinations, rather than HTMV itself, may have been the cause of increased female mortality in these trials.	Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau; IRD, UR 24, Epidemiol & Prevent Res Unit, Dakar, Senegal; MRC Labs, Banjul, Gambia	Aarhus University; Institut de Recherche pour le Developpement (IRD); MRC Laboratory Molecular Biology	Aaby, P (corresponding author), State Serum Inst, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.	psb@mail.gtelecom.gw		Poulsen, Anja/0000-0002-9656-1552; Sodemann, Morten/0000-0001-8992-2500; Simondon, Francois/0000-0003-0395-1314; Aaby, Peter/0000-0001-8331-1389				Aaby P, 1996, T ROY SOC TROP MED H, V90, P326, DOI 10.1016/S0035-9203(96)90275-8; AABY P, 1991, LANCET, V338, P1518, DOI 10.1016/0140-6736(91)92330-5; AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005; Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3; Aaby P, 1996, AM J EPIDEMIOL, V143, P1035, DOI 10.1093/oxfordjournals.aje.a008667; AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; AABY P, ROUTINE VACCINATIONS; Aaby P, 1998, METHODS USES ANTHROP, P223; Akramuzzaman SM, 2000, AM J EPIDEMIOL, V151, P723, DOI 10.1093/oxfordjournals.aje.a010267; [Anonymous], 1992, WKLY EPIDEMIOL REC, V67, P357; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7; Dollimore N, 1997, AM J EPIDEMIOL, V146, P646, DOI 10.1093/oxfordjournals.aje.a009330; GARENNE M, 1991, LANCET, V338, P903, DOI 10.1016/0140-6736(91)91771-L; GARENNE M, 1994, INT J EPIDEMIOL, V23, P632, DOI 10.1093/ije/23.3.632; GARLY ML, IN PRESS VACCINE; *GLOB ADV GROUP, 1990, WKLY EPIDEMIOL REC, V65, P5; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; HOLT EA, 1993, J INFECT DIS, V168, P1087, DOI 10.1093/infdis/168.5.1087; Hussey GD, 1996, J INFECT DIS, V173, P1320, DOI 10.1093/infdis/173.6.1320; Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665; Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435; Libman MD, 2002, PEDIATR INFECT DIS J, V21, P112, DOI 10.1097/00006454-200202000-00006; Lindblad EB, 1997, INFECT IMMUN, V65, P623, DOI 10.1128/IAI.65.2.623-629.1997; Ota MOC, 2002, J IMMUNOL, V168, P919, DOI 10.4049/jimmunol.168.2.919; Pittman PR, 2002, VACCINE, V20, pS48, DOI 10.1016/S0264-410X(02)00172-X; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474	30	173	173	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2183	2188		10.1016/S0140-6736(03)13771-3	http://dx.doi.org/10.1016/S0140-6736(03)13771-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842371				2022-12-28	WOS:000183815600010
J	Crosby, A; Talbot, NP; Harrison, P; Keeling, D; Robbins, PA				Crosby, A; Talbot, NP; Harrison, P; Keeling, D; Robbins, PA			Relation between acute hypoxia and activation of coagulation in human beings	LANCET			English	Article							HYPOBARIC HYPOXIA; FIBRINOLYSIS	The risk of venous thrombosis may be increased during aeroplane flights, which may, partly, relate to activation of coagulation by hypoxia that is caused by the reduction of pressure in the aircraft cabin. To find out whether hypoxia activates coagulation, we exposed eight healthy human participants to 8 h of isocapnic hypoxia and 8 h of air as a control. Venous blood was sampled before and after the exposure and analysed for markers of activated coagulation. There were no significant changes. We conclude that hypoxia has no major effect on coagulation in the general population.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England; Churchill Hosp, Thrombosis Unit, Oxford OX3 7LJ, England	University of Oxford; University of Oxford; University of Oxford	Robbins, PA (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		; Robbins, Peter/C-7846-2016	Harrison, Paul/0000-0003-4610-8909; Robbins, Peter/0000-0002-4975-0609; Keeling, David/0000-0001-6779-6566; Talbot, Nick/0000-0002-9186-8950				BARTSCH P, 1989, J APPL PHYSIOL, V66, P2136, DOI 10.1152/jappl.1989.66.5.2136; Bartsch T, 2001, LANCET, V357, P955; Bendz B, 2000, LANCET, V356, P1657, DOI 10.1016/S0140-6736(00)03165-2; HOWARD LSGE, 1995, J APPL PHYSIOL, V78, P1088, DOI 10.1152/jappl.1995.78.3.1088; Mannucci PM, 2002, THROMB HAEMOSTASIS, V87, P342	5	60	64	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2207	2208		10.1016/S0140-6736(03)13777-4	http://dx.doi.org/10.1016/S0140-6736(03)13777-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842377				2022-12-28	WOS:000183815600016
J	Bouvier, F; Dogbo, O; Camara, B				Bouvier, F; Dogbo, O; Camara, B			Biosynthesis of the food and cosmetic plant pigment bixin (annatto)	SCIENCE			English	Article							CAROTENOIDS; DIOXYGENASE; CLEAVAGE; FLOWERS; COLORS; SEEDS	Bixin, also known as annatto, is a seed-specific pigment widely used in foods and cosmetics since pre-Columbian times. We show that three genes from Bixa orellana, native to tropical America, govern bixin biosynthesis. These genes code for lycopene cleavage dioxygenase, bixin aldehyde dehydrogenase, and norbixin carboxyl methyltransferase, which catalyze the sequential conversion of lycopene into bixin. Introduction of these three genes in Escherichia coli engineered to produce lycopene induced bixin synthesis, thus expanding the supply of this economically important plant product.	Univ Strasbourg, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Univ Abobo Adjarne 02, UFR SN, Abidjan 02, Cote Ivoire	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Camara, B (corresponding author), Univ Strasbourg, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France.	Bilal.camara@ibmp-ulp.u-strasbg.fr						Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Britton G, 1998, CAROTENOIDS BIOSYNTH, P13; COLLINS P, 1992, FOODS INGRED PROCESS, V13, P23; Dudareva N, 2000, PLANT CELL, V12, P949, DOI 10.1105/tpc.12.6.949; LAURO GJ, 1991, CEREAL FOOD WORLD, V36, P949; Mercadante AZ, 1997, J AGR FOOD CHEM, V45, P1050, DOI 10.1021/jf960412k; Mercadante AZ, 1997, PHYTOCHEMISTRY, V46, P1379, DOI 10.1016/S0031-9422(97)00462-7; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; Pichersky E, 2000, TRENDS PLANT SCI, V5, P439, DOI 10.1016/S1360-1385(00)01741-6; Ross JR, 1999, ARCH BIOCHEM BIOPHYS, V367, P9, DOI 10.1006/abbi.1999.1255; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; SKIBBE DS, 2002, PLANT MOL BIOL, V88, P751; TIMBERLAKE CF, 1986, ENDEAVOUR, V10, P31, DOI 10.1016/0160-9327(86)90048-7; Watillon B, 1998, PLANT MOL BIOL, V36, P909, DOI 10.1023/A:1005914506110; Zechmeister L, 1962, CIS T ISOMERIC CAROT	16	175	188	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2089	2091		10.1126/science.1085162	http://dx.doi.org/10.1126/science.1085162			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829782				2022-12-28	WOS:000183774900045
J	Jiang, H; Stein, BE; McHaffie, JG				Jiang, H; Stein, BE; McHaffie, JG			Opposing basal ganglia processes shape midbrain visuomotor activity bilaterally	NATURE			English	Article							NIGRA PARS RETICULATA; SUPERIOR COLLICULUS; SUBSTANTIA-NIGRA; HORSERADISH-PEROXIDASE; TECTOSPINAL NEURONS; NIGROTECTAL PATHWAY; SUBTHALAMIC NUCLEUS; STRIATAL FUNCTIONS; BASIC PROCESS; CAT	The manner in which the nervous system allocates limited motor resources when confronted with conflicting behavioural demands is a crucial issue in understanding how sensory information is transformed into adaptive motor responses. Understanding this selection process is of particular concern in current models of functions of the basal ganglia(1). Here we report that the basal ganglia use simultaneous enhancing and suppressing processes synergistically to modulate sensory activity in the superior colliculi, which are bilaterally paired midbrain structures involved in the control of visual orientation behaviours(2). These complementary processes presumably ensure accurate gaze shifts mediated by the superior colliculi despite the presence of potential distractors.	Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	McHaffie, JG (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; BECKSTEAD RM, 1981, J NEUROSCI, V1, P121; BEHAN M, 1985, J COMP NEUROL, V234, P105, DOI 10.1002/cne.902340108; CHEVALIER G, 1985, BRAIN RES, V334, P215, DOI 10.1016/0006-8993(85)90213-6; CHEVALIER G, 1984, EXP BRAIN RES, V53, P320; CHEVALIER G, 1981, NEUROSCI LETT, V21, P67, DOI 10.1016/0304-3940(81)90059-8; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; Handel A, 2000, J NEUROPHYSIOL, V83, P3042, DOI 10.1152/jn.2000.83.5.3042; HARTING JK, 1988, J COMP NEUROL, V278, P615, DOI 10.1002/cne.902780412; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1285, DOI 10.1152/jn.1983.49.5.1285; INFANTE C, 1986, BRAIN RES, V381, P390, DOI 10.1016/0006-8993(86)90096-X; JOSEPH JP, 1985, EXP BRAIN RES, V57, P286; Kalesnykas R. P., 1999, Society for Neuroscience Abstracts, V25, P1920; KARABELAS AB, 1985, J COMP NEUROL, V239, P309, DOI 10.1002/cne.902390305; Karnath HO, 2001, NAT REV NEUROSCI, V2, P568, DOI 10.1038/35086057; Kha HT, 2001, J COMP NEUROL, V440, P20, DOI 10.1002/cne.1367; KITA H, 1987, J COMP NEUROL, V260, P435, DOI 10.1002/cne.902600309; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; MAY PJ, 1984, J COMP NEUROL, V226, P357, DOI 10.1002/cne.902260306; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; MIZE RR, 1992, J COMP NEUROL, V320, P243, DOI 10.1002/cne.903200208; MUNOZ DP, 1985, BRAIN RES, V341, P184, DOI 10.1016/0006-8993(85)91487-8; Redgrave P, 1999, NEUROSCIENCE, V89, P1009, DOI 10.1016/S0306-4522(98)00319-4; RYAN LJ, 1991, EXP BRAIN RES, V86, P641; Sato M, 2002, J NEUROSCI, V22, P2363, DOI 10.1523/JNEUROSCI.22-06-02363.2002; SPRAGUE JM, 1966, SCIENCE, V153, P1544, DOI 10.1126/science.153.3743.1544; Stein BE., 1993, MERGING SENSES; WALLACE SF, 1990, J COMP NEUROL, V296, P222, DOI 10.1002/cne.902960204; WALLACE SF, 1989, J COMP NEUROL, V284, P429, DOI 10.1002/cne.902840309; Wang S, 1997, NEUROSCIENCE, V81, P967, DOI 10.1016/S0306-4522(97)00191-7	30	95	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					982	986		10.1038/nature01698	http://dx.doi.org/10.1038/nature01698			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827201				2022-12-28	WOS:000183753900049
J	Frey, SE; Newman, FK; Yan, LH; Belshe, RB				Frey, SE; Newman, FK; Yan, LH; Belshe, RB			Response to smallpox vaccine in persons immunized in the distant past	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT	Context There is renewed interest in use of smallpox vaccine due to the potential for a bioterrorist attack. This would involve vaccinating health care workers who were previously vaccinated. Objective To evaluate the use of diluted vaccinia virus in vaccination of previously vaccinated (non-naive) participants. Design, Setting, and Participants Eighty non-naive participants, aged 3 2 to 60 years, were randomized in a single-blinded study to receive either undiluted or diluted (1:3.2, 1:10, or 1:32) doses of smallpox vaccine. A comparison group, aged 18 to 31 years, of 10 vaccinia-naive participants received undiluted vaccine. Participants were enrolled between April 1 and May 15, 2002, at the National Institute of Allergy and infectious Diseases Vaccine and Treatment Evaluation Unit at Saint Louis University, St Louis, Mo. Intervention Smallpox vaccine was administered by scarification using 15 skin punctures in the deltoid region of the arm. Main Outcome Measures Presence of a major reaction, defined as a vesicular or pustular lesion or area of palpable induration surrounding a central lesion following vaccination, and measures, of viral shedding and antibody titers. Results Initial vaccination resulted in a major reaction in 64 of 80 non-naive participants Ninety-five percent of non-naive participants had major reactions in the undiluted group, 90% in the 1:3.2 dilution group, 81% in the 1:10 dilution group, and 52.6% in the 1:32 dilution group. All (n=10) of the vaccinia-naive participants had major reactions. Compared with vaccinia-naive participants, non-naive participants had significantly smaller skin lesions (P=.04) and significantly less incidence of fever (P=.02). Preexisting antibody was present in 76 of 80 non-naive participants. Antibody responses were significantly higher and occurred more rapidly in the non-naive participants compared with the vaccinia-naive participants (P=.002 for day 28 and P=.003 for 6 months). Vaccinia-naive participants shed virus from the vaccination site 2 to 6 days longer and had significantly higher peak mean viral titers when compared with the non-naive participants (P=.002). Conclusions Previously vaccinated persons can be successfully revaccinated with diluted (less than or equal to1:10) smallpox vaccine. Fewer adverse reactions were observed in this study of non-naive participants when compared with events in vaccinia-naive participants, which may be due to immunologic memory.	St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med,Div Infect Dis & Immunol, St Louis, MO 63110 USA; NIAID, Vaccine & Treatment Evaluat Unit, St Louis, MO USA; EMMES Corp, Rockville, MD USA	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emmes Corporation	Frey, SE (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Med,Div Infect Dis & Immunol, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.				NIAID NIH HHS [N01-AI-45150] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		U.S. Public Health Service, 2001, MMWR Recomm Rep, V50, P1; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; HOLANDER M, 1973, NONPARAMETRIC STAT M, P115; IACONOCONNORS LC, 1994, CLIN DIAGN LAB IMMUN, V1, P78, DOI 10.1128/CDLI.1.1.78-82.1994; LANE JM, 1970, PUBLIC HEALTH REP, V85, P928, DOI 10.2307/4594006; Newman FK, 2003, J INFECT DIS, V187, P1319, DOI 10.1086/374564; NEWMAN FK, IN PRESS IMPROVED AS; POLAK MF, 1972, B WORLD HEALTH ORGAN, V47, P185; SAS Institute Inc, 1999, SAS STAT US GUID VER	12	84	85	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3295	3299		10.1001/jama.289.24.3295	http://dx.doi.org/10.1001/jama.289.24.3295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824212	Bronze			2022-12-28	WOS:000183704600024
J	deFilippi, C; Wasserman, S; Rosanio, S; Tiblier, E; Sperger, H; Tocchi, M; Christenson, R; Uretsky, B; Smiley, M; Gold, J; Muniz, H; Badalamenti, J; Herzog, C; Henrich, W				deFilippi, C; Wasserman, S; Rosanio, S; Tiblier, E; Sperger, H; Tocchi, M; Christenson, R; Uretsky, B; Smiley, M; Gold, J; Muniz, H; Badalamenti, J; Herzog, C; Henrich, W			Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR MASS; STAGE RENAL-DISEASE; CARDIOVASCULAR MORTALITY; ARTERY-DISEASE; ALL-CAUSE; INFLAMMATION; MARKERS; DEATH; DIALYSIS; EVENTS	Context Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear. Objective To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD. Design, Setting, and Participants A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms. Main Outcome Measures All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (less than or equal to40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH). Results One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1; quartile 3: HR, 2.7; 95% Cl, 1.5-4.9; quartile 4: HR, 3.0; 95% Cl, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% Cl, 0.5-1.6; quartile 3: HR, 1.8; 95% Cl, 1.1-3.1; quartile 4: HR, 1.8; 95% Cl, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% Cl, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n=67; 0%, 25%, 50%, and 62% prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P=.07). No trend for cTnT levels was found among patients with LVH (P=.45); similarly, no trend for CRP was found among patients with LVH (P=.65) or an LVEF of 40% or less (P=.75). Conclusions Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.	Univ Maryland, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; San Raffaele Univ Hosp, Dept Cardiol, Milan, Italy; Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA; Renal Care Grp, Angleton, TX USA; Renal Specialists, Houston, TX USA; Univ Minnesota, Sch Med, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55455 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Texas System; University of Texas Medical Branch Galveston; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	deFilippi, C (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Cardiol, 22 S Greene St, Baltimore, MD 21201 USA.	cdefilip@medicine.umaryland.edu	Schulz, Sandra/F-6238-2012					Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Apple FS, 2002, CIRCULATION, V106, P2941, DOI 10.1161/01.CIR.0000041254.30637.34; Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; deFilippi CR, 2000, J AM COLL CARDIOL, V35, P1827, DOI 10.1016/S0735-1097(00)00628-8; DEPNER TA, 1999, PRINCIPLES PRACTICE, P97; Dierkes J, 2000, CIRCULATION, V102, P1964, DOI 10.1161/01.CIR.102.16.1964; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Felker GM, 2002, J AM COLL CARDIOL, V39, P210, DOI 10.1016/S0735-1097(01)01738-7; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Freda BJ, 2002, J AM COLL CARDIOL, V40, P2065, DOI 10.1016/S0735-1097(02)02608-6; Heidenreich PA, 2001, J AM COLL CARDIOL, V38, P478, DOI 10.1016/S0735-1097(01)01388-2; HOSMER DW, 2000, WILEY PS TX, P1; Iliou MC, 2001, NEPHROL DIAL TRANSPL, V16, P1452, DOI 10.1093/ndt/16.7.1452; Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Mallamaci F, 2002, AM J KIDNEY DIS, V40, P68, DOI 10.1053/ajkd.2002.33914; Mallamaci F, 2002, KIDNEY INT, V62, P1884, DOI 10.1046/j.1523-1755.2002.00641.x; Ooi DS, 1999, CLIN BIOCHEM, V32, P647, DOI 10.1016/S0009-9120(99)00064-8; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; Park S H, 1996, J Am Soc Echocardiogr, V9, P119, DOI 10.1016/S0894-7317(96)90019-X; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Redberg RF, 2000, J AM COLL CARDIOL, V36, P39, DOI 10.1016/S0735-1097(00)00680-X; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rocco MV, 2002, AM J KIDNEY DIS, V39, P146, DOI 10.1053/ajkd.2002.29905; Roppolo LP, 1999, J AM COLL CARDIOL, V34, P448, DOI 10.1016/S0735-1097(99)00207-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAS Institute, 1997, SAS STAT SOFTW CHANG; Stenvinkel P, 2002, KIDNEY INT, V62, P1791, DOI 10.1046/j.1523-1755.2002.00637.x; Stolear JC, 1999, NEPHROL DIAL TRANSPL, V14, P1961, DOI 10.1093/ndt/14.8.1961; *US REN DATA SYST, 2000, USRDS ANN DAT REP, P581; Wanner C, 2002, KIDNEY INT, V61, pS99, DOI 10.1046/j.1523-1755.61.s80.18.x; Wayand D, 2000, CLIN CHEM, V46, P1345; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9; Zebrack JS, 2002, J AM COLL CARDIOL, V39, P632, DOI 10.1016/S0735-1097(01)01804-6; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	36	307	315	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					353	359		10.1001/jama.290.3.353	http://dx.doi.org/10.1001/jama.290.3.353			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699WK	12865376				2022-12-28	WOS:000184078800029
J	Dayan, CM				Dayan, CM			Human monoclonal thyroid-stimulating autoantibody: how useful is a holy grail?	LANCET			English	Editorial Material							THYROTROPIN RECEPTOR; MOLECULAR-CLONING; TSH RECEPTOR; ANTIBODY		Univ Bristol, Bristol Royal Infirm, Dept Med, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Dayan, CM (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Med, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England.		Dayan, Colin/AAH-6242-2019	Dayan, Colin/0000-0002-6557-3462				Adams D., 1956, P U OTAGO MED SCH, V34, P11; Ando T, 2002, J CLIN INVEST, V110, P1667, DOI 10.1172/JCI200216991; Costagliola S, 2002, THYROID, V12, P1039, DOI 10.1089/105072502321085126; Costagliola S, 2002, BIOCHEM BIOPH RES CO, V299, P891, DOI 10.1016/S0006-291X(02)02762-6; McLachlan SM, 1996, J CLIN ENDOCR METAB, V81, P3152, DOI 10.1210/jc.81.9.3152; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; ROITT IM, 1956, LANCET, V2, P820; Sanders J, 2002, THYROID, V12, P1043, DOI 10.1089/105072502321085135; WEETMAN AP, 1990, J CLIN INVEST, V86, P723, DOI 10.1172/JCI114768	10	1	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					92	93		10.1016/S0140-6736(03)13893-7	http://dx.doi.org/10.1016/S0140-6736(03)13893-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867105				2022-12-28	WOS:000184089200004
J	Denham, TP; Haberle, SG; Lentfer, C; Fullagar, R; Field, J; Therin, M; Porch, N; Winsborough, B				Denham, TP; Haberle, SG; Lentfer, C; Fullagar, R; Field, J; Therin, M; Porch, N; Winsborough, B			Origins of agriculture at Kuk Swamp in the Highlands of New Guinea	SCIENCE			English	Article							PAPUA-NEW-GUINEA; DOMESTICATION; INDONESIA; RECORDS; SAHUL; PLANT	Multidisciplinary investigations at Kuk Swamp in the Highlands of Papua New Guinea show that agriculture arose independently in New Guinea by at least 6950 to 6440 calibrated years before the present (cal yr B. P.). Plant exploitation and some cultivation occurred on the wetland margin at 10,220 to 9910 cal yr B. P. (phase 1), mounding cultivation began by 6950 to 6440 cal yr B. P. ( phase 2), and ditched cultivation began by 4350 to 3980 cal yr B. P. ( phase 3). Clearance of lower montane rainforests began in the early Holocene, with modi. cation to grassland at 6950 to 6440 cal yr B. P. Taro (Colocasia esculenta) was utilized in the early Holocene, and bananas ( Musa spp.) were intensively cultivated by at least 6950 to 6440 cal yr B. P.	Australian Natl Univ, Sch Archaeol & Anthropol, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Pacific & Asian Studies, Resource Management Asia Pacific Program, Canberra, ACT 0200, Australia; So Cross Univ, Sch Environm Sci & Management, Lismore, NSW 2480, Australia; Univ Sydney, Dept Archaeol, Sydney, NSW 2006, Australia; Monash Univ, Sch Geog & Environm Sci, Clayton, Vic 3800, Australia; Winsborough Consulting, Leander, TX 78641 USA	Australian National University; Australian National University; Southern Cross University; University of Sydney; Monash University	Denham, TP (corresponding author), Flinders Univ S Australia, Dept Archaeol, GPO Box 2100, Adelaide, SA 5100, Australia.		Fullagar, Richard/AAT-1155-2020; Field, Judith H/C-7677-2011; Haberle, Simon/U-4118-2019	Haberle, Simon/0000-0001-5802-6535; Field, Judith/0000-0001-6807-1858; Fullagar, Richard/0000-0003-1047-1466; Denham, Tim/0000-0002-8164-2990				[Anonymous], 1962, EVOLUTION BANANAS; Bellwood Peter, 1997, PREHISTORY INDOMALAY; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; Golson J., 1977, SUNDA SAHUL PREHISTO, P601; GOLSON J, 1980, J SOC OCEANISTES, V36, P294; Haberle S., 1994, Tropical archaeobotany: applications and new developments. Derived from a thematic session of the Second World Archaeological Congress, held in Barquisimeto, Venezuela, September 1990., P172; Haberle SG, 1995, VEG HIST ARCHAEOBOT, V4, P195; Haberle SG, 2001, QUATERNARY RES, V55, P97, DOI 10.1006/qres.2000.2188; Haberle SG, 1998, PALAEOGEOGR PALAEOCL, V137, P1, DOI 10.1016/S0031-0182(97)00097-7; HABERLE SG, 1991, J BIOGEOGR, V18, P25, DOI 10.2307/2845242; Hope G, 1995, ANTIQUITY, V69, P818, DOI 10.1017/S0003598X00082363; HUGHES PJ, 1991, Z GEOMORPHOLOGIE S, V83, P227; Lebot V, 1999, GENET RESOUR CROP EV, V46, P619, DOI 10.1023/A:1008748504038; LOY TH, 1992, ANTIQUITY, V66, P898, DOI 10.1017/S0003598X00044811; POWELL J M, 1982, Archaeology in Oceania, V17, P28; Powell J.M., 1982, BIOGEOGRAPHY ECOLOGY, V1, P207; POWELL JM, 1976, NEW GUINEA VEGETATIO, P23; Sauer CO., 1952, AGR ORIGINS THEIR DI; Smith B. D., 1998, EMERGENCE AGR; SPRIGGS M, 1996, ORIGINS SPREAD AGR P, P524; Vavilov N., 1992, ORIGIN GEOGRAPHY CUL, P22; WALKER D, 1994, CLIMATE CHANGE HUMAN, P101; WILSON S M, 1985, Archaeology in Oceania, V20, P90; Yen DE, 1995, ANTIQUITY, V69, P831, DOI 10.1017/S0003598X00082375	24	283	298	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					189	193		10.1126/science.1085255	http://dx.doi.org/10.1126/science.1085255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12817084				2022-12-28	WOS:000184056200035
J	Shergill, SS; Bays, PM; Frith, CD; Wolpert, DM				Shergill, SS; Bays, PM; Frith, CD; Wolpert, DM			Two eyes for an eye: The neuroscience of force escalation	SCIENCE			English	Article							MOVEMENT		UCL, Inst Neurol, London WC1N 3BG, England; Inst Psychiat, London, England	University of London; University College London; University of London; King's College London	Wolpert, DM (corresponding author), UCL, Inst Neurol, Queen Sq, London WC1N 3BG, England.	wolpert@hera.ucl.ac.uk	Shergill, Sukhi S/G-7725-2011; Bays, Paul/B-3999-2009; Frith, Chris/A-2171-2009	Frith, Chris/0000-0002-8665-0690; shergill, sukhi/0000-0003-4928-9100; Bays, Paul/0000-0003-4684-4893				ANGEL RW, 1982, EXP NEUROL, V77, P266, DOI 10.1016/0014-4886(82)90244-8; Blakemore SJ, 1998, NAT NEUROSCI, V1, P635, DOI 10.1038/2870; Blakemore SJ, 1998, J NEUROSCI, V18, P7511; CHAPMAN CE, 1987, EXP BRAIN RES, V68, P516; CLAXTON G, 1975, PERCEPT MOTOR SKILL, V41, P335, DOI 10.2466/pms.1975.41.1.335; Curio G, 2000, HUM BRAIN MAPP, V9, P183, DOI 10.1002/(SICI)1097-0193(200004)9:4<183::AID-HBM1>3.0.CO;2-Z; MILNE RJ, 1988, EXP BRAIN RES, V70, P569; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; von Holst E, 1954, BRIT J ANIM BEHAV, V2, P89, DOI DOI 10.1016/S0950-5601(54)80044-X; WEISKRANTZ L, 1971, NATURE, V230, P598, DOI 10.1038/230598a0; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	11	260	260	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					187	187		10.1126/science.1085327	http://dx.doi.org/10.1126/science.1085327			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855800	Green Submitted			2022-12-28	WOS:000184056200033
J	Berger, T; Rubner, P; Schautzer, F; Egg, R; Ulmer, H; Mayringer, I; Dilitz, E; Deisenhammer, F; Reindl, M				Berger, T; Rubner, P; Schautzer, F; Egg, R; Ulmer, H; Mayringer, I; Dilitz, E; Deisenhammer, F; Reindl, M			Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BASIC-PROTEIN; FOLLOW-UP; DISEASE; CRITERIA; RAT; MRI; CNS; DIAGNOSIS	BACKGROUND: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these patients, the course of the disease is unpredictable at its onset and requires long-term observation or repeated magnetic resonance imaging (MRI). We investigated whether the presence of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with a clinically isolated syndrome predicts the interval to conversion to clinically definite multiple sclerosis. METHODS: A total of 103 patients with a clinically isolated syndrome, positive findings on cerebral MRI, and oligoclonal bands in the cerebrospinal fluid were studied. At base line, serum samples were collected to test for anti-MOG and anti-MBP antibodies with Western blot analysis, and the lesions detected by cerebral MRI were quantified. Neurologic examinations for relapse or disease progression (defined as conversion to clinically definite multiple sclerosis) were performed at base line and subsequently every three months. RESULTS: Patients with anti-MOG and anti-MBP antibodies had relapses more often and earlier than patients without these antibodies. Only 9 of 39 antibody-seronegative patients (23 percent) had a relapse, and the mean (+/-SD) time to relapse was 45.1+/-13.7 months. In contrast, 21 of 22 patients (95 percent) with antibodies against both MOG and MBP had a relapse within a mean of 7.5+/-4.4 months, and 35 of 42 patients (83 percent) with only anti-MOG antibodies had a relapse within 14.6+/-9.6 months (P<0.001 for both comparisons with antibody-seronegative patients). The adjusted hazard ratio for the development of clinically definite multiple sclerosis was 76.5 (95 percent confidence interval, 20.6 to 284.6) among the patients who were seropositive for both antibodies and 31.6 (95 percent confidence interval, 9.5 to 104.5) among the patients who were seropositive only for anti-MOG antibodies, as compared with the seronegative patients. CONCLUSIONS: Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. This finding may be important for the counseling and care of patients with a first demyelinating event suggestive of multiple sclerosis.	Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Biostat, A-6020 Innsbruck, Austria; Cty Hosp, Dept Neurol, Villach, Austria	University of Innsbruck; University of Innsbruck	Berger, T (corresponding author), Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	thomas.berger@uibk.ac.at	Ulmer, Hanno/S-6615-2019; Calabrese, Massimiliano/I-6195-2012; Reindl, Markus/ABE-5880-2020	Ulmer, Hanno/0000-0001-5911-1002; Berger, Thomas/0000-0001-5626-1144; Reindl, Markus/0000-0003-2817-1402				Achiron A, 2000, ARCH NEUROL-CHICAGO, V57, P974, DOI 10.1001/archneur.57.7.974; Adelmann M, 1995, J NEUROIMMUNOL, V63, P17, DOI 10.1016/0165-5728(95)00124-7; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Bruck W, 2001, MULT SCLER J, V7, P173, DOI 10.1177/135245850100700307; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Dalton CM, 2002, ANN NEUROL, V52, P47, DOI 10.1002/ana.10240; DEROSBO NK, 1990, J NEUROCHEM, V55, P583; Egg R, 2001, MULT SCLER J, V7, P285; FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; Galboiz Y, 2002, CURR OPIN NEUROL, V15, P233, DOI 10.1097/00019052-200206000-00002; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Goebels N, 2000, BRAIN, V123, P508, DOI 10.1093/brain/123.3.508; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Jacobs LD, 1997, ANN NEUROL, V41, P392, DOI 10.1002/ana.410410315; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LININGTON C, 1988, AM J PATHOL, V130, P443; LINK H, 1977, SCAND J CLIN LAB INV, V37, P397, DOI 10.3109/00365517709091498; Lucchinetti CF, 1996, BRAIN PATHOL, V6, P259, DOI 10.1111/j.1750-3639.1996.tb00854.x; MATTHEWS B, 1998, MCALPINES MULTIPLE S, P223; MCALPINE D, 1961, BRAIN, V84, P186, DOI 10.1093/brain/84.2.186; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McFarland HI, 1999, J IMMUNOL, V162, P2384; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Riordan JI, 1998, BRAIN, V121, P495, DOI 10.1093/brain/121.3.495; OZAWA K, 1994, BRAIN, V117, P1311, DOI 10.1093/brain/117.6.1311; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; Rudick RA, 1997, NEW ENGL J MED, V337, P1604, DOI 10.1056/NEJM199711273372207; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Stefferl A, 1999, J IMMUNOL, V163, P40; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vanderlugt CL, 2002, NAT REV IMMUNOL, V2, P85, DOI 10.1038/nri724; von Budingen HC, 2002, P NATL ACAD SCI USA, V99, P8207, DOI 10.1073/pnas.122092499; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	36	448	491	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					139	145		10.1056/NEJMoa022328	http://dx.doi.org/10.1056/NEJMoa022328			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853586				2022-12-28	WOS:000184024400006
J	Huang, Y; Unni, AK; Thadani, AN; Rawal, VH				Huang, Y; Unni, AK; Thadani, AN; Rawal, VH			Hydrogen bonding: Single enantiomers from a chiral-alcohol catalyst	NATURE			English	Article							DIELS-ALDER REACTIONS		Univ Chicago, Dept Chem, Chicago, IL 60637 USA	University of Chicago	Huang, Y (corresponding author), Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.	vrawal@uchicago.edu	Rawal, Viresh/M-1311-2014; Huang, Yong/AFP-6186-2022; Huang, Yong/J-5849-2014	Huang, Yong/0000-0001-8377-8923; Huang, Yong/0000-0001-8377-8923				Dalko PI, 2001, ANGEW CHEM INT EDIT, V40, P3726, DOI 10.1002/1521-3773(20011015)40:20<3726::AID-ANIE3726>3.0.CO;2-D; Huang Y, 2002, J AM CHEM SOC, V124, P9662, DOI 10.1021/ja0267627; Jacobsen E. N., 1999, COMPREHENSIVE ASYMME, V1-3; Jorgensen KA, 2000, ANGEW CHEM INT EDIT, V39, P3558, DOI 10.1002/1521-3773(20001016)39:20<3558::AID-ANIE3558>3.0.CO;2-I; KELLY TR, 1990, TETRAHEDRON LETT, V31, P3381, DOI 10.1016/S0040-4039(00)97402-1; Martin TW, 1999, NAT STRUCT BIOL, V6, P403, DOI 10.1038/8195; Prins LJ, 2001, ANGEW CHEM INT EDIT, V40, P2382, DOI 10.1002/1521-3773(20010702)40:13<2382::AID-ANIE2382>3.0.CO;2-G; Schuster T, 2000, ORG LETT, V2, P179, DOI 10.1021/ol991276i; Seebach D, 2001, ANGEW CHEM INT EDIT, V40, P92, DOI 10.1002/1521-3773(20010105)40:1<92::AID-ANIE92>3.3.CO;2-B; Vachal P, 2002, J AM CHEM SOC, V124, P10012, DOI 10.1021/ja027246j	10	405	409	4	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					146	146		10.1038/424146a	http://dx.doi.org/10.1038/424146a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	699AA	12853945	Bronze			2022-12-28	WOS:000184032700030
J	Ip, M; Chan, PKS; Nelson, EAS; Li, A; Gomersall, C				Ip, M; Chan, PKS; Nelson, EAS; Li, A; Gomersall, C			A Hong Kong family with respiratory illness	LANCET			English	Editorial Material							STREPTOCOCCAL INFECTIONS		Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Ip, M (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China.		Nelson, E Anthony S/ABF-4238-2020; Chan, Paul KS/J-9360-2013; Gomersall, Charles D/J-1540-2012; Ip, Margaret/K-1096-2013	Nelson, E Anthony S/0000-0002-2521-3403; Chan, Paul KS/0000-0002-6360-4608; Gomersall, Charles D/0000-0002-8494-8063; Ip, Margaret/0000-0003-1291-6537				Birkhead G, 1998, JAMA-J AM MED ASSOC, V279, P1206, DOI 10.1001/jama.279.15.1206; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; HO W, 2003, LANCET          0408; Johnson DR, 2002, J INFECT DIS, V185, P1586, DOI 10.1086/340576	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					38	38		10.1016/S0140-6736(03)13804-4	http://dx.doi.org/10.1016/S0140-6736(03)13804-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853197				2022-12-28	WOS:000184056900011
J	Kaptchuk, TJ				Kaptchuk, TJ			Effect of interpretive bias on research evidence	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL		Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA	Harvard University; Harvard Medical School	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Osher Inst, 401 Pk Dr, Boston, MA 02215 USA.				NCCIH NIH HHS [1R01 AT00402-01, 1R01 AT001414] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000402, R01AT001414] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		[Anonymous], 1977, N Engl J Med, V297, P1464; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Elstein A. S., 1979, CLIN JUDGMENT CRITIC; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Jones DS, 2000, ISIS, V91, P504, DOI 10.1086/384853; KOEHLER JJ, 1993, ORGAN BEHAV HUM DEC, V56, P28, DOI 10.1006/obhd.1993.1044; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; Lakatos I., 1978, METHODOLOGY SCI RES; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; Nabel EG, 2000, NEW ENGL J MED, V343, P572, DOI 10.1056/NEJM200008243430809; Planck M., 1950, SCI AUTOBIOGRAPHY OT; Resch KI, 2000, J ROY SOC MED, V93, P164, DOI 10.1177/014107680009300402; ROBINSON I, 1991, SOCIAL SCI PERSPECTI; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROSENTHAL R, 1963, AM SCI, V51, P268; ROSENTHAL R, 1963, PSYCHOL REP MONOG, V3, P12; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Thagard P., 1999, SCI EXPLAIN DIS; Toulmin Stephen, 2001, RETURN REASON; Vandenbroucke JP, 1998, LANCET, V352, P2001, DOI 10.1016/S0140-6736(98)10208-8; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	21	129	134	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1453	1455		10.1136/bmj.326.7404.1453	http://dx.doi.org/10.1136/bmj.326.7404.1453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829562	Green Published			2022-12-28	WOS:000183931800024
J	Bucca, C; Rolla, G				Bucca, C; Rolla, G			Nebulised magnesium in asthma: the right solution for an old remedy?	LANCET			English	Editorial Material							INDUCED BRONCHOCONSTRICTION; CLINICAL-TRIAL; SULFATE; SALBUTAMOL; CALCIUM		Univ Turin, Dipartimento Sci Biomed & Oncol Umana, I-10126 Turin, Italy; Univ Turin, Osped Mauriziano, I-10124 Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; Mauritian Umberto I Hospital; University of Turin	Bucca, C (corresponding author), Univ Turin, Dipartimento Sci Biomed & Oncol Umana, I-10126 Turin, Italy.		Bucca, Caterina/C-9886-2009; Rolla, Giovanni/C-9901-2009	Bucca, Caterina/0000-0002-9941-9236; Rolla, Giovanni/0000-0001-5997-7172				Bessmertny O, 2002, ANN EMERG MED, V39, P585, DOI 10.1067/mem.2002.123300; *BRIT THOR SOC, 2003, THORAX, V58, pI32; LEVINE BS, 1984, NEW ENGL J MED, V310, P1253, DOI 10.1056/NEJM198405103101910; Mangat HS, 1998, EUR RESPIR J, V12, P341, DOI 10.1183/09031936.98.12020341; MATHEW R, 1988, MAGNESIUM, V7, P173; Nannini LJ, 1997, CHEST, V111, P858, DOI 10.1378/chest.111.4.858; Nannini LJ, 2000, AM J MED, V108, P193, DOI 10.1016/S0002-9343(99)00463-5; Rodrigo GJ, 2003, CHEST, V123, P1908, DOI 10.1378/chest.123.6.1908; Rodrigo GJ, 2002, CHEST, V121, P1977, DOI 10.1378/chest.121.6.1977; ROLLA G, 1987, MAGNESIUM, V6, P201; ROLLA G, 1987, ALLERGY, V42, P186, DOI 10.1111/j.1398-9995.1987.tb02198.x; Rolla Giovanni, 1994, Magnesium Research, V7, P129; Rosello HJ, 1936, PRENSA MED ARGENT, V29, P1677; RUSSI EW, 1984, CHEST, V86, P475, DOI 10.1378/chest.86.3.475; Silverman RA, 2002, CHEST, V122, P489, DOI 10.1378/chest.122.2.489	15	1	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2095	2096		10.1016/S0140-6736(03)13727-0	http://dx.doi.org/10.1016/S0140-6736(03)13727-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826427				2022-12-28	WOS:000183654200003
J	Nieuwenhuizen, WF; Pieters, RHH; Knippels, LMJ; Jansen, MCJF; Koppelman, SJ				Nieuwenhuizen, WF; Pieters, RHH; Knippels, LMJ; Jansen, MCJF; Koppelman, SJ			Is Candida albicans a trigger in the onset of coeliac disease?	LANCET			English	Article							CELIAC-DISEASE; TISSUE TRANSGLUTAMINASE; DERMATITIS-HERPETIFORMIS; MICE; GLIADIN; COLONIZATION; AUTOANTIGEN; SUBSTRATE; PROTEINS; PEPTIDES	Coeliac disease is a T-cell-mediated autoimmune disease of the small intestine that is induced by ingestion of gluten proteins from wheat, barley, or rye. We postulate that Candida albicans is a trigger in the onset of coeliac disease. The virulence factor of C albicans-hyphal wall protein 1 (HWP1)-contains aminoacid sequences that are identical or highly homologous to known coeliac disease-related a-gliadin and gamma-gliadin T-cell epitopes. HWP1 is a transglutaminase substrate, and is used by C albicans to adhere to the intestinal epithelium. Furthermore, tissue transglutaminase and endomysium components could become covalently linked to the yeast. Subsequently, C albicans might function as an adjuvant that stimulates antibody formation against HWP1 and gluten, and formation of autoreactive antibodies against tissue transglutaminase and endomysium.	TNO, NL-3700 AJ Zeist, Netherlands; Univ Utrecht, Dept Immunotoxicol, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands	Netherlands Organization Applied Science Research; Utrecht University	Nieuwenhuizen, WF (corresponding author), TNO, POB 360, NL-3700 AJ Zeist, Netherlands.							Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; ARRESE JE, 1995, DERMATOLOGY, V190, P119, DOI 10.1159/000246659; Black KE, 2002, J IMMUNOL, V169, P5595, DOI 10.4049/jimmunol.169.10.5595; BRADWAY SD, 1993, CRIT REV ORAL BIOL M, V4, P293, DOI 10.1177/10454411930040030601; DEREPENTIGNY L, 1992, INFECT IMMUN, V60, P4907, DOI 10.1128/IAI.60.11.4907-4914.1992; Hervonen K, 2002, SCAND J GASTROENTERO, V37, P51, DOI 10.1080/003655202753387356; KAGNOFF MF, 1984, J EXP MED, V160, P1544, DOI 10.1084/jem.160.5.1544; Lacour M, 2002, INT J HYG ENVIR HEAL, V205, P257, DOI 10.1078/1438-4639-00159; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; Sardy M, 2002, J EXP MED, V195, P747, DOI 10.1084/jem.20011299; Seissler J, 2001, CLIN EXP IMMUNOL, V125, P216, DOI 10.1046/j.1365-2249.2001.01584.x; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; Stern M, 2000, J PEDIATR GASTR NUTR, V31, P513, DOI 10.1097/00005176-200011000-00012; Sundstrom P, 2002, J INFECT DIS, V185, P521, DOI 10.1086/338836; TlaskalovaHogenova H, 1997, ANN NY ACAD SCI, V815, P503, DOI 10.1111/j.1749-6632.1997.tb52115.x; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; VESY CJ, 1993, MODERN PATHOL, V6, P61	20	43	44	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2152	2154		10.1016/S0140-6736(03)13695-1	http://dx.doi.org/10.1016/S0140-6736(03)13695-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826451				2022-12-28	WOS:000183654200026
J	Wilson, JE				Wilson, JE			Building African AIDS care from the ground up	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					157	160		10.7326/0003-4819-139-2-200307150-00028	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00028			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859173				2022-12-28	WOS:000184163100017
J	Zandbergen, AAM; Baggen, MGA; Lamberts, SWJ; Bootsma, AH; de Zeeuw, D; Ouwendijk, RJT				Zandbergen, AAM; Baggen, MGA; Lamberts, SWJ; Bootsma, AH; de Zeeuw, D; Ouwendijk, RJT			Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus - A randomized clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							ENDOTHELIAL DYSFUNCTION; HYPERTENSIVE PATIENTS; KIDNEY-FUNCTION; RENAL-DISEASE; ENALAPRIL; NEPHROPATHY; MORTALITY; PROTEINURIA; INHIBITION; PREVENTION	Background: Angiotensin-converting enzyme inhibitors have shown antiproteinuric effects in normotensive and hypertensive diabetic patients. Angiotensin-receptor antagonists reduce urinary albumin excretion and the risk for renal and cardiovascular complications in hypertensive patients with type 2 diabetes mellitus. The effect of anglotensin-receptor antagonists in normotensive diabetic patients with microalbuminuria has not yet been reported. Objective: To assess the antiproteinuric effects of losartan in normotensive patients with type 2 diabetes and microalbuminuria. Design: Multicenter randomized, double-blind, placebo-controlled clinical trial. Setting: 19 outpatient clinics in the Netherlands. Patients: 147 normotensive patients with type 2 diabetes mellitus and microalbuminuria. Intervention: 74 patients were randomly assigned to receive losartan and 73 patients were assigned to receive placebo for 10 weeks; 71 patients in each group completed the study. The losartan dose was 50 mg during the first 5 weeks and 100 mg during the subsequent 5 weeks. Measurements: Change in urinary albumin excretion rate after 5 and 10 weeks, change in creatinine clearance and blood pressure, and safety and tolerability of losartan. Results: A significant 25% relative reduction in the albumin excretion rate occurred after 5 weeks of the 50-mg losartan dose, with further improvement over the subsequent 5 weeks with the 100-mg dose (relative reduction, 34%). In the losartan group, creatinine clearance did not improve and blood pressure decreased slightly. Side effects did not differ between treatment groups. Conclusions: The angiotensin-receptor antagonist losartan reduces urinary albumin excretion in normotensive patients with type 2 diabetes and microalbuminuria. In multivariate analysis, the antiproteinuric effect of losartan was independent of the associated reduction in blood pressure. Losartan was safe and well tolerated in these normotensive patients.	Ikazia Hosp, Dept Internal Med, NL-3083 AN Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Rotterdam, Netherlands; Univ Groningen Hosp, Groningen, Netherlands	Ikazia Hospital; Erasmus University Rotterdam; Erasmus MC; University of Groningen	Zandbergen, AAM (corresponding author), Ikazia Hosp, Dept Internal Med, Montessoriweg 1, NL-3083 AN Rotterdam, Netherlands.	adrienne_zandbergen@yahoo.com	de Zeeuw, Dick/E-9080-2014	de Zeeuw, Dick/0000-0003-3434-7777				Ahmad J, 1997, DIABETES CARE, V20, P1576, DOI 10.2337/diacare.20.10.1576; Andersen S, 2000, KIDNEY INT, V57, P601, DOI 10.1046/j.1523-1755.2000.t01-1-00880.x; Arauz-Pacheco C, 2002, DIABETES CARE, V25, P134, DOI 10.2337/diacare.25.1.134; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Buter H, 2001, NEPHROL DIAL TRANSPL, V16, P771, DOI 10.1093/ndt/16.4.771; Chalmers J, 1999, J HYPERTENS, V17, P151; Chan JCN, 1997, AM J NEPHROL, V17, P72, DOI 10.1159/000169075; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; DEPABLOS PL, 1998, CLIN DRUG INVEST, V16, P361; Dinneen SF, 1997, ARCH INTERN MED, V157, P1413, DOI 10.1001/archinte.157.13.1413; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; GANSEVOORT RT, 1993, KIDNEY INT, V44, P579, DOI 10.1038/ki.1993.284; GANSEVOORT RT, 1994, J HYPERTENS, V12, pS37; GRINSTEIN YI, 1999, AM J KIDNEY DIS, V33, pA28; Hostetter TH, 2001, NEW ENGL J MED, V345, P910, DOI 10.1056/NEJM200109203451209; Lacourciere Y, 2000, KIDNEY INT, V58, P762, DOI 10.1046/j.1523-1755.2000.00224.x; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lozano JV, 2001, NEPHROL DIAL TRANSPL, V16, P85, DOI 10.1093/ndt/16.suppl_1.85; Mathiesen ER, 1999, BRIT MED J, V319, P24, DOI 10.1136/bmj.319.7201.24; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Nielsen S, 1997, NEPHROL DIAL TRANSPL, V12, P19; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Rodrigo E, 1997, J HYPERTENS, V15, P613, DOI 10.1097/00004872-199715060-00007; Rutter MK, 2002, J AM COLL CARDIOL, V40, P56, DOI 10.1016/S0735-1097(02)01910-1; Salvetti A, 1999, DRUGS, V57, P665, DOI 10.2165/00003495-199957050-00002; Stearne MR, 1998, BRIT MED J, V317, P713; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	32	47	50	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					90	96		10.7326/0003-4819-139-2-200307150-00008	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859158				2022-12-28	WOS:000184163100002
J	Evans, LS; Hancock, BW				Evans, LS; Hancock, BW			Non-Hodgkin lymphoma	LANCET			English	Review							ANTI-CD20 MONOCLONAL-ANTIBODY; BONE-MARROW-TRANSPLANTATION; B-CELL LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; REFRACTORY LOW-GRADE; PHASE-II; IMMUNE-RESPONSES; RITUXIMAB; THERAPY; CHOP	Non-Hodgkin lymphoma is a non-specific term that includes several lymphoproliferative malignant diseases with different clinical and histological appearances. Here, we concentrate on adult lymphomas. We look at their molecular basis, at the development of a classification system based on a better understanding of the biology of the various subgroups, and at how refinement of adverse prognostic factor groupings helps in clinical management. Lymphomas can present in various ways and be difficult to diagnose. About a quarter of cases arise extranodally and might present special problems. Developments in cytotoxic chemotherapy have led to good long-term survival prospects for aggressive lymphoma; introduction of novel approaches, including monoclonal antibody therapy, offers promise for indolent lymphoma, and should further improve prognosis for aggressive tumours.	Weston Pk Hosp, Sheffield S10 2SJ, S Yorkshire, England	Weston Park Hospital	Hancock, BW (corresponding author), Weston Pk Hosp, Sheffield S10 2SJ, S Yorkshire, England.	b.w.hancock@sheffield.ac.uk						Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; ARMITAGE JO, 1988, J CLIN ONCOL, V6, P1335, DOI 10.1200/JCO.1988.6.8.1335; Balzarotti M, 2002, ANN ONCOL, V13, P1341, DOI 10.1093/annonc/mdf242; Bertoni F, 2002, BLOOD, V99, P2541, DOI 10.1182/blood.V99.7.2541; BIRTWHISLE MB, 2003, EFFECTIVE MANAGEMENT; CARBONE PP, 1971, CANCER RES, V31, P1860; Chan WC, 1997, BLOOD, V89, P3909; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COLTMAN CA, 1986, P S NOV 14 1985 MARC, P71; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; Czuczman MS, 2000, BLOOD, V96, p729A; CZUCZMAN MS, 1999, P AN M AM SOC CLIN, V18, P61; DALLAFAVERA R, 2001, CANC PRINCIPLES PRAC, P2215; Davis TA, 2001, BIOL BLOOD MARROW TR, V7, P517, DOI 10.1053/bbmt.2001.v7.pm11669219; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; DENARDO GL, 1999, STATUS RADIOINMUNOIM, P472; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dobson LS, 1998, INT J ONCOL, V13, P1313; DORREEN MS, 1988, Q J MED, V67, P387; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Feuring-Buske M, 2000, ANN HEMATOL, V79, P493, DOI 10.1007/s002770000163; Gamberi B, 1997, BLOOD, V89, P975; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Gianni AM, 1997, NEW ENGL J MED, V336, P1290, DOI 10.1056/NEJM199705013361804; Gisselbrecht C, 1998, BLOOD, V92, P76; Gisselbrecht C, 2002, J CLIN ONCOL, V20, P2472, DOI 10.1200/JCO.2002.02.125; GRISSLEBRECHT C, 1998, BLOOD, V1, P76; Haioun C, 2000, J CLIN ONCOL, V18, P3025, DOI 10.1200/JCO.2000.18.16.3025; Hancock BW, 2001, CLIN ONCOL-UK, V13, P242; HARRIS NL, 1994, BLOOD, V84, P1361; HARRIS NL, 2001, HEMATOLOGY, V1, P194; HUDSON BV, 1994, BRIT J CANCER, V69, P1088, DOI 10.1038/bjc.1994.213; Itoh K, 2002, ANN ONCOL, V13, P1347, DOI 10.1093/annonc/mdf287; Jaffe ES, 2001, WHO CLASSIFICATION T; Kaiser U, 2002, J CLIN ONCOL, V20, P4413, DOI 10.1200/JCO.2002.07.075; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Khouri IF, 1998, J CLIN ONCOL, V16, P3803, DOI 10.1200/JCO.1998.16.12.3803; Khouri IF, 1998, J CLIN ONCOL, V16, P2817, DOI 10.1200/JCO.1998.16.8.2817; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; Lennert K, 1992, HISTOPATHOLOGY NONHO; LIU AY, 1987, J IMMUNOL, V139, P3521; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; Magrath I, 1996, J CLIN ONCOL, V14, P925, DOI 10.1200/JCO.1996.14.3.925; Maloney DG, 1997, BLOOD, V90, P2188; Maloney DG, 1996, BLOOD, V88, P2535; Martelli M, 2003, J CLIN ONCOL, V21, P1255, DOI 10.1200/JCO.2003.01.117; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Miller TP, 1998, NEW ENGL J MED, V339, P21, DOI 10.1056/NEJM199807023390104; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mounier N, 1998, CANCER-AM CANCER SOC, V82, P1952, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1952::AID-CNCR20>3.3.CO;2-9; MUELLER BM, 1990, J IMMUNOL, V144, P1382; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; PRESS OW, 2002, TREATMENT MANTLE CEL, P407; RATANATHARATHORN V, 1994, BLOOD, V84, P1050; REFF ME, 1994, BLOOD, V83, P435; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rudiger T, 2002, ANN ONCOL, V13, P140, DOI 10.1093/annonc/mdf033; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1989, J CLIN ONCOL, V7, P613, DOI 10.1200/JCO.1989.7.5.613; SolalCeligny P, 1996, J CLIN ONCOL, V14, P514, DOI 10.1200/JCO.1996.14.2.514; TONDINI C, 1993, J CLIN ONCOL, V11, P720, DOI 10.1200/JCO.1993.11.4.720; TOUROUTOGLOU N, 1995, J CLIN ONCOL, V13, P1361, DOI 10.1200/JCO.1995.13.6.1361; Vandenberghe E, 1997, BRIT J HAEMATOL, V99, P842, DOI 10.1046/j.1365-2141.1997.4693273.x; Viardot A, 2002, J CLIN ONCOL, V20, P4523, DOI 10.1200/JCO.2002.12.006; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Zucca E, 2000, ANN ONCOL, V11, P219, DOI 10.1023/A:1011104821629; 2000, REFERRAL GUIDELINES	70	105	109	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					139	146		10.1016/S0140-6736(03)13868-8	http://dx.doi.org/10.1016/S0140-6736(03)13868-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867117				2022-12-28	WOS:000184089200024
J	Law, MR; Wald, NJ; Rudnicka, AR				Law, MR; Wald, NJ; Rudnicka, AR			Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; REDUCTASE INHIBITORS; CONTROLLED TRIALS; CLINICAL-TRIALS; RISK; HYPERCHOLESTEROLEMIA; ATORVASTATIN; SIMVASTATIN; EFFICACY; DRUGS	Objectives To deter-mine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (TFID) events and stroke, according to drug, dose, and duration of treatment, Design Three meta-analyses: 164 short term randomised placebo controlled trials of six statins and LDL cholesterol reduction; 58 randomised trials of cholesterol lowering by any means and IHD events; and nine cohort studies and the same 58 trials on stroke. Main outcome measures Reductions in LDL cholesterol according to statin and dose; reduction in IHD events and stroke for a specified reduction in LDL cholesterol. Results Reductions in LDL cholesterol (in the 164 trials) were 2.8 mmol/l (60%) with rosuvastatin 80 mg/day, 2.6 mmol/l (55%) with atorvastatin 80 mg/day, 1.8 mmol/l (40%) with atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, or rosuvastatin 5 mg/day, all from pretreatment concentrations of 4.8 mmol/l. Pravastatin and fluvastatin achieved smaller reductions. In the 58 trials for an LDL cholesterol reduction of 1.0 mmol/l the risk of IHD events was reduced by 11% in the first year of treatment, 24% in the second year, 33% in years three to five, and by 36% thereafter (P < 0.001 for trend). H-ID events were reduced by 20%, 31%, and 51% in trials grouped by LDL cholesterol reduction (means 0.5 mmol/l, 1.0 mmol/l, and 1.6 mmol/l) after results from first two years of treatment were excluded (P < 0.001 for trend). After several years a reduction of 1.8 mmol/l would reduce IHD events by an estimated 61%. Results from the same 58 trials, corroborated by results from the nine cohort studies, show that lowering LDL cholesterol decreases all stroke by 10% for a I mmol/l reduction and 17% for a 1.8 mmol/l reduction. Estimates allow for the fact that trials tended to recruit people with vascular disease, among whom the effect of LDL cholesterol reduction on stroke is greater because of their higher risk of thromboembolic stroke (rather than haemorrhagic stroke) compared with people in the general population. Conclusions Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 170%.	Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, MR (corresponding author), Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021	Rudnicka, Alicja R/0000-0003-0369-8574				Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Cilla DD, 1996, J CLIN PHARMACOL, V36, P604, DOI 10.1002/j.1552-4604.1996.tb04224.x; Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; *FOOD DRUG ADM CTR, STAT HEP; Gould AL, 1998, CIRCULATION, V97, P946; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LAW MR, 2003, BMJ; Ose L, 2000, CLIN CARDIOL, V23, P39, DOI 10.1002/clc.4960230108; Pignone M, 2000, BRIT MED J, V321, P1; Qizilbash N, 1995, LANCET, V346, P1647; Schectman G, 1996, ANN INTERN MED, V125, P990, DOI 10.7326/0003-4819-125-12-199612150-00011; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185	21	1199	1316	4	89	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1423	1427		10.1136/bmj.326.7404.1423	http://dx.doi.org/10.1136/bmj.326.7404.1423			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829554	Green Published, Bronze			2022-12-28	WOS:000183931800016
J	Calarese, DA; Scanlan, CN; Zwick, MB; Deechongkit, S; Mimura, Y; Kunert, R; Zhu, P; Wormald, MR; Stanfield, RL; Roux, KH; Kelly, JW; Rudd, PM; Dwek, RA; Katinger, H; Burton, DR; Wilson, IA				Calarese, DA; Scanlan, CN; Zwick, MB; Deechongkit, S; Mimura, Y; Kunert, R; Zhu, P; Wormald, MR; Stanfield, RL; Roux, KH; Kelly, JW; Rudd, PM; Dwek, RA; Katinger, H; Burton, DR; Wilson, IA			Antibody domain exchange is an immunological solution to carbohydrate cluster recognition	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; HIV-INACTIVATING PROTEIN; CD4 BINDING-SITE; CYANOVIRIN-N; CRYSTAL-STRUCTURE; DC-SIGN; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEINS; STRUCTURAL BASIS	Human antibody 2G12 neutralizes a broad range of human immunodeficiency virus type 1( HIV-1) isolates by binding an unusually dense cluster of carbohydrate moieties on the "silent" face of the gp120 envelope glycoprotein. Crystal structures of Fab 2G12 and its complexes with the disaccharide Manalpha1-2Man and with the oligosaccharide Man 9 GlcNAc 2 revealed that two Fabs assemble into an interlocked V-H domain-swapped dimer. Further biochemical, biophysical, and mutagenesis data strongly support a Fab-dimerized antibody as the prevalent form that recognizes gp120. The extraordinary configuration of this antibody provides an extended surface, with newly described binding sites, for multivalent interaction with a conserved cluster of oligomannose type sugars on the surface of gp120. The unique interdigitation of Fab domains within an antibody uncovers a previously unappreciated mechanism for high-affinity recognition of carbohydrate or other repeating epitopes on cell or microbial surfaces.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Univ Bodenkultur Wien, Inst Appl Microbiol, A-1180 Vienna, Austria; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of Oxford; University of Natural Resources & Life Sciences, Vienna; State University System of Florida; Florida State University; State University System of Florida; Florida State University	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	burton@scripps.edu; wilson@scripps.edu	Wormald, Mark R/G-2785-2011; Kunert, Renate E/B-9185-2018; Stanfield, Robyn/AAH-3190-2019	Wormald, Mark R/0000-0002-4853-2773; Kunert, Renate E/0000-0002-3397-3621; 	NIAID NIH HHS [AI33292] Funding Source: Medline; NIGMS NIH HHS [GM46192] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033292, R37AI033292] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrientos LG, 2002, BIOCHEM BIOPH RES CO, V298, P598, DOI 10.1016/S0006-291X(02)02489-0; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891; Carrasco B, 2001, BIOPHYS CHEM, V93, P181, DOI 10.1016/S0301-4622(01)00220-4; Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1; CONLEY AJ, 1994, P NATL ACAD SCI USA, V91, P3348, DOI 10.1073/pnas.91.8.3348; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esser MT, 1999, J VIROL, V73, P4360, DOI 10.1128/JVI.73.5.4360-4371.1999; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Ferrantelli F, 2002, CURR OPIN IMMUNOL, V14, P495, DOI 10.1016/S0952-7915(02)00362-X; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Martin ACR, 1996, PROTEINS, V25, P130, DOI 10.1002/(SICI)1097-0134(199605)25:1<130::AID-PROT11>3.3.CO;2-Y; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; O'Keefe BR, 2000, MOL PHARMACOL, V58, P982, DOI 10.1124/mol.58.5.982; Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001; Pei XY, 1997, P NATL ACAD SCI USA, V94, P9637, DOI 10.1073/pnas.94.18.9637; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; PETRESCU AJ, UNPUB; PHILLIPS ML, 1994, MOL IMMUNOL, V31, P1201, DOI 10.1016/0161-5890(94)90034-5; Ragupathi G, 2002, P NATL ACAD SCI USA, V99, P13699, DOI 10.1073/pnas.202427599; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; SCANLON CN, UNPUB; Schulke N, 2002, J VIROL, V76, P7760, DOI 10.1128/JVI.76.15.7760-7776.2002; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; Thomas R, 2002, J BIOL CHEM, V277, P2059, DOI 10.1074/jbc.M104364200; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; Weis WI, 1997, CURR OPIN STRUC BIOL, V7, P624, DOI 10.1016/S0959-440X(97)80070-X; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WILSON IA, 1995, NAT STRUCT BIOL, V2, P433, DOI 10.1038/nsb0695-433; Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693; Zinkernagel RM, 2001, ADV IMMUNOL, V79, P1, DOI 10.1016/S0065-2776(01)79001-3; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	58	639	725	1	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2065	2071		10.1126/science.1083182	http://dx.doi.org/10.1126/science.1083182			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829775				2022-12-28	WOS:000183774900038
J	Mitrofanov, IG; Zuber, MT; Litvak, ML; Boynton, WV; Smith, DE; Drake, D; Hamara, D; Kozyrev, AS; Sanin, AB; Shinohara, C; Saunders, RS; Tretyakov, V				Mitrofanov, IG; Zuber, MT; Litvak, ML; Boynton, WV; Smith, DE; Drake, D; Hamara, D; Kozyrev, AS; Sanin, AB; Shinohara, C; Saunders, RS; Tretyakov, V			CO2 snow depth and subsurface water-ice abundance in the northern hemisphere of Mars	SCIENCE			English	Article							SUMMER TEMPERATURES; ORBITER CAMERA; POLAR-CAP; EVOLUTION; FROST; HYDROGEN; NEUTRONS; BEHAVIOR; DETECTOR; SURFACE	Observations of seasonal variations of neutron flux from the high-energy neutron detector (HEND) on Mars Odyssey combined with direct measurements of the thickness of condensed carbon dioxide by the Mars Orbiter Laser Altimeter (MOLA) on Mars Global Surveyor show a latitudinal dependence of northern winter deposition of carbon dioxide. The observations are also consistent with a shallow substrate consisting of a layer with water ice overlain by a layer of drier soil. The lower ice-rich layer contains between 50 and 75 weight % water, indicating that the shallow subsurface at northern polar latitudes on Mars is even more water rich than that in the south.	Russian Acad Sci, Space Res Inst, Moscow 117997, Russia; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Tech Source, Santa Fe, NM 87505 USA; NASA Headquarters, Washington, DC 20514 USA	Russian Academy of Sciences; Space Research Institute of the Russian Academy of Sciences; Massachusetts Institute of Technology (MIT); University of Arizona; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA)	Mitrofanov, IG (corresponding author), Russian Acad Sci, Space Res Inst, Moscow 117997, Russia.		Litvak, Maxim/C-6453-2017; Sanin, Anton/T-9393-2017	Mitrofanov, Igor/0000-0001-7204-2101				BIEMANN K, 1979, J MOL EVOL, V14, P65, DOI 10.1007/BF01732368; Boynton WV, 2002, SCIENCE, V297, P81, DOI 10.1126/science.1073722; BOYNTON WV, IN PRESS SPACE SCI R; Carr M.H, 1996, WATER MARS; Clifford SM, 2001, ICARUS, V154, P40, DOI 10.1006/icar.2001.6671; DRAKE DM, 1988, J GEOPHYS RES-SOLID, V93, P6353, DOI 10.1029/JB093iB06p06353; FARMER CB, 1979, J GEOPHYS RES, V84, P2881, DOI 10.1029/JB084iB06p02881; FELDMAN WC, 1993, J GEOPHYS RES-PLANET, V98, P20855, DOI 10.1029/93JE02325; Feldman WC, 2002, SCIENCE, V297, P75, DOI 10.1126/science.1073541; Jakosky B. M., 1992, MARS, P969; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; James PB, 2001, ICARUS, V154, P131, DOI 10.1006/icar.2001.6653; JAMES PB, 1992, MARS, P934; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; Kieffer HH, 2000, J GEOPHYS RES-PLANET, V105, P9653, DOI 10.1029/1999JE001136; LEIGHTON RB, 1966, SCIENCE, V153, P136, DOI 10.1126/science.153.3732.136; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; Masarik J, 1996, J GEOPHYS RES-PLANET, V101, P18891, DOI 10.1029/96JE01563; Mitrofanov I, 2002, SCIENCE, V297, P78, DOI 10.1126/science.1073616; PAIGE DA, 1990, J GEOPHYS RES-SOLID, V95, P1319, DOI 10.1029/JB095iB02p01319; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; Smith DE, 2001, SCIENCE, V294, P2141, DOI 10.1126/science.1066556; Squyres S. W., 1992, MARS, P523; Wanke H, 2001, SPACE SCI REV, V96, P317, DOI 10.1023/A:1011961725645; WATERS L, 1999, LAUR996058 LOS AL NA; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341	28	60	60	4	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2081	2084		10.1126/science.1084350	http://dx.doi.org/10.1126/science.1084350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829779				2022-12-28	WOS:000183774900042
J	Somssich, IE				Somssich, IE			Closing another gap in the plant SAR puzzle	CELL			English	Editorial Material							SYSTEMIC ACQUIRED-RESISTANCE; GENE; ARABIDOPSIS; EXPRESSION; ACTIVATION; DEFENSE; NPR1	NPR1 is a key regulator of the salicylic acid (SA) dependent pathogen resistance pathway in plants. In this issue of Cell, Mou and Dong demonstrate that Arabidopsis NPR1 undergoes activation from an inactive oligomer to the active monomer as a result of cellular redox: changes induced by SA during systemic acquired resistance.	Max Planck Inst Zuchtungsforsch, Abt Mol Phytopathol, D-50829 Cologne, Germany	Max Planck Society	Somssich, IE (corresponding author), Max Planck Inst Zuchtungsforsch, Abt Mol Phytopathol, Carl Von Linne Weg 10, D-50829 Cologne, Germany.		Somssich, Imre/GLT-3738-2022	Somssich, Imre/0000-0003-3066-5794				Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; Dong XN, 2001, CURR OPIN PLANT BIOL, V4, P309, DOI 10.1016/S1369-5266(00)00178-3; Fan WH, 2002, PLANT CELL, V14, P1377, DOI 10.1105/tpc.001628; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Kinkema M, 2000, PLANT CELL, V12, P2339, DOI 10.1105/tpc.12.12.2339; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Mou Z, 2003, CELL, V113, P935, DOI 10.1016/S0092-8674(03)00429-X; Spoel SH, 2003, PLANT CELL, V15, P760, DOI 10.1105/tpc.009159; Subramaniam R, 2001, NAT BIOTECHNOL, V19, P769, DOI 10.1038/90831	10	11	30	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					815	816		10.1016/S0092-8674(03)00473-2	http://dx.doi.org/10.1016/S0092-8674(03)00473-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837238	Bronze			2022-12-28	WOS:000183817900004
J	Noh, B; Bandyopadhyay, A; Peer, WA; Spalding, EP; Murphy, AS				Noh, B; Bandyopadhyay, A; Peer, WA; Spalding, EP; Murphy, AS			Enhanced gravi- and phototropism in plant mdr mutants mislocalizing the auxin efflux protein PIN1	NATURE			English	Article							ARABIDOPSIS; TRANSPORT; LIGHT	Many aspects of plant growth and development are dependent on the flow of the hormone auxin down the plant from the growing shoot tip where it is synthesized(1,2). The direction of auxin transport in stems is believed to result from the basal localization within cells of the PIN1 membrane protein, which controls the efflux of the auxin anion(3). Mutations in two genes homologous to those encoding the P-glycoprotein ABC transporters that are especially abundant in multidrug-resistant tumour cells in animals(4) were recently shown to block polar auxin transport in the hypocotyls of Arabidopsis seedlings(5). Here we show that the mdr mutants display faster and greater gravitropism and enhanced phototropism instead of the impaired curvature development expected in mutants lacking polar auxin transport. We find that these phenotypes result from a disruption of the normal accumulation of PIN1 protein along the basal end of hypocotyl cells associated with basipetal auxin flow. Lateral auxin conductance becomes relatively larger as a result, enhancing the growth differentials responsible for tropic responses.	Univ Wisconsin, Dept Bot, Madison, WI 53706 USA; Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA	University of Wisconsin System; University of Wisconsin Madison; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Spalding, EP (corresponding author), Univ Wisconsin, Dept Bot, 430 Lincoln Dr, Madison, WI 53706 USA.		Peer, Wendy/H-2970-2013; Spalding, Edgar P/GWC-1811-2022; Spalding, Edgar P/A-9034-2008; Spalding, Edgar P/ABF-3253-2021	Peer, Wendy/0000-0003-0046-7324; Spalding, Edgar P/0000-0002-6890-4765; Spalding, Edgar P/0000-0002-6890-4765; 				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Folta KM, 2001, PLANT J, V26, P471, DOI 10.1046/j.1365-313x.2001.01038.x; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, PLANT MOL BIOL, V49, P273, DOI 10.1023/A:1015248926412; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Geldner N, 2001, NATURE, V413, P425, DOI 10.1038/35096571; Gil P, 2001, GENE DEV, V15, P1985, DOI 10.1101/gad.905201; Harper JDI, 1996, CYTOBIOS, V87, P71; Muday GK, 2001, J PLANT GROWTH REGUL, V20, P226, DOI 10.1007/s003440010027; Muday GK, 2001, TRENDS PLANT SCI, V6, P535, DOI 10.1016/S1360-1385(01)02101-X; Murphy AS, 2002, PLANT PHYSIOL, V128, P935, DOI 10.1104/pp.010519; Noh B, 2001, PLANT CELL, V13, P2441, DOI 10.1105/tpc.13.11.2441; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623	14	204	223	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					999	1002		10.1038/nature01716	http://dx.doi.org/10.1038/nature01716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827205				2022-12-28	WOS:000183753900053
J	de Jong, JTVM; Komproe, IH; Van Ommeren, M				de Jong, JTVM; Komproe, IH; Van Ommeren, M			Common mental disorders in postconflict settings	LANCET			English	Article								Research into postconflict psychiatric sequelae in low-income countries has been focused largely on symptoms rather than on full psychiatric diagnostic assessment. We assessed 3048 respondents from postconflict communities in Algeria, Cambodia, Ethiopia, and Palestine with the aim of establishing the prevalence of mood disorder, somatoform disorder, posttraumatic stress disorder (PTSD), and other anxiety disorders. PTSD and other anxiety disorders were the most frequent problems. In three countries, PTSD was the most likely disorder in individuals exposed to violence associated with armed conflict, but such violence was a common risk factor for various disorders and comorbidity combinations in different settings. In three countries, anxiety disorder was reported most in people who had not been exposed to such violence. Experience of violence associated with armed conflict was associated with higher rates of disorder that ranged from a risk ratio of 2-10 (95% CI 1.38-2.85) for anxiety in Algeria to 10.03 (5.26-16.65) for PTSD in Palestine. Postconflict mental health programmes should address a range of common disorders beyond PTSD.	TPO, WHO, Collaborating Ctr Refugees & Ethn Minor, NL-1016 EE Amsterdam, Netherlands; Vrije Univ Amsterdam, Amsterdam, Netherlands	World Health Organization; Vrije Universiteit Amsterdam	Komproe, IH (corresponding author), TPO, WHO, Collaborating Ctr Refugees & Ethn Minor, Keizersgracht 329, NL-1016 EE Amsterdam, Netherlands.		Komproe, Ivan/AAJ-8699-2021					de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Kebede D, 1999, ACTA PSYCHIAT SCAND, V100, P18, DOI 10.1111/j.1600-0447.1999.tb10689.x; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Van Ommeren M, 2001, ARCH GEN PSYCHIAT, V58, P475, DOI 10.1001/archpsyc.58.5.475; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	5	262	264	1	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2128	2130		10.1016/S0140-6736(03)13692-6	http://dx.doi.org/10.1016/S0140-6736(03)13692-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826440				2022-12-28	WOS:000183654200016
J	Gunn, J				Gunn, J			Waiting lists: irritation or death sentence?	LANCET			English	Editorial Material									Univ Sheffield, No Gen Hosp, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Gunn, J (corresponding author), Univ Sheffield, No Gen Hosp, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2123	2123		10.1016/S0140-6736(03)13723-3	http://dx.doi.org/10.1016/S0140-6736(03)13723-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826436				2022-12-28	WOS:000183654200012
J	Bivona, TG; Perez de Castro, I; Ahearn, IM; Grana, TM; Chiu, VK; Lockyer, PJ; Cullen, PJ; Pellicer, A; Cox, AD; Philips, MR				Bivona, TG; Perez de Castro, I; Ahearn, IM; Grana, TM; Chiu, VK; Lockyer, PJ; Cullen, PJ; Pellicer, A; Cox, AD; Philips, MR			Phospholipase C gamma activates Ras on the Golgi apparatus by means of RasGRP1	NATURE			English	Article							CALCIUM; DIACYLGLYCEROL; RECRUITMENT; PROTEIN	Ras proteins regulate cellular growth and differentiation, and are mutated in 30% of cancers. We have shown recently that Ras is activated on and transmits signals from the Golgi apparatus as well as the plasma membrane(1,2) but the mechanism of compartmentalized signalling was not determined. Here we show that, in response to Src-dependent activation of phospholipase Cgamma1, the Ras guanine nucleotide exchange factor RasGRP1 translocated to the Golgi where it activated Ras. Whereas Ca2+ positively regulated Ras on the Golgi apparatus through RasGRP1, the same second messenger negatively regulated Ras on the plasma membrane by means of the Ras GTPase-activating protein CAPRI(3). Ras activation after T-cell receptor stimulation in Jurkat cells, rich in RasGRP1, was limited to the Golgi apparatus through the action of CAPRI, demonstrating unambiguously a physiological role for Ras on Golgi. Activation of Ras on Golgi also induced differentiation of PC12 cells, transformed fibroblasts and mediated radioresistance. Thus, activation of Ras on Golgi has important biological consequences and proceeds through a pathway distinct from the one that activates Ras on the plasma membrane.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Babraham Inst, Cambridge CB2 4AT, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	New York University; New York University; New York University; New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Bristol	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.	philim01@med.nyu.edu	de Castro, Ignacio Pérez/A-6260-2012; MARTINEZ, ANTONIO PELLICER/C-4832-2015	de Castro, Ignacio Pérez/0000-0002-8822-8274; Pellicer, Angel/0000-0002-5062-0692; Cullen, Peter/0000-0002-9070-8349; Cox, Adrienne D./0000-0002-4901-2454; Ahearn, Ian/0000-0002-2275-137X; Mark, Philips/0000-0002-1179-8156				Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Park WM, 1997, ONCOGENE, V14, P831, DOI 10.1038/sj.onc.1200893; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	19	346	362	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 7	2003	424	6949					694	698		10.1038/nature01806	http://dx.doi.org/10.1038/nature01806			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	708QE	12845332				2022-12-28	WOS:000184578800050
J	Dudley, CA; Erbel-Sieler, C; Estill, SJ; Reick, M; Franken, P; Pitts, S; McKnight, SL				Dudley, CA; Erbel-Sieler, C; Estill, SJ; Reick, M; Franken, P; Pitts, S; McKnight, SL			Altered patterns of sleep and behavioral adaptability in NPAS2-defficient mice	SCIENCE			English	Article							CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; PHASE-SHIFT; RHYTHM; MOUSE; PERIOD; LIGHT; LOOP; PHOTORECEPTION	Animal behavior is synchronized to the 24-hour light:dark (LD) cycle by regulatory programs that produce circadian fluctuations in gene expression throughout the body. In mammals, the transcription factor CLOCK controls circadian oscillation in the suprachiasmatic nucleus of the brain; its paralog, neuronal PAS domain protein 2 (NPAS2), performs a similar function in other forebrain sites. To investigate the role of NPAS2 in behavioral manifestations of circadian rhythm, we studied locomotor activity, sleep patterns, and adaptability to both light- and restricted food-driven entrainment in NPAS2-deficient mice. Our results indicate that NPAS2 plays a substantive role in maintaining circadian behaviors in normal LD and feeding conditions and that NPAS2 is critical for adaptability to food restriction.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Columbia Univ, Dept Psychol, New York, NY 10027 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; Columbia University	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	smckni@biochem.swmed.edu	Franken, Paul/A-9633-2018; Jansen, Heiko T./A-5770-2008	Franken, Paul/0000-0002-2500-2921; Jansen, Heiko T./0000-0003-0178-396X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH059388] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 64148] Funding Source: Medline; NIDDK NIH HHS [5T3DK07328] Funding Source: Medline; NIMH NIH HHS [4R37 MH59388] Funding Source: Medline; PHS HHS [37919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe H, 2001, EUR J NEUROSCI, V14, P1121, DOI 10.1046/j.0953-816x.2001.01732.x; Abe H, 2001, MOL BRAIN RES, V87, P92, DOI 10.1016/S0169-328X(00)00295-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Challet E, 2001, BRAIN RES, V909, P81, DOI 10.1016/S0006-8993(01)02625-7; DAAN S, 1975, P NATL ACAD SCI USA, V72, P3744, DOI 10.1073/pnas.72.9.3744; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Franken P, 1999, SLEEP, V22, P155; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; GREEN DJ, 1982, BRAIN RES, V245, P198, DOI 10.1016/0006-8993(82)90361-4; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Herzog ED, 1997, BRAIN RES, V757, P285, DOI 10.1016/S0006-8993(97)00337-5; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; LEHMAN MN, 1987, J NEUROSCI, V7, P1626; Marchant EG, 1997, BRAIN RES, V765, P273, DOI 10.1016/S0006-8993(97)00571-4; Mayeda AR, 1999, BEHAV GENET, V29, P171, DOI 10.1023/A:1021639901679; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Pitts SN, 2003, AM J PHYSIOL-REG I, V285, pR57, DOI 10.1152/ajpregu.00023.2003; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; SCHWARTZ WJ, 1980, J COMP NEUROL, V189, P157, DOI 10.1002/cne.901890109; SHIBATA S, 1982, BRAIN RES, V247, P154, DOI 10.1016/0006-8993(82)91041-1; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tankersley CG, 2002, J APPL PHYSIOL, V92, P870, DOI 10.1152/japplphysiol.00904.2001; Valentinuzzi VS, 1997, AM J PHYSIOL-REG I, V273, pR1957, DOI 10.1152/ajpregu.1997.273.6.R1957; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wakamatsu H, 2001, EUR J NEUROSCI, V13, P1190, DOI 10.1046/j.0953-816x.2001.01483.x; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	48	305	315	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	2003	301	5631					379	383		10.1126/science.1082795	http://dx.doi.org/10.1126/science.1082795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12843397				2022-12-28	WOS:000184207300048
J	Green, CB; Menaker, M				Green, CB; Menaker, M			Clocks on the brain	SCIENCE			English	Editorial Material							MAMMALS		Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ Virginia, Ctr Biol Timing, Charlottesville, VA 22904 USA	University of Virginia; University of Virginia	Green, CB (corresponding author), Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA.							Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	11	27	29	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	2003	301	5631					319	320		10.1126/science.1087824	http://dx.doi.org/10.1126/science.1087824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12843400				2022-12-28	WOS:000184207300024
J	Simini, B; Bertolini, G				Simini, B; Bertolini, G		GiViTI grp	Should same anaesthetist do preoperative anaesthetic visit and give subsequent anaesthetic? Questionnaire survey of anaesthetists	BRITISH MEDICAL JOURNAL			English	Article									Osped Gen Prov, I-55100 Lucca, Italy; Ist Ric Farmacol Mario Negri, Lab Epidemiol Clin, I-24020 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Simini, B (corresponding author), Osped Gen Prov, I-55100 Lucca, Italy.		Bertolini, Guido/AAA-8005-2020	Bertolini, Guido/0000-0002-3101-4259				EGBERT LD, 1963, JAMA-J AM MED ASSOC, V188, P87; NIGHTINGALE JJ, 1992, ANAESTHESIA, V47, P801, DOI 10.1111/j.1365-2044.1992.tb03261.x; Roizen MF, 2000, NEW ENGL J MED, V342, P204, DOI 10.1056/NEJM200001203420311; *ROYAL COLL AN, 1999, GUID PROV AN SERV, P8; Simini B, 2001, ANAESTHESIA, V56, P591	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					79	80		10.1136/bmj.327.7406.79	http://dx.doi.org/10.1136/bmj.327.7406.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855526	Green Published, Bronze			2022-12-28	WOS:000184229400019
J	Ozanne, CMP; Anhuf, D; Boulter, SL; Keller, M; Kitching, RL; Korner, C; Meinzer, FC; Mitchell, AW; Nakashizuka, T; Dias, PLS; Stork, NE; Wright, SJ; Yoshimura, M				Ozanne, CMP; Anhuf, D; Boulter, SL; Keller, M; Kitching, RL; Korner, C; Meinzer, FC; Mitchell, AW; Nakashizuka, T; Dias, PLS; Stork, NE; Wright, SJ; Yoshimura, M			Biodiversity meets the atmosphere: A global view of forest canopies	SCIENCE			English	Review							ELEVATED CO2; HERBIVOROUS INSECTS; TREES; RESPONSES; PATTERNS; ECOLOGY; GROWTH; MODEL; SPECIFICITY; POLLINATION	The forest canopy is the functional interface between 90% of Earth's terrestrial biomass and the atmosphere. Multidisciplinary research in the canopy has expanded concepts of global species richness, physiological processes, and the provision of ecosystem services. Trees respond in a species-specific manner to elevated carbon dioxide levels, while climate change threatens plant-animal interactions in the canopy and will likely alter the production of biogenic aerosols that affect cloud formation and atmospheric chemistry.	Univ Surrey Roehampton, Sch Life & Sport Sci, Ctr Res Ecol & Environm, London SW15 3SN, England; Univ Sao Paulo, Inst Estudos Avancados, BR-05508900 Sao Paulo, Brazil; Griffith Univ, Environm Sci & Rainforest Cooperat Res Ctr, Nathan, Qld 4111, Australia; US Forest Serv, Int Inst Trop Forestry, USDA, San Juan, PR 00926 USA; Univ Basel, Inst Bot, CH-4056 Basel, Switzerland; US Forest Serv, USDA, Pacific NW Res Stn, Corvallis, OR 97331 USA; Univ Oxford, Global Canopy Programme, Oxford OX1 3UB, England; Res Inst Human & Nat, Kamigyo Ku, Kyoto 6020878, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka, Japan; Univ Sao Paulo, Inst Astron & Geofis, BR-05508900 Sao Paulo, Brazil; James Cook Univ N Queensland, Rainforest Cooperat Res Ctr, Cairns, Qld 4870, Australia; Smithsonian Trop Res Inst, Balboa, Panama	Roehampton University; University of Surrey; Universidade de Sao Paulo; Griffith University; United States Department of Agriculture (USDA); United States Forest Service; University of Basel; United States Department of Agriculture (USDA); United States Forest Service; University of Oxford; Research Institute for Humanity & Nature (RIHN); Japan Science & Technology Agency (JST); Universidade de Sao Paulo; James Cook University; Smithsonian Institution; Smithsonian Tropical Research Institute	Ozanne, CMP (corresponding author), Univ Surrey Roehampton, Sch Life & Sport Sci, Ctr Res Ecol & Environm, West Hill, London SW15 3SN, England.	c.ozanne@roehampton.ac.uk	da Silva Dias, Pedro Leite/H-1183-2016; Körner, Christian/B-6592-2014; Wright, Stuart Joseph/M-3311-2013; Keller, Michael/A-8976-2012; Kitching, Roger/C-5102-2009; Nakashizuka, Tohru/AAO-1081-2020; Meinzer, Frederick C/C-3496-2012; Meinzer, Frederick/N-8373-2019	da Silva Dias, Pedro Leite/0000-0002-4051-2962; Körner, Christian/0000-0001-7768-7638; Wright, Stuart Joseph/0000-0003-4260-5676; Keller, Michael/0000-0002-0253-3359; Meinzer, Frederick/0000-0003-2387-2031; Stork, Nigel/0000-0001-7812-2452; Boulter, Sarah/0000-0003-4325-2286				Anthoni PM, 1999, AGR FOREST METEOROL, V95, P151, DOI 10.1016/S0168-1923(99)00029-5; Barrios H, 2003, ARTHROPODS OF TROPICAL FORESTS, P282; Barton CVM, 2001, REMOTE SENS ENVIRON, V78, P264, DOI 10.1016/S0034-4257(01)00224-3; BASSET Y, 1991, OECOLOGIA, V88, P211, DOI 10.1007/BF00320813; Basset Y, 2003, ARTHROPODS OF TROPICAL FORESTS, P17; Basset Y., 2003, STUDYING FOREST CANO; Calder IR, 2001, PLANT ECOL, V153, P203, DOI 10.1023/A:1017580311070; Castelletta M, 2000, CONSERV BIOL, V14, P1870, DOI 10.1111/j.1523-1739.2000.99285.x; Chambers JQ, 2001, NATURE, V410, P429, DOI 10.1038/35068624; Chen JY, 2002, SCIENCE, V295, P838, DOI 10.1126/science.1065835; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Davidson DW, 2003, SCIENCE, V300, P969, DOI 10.1126/science.1082074; Davis Andrew J., 1998, Diversity and Distributions, V4, P167, DOI 10.1046/j.1472-4642.1998.00017.x; DIAS MAF, 2002, J GEOPHYS RES, V107, P461; Enquist BJ, 1999, NATURE, V401, P907, DOI 10.1038/44819; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; Facchini MC, 1999, NATURE, V401, P257, DOI 10.1038/45758; Faegri K., 1979, PRINCIPLES POLLINATI; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Foggo A, 2001, PLANT ECOL, V153, P347, DOI 10.1023/A:1017594108769; Franks PJ, 1999, PLANT CELL ENVIRON, V22, P1337, DOI 10.1046/j.1365-3040.1999.00494.x; Ghazoul J, 2001, PLANT ECOL, V153, P335, DOI 10.1023/A:1017542124699; Goldstein G, 1998, PLANT CELL ENVIRON, V21, P397, DOI 10.1046/j.1365-3040.1998.00273.x; Goosem Miriam, 1997, P241; Graham EA, 2003, P NATL ACAD SCI USA, V100, P572, DOI 10.1073/pnas.0133045100; Granados J, 2002, GLOBAL CHANGE BIOL, V8, P1109, DOI 10.1046/j.1365-2486.2002.00533.x; Grove SJ, 2002, ANNU REV ECOL SYST, V33, P1, DOI 10.1146/annurev.ecolsys.33.010802.150507; Gu LH, 2003, SCIENCE, V299, P2035, DOI 10.1126/science.1078366; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; Hammond P. M., 1997, P184; Hammond Peter M., 1996, Ecotropica, V2, P99; Hattenschwiler S, 1997, GLOB CHANGE BIOL, V3, P463, DOI 10.1046/j.1365-2486.1997.00105.x; Keller M, 1999, GLOBAL BIOGEOCHEM CY, V13, P19, DOI 10.1029/1998GB900007; Korner C, 2003, SCIENCE, V300, P1242, DOI 10.1126/science.1084460; Korner C, 2001, ECOLOGY: ACHIEVEMENT AND CHALLENGE, P227; KORNER C, 1995, PLANT CELL ENVIRON, V18, P1101, DOI 10.1111/j.1365-3040.1995.tb00622.x; Lerdau M, 1997, BIOSCIENCE, V47, P373, DOI 10.2307/1313152; Lewis OT, 2001, CONSERV BIOL, V15, P389, DOI 10.1046/j.1523-1739.2001.015002389.x; Malcolm JR, 2000, CONSERV BIOL, V14, P1623, DOI [10.1046/j.1523-1739.2000.99070.x, 10.1111/j.1523-1739.2000.99070.x]; Malhi Y, 2000, TRENDS ECOL EVOL, V15, P332, DOI 10.1016/S0169-5347(00)01906-6; May Robert M., 2000, P30; Meinzer FC, 2002, PLANT CELL ENVIRON, V25, P265, DOI 10.1046/j.1365-3040.2002.00781.x; Meinzer FC, 2001, TREE PHYSIOL, V21, P19, DOI 10.1093/treephys/21.1.19; Michaloud G, 1996, J BIOGEOGR, V23, P513, DOI 10.1111/j.1365-2699.1996.tb00013.x; Mitchell A.W., 2002, GLOBAL CANOPY HDB; NADKARNI NM, 1981, SCIENCE, V214, P1023, DOI 10.1126/science.214.4524.1023; Newell EA, 2002, OECOLOGIA, V131, P333, DOI 10.1007/s00442-002-0888-6; Novotny V, 2002, NATURE, V416, P841, DOI 10.1038/416841a; Odegaard F, 2000, J BIOGEOGR, V27, P283, DOI 10.1046/j.1365-2699.2000.00404.x; Oltchev A., 1997, J HYDROL HYDROMECH, V45, P5; Ozanne C. M. P., 1997, P534; Peakall R, 1996, EVOLUTION, V50, P2207, DOI 10.1111/j.1558-5646.1996.tb03611.x; Pepin S, 2002, OECOLOGIA, V133, P1, DOI 10.1007/s00442-002-1008-3; Phillips OL, 2002, NATURE, V418, P770, DOI 10.1038/nature00926; Richey JE, 2002, NATURE, V416, P617, DOI 10.1038/416617a; Rodgers DJ, 1998, ECOGRAPHY, V21, P392, DOI 10.1111/j.1600-0587.1998.tb00404.x; Sakai S, 1999, AM J BOT, V86, P62, DOI 10.2307/2656955; SALATI E, 1984, SCIENCE, V225, P129, DOI 10.1126/science.225.4658.129; Schmidt G, 2001, PLANT ECOL, V153, P65, DOI 10.1023/A:1017521204284; Schnitzer SA, 2002, TRENDS ECOL EVOL, V17, P223, DOI 10.1016/S0169-5347(02)02491-6; SCHOWALTER TD, 1981, ECOLOGY, V62, P1010, DOI 10.2307/1937000; Sorensen LL, 2003, ARTHROPODS OF TROPICAL FORESTS, P92; Stanhill G, 2001, AGR FOREST METEOROL, V107, P255, DOI 10.1016/S0168-1923(00)00241-0; STORK NE, 1988, BIOL J LINN SOC, V35, P321, DOI 10.1111/j.1095-8312.1988.tb00474.x; THIOLLAY JM, 1995, CONSERV BIOL, V9, P335, DOI 10.1046/j.1523-1739.1995.9020335.x; TYREE MT, 1991, NEW PHYTOL, V119, P345, DOI 10.1111/j.1469-8137.1991.tb00035.x; Walter DE, 1998, AUST J ECOL, V23, P501, DOI 10.1111/j.1442-9993.1998.tb00760.x; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; Whittaker JB, 1999, EUR J ENTOMOL, V96, P149; Winchester NN, 1999, PEDOBIOLOGIA, V43, P391; Wright S. Joseph, 1996, P440	71	216	254	7	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					183	186		10.1126/science.1084507	http://dx.doi.org/10.1126/science.1084507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855799				2022-12-28	WOS:000184056200032
J	Camann, W; Marquardt, J				Camann, W; Marquardt, J			Images in clinical medicine: Complex umbilical-cord knot.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Camann, W (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	9	9	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					159	159		10.1056/NEJMicm020847	http://dx.doi.org/10.1056/NEJMicm020847			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853589				2022-12-28	WOS:000184024400009
J	Lee, AYY; Levine, MN; Baker, RI; Bowden, C; Kakkar, AK; Prins, M; Rickles, FR; Julian, JA; Haley, S; Kovacs, MJ; Gent, M				Lee, AYY; Levine, MN; Baker, RI; Bowden, C; Kakkar, AK; Prins, M; Rickles, FR; Julian, JA; Haley, S; Kovacs, MJ; Gent, M		CLOT	Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; LONG-TERM TREATMENT; PULMONARY-EMBOLISM; BLEEDING COMPLICATIONS; WARFARIN; THROMBOSIS; ACENOCOUMAROL; ANGIOGRAPHY; MANAGEMENT; CT	BACKGROUND: Patients with cancer have a substantial risk of recurrent thrombosis despite the use of oral anticoagulant therapy. We compared the efficacy of a low-molecular-weight heparin with that of an oral anticoagulant agent in preventing recurrent thrombosis in patients with cancer. METHODS: Patients with cancer who had acute, symptomatic proximal deep-vein thrombosis, pulmonary embolism, or both were randomly assigned to receive low-molecular-weight heparin (dalteparin) at a dose of 200 IU per kilogram of body weight subcutaneously once daily for five to seven days and a coumarin derivative for six months (target international normalized ratio, 2.5) or dalteparin alone for six months (200 IU per kilogram once daily for one month, followed by a daily dose of approximately 150 IU per kilogram for five months). RESULTS: During the six-month study period, 27 of 336 patients in the dalteparin group had recurrent venous thromboembolism, as compared with 53 of 336 patients in the oral-anticoagulant group (hazard ratio, 0.48; P=0.002). The probability of recurrent thromboembolism at six months was 17 percent in the oral-anticoagulant group and 9 percent in the dalteparin group. No significant difference between the dalteparin group and the oral-anticoagulant group was detected in the rate of major bleeding (6 percent and 4 percent, respectively) or any bleeding (14 percent and 19 percent, respectively). The mortality rate at six months was 39 percent in the dalteparin group and 41 percent in the oral-anticoagulant group. CONCLUSIONS: In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Hamilton Hlth Sci, Henderson Res Ctr, Hamilton, ON, Canada; Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Pharmacia Corp, Peapack, NJ USA; Univ London Imperial Coll Sci Technol & Med, Dept Surg Oncol & Technol, London SW7 2AZ, England; Univ Limburg, Acad Hosp Maastricht, Maastricht, Netherlands; George Washington Univ, Dept Med & Pediat, Washington, DC USA; Univ Western Ontario, Dept Med, London, ON, Canada	McMaster University; McMaster University; McMaster University; University of Western Australia; Pfizer; Imperial College London; Hasselt University; Maastricht University; Maastricht University Medical Centre (MUMC); George Washington University; Western University (University of Western Ontario)	Levine, MN (corresponding author), Henderson Gen Hosp, Rm 9,90 Wing,711 Concess St, Hamilton, ON L8V 1C3, Canada.		Kovacs, Michael/G-3315-2011; Baker, Ross/AAG-5798-2021	Baker, Ross/0000-0002-2728-6788				Das SK, 1996, WORLD J SURG, V20, P521, DOI 10.1007/s002689900081; Eikelboom JW, 1998, AM J HEMATOL, V59, P260, DOI 10.1002/(SICI)1096-8652(199811)59:3<260::AID-AJH17>3.0.CO;2-2; Gonzalez-Fajardo JA, 1999, J VASC SURG, V30, P283, DOI 10.1016/S0741-5214(99)70139-4; Hull R, 2000, BLOOD, V96, p449A; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; Hutten BA, 2000, J CLIN ONCOL, V18, P3078, DOI 10.1200/JCO.2000.18.17.3078; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee AYY, 2000, ONCOLOGY-NY, V14, P409; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Lopaciuk S, 1999, THROMB HAEMOSTASIS, V81, P26; Luk C, 2001, AM J MED, V111, P270, DOI 10.1016/S0002-9343(01)00840-3; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Meyer G, 2002, ARCH INTERN MED, V162, P1729, DOI 10.1001/archinte.162.15.1729; Palareti G, 2000, THROMB HAEMOSTASIS, V84, P805; PINI M, 1994, THROMB HAEMOSTASIS, V72, P191; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Qanadli SD, 2000, RADIOLOGY, V217, P447, DOI 10.1148/radiology.217.2.r00nv01447; RemyJardin M, 1996, RADIOLOGY, V200, P699, DOI 10.1148/radiology.200.3.8756918; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Veiga F, 2000, THROMB HAEMOSTASIS, V84, P559; WalshMcMonagle D, 1997, CANCER-AM CANCER SOC, V80, P649, DOI 10.1002/(SICI)1097-0142(19970815)80:4<649::AID-CNCR1>3.0.CO;2-I; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Weitz JI, 1997, NEW ENGL J MED, V337, P1567; Zubrod C.G., 1960, J CHRON DIS, V11, P7	26	1788	1853	4	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					146	153		10.1056/NEJMoa025313	http://dx.doi.org/10.1056/NEJMoa025313			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853587	Bronze			2022-12-28	WOS:000184024400007
J	Wolfe, JT; Wang, HG; Howard, J; Garrison, JC; Barrett, PQ				Wolfe, JT; Wang, HG; Howard, J; Garrison, JC; Barrett, PQ			T-type calcium channel regulation by specific G-protein beta gamma subunits	NATURE			English	Article							CA2+ CHANNEL; DOPAMINE-RECEPTORS; INHIBITION; CURRENTS; MODULATION; EXPRESSION; BINDING; CELLS; K+	Low-voltage-activated (LVA) T-type calcium channels have a wide tissue distribution and have well-documented roles in the control of action potential burst generation and hormone secretion(1). In neurons of the central nervous system and secretory cells of the adrenal and pituitary, LVA channels are inhibited by activation of G-protein-coupled receptors that generate membrane-delimited signals(2-5), yet these signals have not been identified. Here we show that the inhibition of alpha(1H) (Ca(v)3.2), but not alpha(1G) (Ca(v)3.1) LVA Ca2+ channels is mediated selectively by beta(2)gamma(2) subunits that bind to the intracellular loop connecting channel transmembrane domains II and III. This region of the alpha(1H) channel is crucial for inhibition, because its replacement abrogates inhibition and its transfer to non-modulated alpha(1G) channels confers beta(2)gamma(2)-dependent inhibition. betagamma reduces channel activity independent of voltage, a mechanism distinct from the established betagamma-dependent inhibition of non-L-type high-voltage-activated channels of the Ca(v)2 family(6,7). These studies identify the alpha(1H) channel as a new effector for G-protein betagamma subunits, and highlight the selective signalling roles available for particular betagamma combinations.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Barrett, PQ (corresponding author), Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA.	pqb4b@virginia.edu	Wolfe, Joshua/H-3821-2013; Barrett, Paula/AAY-1056-2021		NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Cooper CB, 2000, J BIOL CHEM, V275, P40777, DOI 10.1074/jbc.C000673200; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Downes GB, 1999, GENOMICS, V62, P544, DOI 10.1006/geno.1999.5992; Drolet P, 1997, MOL ENDOCRINOL, V11, P503, DOI 10.1210/me.11.4.503; FISHMAN MC, 1981, P NATL ACAD SCI-BIOL, V78, P5245, DOI 10.1073/pnas.78.8.5245; GRABER SG, 1996, METH NEUROSCI, V29, P207; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZASA T, 1999, CRC METH SIG TRANS, P23; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LLEDO PM, 1990, ENDOCRINOLOGY, V127, P990, DOI 10.1210/endo-127-3-990; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Safa P, 2001, J BIOL CHEM, V276, P38727, DOI 10.1074/jbc.M103724200; Schrier AD, 2001, AM J PHYSIOL-CELL PH, V280, pC265, DOI 10.1152/ajpcell.2001.280.2.C265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; WILLIAMS PJ, 1990, J NEUROSCI, V10, P757; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	30	113	120	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					209	213		10.1038/nature01772	http://dx.doi.org/10.1038/nature01772			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853961				2022-12-28	WOS:000184032700046
J	Yudkin, P; Hey, K; Roberts, S; Welch, S; Murphy, M; Walton, R				Yudkin, P; Hey, K; Roberts, S; Welch, S; Murphy, M; Walton, R			Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; NASAL SPRAY; FOLLOW-UP; CESSATION		Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England; Inst Hlth Sci, Canc Res UK Gen Practice Res Grp, Oxford OX3 7LF, England; Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford	Yudkin, P (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England.			Walton, Robert/0000-0001-7700-1907				Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; BURKE P, 1994, BRIT MED J, V308, P1476; BURKE P, 1993, BRIT MED J, V306, P1304; ClavelChapelon F, 1997, PREV MED, V26, P25, DOI 10.1006/pmed.1996.9997; Stapleton JA, 1998, BRIT MED J, V316, P830, DOI 10.1136/bmj.316.7134.830	5	67	71	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					28	29		10.1136/bmj.327.7405.28	http://dx.doi.org/10.1136/bmj.327.7405.28			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842953	Green Published, Bronze			2022-12-28	WOS:000184062700023
J	Heintz, N				Heintz, N			Ataxin-1 regulators in the spotlight	SCIENCE			English	Editorial Material							BULBAR MUSCULAR-ATROPHY; TRANSGENIC MOUSE MODEL; 14-3-3 PROTEINS; DISEASE BRAINS		Rockefeller Univ, Dept Mol Biol, New York, NY 10021 USA	Rockefeller University	Heintz, N (corresponding author), Rockefeller Univ, Dept Mol Biol, 1230 York Ave, New York, NY 10021 USA.							Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Katsuno M, 2003, NAT MED, V9, P768, DOI 10.1038/nm878; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401	8	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					59	60		10.1126/science.1086311	http://dx.doi.org/10.1126/science.1086311			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843383				2022-12-28	WOS:000183914700029
J	Pinyopich, A; Ditta, GS; Savidge, B; Liljegren, SJ; Baumann, E; Wisman, E; Yanofsky, MF				Pinyopich, A; Ditta, GS; Savidge, B; Liljegren, SJ; Baumann, E; Wisman, E; Yanofsky, MF			Assessing the redundancy of MADS-box genes during carpel and ovule development	NATURE			English	Article							FLORAL ORGAN IDENTITY; ARABIDOPSIS-THALIANA; EXPRESSION; TRANSCRIPTION; DETERMINES; SPATULA; PETUNIA; PROTEIN; PLANTS	Carpels are essential for sexual plant reproduction because they house the ovules and subsequently develop into fruits that protect, nourish and ultimately disperse the seeds. The AGAMOUS (AG) gene is necessary for plant sexual reproduction because stamens and carpels are absent from ag mutant flowers(1),(2). However, the fact that sepals are converted into carpelloid organs in certain mutant backgrounds even in the absence of AG activity indicates that an AG-independent carpel-development pathway exists(2). AG is a member of a monophyletic clade of MADS-box genes that includes SHATTERPROOF1 (SHP1), SHP2 and SEEDSTICK (STK)(3), indicating that these four genes might share partly redundant activities. Here we show that the SHP genes are responsible for AG-independent carpel development. We also show that the STK gene is required for normal development of the funiculus, an umbilical-cord-like structure that connects the developing seed to the fruit, and for dispersal of the seeds when the fruit matures. We further show that all four members of the AG clade are required for specifying the identity of ovules, the landmark invention during the course of vascular plant evolution that enabled seed plants to become the most successful group of land plants(4).	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	University of California System; University of California San Diego; Max Planck Society	Yanofsky, MF (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.							Alvarez J, 1999, DEVELOPMENT, V126, P2377; ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COLOMBO L, 1995, PLANT CELL, V7, P1859, DOI 10.1105/tpc.7.11.1859; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Flanagan CA, 1996, PLANT J, V10, P343, DOI 10.1046/j.1365-313X.1996.10020343.x; Heisler MGB, 2001, DEVELOPMENT, V128, P1089; Kempin SA, 1997, NATURE, V389, P802, DOI 10.1038/39770; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SAVIDGE B, 1995, PLANT CELL, V7, P721, DOI 10.1105/tpc.7.6.721; Sessions A, 1999, PLANT J, V20, P259, DOI 10.1046/j.1365-313x.1999.00594.x; Stewart W.N., 1993, PALEOBOTANY EVOLUTIO; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; Western TL, 1999, PLANT J, V18, P329, DOI 10.1046/j.1365-313X.1999.00448.x; Wisman E, 1998, PLANT MOL BIOL, V37, P989, DOI 10.1023/A:1006082009151; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	22	533	611	11	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					85	88		10.1038/nature01741	http://dx.doi.org/10.1038/nature01741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840762				2022-12-28	WOS:000183912800045
J	Lamont, EB; Christakis, NA				Lamont, EB; Christakis, NA			Complexities in prognostication in advanced cancer - "To help them live their lives the way they want to"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; CELL LUNG-CANCER; KARNOFSKY PERFORMANCE STATUS; RANDOMIZED CONTROLLED TRIAL; METASTATIC BREAST-CANCER; TERMINALLY ILL PATIENTS; SUPPORTIVE CARE BSC; BREAKING BAD-NEWS; HEPATOCELLULAR-CARCINOMA; CHEMOTHERAPY PLUS		Univ Chicago, Med Ctr, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lamont, EB (corresponding author), Univ Chicago, Med Ctr, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.		Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	Lamont, Elizabeth/0000-0001-6604-678X	NCI NIH HHS [K07 CA-93892, K07 CA093892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA093892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLARD P, 1995, J PALLIAT CARE, V11, P20, DOI 10.1177/082585979501100305; *AM JOINT COMM CAN, 1992, HDB STAG CANC; Anderson H, 2000, BRIT J CANCER, V83, P447, DOI 10.1054/bjoc.2000.1307; [Anonymous], SURVEILLANCE EPIDEMI; [Anonymous], 1999, DEATH FORETOLD PROPH; ATTALI P, 1987, CANCER, V59, P2108, DOI 10.1002/1097-0142(19870615)59:12<2108::AID-CNCR2820591225>3.0.CO;2-3; Baile WF, 2002, J CLIN ONCOL, V20, P2189, DOI 10.1200/JCO.2002.08.004; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P82, DOI 10.1016/0885-3924(92)90118-2; Buckman R., 1992, BREAK BAD NEWS GUIDE; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Coates A, 1997, EUR J CANCER, V33, P1025, DOI 10.1016/S0959-8049(97)00049-X; Cunningham D, 1999, SEMIN ONCOL, V26, P6; Davison B J, 1995, Oncol Nurs Forum, V22, P1401; De Vita Jr VT, 1993, CANC PRINCIPLES PRAC; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; EVANS C, 1985, LANCET, V1, P1204; FEINSTEIN AR, 1969, ARCH INTERN MED, V123, P232; Feinstein AR, 1967, CLIN JUDGEMENT; Fischer GS, 2000, TOPICS PALLIATIVE CA, V4; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; Gallo C, 1998, LANCET, V352, P17; GLARE P, IN PRESS OXFORD TXB; Glimelius B, 1997, ANN ONCOL, V8, P163, DOI 10.1023/A:1008243606668; GOCKERMAN JP, 1986, CANCER TREAT REP, V70, P1199; HARDY JR, 1994, EUR J CANCER, V30A, P284, DOI 10.1016/0959-8049(94)90242-9; HARRISON JD, 1989, CANCER-AM CANCER SOC, V64, P1007, DOI 10.1002/1097-0142(19890901)64:5<1007::AID-CNCR2820640506>3.0.CO;2-U; Heyse-Moore LH., 1987, PALLIATIVE MED, V1, P165, DOI DOI 10.1177/026921638700100213; HYDE L, 1973, CHEST, V64, P309, DOI 10.1378/chest.64.3.309; JANISCH L, 1994, CANCER-AM CANCER SOC, V74, P1965, DOI 10.1002/1097-0142(19941001)74:7<1965::AID-CNCR2820740723>3.0.CO;2-1; Johnstone PAS, 2000, J SURG ONCOL, V73, P273, DOI 10.1002/(SICI)1096-9098(200004)73:4<273::AID-JSO15>3.0.CO;2-H; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; KEATING JJ, 1989, BRIT J CANCER, V60, P789, DOI 10.1038/bjc.1989.361; Kowalski LP, 2000, EUR J CANCER, V36, P1032, DOI 10.1016/S0959-8049(00)00054-X; Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; LAMONT EB, 2002, PRINCIPLES PRACTICE; Llobera J, 2000, EUR J CANCER, V36, P2036, DOI 10.1016/S0959-8049(00)00291-4; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P601, DOI 10.1200/JCO.1994.12.3.601; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MALTONI M, 1994, EUR J CANCER, V30A, P764, DOI 10.1016/0959-8049(94)90289-5; MALTONI M, 1995, CANCER-AM CANCER SOC, V75, P2613, DOI 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032>3.0.CO;2-1; Maltoni M, 1997, J PAIN SYMPTOM MANAG, V13, P1, DOI 10.1016/S0885-3924(96)00265-5; MCCUSKER J, 1984, J CHRON DIS, V37, P377, DOI 10.1016/0021-9681(84)90104-8; MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Morita T, 1999, SUPPORT CARE CANCER, V7, P128, DOI 10.1007/s005200050242; Morita T, 1999, J PAIN SYMPTOM MANAG, V18, P2; *NAT CANC I SURV R, SEER STAR STAT SOFTW; Parker PA, 2001, J CLIN ONCOL, V19, P2049, DOI 10.1200/JCO.2001.19.7.2049; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; Peethambaram PP, 1999, BREAST CANCER RES TR, V54, P117, DOI 10.1023/A:1006185805079; Pirovano M, 1999, J PAIN SYMPTOM MANAG, V17, P231, DOI 10.1016/S0885-3924(98)00145-6; POSES RM, 1990, ARCH INTERN MED, V150, P1874, DOI 10.1001/archinte.150.9.1874; Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496; Rabow MW, 1999, WESTERN J MED, V171, P260; REUBEN DB, 1988, ARCH INTERN MED, V148, P1586, DOI 10.1001/archinte.148.7.1586; Rosenthal Mark A., 1993, Palliative Medicine, V7, P199, DOI 10.1177/026921639300700306; Roszkowski K, 2000, LUNG CANCER-J IASLC, V27, P145, DOI 10.1016/S0169-5002(00)00094-5; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; Shimozuma K, 2000, SURG TODAY, V30, P255, DOI 10.1007/s005950050055; Tamburini M, 1996, J PAIN SYMPTOM MANAG, V11, P32, DOI 10.1016/0885-3924(95)00135-2; TAYLOR SG, 1986, ANN INTERN MED, V104, P455, DOI 10.7326/0003-4819-104-4-455; Thongprasert S, 1999, LUNG CANCER-J IASLC, V24, P17, DOI 10.1016/S0169-5002(99)00017-3; Vigano A, 1999, CANCER, V86, P170, DOI 10.1002/(SICI)1097-0142(19990701)86:1<170::AID-CNCR23>3.0.CO;2-S; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; YATES JW, 1980, CANCER, V45, P2220, DOI 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q; Zubrod C.G., 1960, J CHRON DIS, V11, P7	72	143	144	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					98	104		10.1001/jama.290.1.98	http://dx.doi.org/10.1001/jama.290.1.98			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837717	Green Published			2022-12-28	WOS:000183868600025
J	Rossetti, S; Chauveau, D; Kubly, V; Slezak, JM; Saggar-Malik, AK; Pei, Y; Ong, ACM; Stewart, F; Watson, ML; Bergstralh, EJ; Winearls, CG; Torres, VE; Harris, PC				Rossetti, S; Chauveau, D; Kubly, V; Slezak, JM; Saggar-Malik, AK; Pei, Y; Ong, ACM; Stewart, F; Watson, ML; Bergstralh, EJ; Winearls, CG; Torres, VE; Harris, PC			Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype	LANCET			English	Article							POLYCYSTIC KIDNEY-DISEASE; INTRACRANIAL ANEURYSMS; EXPRESSION; PROTEIN; ENCODES	Background Patients with autosomal dominant polycystic kidney disease (ADPKD) are at risk of developing intracranial aneurysms, and subarachnoid haemorrhage is a major cause of death and disability. Familial clustering of intracranial aneurysms suggests that genetic factors are important in the aetiology. We tested whether the germline mutation predisposes to this vascular phenotype. Methods DNA samples from patients with ADPKD and vascular complications were screened for mutations throughout the PKD1 and PKD2 genes. Comparisons were made between the PKD1 and PKD2 populations and with a control PKD1 cohort (without the vascular phenotype). Findings Mutations were characterised in 58 ADPKD families with vascular complications; 51 were PKD1 (88%) and seven PKD2 (12%). The median position of the PKD1 mutation was significantly further 5' in the vascular population than in the 87 control pedigrees (aminoacid position 2163 vs 2773, p=0.0034). Subsets of the vascular population with aneurysmal rupture, early rupture, or families with more than one vascular case had median mutation locations further 5' (aminoacid position 1811, p=0.0018; 1671, p=0.0052; and 1587, p=0.0003). Interpretation Patients with PKD2, as well as those with PKD1, are at risk of intracranial aneurysm. The position of the mutation in PKD1 is predictive for development of intracranial aneurysms (5' mutations are more commonly associated with vascular disease) and is therefore of prognostic importance. Since the PKD1 phenotype is associated with mutation position, the disease is not simply due to loss of all disease allele products.	Mayo Clin, Div Nephrol, Rochester, MN 55905 USA; Mayo Clin, Div Biostat, Rochester, MN USA; Hop Necker Enfants Malad, Serv Nephrol, Paris, France; Hop Necker Enfants Malad, INSERM, U507, Paris, France; Univ London St Georges Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Toronto Gen Hosp, Div Nephrol & Genom Med, Toronto, ON, Canada; Univ Sheffield, Sheffield Kidney Inst, Sheffield, S Yorkshire, England; Belfast City Hosp, No Ireland Reg Genet Ctr, Belfast BT9 7AD, Antrim, North Ireland; Royal Infirm, Dept Med, Edinburgh, Midlothian, Scotland; Oxford Radcliffe Hosp, Oxford Renal Unit, Oxford, England	Mayo Clinic; Mayo Clinic; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; St Georges University London; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Sheffield; Belfast City Hospital; Royal Infirmary of Edinburgh; University of Oxford	Harris, PC (corresponding author), Mayo Clin, Div Nephrol, 760 Stabile Bldg,200 1st St SW, Rochester, MN 55905 USA.	harris.peter@mayo.edu	Ong, Albert/AAN-9430-2021	Ong, Albert/0000-0002-7211-5400; Torres, Vicente/0000-0003-2008-1576	NIDDK NIH HHS [DK58816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belz MM, 2001, AM J KIDNEY DIS, V38, P770, DOI 10.1053/ajkd.2001.27694; Bobrie G, 1998, NEPHROL DIAL TRANSPL, V13, P2138, DOI 10.1093/ndt/13.8.2138; Butler WE, 1996, NEUROSURGERY, V38, P506; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; CHAUVEAU D, 1994, KIDNEY INT, V45, P1140, DOI 10.1038/ki.1994.151; FICK GM, 1995, J AM SOC NEPHROL, V5, P2048; Griffin MD, 1997, J AM SOC NEPHROL, V8, P616; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Huston J, 1996, J AM SOC NEPHROL, V7, P2135; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Igarashi P, 2002, J AM SOC NEPHROL, V13, P2384, DOI 10.1097/01.ASN.0000028643.17901.42; Kim K, 2000, P NATL ACAD SCI USA, V97, P1731, DOI 10.1073/pnas.040550097; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Pirson Y, 2002, J AM SOC NEPHROL, V13, P269, DOI 10.1681/ASN.V131269; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; Rossetti S, 2002, KIDNEY INT, V61, P1588, DOI 10.1046/j.1523-1755.2002.00326.x; Rossetti S, 2002, J AM SOC NEPHROL, V13, P1230, DOI 10.1097/01.ASN.0000013300.11876.37; Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939; SCHIEVINK WI, 1992, J AM SOC NEPHROL, V3, P88; Schievink WI, 1997, J AM SOC NEPHROL, V8, P1298; Torres VE, 2001, J AM SOC NEPHROL, V12, P1, DOI 10.1681/ASN.V1211; vanDijk MA, 1995, J AM SOC NEPHROL, V6, P1670; Watnick T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	30	133	144	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2196	2201		10.1016/S0140-6736(03)13773-7	http://dx.doi.org/10.1016/S0140-6736(03)13773-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842373				2022-12-28	WOS:000183815600012
J	Richardson, PG; Barlogie, B; Berenson, J; Singhal, S; Jagannath, S; Irwin, D; Rajkumar, SV; Srkalovic, G; Alsina, M; Alexanian, R; Siegel, D; Orlowski, RZ; Kuter, D; Limentani, SA; Lee, S; Hideshima, T; Esseltine, DL; Kauffman, M; Adams, J; Schenkein, DP; Anderson, KC				Richardson, PG; Barlogie, B; Berenson, J; Singhal, S; Jagannath, S; Irwin, D; Rajkumar, SV; Srkalovic, G; Alsina, M; Alexanian, R; Siegel, D; Orlowski, RZ; Kuter, D; Limentani, SA; Lee, S; Hideshima, T; Esseltine, DL; Kauffman, M; Adams, J; Schenkein, DP; Anderson, KC			A phase 2 study of bortezomib in relapsed, refractory myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEASOME INHIBITOR PS-341; HUMAN MULTIPLE-MYELOMA; NF-KAPPA-B; OVERCOMES DRUG-RESISTANCE; THERAPEUTIC APPLICATIONS; 26S PROTEASOME; PANCREATIC-CANCER; IN-VIVO; CELLS; GROWTH	BACKGROUND: Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity. METHODS: In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled 202 patients with relapsed myeloma that was refractory to the therapy they had received most recently. Patients received 1.3 mg of bortezomib per square meter of body-surface area twice weekly for 2 weeks, followed by 1 week without treatment, for up to eight cycles (24 weeks). In patients with a suboptimal response, oral dexamethasone (20 mg daily, on the day of and the day after bortezomib administration) was added to the regimen. The response was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation and confirmed by an independent review committee. RESULTS: Of 193 patients who could be evaluated, 92 percent had been treated with three or more of the major classes of agents for myeloma, and in 91 percent, the myeloma was refractory to the therapy received most recently. The rate of response to bortezomib was 35 percent, and those with a response included 7 patients in whom myeloma protein became undetectable and 12 in whom myeloma protein was detectable only by immunofixation. The median overall survival was 16 months, with a median duration of response of 12 months. Grade 3 adverse events included thrombocytopenia (in 28 percent of patients), fatigue (in 12 percent), peripheral neuropathy (in 12 percent), and neutropenia (in 11 percent). Grade 4 events occurred in 14 percent of patients. CONCLUSIONS: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Univ Arkansas, Little Rock, AR 72204 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Northwestern Univ, Med Ctr, Chicago, IL 60611 USA; St Vincents Catholic Med Ctr, New York, NY USA; Alta Bates Canc Ctr, Berkeley, CA USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Carol G Simon Canc Ctr, Morristown, NJ USA; Univ N Carolina, Chapel Hill, NC USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Charlotte Med Clin, Charlotte, NC USA; Millennium Pharmaceut, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Cedars Sinai Medical Center; Northwestern University; Saint Vincents Hospital Manhattan; Mayo Clinic; Cleveland Clinic Foundation; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Texas System; UTMD Anderson Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Richardson, PG (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St,Dana 1B12, Boston, MA 02115 USA.		Kuter, David/AAS-1123-2020; Rajkumar, S. Vincent/AAV-1834-2021	Rajkumar, S. Vincent/0000-0002-5862-1833; Orlowski, Robert/0000-0002-5723-4129				Adams J, 1999, CANCER RES, V59, P2615; Allison P. D., 1995, SURVIVAL ANAL USING; American Cancer Society, 2002, CANC FACTS FIG 2002; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; Blade J, 2000, ACTA ONCOL, V39, P843; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Bold RJ, 2001, J SURG RES, V100, P11, DOI 10.1006/jsre.2001.6194; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHAMBERLAIN G, 1985, LONGITUDINAL ANAL LA; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cusack JC, 2001, CANCER RES, V61, P3535; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Gertz MA, 1995, AM J CLIN ONCOL-CANC, V18, P475; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; LeBlanc R, 2002, CANCER RES, V62, P4996; Lee CK, 2002, BONE MARROW TRANSPL, V30, P873, DOI 10.1038/sj.bmt.1703715; Maki CG, 1996, CANCER RES, V56, P2649; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Nix D., 2001, P AN M AM SOC CLIN, V20, p86a; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pervan M, 2001, AM J CLIN ONCOL-CANC, V24, P481, DOI 10.1097/00000421-200110000-00013; Pink Melissa M., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P158; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Shah SA, 2001, J CELL BIOCHEM, V82, P110, DOI 10.1002/jcb.1150; SIMON R, 1984, STAT MED, V3, P35, DOI 10.1002/sim.4780030106; Singhal S, 2000, NEW ENGL J MED, V342, P364; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tatebe H, 2000, CURR BIOL, V10, P1329, DOI 10.1016/S0960-9822(00)00773-9; Teicher BA, 1999, CLIN CANCER RES, V5, P2638	42	2151	2280	2	135	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2609	2617		10.1056/NEJMoa030288	http://dx.doi.org/10.1056/NEJMoa030288			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826635	Green Published			2022-12-28	WOS:000183726400004
J	Talbot, TR; Bredenberg, HK; Smith, M; LaFleur, BJ; Boyd, A; Edwards, KM				Talbot, TR; Bredenberg, HK; Smith, M; LaFleur, BJ; Boyd, A; Edwards, KM			Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXANTHEMATOUS PUSTULOSIS; COMPLICATIONS; SURVEILLANCE	Context With the reintroduction of smallpox vaccination, detailed contemporary descriptions of adverse reactions to the vaccine are needed to adequately inform the public and clinicians. During a multicenter, randomized controlled trial investigating the efficacy of various dilutions of smallpox vaccine, we observed the appearance of a papulovesicular eruption (focal and generalized) in study volunteers. Objective To characterize the papulovesicular eruptions by clinical, virologic, and histopathological characteristics. Design, Setting, and Participants Prospective case series of papulovesicular eruptions following smallpox vaccination in healthy, vaccinia-naive adult participants compared with noncases conducted from October 2002 to March 2003. Variables potentially related to these eruptions were collected retrospectively through chart review. Eruptions were described based on viral culture, clinical examination, and histopathological evaluation (1 biopsy specimen from 1 case). Main Outcome Measure Cases of papulovesicular eruptions following vaccination. Results During the trial, of 148 volunteers (56% women; mean age 23.6 years), 4 participants (2.7%) developed generalized eruptions and 11 (7.4%) noted focal eruptions. Viral cultures of sample lesions were negative for vaccinia. The result of a skin biopsy sample from 1 case of generalized rash revealed suppurative folliculitis without evidence of viral infection. All lesions resolved without scarring. In the cohort, cases and noncases did not show significant differences in term's of sex, in the use of nonsteroidal anti-inflammatory drugs or oral or depo contraceptives, in medication allergies, in the incidence of fever or lymphadenopathy after vaccination, or in the dilution of vaccine received. Conclusions Folliculitis is a common and benign eruption observed in vaccinia-naive adult volunteers following smallpox vaccination. This eruption may be seen in volunteers receiving the vaccine in the newly instituted vaccination programs and may be met with heightened anxiety, potentially being confused with generalized vaccinia. This description of folliculitis using clinical, virologic, and histopathological findings should. allay these concerns and provide additional insight into this eruption.	Vanderbilt Univ, Med Ctr, Sch Med, Med Ctr N A3310,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Talbot, TR (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Med Ctr N A3310,Dept Med, Nashville, TN 37232 USA.	tom.talbot@vanderbilt.edu	LaFleur, Bonnie J/GPJ-9592-2022	LaFleur, Bonnie J/0000-0002-4939-9337; Talbot, Thomas/0000-0002-6139-212X	PHS HHS [02-054] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*CDCP, 2003, MMWR-MORBID MORTAL W, V52, P156; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; GOLDSTEIN JA, 1975, PEDIATRICS, V55, P342; GRAHAM BS, 1992, J INFECT DIS, V166, P244, DOI 10.1093/infdis/166.2.244; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HSIUNG GD, 1982, DIAGNOSTIC VIROLOGY; Jezek Z, 1988, HUMAN MONKEYPOX; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; NEFF JM, 1967, NEW ENGL J MED, V276, P125, DOI 10.1056/NEJM196701192760301; NEFF JM, 1967, PEDIATRICS, V39, P916; NEFF JM, 1972, PEDIATRICS, V50, P481; NEFF JM, 2000, MANDELL DOUGLAS BENN, P1553; RATNER LH, 1970, AM J EPIDEMIOL, V91, P278, DOI 10.1093/oxfordjournals.aje.a121137; Schmid S, 2002, AM J PATHOL, V161, P2079, DOI 10.1016/S0002-9440(10)64486-0; Sidoroff A, 2001, J CUTAN PATHOL, V28, P113, DOI 10.1034/j.1600-0560.2001.028003113.x; WINKENWERDER W, 2003, DEP DEFENSE SMALLPOX	18	31	31	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3290	3294		10.1001/jama.289.24.3290	http://dx.doi.org/10.1001/jama.289.24.3290			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824211	Bronze			2022-12-28	WOS:000183704600023
J	Potts, M; Walsh, J				Potts, M; Walsh, J			Tackling India's HIV epidemic: lessons from Africa	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE CIRCUMCISION; INTERVENTIONS; TRANSMISSION; IMPACT; CORE	India stands on the brink of a major HIV epidemic. However, by examining where public health initiatives went wrong in Africa, die international community may be able to help India avoid the devastating effects seen in Africa.	Univ Calif Berkeley, Sch Publ Hlth, Bay Area Int Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Inst Human Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Potts, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Bay Area Int Grp, Berkeley, CA 94720 USA.	pottsmalcolm@yahoo.com						Attaran A, 2001, LANCET, V357, P57, DOI 10.1016/S0140-6736(00)03576-5; Boily MC, 2002, SEX TRANSM INFECT, V78, pI78, DOI 10.1136/sti.78.suppl_1.i78; Chen SY, 2002, AM J PUBLIC HEALTH, V92, P1387, DOI 10.2105/AJPH.92.9.1387-a; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; Gray RH, 2000, AIDS, V14, P2371, DOI 10.1097/00002030-200010200-00019; GREEN R, 2001, INT HLTH EC ASS 3 IN; Hawkes S, 2002, SEX TRANSM INFECT, V78, pI31, DOI 10.1136/sti.78.suppl_1.i31; *INT LESB GAY ASS, SIT HOM IND REP SWED; Jha P, 2002, SCIENCE, V295, P2036, DOI 10.1126/science.295.5562.2036; LAZARO FD, AIDS CHALLENGE THAIL; Lowndes CM, 2002, SEX TRANSM INFECT, V78, pI69, DOI 10.1136/sti.78.suppl_1.i69; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MASAKI E, COST EFFECTIVENESS H; MCNEIL D, 2002, NY TIMES        1009; Nagelkerke NJD, 2002, B WORLD HEALTH ORGAN, V80, P89; National Intelligence Council, 2002, NEXT WAV HIV AIDS NI; Parkhurst JO, 2002, LANCET, V360, P78, DOI 10.1016/S0140-6736(02)09340-6; *ROCK FDN, 2002, MICR IN MOB MICR DEC; Shelton JD, 2001, BRIT MED J, V323, P139, DOI 10.1136/bmj.323.7305.139; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; Szabo R, 2000, BRIT MED J, V320, P1592, DOI 10.1136/bmj.320.7249.1592; *UN POP FUND, 2003, SEC ESS SUPPL; *UNAIDS, 2000, REP GLOB HIV AIDS EP; LEMONAIDS	24	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2003	326	7403					1389	1392		10.1136/bmj.326.7403.1389	http://dx.doi.org/10.1136/bmj.326.7403.1389			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816832	Green Published			2022-12-28	WOS:000183756400030
J	Saez-Llorens, X; McCracken, GH				Saez-Llorens, X; McCracken, GH			Bacterial meningitis in children	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; RESISTANT STREPTOCOCCUS-PNEUMONIAE; SEVERE MENINGOCOCCAL SEPSIS; CEREBROSPINAL-FLUID VALUES; NEISSERIA-MENINGITIDIS; DEXAMETHASONE THERAPY; CONJUGATE VACCINE; UNITED-STATES	This review comprises aspects of the epidemiology, microbiology, pathophysiology, clinical manifestations, diagnosis, management, prognosis, and prevention of bacterial meningitis, with emphasis on the paediatric population. The beginning of this millennium has witnessed the virtual disappearance of Haemophilus invasive disease in some countries, emergence of pneumococcal strains that are resistant to multiple antibiotics, isolation of pneumococci with tolerance to vancomycin, outbreaks and clusters of meningococcal meningitis in several geographical areas, and intense research in development of effective conjugate pneumococcal and meningococcal vaccines. Bacterial meningitis has become an uncommon disease in the developed world. Unfortunately, because of limited economic resources and poor living conditions, many developing countries are still affected by the devastating consequences of this life-threatening systemic infection. Basic and clinical research is needed to discover new antimicrobial and antiinflammatory agents to improve outcome from disease. Novel strategies are needed to distribute and implement effective vaccines worldwide to prevent bacterial meningitis.	Univ Panama Sch Med, Hosp Nino, Panama City, Panama; Univ Texas, SW Med Ctr, Dallas, TX USA	Universidad de Panama; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Saez-Llorens, X (corresponding author), Univ Panama Sch Med, Hosp Nino, Panama City, Panama.	xsaezll@cwpanama.net	Booy, Robert/D-4188-2011	SAEZ LLORENS, XAVIER/0000-0002-1149-5905				ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Ahmed A, 1999, ANTIMICROB AGENTS CH, V43, P876, DOI 10.1128/AAC.43.4.876; Andes DR, 1999, INFECT DIS CLIN N AM, V13, P595, DOI 10.1016/S0891-5520(05)70096-9; ARDITI M, 1989, J INFECT DIS, V160, P1005, DOI 10.1093/infdis/160.6.1005; Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; Ashwal S, 1994, Curr Probl Pediatr, V24, P267, DOI 10.1016/0045-9380(94)90042-6; AUSLANDER MC, 1988, LARYNGOSCOPE, V98, P940; BAKER CJ, 1983, PEDIATR INFECT DIS J, V2, P1; Baker CJ, 2000, J INFECT DIS, V182, P1129, DOI 10.1086/315839; Baltimore RS, 2001, CURR OPIN PEDIATR, V13, P47, DOI 10.1097/00008480-200102000-00008; Baltimore RS, 2001, PEDIATRICS, V108, P1094, DOI 10.1542/peds.108.5.1094; Baucher H, 2000, ARCH DIS CHILD, V83, P396; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; Braun J S, 1999, Adv Pediatr Infect Dis, V14, P49; Cartwright K, 2002, EUR J PEDIATR, V161, P188, DOI 10.1007/s00431-001-0907-3; *CDC, 2002, MMWR-MORBID MORTAL W, V51, P234; CONVERSE GM, 1973, J PEDIATR-US, V83, P220, DOI 10.1016/S0022-3476(73)80479-2; Coscojuela NM, 2002, EUR J CLIN MICROBIOL, V21, P67, DOI 10.1007/s10096-001-0656-2; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; de Kleijn ED, 2001, J INFECT DIS, V184, P98, DOI 10.1086/320993; DELRIO MDA, 1983, LANCET, V1, P1241; Di Fabio JL, 2001, PEDIATR INFECT DIS J, V20, P959, DOI 10.1097/00006454-200110000-00009; Diaz JM, 2001, REV MED CHILE, V129, P719; Duke T, 2002, ANN TROP PAEDIATR, V22, P145, DOI 10.1179/027249302125000878; FELDMAN WE, 1976, J PEDIATR-US, V88, P549, DOI 10.1016/S0022-3476(76)80003-0; FELDMAN WE, 1977, NEW ENGL J MED, V296, P433, DOI 10.1056/NEJM197702242960806; FINK S, 1987, PEDIATRICS, V80, P873; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GIRGIS NI, 1989, PEDIATR INFECT DIS J, V8, P848, DOI 10.1097/00006454-198912000-00004; Giroir BP, 1997, LANCET, V350, P1439, DOI 10.1016/S0140-6736(97)06468-4; GRAHAM DR, 1981, JAMA-J AM MED ASSOC, V245, P1923, DOI 10.1001/jama.245.19.1923; Hussein AA, 2002, SAUDI MED J, V23, P797; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; Jodar L, 2002, LANCET, V359, P1499, DOI 10.1016/S0140-6736(02)08416-7; KANRA GY, 1995, PEDIATR INFECT DIS J, V14, P490, DOI 10.1097/00006454-199506000-00005; Kaplan S L, 1995, Adv Pediatr Infect Dis, V10, P167; Kaplan SL, 2002, PEDIATR INFECT DIS J, V21, P589, DOI 10.1097/00006454-200206000-00034; Kaplan SL, 1999, INFECT DIS CLIN N AM, V13, P579, DOI 10.1016/S0891-5520(05)70095-7; KENNEDY WA, 1991, AM J DIS CHILD, V145, P1374, DOI 10.1001/archpedi.1991.02160120042016; KESSLER SL, 1990, PEDIATR INFECT DIS J, V9, P61, DOI 10.1097/00006454-199001000-00016; KILPI T, 1995, PEDIATR INFECT DIS J, V14, P270, DOI 10.1097/00006454-199504000-00005; KLEIN JO, 1986, PEDIATRICS, V75, P959; KLUGMAN KP, 1995, ANTIMICROB AGENTS CH, V39, P1988, DOI 10.1128/AAC.39.9.1988; Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473-3099(02)00450-4; Kyaw MH, 2002, EPIDEMIOL INFECT, V128, P149, DOI 10.1017/S0950268801006549; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEBEL MH, 1989, J PEDIATR-US, V114, P1049, DOI 10.1016/S0022-3476(89)80462-7; Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; Lingappa JR, 2001, VACCINE, V19, P4566, DOI 10.1016/S0264-410X(01)00209-2; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; Lutsar I, 1998, CLIN INFECT DIS, V27, P1117, DOI 10.1086/515003; Martinez-Lacasa J, 2002, J ANTIMICROB CHEMOTH, V49, P507, DOI 10.1093/jac/49.3.507; MCCRACKEN GH, 1995, PEDIATR INFECT DIS J, V14, P424, DOI 10.1097/00006454-199505001-00004; McCracken GH, 2002, LANCET, V360, P183, DOI 10.1016/S0140-6736(02)09499-0; MCCRACKEN GH, 1989, AM J DIS CHILD, V143, P287, DOI 10.1001/archpedi.1989.02150150041013; MCCRACKEN GH, 1984, PEDIATR INFECT DIS J, V3, pS32, DOI 10.1097/00006454-198405001-00012; McIntyre PB, 1997, JAMA-J AM MED ASSOC, V278, P925, DOI 10.1001/jama.278.11.925; Meli DN, 2002, CURR OPIN INFECT DIS, V15, P253, DOI 10.1097/00001432-200206000-00007; MERTSOLA J, 1989, Pediatric Infectious Disease Journal, V8, P904, DOI 10.1097/00006454-198912000-00036; Mitchell L, 2001, PEDIATR INFECT DIS J, V20, P531, DOI 10.1097/00006454-200105000-00012; Moller K, 2001, SCAND J INFECT DIS, V33, P13; Molyneux EM, 2002, LANCET, V360, P211, DOI 10.1016/S0140-6736(02)09458-8; MORENO MT, 1994, PEDIATR INFECT DIS J, V13, P516, DOI 10.1097/00006454-199406000-00010; MUSTAFA MM, 1990, AM J DIS CHILD, V144, P883, DOI 10.1001/archpedi.1990.02150320047024; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; NELSON JD, 1984, PEDIATR INFECT DIS J, V3, pS30, DOI 10.1097/00006454-198405001-00011; Neuman HB, 2001, CLIN PEDIATR, V40, P595, DOI 10.1177/000992280104001102; Ni Chonghaile C, 2002, LANCET, V360, P2054, DOI 10.1016/S0140-6736(02)12050-2; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; ODIO CM, 1991, NEW ENGL J MED, V324, P1525, DOI 10.1056/NEJM199105303242201; Pallares R, 1998, MICROB DRUG RESIST, V4, P339, DOI 10.1089/mdr.1998.4.339; Peltola H, 1999, INFECT DIS CLIN N AM, V13, P685, DOI 10.1016/S0891-5520(05)70101-X; Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PFISTER HW, 1994, CLIN INFECT DIS, V19, P463, DOI 10.1093/clinids/19.3.463; Pollard AJ, 2002, ARCH PATHOL LAB MED, V126, P1209; PORTNOY JM, 1985, PEDIATRICS, V75, P484; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rennels MB, 2001, PEDIATR INFECT DIS J, V20, P153, DOI 10.1097/00006454-200102000-00007; Richter SS, 2001, DIAGN MICR INFEC DIS, V41, P83, DOI 10.1016/S0732-8893(01)00289-9; RIEDO FX, 1995, PEDIATR INFECT DIS J, V14, P643, DOI 10.1097/00006454-199508000-00001; RODRIGUEZ AF, 1990, J PEDIATR-US, V116, P971, DOI 10.1016/S0022-3476(05)80663-8; Rodriguez-Cerrato V, 2003, ANTIMICROB AGENTS CH, V47, P211, DOI 10.1128/AAC.47.1.211-215.2003; Rodriguez-Cerrato V, 2001, ANTIMICROB AGENTS CH, V45, P3092, DOI 10.1128/AAC.45.11.3092-3097.2001; Saez-Llorens X, 1990, Infect Dis Clin North Am, V4, P623; Saez-Llorens X, 2002, PEDIATR INFECT DIS J, V21, P14, DOI 10.1097/00006454-200201000-00004; Saez-Llorens X, 2001, PEDIATR INFECT DIS J, V20, P356, DOI 10.1097/00006454-200103000-00035; Saez-Llorens X, 1999, INFECT DIS CLIN N AM, V13, P619, DOI 10.1016/S0891-5520(05)70097-0; SAEZLLORENS X, 1990, J PEDIATR-US, V116, P671, DOI 10.1016/S0022-3476(05)82647-2; Salisbury D, 2001, J Paediatr Child Health, V37, pS34, DOI 10.1046/j.1440-1754.2001.00738.x; Salleras L, 2001, J EPIDEMIOL COMMUN H, V55, P283, DOI 10.1136/jech.55.4.283; Sande M A, 1989, Pediatr Infect Dis J, V8, P929, DOI 10.1097/00006454-198912000-00048; Saravolatz LD, 2003, CLIN INFECT DIS, V36, P40, DOI 10.1086/345438; SCHAAD UB, 1993, LANCET, V342, P457, DOI 10.1016/0140-6736(93)91592-A; SCHWARTZ B, 1988, LANCET, V1, P1239; SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003; SHAPIRO ED, 1982, PEDIATR INFECT DIS J, V1, P132, DOI 10.1097/00006454-198203000-00015; SINGHI SC, 1995, PEDIATR INFECT DIS J, V14, P495, DOI 10.1097/00006454-199506000-00006; SNEDEKER JD, 1990, PEDIATRICS, V86, P163; SYROGIANNOPOULOS GA, 1994, J INFECT DIS, V169, P853, DOI 10.1093/infdis/169.4.853; TAUBER MG, 1989, PEDIATR INFECT DIS J, V8, P842; Tikhomirov E, 1987, World Health Stat Q, V40, P98; TUOMANEN E, 1987, PEDIATR INFECT DIS J, V6, P1146; WAAGE A, 1987, LANCET, V1, P355; WALD ER, 1995, PEDIATRICS, V95, P21	111	300	332	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	2003	361	9375					2139	2148		10.1016/S0140-6736(03)13693-8	http://dx.doi.org/10.1016/S0140-6736(03)13693-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826449				2022-12-28	WOS:000183654200024
J	Chiba, D; Yamanouchi, M; Matsukura, F; Ohno, H				Chiba, D; Yamanouchi, M; Matsukura, F; Ohno, H			Electrical manipulation of magnetization reversal in a ferromagnetic semiconductor	SCIENCE			English	Article							III-V SEMICONDUCTORS; MULTILAYER; TEMPERATURE	We report electrical manipulation of magnetization processes in a ferromagnetic semiconductor, in which low-density carriers are responsible for the ferromagnetic interaction. The coercive force H-C at which magnetization reversal occurs can be manipulated by modifying the carrier density through application of electric fields in a gated structure. Electrically assisted magnetization reversal, as well as electrical demagnetization, has been demonstrated through the effect. This electrical manipulation offers a functionality not previously accessible in magnetic materials and may become useful for reversing magnetization of nanoscale bits for ultrahigh-density information storage.	Tohoku Univ, Lab Elect Intelligent Syst, Res Inst Elect Commun, Aoba Ku, Sendai, Miyagi 9808577, Japan; Japan Sci & Technol Corp, Semicond Spintron Project, Exporatory Res Adv Technol, Tokyo, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Ohno, H (corresponding author), Tohoku Univ, Lab Elect Intelligent Syst, Res Inst Elect Commun, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.		Chiba, Daichi/D-3438-2015; Ohno, Hideo/E-6453-2010; Yamanouchi, Michihiko/G-9635-2014	Chiba, Daichi/0000-0002-6631-5131; Ohno, Hideo/0000-0001-9688-8259; 				Albert FJ, 2000, APPL PHYS LETT, V77, P3809, DOI 10.1063/1.1330562; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Bertotti G., 1998, HYSTERESIS MAGNETISM; Chiba D, 2003, APPL PHYS LETT, V82, P3020, DOI 10.1063/1.1571666; CHIBA D, UNPUB; Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019; Dietl T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.241201; Dietl T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.195205; Erwin SC, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.227201; Maca F, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.235209; MUNEKATA H, 1993, APPL PHYS LETT, V63, P2929, DOI 10.1063/1.110276; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; Ohno H, 2003, J CRYST GROWTH, V251, P285, DOI 10.1016/S0022-0248(02)02290-X; Ohno H., 2002, JSAP International, P4; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; OHNO H, 1992, PHYS REV LETT, V68, P2664, DOI 10.1103/PhysRevLett.68.2664; Ohno H, 2000, NATURE, V408, P944, DOI 10.1038/35050040; Shono T, 2000, APPL PHYS LETT, V77, P1363, DOI 10.1063/1.1290273; SLONCZEWSKI JC, 1996, J MAGN MAGN MATER, V159, P1; Tsoi M, 1998, PHYS REV LETT, V80, P4281, DOI 10.1103/PhysRevLett.80.4281; Welp U, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.167206; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Yu KM, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.201303	23	564	585	4	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					943	945		10.1126/science.1086608	http://dx.doi.org/10.1126/science.1086608			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12855816				2022-12-28	WOS:000184755900032
J	Levey, AS; Coresh, J; Balk, E; Kausz, AT; Levin, A; Steffes, MW; Hogg, RJ; Perrone, RD; Lau, J; Eknoyan, G				Levey, AS; Coresh, J; Balk, E; Kausz, AT; Levin, A; Steffes, MW; Hogg, RJ; Perrone, RD; Lau, J; Eknoyan, G			National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification	ANNALS OF INTERNAL MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; GLOMERULAR-FILTRATION-RATE; CHRONIC RENAL-DISEASE; SERUM CREATININE; CARDIOVASCULAR-DISEASE; SPECIALIST EVALUATION; URINE SAMPLES; PREVALENCE; RISK; HEALTH	Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease. Current evidence suggests that some of these adverse outcomes can be prevented or delayed by early detection and treatment. Unfortunately, chronic kidney disease is underdiagnosed and undertreated, in part as a result of lack of agreement on a definition and classification of its stages of progression. Recent clinical practice guidelines by the National Kidney Foundation 1) define chronic kidney disease and classify its stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of kidney disease, 3) associate the level of kidney function with complications of chronic kidney disease, and 4) stratify the risk for loss of kidney function and development of cardiovascular disease. The guidelines were developed by using an approach based on the procedure outlined by the Agency for Healthcare Research and Quality. This paper presents the definition and five-stage classification system of chronic kidney disease and summarizes the major recommendations on early detection in adults. Recommendations include identifying persons at increased risk (those with diabetes, those with hypertension, those with a family history of chronic kidney disease, those older than 60 years of age, or those with U.S. racial or ethnic minority status), detecting kidney damage by measuring the albumin-creatinine ratio in untimed ("spot") urine specimens, and estimating the glomerular filtration rate from serum creatinine measurements by using prediction equations. Because of the high prevalence of early stages of chronic kidney disease in the general population (approximately 11% of adults), this information is particularly important for general internists and specialists.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Minnesota, Minneapolis, MN USA; Baylor Coll Med, Houston, TX 77030 USA; N Texas Hosp Children, Dallas, TX USA	Tufts Medical Center; Tufts University; Tufts University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine	Levey, AS (corresponding author), Natl Kidney Fdn, 30 E 33rd St,Suite 1100, New York, NY 10016 USA.		Balk, Ethan/AAJ-2547-2020					Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; [Anonymous], 1996, J Am Coll Cardiol, V27, P957; [Anonymous], 2001, PROF GEN DEM CHAR 20; ARONOFF GR, 2002, DRUG PRESCRIBING REN; Bostom AG, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022011.35035.F3; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clase CM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013291.78621.26; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coladonato J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019646.05890.EA; Collins AJ, 2003, AM J KIDNEY DIS, V41, pV, DOI 10.1016/S0272-6386(03)80001-X; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Coresh J, 2002, J AM SOC NEPHROL, V13, P2811, DOI 10.1097/01.ASN.0000037420.89149.C9; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; DAVIES DF, 1950, J CLIN INVEST, V29, P496, DOI 10.1172/JCI102286; DAY JC, 1996, PS251130 US CENS BUR; ELIXHAUSER A, 2001, 2 HCUP AG HLTH RES Q; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; FRIES JF, 1991, J RHEUMATOL, V18, P6; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hsu C, 2000, AM J KIDNEY DIS, V36, P415, DOI 10.1053/ajkd.2000.8996; Hsu CY, 2002, KIDNEY INT, V61, P1567, DOI 10.1046/j.1523-1755.2002.00299.x; Ismail N, 1998, NEPHROL DIAL TRANSPL, V13, P246, DOI 10.1093/ndt/13.2.246; Jacobs DR, 2002, AM J EPIDEMIOL, V155, P1114, DOI 10.1093/aje/155.12.1114; Keane WF, 1999, AM J KIDNEY DIS, V33, P1004, DOI 10.1016/S0272-6386(99)70442-7; Kinchen KS, 2002, ANN INTERN MED, V137, P479, DOI 10.7326/0003-4819-137-6-200209170-00007; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 2002, NEW ENGL J MED, V347, P1505, DOI 10.1056/NEJMcp013462; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levinsky NG, 2002, ANN INTERN MED, V137, P542, DOI 10.7326/0003-4819-137-6-200209170-00016; Lewis J, 2001, AM J KIDNEY DIS, V38, P744, DOI 10.1053/ajkd.2001.27691; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; McClellan W, 2002, J AM SOC NEPHROL, V13, P2817, DOI 10.1097/01.ASN.0000037423.89149.12; McClellan WM, 1997, AM J KIDNEY DIS, V29, P368, DOI 10.1016/S0272-6386(97)90197-9; McGoldrick MD, 1997, ANN PHARMACOTHER, V31, P221, DOI 10.1177/106002809703100214; NATHAN DM, 1987, DIABETES CARE, V10, P414, DOI 10.2337/diacare.10.4.414; Obrador GT, 1999, KIDNEY INT, V56, P2227, DOI 10.1046/j.1523-1755.1999.00779.x; Obrador GT, 1999, J AM SOC NEPHROL, V10, P1793; Obrador GT, 1998, AM J KIDNEY DIS, V31, P398, DOI 10.1053/ajkd.1998.v31.pm9506677; PERRONE RD, 1992, CLIN CHEM, V38, P1933; Remuzzi G, 2002, ANN INTERN MED, V136, P604, DOI 10.7326/0003-4819-136-8-200204160-00010; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Rodby RA, 1995, AM J KIDNEY DIS, V26, P904, DOI 10.1016/0272-6386(95)90054-3; Ross JW, 1998, ARCH PATHOL LAB MED, V122, P587; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; Sarnak MJ, 2000, AM J KIDNEY DIS, V35, pS117, DOI 10.1016/S0272-6386(00)70239-3; SCHWAB SJ, 1987, ARCH INTERN MED, V147, P943, DOI 10.1001/archinte.147.5.943; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; Shlipak MG, 2002, KIDNEY INT, V62, P997, DOI 10.1046/j.1523-1755.2002.00522.x; SMITH HW, 1951, KIDNEY STRUCTURE FUN, P520; Solomon D, 2002, ARCH INTERN MED, V162, P2640, DOI 10.1001/archinte.162.17.2002; Steinberg EP, 2000, AM J KIDNEY DIS, V36, P1; U.S. Preventive Services Task Force, 2003, GUID CLIN PREV SERV; *US REN DAT SYST, 2000, AM J KIDNEY DIS S, V36, pS1; Warram JH, 1996, J AM SOC NEPHROL, V7, P930; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; WOOLF SH, 1991, MANUAL CLIN PRACTICE; Zelmanovitz T, 1997, DIABETES CARE, V20, P516, DOI 10.2337/diacare.20.4.516; 2003, HCUPNET HEALTHCARE U	64	3357	3531	2	246	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					137	147		10.7326/0003-4819-139-2-200307150-00013	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859163				2022-12-28	WOS:000184163100007
J	Gudmundsson, KG; Jonnson, T; Arngrimsson, R				Gudmundsson, KG; Jonnson, T; Arngrimsson, R			Guillaume Dupuytren and finger contractures	LANCET			English	Article							DISEASE		HNLFI Hlth Clin, IS-810 Hveragerdi, Iceland; Natl Hosp, Inst Immunol IMMI, Oslo, Norway; Univ Iceland, Fac Med, Med Genet Unit, Reykjavik, Iceland; Kopavogur Hlth Ctr, Kopavogur, Iceland	University of Oslo; National Hospital Norway; University of Iceland	Gudmundsson, KG (corresponding author), Deildaras 19, IS-110 Reykjavik, Iceland.			Arngrimsson, Reynir/0000-0003-1142-2914				Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; Burge P, 1999, HAND CLIN, V15, P63; Dupuytren B, 1834, LANCET, V2, P222; Elliot D, 1999, HAND CLIN, V15, P1; Gudmundsson KG, 2000, J CLIN EPIDEMIOL, V53, P291, DOI 10.1016/S0895-4356(99)00145-6; Gudmundsson KG, 1998, J HAND SURG-BRIT EUR, V23B, P724, DOI 10.1016/S0266-7681(98)80083-1; Gudmundsson KG, 2002, J CLIN EPIDEMIOL, V55, P5, DOI 10.1016/S0895-4356(01)00413-9; Jabaley ME, 1999, HAND CLIN, V15, P109; KANAVEL AB, 1929, SURG GYNECOL OBSTET, V48, P145; LECLERCQ C, 2000, DUPUYTRENS DIS, P121; Lurie S N, 1987, N C Med J, V48, P452; PANOTTA A, 2002, J ORTHOPEDIC RES, V20, P163; Rayan GM, 1999, HAND CLIN, V15, P87; SCHUM DT, 1988, J HAND SURG A, V13, P61; Tubiana R, 2000, DUPUYTRENS DIS, V1, P11	15	18	20	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					165	168		10.1016/S0140-6736(03)13871-8	http://dx.doi.org/10.1016/S0140-6736(03)13871-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867120				2022-12-28	WOS:000184089200027
J	Woolf, AD; Akesson, K				Woolf, AD; Akesson, K			Preventing fractures in elderly people	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RISK-FACTORS; RANDOMIZED-TRIAL; HIP FRACTURE; VERTEBRAL FRACTURES; OSTEOPOROSIS; FALLS; RISEDRONATE; MASS	Preventing fractures in elderly people is a priority, especially as it has been predicted that in 20 years almost a quarter of people in Europe will be aged over 65. This article describes the factors contributing to fracture, interventions to prevent fracture, and the various treatments.	Royal Cornwall Hosp, Inst Hlth & Social Care, Peninsula Med Sch, Truro TR1 3LJ, England; Lund Univ, Malmo Univ Hosp, Dept Orthopaed, S-20502 Malmo, Sweden	Royal Cornwall Hospital; University of Exeter; University of Plymouth; Lund University; Skane University Hospital	Woolf, AD (corresponding author), Royal Cornwall Hosp, Inst Hlth & Social Care, Peninsula Med Sch, Truro TR1 3LJ, England.	anthony.woolf@rcht.swest.nhs.uk		Woolf, Anthony/0000-0001-8482-8056				AKESSON K, 1993, CALCIFIED TISSUE INT, V53, P162, DOI 10.1007/BF01321832; Bischoff HA, 2003, J BONE MINER RES, V18, P343, DOI 10.1359/jbmr.2003.18.2.343; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223-002-2011-8; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Chesnut CH, 2000, AM J MED, V109, P267, DOI 10.1016/S0002-9343(00)00490-3; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Clowes JA, 2000, BEST PRACT RES CL EN, V14, P213, DOI 10.1053/beem.2000.0070; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Department of Health, 2001, NAT SERV FRAM OLD PE; DOHERTY M, 1992, ANN RHEUM DIS, V51, P1165, DOI 10.1136/ard.51.10.1165; Espallargues M, 2001, OSTEOPOROSIS INT, V12, P811, DOI 10.1007/s001980170031; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; *EUR COMM, 1998, REP OSTEOP EUR COMM; Feder G, 2000, BRIT MED J, V321, P1007, DOI 10.1136/bmj.321.7267.1007; Gerdhem P, 2002, OSTEOPOROSIS INT, V13, P932, DOI 10.1007/s001980200130; GILLESPIE LD, 2001, COCHRANE DB SYST REV, V3; Gluer CC, 1999, OSTEOPOROSIS INT, V9, P193, DOI 10.1007/s001980050135; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215; Jordan KM, 2002, BEST PRACT RES CL RH, V16, P795, DOI 10.1053/berh.2002.0264; Kanis JA, 2002, BONE, V30, P251, DOI 10.1016/S8756-3282(01)00653-6; Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140-6736(02)08761-5; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; *NAT OST SOC, 2002, PRIM CAR STRAT OST F; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; PARKER MJ, 2001, COCHRANE DB SYST REV; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; Rizzoli R, 2001, JOINT BONE SPINE, V68, P383, DOI 10.1016/S1297-319X(01)00295-0; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Rogmark C, 1999, ACTA ORTHOP SCAND, V70, P19, DOI 10.3109/17453679909000950; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; *ROYAL COLL PHYS, 2000, OST CLIN GUID PREV T; Royal College of Physicians, 1999, OST CLIN GUID PREV T; Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Wallace BA, 2000, CALCIFIED TISSUE INT, V67, P10, DOI 10.1007/s00223001089; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; Young PP, 1999, J ILLUM ENG SOC, V28, P190	47	97	107	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2003	327	7406					89	95		10.1136/bmj.327.7406.89	http://dx.doi.org/10.1136/bmj.327.7406.89			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855529	Green Published, Green Submitted			2022-12-28	WOS:000184229400023
J	Tseng, CW; Brook, RH; Keeler, E; Mangione, CM				Tseng, CW; Brook, RH; Keeler, E; Mangione, CM			Impact of an annual dollar limit or "cap" on prescription drug benefits for medicare patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENEFICIARIES; COVERAGE; COST	Context Annual dollar limits, or "caps," on drug benefits are common in Medicare managed care (Medicare + Choice) and have been part of several proposals for a national Medicare drug benefit. Objectives To determine how cap levels affect the percentage of patients exceeding the cap and their out-of-pocket drug costs and to identify the medications that contribute most to prescription costs. Design and Setting Cross-sectional analysis of 2001 pharmacy claims data from a large Medicare + Choice plan in a mature market with caps of $750 to $2000 per year applied to the plan's share of prescription costs. Participants Patients who filled at least 1 prescription in 2001 (n=438802). Main Outcome Measures Percentages of patients exceeding caps, identified from prescription claims; out-of-pocket patient costs before exceeding caps, calculated from patients' co-payments; and out-of-pocket patient costs after exceeding caps, estimated from total prescription costs before exceeding the cap. Each unique drug was ranked by total expenditures, which included spending by patients who exceeded caps and by the plan for that drug. Results A total of 22%, 14%, and 4% of Medicare patients exceeded caps of $750, $1000, and $2000, respectively. Across caps, patients faced a potential 2- to 3-fold increase in median out-of-pocket costs after exceeding caps ($179-$305/mo) to continue the same prescription use as before exceeding caps ($794100/mo). For patients who exceeded a cap of $750, yearly out-of-pocket drug costs ranged from $564 to $4201 (5th-95th percentiles). Fifteen of the 20 medications with the highest total prescription expenditures for patients who exceeded the cap were for chronic conditions. Seven had lower-cost generic versions or a generic medication available in the same treatment class. Conclusions At lower caps, a substantial proportion of Medicare patients exceeded their annual drug benefit. To continue the same medication use as before exceeding caps, these patients faced potentially high increases in out-of-pocket costs for medications used primarily to treat chronic conditions. Generic options were not available for many of these drugs.	Univ Hawaii, Dept Family Practice & Community Hlth, Honolulu, HI 96822 USA; Pacific Hlth Res Inst, Honolulu, HI USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, Los Angeles, CA USA; RAND Corp, Hlth, Santa Monica, CA USA	University of Hawaii System; Pacific Health Research & Education Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Robert Wood Johnson Foundation (RWJF); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation	Tseng, CW (corresponding author), 846 S Hotel St,Suite 303, Honolulu, HI 96813 USA.				NIA NIH HHS [AG-02-004] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams AS, 2001, HEALTH AFFAIR, V20, P276, DOI 10.1377/hlthaff.20.1.276; *C BUDG OFF, 2002, ISS DES PRESCR DRUG; *COMM FUND, 1999, TRENDS MED PLUS CHOI; Cox ER, 2001, MED CARE, V39, P296, DOI 10.1097/00005650-200103000-00009; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; *HJ KAIS FAM FDN C, SEN PRESCR DRUGS FIN; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; LASCHOBER MA, 1996, TRENDS MEDICARE S IN; Lichtenberg FR, 2001, HEALTH AFFAIR, V20, P241, DOI 10.1377/hlthaff.20.5.241; McClellan M, 2000, HEALTH AFFAIR, V19, P26, DOI 10.1377/hlthaff.19.2.26; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Rector TS, 2000, JAMA-J AM MED ASSOC, V283, P2163, DOI 10.1001/jama.283.16.2163; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; Stuart B, 1998, MED CARE, V36, P202, DOI 10.1097/00005650-199802000-00009; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; 2002, HJ KAISER FAMILY FDN	18	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					222	227		10.1001/jama.290.2.222	http://dx.doi.org/10.1001/jama.290.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851277	Bronze, Green Submitted			2022-12-28	WOS:000183989800027
J	Dargie, HJ				Dargie, HJ			beta blockers in heart failure	LANCET			English	Editorial Material							IDIOPATHIC DILATED CARDIOMYOPATHY; QUALITY-OF-CARE; SURVEY PROGRAM; TRIAL; REVASCULARIZATION; CARVEDILOL; METOPROLOL; EUROPE		Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland		Dargie, HJ (corresponding author), Western Infirm & Associated Hosp, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.							Allman KC, 2002, J AM COLL CARDIOL, V39, P1151, DOI 10.1016/S0735-1097(02)01726-6; Bristow MR, 2000, CIRCULATION, V102, P484; Cleland JGF, 2003, EUR J HEART FAIL, V5, P295, DOI 10.1016/S1388-9842(03)00056-4; Cleland JGF, 2003, EUR HEART J, V24, P442, DOI 10.1016/S0195-668X(02)00823-0; Hjalmarson A, 1999, LANCET, V353, P2001; Komajda M, 2003, EUR HEART J, V24, P464, DOI 10.1016/S0195-668X(02)00700-5; Lechat P, 1999, LANCET, V353, P9; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426	12	35	38	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					2	3		10.1016/S0140-6736(03)13842-1	http://dx.doi.org/10.1016/S0140-6736(03)13842-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853188				2022-12-28	WOS:000184056900002
J	Golombek, MP				Golombek, MP			The surface of Mars: Not just dust and rocks	SCIENCE			English	Editorial Material									CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Golombek, MP (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Christensen, 1992, MARS, P686; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; Mellon MT, 2000, ICARUS, V148, P437, DOI 10.1006/icar.2000.6503; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0	6	6	6	3	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2043	2044		10.1126/science.1082927	http://dx.doi.org/10.1126/science.1082927			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829771				2022-12-28	WOS:000183774900031
J	Seo, HS; Yang, JY; Ishikawa, M; Bolle, C; Ballesteros, ML; Chua, NH				Seo, HS; Yang, JY; Ishikawa, M; Bolle, C; Ballesteros, ML; Chua, NH			LAF1 ubiquitination by COP1 controls photomorphogenesis and is stimulated by SPA1	NATURE			English	Article							RING FINGER MOTIF; PHYTOCHROME-A; SIGNAL-TRANSDUCTION; ARABIDOPSIS-THALIANA; GENE-EXPRESSION; LIGHT CONTROL; PROTEIN; REPRESSOR; INTERACTS; DEFINES	Far-red light regulates many aspects of seedling development, such as inhibition of hypocotyl elongation and the promotion of greening(1), acting in part through phytochrome A ( phyA). The RING motif protein COP1 is also important because cop1 mutants exhibit constitutive photomorphogenesis in darkness(2,3). COP1 is present in the nucleus in darkness but is gradually relocated to the cytoplasm upon illumination(4). Here we show that COP1 functions as an E3 ligase ubiquitinating both itself and the myb transcription activator LAF1, which is required for complete phyA responses(5). In transgenic plants, inducible COP1 overexpression leads to a decrease in LAF1 concentrations, but is blocked by the proteasome inhibitor MG132. The coiled-coil domain of SPA1, a negative regulator of phyA signalling(6), has no effect on COP1 auto-ubiquitination but facilitates LAF1 ubiquitination at low COP1 concentrations. These results indicate that, in darkness, COP1 functions as a repressor of photomorphogenesis by promoting the ubiquitin-mediated proteolysis of a subset of positive regulators, including LAF1. After the activation of phyA, SPA1 stimulates the E3 activity of residual nuclear COP1 to ubiquitinate LAF1, thereby desensitizing phyA signals.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.		Yang, Jun-Yi/ABA-2044-2021; Ishikawa, Masaki/Q-7598-2018; Ishikawa, Masaki/AAC-8162-2022; Bolle, Cordelia/C-5569-2011	Yang, Jun-Yi/0000-0002-6332-6265; Ishikawa, Masaki/0000-0002-6491-5539; Ishikawa, Masaki/0000-0002-6491-5539; Bolle, Cordelia/0000-0002-4399-0070				Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Ballesteros ML, 2001, GENE DEV, V15, P2613, DOI 10.1101/gad.915001; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; Dieterle M, 2001, GENE DEV, V15, P939, DOI 10.1101/gad.197201; Hardtke CS, 2002, PLANT J, V30, P385, DOI 10.1046/j.1365-313X.2002.01298.x; Hardtke CS, 2000, PLANT PHYSIOL, V124, P1548, DOI 10.1104/pp.124.4.1548; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; Hoecker U, 2001, J BIOL CHEM, V276, P38173; Hoecker U, 1999, SCIENCE, V284, P496, DOI 10.1126/science.284.5413.496; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Kost B, 1998, PLANT J, V16, P393, DOI 10.1046/j.1365-313x.1998.00304.x; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Ma LG, 2001, PLANT CELL, V13, P2589, DOI 10.1105/tpc.13.12.2589; Nagy F, 2002, ANNU REV PLANT BIOL, V53, P329, DOI 10.1146/annurev.arplant.53.100301.135302; Neff MM, 2000, GENE DEV, V14, P257; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Stacey MG, 1999, J BIOL CHEM, V274, P27231, DOI 10.1074/jbc.274.38.27231; Torii KU, 1999, J BIOL CHEM, V274, P27674, DOI 10.1074/jbc.274.39.27674; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; vonArnim AG, 1997, PLANT PHYSIOL, V114, P779, DOI 10.1104/pp.114.3.779; Wilson JF, 2002, LANCET NEUROL, V1, P4, DOI 10.1016/S1474-4422(02)00025-X; Xie Q, 2000, GENE DEV, V14, P3024, DOI 10.1101/gad.852200; Xie Q, 2002, NATURE, V419, P167, DOI 10.1038/nature00998; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	30	374	409	6	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					995	999		10.1038/nature01696	http://dx.doi.org/10.1038/nature01696			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827204				2022-12-28	WOS:000183753900052
J	Li, CI; Malone, KE; Porter, PL; Weiss, NS; Tang, MTC; Cushing-Haugen, KL; Daling, JR				Li, CI; Malone, KE; Porter, PL; Weiss, NS; Tang, MTC; Cushing-Haugen, KL; Daling, JR			Relationship between long durations and different regimens of hormone therapy and risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; RECEPTOR STATUS; ESTROGEN USE; CARCINOMA; PROGESTIN; HEALTH; METAANALYSIS; INFORMATION; RELIABILITY	Context Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking. Objective To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status. Design Population-based case-control study. Setting Three counties in western Washington State. Participants Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases and 75 cases with unknown ER/PR status were not included in the analyses herein]) and 1007 population controls. Main Outcome Measures Risks of invasive lobular, ductal, ER+/PR+, ER+/PR-, and ER-/PR- breast carcinomas. Results Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use), even for 25 years or longer, had no appreciable increase in risk of breast cancer, although the associated odds ratios were not inconsistent with a possible small effect. Ever users of CHRT (includes CHRT users who also had used ERT) had a 1.7-fold (95% confidence interval (01, 1.3-2.2) increased risk of breast cancer, including a 2.7-fold (95% Cl, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% Cl, 1.1-2.0) increased risk of invasive ductal carcinoma, and a 2.0-fold (95% Cl, 1.5-2.7) increased risk of ER+/PR+ breast cancers. The increase in risk was greatest in those using CHRT for longer durations (users for 5-14.9 years and 15 years had 1.5-fold [95% Cl, 1.0-2.3] and 1.6-fold [95% Cl, 1.0-2.6] increases in risk of invasive ductal carcinoma, respectively, and 3.7-fold [95% Cl, 2.0-6.6] and 2.6-fold [95% Cl, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively. Associations of similar magnitudes were seen among users of both sequential and continuous CHRT. Risks of ER+/PR- and ER-/ PR- tumors were not increased by use of any form of hormone replacement therapy; however,,small numbers of these tumors limited power to detect possible associations. Conclusion These data suggest that use of CHRT is associated with an increased risk of breast cancer, particularly invasive lobular tumors, whether the progestin component was taken in a sequential or in a continuous manner.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Li, CI (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP 381,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [R01 CA072787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGG CB, 1984, BIOMETRIKA, V71, P11, DOI 10.2307/2336391; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Breslow NE, 1980, ANAL CASE CONTROL ST; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Cobleigh MA, 1999, JAMA-J AM MED ASSOC, V281, P1528, DOI 10.1001/jama.281.16.1528; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Daling JR, 2002, CANCER-AM CANCER SOC, V95, P2455, DOI 10.1002/cncr.10984; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; DUTOIT RS, 1991, EUR J SURG ONCOL, V17, P251; *F HUTCH CANC RES, CSS REP PUBL FAQS; GOODMAN MT, 1990, AM J EPIDEMIOL, V131, P815, DOI 10.1093/oxfordjournals.aje.a115572; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Jain MG, 1999, EPIDEMIOLOGY, V10, P260, DOI 10.1097/00001648-199905000-00012; Kirsh V, 2002, CANCER CAUSE CONTROL, V13, P583, DOI 10.1023/A:1016330024268; Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.3.CO;2-O; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; Lower EE, 1999, BREAST CANCER RES TR, V58, P205, DOI 10.1023/A:1006315607241; *NCI, 2003, SEER; Newcomb PA, 2002, CANCER EPIDEM BIOMAR, V11, P593; Newcomer LM, 1999, AM J EPIDEMIOL, V149, pS79; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PERSSON I, 1987, INT J EPIDEMIOL, V16, P222, DOI 10.1093/ije/16.2.222; POTTER JD, 1995, CANCER EPIDEM BIOMAR, V4, P319; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; STIERER M, 1993, ANN SURG, V218, P13, DOI 10.1097/00000658-199307000-00004; WHO, 2000, INT CLASSIFICATION D, V3rd	31	296	313	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3254	3263		10.1001/jama.289.24.3254	http://dx.doi.org/10.1001/jama.289.24.3254			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824206	Bronze			2022-12-28	WOS:000183704600018
J	Hunt, GM; Oakeshott, P				Hunt, GM; Oakeshott, P			Outcome in people with open spina bifida at age 35: prospective community based cohort study	BRITISH MEDICAL JOURNAL			English	Article									Addenbrookes Hosp, Cambridge CB2 2QQ, England; St George Hosp, Sch Med, Dept Community Hlth, London SW17 0RE, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; St Georges University London	Hunt, GM (corresponding author), 65 Grantchester St, Cambridge CB3 9HZ, England.			Oakeshott, Pippa/0000-0003-2568-8211				HUNT G, 1973, BRIT MED J, V4, P197, DOI 10.1136/bmj.4.5886.197; HUNT GM, 1995, DEV MED CHILD NEUROL, V37, P19; Hunt GM, 1999, J NEUROL NEUROSUR PS, V67, P591, DOI 10.1136/jnnp.67.5.591; LAURENCE KM, 1974, LANCET, V1, P301; SMITH GK, 1973, BRIT MED J, V4, P189, DOI 10.1136/bmj.4.5886.189	5	72	74	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1365	1366		10.1136/bmj.326.7403.1365	http://dx.doi.org/10.1136/bmj.326.7403.1365			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816823	Bronze, Green Published			2022-12-28	WOS:000183756400021
J	Radermacher, J; Mengel, M; Ellis, S; Stuht, S; Hiss, M; Schwarz, A; Eisenberger, U; Burg, M; Luft, FC; Gwinner, W; Haller, H				Radermacher, J; Mengel, M; Ellis, S; Stuht, S; Hiss, M; Schwarz, A; Eisenberger, U; Burg, M; Luft, FC; Gwinner, W; Haller, H			The renal arterial resistance index and renal allograft survival	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLOR DOPPLER SONOGRAPHY; RESISTIVE INDEX; KIDNEY-TRANSPLANTATION; HYPERTENSIVE PATIENTS; VASCULAR-RESISTANCE; CYCLOSPORINE-A; GRAFT FUNCTION; FOLLOW-UP; FAILURE; ULTRASONOGRAPHY	BACKGROUND: Most renal transplants fail because of chronic allograft nephropathy or because the recipient dies, but no reliable factor predicting long-term outcome has been identified. We tested whether a renal arterial resistance index of less than 80 was predictive of long-term allograft survival. METHODS: The renal segmental arterial resistance index (the percentage reduction of the end-diastolic flow as compared with the systolic flow) was measured by Doppler ultrasonography in 601 patients at least three months after transplantation between August 1997 and November 1998. All patients were followed for three or more years. The combined end point was a decrease of 50 percent or more in the creatinine clearance rate, allograft failure (indicated by the need for dialysis), or death. RESULTS: A total of 122 patients (20 percent) had a resistance index of 80 or higher. Eighty-four of these patients (69 percent) had a decrease of 50 percent or more in creatinine clearance, as compared with 56 of the 479 patients with a resistance index of less than 80 (12 percent); 57 patients with a higher resistance index (47 percent) required dialysis, as compared with 43 patients with a lower resistance index (9 percent); and 36 patients with a higher resistance index (30 percent) died, as compared with 33 patients with a lower resistance index (7 percent) (P<0.001 for all comparisons). A total of 107 patients with a higher resistance index (88 percent) reached the combined end point, as compared with 83 of those with a lower resistance index (17 percent, P<0.001). The multivariate relative risk of graft loss among patients with a higher resistance index was 9.1 (95 percent confidence interval, 6.6 to 12.7). Proteinuria (protein excretion, 1 g per day or more), symptomatic cytomegalovirus infection, and a creatinine clearance rate of less than 30 ml per minute per 1.73 m(2) of body-surface area after transplantation also increased the risk. CONCLUSIONS: A renal arterial resistance index of 80 or higher measured at least three months after transplantation is associated with poor subsequent allograft performance and death.	Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, Hannover, Germany; Humboldt Univ, HELIOS Klinikum Berlin, Franz Volhard Clin, Berlin, Germany	Hannover Medical School; Hannover Medical School; Franz-Volhard Clinical Research Center; Helios Kliniken; Humboldt University of Berlin	Radermacher, J (corresponding author), Hannover Med Sch, Dept Nephrol, POB 610180, D-30625 Hannover, Germany.			Luft, Friedrich/0000-0002-8635-1199; Eisenberger, Ute/0000-0003-3862-6933				Alterini B, 1996, Ann Ital Med Int, V11, P107; BITTARD H, 1991, J UROLOGY, V146, P1; Boddi M, 1996, AM J HYPERTENS, V9, P461, DOI 10.1016/0895-7061(96)00027-1; BREITENSEHER M, 1994, ULTRASCHALL MED, V15, P24, DOI 10.1055/s-2007-1004000; DON S, 1989, RADIOLOGY, V171, P709, DOI 10.1148/radiology.171.3.2655003; Drudi F M, 2001, Radiol Med, V101, P243; GAULT MH, 1992, NEPHRON, V62, P249, DOI 10.1159/000187054; Gerhardt U, 1999, INT J CARDIOL, V68, P203, DOI 10.1016/S0167-5273(98)00368-4; Giral-Classe M, 1998, KIDNEY INT, V54, P972, DOI 10.1046/j.1523-1755.1998.00071.x; HENNIGE M, 1986, TRANSPLANTATION, V42, P491, DOI 10.1097/00007890-198611000-00009; Howard RJ, 2002, TRANSPLANTATION, V73, P1923, DOI 10.1097/00007890-200206270-00013; Kosch M, 2002, J HYPERTENS, V20, P501, DOI 10.1097/00004872-200203000-00026; Kreis HA, 2001, TRANSPLANTATION, V71, pSS5; Krumme B, 1997, J AM SOC NEPHROL, V8, P813; Leoncini G, 2002, NEPHRON, V90, P169, DOI 10.1159/000049038; Mange KC, 2000, JAMA-J AM MED ASSOC, V283, P633, DOI 10.1001/jama.283.5.633; Martinoli C, 1998, EUR RADIOL, V8, P765, DOI 10.1007/s003300050469; OPELZ G, 1978, TRANSPLANTATION, V25, P212, DOI 10.1097/00007890-197804000-00011; Petersen LJ, 1997, NEPHROL DIAL TRANSPL, V12, P1376, DOI 10.1093/ndt/12.7.1376; Ponticelli C, 2002, KIDNEY INT, V62, P1848, DOI 10.1046/j.1523-1755.2002.00612.x; Pontremoli R, 1999, NEPHROL DIAL TRANSPL, V14, P360, DOI 10.1093/ndt/14.2.360; POZNIAK MA, 1988, INVEST RADIOL, V23, P899, DOI 10.1097/00004424-198812000-00004; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Radermacher J, 2001, NEW ENGL J MED, V344, P410, DOI 10.1056/NEJM200102083440603; Radermacher J, 1998, TRANSPLANT INT, V11, P3, DOI 10.1111/j.1432-2277.1998.tb00948.x; Radermacher J, 2000, CLIN NEPHROL, V53, P333; Radermacher J, 2002, HYPERTENSION, V39, P699, DOI 10.1161/hy0202.103782; RADERMACHER J, 2002, IMAGING DECIS, V6, P15; Restrepo-Schafer IK, 1999, ULTRASCHALL MED, V20, P87, DOI 10.1055/s-1999-14242; SCHWERK WB, 1993, ULTRASCHALL MED, V14, P117, DOI 10.1055/s-2007-1005230; Scorza R, 1997, J RHEUMATOL, V24, P1944; Shimizu Y, 2001, HYPERTENS RES, V24, P13, DOI 10.1291/hypres.24.13; SKOTNICKI SH, 1989, TRANSPLANT INT, V2, P16; Takano R, 2001, J CLIN ULTRASOUND, V29, P384; Takemoto SK, 2000, NEW ENGL J MED, V343, P1078, DOI 10.1056/NEJM200010123431504; Trillaud H, 1998, AM J ROENTGENOL, V171, P1611, DOI 10.2214/ajr.171.6.9843297	36	288	303	2	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					115	124		10.1056/NEJMoa022602	http://dx.doi.org/10.1056/NEJMoa022602			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853584	Green Accepted, Bronze			2022-12-28	WOS:000184024400004
J	Redline, RW				Redline, RW			Nonidentical twins with a single placenta - Disproving dogma in perinatal pathology	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Redline, RW (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.								0	30	31	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					111	114		10.1056/NEJMp030097	http://dx.doi.org/10.1056/NEJMp030097			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853583				2022-12-28	WOS:000184024400003
J	Ronthal, M; Gonzalez, RG; Smith, RN; Frosch, MP				Ronthal, M; Gonzalez, RG; Smith, RN; Frosch, MP			A man with repetitive strokes in the posterior circulation - Giant-cell arteritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; WEGENERS-GRANULOMATOSIS; DISEASE; AORTITIS; TUBERCULOSIS; VASCULITIS; PATIENT; MANIFESTATIONS		Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Div Neuroradiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ronthal, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.		Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861				ALCHALABI A, 1994, CLIN LAB HAEMATOL, V16, P363; BABIKIAN VL, 1990, STROKE, V21, P1268; BARANGER TAR, 1994, J RHEUMATOL, V21, P871; BOSCH X, 1991, J RHEUMATOL, V18, P787; Brey RL, 1998, LUPUS, V7, pS67, DOI 10.1177/096120339800700216; BRILEY DP, 1989, ANN NEUROL, V25, P221, DOI 10.1002/ana.410250303; CATS HA, 1993, ADV EXP MED BIOL, V336, P363; Duhaut P, 1998, ARTHRITIS RHEUM-US, V41, P701, DOI 10.1002/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P; Espinosa G, 2001, SEMIN ARTHRITIS RHEU, V31, P12, DOI 10.1053/sarh.2001.23499; Gagne PJ, 1996, ANN VASC SURG, V10, P546, DOI 10.1007/BF02000443; Gilkeson RC, 1998, J COMPUT ASSIST TOMO, V22, P241, DOI 10.1097/00004728-199803000-00015; GLASS J, 1993, CANCER-AM CANCER SOC, V71, P3156, DOI 10.1002/1097-0142(19930515)71:10<3156::AID-CNCR2820711043>3.0.CO;2-O; Gravanis MB, 2000, INT J CARDIOL, V75, pS21, DOI 10.1016/S0167-5273(00)00184-4; GREER JM, 1988, MEDICINE, V67, P220, DOI 10.1097/00005792-198807000-00003; HAMMOUDEH M, 1982, J RHEUMATOL, V9, P443; Hayreh SS, 1997, AM J OPHTHALMOL, V123, P285, DOI 10.1016/S0002-9394(14)70123-0; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; KERSLAKE R, 1991, NEURORADIOLOGY, V33, P269, DOI 10.1007/BF00588234; KINARE SG, 1970, J PATHOL, V100, P69, DOI 10.1002/path.1711000108; Levine SM, 2002, CURR OPIN RHEUMATOL, V14, P3, DOI 10.1097/00002281-200201000-00002; LEVINE SR, 1987, ARCH NEUROL-CHICAGO, V44, P876, DOI 10.1001/archneur.1987.00520200078024; LEVINE SR, 1995, ANN NEUROL, V38, P119, DOI 10.1002/ana.410380119; MCHUGH NJ, 1990, J RHEUMATOL, V17, P916; NISHINO H, 1993, ANN NEUROL, V33, P4, DOI 10.1002/ana.410330103; PANTELL RH, 1981, PEDIATRICS, V67, P84; Sandercock P, 1999, ARCH NEUROL-CHICAGO, V56, P1160, DOI 10.1001/archneur.56.9.1160; SAVITZ JM, 1994, STROKE, V25, P214, DOI 10.1161/01.STR.25.1.214; Segelmark M, 2000, CLIN EXP RHEUMATOL, V18, P629; SIEBER SC, 1990, ARCH PATHOL LAB MED, V114, P1223; Soubrier M, 1995, INT ANGIOL, V14, P233; Staunton H, 2000, ARCH NEUROL-CHICAGO, V57, P581, DOI 10.1001/archneur.57.4.581; Tateishi U, 2001, AM J NEURORADIOL, V22, P1283; UMERAH BC, 1982, BRIT J RADIOL, V55, P201, DOI 10.1259/0007-1285-55-651-201; WAGNER AD, 1994, J CLIN INVEST, V94, P1134, DOI 10.1172/JCI117428; Wagner AD, 1996, AM J PATHOL, V148, P1925; WEINSTEIN A, 1982, J RHEUMATOL, V9, P349; Weyand CM, 1996, J CLIN INVEST, V98, P1642, DOI 10.1172/JCI118959; WILKINSON IM, 1972, ARCH NEUROL-CHICAGO, V27, P378, DOI 10.1001/archneur.1972.00490170010003; WONG RL, 1986, AM J MED, V80, P959, DOI 10.1016/0002-9343(86)90645-5	39	27	28	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					170	180		10.1056/NEJMcpc020034	http://dx.doi.org/10.1056/NEJMcpc020034			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853591				2022-12-28	WOS:000184024400012
J	Delhanty, JDA				Delhanty, JDA			beta thalassaemia: fetal HLA typing	LANCET			English	Editorial Material									UCL, Dept Obstet & Gynaecol, London WC1E 6HX, England	University of London; University College London	Delhanty, JDA (corresponding author), UCL, Dept Obstet & Gynaecol, London WC1E 6HX, England.	j.delhanty@ucl.ac.uk						ARGIOLU F, 2000, HAEMATOLOGICA, V85, P67; BOYO A, 1983, Bulletin of the World Health Organization, V61, P63; Sermon K, 2002, HUM REPROD, V17, P233; Wells D, 2000, MOL HUM REPROD, V6, P1055, DOI 10.1093/molehr/6.11.1055	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					6	6		10.1016/S0140-6736(03)13845-7	http://dx.doi.org/10.1016/S0140-6736(03)13845-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853191				2022-12-28	WOS:000184056900005
J	Maiuri, L; Ciacci, C; Ricciardelli, I; Vacca, L; Raia, V; Auricchio, S; Picard, J; Osman, M; Quaratino, S; Londei, M				Maiuri, L; Ciacci, C; Ricciardelli, I; Vacca, L; Raia, V; Auricchio, S; Picard, J; Osman, M; Quaratino, S; Londei, M			Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease	LANCET			English	Article							BLOOD MONOCYTES; DENDRITIC CELLS; ORGAN-CULTURE; MESSENGER-RNA; GLUTEN; CHALLENGE; MACROPHAGES; EXPRESSION; PEPTIDES; TOXICITY	Background The adaptive immune system is central to the development of coeliac disease. Adaptive immune responses are, however, controlled by a preceding activation of the innate immune system. We investigated whether gliadin, a protein present in wheat flour, could activate an innate as well as an adaptive immune response in patients with coeliac disease. Methods Duodenal biopsy samples from 42 patients with untreated coeliac disease, 37 treated patients, and 18 controls, were cultured in vitro for 3 h or 24 h, in the presence of either immunodominant gliadin epitopes (palpha-2 and palpha-9) or a non-immunodominant peptide.(p31-43) known to induce small intestine damage in coeliac disease. We also incubated biopsy samples from nine untreated and six treated patients with a non-immunodominant peptide for 3 h, before incubation with immunodominant gliadin epitopes. Different combinations of interleukin-15 or signal transduction inhibitors were added to selected incubations. Findings Only the non-immunodominant peptide induced rapid expression of interleukin-15, CD83, cyclo-oxygenase (COX)-2, and CD25 by CD3- cells (p=0.005 vs medium alone) and enterocyte apoptosis (p<0.0001). Only the non-immunodominant peptide induced p38 MAP kinase activation in CD3- cells. Pre-incubation with the non-immunodominant peptide enabled immunodominant epitopes to induce T-cell activation (p=0.001) and enterocyte apoptosis. Inhibition of interleukin-15 or of p38 MAP kinase controlled such activity. Interpretation A gliadin fragment can activate the innate immune system, affecting the in situ T-cell recognition of dominant gliadin epitopes. Although our findings emphasise the key role of gliadin-specific T cells, they suggest a complex pathogenic situation; and show that inhibition of interleukin-15 or p38 MAP kinase might have the potential to control coeliac disease.	UCL, Inst Child Hlth, London WC1N 1EH, England; Univ Naples Federico 2, Dept Paediat, Naples, Italy; Univ Naples Federico 2, Dept Gastroenterol, Naples, Italy; European Lab Invest Food Induced Dis, Naples, Italy; Hammersmith Hosp, MRC, Ctr Clin Sci, London, England; Univ Southampton, Southampton Gen Hosp, Canc Res UK Canc Sci Div, Southampton, Hants, England	University of London; University College London; University of Naples Federico II; University of Naples Federico II; Imperial College London; University of Southampton	Londei, M (corresponding author), UCL, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	m.londei@ich.ucl.ac.uk	Raia, Valeria/AAC-3029-2022; carolina, ciacci/A-2594-2012	carolina, ciacci/0000-0002-7426-1145				Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Cammarota G, 2000, LANCET, V356, P1494, DOI 10.1016/S0140-6736(00)02880-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Greco L, 2002, GUT, V50, P624, DOI 10.1136/gut.50.5.624; HALSTENSEN TS, 1993, SCAND J IMMUNOL, V38, P581, DOI 10.1111/j.1365-3083.1993.tb03245.x; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hmama Z, 1998, J IMMUNOL, V161, P4882; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Lohmann T, 2000, LANCET, V356, P31, DOI 10.1016/S0140-6736(00)02431-4; Maiuri L, 2000, GASTROENTEROLOGY, V119, P996, DOI 10.1053/gast.2000.18149; Maiuri L, 1998, GASTROENTEROLOGY, V115, P564, DOI 10.1016/S0016-5085(98)70135-0; Maiuri L, 1996, GASTROENTEROLOGY, V110, P1368, DOI 10.1053/gast.1996.v110.pm8613040; Maiuri L, 2001, GUT, V48, P418, DOI 10.1136/gut.48.3.418; MARSH MN, 1995, GASTROENTEROLOGY, V108, pA871; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McAdam SN, 2000, GUT, V47, P743, DOI 10.1136/gut.47.6.743; MEAGHER L, 1994, J IMMUNOL METHODS, V175, P237, DOI 10.1016/0022-1759(94)90366-2; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Quaratino S, 2000, P NATL ACAD SCI USA, V97, P10911, DOI 10.1073/pnas.190204697; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; SHIDRAWI RG, 1995, SCAND J GASTROENTERO, V30, P758, DOI 10.3109/00365529509096324; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; Subbarayan V, 2001, CANCER RES, V61, P2720; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	30	465	483	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					30	37		10.1016/S0140-6736(03)13803-2	http://dx.doi.org/10.1016/S0140-6736(03)13803-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853196				2022-12-28	WOS:000184056900010
J	Chen, HSV; Pinto, DS				Chen, HSV; Pinto, DS			Prinzmetal's angina	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Chen, HSV (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.			Pinto, Duane/0000-0002-2309-8480					0	5	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					E1	E1		10.1056/ENEJMicm020631	http://dx.doi.org/10.1056/ENEJMicm020631			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840104				2022-12-28	WOS:000183896100009
J	Kuperman, GJ; Gibson, RF				Kuperman, GJ; Gibson, RF			Computer physician order entry: Benefits, costs, and issues	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; RANDOMIZED-TRIAL; PREVENTIVE CARE; IMPACT; IMPLEMENTATION; INTERVENTION; SYSTEM; APPROPRIATENESS; SATISFACTION; GUIDELINES	Several analyses have detected substantial quality problems throughout the health care system. Information technology has consistently been identified as an important component of any approach for improvement. Computerized physician order entry (CPOE) is a promising technology that allows physicians to enter orders into a computer instead of handwriting them. Because CPOE fundamentally changes the ordering process, it can substantially decrease the overuse, underuse, and misuse of health care services. Studies have documented that CPOE can decrease costs, shorten length of stay, decrease medical errors, and improve compliance with several types of guidelines. The costs of CPOE are substantial both in terms of technology and organizational process analysis and redesign, system implementation, and user training and support. Computerized physician order entry is a relatively new technology, and there is no consensus on the best approaches to many of the challenges it presents. This technology can yield many significant benefits and is an important platform for future changes to the health care system. Organizational leaders must advocate for CPOE as a critical tool in improving health care quality.	Partners Healthcare Syst, Wellesley, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Providence Hlth Syst, Portland, OR USA	Partners Healthcare System; Harvard University; Harvard Medical School	Kuperman, GJ (corresponding author), Partners Healthcare Syst, 93 Worcester St,2nd Floor, Wellesley, MA USA.	gkuperman@partners.org	Tao, Youyou/D-2367-2014	Kuperman, Gilad/0000-0002-4130-1577				*1 CONS GROUP, 2003, COMP PHYS ORD ENTR C; Ahmad A, 2002, J AM MED INFORM ASSN, V9, P16, DOI 10.1136/jamia.2002.0090016; *AM HOSP ASS, 2000, AHA GUID COMP ORD EN; Ash JS, 1998, J AM MED INFORM ASSN, P235; Ash JS, 2003, J AM MED INFORM ASSN, V10, P229, DOI 10.1197/jamia.M1204; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, ARCH INTERN MED, V157, P2501, DOI 10.1001/archinte.157.21.2501; BATES DW, 1994, J AM MED INFORM ASSN, P996; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; *CAL HEALTHC FDN, 2000, PRIM PHYS ORD ENTR; Canas F, 1999, ARCH INTERN MED, V159, P363, DOI 10.1001/archinte.159.4.363; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; Chin HL, 1999, J AM MED INFORM ASSN, P221; Davis D., 1999, 5 ANN NICH E DAV AW, P77; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Harpole LH, 1997, J AM MED INFORM ASSN, V4, P511, DOI 10.1136/jamia.1997.0040511; HICKAM DH, 1985, ANN INTERN MED, V103, P928, DOI 10.7326/0003-4819-103-6-928; *HIMSS, 2002, HOT TOP SURV; *I MED, 1999, ERR IS HUM BUILD SAF; *I MED, 2000, CROSS QUAL CHASM NEW; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Kuperman G J, 2001, Jt Comm J Qual Improv, V27, P509; KUPERMAN GJ, 1998, MEDINFO, V9, P467; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; *LEAPFR GROUP PAT, 2003, REW HIGH STAND; Lee F, 1996, J AM MED INFORM ASSN, V3, P42, DOI 10.1136/jamia.1996.96342648; Lehman ML, 2001, J AM MED INFORM ASSN, P359; MASSARO TA, 1993, ACAD MED, V68, P20, DOI 10.1097/00001888-199301000-00003; McNutt RA, 2002, JAMA-J AM MED ASSOC, V287, P1997, DOI 10.1001/jama.287.15.1997; Mekhjian HS, 2002, J AM MED INFORM ASSN, V9, P529, DOI 10.1197/jamia.M1038; METZGER J, 2001, COMPUTERIZED ORDER E; Murff HJ, 2001, J AM MED INFORM ASSN, V8, P499, DOI 10.1136/jamia.2001.0080499; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Overhage JM, 2001, J AM MED INFORM ASSN, V8, P361, DOI 10.1136/jamia.2001.0080361; Overhage JM, 1996, ARCH INTERN MED, V156, P1551, DOI 10.1001/archinte.156.14.1551; Payne TH, 1999, J AM MED INFORM ASSN, P589; Sanders DL, 2001, J AM MED INFORM ASSN, P583; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; Shu K, 2001, ST HEAL T, V84, P1207; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Solomon DH, 1999, J RHEUMATOL, V26, P2578; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Teich JM, 1999, INT J MED INFORM, V54, P197, DOI 10.1016/S1386-5056(99)00007-6; Tierney W M, 1996, Proc AMIA Annu Fall Symp, P459; TIERNEY WM, 1994, ACAD MED, V69, P386, DOI 10.1097/00001888-199405000-00013; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; Valenstein P, 1999, ARCH PATHOL LAB MED, V123, P1145; Weiner M, 1999, J AM MED INFORM ASSN, V6, P234, DOI 10.1136/jamia.1999.0060234; 2003, LOS ANGELES TIM 0122; 2003, EMPIRE SAYS INCENTIV	62	286	289	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					31	39		10.7326/0003-4819-139-1-200307010-00010	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834316				2022-12-28	WOS:000183823200005
J	Peng, WT; Robinson, MD; Mnaimneh, S; Krogan, NJ; Cagney, G; Morris, Q; Davierwala, AP; Grigull, J; Yang, XQ; Zhang, W; Mitsakakis, N; Ryan, OW; Datta, N; Jojic, V; Pal, C; Canadien, V; Richards, D; Beattie, B; Wu, LF; Altschuler, SJ; Roweis, S; Frey, BJ; Emili, A; Greenblatt, JF; Hughes, TR				Peng, WT; Robinson, MD; Mnaimneh, S; Krogan, NJ; Cagney, G; Morris, Q; Davierwala, AP; Grigull, J; Yang, XQ; Zhang, W; Mitsakakis, N; Ryan, OW; Datta, N; Jojic, V; Pal, C; Canadien, V; Richards, D; Beattie, B; Wu, LF; Altschuler, SJ; Roweis, S; Frey, BJ; Emili, A; Greenblatt, JF; Hughes, TR			Panoramic view of yeast noncoding RNA processing	CELL			English	Article							PRE-RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; PROTEIN; BIOGENESIS; MATURATION; SNORNA; IDENTIFICATION; MULTIPLE; HOMOLOG	Predictive analysis using publicly available yeast functional genomics and proteomics data suggests that many more proteins may be involved in biogenesis of ribonucleoproteins than are currently known. Using a microarray that monitors abundance and processing of noncoding RNAs, we analyzed 468 yeast strains carrying mutations in protein-coding genes, most of which have not previously been associated with RNA or RNP synthesis. Many strains mutated in uncharacterized genes displayed aberrant noncoding RNA profiles. Ten factors involved in noncoding RNA biogenesis were verified by further experimentation, including a protein required for 20S pre-rRNA processing (Tsr2p), a protein associated with the nuclear exosome (Lrp1p), and a factor required for box C/D snoRNA accumulation (Bcd1p). These data present a global View of yeast noncoding RNA processing and confirm that many currently uncharacterized yeast proteins are involved in biogenesis of noncoding RNA.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Elect & Comp Engn, Probabilist & Stat Inference Grp, Toronto, ON M5S 3G4, Canada; Univ Toronto, Dept Comp Sci, Probabilist & Stat Inference Grp, Toronto, ON M5S 3G4, Canada; Affinium Pharmaceut, Toronto, ON M5J 1V6, Canada; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	University of Toronto; University of Toronto; University of Toronto; Harvard University	Hughes, TR (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	t.hughes@utoronto.ca	Robinson, Mark D/A-6432-2015; Cagney, Gerard/A-4648-2009; Robinson, Mark D./O-2254-2019; Morris, Quaid/ABE-8343-2020	Robinson, Mark D/0000-0002-3048-5518; Robinson, Mark D./0000-0002-3048-5518; Cagney, Gerard/0000-0001-7189-9496; Morris, Quaid/0000-0002-2760-6999				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; BISHOP C, 1995, NEURAL NETOWRKS PATT; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Duda R. O., 2001, PATTERN CLASSIFICATI; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Fatica A, 2002, RNA, V8, P1502, DOI 10.1017/S1355838202022094; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; Galardi S, 2002, MOL CELL BIOL, V22, P6663, DOI 10.1128/MCB.22.19.6663-6668.2002; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gelperin D, 2001, RNA, V7, P1268, DOI 10.1017/S1355838201013073; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Gromadka R, 2000, ACTA BIOCHIM POL, V47, P993, DOI 10.18388/abp.2000_3953; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Juhnke H, 2000, MOL MICROBIOL, V35, P936, DOI 10.1046/j.1365-2958.2000.01768.x; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Milkereit P, 2003, NUCLEIC ACIDS RES, V31, P799, DOI 10.1093/nar/gkg165; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; Nguyen Allen, 2002, BMC Biotechnol, V2, P14, DOI 10.1186/1472-6750-2-14; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saveanu C, 2001, EMBO J, V20, P6475, DOI 10.1093/emboj/20.22.6475; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Tone Y, 2002, GENE DEV, V16, P3142, DOI 10.1101/gad.1025602; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Hoof A, 2000, EMBO J, V19, P1357, DOI 10.1093/emboj/19.6.1357; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Verheggen C, 2001, EMBO J, V20, P5480, DOI 10.1093/emboj/20.19.5480; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Xing F, 2002, RNA, V8, P370, DOI 10.1017/S1355838202029825; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	69	203	217	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					919	933		10.1016/S0092-8674(03)00466-5	http://dx.doi.org/10.1016/S0092-8674(03)00466-5			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837249	Green Submitted, Bronze			2022-12-28	WOS:000183817900015
J	Choi, KH; Liu, H; Guo, YQ; Han, L; Mandel, JS; Rutherford, GW				Choi, KH; Liu, H; Guo, YQ; Han, L; Mandel, JS; Rutherford, GW			Emerging HIV-1 epidemic in China in men who have sex with men	LANCET			English	Article								China is currently undergoing a serious HIV-1 epidemic in intravenous drug users, sex workers, and former plasma donors. Little is known, however, about HIV-1 risk in Chinese men who have sex with men. In this study of seroprevalence in such men in Beijing, we recorded 15 (3.1%, 95% Cl 1.8-5.1) of 481 men infected with HIV-1. Overall, 238 (49%) of participants reported unprotected anal intercourse during the previous 6 months. HIV-1 seropositivtty was independently associated with being older than 39 years and having had more than 20 male sexual partners. Most men older than 39 years had been married. Our findings suggest the potential for spread of HIV-1 between men who have sex with men and to their heterosexual partners.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94105 USA; Beijing Municipal STD Clin, Beijing, Peoples R China; Beijing Tongzhi Hotline Programme, Beijing, Peoples R China	University of California System; University of California San Francisco	Choi, KH (corresponding author), Univ Calif San Francisco, Ctr AIDS Prevent Studies, 74 New Montgomery,Suite 600, San Francisco, CA 94105 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beach M, 2001, LANCET, V358, P1792, DOI 10.1016/S0140-6736(01)06856-8; KUMTA S, 2002, 14 INT C AIDS BARC S; United Nations Theme Group on HIV/AIDS in China, 2002, HIV AIDS CHIN TIT PE; Zhang BC, 2000, AM J PUBLIC HEALTH, V90, P1949, DOI 10.2105/AJPH.90.12.1949; Zhang KL, 2002, BMJ-BRIT MED J, V324, P803, DOI 10.1136/bmj.324.7341.803	5	117	138	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2125	2126		10.1016/S0140-6736(03)13690-2	http://dx.doi.org/10.1016/S0140-6736(03)13690-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	692GY	12826438				2022-12-28	WOS:000183654200014
J	Kawaler, SD				Kawaler, SD			Taking the pulse of a massive star	SCIENCE			English	Editorial Material									Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA	Iowa State University	Kawaler, SD (corresponding author), Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA.	sdk@iastate.edu		Kawaler, Steven/0000-0002-6536-6367				Aerts C, 2003, SCIENCE, V300, P1926, DOI 10.1126/science.1084993; Bedding TR, 2001, ASTROPHYS J, V549, pL105, DOI 10.1086/319139; Breger M., 2000, BALT ASTRON, V9, P149, DOI [10.1515/astro-2000-0122, DOI 10.1515/ASTRO-2000-0122]; Charpinet S, 1996, ASTROPHYS J, V471, pL103, DOI 10.1086/310335; Gough D, 2001, SCIENCE, V291, P2325, DOI 10.1126/science.1060088; Kawaler SD, 2000, NATO ADV SCI I C-MAT, V544, P511; Kilkenny D, 1997, MON NOT R ASTRON SOC, V285, P640, DOI 10.1093/mnras/285.3.640; Kurtz DW, 2003, ASTROPHYS SPACE SCI, V284, P29, DOI 10.1023/A:1023268108380; LANDOLT AU, 1968, ASTROPHYS J, V153, P151, DOI 10.1086/149645; NATHER RE, 1990, ASTROPHYS J, V361, P309, DOI 10.1086/169196	10	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1885	1886		10.1126/science.1086421	http://dx.doi.org/10.1126/science.1086421			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817130				2022-12-28	WOS:000183619400025
J	Courchesne, E; Carper, R; Akshoomoff, N				Courchesne, E; Carper, R; Akshoomoff, N			Evidence of brain overgrowth in the first year of life in autism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEAD CIRCUMFERENCE; YOUNG-CHILDREN; ABNORMALITIES; CORTEX; WEIGHT; VOLUME; AGE; CEREBELLAR; PATTERNS	Context Autism most commonly appears by 2 to 3 years of life, at which time the brain is already abnormally large. This raises the possibility that brain overgrowth begins much earlier, perhaps before the first clinically noticeable behavioral symptoms. Objectives To determine whether pathological brain overgrowth precedes the first clinical signs of autism spectrum disorder (ASD) and whether the rate of overgrowth during the first year is related to neuroanatomical and clinical outcome in early childhood. Design, Setting, and Participants Head circumference (HQ, body length, and body weight measurements during the first year were obtained from the medical records of 48 children with ASD aged 2 to 5 years who had participated in magnetic resonance imaging studies. Of these children, 15 (longitudinal group) had measurement at 4 periods during infancy: birth, 1 to 2 months, 3 to months, and 6 to 14 months; and 33 (partial HC data group) had measurements at birth and 6 to 14 months (n=7), and at birth only (n=28). Main Outcome Measures Age-related changes in infants with ASD who had multiple-age measurements, and the relationship of these changes to brain anatomy and clinical and diagnostic outcome at 2 to 5 years were evaluated by using 2 nationally recognized normative databases: cross-sectional normative data from a national survey and longitudinal data of individual growth. Results Compared with normative data of healthy infants, birth HC in infants with ASD was significantly smaller (z= -0.66, P<.001); after birth, HC increased 1.67 SDS and mean HC was at the 84th percentile by 6 to 14 months. Birth HC was related to cerebellar gray matter volume at 2 to 5 years, although the excessive increase in HC between birth and 6 to 14 months was related to greater cerebral cortex volume at 2 to 5 years. Within the ASD group, every child with autistic disorder had a greater increase in HC between birth and 6 to 14 months (mean [SD], 2.19 [0.98]) than infants with pervasive developmental disorder-not otherwise specified (0.58 [0.35]). Only 6% of the individual healthy infants in the longitudinal data showed accelerated HC growth trajectories (>2.0 SDs) from birth to 6 to 14 months; 59% of infants with autistic disorder showed these accelerated growth trajectories. Conclusions The clinical onset of autism appears to be preceded by 2 phases of brain growth abnormality: a reduced head size at birth and a sudden and excessive increase in head size between 1 to 2 months and 6 to 14 months. Abnormally accelerated rate of growth may serve as an early warning signal of risk for autism.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA; Childrens Hosp Res Ctr, Ctr Autism Res, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Courchesne, E (corresponding author), Ctr Autism Res, 8110 La Jolla Shores Dr, La Jolla, CA 92037 USA.	ecourchesne@ucsd.edu	Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019855] Funding Source: NIH RePORTER; NINDS NIH HHS [2-RO1-NS-19855] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akshoomoff N, 2002, DEV PSYCHOPATHOL, V14, P613, DOI 10.1017/S0954579402003115; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ARTHUR G, 1980, ARTHUR ADAPTATION LE; Aylward EH, 2002, NEUROLOGY, V59, P175, DOI 10.1212/WNL.59.2.175; Bailey A, 1998, BRAIN, V121, P889, DOI 10.1093/brain/121.5.889; BARONCOHEN S, 1992, BRIT J PSYCHIAT, V161, P839, DOI 10.1192/bjp.161.6.839; Bartholomeusz HH, 2002, NEUROPEDIATRICS, V33, P239, DOI 10.1055/s-2002-36735; Blinkov SM., 1968, HUMAN BRAIN FIGURES; Carper RA, 2000, BRAIN, V123, P836, DOI 10.1093/brain/123.4.836; Carper RA, 2002, NEUROIMAGE, V16, P1038, DOI 10.1006/nimg.2002.1099; Casanova MF, 2002, NEUROLOGY, V58, P428, DOI 10.1212/WNL.58.3.428; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Courchesne E, 1997, CURR OPIN NEUROBIOL, V7, P269, DOI 10.1016/S0959-4388(97)80016-5; Courchesne E, 1999, NEUROLOGY, V52, P1057, DOI 10.1212/WNL.52.5.1057; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; COURCHESNE E, 1994, MANUAL DEV PSYCHOPAT, P195; COURCHESNE E, IN PRESS BIOL PSYCHI; DAHLGREN SO, 1989, EUR ARCH PSY CLIN N, V238, P169; De Giacomo A, 1998, EUR CHILD ADOLES PSY, V7, P131, DOI 10.1007/s007870050058; Durston S, 2001, J AM ACAD CHILD PSY, V40, P1012, DOI 10.1097/00004583-200109000-00009; Fatemi SH, 2001, NEUROREPORT, V12, P929, DOI 10.1097/00001756-200104170-00013; FRIEDLANDER MJ, 1991, J NEUROSCI, V11, P3268; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; GUO S, 1988, J PEDIATR-US, V113, P490, DOI 10.1016/S0022-3476(88)80634-6; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kemper TL, 1998, J NEUROPATH EXP NEUR, V57, P645, DOI 10.1097/00005072-199807000-00001; Lainhart JE, 1997, J AM ACAD CHILD PSY, V36, P282, DOI 10.1097/00004583-199702000-00019; Lamb JA, 2000, HUM MOL GENET, V9, P861, DOI 10.1093/hmg/9.6.861; LECOUTEUR A, 1989, J AUTISM DEV DISORD, V19, P363, DOI 10.1007/BF02212936; Lee M, 2002, BRAIN, V125, P1483, DOI 10.1093/brain/awf160; LEMONS JA, 1981, HUM BIOL, V53, P351; Lord C, 2001, AM J MED GENET, V105, P36, DOI 10.1002/1096-8628(20010108)105:1<36::AID-AJMG1053>3.3.CO;2-W; LORD C, 2000, AUTISM SPECTRUM DISO, P167; LORD C, 1998, AUTISM DIAGNOSTIC OB; Mercado E, 2001, NEUROREPORT, V12, P2283, DOI 10.1097/00001756-200107200-00047; Mullen E.M., 1995, MULLEN SCALES EARLY; Nelson KB, 2001, ANN NEUROL, V49, P597, DOI 10.1002/ana.1024.abs; Orstavik KH, 1997, J MED GENET, V34, P849, DOI 10.1136/jmg.34.10.849; Penn AA, 1999, PEDIATR RES, V45, P447, DOI 10.1203/00006450-199904010-00001; Perry EK, 2001, AM J PSYCHIAT, V158, P1058, DOI 10.1176/appi.ajp.158.7.1058; Quartz SR, 1997, BEHAV BRAIN SCI, V20, P537; Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2; ROGERS SJ, 1990, J AM ACAD CHILD PSY, V29, P863, DOI 10.1097/00004583-199011000-00004; Rutter M., 1995, AUTISM DIAGNOSTIC IN; SANES DH, 1983, SCIENCE, V221, P1183, DOI 10.1126/science.6612332; Sattler, 1986, STANFORD BINET INTEL; Schopler E., 1988, CHILDHOOD AUTISM RAT; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; Stevenson RE, 1997, LANCET, V349, P1744, DOI 10.1016/S0140-6736(05)62956-X; Wechsler D., 1991, WISC 3 WECHSLER INTE; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Zhang LI, 2002, P NATL ACAD SCI USA, V99, P2309, DOI 10.1073/pnas.261707398	55	705	727	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	2003	290	3					337	344		10.1001/jama.290.3.337	http://dx.doi.org/10.1001/jama.290.3.337			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699WK	12865374				2022-12-28	WOS:000184078800027
J	Sanders, J; Evans, M; Premawardhana, LDKE; Depraetere, H; Jeffreys, J; Richards, T; Furmaniak, J; Smith, BR				Sanders, J; Evans, M; Premawardhana, LDKE; Depraetere, H; Jeffreys, J; Richards, T; Furmaniak, J; Smith, BR			Human monoclonal thyroid stimulating autoantibody	LANCET			English	Article								A monoclonal autoantibody (MAb) with powerful thyroid stimulating activity has been produced from lymphocytes from a patient with Graves' disease. The autoantibody and its Fab fragment bind to the thyroid stimulating hormone (TSH) receptor (TSHR) with high affinity, inhibit labelled TSH binding to the receptor and stimulate cyclic AMP production in Chinese hamster ovary cells transfected with TSHR. TSHR autoantibodies with TSH agonist or antagonist activities from patients' serum samples are effective inhibitors of labelled monoclonal autoantibody binding to TSHR. Thus, the human monoclonal autoantilbody has all the characteristics of serum TSHR autoantibodies. Its availability has important implications for new studies on the pathogenesis of Graves' disease.	RSR Ltd, FIRS Labs, Cardiff CF14 5DU, S Glam, Wales; Caerphilly Dist Miners Hosp, Dept Adult Med, Caerphilly, Wales	RSR LTD	Smith, BR (corresponding author), RSR Ltd, FIRS Labs, Parc Ty Glas, Cardiff CF14 5DU, S Glam, Wales.	firs.rsrltd@virgin.net	Premawardhana, Lakdasa/L-4031-2019	Premawardhana, Lakdasa/0000-0003-0931-3700; Depraetere, Hilde/0000-0001-7196-7911				Ando T, 2002, J CLIN INVEST, V110, P1667, DOI 10.1172/JCI200216991; Hayakawa N, 2002, AUTOIMMUNITY, V35, P343, DOI 10.1080/0891693021000003206; McLachlan SM, 1996, J CLIN ENDOCR METAB, V81, P3152, DOI 10.1210/jc.81.9.3152; Sanders J, 2002, THYROID, V12, P1043, DOI 10.1089/105072502321085135; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106	5	133	136	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					126	128		10.1016/S0140-6736(03)13866-4	http://dx.doi.org/10.1016/S0140-6736(03)13866-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867115				2022-12-28	WOS:000184089200014
J	Dumas, JJ; Kumar, R; Seehra, J; Somers, WS; Mosyak, L				Dumas, JJ; Kumar, R; Seehra, J; Somers, WS; Mosyak, L			Crystal structure of the GpIb alpha-thrombin complex essential for platelet aggregation	SCIENCE			English	Article							GLYCOPROTEIN-IB-ALPHA; VON-WILLEBRAND-FACTOR; BINDING-SITE; IDENTIFICATION; RECEPTOR; ADHESION; GLYCOCALICIN; RESIDUES; DOMAIN; LOCALIZATION	Direct interaction between platelet receptor glycoprotein Ibalpha (GpIbalpha) and thrombin is required for platelet aggregation and activation at sites of vascular injury. Abnormal GpIbalpha-thrombin binding is associated with many pathological conditions, including occlusive arterial thrombosis and bleeding disorders. The crystal structure of the GpIbalpha-thrombin complex at 2.6 angstrom resolution reveals simultaneous interactions of GpIbalpha with exosite I of one thrombin molecule, and with exosite II of a second thrombin molecule. In the crystal lattice, the periodic arrangement of GpIbalpha-thrombin complexes mirrors a scaffold that could serve as a driving force for tight platelet adhesion. The details of these interactions reconcile GpIbalpha-thrombin binding modes that are presently controversial, highlighting two distinct interfaces that are potential targets for development of novel antithrombotic drugs.	Wyeth, Dept Chem & Screening Sci, Cambridge, MA 02140 USA	Pfizer	Mosyak, L (corresponding author), Wyeth, Dept Chem & Screening Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	wsomers@wyeth.com; lmosyak@wyeth.com						Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; Bouton MC, 1998, THROMB HAEMOSTASIS, V80, P310, DOI 10.1055/s-0037-1615193; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; de Cristofaro R, 1998, BIOCHEM J, V332, P643, DOI 10.1042/bj3320643; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; DeCandia E, 1997, THROMB HAEMOSTASIS, V77, P735; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; DUMAS JC, UNPUB; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; HARMON JT, 1986, J BIOL CHEM, V261, P3224; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; JANDROTPERRUS M, 1991, THROMB HAEMOSTASIS, V66, P300; JANDROTPERRUS M, 1992, SEMIN THROMB HEMOST, V18, P261, DOI 10.1055/s-2007-1002433; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34; NICHOLLS A, 1993, GRASP; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Ravanat C, 2000, THROMB HAEMOSTASIS, V83, P327; Ruggeri ZM, 2003, CURR OPIN HEMATOL, V10, P142, DOI 10.1097/00062752-200303000-00008; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Wang JH, 2002, TRENDS BIOCHEM SCI, V27, P122, DOI 10.1016/S0968-0004(01)02038-2; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	42	134	137	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					222	226		10.1126/science.1083917	http://dx.doi.org/10.1126/science.1083917			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855811				2022-12-28	WOS:000184056200046
J	Matsumoto, K; Suzuki, W; Tanaka, K				Matsumoto, K; Suzuki, W; Tanaka, K			Neuronal correlates of goal-based motor selection in the prefrontal cortex	SCIENCE			English	Article							ANTERIOR CINGULATE CORTEX; ORBITOFRONTAL CORTEX; REWARD EXPECTANCY; COGNITIVE CONTROL; UNIT-ACTIVITY; HUMAN BRAIN; BEHAVIOR; SIGNALS; MACAQUE; MONKEY	Choosing an action that leads to a desired goal requires an understanding of the linkages between actions and their outcomes. We investigated neural mechanisms of such goal-based action selection. We trained monkeys on a task in which the relation between visual cues, action types, and reward conditions changed regularly, such that the monkeys selected their actions based on anticipated reward conditions. A significant number of neurons in the medial prefrontal cortex were activated, after cue presentation and before motor execution, only by particular action-reward combinations. This prefrontal activity is likely to underlie goal-based action selection.	RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, Wako, Saitama 3510198, Japan	RIKEN	Matsumoto, K (corresponding author), RIKEN, Brain Sci Inst, Cognit Brain Mapping Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsumot@postman.riken.go.jp	Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427; Matsumoto, Kenji/0000-0003-0883-4280				Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Critchley HD, 2001, NEURON, V29, P537, DOI 10.1016/S0896-6273(01)00225-2; Duncan John, 1995, P721; Funahashi S, 2001, NEUROSCI RES, V39, P147, DOI 10.1016/S0168-0102(00)00224-8; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; Hadland KA, 2003, J NEUROPHYSIOL, V89, P1161, DOI 10.1152/jn.00634.2002; Kobayashi S, 2002, J NEUROPHYSIOL, V87, P1488, DOI 10.1152/jn.00472.2001; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; Overmier JB, 2001, INTEGR PHYS BEH SCI, V36, P173, DOI 10.1007/BF02734091; PETERSON GB, 1980, LEARN MOTIV, V11, P267, DOI 10.1016/0023-9690(80)90001-6; Procyk E, 2000, NAT NEUROSCI, V3, P502, DOI 10.1038/74880; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; Savage LM, 2001, INTEGR PHYS BEH SCI, V36, P182, DOI 10.1007/BF02734092; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Thut G, 1997, NEUROREPORT, V8, P1225, DOI 10.1097/00001756-199703240-00033; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; van Veen V, 2001, NEUROIMAGE, V14, P1302, DOI 10.1006/nimg.2001.0923; Watanabe M, 2002, J NEUROSCI, V22, P2391, DOI 10.1523/JNEUROSCI.22-06-02391.2002; WATANABE M, 1990, EXP BRAIN RES, V80, P296; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0	28	302	306	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					229	232		10.1126/science.1084204	http://dx.doi.org/10.1126/science.1084204			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	699KN	12855813				2022-12-28	WOS:000184056200048
J	Valle, M; Zavialov, A; Sengupta, J; Rawat, U; Ehrenberg, M; Frank, J				Valle, M; Zavialov, A; Sengupta, J; Rawat, U; Ehrenberg, M; Frank, J			Locking and unlocking of ribosomal motions	CELL			English	Article							ELONGATION-FACTOR-G; COLI 70S RIBOSOME; 3-DIMENSIONAL CRYOELECTRON MICROSCOPY; TRANSFER-RNA TRANSLOCATION; AMINOACYL-TRANSFER-RNA; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; PROTEIN-SYNTHESIS; GTPASE ACTIVITY; PROMOTES TRANSLOCATION	During the ribosomal translocation, the binding of elongation factor G (EF-G) to the pretranslocational ribosome leads to a ratchet-like rotation of the 30S subunit relative to the 50S subunit in the direction of the mRNA movement. By means of cryo-electron microscopy we observe that this rotation is accompanied by a 20 Angstrom movement of the L1 stalk of the 50S subunit, implying that this region is involved in the translocation of deacylated tRNAs from the P to the E site. These ribosomal motions can occur only when the P-site tRNA is deacylated. Prior to peptidyl-transfer to the A-site tRNA or peptide removal, the presence of the charged P-site tRNA locks the ribosome and prohibits both of these motions.	SUNY Albany, Howard Hughes Med Inst, Albany, NY 12201 USA; SUNY Albany, Htlh Res Inc, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Htlh Res Inc, Dept Biomed Sci, Albany, NY 12201 USA; Biomed Ctr, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Howard Hughes Medical Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Frank, J (corresponding author), SUNY Albany, Howard Hughes Med Inst, Empire State Plaza, Albany, NY 12201 USA.		Valle, Mikel/F-7598-2011	Valle, Mikel/0000-0001-8268-6912; Zavialov, Andrey/0000-0001-6420-0368	NIGMS NIH HHS [R01 GM55440, R37 GM29169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055440, R37GM029169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P53; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 2000, METHOD ENZYMOL, V317, P276; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; Gomez-Lorenzo MG, 2000, EMBO J, V19, P2710, DOI 10.1093/emboj/19.11.2710; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HIGHLAND JH, 1975, J BIOL CHEM, V250, P1141; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; ISHITSUKA H, 1970, J BIOL CHEM, V245, P3346; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; Laurberg M, 2000, J MOL BIOL, V303, P593, DOI 10.1006/jmbi.2000.4168; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Marquez V, 2002, BIOCHEM SOC T, V30, P133, DOI 10.1042/BST0300133; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; Peske F, 2000, MOL CELL, V6, P501, DOI 10.1016/S1097-2765(00)00049-6; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Rodnina MV, 2001, MOL BIOL+, V35, P559, DOI 10.1023/A:1010523026531; Savelsbergh A, 2000, J BIOL CHEM, V275, P890, DOI 10.1074/jbc.275.2.890; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; SUBRAMANIAN AR, 1980, EUR J BIOCHEM, V112, P425, DOI 10.1111/j.1432-1033.1980.tb07222.x; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	48	485	507	0	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 11	2003	114	1					123	134		10.1016/S0092-8674(03)00476-8	http://dx.doi.org/10.1016/S0092-8674(03)00476-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859903	Bronze			2022-12-28	WOS:000184219900011
J	Antel, JP; Bar-Or, A				Antel, JP; Bar-Or, A			Do myelin-directed antibodies predict multiple sclerosis?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada	McGill University	Antel, JP (corresponding author), McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.		Bar-Or, Amit/C-4213-2011	Bar-Or, Amit/0000-0001-7179-0335; antel, jack/0000-0002-5148-0636					0	26	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					107	109		10.1056/NEJMp030098	http://dx.doi.org/10.1056/NEJMp030098			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853581				2022-12-28	WOS:000184024400001
J	Elliot, JL; Ates, A; Babcock, BA; Bosh, AS; Buie, MW; Clancy, KB; Dunham, EW; Eikenberry, SS; Hall, DT; Kern, SD; Leggett, SK; Levine, SE; Moon, DS; Olkin, CB; Osip, DJ; Pasachoff, JM; Penprase, BE; Person, MJ; Qu, S; Rayner, JT; Roberts, LC; Salyk, CV; Souza, SP; Stone, RC; Taylor, BW; Tholen, DJ; Thomas-Osip, JE; Ticehurst, DR; Wasserman, LH				Elliot, JL; Ates, A; Babcock, BA; Bosh, AS; Buie, MW; Clancy, KB; Dunham, EW; Eikenberry, SS; Hall, DT; Kern, SD; Leggett, SK; Levine, SE; Moon, DS; Olkin, CB; Osip, DJ; Pasachoff, JM; Penprase, BE; Person, MJ; Qu, S; Rayner, JT; Roberts, LC; Salyk, CV; Souza, SP; Stone, RC; Taylor, BW; Tholen, DJ; Thomas-Osip, JE; Ticehurst, DR; Wasserman, LH			The recent expansion of Pluto's atmosphere	NATURE			English	Article							STELLAR OCCULTATION; PLANETARY-ATMOSPHERES; ABSORPTION; PRESSURE; TRITON; MODELS	Stellar occultations - the passing of a relatively nearby body in front of a background star - can be used to probe the atmosphere of the closer body with a spatial resolution of a few kilometres (ref. 1). Such observations can yield the scale height, temperature profile, and other information about the structure of the occulting atmosphere. Occultation data acquired for Pluto's atmosphere in 1988 revealed a nearly isothermal atmosphere(2) above a radius of similar to1,215 km. Below this level, the data could be interpreted as indicating either an extinction layer or the onset of a large thermal gradient, calling into question the fundamental structure of this atmosphere. Another question is to what extent Pluto's atmosphere might be collapsing as it recedes from the Sun ( passing perihelion in 1989 in its 248-year orbital period), owing to the extreme sensitivity of the equilibrium surface pressure to the surface temperature. Here we report observations at a variety of visible and infrared wavelengths of an occultation of a star by Pluto in August 2002. These data reveal evidence for extinction in Pluto's atmosphere and show that it has indeed changed, having expanded rather than collapsed, since 1988.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Dept Aeronaut & Astronaut, Cambridge, MA 02139 USA; Lowell Observ, Flagstaff, AZ 86001 USA; Pomona Coll, Dept Phys & Astron, Claremont, CA 91711 USA; Williams Coll, Dept Phys, Williamstown, MA 01267 USA; Williams Coll, Hopkins Observ, Williamstown, MA 01267 USA; Boston Univ, Inst Astrophys Res, Boston, MA 02215 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Boeing Co, Kihei, HI 96753 USA; USN Observ, Flagstaff Stn, Flagstaff, AZ 86002 USA; NASA Infrared Telescope Facil, Honolulu, HI 96822 USA; Inst Astron, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Claremont Colleges; Pomona College; Williams College; Johns Hopkins University; Williams College; Boston University; Cornell University; Boeing; United States Department of Defense; United States Navy; National Aeronautics & Space Administration (NASA)	Elliot, JL (corresponding author), Carnegie Observ, Las Campanas Observ, Casilla 601, La Serena, Chile.		Olkin, Catherine/AAF-5160-2019; Souza, Steven P/T-4303-2018	Olkin, Catherine/0000-0002-5846-716X; Rayner, John/0000-0002-3165-159X; Leggett, Sandy/0000-0002-3681-2989; Taylor, Brian/0000-0003-2886-9341				Brown G. N.  Jr., 1980, Advances in Cryogenic Engineering. Vol.25. Proceedings of the 1979 Cryogenic Engineering Conference, P662; Buie MW, 2002, B AM ASTRON SOC, V34, P877; BUIE MW, 1993, BAAS, V25, P1115; DUNHAM EW, 1995, P AIRB ASTR S GAL EC, P517; ELLIOT JL, 1989, ICARUS, V77, P148, DOI 10.1016/0019-1035(89)90014-6; Elliot JL, 1998, NATURE, V393, P765, DOI 10.1038/31651; Elliot JL, 1996, ANNU REV EARTH PL SC, V24, P89, DOI 10.1146/annurev.earth.24.1.89; Elliot JL, 2000, ICARUS, V148, P347, DOI 10.1006/icar.2000.6508; ELLIOT JL, 1992, ASTRON J, V103, P991, DOI 10.1086/116121; ELLIOT JL, IN PRESS ASTRON J; ESHLEMAN VR, 1989, ICARUS, V80, P439, DOI 10.1016/0019-1035(89)90150-4; Frohlich C, 2002, ADV SPACE RES-SERIES, V29, P1409, DOI 10.1016/S0273-1177(02)00203-X; Hansen CJ, 1996, ICARUS, V120, P247, DOI 10.1006/icar.1996.0049; HUBBARD WB, 1990, ICARUS, V84, P1, DOI 10.1016/0019-1035(90)90154-2; HUBBARD WB, 1988, NATURE, V336, P452, DOI 10.1038/336452a0; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; McDonald SW, 2000, ASTRON J, V120, P1599, DOI 10.1086/301543; McDonald SW, 1996, ASTRON J, V112, P788, DOI 10.1086/118054; MILLIS RL, 1993, ICARUS, V105, P282, DOI 10.1006/icar.1993.1126; OLKIN CB, IN PRESS ICARUS; PUXLEY PJ, 1994, P SOC PHOTO-OPT INS, V2198, P350, DOI 10.1117/12.176713; Rannou P, 1999, PLANET SPACE SCI, V47, P385, DOI 10.1016/S0032-0633(99)00007-0; Rannou P, 1995, ICARUS, V118, P355, DOI 10.1006/icar.1995.1196; Rayner JT, 2003, PUBL ASTRON SOC PAC, V115, P362, DOI 10.1086/367745; Sicardy B, 2003, NATURE, V424, P168, DOI 10.1038/nature01766; STANSBERRY JA, 1989, GEOPHYS RES LETT, V16, P1221, DOI 10.1029/GL016i011p01221; Summers M. E., 1997, PLUTO CHARON, P391; Thomas-Osip J.E., 2002, B AM ASTRON SOC, V34, P1212; Vacca WD, 2003, PUBL ASTRON SOC PAC, V115, P389, DOI 10.1086/346193; van de Hulst H.C., 1981, LIGHT SCATTERING SMA	30	92	92	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					165	168		10.1038/nature01762	http://dx.doi.org/10.1038/nature01762			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853949				2022-12-28	WOS:000184032700034
J	Leigh, DA; Wong, JKY; Dehez, F; Zerbetto, F				Leigh, DA; Wong, JKY; Dehez, F; Zerbetto, F			Unidirectional rotation in a mechanically interlocked molecular rotor	NATURE			English	Article							ROTARY MOTION; MOTOR; ACCELERATION; SYSTEM	Molecular motor proteins are ubiquitous in nature(1) and have inspired attempts to create artificial machines(2) that mimic their ability to produce controlled motion on the molecular level. A recent example of an artificial molecular rotor is a molecule undergoing a unidirectional 120degrees intramolecular rotation around a single bond(3,4); another is a molecule capable of repetitive unimolecular rotation driven by multiple and successive isomerization of its central double bond(5-8). Here we show that sequential and unidirectional rotation can also be induced in mechanically interlocked assemblies comprised of one or two small rings moving around one larger ring. The small rings in these [2]- and [3] catenanes(9) move in discrete steps between different binding sites located on the larger ring, with the movement driven by light, heat or chemical stimuli that change the relative affinity of the small rings for the different binding sites(10-12). We find that the small ring in the [2] catenane moves with high positional integrity but without control over its direction of motion, while the two rings in the [3] catenane mutually block each other's movement to ensure an overall stimuli-induced unidirectional motion around the larger ring.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy	University of Edinburgh; University of Bologna	Leigh, DA (corresponding author), Univ Edinburgh, Sch Chem, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.		Zerbetto, Francesco/D-2503-2014; Leigh, David/K-5965-2015	Zerbetto, Francesco/0000-0002-2419-057X; Leigh, David/0000-0002-1202-4507; Dehez, Francois/0000-0001-8076-6222				Altieri A, 2003, ANGEW CHEM INT EDIT, V42, P2296, DOI 10.1002/anie.200250745; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Brouwer AM, 2001, SCIENCE, V291, P2124, DOI 10.1126/science.1057886; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Feringa BL, 2002, APPL PHYS A-MATER, V75, P301, DOI 10.1007/s003390201338; Feynman R.P., 1963, FEYNMAN LECT PHYS; Frkanec L, 2002, J AM CHEM SOC, V124, P9716, DOI 10.1021/ja027189u; Gatti FG, 2003, P NATL ACAD SCI USA, V100, P10, DOI 10.1073/pnas.0134757100; Gatti FG, 2001, J AM CHEM SOC, V123, P5983, DOI 10.1021/ja001697r; Kelly TR, 2000, J AM CHEM SOC, V122, P6935, DOI 10.1021/ja001048f; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; KELLY TR, 1994, J AM CHEM SOC, V116, P3657, DOI 10.1021/ja00087a085; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Koumura N, 2002, J AM CHEM SOC, V124, P5037, DOI 10.1021/ja012499i; Sauvage, 1999, MOL CATENANES ROTAXA; SCHLIWA M, 2003, MOL MOTORS; Trnka TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/ar000114f; van Delden RA, 2002, P NATL ACAD SCI USA, V99, P4945, DOI 10.1073/pnas.062660699; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	19	735	738	4	233	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					174	179		10.1038/nature01758	http://dx.doi.org/10.1038/nature01758			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853952				2022-12-28	WOS:000184032700037
J	Anderson, GG; Palermo, JJ; Schilling, JD; Roth, R; Heuser, J; Hultgren, SJ				Anderson, GG; Palermo, JJ; Schilling, JD; Roth, R; Heuser, J; Hultgren, SJ			Intracellular bacterial biofilm-like pods in urinary tract infections	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; COMPLETE GENOME SEQUENCE; HOST DEFENSES; OUTER-MEMBRANE; BLADDER; PROTEIN; RESISTANCE; INVASION; CELLS; MICE	Escherichia coli entry into the bladder is met with potent innate defenses, including neutrophil influx and epithelial exfoliation. Bacterial subversion of innate responses involves invasion into bladder superficial cells. We discovered that the intracellular bacteria matured into biofilms, creating pod-like bulges on the bladder surface. Pods contained bacteria encased in a polysaccharide-rich matrix surrounded by a protective shell of uroplakin. Within the biofilm, bacterial structures interacted extensively with the surrounding matrix, and biofilm associated factors had regional variation in expression. The discovery of intracellular biofilm-like pods explains how bladder infections can persist in the face of robust host defenses.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	hultgren@borcim.wustl.edu			NIAID NIH HHS [AI29549, AI48689] Funding Source: Medline; NIDDK NIH HHS [DK64540, DK51406] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048689, R01AI029549, R37AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406, P50DK064540] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Danese PN, 2000, MOL MICROBIOL, V37, P424, DOI 10.1046/j.1365-2958.2000.02008.x; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Dunne WM, 2002, CLIN MICROBIOL REV, V15, P155, DOI 10.1128/CMR.15.2.155-166.2002; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; Foxman B, 2002, AM J MED, V113, p5S; Fulcher TP, 2001, OPHTHALMOLOGY, V108, P1088, DOI 10.1016/S0161-6420(01)00561-9; Haraoka M, 1999, J INFECT DIS, V180, P1220, DOI 10.1086/315006; HEUSER JE, 1987, J MUSCLE RES CELL M, V8, P303, DOI 10.1007/BF01568887; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hu P, 2002, AM J PHYSIOL-RENAL, V283, pF1200, DOI 10.1152/ajprenal.00043.2002; JUSTICE S, UNPUB; Lewis SA, 2000, AM J PHYSIOL-RENAL, V278, pF867; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Mysorekar IU, 2002, J BIOL CHEM, V277, P7412, DOI 10.1074/jbc.M110560200; Olsson LE, 1998, J PHARMACOL EXP THER, V284, P1203; Otto G, 1999, J INFECT DIS, V179, P172, DOI 10.1086/314534; OWEN P, 1987, J BACTERIOL, V169, P3770, DOI 10.1128/jb.169.8.3770-3777.1987; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Schilling JD, 2002, INFECT IMMUN, V70, P7042, DOI 10.1128/IAI.70.12.7042-7049.2002; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799; WU XR, 1990, J BIOL CHEM, V265, P19170	31	737	773	0	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					105	107		10.1126/science.1084550	http://dx.doi.org/10.1126/science.1084550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843396				2022-12-28	WOS:000183914700044
J	Hippisley-Cox, J; Pringle, M; Cater, R; Wynn, A; Hammersley, V; Coupland, C; Hapgood, R; Horsfield, P; Teasdale, S; Johnson, C				Hippisley-Cox, J; Pringle, M; Cater, R; Wynn, A; Hammersley, V; Coupland, C; Hapgood, R; Horsfield, P; Teasdale, S; Johnson, C			The electronic patient record in primary care-regression or progression? A cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							COMPUTERIZED DECISION-SUPPORT; ORAL ANTICOAGULATION; COMPLETENESS; SCOTLAND; SYSTEM	Objectives To determine whether paperless medical records contained less information than paper based medical records and whether that information was harder to retrieve. Design Cross sectional study with review of medical records and interviews with general practitioners. Setting 25 general practices in Trent region. Participants 53 British general practitioners (25 using paperless records and 28 using paper based records) who each provided records of 10 consultations. Main outcome measures Content of a sample of records and doctor recall of consultations for which paperless or paper based records had been made. Results Compared with paper based records, more paperless records were fully understandable (89.2% v 69.9%, P = 0.0001) and fully legible (100% v 64.3%, P < 0.0001). Paperless records were significantly more likely to have at least one diagnosis recorded (48.2% v 33.2%, P = 0.05), to record that advice had been given (23.7% vs 10.7%, P = 0.017), and, when a referral had been made, were more likely to contain details of the specialty (77.4% v 59.5%, P = 0.03). When a prescription had been issued, paperless records were more likely to specify the drug dose (86.6% v 66.2%, P = 0.005). Paperless records contained significantly more words, abbreviations, and symbols (P < 0.01 for all). At doctor interview, there was no difference between the groups for the proportion of patients or consultations that could be recalled. Doctors using paperless records were able to recall more advice given to patients (38.6% v 26.8%, P = 0.03). Conclusion We found no evidence to support our hypotheses that paperless records would be truncated and contain more local abbreviations; and that the absence of writing would decrease subsequent recall. Conversely we found that the paperless records compared favourably with manual records.	Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England; Univ Sheffield, ScHARR, Sheffield Ctr Integrated Genet, Sect Publ Hlth, Sheffield S1 4DA, S Yorkshire, England; Univ Sheffield, PRIMIS, Sheffield S1 4DA, S Yorkshire, England	University of Nottingham; University of Sheffield; University of Sheffield	Hippisley-Cox, J (corresponding author), Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				ANDERSON R, 1995, BRIT MED J, V311, P5, DOI 10.1136/bmj.311.6996.5; Anderson R, 1996, BRIT MED J, V312, P109; BURNS F, 1998, INFORMATION HLTH INF; *DEP HLTH, 2002, NAT SPEC INT CAR REC; Department of Health, 2000, NAT SERV FRAM COR AR; Dovey SM, 1996, BRIT J GEN PRACT, V46, P749; Fitzmaurice DA, 1998, FAM PRACT, V15, P144, DOI 10.1093/fampra/15.2.144; Fitzmaurice DA, 1996, BRIT J GEN PRACT, V46, P533; Hippisley-Cox J, 2001, BRIT MED J, V323, P320, DOI 10.1136/bmj.323.7308.320; HOBBS FDR, 1995, FAM PRACT, V12, P221, DOI 10.1093/fampra/12.2.221; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Purves IN, 1998, BRIT J GEN PRACT, V48, P1552; *SECR STAT HLTH, 2000, NHS PLAN PLAN INV PL; Southgate L, 2001, MED EDUC, V35, P9, DOI 10.1046/j.1365-2923.2001.00002.x; Tang PC, 1999, J AM MED INFORM ASSN, V6, P245, DOI 10.1136/jamia.1999.0060245; Vadher B, 1997, BMJ-BRIT MED J, V314, P1252, DOI 10.1136/bmj.314.7089.1252; Walton RT, 1997, BRIT MED J, V315, P791; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181	20	103	105	2	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1439	1443		10.1136/bmj.326.7404.1439	http://dx.doi.org/10.1136/bmj.326.7404.1439			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829558	Bronze, Green Published			2022-12-28	WOS:000183931800020
J	Finlay, CC; Jackson, A				Finlay, CC; Jackson, A			Equatorially dominated magnetic field change at the surface of Earth's core	SCIENCE			English	Article							HYDROMAGNETIC-WAVES; TEMPERATURE; CONVECTION; GEODYNAMO; MANTLE	Slow temporal variations in Earth's magnetic field originate in the liquid outer core. We analyzed the evolution of nonaxisymmetric magnetic flux at the core surface over the past 400 years. We found that the most robust feature is westward motion at 17 kilometers per year, in a belt concentrated around the equator beneath the Atlantic hemisphere. Surprisingly, this motion is dominated by a single wavenumber and persists throughout the observation period. This phenomenon could be produced by an equatorial jet of core fluid, by hydromagnetic wave propagation, or by a combination of both. Discrimination between these mechanisms would provide useful constraints on the dynamics of Earth's core.	Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Finlay, CC (corresponding author), Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England.	c.finlay@earth.leeds.ac.uk	Finlay, Christopher C/B-5062-2014	Finlay, Christopher C/0000-0002-4592-2290				Aubert J, 2001, PHYS EARTH PLANET IN, V128, P51, DOI 10.1016/S0031-9201(01)00277-1; BLOXHAM J, 1989, GEOPHYS J INT, V99, P173, DOI 10.1111/j.1365-246X.1989.tb02022.x; BLOXHAM J, 1989, PHILOS T R SOC A, V329, P415, DOI 10.1098/rsta.1989.0087; BRAGINSKII SI, 1964, SOV PHYS JETP, V47, P1084; Braginskiy S. I., 1967, Geomagnetism and Aeronomy, V7, P851; BULLARD EC, 1950, PHILOS TR R SOC S-A, V243, P67, DOI 10.1098/rsta.1950.0014; Chelton DB, 1996, SCIENCE, V272, P234, DOI 10.1126/science.272.5259.234; Dormy E, 2000, GEOCHEM GEOPHY GEOSY, V1; GUBBINS D, 1985, GEOPHYS J ROY ASTR S, V80, P695, DOI 10.1111/j.1365-246X.1985.tb05119.x; HIDE R, 1966, PHILOS TR R SOC S-A, V259, P615, DOI 10.1098/rsta.1966.0026; HIDE R, 1967, SCIENCE, V157, P55, DOI 10.1126/science.157.3784.55; Hill KL, 2000, J GEOPHYS RES-OCEANS, V105, P21927, DOI 10.1029/2000JC900067; Hovmoller E, 1949, TELLUS, V1, P62, DOI [10.1111/j.2153-3490.1949.tb01260.x, DOI 10.1111/J.2153-3490.1949.TB01260.X]; Jackson A, 2000, PHILOS T ROY SOC A, V358, P957, DOI 10.1098/rsta.2000.0569; JACKSON A, UNPUB; JEANS SR, 1988, RADON TRANSFORM SOME; Kono M, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000102; Olson P, 1999, J GEOPHYS RES-SOL EA, V104, P10383, DOI 10.1029/1999JB900013; ROBERTS PH, 1972, ANNU REV FLUID MECH, V4, P117, DOI 10.1146/annurev.fl.04.010172.001001; Roberts PH, 2000, REV MOD PHYS, V72, P1081, DOI 10.1103/RevModPhys.72.1081; Wheeler M, 1999, J ATMOS SCI, V56, P374, DOI 10.1175/1520-0469(1999)056<0374:CCEWAO>2.0.CO;2; ZHANG K, 1994, GEOPHYS ASTRO FLUID, V77, P133, DOI 10.1080/03091929408203679; Zhang K, 2002, MATH COMPUT MODEL, V36, P389, DOI 10.1016/S0895-7177(02)00133-4	23	109	109	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2084	2086		10.1126/science.1083324	http://dx.doi.org/10.1126/science.1083324			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829780				2022-12-28	WOS:000183774900043
J	Zhou, FQ; Zhong, J; Snider, WD				Zhou, FQ; Zhong, J; Snider, WD			Extracellular crosstalk: When GDNF meets N-CAM	CELL			English	Editorial Material							LIPID RAFTS; FAMILY	N-CAM has now been identified as a receptor for glial cell line-derived neurotrophic factor (GDNF). This finding solves a long-standing question regarding RET-independent GDNF signaling, and reveals a novel pathway distinct from both GDNF-RET and N-CAM-N-CAM signaling. Functional assays of Schwann cell migration and axon growth of CNS neurons suggest physiological significance for this GDNF-N-CAM pathway.	Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Zhou, FQ (corresponding author), Univ N Carolina, Ctr Neurosci, Neurosci Res Bldg, Chapel Hill, NC 27599 USA.							Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Panicker AK, 2003, FRONT BIOSCI, V8, pD900, DOI 10.2741/1014; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8	8	17	18	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					814	815		10.1016/S0092-8674(03)00467-7	http://dx.doi.org/10.1016/S0092-8674(03)00467-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837237	Bronze			2022-12-28	WOS:000183817900003
J	Kenichi, T; Kyoko, S; Hiroshi, F; Mitsuko, O				Kenichi, T; Kyoko, S; Hiroshi, F; Mitsuko, O			Modulated structure of solid iodine during its molecular dissociation under high pressure	NATURE			English	Article							X-RAY; METALLIC STATE; TRANSFORMATION; PHASE	The application of pressure to solid iodine forces the molecules in the crystal to approach each other until intermolecular distances become comparable to the bond length of iodine; at this point, the molecules lose their identity and are essentially dissociated. According to room-temperature X-ray diffraction studies(1), this process involves direct dissociation of iodine molecules at about 21 GPa, whereas spectroscopic observations(2,3) have identified intermediate molecular phases at pressures ranging from 15 to 30 GPa. Here we present quasi-hydrostatic powder X-ray diffraction measurements that clearly reveal an intermediate phase during the pressure-induced dissociation of solid iodine. We find that, similar to the behaviour seen in uranium(4), the structure of this intermediate phase is incommensurately modulated, with the nearest interatomic distances continuously distributed over the range 2.86 - 3.11 Angstrom. The shortest of these interatomic distances falls between the bond length of iodine in the molecular crystal (2.75 Angstrom) and the nearest interatomic distance in the fully dissociated monatomic crystal (2.89 Angstrom), implying that the intermediate phase is a transient state during molecular dissociation. We expect that further measurements at different temperatures will help to elucidate the origin and stability of the incommensurate structure, which might lead to a better understanding of the molecular-level mechanism of the pressure-induced dissociation seen here and in the molecular crystals of hydrogen(5), oxygen(6) and nitrogen(7).	Natl Inst Mat Sci, Adv Mat Lab, Tsukuba, Ibaraki 3050044, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1020083, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mat & Chem Proc, Tsukuba, Ibaraki 3058565, Japan	National Institute for Materials Science; Japan Society for the Promotion of Science; National Institute of Advanced Industrial Science & Technology (AIST)	Kenichi, T (corresponding author), Natl Inst Mat Sci, Adv Mat Lab, Tsukuba, Ibaraki 3050044, Japan.	takemura.kenichi@nims.go.jp	Fujihisa, Hiroshi/AAH-3720-2020; Fujihisa, Hiroshi/L-6219-2018	Fujihisa, Hiroshi/0000-0001-9308-153X; Fujihisa, Hiroshi/0000-0001-9308-153X				Eremets ML, 2001, NATURE, V411, P170, DOI 10.1038/35075531; FUJIHISA H, 1995, J PHYS CHEM SOLIDS, V56, P1439, DOI 10.1016/0022-3697(95)00081-X; FUJII Y, 1987, PHYS REV LETT, V58, P796, DOI 10.1103/PhysRevLett.58.796; FUJII Y, 1986, SOLID STATE COMMUN, V59, P85, DOI 10.1016/0038-1098(86)90291-7; FUJII Y, 1989, PHYS REV LETT, V63, P536, DOI 10.1103/PhysRevLett.63.536; Kenichi T, 2003, REV SCI INSTRUM, V74, P3017, DOI 10.1063/1.1571953; LUTY T, 1988, CAN J CHEM, V66, P812, DOI 10.1139/v88-141; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; Nelmes RJ, 1999, PHYS REV LETT, V83, P4081, DOI 10.1103/PhysRevLett.83.4081; OLIJNYK H, 1994, PHYS REV B, V50, P712, DOI 10.1103/PhysRevB.50.712; PASTERNAK M, 1987, PHYS REV LETT, V58, P575, DOI 10.1103/PhysRevLett.58.575; REICHLIN R, 1994, PHYS REV B, V49, P3725, DOI 10.1103/PhysRevB.49.3725; RIGGLEMAN BM, 1963, J CHEM PHYS, V38, P2721, DOI 10.1063/1.1733579; SAKAI N, 1982, J PHYS SOC JPN, V51, P1811, DOI 10.1143/JPSJ.51.1811; SHIMOMURA O, 1978, PHYS REV B, V18, P715, DOI 10.1103/PhysRevB.18.715; SHIMOMURA O, 1992, REV SCI INSTRUM, V63, P967, DOI 10.1063/1.1143793; TAKEMURA K, 1980, PHYS REV LETT, V45, P1881, DOI 10.1103/PhysRevLett.45.1881; TAKEMURA K, 1982, PHYS REV B, V26, P998, DOI 10.1103/PhysRevB.26.998; Takemura K, 2001, J APPL PHYS, V89, P662, DOI 10.1063/1.1328410; Takemura K., 2001, REV SCI INSTRUM, V72, P3873; VANSMAALEN S, 1987, PHYS REV B, V35, P7939, DOI 10.1103/PhysRevB.35.7939; Weck G, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevB.88.035504; WILSON AJC, 1999, INT TABLES CRYSTALLO, VC, P914; YAMAMOTO A, 1990, PHYS REV B, V42, P4228, DOI 10.1103/PhysRevB.42.4228; Zha CS, 2000, P NATL ACAD SCI USA, V97, P13494, DOI 10.1073/pnas.240466697	25	70	71	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					971	974		10.1038/nature01724	http://dx.doi.org/10.1038/nature01724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827197				2022-12-28	WOS:000183753900045
J	Grech, ED				Grech, ED			ABC of interventional cardiology - Non-coronary percutaneous intervention	BRITISH MEDICAL JOURNAL			English	Review							CARDIOMYOPATHY		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Grech, ED (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.							Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Braun MU, 2002, J AM COLL CARDIOL, V39, P2019, DOI 10.1016/S0735-1097(02)01904-6; INOUE K, 2002, PRACTICAL INTERVENTI, P373; Nagueh SF, 2001, J AM COLL CARDIOL, V38, P1701, DOI 10.1016/S0735-1097(01)01614-X; WAIGHT DJ, 2002, PRACTICAL INTERVENTI, P390; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; WILKINS GT, 1988, BRIT HEART J, V60, P299	7	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					97	100		10.1136/bmj.327.7406.97	http://dx.doi.org/10.1136/bmj.327.7406.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855531	Green Published			2022-12-28	WOS:000184229400025
J	Gozani, O; Karuman, P; Jones, DR; Ivanov, D; Cha, J; Lugovskoy, AA; Baird, CL; Zhu, H; Field, SJ; Lessnick, SL; Villasenor, J; Mehrotra, B; Chen, J; Rao, VR; Brugge, JS; Ferguson, CG; Payrastre, B; Myszka, DG; Cantley, LC; Wagner, G; Divecha, N; Prestwich, GD; Yuan, JY				Gozani, O; Karuman, P; Jones, DR; Ivanov, D; Cha, J; Lugovskoy, AA; Baird, CL; Zhu, H; Field, SJ; Lessnick, SL; Villasenor, J; Mehrotra, B; Chen, J; Rao, VR; Brugge, JS; Ferguson, CG; Payrastre, B; Myszka, DG; Cantley, LC; Wagner, G; Divecha, N; Prestwich, GD; Yuan, JY			The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor	CELL			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; ZINC-FINGER; CELL-CYCLE; BINDING; DNA; COMPLEX; PTDINS(4,5)P-2; IDENTIFICATION; TRANSCRIPTION	Phosphoinositides (PtdInsPs) play critical roles in cytoplasmic signal transduction pathways. However, their functions in the nucleus are unclear, as specific nuclear receptors for PtdInsPs have not been identified. Here, we show that ING2, a candidate tumor suppressor protein, is a nuclear PtdInsP receptor. ING2 contains a plant homeodomain (PHD) finger, a motif common to many chromatin-regulatory proteins. We find that the PHD fingers of ING2 and other diverse nuclear proteins bind in vitro to PtdInsPs, including the rare PtdInsP species, phosphatidylinositol 5-phosphate (PtdIns(5)P). Further, we demonstrate that the ING2 PHD finger interacts with PtdIns(5)P in vivo and provide evidence that this interaction regulates the ability of ING2 to activate p53 and p53-dependent apoptotic pathways. Together, our data identify the PHD finger as a phosphoinositide binding module and a nuclear PtdInsP receptor, and suggest that PHD-phosphoinositide interactions directly regulate nuclear responses to DNA damage.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Utah, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Echelon Biosci Inc, Salt Lake City, UT 84108 USA; Hop Purpan, INSERM, U563, Dept Oncogenesis,IFR30, F-31059 Toulouse, France	Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Netherlands Cancer Institute; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Ferguson, Colin/AAY-2524-2021; Ivanov, Dmitri/B-4600-2011; Baird, Cheryl/AGM-0065-2022; Gozani, Or P/I-6157-2013; Cantley, Lewis C/D-1800-2014; Baird, Cheryl L/F-6569-2011	Ferguson, Colin/0000-0002-9021-4533; Cantley, Lewis C/0000-0002-1298-7653; Gozani, Or/0000-0002-1365-4463; divecha, nullin/0000-0001-9695-6039; Zhu, Hong/0000-0002-2575-4031; , Bernard/0000-0002-8693-0190; Field, Seth/0000-0002-8893-4806	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R42GM057705, R41GM057705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG019245, R01AG016674] Funding Source: NIH RePORTER; NIA NIH HHS [AG16674, KO8AG19245] Funding Source: Medline; NIGMS NIH HHS [GM36624, GM57705] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Aravind L, 2003, CELL CYCLE, V2, P123, DOI 10.4161/cc.2.2.335; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; DOWLER S, 2002, PROTEIN LIPID OVERLA; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; IRVINE R, 2000, NUCL LIPID SIGNALING; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lau WTW, 1998, GENETICS, V150, P1349; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Osborne SL, 2001, J CELL SCI, V114, P2501; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Watt SA, 2002, BIOCHEM J, V363, P657, DOI 10.1042/0264-6021:3630657; Yokogawa T, 2000, FEBS LETT, V473, P222, DOI 10.1016/S0014-5793(00)01535-0; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	56	400	415	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					99	111		10.1016/S0092-8674(03)00480-X	http://dx.doi.org/10.1016/S0092-8674(03)00480-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859901	Bronze			2022-12-28	WOS:000184219900009
J	Manzke, T; Guenther, U; Ponimaskin, EG; Haller, M; Dutschmann, M; Schwarzacher, S; Richter, DW				Manzke, T; Guenther, U; Ponimaskin, EG; Haller, M; Dutschmann, M; Schwarzacher, S; Richter, DW			5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia	SCIENCE			English	Article							5-HYDROXYTRYPTAMINE 4(A) RECEPTOR; ISOLATED RESPIRATORY NETWORK; PREBOTZINGER COMPLEX; RAT-BRAIN; NEURONS; PHARMACOLOGY; SEROTONIN; CLONING; RHYTHM	Opiates are widely used analgesics in anesthesiology, but they have serious adverse effects such as depression of breathing. This is caused by direct inhibition of rhythm-generating respiratory neurons in the Pre-Boetzinger complex (PBC) of the brainstem. We report that serotonin 4(a) [5-HT4(a)] receptors are strongly expressed in respiratory PBC neurons and that their selective activation protects spontaneous respiratory activity. Treatment of rats with a 5-HT4 receptor specific agonist overcame fentanyl-induced respiratory depression and reestablished stable respiratory rhythm without loss of fentanyl's analgesic effect. These findings imply the prospect of a fine-tuned recovery from opioid-induced respiratory depression, through adjustment of intracellular adenosine 3', 5'-monophosphate levels through the convergent signaling pathways in neurons.	Univ Gottingen, Dept Neuro & Sensory Physiol, D-37073 Gottingen, Germany; Univ Gottingen, Ctr Anesthesiol, D-37075 Gottingen, Germany; Dept Anat, D-37075 Gottingen, Germany	University of Gottingen; University of Gottingen	Richter, DW (corresponding author), Univ Gottingen, Dept Neuro & Sensory Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.			Ponimaskin, evgeni/0000-0002-4570-5130; Dutschmann, Mathias/0000-0002-0692-746X				Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BOCKAERT J, 1990, MOL PHARMACOL, V37, P408; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Compan V, 1996, EUR J NEUROSCI, V8, P2591, DOI 10.1111/j.1460-9568.1996.tb01553.x; DENAVITSAUBIE M, 1978, BRAIN RES, V155, P55, DOI 10.1016/0006-8993(78)90305-0; Dunn EB, 2000, VET HUM TOXICOL, V42, P36; Gray PA, 2001, NAT NEUROSCI, V4, P927, DOI 10.1038/nn0901-927; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Guyenet PG, 2001, J NEUROPHYSIOL, V86, P438, DOI 10.1152/jn.2001.86.1.438; Heine M, 2002, PFLUG ARCH EUR J PHY, V443, P418, DOI 10.1007/s004240100690; HOYER D, 1994, PHARMACOL REV, V46, P157; Hynie S, 1995, Cesk Fysiol, V44, P135; LI YW, 1997, AM J PHYSIOL, V273, P805; MANZKE T, 2002, FENS FOR ABSTR, V1, P77; MORIN D, 1990, BRAIN RES, V535, P281, DOI 10.1016/0006-8993(90)91611-J; PATON JF, 1996, J NEUROSCI METH, V65, P6; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Richter DW, 1997, RESP PHYSIOL, V110, P113, DOI 10.1016/S0034-5687(97)00077-7; Richter DW, 2000, NEUROSCIENTIST, V6, P181, DOI 10.1177/107385840000600309; SMITH JC, 1992, NEUROSCI LETT, V134, P153, DOI 10.1016/0304-3940(92)90504-Z; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Vilaro MT, 2002, NEUROPHARMACOLOGY, V42, P60, DOI 10.1016/S0028-3908(01)00154-X; Vilaro MT, 1996, MOL BRAIN RES, V43, P356, DOI 10.1016/S0169-328X(96)00248-3	25	204	230	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					226	229		10.1126/science.1084674	http://dx.doi.org/10.1126/science.1084674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855812				2022-12-28	WOS:000184056200047
J	Zavialov, AV; Ehrenberg, M				Zavialov, AV; Ehrenberg, M			Peptidyl-tRNA regulates the GTPase activity of translation factors	CELL			English	Article							ELONGATION-FACTOR-G; RIBOSOME RECYCLING FACTOR; ESCHERICHIA-COLI RIBOSOME; INITIATION-FACTOR IF2; RELEASE FACTORS; 70S RIBOSOME; TERMINATION COMPLEX; PROTEIN-SYNTHESIS; BINDING-SITES; GGQ MOTIF	Rapid protein synthesis in bacteria requires the G proteins IF2, EF-Tu, EF-G, and RF3. These factors catalyze all major steps of mRNA translation in a GTP-dependent manner. Here, it is shown how the position of peptidyl-tRNA in the ribosome and presence of its peptide control the binding and GTPase activity of these translation factors. The results explain how idling GTPase activity and negative interference between different translation factors are avoided and suggest that hybrid sites for tRNA on the ribosome play essential roles in translocation of tRNAs, recycling of class 1 release factors by RF3, and recycling of ribosomes back to a new round of initiation. We also propose a model for translocation of tRNAs in two separate steps, which clarifies the roles of EF-G(.)GTP and GTP hydrolysis in this process.	Uppsala Univ, BMC, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Uppsala University	Zavialov, AV (corresponding author), Uppsala Univ, BMC, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.			Zavialov, Andrey/0000-0001-6420-0368				Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; BURNS K, 1974, FEBS LETT, V40, P219, DOI 10.1016/0014-5793(74)80932-4; Cameron DM, 2002, J MOL BIOL, V319, P27, DOI 10.1016/S0022-2836(02)00235-8; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; INOUEYOKOSAWA N, 1974, J BIOL CHEM, V249, P4321; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Katunin VI, 2002, BIOCHEMISTRY-US, V41, P12806, DOI 10.1021/bi0264871; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; LAALAMI S, 1991, BIOCHIMIE, V73, P1557, DOI 10.1016/0300-9084(91)90191-3; Lancaster L, 2002, CELL, V111, P129, DOI 10.1016/S0092-8674(02)00938-8; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; Marquez V, 2002, BIOCHEM SOC T, V30, P133, DOI 10.1042/BST0300133; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; RUUSALA T, 1982, EMBO J, V1, P741, DOI 10.1002/j.1460-2075.1982.tb01240.x; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; THOMPSON RC, 1977, P NATL ACAD SCI USA, V74, P198, DOI 10.1073/pnas.74.1.198; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; Wu XQ, 1997, J BIOL CHEM, V272, P1891, DOI 10.1074/jbc.272.3.1891; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	34	112	117	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 11	2003	114	1					113	122		10.1016/S0092-8674(03)00478-1	http://dx.doi.org/10.1016/S0092-8674(03)00478-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859902	Bronze			2022-12-28	WOS:000184219900010
J	Wehrens, XHT; Lehnart, SE; Huang, F; Vest, JA; Reiken, SR; Mohler, PJ; Sun, J; Guatimosim, S; Song, LS; Rosemblit, N; D'Armiento, JM; Napolitano, C; Memmi, M; Priori, SG; Lederer, WJ; Marks, AR				Wehrens, XHT; Lehnart, SE; Huang, F; Vest, JA; Reiken, SR; Mohler, PJ; Sun, J; Guatimosim, S; Song, LS; Rosemblit, N; D'Armiento, JM; Napolitano, C; Memmi, M; Priori, SG; Lederer, WJ; Marks, AR			FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death	CELL			English	Article							POLYMORPHIC VENTRICULAR-TACHYCARDIA; FAILING HEARTS; PHOSPHORYLATION; PROTEIN; ARRHYTHMIAS; MECHANISMS; GENE; AFTERDEPOLARIZATIONS; MUTATIONS; FAILURE	Arrhythmias, a common cause of sudden cardiac death, can occur in structurally normal hearts, although the mechanism is not known. In cardiac muscle, the ryanodine receptor (RyR2) on the sarcoplasmic reticulum releases the calcium required for muscle contraction. The FK506 binding protein (FKBP12.6) stabilizes RyR2, preventing aberrant activation of the channel during the resting phase of the cardiac cycle. We show that during exercise, RyR2 phosphorylation by cAMP-dependent protein kinase A (PKA) partially dissociates FKBP12.6 from the channel, increasing intracellular Ca2+ release and cardiac contractility. FKBP12.6(-/-) mice consistently exhibited exercise-induced cardiac ventricular arrhythmias that cause sudden cardiac death. Mutations in RyR2 linked to exercise-induced arrhythmias (in patients with catecholaminergic polymorphic ventricular tachycardia [CPVT]) reduced the affinity of FKBP12.6 for RyR2 and increased single-channel activity under conditions that simulate exercise. These data suggest that "leaky" RyR2 channels can trigger fatal cardiac arrhythmias, providing a possible explanation for CPVT.	Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Dept Med, Ctr Mol Cardiol, New York, NY 10032 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA; Univ Maryland, Sch Med, Dept Physiol, Biotechnol Inst,Med Biotechnol Ctr, Baltimore, MD 21201 USA; Univ Pavia, IRCCS, I-27100 Pavia, Italy	Columbia University; Duke University; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore; University of Pavia	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, Dept Med, Ctr Mol Cardiol, 630 W 168th St, New York, NY 10032 USA.		Wehrens, Xander/AAQ-9574-2020; memmi, mirella/AAB-9428-2020; Lederer, William/B-1285-2010; Priori, Silvia G/ABH-6894-2020; Song, Long-Sheng/D-5899-2012; Napolitano, Carlo/K-4760-2016; napolitano, carlo/ABI-4608-2020; Guatimosim, Silvia/AAN-7441-2021; Priori, Silvia G G/A-6116-2014	Wehrens, Xander/0000-0001-5044-672X; memmi, mirella/0000-0003-4006-5661; Priori, Silvia G/0000-0001-6877-0288; Napolitano, Carlo/0000-0002-7643-4628; napolitano, carlo/0000-0002-7643-4628; Guatimosim, Silvia/0000-0001-8386-3722; Priori, Silvia G G/0000-0001-6877-0288; Song, Long-Sheng/0000-0002-6035-8106	Telethon [GP0227Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Bennett JA, 1998, MAMM GENOME, V9, P1069, DOI 10.1007/s003359900928; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Fisher JD, 1999, J AM COLL CARDIOL, V34, P2015, DOI 10.1016/S0735-1097(99)00438-6; FOZZARD HA, 1992, BASIC RES CARDIOL, V87, P105; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Jiang DW, 2002, CIRC RES, V91, P218, DOI 10.1161/01.RES.0000028455.36940.5E; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Laitinen PJ, 2001, CIRCULATION, V103, P485, DOI 10.1161/01.CIR.103.4.485; LEENHARDT A, 1995, CIRCULATION, V91, P1512, DOI 10.1161/01.CIR.91.5.1512; MARBAN E, 1986, J CLIN INVEST, V78, P1185, DOI 10.1172/JCI112701; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Pogwizd SM, 2001, CIRC RES, V88, P1159, DOI 10.1161/hh1101.091193; Pogwizd SM, 1998, CIRCULATION, V98, P2404, DOI 10.1161/01.CIR.98.22.2404; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; Priori SG, 2001, CIRCULATION, V103, P196; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; SONG YJ, 1994, AM J PHYSIOL-HEART C, V267, pH2005, DOI 10.1152/ajpheart.1994.267.5.H2005; Swan H, 1999, J AM COLL CARDIOL, V34, P2035, DOI 10.1016/S0735-1097(99)00461-1; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIT AL, 1983, AM HEART J, V106, P798, DOI 10.1016/0002-8703(83)90003-0; Xin HB, 2002, NATURE, V416, P334, DOI 10.1038/416334a	29	552	587	1	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					829	840		10.1016/S0092-8674(03)00434-3	http://dx.doi.org/10.1016/S0092-8674(03)00434-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837242	Bronze			2022-12-28	WOS:000183817900008
J	Basole, A; White, LE; Fitzpatrick, D				Basole, A; White, LE; Fitzpatrick, D			Mapping multiple features in the population response of visual cortex	NATURE			English	Article							CATS STRIATE CORTEX; COMPLEX CELLS; SPATIAL-FREQUENCY; DOT PATTERNS; DIRECTION; MOTION; MAPS; ORIENTATION; ORGANIZATION; SELECTIVITY	Stimulus features such as edge orientation, motion direction and spatial frequency are thought to be encoded in the primary visual cortex by overlapping feature maps arranged so that the location of neurons activated by a particular combination of stimulus features can be predicted from the intersections of these maps(1-8). This view is based on the use of grating stimuli, which limit the range of stimulus combinations that can be examined. We used optical imaging of intrinsic signals(9) in ferrets to assess patterns of population activity evoked by the motion of a texture ( a field of iso-oriented bars). Here we show that the same neural population can be activated by multiple combinations of orientation, length, motion axis and speed. Rather than reflecting the intersection of multiple maps, our results indicate that population activity in primary visual cortex is better described as a single map of spatiotemporal energy.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA	Duke University; Duke University	Fitzpatrick, D (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.							ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; Bonhoeffer Tobias, 1996, P55; Carandini M., 1999, CEREB CORTEX, V13, P401, DOI DOI 10.1007/978-1-4615-4903-1_7; DEVALOIS KK, 1979, J PHYSIOL-LONDON, V291, P483, DOI 10.1113/jphysiol.1979.sp012827; DeValois RL, 1988, SPATIAL VISION; Everson RM, 1998, P NATL ACAD SCI USA, V95, P8334, DOI 10.1073/pnas.95.14.8334; GALUSKE RAW, 2001, SOC NEUR ABSTR, V27; Geisler WS, 2001, VISUAL NEUROSCI, V18, P501, DOI 10.1017/S0952523801184014; GILBERT CD, 1977, J PHYSIOL-LONDON, V268, P391, DOI 10.1113/jphysiol.1977.sp011863; GIZZI MS, 1990, J NEUROPHYSIOL, V63, P1529, DOI 10.1152/jn.1990.63.6.1529; HAMMOND P, 1983, J PHYSIOL-LONDON, V342, P35, DOI 10.1113/jphysiol.1983.sp014838; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; Hubener M, 1997, J NEUROSCI, V17, P9270; Issa NP, 2000, J NEUROSCI, V20, P8504, DOI 10.1523/JNEUROSCI.20-22-08504.2000; LORENCEAU J, 1993, VISION RES, V33, P1207, DOI 10.1016/0042-6989(93)90209-F; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P79, DOI 10.1113/jphysiol.1978.sp012489; Pack CC, 2001, NATURE, V409, P1040, DOI 10.1038/35059085; Shmuel A, 1996, J NEUROSCI, V16, P6945; Shoham D, 1997, NATURE, V385, P529, DOI 10.1038/385529a0; SKOTTUN BC, 1988, J NEUROPHYSIOL, V59, P1719, DOI 10.1152/jn.1988.59.6.1719; SKOTTUN BC, 1994, VISUAL NEUROSCI, V11, P885, DOI 10.1017/S0952523800003849; Swindale NV, 2000, CEREB CORTEX, V10, P633, DOI 10.1093/cercor/10.7.633; Swindale NV, 2000, NAT NEUROSCI, V3, P822, DOI 10.1038/77731; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; White LE, 1999, J NEUROSCI, V19, P7089, DOI 10.1523/JNEUROSCI.19-16-07089.1999; Wuerger S, 1996, PERCEPTION, V25, P1317, DOI 10.1068/p251317	29	128	131	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					986	990		10.1038/nature01721	http://dx.doi.org/10.1038/nature01721			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827202				2022-12-28	WOS:000183753900050
J	DiMauro, S; Schon, EA				DiMauro, S; Schon, EA			Mechanisms of disease: Mitochondrial respiratory-chain diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COMPLEX-II GENE; MULTIPLE DELETIONS; DNA DEPLETION; SPASTIC PARAPLEGIA; THYMIDINE KINASE; OPTIC ATROPHY; MUTATIONS; PROTEIN; MTDNA		Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	sd12@columbia.edu			NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS28828, NS39854, NS11766] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, R01NS028828, P01NS011766, R01NS039854] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489; Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200; Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Beal M.F., 2002, MITOCHONDRIAL DISORD, P17, DOI [10.1007/978-2-8178-0929-8_3, DOI 10.1007/978-2-8178-0929-8_3]; Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A; Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329; Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Carelli V., 2002, MITOCHONDRIAL DISORD, P115; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; CHEN X, 1995, AM J HUM GENET, V57, P239; Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426; Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222; de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0; DiMauro S, 2002, ADV NEUROL, V89, P217; DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194; DiMauro S, 2000, NEUROL SCI, V21, pS901; DIMAURO S, 1996, MOL GENETIC BASIS NE, P201; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FENTON WA, 1995, AM J HUM GENET, V57, P235; Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695; Gimm O, 2000, CANCER RES, V60, P6822; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; Hirano M, 2001, CURR OPIN CARDIOL, V16, P201, DOI 10.1097/00001573-200105000-00008; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931; Langin D, 2002, NEW ENGL J MED, V346, P634; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A; Mandel H, 2001, NAT GENET, V29, P491, DOI 10.1038/ng1201-491a; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Nishino I, 2000, ANN NEUROL, V47, P792; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284; Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176; Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053; Servidei Serenella, 2002, Neuromuscul Disord, V12, P101; Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378; Shoubridge EA, 2001, SEMIN NEUROL, V21, P261, DOI 10.1055/s-2001-17943; Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277; Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spelbrink JN, 2001, NAT GENET, V29, P100; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Sue CM, 2000, BRAIN PATHOL, V10, P442; Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244; Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047; Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Visapaa I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Zeviani M, 2001, SEMIN CELL DEV BIOL, V12, P407, DOI 10.1006/scdb.2001.0278	85	1146	1213	1	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2656	2668		10.1056/NEJMra022567	http://dx.doi.org/10.1056/NEJMra022567			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826641				2022-12-28	WOS:000183726400010
J	Ghazanfar, AA; Logothetis, NK				Ghazanfar, AA; Logothetis, NK			Neuroperception: Facial expressions linked to monkey calls	NATURE			English	Editorial Material							PERCEPTION; SPEECH; LIPS		Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany	Max Planck Society	Ghazanfar, AA (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	asifg@tuebingen.mpg.de	Logothetis, Nikos/U-9282-2019					Darwin C., 1872, EXPRESSION EMOTION A; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; HAUSER MD, 1993, ANIM BEHAV, V45, P423, DOI 10.1006/anbe.1993.1054; HINDE R. A., 1962, PROC ZOOL SOC LONDON, V138, P1; KUHL PK, 1982, SCIENCE, V218, P1138, DOI 10.1126/science.7146899; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; Partan SR, 2002, BEHAVIOUR, V139, P993, DOI 10.1163/15685390260337877; Patterson ML, 1999, INFANT BEHAV DEV, V22, P237, DOI 10.1016/S0163-6383(99)00003-X; ROWELL T. E., 1962, PROC ZOOL SOC LONDON, V138, P279; SUMBY WH, 1954, J ACOUST SOC AM, V26, P212, DOI 10.1121/1.1907309	11	132	133	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					937	938		10.1038/423937a	http://dx.doi.org/10.1038/423937a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	694BL	12827188				2022-12-28	WOS:000183753900035
J	Kramer, HJ; Nguyen, QD; Curhan, G; Hsu, CY				Kramer, HJ; Nguyen, QD; Curhan, G; Hsu, CY			Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERIAL-HYPERTENSION; NEPHROPATHY; PREVALENCE; MICROALBUMINURIA; DISEASE; CREATININE; PREDICTION; HEALTH; STAGE	Context Kidney disease in type 2 diabetes mellitus (DM) is more heterogeneous than in type 1 DM. Reduced glomerular-filtration rate (GFR) among individuals with type 2 DM may not always be due to classic diabetic glomerulosclerosis, which is associated with albuminuria and retinopathy. Objective To determine the prevalence of chronic renal insufficiency (CRI), defined as a GFR less than 60 mL/min per 1.73 m(2) body surface area (BSA) in the absence of microalbuminuria or macroalbuminuria and diabetic retinopathy among adults with type 2 DM. Design, Setting, and Participants Cross-sectional analysis of adults aged 40 years or older with type 2 DM in the Third National Health and Nutrition Examination Survey, a probability sample of the total civilian US non institutionalized population conducted from 1988-1994. Main Outcome Measures The GFR per 1.73 m(2) BSA, calculated with serum creatinine, urea nitrogen, and serum albumin levels using the Modification of Diet in Renal Disease Study prediction equation; albuminuria, assessed using spot urine albumin/ creatinine ratio; and presence of retinopathy, determined with fundus photography. Results Overall, 13% (sampled n=171) of adults with type 2 DM (n=1197) had CRI with a population estimate of 1.1 million. Among these adults with CRI, diabetic retinopathy was noted in 28% (n=58), while the frequencies of microalbuminuria and macroalbuminuria were 45% (n=64) and 19% (n=47), respectively. Retinopathy and albuminuria (microalbuminuria or macroalbuminuria) were both absent in 30% (n=51) of adults with type 2 DM and CRI. The population estimate of adults with type 2 DM and CRI in the absence of diabetic retinopathy or albuminuria was approximately 0.3 million. Conclusions A substantial burden of CRI among persons with type 2 DM in the United States is likely due to renal parenchymal disease other than classic diabetic glomerulosclerosis. Approaches to screening renal disease in the type 2 DM population should incorporate assessment of GFR in addition to monitoring urine albumin excretion and funduscopic changes to ensure that individuals with type 2 DM and CRI not due to diabetic glomerulosclerosis will receive appropriate intervention.	Loyola Univ, Med Ctr, Dept Epidemiol & Prevent Med, Div Nephrol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Div Nephrol, Maywood, IL 60153 USA; Johns Hopkins Med Inst, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA; Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA	Loyola University Chicago; Loyola University Chicago; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco	Kramer, HJ (corresponding author), Loyola Univ, Med Ctr, Dept Epidemiol & Prevent Med, Div Nephrol, 2160 S 1st Ave, Maywood, IL 60153 USA.	hkramer@lumc.edu		Hsu, Chi-yuan/0000-0001-8182-1238; Kramer, Holly/0000-0002-6374-837X	NATIONAL EYE INSTITUTE [K23EY013552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052866, K23DK061520] Funding Source: NIH RePORTER; NEI NIH HHS [EY13552] Funding Source: Medline; NIDDK NIH HHS [DK61520, DK52866] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; GALL MA, 1991, DIABETOLOGIA, V34, P655, DOI 10.1007/BF00400995; Gavin JR, 1997, DIABETES CARE, V20, P1183; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; *NIH NAT I DIAB DI, 2002, USRDS 2002 ANN DAT R; OLSON JL, 1998, HEPTINSTALLS PATHOLO, P1247; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Remuzzi G, 2002, NEW ENGL J MED, V346, P1145, DOI 10.1056/NEJMcp011773; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; Rychlik I., 1999, NEPHROPATHY TYPE 2 D, P7; VIBERTI GC, 1982, LANCET, V1, P1430; Warram JH, 1996, J AM SOC NEPHROL, V7, P930; Wilmer WA, 1999, AM J KIDNEY DIS, V34, P308, DOI 10.1016/S0272-6386(99)70360-4; Xue JL, 2001, J AM SOC NEPHROL, V12, P2753, DOI 10.1681/ASN.V12122753	26	433	470	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3273	3277		10.1001/jama.289.24.3273	http://dx.doi.org/10.1001/jama.289.24.3273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824208	Bronze			2022-12-28	WOS:000183704600020
J	Thomas, KW; Hunninghake, GW				Thomas, KW; Hunninghake, GW			Sarcoidosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PULMONARY SARCOIDOSIS; CORTICOSTEROID-THERAPY; PROGNOSIS; HOKKAIDO; FINLAND; JAPAN; EPIDEMIOLOGY; MAINTENANCE; 5-YEAR; BIOPSY		Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Thomas, KW (corresponding author), Univ Iowa Hosp & Clin, Div Pulm Crit Care & Occupat Med, 200 Hawkins Dr,C-33 GH, Iowa City, IA 52242 USA.	karl-thomas@uiowa.edu			NHLBI NIH HHS [HL60316-05] Funding Source: Medline; NIEHS NIH HHS [ES09607-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046; Baughman RP, 2001, SARCOIDOSIS VASC DIF, V18, P70; Berlin M, 1997, AM J RESP CRIT CARE, V156, P1601, DOI 10.1164/ajrccm.156.5.9704069; Capelli A, 2002, AM J RESP CRIT CARE, V165, P236, DOI 10.1164/ajrccm.165.2.2106084; Chappell AG, 2000, SARCOIDOSIS VASC DIF, V17, P167; Costabel U, 2001, EUR RESPIR J, V18, p56S; EDMONDSTONE WM, 1985, BRIT J DIS CHEST, V79, P27, DOI 10.1016/0007-0971(85)90004-X; HILLERDAL G, 1984, AM REV RESPIR DIS, V130, P29; HUNNINGHAKE CW, 1994, AM J RESP CRIT CARE, V149, P893, DOI 10.1164/ajrccm.149.4.8143052; HUNNINGHAKE GW, 1980, NEW ENGL J MED, V302, P594, DOI 10.1056/NEJM198003133021102; Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; Judson MA, 2003, CHEST, V123, P406, DOI 10.1378/chest.123.2.406; Kajdasz DK, 2001, ANN EPIDEMIOL, V11, P111, DOI 10.1016/S1047-2797(00)00179-4; Mana J, 1999, AM J MED, V107, P240, DOI 10.1016/S0002-9343(99)00223-5; NEVILLE E, 1983, Q J MED, V52, P525; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Paramothayan S, 2002, JAMA-J AM MED ASSOC, V287, P1301, DOI 10.1001/jama.287.10.1301; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420; PIETINALHO A, 1995, SARCOIDOSIS, V12, P61; Pietinalho A, 1996, SARCOIDOSIS VASC DIF, V13, P159; Pietinalho A, 2000, SARCOIDOSIS VASC DIF, V17, P158; Prezant DJ, 1999, CHEST, V116, P1183, DOI 10.1378/chest.116.5.1183; Reich JM, 2002, CHEST, V121, P32, DOI 10.1378/chest.121.1.32; Rybicki BA, 1997, AM J EPIDEMIOL, V145, P234, DOI 10.1093/oxfordjournals.aje.a009096; Rybicki BA, 2003, AM J RESP CRIT CARE, V167, P444, DOI 10.1164/rccm.2112060; Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001; Schurmann M, 2001, AM J RESP CRIT CARE, V164, P840, DOI 10.1164/ajrccm.164.5.2007056; Shigehara K, 2003, CLIN EXP IMMUNOL, V132, P152, DOI 10.1046/j.1365-2249.2003.02105.x; SILTZBACH LE, 1974, AM J MED, V57, P847, DOI 10.1016/0002-9343(74)90160-0; Tambouret R, 2000, CHEST, V117, P1004, DOI 10.1378/chest.117.4.1004; TURNERWARWICK M, 1986, THORAX, V41, P903, DOI 10.1136/thx.41.12.903; Wells A, 1998, SARCOIDOSIS VASC DIF, V15, P140; 1997, MMWR MORB MORTAL WKL, V46, P539	34	160	165	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3300	3303		10.1001/jama.289.24.3300	http://dx.doi.org/10.1001/jama.289.24.3300			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824213				2022-12-28	WOS:000183704600025
J	James, A				James, A			The Wakley Prize 2003	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		James, A (corresponding author), The Lancet, London NW1 7BY, England.							de Costa C, 2001, LANCET, V358, P2162, DOI 10.1016/S0140-6736(01)07228-2; Karlawish J, 1997, LANCET, V350, P1833, DOI 10.1016/S0140-6736(97)11309-5; Loefler IJP, 1996, LANCET, V348, P1703, DOI 10.1016/S0140-6736(96)12006-7; Nauwelaers J, 2000, LANCET, V356, P2169, DOI 10.1016/S0140-6736(00)03505-4; Parrish AG, 2002, LANCET, V360, P2059, DOI 10.1016/S0140-6736(02)11996-9; Power L, 1998, LANCET, V352, P1999, DOI 10.1016/S0140-6736(98)11283-7; Whitty CJM, 1999, LANCET, V354, P2147, DOI 10.1016/S0140-6736(99)11155-3	7	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2098	2098		10.1016/S0140-6736(03)13730-0	http://dx.doi.org/10.1016/S0140-6736(03)13730-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826430				2022-12-28	WOS:000183654200006
J	Zhou, Q; Tao, HZW; Poo, MM				Zhou, Q; Tao, HZW; Poo, MM			Reversal and stabilization of synaptic modifications in a developing visual system	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEVELOPING RETINOTECTAL SYNAPSES; LOW-FREQUENCY STIMULATION; NMDA RECEPTOR; IN-VIVO; PLASTICITY; MEMORY; INPUT; LTP; HIPPOCAMPUS	Persistent synaptic modi. cations are essential for experience-dependent refinement of developing circuits. However, in the developing Xenopus retinotectal system, activity-induced synaptic modi. cations were quickly reversed either by subsequent spontaneous activity in the tectum or by exposure to random visual inputs. This reversal depended on the burst spiking and activation of the N-methyl-D-aspartate subtype of glutamate receptors. Stabilization of synaptic modi. cations can be achieved by an appropriately spaced pattern of induction stimuli. These findings underscore the vulnerable nature of activity-induced synaptic modi. cations in vivo and suggest a temporal constraint on the pattern of visual inputs for effective induction of stable synaptic modifications.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Poo, MM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.		Tao, Huizhong W/HDM-9767-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036999] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 36999] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Dudai Y, 2002, CURR OPIN NEUROBIOL, V12, P211, DOI 10.1016/S0959-4388(02)00305-7; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Engert F, 2002, NATURE, V419, P470, DOI 10.1038/nature00988; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Huang CC, 1999, J NEUROSCI, V19, P9728; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; LARSON J, 1993, BRAIN RES, V600, P97, DOI 10.1016/0006-8993(93)90406-D; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; O'Dell T J, 1994, Learn Mem, V1, P129; Penn AA, 1999, PEDIATR RES, V45, P447, DOI 10.1203/00006450-199904010-00001; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Staubli U, 1996, J NEUROSCI, V16, P853; Tao HZW, 2001, NEURON, V31, P569, DOI 10.1016/S0896-6273(01)00393-2; Udin SB, 1999, PROG NEUROBIOL, V59, P81, DOI 10.1016/S0301-0082(98)00096-3; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665; Zhang LI, 2000, NAT NEUROSCI, V3, P708, DOI 10.1038/76665; Zhang LI, 2001, NAT NEUROSCI, V4, P1207, DOI 10.1038/nn753	24	115	117	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1953	1957		10.1126/science.1082212	http://dx.doi.org/10.1126/science.1082212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817152				2022-12-28	WOS:000183619400050
J	Asada, S; Kawasaki, T				Asada, S; Kawasaki, T			Emphysematous cystitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Matsushita Mem Hosp, Osaka 5708540, Japan		Asada, S (corresponding author), Matsushita Mem Hosp, Osaka 5708540, Japan.								0	11	11	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					258	258		10.1056/NEJMicm020703	http://dx.doi.org/10.1056/NEJMicm020703			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867609				2022-12-28	WOS:000184165700009
J	Chen, GN; Yanofsky, C				Chen, GN; Yanofsky, C			Tandem transcription and translation regulatory sensing of uncharged tryptophan tRNA	SCIENCE			English	Article							BINDING ATTENUATION PROTEIN; BACILLUS-SUBTILIS; LEADER RNA; TRAP; EXPRESSION; TRPG; REPEATS; GENES	The Bacillus subtilis AT (anti-TRAP) protein inhibits the regulatory protein TRAP (trp RNA-binding attenuation protein), thereby eliminating transcription termination in the leader region of the trp operon. Transcription of the AT operon is activated by uncharged tryptophan transfer RNA (tRNA(Trp)). Here we show that translation of AT also is regulated by uncharged tRNATrp. A 10-residue coding region containing three consecutive tryptophan codons is located immediately preceding the AT structural gene. Completion of translation of this coding region inhibits AT synthesis, whereas incomplete translation increases AT production. Tandem sensing of uncharged tRNATrp therefore regulates synthesis of AT, which in turn regulates TRAP's ability to inhibit trp operon expression.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	yanofsky@cmgm.stanford.edu						Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; GOLLNICK P, 2001, BACILLUS SUBTILIS IT, P233; Henkin TM, 2000, CURR OPIN MICROBIOL, V3, P149, DOI 10.1016/S1369-5274(00)00067-9; Henner Dennis, 1993, P269; Lee AI, 1996, J BACTERIOL, V178, P6518, DOI 10.1128/jb.178.22.6518-6524.1996; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, P NATL ACAD SCI USA, V97, P2656, DOI 10.1073/pnas.050578997; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEKIGUCHI J, 1975, J BACTERIOL, V121, P688, DOI 10.1128/JB.121.2.688-694.1975; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; STEINBERG W, 1974, J BACTERIOL, V117, P1023, DOI 10.1128/JB.117.3.1023-1034.1974; Sudershana S, 1999, J BACTERIOL, V181, P5742, DOI 10.1128/JB.181.18.5742-5749.1999; Valbuzzi A, 2001, SCIENCE, V293, P2057, DOI 10.1126/science.1062187; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995	25	26	27	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					211	213		10.1126/science.1084902	http://dx.doi.org/10.1126/science.1084902			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855807				2022-12-28	WOS:000184056200042
J	Wekerle, H; Hohlfeld, R				Wekerle, H; Hohlfeld, R			Molecular mimicry in multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYELIN BASIC-PROTEIN; STRUCTURAL BASIS; HLA-DR2		Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany	Max Planck Society	Wekerle, H (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Martinsried, Germany.							Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	5	44	46	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					185	186		10.1056/NEJMcibr035136	http://dx.doi.org/10.1056/NEJMcibr035136			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853593				2022-12-28	WOS:000184024400014
J	Davis, D; Evans, M; Jadad, A; Perrier, L; Rath, D; Ryan, D; Sibbald, G; Straus, S; Rappolt, S; Wowk, M; Zwarenstein, M				Davis, D; Evans, M; Jadad, A; Perrier, L; Rath, D; Ryan, D; Sibbald, G; Straus, S; Rappolt, S; Wowk, M; Zwarenstein, M			The case for knowledge translation: shortening the journey from evidence to effect	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIAL; PHYSICIAN; EDUCATION; QUALITY; CARE		Univ Toronto, Fac Med, Knowledge Translat Programme, Toronto, ON M5G 1VJ, Canada; Univ Toronto, Fac Med, Ctr Global eHlth Innovat, Toronto, ON M5G 1VJ, Canada; Univ Toronto, Fac Med, Dept Med, Toronto, ON M5G 1VJ, Canada	University of Toronto; University of Toronto; University of Toronto	Davis, D (corresponding author), Univ Toronto, Fac Med, Knowledge Translat Programme, Toronto, ON M5G 1VJ, Canada.	dave.davis@utoronto.ca	Greiver, Michelle/N-8764-2015; Zwarenstein, Merrick F/P-5210-2014; Perrier, Laure/D-4638-2011	Greiver, Michelle/0000-0001-8957-0285; Zwarenstein, Merrick F/0000-0003-0162-7027; Perrier, Laure/0000-0001-9941-7129				Bandura A., 1986, SOCIAL FDN THOUGHT A; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; *CAN I HLTH RES, KNOWL TRANSL FRAM; Candy P. C., 1991, SELF DIRECTION LIFE; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 2002, CONTINUING PROFESSIO, P9; DICENSO A, 2002, HOSP Q, V25, P55; Eisenberg MJ, 1997, AM J CARDIOL, V79, P867, DOI 10.1016/S0002-9149(97)00005-2; Fox RD., 1989, CHANGING LEARNING LI; GEERTSMA RH, 1982, J MED EDUC, V57, P752; Green LW., 1980, HLTH ED PLANNING DIA, V1; Grimshaw JM, 2001, MED CARE, V39, pII2; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Knowles MS, 1998, ADULT LEARNER DEFINI; MILLER GE, 1967, J MED EDUC, V42, P320; Mowatt G, 2001, J Contin Educ Health Prof, V21, P55, DOI 10.1002/chp.1340210109; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; Schon D.A., 1990, ED REFLECTIVE PRACTI; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P525; Tu K, 2003, CAN MED ASSOC J, V168, P553; Tyler RW., 1949, BASIC PRINCIPLES CUR; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wenger Etienne., 1998, COMMUNITIES PRACTICE, V18th ed; Wennberg DE, 1996, JAMA-J AM MED ASSOC, V275, P1161, DOI 10.1001/jama.275.15.1161	28	431	442	1	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2003	327	7405					33	35		10.1136/bmj.327.7405.33	http://dx.doi.org/10.1136/bmj.327.7405.33			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699NK	12842955	Green Published, Bronze			2022-12-28	WOS:000184062700025
J	Fearnhead, NS				Fearnhead, NS			Familial adenomatous polyposis and MYH	LANCET			English	Editorial Material							SOMATIC G-C->T-A MUTATIONS; ESCHERICHIA-COLI; DNA-SYNTHESIS; MUTY GENE; CLONING; EXPRESSION; HOMOLOG; ENZYME; REPAIR; CDNA		John Radcliffe Hosp, Dept Colorectal Surg, Oxford OX3 9DU, England; Canc Res UK, Weatherall Inst Mol Med, Canc Immunogenet Lab, Oxford, England	University of Oxford; Cancer Research UK; University of Oxford	Fearnhead, NS (corresponding author), John Radcliffe Hosp, Dept Colorectal Surg, Oxford OX3 9DU, England.							Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996	11	12	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					5	6		10.1016/S0140-6736(03)13844-5	http://dx.doi.org/10.1016/S0140-6736(03)13844-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853190				2022-12-28	WOS:000184056900004
J	Jones, G; Steketee, RW; Black, RE; Bhutta, ZA; Morris, SS				Jones, G; Steketee, RW; Black, RE; Bhutta, ZA; Morris, SS		Bellagio Child Survival Study Grp	How many child deaths can we prevent this year?	LANCET			English	Article							PERENNIAL MALARIA TRANSMISSION; ORAL REHYDRATION THERAPY; TREATED BED NETS; DEVELOPING-COUNTRIES; NEONATAL-MORTALITY; RANDOMIZED TRIAL; WESTERN KENYA; YOUNG-CHILDREN; DIARRHEA; TETANUS	This is the second of five papers in the child survival series. The first focused on continuing high rates of child mortality (over 10 million each year) from preventable causes: diarrhoea, pneumonia, measles, malaria, HIV/AIDS, the underlying cause of undernutrition, and a small group of causes leading to neonatal deaths. We review child survival interventions feasible for delivery at high coverage in low-income. settings, and classify these as level 1 (sufficient evidence of effect), level 2 (limited evidence), or level 3 (inadequate evidence). Our results show that at least one level-1 intervention is available for preventing or treating each main cause of death among children younger than 5 years, apart from birth asphyxia, for which a level-2 intervention is available. There is also limited evidence for several other interventions. However, global coverage for most interventions is below 50%. If level 1 or 2 interventions were universally available, 63% of child deaths could be prevented. These findings show that the interventions needed to achieve the millennium development goal of reducing child mortality by two-thirds by 2015 are available, but that they are not being delivered to the mothers and children who need them.	UN Childrens Fund, Div Policy & Planning, New York, NY 10017 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA; Johns Hopkins Bloomberg Sch Publ Hlth, Div Int Hlth, Baltimore, MD USA; Aga Khan Univ, Dept Paediat, Karachi, Pakistan; London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, London WC1, England	Centers for Disease Control & Prevention - USA; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Aga Khan University; University of London; London School of Hygiene & Tropical Medicine	Jones, G (corresponding author), UN Childrens Fund, Div Policy & Planning, 3 UN Plaza, New York, NY 10017 USA.	gjones@unicef.org		Black, Robert/0000-0001-9926-7984; Morris, Saul/0000-0002-9372-7342				Aaby P, 1996, T ROY SOC TROP MED H, V90, P326, DOI 10.1016/S0035-9203(96)90275-8; Arifeen S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e67; ASHRAF RN, 1991, ARCH DIS CHILD, V66, P488, DOI 10.1136/adc.66.4.488; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; BEATON GH, 1993, ACC SCN STAT ART SER; BHUTTA Z, 2003, USING EVIDENCE SAVE; Bhutta ZA, 1997, AM J PERINAT, V14, P577, DOI 10.1055/s-2007-994338; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BOERMA JT, 1991, DEMOGRAPHIC HLTH SUR, V4; Brabin BJ, 2001, J NUTR, V131, p636S, DOI 10.1093/jn/131.2.636S; BRYCE J, IN PRESS LANCET; Caufield LE, 1999, FOOD NUTR BULL, V20, P183; CAULFIELD L, 2003, IN PRESS COMP QUANTI; CONDEAGUDELO A, 2003, COCHRANE LIB; CROWLEY P, 2002, COCHRANE LIB; Cunliffe NA, 2002, J INFECTION, V45, P1, DOI 10.1053/jinf.2002.1012; DAlessandro U, 1996, T ROY SOC TROP MED H, V90, P487, DOI 10.1016/S0035-9203(96)90289-8; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Deorari AK, 2001, ANN TROP PAEDIATR, V21, P29, DOI 10.1080/02724930020028885; ESREY SA, 1985, B WORLD HEALTH ORGAN, V63, P757; FISHMAN S, IN PRESS COMP QUANTI; Gosavi DV, 1998, TROP DOCT, V28, P101, DOI 10.1177/004947559802800217; GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q; Hawley WA, 2003, AM J TROP MED HYG, V68, P168, DOI 10.4269/ajtmh.2003.68.168; HILL Z, IN PRESS FAMILY COMM; *IARC, IARC MON PROGR EV CA; KENYON S, 2002, COCHRANE LIB; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; LENGELER C, 2003, COCHRANE LIB; *MACR INT, DEM HLTH SURV; MILLS A, 2002, IMPROVING HLTH OUTCO; Mosley WH, 1984, POPUL DEV REV, V10, P25, DOI 10.2307/2807954; Muhuri PK, 1996, B WORLD HEALTH ORGAN, V74, P135; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; RAHMAN M, 1982, B WORLD HEALTH ORGAN, V60, P261; RAHMAN S, 1982, J TROP PEDIATRICS, V28, P163, DOI 10.1093/tropej/28.4.163; RICE AL, 2003, IN PRESS COMP QUANTI; SACK DA, 1991, DRUGS, V41, P566, DOI 10.2165/00003495-199141040-00005; SALAM MA, 1991, REV INFECT DIS, V13, pS332; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; SETTYVENUGOPAL V, 2002, POPULATION REPORTS L, V13; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; STROH G, 1987, B WORLD HEALTH ORGAN, V65, P309; ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50, DOI 10.4269/ajtmh.2003.68.50; Tulloch J, 1999, LANCET, V354, pS16; *UN GEN ASS, 2001, ROAP MAP IMPL UN MIL; UNICEF, 2003, STAT WORLDS CHILDR 2; United Nations Children's Fund (UNICEF), MULT IND CLUST SURV; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; VICTORA CG, IN PRESS LANCET; West KP, 2002, J NUTR, V132, p2857S, DOI 10.1093/jn/132.9.2857S; World Health Organization, WORLD HLTH REP 2002; World Health Organization, 2001, OPT DUR EXCL BREASTF; World Health Organization Expert Committee on Nutrition, 1995, PHYS STAT US INT ANT; World Health Organization (WHO), 2001, PREV MOTH TO CHILD T; 1987, WKLY EPIDEMIOL REC, V62, P332	62	1534	1587	0	94	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2003	362	9377					65	71		10.1016/S0140-6736(03)13811-1	http://dx.doi.org/10.1016/S0140-6736(03)13811-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853204				2022-12-28	WOS:000184056900026
J	Orofino, MG; Argiolu, F; Sanna, MA; Rosatelli, MC; Tuveri, T; Scalas, MT; Badiali, M; Cossu, P; Puddu, R; Lai, ME; Cao, A				Orofino, MG; Argiolu, F; Sanna, MA; Rosatelli, MC; Tuveri, T; Scalas, MT; Badiali, M; Cossu, P; Puddu, R; Lai, ME; Cao, A			Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation	LANCET			English	Article								Stem-cell transplantation can cure beta thalassaemia. We aimed to assess whether fetal HLA typing done early in the-pregnancy of couples who were at risk of beta thalassaemia could provide an alternative to pregnancy termination if the prospect of a bone-marrow transplantation from a family member was available. In our clinic in Sardinia, we did fetal HLA typing for 49 couples at risk of having a baby with beta thalassaemia. Two affected children were born and successfully received a transplantation from a family donor. Five non-affected fetuses were HLA compatible with an affected sibling and their cord blood was harvested for a future transplantation.	Univ Cagliari, Dept Biomed Sci & Biotechnol, Paediat Clin Bone Marrow Transplant Ctr, Cagliari, Italy	University of Cagliari	Argiolu, F (corresponding author), Univ Cagliari, Dept Biomed Sci & Biotechnol, Paediat Clin Bone Marrow Transplant Ctr, Cagliari, Italy.			ROSATELLI, MARIA CRISTINA/0000-0001-6821-3190				ARGIOLU F, 2000, HAEMATOLOGICA, V85, P37; Bugert P, 2001, TISSUE ANTIGENS, V58, P103, DOI 10.1034/j.1399-0039.2001.580208.x; DYER C, 2002, BRIT MED J, V321, P503; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; van den Berg H, 2000, BONE MARROW TRANSPL, V25, P579, DOI 10.1038/sj.bmt.1702219	5	16	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					41	42		10.1016/S0140-6736(03)13806-8	http://dx.doi.org/10.1016/S0140-6736(03)13806-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853199				2022-12-28	WOS:000184056900013
J	Pedley, DK; Bissett, K; Connolly, EM; Goodman, CG; Golding, I; Pringle, TH; McNeill, GP; Pringle, SD; Jones, MC				Pedley, DK; Bissett, K; Connolly, EM; Goodman, CG; Golding, I; Pringle, TH; McNeill, GP; Pringle, SD; Jones, MC			Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics	BRITISH MEDICAL JOURNAL			English	Article							EARLY ANISTREPLASE TRIAL; NEEDLE TIMES; THERAPY; MORTALITY; CALL	Objectives To evaluate a system of prehospital thrombolysis, delivered by paramedics, in meeting the national service framework's targets for the management of acute myocardial infarction. Design Prospective observational cohort study comparing patients with suspected acute myocardial infarction considered for thrombolysis in the prehospital environment With patients treated in hospital. Setting The catchment area of a large teaching hospital, including urban and rural areas. Participants 201 patients presenting concurrently over a 12 month period who had changes to the electrocardiogram that were diagnostic of acute myocardial infarction or who received thrombolysis for suspected acute myocardial infarction. Main outcome measures Time from first medical contact to initiation of thrombolysis (call to needle time), number of patients given thrombolysis appropriately, and all cause mortality in hospital. Results The median call to needle time for patients treated before arriving in hospital (n=28) was 52 (95% confidence interval 41 to 62) minutes. Patients from similar rural areas who were treated in hospital (n=43) had a median time of 125 (104 to 140) minutes. This represents a median time saved of 73 minutes (P < 0.001). Sixty minutes after medical contact 64% of, patients (18/28) treated before arrival in hospital had received thrombolysis; this compares with 4% of patients (2/43) in a cohort from similar areas. Median call to needle time for patients from urban areas (n=107) was 80 (78 to 93) minutes. Myocardial infarction was confirmed in 89% of patients (25/28) who had received prehospital thrombolysis; this compares with 92% (138/150) in the two groups of patients receiving thrombolysis in hospital. Conclusions Thrombolysis delivered by paramedics with support from the base hospital can meet the national targets for early thrombolysis. The system has been shown to work well and can be introduced without delay.	Univ Dundee, Ninewells Hosp & Med Sch, Chest Pain Serv, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Med & Cardiovasc Grp, Dundee DD1 9SY, Scotland; Scottish Ambulance Serv, Dundee DD3 8PQ, Scotland	University of Dundee; University of Dundee	Pedley, DK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Chest Pain Serv, Dundee DD1 9SY, Scotland.							[Anonymous], 1988, LANCET, V332, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; *DEP HLTH, 2000, NAT SERV FRAM COR HE; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; Rawles J, 1998, BRIT MED J, V317, P576, DOI 10.1136/bmj.317.7158.576; Rawles J, 1999, BRIT MED J, V318, P1554; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; 2002, J AM COLL CARDIOL, V3, P71	13	53	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					22	26		10.1136/bmj.327.7405.22	http://dx.doi.org/10.1136/bmj.327.7405.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842951	Green Published, Bronze			2022-12-28	WOS:000184062700018
J	Tan, SB; Dear, KBG; Bruzzi, P; Machin, D				Tan, SB; Dear, KBG; Bruzzi, P; Machin, D			Strategy for randomised clinical trials in rare cancers	BRITISH MEDICAL JOURNAL			English	Article							SURROGATE END-POINTS; HEPATOCELLULAR-CARCINOMA; BAYESIAN METHODS; DESIGN		Natl Canc Ctr, Div Clin Trials & Epidemiol Sci, Singapore 169610, Singapore; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; Natl Inst Canc Res, Unit Clin Epidemiol & Trials, Genoa, Italy; Univ Leicester, UK Childrens Canc Study Grp, Leicester, Leics, England	National Cancer Centre Singapore (NCCS); Australian National University; University of Genoa; IRCCS AOU San Martino IST; University of Leicester	Tan, SB (corresponding author), Natl Canc Ctr, Div Clin Trials & Epidemiol Sci, 11 Hosp Dr, Singapore 169610, Singapore.		Tan, Say Beng/H-1793-2011; Bruzzi, Paolo/AAU-3363-2021	Bruzzi, Paolo/0000-0002-7874-2077; Dear, Keith/0000-0002-0788-7404				Begg CB, 2000, J ROY STAT SOC A STA, V163, P15, DOI 10.1111/1467-985X.00153; Edwards SJL, 1997, LANCET, V350, P804, DOI 10.1016/S0140-6736(97)02290-3; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Lilford R, 2002, BRIT J SURG, V89, P129; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; MACHIN D, 1994, STAT MED, V13, P1385, DOI 10.1002/sim.4780131313; Parmar MKB, 2001, LANCET, V358, P375, DOI 10.1016/S0140-6736(01)05558-1; PARMAR MKB, 1994, STAT MED, V13, P1297, DOI 10.1002/sim.4780131304; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Tan SB, 2003, CONTROL CLIN TRIALS, V24, P110, DOI 10.1016/S0197-2456(02)00318-5; Tan SB, 2002, J CLIN ONCOL, V20, P1709, DOI 10.1200/JCO.2002.20.6.1709	15	54	54	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 5	2003	327	7405					47	49		10.1136/bmj.327.7405.47	http://dx.doi.org/10.1136/bmj.327.7405.47			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842959	Green Published			2022-12-28	WOS:000184062700029
J	Ittekkot, V				Ittekkot, V			A new story from the ol' man river	SCIENCE			English	Editorial Material							NORTH-AMERICA; EUROPE; CO2		Ctr Trop Marine Ecol, D-28359 Bremen, Germany	Leibniz Zentrum fur Marine Tropenforschung (ZMT)	Ittekkot, V (corresponding author), Ctr Trop Marine Ecol, Fahrenheitsstr 6, D-28359 Bremen, Germany.		Ittekkot, Venugopalan/AAC-3437-2022	Ittekkot, Venugopalan/0000-0003-2667-5068				Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; BERNER RA, 1998, CHEM WEATHERING RATE, P565; Bolin B., 1979, GLOBAL CARBON CYCLE; DEGENS ET, 1991, BIOGEOCHEMISTRY MAJO; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; *FAO, 1995, WORLD AGR 2010 FAO S; Ittekkot V, 2000, BIOSCIENCE, V50, P776, DOI 10.1641/0006-3568(2000)050[0776:HAAMBA]2.0.CO;2; Ittekkot V, 1989, GLOBAL BIOGEOCHEM CY, V3, P383, DOI 10.1029/GB003i004p00383; Janssens IA, 2003, SCIENCE, V300, P1538, DOI 10.1126/science.1083592; Markewitz D, 2001, NATURE, V410, P802, DOI 10.1038/35071052; Raymond PA, 2003, SCIENCE, V301, P88, DOI 10.1126/science.1083788; Richey JE, 2002, NATURE, V416, P617, DOI 10.1038/416617a; SCHLESINGER WH, 1997, BIOGEOCHEMISTRY, P545; Stoddard JL, 1999, NATURE, V401, P575, DOI 10.1038/44114; WHITE AF, 1995, GEOCHIM COSMOCHIM AC, V59, P1729, DOI 10.1016/0016-7037(95)00078-E	15	9	11	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					56	58		10.1126/science.1086419	http://dx.doi.org/10.1126/science.1086419			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843381				2022-12-28	WOS:000183914700027
J	Dacke, M; Nilsson, DE; Scholtz, CH; Byrne, M; Warrant, EJ				Dacke, M; Nilsson, DE; Scholtz, CH; Byrne, M; Warrant, EJ			Insect orientation to polarized moonlight	NATURE			English	Article									Lund Univ, Dept Cell & Organism Biol, S-22362 Lund, Sweden; Univ Witwatersrand, Dept Anim Plant & Environm Sci, Ecophysiol Studies Res Grp, ZA-2050 Johannesburg, South Africa; Univ Pretoria, Dept Zool & Entomol, ZA-0001 Pretoria, South Africa	Lund University; University of Witwatersrand; University of Pretoria	Dacke, M (corresponding author), Lund Univ, Dept Cell & Organism Biol, S-22362 Lund, Sweden.	marie.dacke@cob.lu.se	Byrne, Marcus/AAF-9789-2021; Scholtz, Clarke/E-7121-2010	Byrne, Marcus/0000-0002-5155-2599; Warrant, Eric/0000-0001-7480-7016				Dacke M, 2003, J EXP BIOL, V206, P1535, DOI 10.1242/jeb.00289; Gal J, 2001, J GEOPHYS RES-ATMOS, V106, P22647, DOI 10.1029/2000JD000085; Strutt J. W., 1871, PHILOS MAG, V41, P107, DOI DOI 10.1080/14786447108640452; Waterman T.H., 1981, HDB SENSORY PHYSL, P281; Wehner R, 2001, J EXP BIOL, V204, P2589	5	178	196	3	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					33	33		10.1038/424033a	http://dx.doi.org/10.1038/424033a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840748				2022-12-28	WOS:000183912800029
J	Baglione, V; Canestrari, D; Marcos, JM; Ekman, J				Baglione, V; Canestrari, D; Marcos, JM; Ekman, J			Kin selection in cooperative alliances of carrion crows	SCIENCE			English	Article							DISPERSAL; BEHAVIOR	In most cooperative vertebrates, delayed natal dispersal is the mechanism that leads to the formation of kin societies. Under this condition, the possibility that kin-based cooperative breeding is an unselected consequence of dispersal patterns can never be ruled out because helpers can only help their relatives. Here we show that a population of carrion crows (Corvus corone corone) fully fits the central prediction of kin selection theory that cooperative breeding should arise among relatives. On their territory, resident breeders are aided not only by nonbreeding retained offspring but also by immigrants ( mainly males), with whom they share matings. Philopatry cannot account, however, for the high degree of genetic relatedness found between breeders and immigrants of the same sex that cooperate at a nest, indicating that crows actively choose to breed cooperatively with their relatives.	Uppsala Univ, Populat Biol Evolutionary Biol Ctr, SE-75236 Uppsala, Sweden; Univ Seville, Seville 41071, Spain	Uppsala University; University of Sevilla	Baglione, V (corresponding author), Uppsala Univ, Populat Biol Evolutionary Biol Ctr, Norbyvagen 18D, SE-75236 Uppsala, Sweden.	vittorio.baglione@ebc.uu.se	Baglione, Vittorio/D-6456-2014; Canestrari, Daniela/F-9696-2016	Canestrari, Daniela/0000-0001-9112-0208; Baglione, Vittorio/0000-0001-8464-7861				Baglione V, 2002, ANIM BEHAV, V64, P887, DOI 10.1006/anbe.2002.2007; Baglione V, 2002, AUK, V119, P790, DOI 10.1642/0004-8038(2002)119[0790:CBGOCC]2.0.CO;2; Baglione V, 2002, P ROY SOC B-BIOL SCI, V269, P1247, DOI 10.1098/rspb.2002.2016; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; EKMAN J, 1994, BEHAV ECOL, V5, P245, DOI 10.1093/beheco/5.3.245; EMLEN ST, 1988, BEHAV ECOL SOCIOBIOL, V23, P305, DOI 10.1007/BF00300577; EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092; Griffin AS, 2002, TRENDS ECOL EVOL, V17, P15, DOI 10.1016/S0169-5347(01)02355-2; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; Koenig WD, 2000, CONDOR, V102, P492, DOI 10.1650/0010-5422(2000)102[0492:NDITCB]2.0.CO;2; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; QUELLER DC, 1992, TRENDS ECOL EVOL, V7, P322, DOI 10.1016/0169-5347(92)90120-Z; Russell AF, 2001, P ROY SOC B-BIOL SCI, V268, P2169, DOI 10.1098/rspb.2001.1790; Spong G, 2001, P ROY SOC B-BIOL SCI, V268, P2571, DOI 10.1098/rspb.2001.1835; TAYLOR PD, 1992, EVOL ECOL, V6, P352, DOI 10.1007/BF02270971; West SA, 2002, SCIENCE, V296, P72, DOI 10.1126/science.1065507; Zar JH., 1999, BIOSTAT ANAL, V663rd; [No title captured]	20	82	83	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1947	1949		10.1126/science.1082429	http://dx.doi.org/10.1126/science.1082429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817149				2022-12-28	WOS:000183619400047
J	Garsin, DA; Villanueva, JM; Begun, J; Kim, DH; Sifri, CD; Calderwood, SB; Ruvkun, G; Ausubel, FM				Garsin, DA; Villanueva, JM; Begun, J; Kim, DH; Sifri, CD; Calderwood, SB; Ruvkun, G; Ausubel, FM			Long-lived C-elegans daf-2 mutants are resistant to bacterial pathogens	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; HOST		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Ausubel, FM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.	Ausubel@molbio.mgh.harvard.edu	Begun, Jakob/J-6793-2014	Begun, Jakob/0000-0001-5256-7672; Sifri, Costi/0000-0001-6033-2515	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048707, R01GM048707] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48707] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aballay A, 2002, CURR OPIN MICROBIOL, V5, P97, DOI 10.1016/S1369-5274(02)00293-X; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Garigan D, 2002, GENETICS, V161, P1101; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Mallo GV, 2002, CURR BIOL, V12, P1209, DOI 10.1016/S0960-9822(02)00928-4; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	7	415	430	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1921	1921		10.1126/science.1080147	http://dx.doi.org/10.1126/science.1080147			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817143				2022-12-28	WOS:000183619400038
J	Fihn, SD				Fihn, SD			Acute uncomplicated urinary tract infection in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPERMICIDE-COATED CONDOMS; RISK-FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE; POSTMENOPAUSAL WOMEN; ESCHERICHIA-COLI; YOUNG-WOMEN; RANDOMIZED TRIAL; ANTIMICROBIAL RESISTANCE; ACUTE CYSTITIS; DOUBLE-BLIND		VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA; Univ Washington, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Fihn, SD (corresponding author), VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, 152,1660 S Columbian Way, Seattle, WA 98108 USA.		Fihn, Stephan/ABA-1040-2020		NIDDK NIH HHS [2-R01-DK431341-07] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1992, ALLERGY, V47, P340, DOI 10.1111/j.1398-9995.1992.tb02067.x; AVORN J, 1994, JAMA-J AM MED ASSOC, V271, P751, DOI 10.1001/jama.271.10.751; Barry HC, 2001, J FAM PRACTICE, V50, P589; Bent S, 2002, JAMA-J AM MED ASSOC, V287, P2701, DOI 10.1001/jama.287.20.2701; Boyko EJ, 2002, DIABETES CARE, V25, P1778, DOI 10.2337/diacare.25.10.1778; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P242, DOI 10.1159/000245189; Brown JS, 2001, OBSTET GYNECOL, V98, P1045, DOI 10.1016/S0029-7844(01)01630-1; Cardozo L, 1998, BRIT J OBSTET GYNAEC, V105, P403, DOI 10.1111/j.1471-0528.1998.tb10124.x; Chew LD, 1999, WESTERN J MED, V170, P274; Eriksen BC, 1999, AM J OBSTET GYNECOL, V180, P1072, DOI 10.1016/S0002-9378(99)70597-1; Fenwick EAL, 2000, BRIT J GEN PRACT, V50, P635; Fihn SD, 1996, AM J EPIDEMIOL, V144, P512, DOI 10.1093/oxfordjournals.aje.a008958; FIHN SD, 1988, ANN INTERN MED, V108, P350, DOI 10.7326/0003-4819-108-3-350; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; Fihn SD, 1998, ARCH INTERN MED, V158, P281, DOI 10.1001/archinte.158.3.281; Foo LY, 2000, J NAT PROD, V63, P1225, DOI 10.1021/np000128u; FOWLER JE, 1981, NEW ENGL J MED, V304, P462, DOI 10.1056/NEJM198102193040805; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; Gupta K, 2001, ANN INTERN MED, V135, P9, DOI 10.7326/0003-4819-135-1-200107030-00004; Hooton TM, 2001, INT J ANTIMICROB AG, V17, P259, DOI 10.1016/S0924-8579(00)00350-2; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; HOOTON TM, 1991, ANTIMICROB AGENTS CH, V35, P1479, DOI 10.1128/AAC.35.7.1479; HOOTON TM, 1989, ANTIMICROB AGENTS CH, V33, P1308, DOI 10.1128/AAC.33.8.1308; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; KLEIN M, 2002, VACCINIUM MCROCARPON; Kontiokari T, 2001, BMJ-BRIT MED J, V322, P1571, DOI 10.1136/bmj.322.7302.1571; KUNIN CM, 1978, NEW ENGL J MED, V298, P336; Manges AR, 2001, NEW ENGL J MED, V345, P1007, DOI 10.1056/NEJMoa011265; Mulvey MA, 2002, CELL MICROBIOL, V4, P257, DOI 10.1046/j.1462-5822.2002.00193.x; Nelson C, 1999, VITAL HLTH STAT, V13; NICOLLE LE, 1982, J INFECT DIS, V146, P574; Ouslander JG, 2001, J AM GERIATR SOC, V49, P803, DOI 10.1046/j.1532-5415.2001.49160.x; POWERS JS, 1988, SOUTHERN MED J, V81, P734, DOI 10.1097/00007611-198806000-00012; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; Raz R, 2000, CLIN INFECT DIS, V30, P152, DOI 10.1086/313596; Ronald A, 2002, AM J MED, V113, p14S; Saint S, 1999, AM J MED, V106, P636, DOI 10.1016/S0002-9343(99)00122-9; Scholes D, 2000, J INFECT DIS, V182, P1177, DOI 10.1086/315827; Shi CW, 2003, J GEN INTERN MED, V18, P281, DOI 10.1046/j.1525-1497.2003.20709.x; SOURANDER LB, 1966, ANN MED INTERN FEN S, V45, P7; STAMM WE, 1991, REV INFECT DIS, V13, P77; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STAMM WE, 1987, ANN INTERN MED, V106, P341, DOI 10.7326/0003-4819-106-3-341; STAPLETON A, 1990, JAMA-J AM MED ASSOC, V264, P703, DOI 10.1001/jama.264.6.703; Steinke DT, 1999, J ANTIMICROB CHEMOTH, V43, P841, DOI 10.1093/jac/43.6.841; Stothers Lynn, 2002, Can J Urol, V9, P1558; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WONG ES, 1985, ANN INTERN MED, V102, P302, DOI 10.7326/0003-4819-102-3-302; Wright SW, 1999, J GEN INTERN MED, V14, P606, DOI 10.1046/j.1525-1497.1999.10128.x; 2001, CONSUMER REPORTS, V66, P8	54	163	183	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					259	266		10.1056/NEJMcp030027	http://dx.doi.org/10.1056/NEJMcp030027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867610				2022-12-28	WOS:000184165700011
J	Mao, YH; Abrieu, A; Cleveland, DW				Mao, YH; Abrieu, A; Cleveland, DW			Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1	CELL			English	Article							SPINDLE ASSEMBLY CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; PUTATIVE KINETOCHORE MOTOR; SACCHAROMYCES-CEREVISIAE; UNATTACHED KINETOCHORES; CHROMOSOME ALIGNMENT; CHROMATID SEPARATION; KINASE-ACTIVITY; PROTEIN BUBR1; MAD2	The mitotic checkpoint prevents advance to anaphase prior to successful attachment of every centromere/ kinetochore to mitotic spindle microtubules. Using purified components and Xenopus egg extracts, the kinetochore-associated microtubule motor CENP-E is now shown to be the activator of the essential checkpoint kinase BubR1. Since kinase activity and the checkpoint are silenced following CENP-E-dependent microtubule attachment in extracts or binding of CENP-E antibodies that do not disrupt CENP-E association with BubR1, CENP-E mediates silencing of BubR1 signaling. Checkpoint signaling requires the normal level of BubR1 containing a functional Mad3 domain implicated in Cdc20 binding, but only a small fraction need be kinase competent. This supports bifunctional roles for BubR1 in the checkpoint: an enzymatic one requiring CENP-E-dependent activation of its kinase activity at kinetochores and a stoichiometric one as a direct inhibitor of Cdc20.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.		Abrieu, Ariane/P-3307-2019; Cleveland, Don/AAN-9783-2021; Abrieu, Ariane/G-6336-2013	Abrieu, Ariane/0000-0002-0942-8877; Mao, Yinghui/0000-0002-4078-129X; Cleveland, Don/0000-0002-1934-3682				Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; Taylor TE, 1998, TROP MED INT HEALTH, V3, P3, DOI 10.1046/j.1365-3156.1998.00166.x; Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071; WEAVER BAA, 2003, IN PRESS J CELL BIOL; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; Wu HY, 2000, ONCOGENE, V19, P4557, DOI 10.1038/sj.onc.1203803; Yamaguchi S, 2003, EMBO J, V22, P1075, DOI 10.1093/emboj/cdg100; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	42	190	196	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 11	2003	114	1					87	98		10.1016/S0092-8674(03)00475-6	http://dx.doi.org/10.1016/S0092-8674(03)00475-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859900	Bronze			2022-12-28	WOS:000184219900008
J	Roff, D				Roff, D			Evolutionary danger for rainforest species	SCIENCE			English	Editorial Material							CORRELATED RESPONSES; DROSOPHILA-SERRATA; POPULATIONS; RESISTANCE; SELECTION; GENETICS		Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Roff, D (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.							Baer CF, 2000, EVOLUTION, V54, P238, DOI 10.1111/j.0014-3820.2000.tb00024.x; BLOWS MW, 1993, EVOLUTION, V47, P1255, DOI 10.1111/j.1558-5646.1993.tb02151.x; Hendry AP, 1999, EVOLUTION, V53, P1637, DOI 10.1111/j.1558-5646.1999.tb04550.x; Hoffmann AA, 2003, SCIENCE, V301, P100, DOI 10.1126/science.1084296; HOFFMANN AA, 1993, J EVOLUTION BIOL, V6, P643, DOI 10.1046/j.1420-9101.1993.6050643.x; Kelemen L, 1999, EVOLUTION, V53, P1306, DOI [10.2307/2640835, 10.1111/j.1558-5646.1999.tb04545.x]; Potvin C, 1996, OECOLOGIA, V108, P683, DOI 10.1007/BF00329043; Reznick DN, 1997, SCIENCE, V275, P1934, DOI 10.1126/science.275.5308.1934; Roff D.A., 1997, EVOLUTIONARY QUANTIT; ROFF DA, 1987, HEREDITY, V58, P103, DOI 10.1038/hdy.1987.15	10	4	4	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					58	59		10.1126/science.1087384	http://dx.doi.org/10.1126/science.1087384			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843382				2022-12-28	WOS:000183914700028
J	Selzer, RR; Rosenblatt, DS; Laxova, R; Hogan, K				Selzer, RR; Rosenblatt, DS; Laxova, R; Hogan, K			Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE; METHIONINE SYNTHASE; S-ADENOSYLMETHIONINE; COMMON MUTATION; RISK-FACTOR; INACTIVATION; GENE; MTHFR; PATIENT; POLYMORPHISM		Univ Wisconsin, Sch Med, Dept Anesthesiol, Clin Sci Ctr B6 319, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Med Genet, Madison, WI 53792 USA; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; McGill University; McGill University; McGill University; McGill University	Hogan, K (corresponding author), Univ Wisconsin, Sch Med, Dept Anesthesiol, Clin Sci Ctr B6 319, 600 Highland Ave, Madison, WI 53792 USA.	khogan@facstaff.wisc.edu						Beckman D R, 1987, Birth Defects Orig Artic Ser, V23, P47; Castera L, 2001, AM J GASTROENTEROL, V96, P1553; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CHRISTENSEN B, 1994, PEDIATR RES, V35, P3, DOI 10.1203/00006450-199401000-00002; CHRISTENSEN B, 1994, ANESTHESIOLOGY, V80, P1046, DOI 10.1097/00000542-199405000-00014; DEACON R, 1980, EUR J BIOCHEM, V104, P419, DOI 10.1111/j.1432-1033.1980.tb04443.x; Felmet K, 2000, J PEDIATR-US, V137, P427, DOI 10.1067/mpd.2000.107387; Fiskerstrand T, 1997, J PHARMACOL EXP THER, V282, P1305; FRASCA V, 1986, J BIOL CHEM, V261, P5823; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Gaughan DJ, 2000, GENE, V257, P279, DOI 10.1016/S0378-1119(00)00392-9; Goyette P, 2000, HUM MUTAT, V16, P132, DOI 10.1002/1098-1004(200008)16:2<132::AID-HUMU5>3.0.CO;2-T; GOYETTE P, 1995, AM J HUM GENET, V56, P1052; Goyette P, 1996, AM J HUM GENET, V59, P1268; GOYETTE P, 1994, NAT GENET, V7, P551, DOI 10.1038/ng0894-551a; Harmon DL, 1999, GENET EPIDEMIOL, V17, P298, DOI 10.1002/(SICI)1098-2272(199911)17:4<298::AID-GEPI5>3.0.CO;2-V; Homberger A., 2001, Journal of Inherited Metabolic Disease, V24, P50; Homberger A, 2000, EUR J HUM GENET, V8, P725, DOI 10.1038/sj.ejhg.5200522; KANWAR YS, 1976, PEDIATR RES, V10, P598, DOI 10.1203/00006450-197606000-00008; Keating HJ, 1996, J PAIN SYMPTOM MANAG, V11, P126, DOI 10.1016/0885-3924(95)00149-2; Kluijtmans LAJ, 1998, EUR J HUM GENET, V6, P257, DOI 10.1038/sj.ejhg.5200182; KOBLIN DD, 1981, ANESTHESIOLOGY, V54, P318, DOI 10.1097/00000542-198104000-00012; KOBLIN DD, 1982, ANESTH ANALG, V61, P75; KONDO H, 1981, J CLIN INVEST, V67, P1270, DOI 10.1172/JCI110155; Krauss B, 2001, ANN EMERG MED, V37, P61, DOI 10.1067/mem.2001.112004; Luhmann JD, 2001, ANN EMERG MED, V37, P20, DOI 10.1067/mem.2001.112003; McNeely JK, 2000, ANESTHESIOLOGY, V93, P1549, DOI 10.1097/00000542-200012000-00036; MOLLOY AM, 1992, BIOCHEM PHARMACOL, V44, P1349, DOI 10.1016/0006-2952(92)90536-R; Orkin FK, 2000, ANESTHESIA, V2, P2577; Peretz B, 1998, INT DENT J, V48, P17, DOI 10.1111/j.1875-595X.1998.tb00689.x; Riedel B, 1999, BIOCHEM J, V341, P133, DOI 10.1042/0264-6021:3410133; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; ROSENBLATT DS, 1977, PEDIATR RES, V11, P1137, DOI 10.1203/00006450-197711000-00004; ROYSTON BD, 1988, ANESTHESIOLOGY, V68, P213, DOI 10.1097/00000542-198802000-00006; Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004; Sibani S, 2000, HUM MUTAT, V15, P280, DOI 10.1002/(SICI)1098-1004(200003)15:3<280::AID-HUMU9>3.3.CO;2-9; Tonetti C, 2001, J INHERIT METAB DIS, V24, P833, DOI 10.1023/A:1013988123902; Tsai MY, 1996, AM J HUM GENET, V59, P1262; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879	41	100	107	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					45	50		10.1056/NEJMoa021867	http://dx.doi.org/10.1056/NEJMoa021867			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840091				2022-12-28	WOS:000183896100007
J	Wainwright, C; Altamirano, L; Cheney, M; Cheney, J; Barber, S; Price, D; Moloney, S; Kimberley, A; Woolfield, N; Cadzow, S; Fiumara, F; Wilson, P; Mego, S; VandeVelde, D; Sanders, S; O'Rourke, P; Francis, P				Wainwright, C; Altamirano, L; Cheney, M; Cheney, J; Barber, S; Price, D; Moloney, S; Kimberley, A; Woolfield, N; Cadzow, S; Fiumara, F; Wilson, P; Mego, S; VandeVelde, D; Sanders, S; O'Rourke, P; Francis, P			A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RACEMIC EPINEPHRINE; SALBUTAMOL; EFFICACY; MANAGEMENT; CHILDREN; INFECTIONS; ADRENALINE; MECHANICS	BACKGROUND: The treatment of infants with bronchiolitis is largely supportive. The role of bronchodilators is controversial. Most studies of the use of bronchodilators have enrolled small numbers of subjects and have examined only short-term outcomes, such as clinical scores. METHODS: We conducted a randomized, double-blind, controlled trial comparing nebulized single-isomer epinephrine with placebo in 194 infants admitted to four hospitals in Queens-land, Australia, with a clinical diagnosis of bronchiolitis. Three 4-ml doses of 1 percent nebulized epinephrine or three 4-ml doses of normal saline were administered at four-hour intervals after hospital admission. Observations were made at admission and just before, 30 minutes after, and 60 minutes after each dose. The primary outcome measures were the length of the hospital stay and the time until the infant was ready for discharge. The secondary outcome measures were the degree of change in the respiratory rate, the heart rate, and the respiratory-effort score and the time that supplemental oxygen was required. RESULTS: There were no significant overall differences between the groups in the length of the hospital stay (P=0.16) or the time until the infant was ready for discharge (P=0.86). Among infants who required supplemental oxygen and intravenous fluids, the time until the infant was ready for discharge was significantly longer in the epinephrine group than in the placebo group (P=0.02). The need for supplemental oxygen at admission had the greatest influence on the score for severity of illness and strongly predicted the length of the hospital stay and the time until the infant was ready for discharge (P<0.001). There were no significant changes in the respiratory rate, blood pressure, or respiratory-effort scores from before each treatment to after each treatment. The heart rate was significantly increased after each treatment with epinephrine (P=0.02 to P<0.001). CONCLUSIONS: The use of nebulized epinephrine did not significantly reduce the length of the hospital stay or the time until the infant was ready for discharge among infants admitted to the hospital with bronchiolitis.	Royal Childrens Hosp, Dept Resp Med, Brisbane, Qld 4029, Australia; Gold Coast Hosp, Gold Coast, Qld, Australia; Caboolture Hosp, Caboolture, Qld, Australia; Redcliffe Hosp, Redcliffe, Qld, Australia; Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia	Royal Children's Hospital Brisbane; Gold Coast University Hospital; University of Queensland	Wainwright, C (corresponding author), Royal Childrens Hosp, Dept Resp Med, Herston Rd, Brisbane, Qld 4029, Australia.	claire_wainwright@health.qld.gov.au	Wainwright, Claire E/G-4218-2013; Wilson, Peter/E-6127-2011	Wainwright, Claire E/0000-0001-8389-3809; Moloney, Susan/0000-0002-9724-8816; Sanders, Sharon/0000-0001-7966-9708				Barben JU, 2000, J PAEDIATR CHILD H, V36, P491, DOI 10.1046/j.1440-1754.2000.00558.x; Bertrand P, 2001, PEDIATR PULM, V31, P284, DOI 10.1002/ppul.1040; GEELHOED GC, 1994, ANN EMERG MED, V23, P1236, DOI 10.1016/S0196-0644(94)70347-7; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; Kellner JD, 2000, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD001266, DOI 10.1002/14651858.CD001266]; Kimpen JLL, 1997, PEDIATR INFECT DIS J, V16, P479, DOI 10.1097/00006454-199705000-00004; KRISTJANSSON S, 1993, ARCH DIS CHILD, V69, P650, DOI 10.1136/adc.69.6.650; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; LENNEY W, 1978, ARCH DIS CHILD, V53, P707, DOI 10.1136/adc.53.9.707; LODRUP K C, 1991, American Review of Respiratory Disease, V143, pA507; LOWELL DI, 1987, PEDIATRICS, V79, P939; MENON K, 1995, J PEDIATR-US, V126, P1004, DOI 10.1016/S0022-3476(95)70234-2; Newth CJL, 1997, PEDIATR RES, V42, P157, DOI 10.1203/00006450-199708000-00005; Numa AH, 2001, AM J RESP CRIT CARE, V164, P86, DOI 10.1164/ajrccm.164.1.2008090; PHELAN P, 1994, CLIN PATTERNS ACUTE, P52; REIJONEN T, 1995, ARCH PEDIAT ADOL MED, V149, P686, DOI 10.1001/archpedi.1995.02170190096017; Rusconi F, 1996, J PEDIATR-US, V128, P441, DOI 10.1016/S0022-3476(96)70312-8; RUSCONI F, 1994, PEDIATRICS, V94, P350; SANCHEZ I, 1993, J PEDIATR-US, V122, P145, DOI 10.1016/S0022-3476(05)83508-5; Wang EEL, 1996, J PEDIATR-US, V129, P390, DOI 10.1016/S0022-3476(96)70071-9; WENNERGREN G, 1991, ACTA PAEDIATR SCAND, V80, P375, DOI 10.1111/j.1651-2227.1991.tb11865.x; WOHL MEB, 1978, AM REV RESPIR DIS, V118, P759, DOI 10.1164/arrd.1978.118.4.759	22	144	157	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					27	35		10.1056/NEJMoa022226	http://dx.doi.org/10.1056/NEJMoa022226			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840089				2022-12-28	WOS:000183896100005
J	Morris, CD; Carson, S				Morris, CD; Carson, S			Routine vitamin supplementation to prevent cardiovascular disease: A summary of the evidence for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; BETA-CAROTENE SUPPLEMENTATION; HEALTH-CARE PROFESSIONALS; ANTIOXIDANT VITAMINS; ALPHA-TOCOPHEROL; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE; E CONSUMPTION; DOUBLE-BLIND; LUNG-CANCER	Background: Antioxidant vitamins are thought to play a role in atherosclerosis. Supplementation of these nutrients has been explored as a means of reducing cardiovascular morbidity and mortality. Purpose: To assess the evidence of the effectiveness of vitamin supplementation, specifically vitamins A, C, and E; beta-carotene; folic acid; antioxidant combinations; and multivitamin supplements, in preventing cardiovascular disease. Data Sources: Cochrane Controlled Trials Registry and MEDLINE (1966 to September 2001), reference lists, and experts. Study Selection: The researchers selected English-language reports of randomized trials and cohort studies that assessed vitamin supplementation in western populations and reported incidence of or death from cardiovascular events. They also included reports of good- or fair-quality clinical trials of primary and secondary prevention and good- or fair-quality prospective cohort studies. Studies that examined only dietary nutrients or did not provide separate estimates for supplements were not included. Data Extraction: Two reviewers abstracted descriptive information and data on cardiovascular outcomes and mortality from included studies. The researchers assessed study quality using predetermined criteria. Data Synthesis: Evidence tables were constructed to summarize data from included studies. The researchers summarized the strength, level, and quality of the overall evidence for the effectiveness of each of the vitamin supplements in preventing or treating cardiovascular disease. Conclusions: Some good-quality cohort studies have reported an association between the use of vitamin supplements and lower risk for cardiovascular disease. Randomized, controlled trials of specific supplements, however, have failed to demonstrate a consistent or significant effect of any single vitamin or combination of vitamins on incidence of or death from cardiovascular disease. Understanding the sources of these differences will permit researchers to better analyze the cohort study data and to better design long-term clinical trials.	Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA	Oregon Health & Science University	Morris, CD (corresponding author), Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA.							ALAIMO K, 1994, DIET INTAKE VITAMINS; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; American Heart Association, 1999, 1999 HEART STROK STA; ANDERSON TW, 1974, AM J CLIN NUTR, V27, P1174, DOI 10.1093/ajcn/27.8.1174; Asplund K, 2002, J INTERN MED, V251, P372, DOI 10.1046/j.1365-2796.2002.00973.x; Benditt DG, 1996, BAKKEN RES, V10, P1; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; DEMAIO SJ, 1992, J AM COLL NUTR, V11, P68; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116; GAZIANO JM, 1990, CIRCULATION, V82, P201; Gaziano JM, 1996, CIRCULATION S1, V94, P508; GILLILAN RE, 1977, AM HEART J, V93, P444, DOI 10.1016/S0002-8703(77)80406-7; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hercberg S, 1999, AM J PUBLIC HEALTH, V89, P289, DOI 10.2105/AJPH.89.3.289; Hodis HN, 2002, CIRCULATION, V106, P1453, DOI 10.1161/01.CIR.0000029092.99946.08; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; Jialal I, 2001, CURR OPIN LIPIDOL, V12, P49, DOI 10.1097/00041433-200102000-00009; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Klipstein-Grobusch K, 1999, AM J CLIN NUTR, V69, P261; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Kushi LH, 1999, AM J CLIN NUTR, V69, p1322S; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Lee IM, 2002, BRIT J CANCER, V86, P698, DOI 10.1038/sj.bjc.6600147; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178; Muntwyler J, 2002, ARCH INTERN MED, V162, P1472, DOI 10.1001/archinte.162.13.1472; Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pearce KA, 2000, AM FAM PHYSICIAN, V62, P1359; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Price JF, 1997, EUR HEART J, V18, P719; Rapola JM, 1998, HEART, V79, P454, DOI 10.1136/hrt.79.5.454; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; Redlich CA, 1999, ATHEROSCLEROSIS, V145, P423, DOI 10.1016/S0021-9150(99)00270-1; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rimm EB, 2000, MED CLIN N AM, V84, P239, DOI 10.1016/S0025-7125(05)70216-9; Rodes J, 1998, CIRCULATION, V97, P429; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Tomoda H, 1996, AM J CARDIOL, V78, P1284, DOI 10.1016/S0002-9149(96)00613-3; Tribble DL, 1999, CIRCULATION, V99, P591, DOI 10.1161/01.CIR.99.4.591; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Watkins ML, 2000, AM J EPIDEMIOL, V152, P149, DOI 10.1093/aje/152.2.149; Winder AF, 1997, J CLIN PATHOL, V50, P269, DOI 10.1136/jcp.50.4.269; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	65	138	145	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					56	70		10.7326/0003-4819-139-1-200307010-00014	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00014			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834320				2022-12-28	WOS:000183823200009
J	McCarthy, M				McCarthy, M			Health impacts of transport: convicted drivers	LANCET			English	Editorial Material									UCL, London WC1E 6BT, England	University of London; University College London	McCarthy, M (corresponding author), UCL, Mortimer St, London WC1E 6BT, England.	m.mccarthy@ucl.ac.uk	McCarthy, Mark/C-1117-2009					[Anonymous], INJ VIOL PREV; DAVIS A, 1999, INEQUALITIES HLTH EV, P170; Dora C, 2000, EUROPEAN SERIES; MAKINEN T, 2002, TRAFFIC ENFORCEMENT; MCCARTHY M, 1999, SOCIAL DETERMINANTS, P132; Morrison DS, 2003, J EPIDEMIOL COMMUN H, V57, P327, DOI 10.1136/jech.57.5.327; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Roberts I, 2002, BMJ-BRIT MED J, V324, P1107, DOI 10.1136/bmj.324.7346.1107; Smith CA, 2003, INJ PREV, V9, P89, DOI 10.1136/ip.9.1.89; *UK DEP TRANSP, 2002, SOFT FACT REP, pCH6; *UK OFF DEP PRIM M, 2003, SUST COMM BUILD FUT	11	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2168	2168		10.1016/S0140-6736(03)13782-8	http://dx.doi.org/10.1016/S0140-6736(03)13782-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842363				2022-12-28	WOS:000183815600002
J	Huber, GW; Shabaker, JW; Dumesic, JA				Huber, GW; Shabaker, JW; Dumesic, JA			Raney Ni-Sn catalyst for H-2 production from biomass-derived hydrocarbons	SCIENCE			English	Article							PLATINIZED PLATINUM; ETHYLENE-GLYCOL; ADSORPTION; CO; ALCOHOLS; METHANOL; NICKEL	Hydrogen (H-2) was produced by aqueous-phase reforming of biomass-derived oxygenated hydrocarbons at temperatures near 500 kelvin over a tin-promoted Raney-nickel catalyst. The performance of this non - precious metal catalyst compares favorably with that of platinum-based catalysts for production of hydrogen from ethylene glycol, glycerol, and sorbitol. The addition of tin to nickel decreases the rate of methane formation from C-O bond cleavage while maintaining the high rates of C-C bond cleavage required for hydrogen formation.	Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dumesic, JA (corresponding author), Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA.	dumesic@engr.wisc.edu	Huber, George/D-2569-2018; Huber, George/Y-2473-2019	Huber, George/0000-0002-7838-6893				AGNELLI M, 1990, J CATAL, V121, P236, DOI 10.1016/0021-9517(90)90234-B; Alper J, 2003, SCIENCE, V299, P1686, DOI 10.1126/science.299.5613.1686; BECKER L, 1993, PHYS REV B, V47, P9710, DOI 10.1103/PhysRevB.47.9710; Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Cole-Hamilton DJ, 2003, SCIENCE, V299, P1702, DOI 10.1126/science.1081881; Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009; Dahl S, 1999, PHYS REV LETT, V83, P1814, DOI 10.1103/PhysRevLett.83.1814; Davda RR, 2003, APPL CATAL B-ENVIRON, V43, P13, DOI 10.1016/S0926-3373(02)00277-1; DAVDA RR, IN PRESS ANGEW CHEM; Gallezot P, 1998, J CATAL, V180, P51, DOI 10.1006/jcat.1998.2261; Gootzen JFE, 1997, LANGMUIR, V13, P1659, DOI 10.1021/la960991n; Gootzen JFE, 1996, LANGMUIR, V12, P5076, DOI 10.1021/la960103o; Greeley J, 2003, J CATAL, V213, P63, DOI 10.1016/S0021-9517(02)00040-4; Ma FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5; Mavrikakis M, 1998, J MOL CATAL A-CHEM, V131, P135, DOI 10.1016/S1381-1169(97)00261-6; NASH P, 1992, BINARY ALLOY PHASE D, V3, P2863; ROBERTSO.SD, 1972, J CATAL, V24, P130, DOI 10.1016/0021-9517(72)90017-6; Rolison DR, 2003, SCIENCE, V299, P1698, DOI 10.1126/science.1082332; Rostrup-Nielsen JR, 2001, PHYS CHEM CHEM PHYS, V3, P283, DOI 10.1039/b004660o; Schoemaker HE, 2003, SCIENCE, V299, P1694, DOI 10.1126/science.1079237; Shabaker JW, 2003, J CATAL, V215, P344, DOI 10.1016/S0021-9517(03)00032-0; Shabaker JW, 2003, CATAL LETT, V88, P1, DOI 10.1023/A:1023538917186; STEINRUCK HP, 1986, SURF SCI, V172, pL561, DOI 10.1016/0039-6028(86)90496-6; TRONCONI E, 1992, CHEM ENG SCI, V47, P2451, DOI 10.1016/0009-2509(92)87075-2; XU C, 1995, SURF SCI, V327, P38, DOI 10.1016/0039-6028(94)00816-7	25	796	853	15	586	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2075	2077		10.1126/science.1085597	http://dx.doi.org/10.1126/science.1085597			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	694KZ	12829777	Green Published			2022-12-28	WOS:000183774900040
J	Lin, SY; Elledge, SJ				Lin, SY; Elledge, SJ			Multiple tumor suppressor pathways negatively regulate telomerase	CELL			English	Article							REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; CELLULAR SENESCENCE; MENIN INTERACTS; DOWN-REGULATION; IMMORTAL CELLS; CANCER-CELLS; LIFE-SPAN; EXPRESSION; P53	Telomerase expression is repressed in most somatic cells but is observed in stem cells and a high percentage of human cancers and has been hypothesized to contribute to tumorigenesis and maintenance of stem cell states. To explore telomerase regulation, we employed a general genetic screen to identify negative regulators of hTERT. We discovered three tumor suppressor/oncogene pathways involved in hTERT repression. One, the Mad1/c-Myc pathway, had been previously implicated in hTERT regulation. The second, SIPI, a transcriptional target of the TGF-beta pathway, mediates the TGF-beta regulated repression of hTERT. The third, the tumor suppressor Menin, is a direct repressor of hTERT. Depleting Menin immortalizes primary human fibroblasts and causes a transformation phenotype when coupled with expression of SV40 Large and Small T antigen and oncogenic ras. These studies suggest that multiple tumor suppressor/oncogene pathways coordinately repress hTERT expression and imply that telomerase is reactivated in human tumors through oncogenic mutations.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	selledge@bcm.tmc.edu			NCI NIH HHS [1 F32 CA93943] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1996, MOL CELL BIOL, V38, P2222; Blasco MA, 2002, EUR J CANCER, V38, P2222, DOI 10.1016/S0959-8049(02)00450-1; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cawthon RM, 2003, LANCET, V361, P393, DOI 10.1016/S0140-6736(03)12384-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRAVEN RJ, 1995, CANCER RES, V55, P3969; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2001, ANN MED, V33, P123, DOI 10.3109/07853890109002067; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Liu D, 2000, ONCOGENE, V19, P5964, DOI 10.1038/sj.onc.1203992; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Mason PJ, 2003, BIOESSAYS, V25, P126, DOI 10.1002/bies.10229; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; REARDON DB, 1993, J BIOL CHEM, V268, P18136; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Sood AK, 2002, CANCER BIOL THER, V1, P511, DOI 10.4161/cbt.1.5.167; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Takakura M, 1999, CANCER RES, V59, P551; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	68	349	371	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					881	889		10.1016/S0092-8674(03)00430-6	http://dx.doi.org/10.1016/S0092-8674(03)00430-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837246	Bronze			2022-12-28	WOS:000183817900012
J	Miyazawa, A; Fujiyoshi, Y; Unwin, N				Miyazawa, A; Fujiyoshi, Y; Unwin, N			Structure and gating mechanism of the acetylcholine receptor pore	NATURE			English	Article							ION-CHANNEL; M2 DOMAIN; TUBULAR CRYSTALS; LIGAND-BINDING; DELTA-SUBUNIT; ALPHA-SUBUNIT; PROTEIN; RESOLUTION; LOCATION; SEGMENT	The nicotinic acetylcholine receptor controls electrical signalling between nerve and muscle cells by opening and closing a gated, membrane-spanning pore. Here we present an atomic model of the closed pore, obtained by electron microscopy of crystalline postsynaptic membranes. The pore is shaped by an inner ring of 5 alpha-helices, which curve radially to create a tapering path for the ions, and an outer ring of 15 alpha-helices, which coil around each other and shield the inner ring from the lipids. The gate is a constricting hydrophobic girdle at the middle of the lipid bilayer, formed by weak interactions between neighbouring inner helices. When acetylcholine enters the ligand-binding domain, it triggers rotations of the protein chains on opposite sides of the entrance to the pore. These rotations are communicated through the inner helices, and open the pore by breaking the girdle apart.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; RIKEN, Harima Inst, Sayo, Hyogo 6795148, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	MRC Laboratory Molecular Biology; RIKEN; Kyoto University	Unwin, N (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mas@mrc-lmb.cam.ac.uk	Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Beckstein O, 2001, J PHYS CHEM B, V105, P12902, DOI 10.1021/jp012233y; Beroukhim R, 1997, ULTRAMICROSCOPY, V70, P57, DOI 10.1016/S0304-3991(97)00070-3; Blanton MP, 1998, J BIOL CHEM, V273, P8659, DOI 10.1074/jbc.273.15.8659; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; Colquhoun D., 2003, BURGERS MED CHEM DRU, P357; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Croxen R, 1997, HUM MOL GENET, V6, P767, DOI 10.1093/hmg/6.5.767; DeRosier DJ, 2000, ULTRAMICROSCOPY, V81, P83, DOI 10.1016/S0304-3991(99)00120-5; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; HENDERSON R, 1992, ULTRAMICROSCOPY, V46, P1, DOI 10.1016/0304-3991(92)90003-3; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P199, DOI 10.1107/S0365110X58000517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	48	1020	1058	4	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					949	955		10.1038/nature01748	http://dx.doi.org/10.1038/nature01748			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827192				2022-12-28	WOS:000183753900040
J	Pearce, EN; Farwell, AP; Braverman, LE				Pearce, EN; Farwell, AP; Braverman, LE			Current concepts: Thyroiditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AMIODARONE-INDUCED THYROTOXICOSIS; CHRONIC LYMPHOCYTIC THYROIDITIS; ALPHA-INTERFERON THERAPY; TERM FOLLOW-UP; POSTPARTUM THYROIDITIS; SUBACUTE THYROIDITIS; SUBCLINICAL HYPOTHYROIDISM; AUTOIMMUNE-THYROIDITIS; HASHIMOTOS-THYROIDITIS; PEROXIDASE ANTIBODIES		Boston Univ, Sch Med, Boston Med Ctr, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA; Univ Massachusetts, Med Ctr, Div Endocrinol, Worcester, MA USA	Boston Medical Center; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Braverman, LE (corresponding author), Boston Univ, Sch Med, Boston Med Ctr, Sect Endocrinol Diabet & Nutr, 88 E Newton St,Evans 201, Boston, MA 02118 USA.			Braverman, Lewis/0000-0003-1263-1099; Farwell, Alan/0000-0001-7716-2719				AMINO N, 1981, J CLIN ENDOCR METAB, V53, P113, DOI 10.1210/jcem-53-1-113; ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BARCLAY ML, 1994, CLIN ENDOCRINOL, V40, P759, DOI 10.1111/j.1365-2265.1994.tb02509.x; BARTALENA L, 1994, J CLIN ENDOCR METAB, V78, P423, DOI 10.1210/jc.78.2.423; Bocchetta A, 2001, J CLIN PSYCHOPHARM, V21, P594, DOI 10.1097/00004714-200112000-00009; Bogazzi F, 2003, J CLIN ENDOCR METAB, V88, P1999, DOI 10.1210/jc.2002-021874; Bogazzi F, 2002, J ENDOCRINOL INVEST, V25, P176, DOI 10.1007/BF03343984; BrowneMartin K, 1997, CLIN OBSTET GYNECOL, V40, P90, DOI 10.1097/00003081-199703000-00010; CHIOVATO L, 1993, J CLIN ENDOCR METAB, V77, P1700, DOI 10.1210/jc.77.6.1700; CHIOVATO L, 1986, J ENDOCRINOL INVEST, V9, P299, DOI 10.1007/BF03346932; Chopra IJ, 2001, J CLIN ENDOCR METAB, V86, P4707, DOI 10.1210/jc.86.10.4707; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; Danahey DG, 1996, OTOLARYNG HEAD NECK, V114, P158, DOI 10.1016/S0194-5998(96)70304-2; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; DELANGE WE, 1989, Q J MED, V72, P709; Dickstein G, 1997, AM J MED, V102, P454, DOI 10.1016/S0002-9343(97)00047-8; Eaton SEM, 2002, CLIN ENDOCRINOL, V56, P33, DOI 10.1046/j.0300-0664.2001.01457.x; EMERSON CH, 2000, WERNER INGBARS THYRO, P578; Farwell AP, 1996, OTOLARYNG CLIN N AM, V29, P541; Farwell AP, 2000, WERNER INGBARS THYRO, P1044; Few J, 1996, SURGERY, V120, P993, DOI 10.1016/S0039-6060(96)80045-6; Fukata S, 1996, J ENDOCRINOL INVEST, V19, P607, DOI 10.1007/BF03349026; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Golshan MM, 1997, SURGERY, V121, P593, DOI 10.1016/S0039-6060(97)90118-5; GREENE JN, 1971, AM J MED, V51, P97, DOI 10.1016/0002-9343(71)90327-5; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; Harjai KJ, 1997, ANN INTERN MED, V126, P63, DOI 10.7326/0003-4819-126-1-199701010-00009; HAYASHI Y, 1985, J CLIN ENDOCR METAB, V61, P1172, DOI 10.1210/jcem-61-6-1172; HEGEDUS L, 1991, CLIN ENDOCRINOL, V35, P235, DOI 10.1111/j.1365-2265.1991.tb03528.x; Hiromatsu Y, 1999, THYROID, V9, P1189, DOI 10.1089/thy.1999.9.1189; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; HOLM LE, 1985, NEW ENGL J MED, V312, P601, DOI 10.1056/NEJM198503073121001; Huber G, 2002, J CLIN ENDOCR METAB, V87, P3221, DOI 10.1210/jc.87.7.3221; Iitaka M, 1996, J CLIN ENDOCR METAB, V81, P466, DOI 10.1210/jc.81.2.466; Imaizumi M, 2002, ENDOCRINOLOGY, V143, P247, DOI 10.1210/en.143.1.247; JENKINS D, 1992, CLIN ENDOCRINOL, V37, P141, DOI 10.1111/j.1365-2265.1992.tb02298.x; KITCHENER MI, 1989, CLIN NUCL MED, V14, P439, DOI 10.1097/00003072-198906000-00010; Klintschar M, 2001, J CLIN ENDOCR METAB, V86, P2494, DOI 10.1210/jc.86.6.2494; KUHR T, 1994, J AUTOIMMUN, V7, P13, DOI 10.1006/jaut.1994.1002; Laurberg P, 1998, J CLIN ENDOCR METAB, V83, P765, DOI 10.1210/jc.83.3.765; Lazarus JH, 1996, QJM-INT J MED, V89, P429; Lazarus JH, 1997, BRIT J GEN PRACT, V47, P305; Lazarus JH, 1998, THYROID, V8, P909, DOI 10.1089/thy.1998.8.909; Marazuela M, 1996, CLIN ENDOCRINOL, V44, P635, DOI 10.1046/j.1365-2265.1996.751768.x; Martino E, 2001, ENDOCR REV, V22, P240, DOI 10.1210/er.22.2.240; MARTINO E, 1987, J ENDOCRINOL INVEST, V10, P321, DOI 10.1007/BF03348138; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Miller KK, 2001, CLIN ENDOCRINOL, V55, P501, DOI 10.1046/j.1365-2265.2001.01381.x; MIZUKAMI Y, 1995, J CLIN PATHOL, V48, P582, DOI 10.1136/jcp.48.6.582; Muller AF, 2001, ENDOCR REV, V22, P605, DOI 10.1210/er.22.5.605; NIKOLAI TF, 1987, ARCH INTERN MED, V147, P221, DOI 10.1001/archinte.147.2.221; NIKOLAI TF, 1981, ARCH INTERN MED, V141, P1455, DOI 10.1001/archinte.141.11.1455; PARKES AB, 1994, CLIN ENDOCRINOL, V41, P9, DOI 10.1111/j.1365-2265.1994.tb03777.x; PEARCE EN, IN PRESS THYROID; Premawardhana LDKE, 2000, J CLIN ENDOCR METAB, V85, P71, DOI 10.1210/jc.85.1.71; RONNBLOM LE, 1991, ANN INTERN MED, V115, P178, DOI 10.7326/0003-4819-115-3-178; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; Ross DS, 1998, ENDOCRIN METAB CLIN, V27, P169, DOI 10.1016/S0889-8529(05)70305-4; ROTI E, 1992, J CLIN ENDOCR METAB, V74, P3, DOI 10.1210/jc.74.1.3; SINGER PA, 1991, MED CLIN N AM, V75, P61, DOI 10.1016/S0025-7125(16)30472-2; TAMAKI H, 1990, J CLIN ENDOCR METAB, V71, P1382, DOI 10.1210/jcem-71-5-1382; TANDON N, 1991, CLIN ENDOCRINOL, V34, P383; TANDON N, 1994, CLIN ENDOCRINOL, V40, P702; Tomer Y, 1999, J CLIN ENDOCR METAB, V84, P4656, DOI 10.1210/jc.84.12.4656; Tsuboi K, 1993, 80 YEARS HASHIMOTO D, P69; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Utiger R., 2000, WERNER INGBARS THYRO, P721; Vaidya B, 1997, POSTGRAD MED J, V73, P817, DOI 10.1136/pgmj.73.866.817; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; VARGAS MT, 1988, J CLIN ENDOCR METAB, V67, P327, DOI 10.1210/jcem-67-2-327; VITUG AC, 1985, ARCH INTERN MED, V145, P473, DOI 10.1001/archinte.145.3.473; VOLPE R, 1967, J CLIN ENDOCR METAB, V27, P1275, DOI 10.1210/jcem-27-9-1275; Waterman EA, 1998, CLIN ENDOCRINOL, V49, P251, DOI 10.1046/j.1365-2265.1998.00537.x; Wong V, 2002, CLIN ENDOCRINOL, V56, P793, DOI 10.1046/j.1365-2265.2002.01553.x; Woolf P D, 1980, Endocr Rev, V1, P411	77	519	551	0	40	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2646	2655		10.1056/NEJMra021194	http://dx.doi.org/10.1056/NEJMra021194			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826640				2022-12-28	WOS:000183726400009
J	Grabenstein, JD; Winkenwerder, W				Grabenstein, JD; Winkenwerder, W			US military smallpox vaccination program experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; VACCINIA; RISKS	Context The United States recently implemented smallpox vaccination of selected military personnel in a national program of preparedness against use of smallpox as a biological. weapon. The resumption of smallpox vaccinations raises important questions regarding implementation and safety. Objective To describe the US military smallpox vaccination program. Design Descriptive study of the vaccination program from its inception on December 13, 2002, through May 28, 2003. Setting US Department of Defense (DoD) fixed and field medical treatment facilities on multiple continents and ships at sea. Subjects US service members and DoD civilian workers eligible for smallpox vaccination. Main Outcome Measures Numbers of vaccinations and rates of vaccination exemptions, symptoms, and adverse events. Data were collected via reports to headquarters and rigorous surveillance for sentinel events. Results In 5.5 months, the DoD administered 450293 smallpox vaccinations (70.5% primary vaccinees and 29.5% revaccinees). In 2 settings, 0.5% and 3.0% of vaccine recipients needed short-term sick leave. Most adverse events occurred at rates below historical rates. One case of encephalitis and 37 cases of acute myopericarditis developed after vaccination; all cases recovered. Among 19461 worker-months of clinical contact, there were no cases of transmission of vaccinia from worker to patient, no cases of eczema vaccinatum or progressive vaccinia, and no attributed deaths. Conclusions Mass smallpox vaccinations can be conducted safely with very low rates of serious adverse events. Program implementation emphasized human factors: careful staff training, contraindication screening, recipient education, and attention to bandaging. Our experience suggests that broad smallpox vaccination programs may be implemented with fewer serious adverse events than previously believed.	USA, Mil Vaccine Agcy, Med Command, Falls Church, VA 22041 USA; Pentagon, Washington, DC USA		Grabenstein, JD (corresponding author), USA, Mil Vaccine Agcy, Med Command, 5111 Leesburg Pike,Suite 401, Falls Church, VA 22041 USA.	john.grabenstein@us.army.mil	Grabenstein, John/Y-7322-2019					*ADV COMM IMM PRAC, 2003, MMWR RECOMM REP, V52, P1; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P1; *ARM FORC EP BOARD, 1977, REP AD HOC SUBC SMAL; *ARM FORC EP BOARD, 1981, MIN JUN 11 1981 M; CDC Center for Disease Control and Prevention, 1985, MMWR-MORBID MORTAL W, V34, P182; *CDCP, 1982, MMWR-MORBID MORTAL W, V31, P682; *CDCP, 1984, MMWR-MORBID MORTAL W, V33, P37; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P419; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P191; *CDCP, 2002, SMALL POX RESP PLAN; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P180; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P256; *CDCP, 1983, MMWR-MORBID MORTAL W, V32, P403; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P386; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P278; COATES JB, 1964, MED DEP US ARMY WORL, V7, P17; COATES JB, 1955, MED DEP US ARMY WORL, V3, P280; DUNCAN LC, 1932, MIL SURG, V71, P439; GILLETT MC, 1981, ARMY MED DEP 1775 18, P56; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; *I MED, 2003, 1 I MED NAT AC SCI; Jezek Z, 1988, HUMAN MONKEYPOX; KARJALAINEN J, 1983, ACTA MED SCAND, V213, P65; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; Lane JM, 2003, ANN INTERN MED, V138, P488, DOI 10.7326/0003-4819-138-6-200303180-00014; LANE JM, 1971, AM J EPIDEMIOL, V93, P238, DOI 10.1093/oxfordjournals.aje.a121252; LANE JM, 1971, ANNU REV MED, V22, P251, DOI 10.1146/annurev.me.22.020171.001343; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; *WYETH LAB, 2002, SMALLP VACC DRIED CA; 1995, US DEP DEFENSE SMALL	32	153	157	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3278	3282		10.1001/jama.289.24.3278	http://dx.doi.org/10.1001/jama.289.24.3278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824209	Bronze			2022-12-28	WOS:000183704600021
J	Hoye, A; Clark, A				Hoye, A; Clark, A			Iatrogenic hyperkalaemia	LANCET			English	Editorial Material							POTASSIUM		Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU6 7RX, N Humberside, England	University of Hull	Hoye, A (corresponding author), Univ Hull, Castle Hill Hosp, Dept Cardiol, Kingston Upon Hull HU6 7RX, N Humberside, England.			Hoye, Angela/0000-0003-0577-2395				Halperin ML, 1998, LANCET, V352, P135; SINGER GG, HARRISONS PRINCIPLES, pCH49; Webster A, 2002, EMERG MED J, V19, P74, DOI 10.1136/emj.19.1.74	3	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2124	2124		10.1016/S0140-6736(03)13724-5	http://dx.doi.org/10.1016/S0140-6736(03)13724-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826437				2022-12-28	WOS:000183654200013
J	Ackermann, M; Stearns, SC; Jenal, U				Ackermann, M; Stearns, SC; Jenal, U			Senescence in a bacterium with asymmetric division	SCIENCE			English	Article									Univ Basel, Bioctr, Div Mol Microbiol, CH-4056 Basel, Switzerland; Yale Univ, Osborn Mem Labs, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	University of Basel; Yale University	Ackermann, M (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.	MKAckerm@ucsd.edu	Ackermann, Martin/V-4554-2017	Ackermann, Martin/0000-0003-0087-4819; Stearns, Stephen/0000-0002-6621-4373				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; MEDAWAR PB, 2002, UNSOLVED PROBLEM BIO; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; Shapiro L, 2002, SCIENCE, V298, P1942, DOI 10.1126/science.1072163; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	8	183	188	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1920	1920		10.1126/science.1083532	http://dx.doi.org/10.1126/science.1083532			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817142				2022-12-28	WOS:000183619400037
J	Ostriker, JP; Steinhardt, P				Ostriker, JP; Steinhardt, P			New light on dark matter	SCIENCE			English	Review							COSMOLOGICAL CONSTANT; INFLATIONARY UNIVERSE; DENSITY PROFILES; ROTATION CURVES; LAMBDA; SUBSTRUCTURE; GALAXIES; HALOS; FLUCTUATIONS; CONSTRAINTS	Dark matter, proposed decades ago as a speculative component of the universe, is now known to be the vital ingredient in the cosmos: six times more abundant than ordinary matter, one-quarter of the total energy density, and the component that has controlled the growth of structure in the universe. Its nature remains a mystery, but assuming that it is composed of weakly interacting subatomic particles, is consistent with large-scale cosmic structure. However, recent analyses of structure on galactic and subgalactic scales have suggested discrepancies and stimulated numerous alternative proposals. We discuss how studies of the density, demography, history, and environment of smaller-scale structures may distinguish among these possibilities and shed new light on the nature of dark matter.	Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University	Ostriker, JP (corresponding author), Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA.			Steinhardt, Paul/0000-0003-3488-1603				BARDEEN JM, 1983, PHYS REV D, V28, P679, DOI 10.1103/PhysRevD.28.679; Begelman MC, 2003, SCIENCE, V300, P1898, DOI 10.1126/science.1085325; Binney JJ, 2001, MON NOT R ASTRON SOC, V327, pL27, DOI 10.1046/j.1365-8711.2001.04968.x; Bode P, 2001, ASTROPHYS J, V556, P93, DOI 10.1086/321541; Cen RY, 2001, ASTROPHYS J, V546, pL77, DOI 10.1086/318861; Chiu WA, 2001, ASTROPHYS J, V563, P21, DOI 10.1086/323685; Dalal N, 2002, ASTROPHYS J, V572, P25, DOI 10.1086/340303; Dave R, 2001, ASTROPHYS J, V547, P574, DOI 10.1086/318417; Debattista V. P., 1998, APJ, V493, P5; EINASTO J, 1974, NATURE, V250, P309, DOI 10.1038/250309a0; Font AS, 2001, ASTROPHYS J, V563, pL1, DOI 10.1086/338479; Ghigna S, 2000, ASTROPHYS J, V544, P616, DOI 10.1086/317221; Goodman J, 2000, NEW ASTRON, V5, P103, DOI 10.1016/S1384-1076(00)00015-4; GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347; GUTH AH, 1982, PHYS REV LETT, V49, P1110, DOI 10.1103/PhysRevLett.49.1110; HAWKING SW, 1982, PHYS LETT B, V115, P295, DOI 10.1016/0370-2693(82)90373-2; Hennawi JF, 2002, ASTROPHYS J, V572, P41, DOI 10.1086/340226; Hu W, 2000, PHYS REV LETT, V85, P1158, DOI 10.1103/PhysRevLett.85.1158; Kaplinghat M, 2000, PHYS REV LETT, V85, P3335, DOI 10.1103/PhysRevLett.85.3335; Kirshner RP, 2003, SCIENCE, V300, P1914, DOI 10.1126/science.1086879; KRAUSS LM, 1995, GEN RELAT GRAVIT, V27, P1137, DOI 10.1007/BF02108229; Kravtsov AV, 1998, ASTROPHYS J, V502, P48, DOI 10.1086/305884; LACEY CG, 1985, ASTROPHYS J, V299, P633, DOI 10.1086/163729; MUKHANOV VF, 1981, JETP LETT+, V33, P532; Nagamine K, 2001, MON NOT R ASTRON SOC, V327, pL10, DOI 10.1046/j.1365-8711.2001.04905.x; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Navarro JF, 2000, ASTROPHYS J, V528, P607, DOI 10.1086/308225; OSTRIKER JP, 1995, NATURE, V377, P600, DOI 10.1038/377600a0; OSTRIKER JP, 1974, ASTROPHYS J, V193, pL1, DOI 10.1086/181617; PEEBLES PJE, 1984, ASTROPHYS J, V284, P439, DOI 10.1086/162425; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Power C, 2003, MON NOT R ASTRON SOC, V338, P14, DOI 10.1046/j.1365-8711.2003.05925.x; REISS A, 1998, ASTRON J, V116, P109; ROBERTS MS, 1973, ASTRON ASTROPHYS, V26, P483; RUBIN VC, 1978, ASTROPHYS J, V225, pL107, DOI 10.1086/182804; SILK J, 1977, ASTROPHYS J, V211, P638, DOI 10.1086/154972; Spergel DN, 2000, PHYS REV LETT, V84, P3760, DOI 10.1103/PhysRevLett.84.3760; STAROBINSKY AA, 1982, PHYS LETT B, V117, P175, DOI 10.1016/0370-2693(82)90541-X; Stoehr F, 2002, MON NOT R ASTRON SOC, V335, pL84, DOI 10.1046/j.1365-8711.2002.05891.x; TOTH G, 1992, ASTROPHYS J, V389, P5, DOI 10.1086/171185; Tyson JA, 1998, ASTROPHYS J, V498, pL107, DOI 10.1086/311314; van den Bosch FC, 2000, ASTRON J, V119, P1579, DOI 10.1086/301315; Wang LM, 2000, ASTROPHYS J, V530, P17, DOI 10.1086/308331; Yoshida N, 2000, ASTROPHYS J, V544, pL87, DOI 10.1086/317306; Zwicky F, 1937, ASTROPHYS J, V86, P217, DOI 10.1086/143864	48	129	130	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1909	1913		10.1126/science.1085976	http://dx.doi.org/10.1126/science.1085976			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817140				2022-12-28	WOS:000183619400035
J	Spietz, L; Lehnert, KW; Siddiqi, I; Schoelkopf, RJ				Spietz, L; Lehnert, KW; Siddiqi, I; Schoelkopf, RJ			Primary electronic thermometry using the shot noise of a tunnel junction	SCIENCE			English	Article							COULOMB-BLOCKADE THERMOMETRY; TEMPERATURE; PREAMPLIFIER; RADIATION; JOSEPHSON; ARRAYS	We present a thermometer based on the electrical noise from a tunnel junction. In this thermometer, temperature is related to the voltage across the junction by a relative noise measurement with only the use of the electron charge, Boltzmann's constant, and assumption that electrons in a metal obey Fermi-Dirac statistics. We demonstrate proof-of-concept operation of this primary thermometer over four orders of magnitude in temperature, with as high as 0.1% accuracy and 0.02% precision in the range near 1 kelvin. The self-calibrating nature of this sensor allows for a much faster and simpler measurement than traditional Johnson noise thermometry, making it potentially attractive for metrology and for general use in cryogenic systems.	Yale Univ, Dept Phys, Dept Appl Phys, New Haven, CT 06520 USA; Univ Colorado, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA	Yale University; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA	Spietz, L (corresponding author), Yale Univ, Dept Phys, Dept Appl Phys, New Haven, CT 06520 USA.		Lehnert, Konrad/B-7577-2009; Schoelkopf, Robert J/J-8178-2012; Lehnert, Konrad W/O-7555-2019; Siddiqi, Irfan/E-5548-2015	Lehnert, Konrad/0000-0002-0750-9649; Lehnert, Konrad W/0000-0002-0750-9649; 				BENZ SP, P TEMPM 2001; Callendar HL., 1899, PHILOS MAG, V48, P519; DAHM AJ, 1969, PHYS REV LETT, V22, P1416, DOI 10.1103/PhysRevLett.22.1416; DELSING P, 1994, PHYSICA B, V194, P27, DOI 10.1016/0921-4526(94)90343-3; DICKE RH, 1946, REV SCI INSTRUM, V17, P268, DOI 10.1063/1.1770483; DOLAN GJ, 1977, APPL PHYS LETT, V31, P337, DOI 10.1063/1.89690; Johnson JB, 1928, PHYS REV, V32, P97, DOI 10.1103/PhysRev.32.97; Johnson JB, 1927, NATURE, V119, P50, DOI 10.1038/119050c0; KAMPER RA, 1971, J APPL PHYS, V42, P132, DOI 10.1063/1.1659545; Kauppinen JP, 1998, REV SCI INSTRUM, V69, P4166, DOI 10.1063/1.1149265; Kauppinen JP, 1996, PHYS REV LETT, V77, P3889, DOI 10.1103/PhysRevLett.77.3889; Kauppinen JP, 1996, PHYS REV B, V54, pR8353, DOI 10.1103/PhysRevB.54.R8353; Kraus J. D., 1986, RADIO ASTRONOMY, P7; Lusher CP, 2001, MEAS SCI TECHNOL, V12, P1, DOI 10.1088/0957-0233/12/1/301; Manninen AJ, 2000, PHYSICA B, V284, P2010, DOI 10.1016/S0921-4526(99)02795-7; Mohr PJ, 1999, J PHYS CHEM REF DATA, V28, P1713, DOI 10.1063/1.556049; MOLDOVER MR, 1988, PHYS REV LETT, V60, P249, DOI 10.1103/PhysRevLett.60.249; Niemeyer J, 1974, PTB-MITT, V84, P251; Nyquist H, 1928, PHYS REV, V32, P110, DOI 10.1103/PhysRev.32.110; Page L, 1999, REV MOD PHYS, V71, pS173, DOI 10.1103/RevModPhys.71.S173; PEKOLA JP, 1994, PHYS REV LETT, V73, P2903, DOI 10.1103/PhysRevLett.73.2903; Pekola JP, 2002, J LOW TEMP PHYS, V128, P263, DOI 10.1023/A:1019636703568; PRESTONTHOMAS H, 1990, METROLOGIA, V27, P3, DOI 10.1088/0026-1394/27/1/002; PUCEL RA, 1961, P IRE, V49, P1080; ROGOVIN D, 1974, ANN PHYS-NEW YORK, V86, P1, DOI 10.1016/0003-4916(74)90430-8; Rusby RL, 1996, METROLOGIA, V33, P409, DOI 10.1088/0026-1394/33/4/17; Schoelkopf RJ, 1997, PHYS REV LETT, V78, P3370, DOI 10.1103/PhysRevLett.78.3370; Schottky W, 1918, ANN PHYS-BERLIN, V57, P541; SOULEN RJ, 1994, J LOW TEMP PHYS, V94, P385, DOI 10.1007/BF00753823; TAYLOR BN, 1989, METROLOGIA, V26, P47, DOI 10.1088/0026-1394/26/1/004; TOLPYGO SK, IN PRESS IEEE T APPL; VANDUZER T, 1981, PRINCIPLES SUPERCOND, P75; WEBB RA, 1973, J LOW TEMP PHYS, V13, P383, DOI 10.1007/BF00654076; White DR, 1996, METROLOGIA, V33, P325, DOI 10.1088/0026-1394/33/4/6; White DR, 2000, METROLOGIA, V37, P11, DOI 10.1088/0026-1394/37/1/3	36	127	128	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1929	1932		10.1126/science.1084647	http://dx.doi.org/10.1126/science.1084647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817144				2022-12-28	WOS:000183619400041
J	Terreehorst, I; Hak, E; Oosting, AJ; Tempels-Pavlica, Z; de Monchy, JGR; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Gerth van Wijk, R				Terreehorst, I; Hak, E; Oosting, AJ; Tempels-Pavlica, Z; de Monchy, JGR; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Gerth van Wijk, R			Evaluation of impermeable covers for bedding in patients with allergic rhinitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOUSE-DUST-MITE; INTRANASAL CAPSAICIN; PERENNIAL RHINITIS; AVOIDANCE MEASURES; ASTHMATIC-PATIENTS; CUTOFF VALUES; DOUBLE-BLIND; CHILDREN; SYMPTOMS; OPTIMIZATION	Background: Encasing bedding in impermeable covers reduces exposure to house-dust mites, but the clinical benefit of this intervention as part of mite-avoidance measures for patients with allergic rhinitis is not known. We performed a multicenter, randomized, placebo-controlled trial of one year of use of impermeable bedding covers in the bedrooms of patients with rhinitis who were sensitized to house-dust mites to determine the effects on the signs and symptoms of disease. Methods: Three participating university medical centers enrolled 279 patients with allergic rhinitis who were randomly assigned to receive impermeable or non-impermeable (control) covers for their mattress, pillow, and duvet or blanket. At the start of the study, all participants received information on general allergen-avoidance measures. The severity of rhinitis was measured on a rhinitis-specific visual-analogue scale and by means of a daily symptom score and nasal allergen provocation testing. We also measured the concentrations of Dermatophagoides pteronyssinus (Der p1) and D. farinae (Der f 1) in dust from patients' mattresses, bedroom floors, and living-room floors at base line and after 12 months as a measure of the efficacy of the intervention. Results: A total of 232 patients completed the study. There was a significant reduction in Der p1 and Der f 1 concentrations in the mattresses of the impermeable-cover group, whereas there was no significant reduction in the control group. However, there was no significant effect on the clinical outcome measures. Analyses of subgroups defined according to age, level of exposure, type and severity of sensitization, or characteristics of the patient's home had similar results. Conclusions: Mite-proof bedding covers, as part of a structured allergy-control program, reduced the level of exposure to mite allergens. Despite the success of the intervention, this single avoidance measure did not lead to a significant improvement of clinical symptoms in patients with allergic rhinitis.	Erasmus MC, Dept Allergol, NL-3015 GD Rotterdam, Netherlands; Albert Scheitzer Hosp, Dept Internal Med, Dordrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol, Utrecht, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands; Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Utrecht University; University of Groningen; Utrecht University	Gerth van Wijk, R (corresponding author), Erasmus MC, Dept Allergol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.	r.gerthvanwijk@erasmusmc.nl		Terreehorst, Ingrid/0000-0002-3264-2740				*AM AC ALL ASTHM I, 2001, ALL REP 2000; BEAUMONT F, 1985, ALLERGY, V40, P181, DOI 10.1111/j.1398-9995.1985.tb00214.x; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; deGraafintVeld C, 1997, THORAX, V52, P143, DOI 10.1136/thx.52.2.143; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V103, P203, DOI 10.1016/S0091-6749(99)70491-4; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Herman D, 1997, INT J PEDIATR OTORHI, V39, P1, DOI 10.1016/S0165-5876(96)01457-7; Koepke JW, 1999, ALLERGY ASTHMA PROC, V20, P337; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Malm L, 2000, RHINOLOGY, V38, P1; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Moon JS, 1999, YONSEI MED J, V40, P238, DOI 10.3349/ymj.1999.40.3.238; NIEMEIJER NR, 1993, ALLERGY, V48, P491, DOI 10.1111/j.1398-9995.1993.tb01104.x; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; Oosting AJ, 2002, J ALLERGY CLIN IMMUN, V110, P500, DOI 10.1067/mai.2002.126791; SHEIKH A, 2001, COCHRANE DB SYST REV, V4; Terreehorst I, 2002, CLIN EXP ALLERGY, V32, P1160, DOI 10.1046/j.1365-2745.2002.01461.x; TVELD TDGI, 1995, ANN ALLERG ASTHMA IM, V75, P261; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693, DOI 10.1289/ehp.021100693; Van Wijk RG, 2000, CLIN EXP ALLERGY, V30, P1792, DOI 10.1046/j.1365-2222.2000.00920.x; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; VANREE R, 1994, ALLERGY, V49, P254; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262	34	139	148	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					237	246		10.1056/NEJMoa023171	http://dx.doi.org/10.1056/NEJMoa023171			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867607	Green Published			2022-12-28	WOS:000184165700007
J	Modi, A; Koratkar, N; Lass, E; Wei, BQ; Ajayan, PM				Modi, A; Koratkar, N; Lass, E; Wei, BQ; Ajayan, PM			Miniaturized gas ionization sensors using carbon nanotubes	NATURE			English	Article							CO2; SENSITIVITY; NO2	Gas sensors operate by a variety of fundamentally different mechanisms(1-14). Ionization sensors(13-14) work by fingerprinting the ionization characteristics of distinct gases, but they are limited by their huge, bulky architecture, high power consumption and risky high-voltage operation. Here we report the fabrication and successful testing of ionization microsensors featuring the electrical breakdown of a range of gases and gas mixtures at carbon nanotube tips. The sharp tips of nanotubes generate very high electric fields at relatively low voltages, lowering breakdown voltages several-fold in comparison to traditional electrodes, and thereby enabling compact, battery-powered and safe operation of such sensors. The sensors show good sensitivity and selectivity, and are unaffected by extraneous factors such as temperature, humidity, and gas flow. As such, the devices offer several practical advantages over previously reported nanotube sensor systems(15-17). The simple, low-cost, sensors described here could be deployed for a variety of applications, such as environmental monitoring, sensing in chemical processing plants, and gas detection for counter-terrorism.	Rensselaer Polytech Inst, Dept Mech Aerosp & Nucl Engn, Troy, NY 12180 USA; Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA	Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute	Koratkar, N (corresponding author), Rensselaer Polytech Inst, Dept Mech Aerosp & Nucl Engn, Troy, NY 12180 USA.	koratn@rpi.edu; ajayan@rpi.edu	Wei, Bingqing/A-4525-2008; Lass, Eric A/B-4586-2014; Lass, Eric/AAE-9593-2019	Wei, Bingqing/0000-0002-9416-1731; Lass, Eric A/0000-0003-1428-3585; Lass, Eric/0000-0003-1428-3585				Abdel-Salam M., 2000, HIGH VOLTAGE ENG THE; Ajayan PM, 2001, TOP APPL PHYS, V80, P391; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Capone S, 1999, LANGMUIR, V15, P1748, DOI 10.1021/la980608+; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Currie JF, 1999, SENSOR ACTUAT B-CHEM, V59, P235, DOI 10.1016/S0925-4005(99)00227-0; de Jonge N, 2002, NATURE, V420, P393, DOI 10.1038/nature01233; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; Drotar JT, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.125417; Edgcombe CJ, 2001, J MICROSC-OXFORD, V203, P188, DOI 10.1046/j.1365-2818.2001.00890.x; Endres HE, 1999, SENSOR ACTUAT B-CHEM, V57, P83, DOI 10.1016/S0925-4005(99)00060-X; *ENV RESP TEAM, 1994, 2114 EPA ENV RESP TE; Forbes RG, 2003, ULTRAMICROSCOPY, V95, P57, DOI 10.1016/S0304-3991(02)00297-8; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Lee MS, 2000, SENSOR ACTUAT B-CHEM, V68, P293, DOI 10.1016/S0925-4005(00)00447-0; LONGERGAN MC, 1996, CHEM MATER, V8, P2298; Matsubara S, 2000, SENSOR ACTUAT B-CHEM, V65, P128, DOI 10.1016/S0925-4005(99)00407-4; Meek J.M., 1978, ELECT BREAKDOWN GASE; MIASIK JJ, 1986, J CHEM SOC FARAD T 1, V82, P1117, DOI 10.1039/f19868201117; PENG S, 2001, 3 INT WORKSH STRUCT, P1142; Shimizu Y, 1999, MRS BULL, V24, P18, DOI 10.1557/S0883769400052465; *SRI INSTR, 1998, FLAM ION DET PROD DA; TAKAO Y, 1994, J ELECTROCHEM SOC, V141, P1028, DOI 10.1149/1.2054836; WATSON J, 1999, MAT RES B, V24; Wei BQ, 2002, NATURE, V416, P495, DOI 10.1038/416495a; Zhang ZJ, 2000, APPL PHYS LETT, V77, P3764, DOI 10.1063/1.1330751	26	784	827	9	413	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					171	174		10.1038/nature01777	http://dx.doi.org/10.1038/nature01777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853951				2022-12-28	WOS:000184032700036
J	Swingler, S; Brichacek, B; Jacque, JM; Ulich, C; Zhou, J; Stevenson, M				Swingler, S; Brichacek, B; Jacque, JM; Ulich, C; Zhou, J; Stevenson, M			HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection	NATURE			English	Article							T-CELLS; ACTIVATION; REPLICATION; VIRUS; LYMPHOCYTES; INHIBITION; EVASION; THERAPY	All primate lentiviruses (HIV-1, HIV-2, SIV) encode Nef proteins, which are important for viral replication and pathogenicity in vivo(1-3). It is not known how Nef regulates these processes. It has been suggested that Nef protects infected cells from apoptosis and recognition by cytotoxic T lymphocytes(4-6). Other studies suggest that Nef influences the activation state of the infected cell, thereby enhancing the ability of that cell to support viral replication(7-10). Here we show that macrophages that express Nef or are stimulated through the CD40 receptor release a paracrine factor that renders T lymphocytes permissive to HIV-1 infection. This activity requires the upregulation of B-cell receptors involved in the alternative pathway of T-lymphocyte stimulation. T lymphocytes stimulated through this pathway become susceptible to viral infection without progressing through the cell cycle. We identify two proteins, soluble CD23 and soluble ICAM, that are induced from macrophages by Nef and CD40L, and which mediate their effects on lymphocyte permissivity. Our results reveal a mechanism by which Nef expands the cellular reservoir of HIV-1 by permitting the infection of resting T lymphocytes.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Jacque, Jean-Marc/B-6875-2008		NIAID NIH HHS [R01 AI032890, R01 AI037475] Funding Source: Medline; NIMH NIH HHS [R01 MH093306, R01 MH064411] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; Collins KL, 1999, IMMUNOL REV, V168, P65, DOI 10.1111/j.1600-065X.1999.tb01283.x; Davis SJ, 1996, SCIENCE, V273, P1241, DOI 10.1126/science.273.5279.1241; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; GRUBER MF, 1995, J IMMUNOL, V154, P5528; Jamieson BD, 1998, J VIROL, V72, P6520, DOI 10.1128/JVI.72.8.6520-6526.1998; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; KALTER DC, 1991, J IMMUNOL, V146, P298; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Lisignoli G, 1996, EUR J IMMUNOL, V26, P17, DOI 10.1002/eji.1830260104; Pierson TC, 2002, J VIROL, V76, P8518, DOI 10.1128/JVI.76.17.8518-8513.2002; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	28	190	195	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2003	424	6945					213	219		10.1038/nature01749	http://dx.doi.org/10.1038/nature01749			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853962	Green Accepted			2022-12-28	WOS:000184032700047
J	Hajjar, I; Kotchen, TA				Hajjar, I; Kotchen, TA			Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; BLOOD-PRESSURE; NATIONAL-HEALTH; POPULATION	Context Prior analyses of National Health and Nutrition Examination Survey (NHANES) data through 1991 have suggested that hypertension prevalence is declining, but more recent self-reported rates of hypertension suggest that the rate is increasing. Objective To describe trends in the prevalence, awareness, treatment, and control of hypertension in the United States using NHANES data. Design, Setting, and Participants Survey using a stratified multistage probability sample of the civilian noninstitutionalized population. The most recent NHANES survey, conducted in 1999-2000 (n=5448), was compared with the 2 phases of NHANES III conducted in 1988-1991 (n=9901) and 1991-1994 (n =9717). Individuals aged 18 years or older were included in this analysis. Main Outcome Measures Hypertension, defined as a measured blood pressure of 140/90 mm Hg or greater or reported use of anti hypertensive medications. Hypertension awareness and treatment were assessed with standardized questions. Hypertension control was defined as treatment with anti hypertensive medication and a measured blood pressure of less than 140/90 mm Hg. Results In 1999-2000, 28.7% of NHANES participants had hypertension, an increase of 3.7% (95% confidence interval [CI], 0%-8.3%) from 1988-1991. Hypertension prevalence was highest in non-Hispanic blacks (33.5%), increased with age (65.4% among those aged greater than or equal to60 years), and tended to be higher in women (30.1%). In a multiple regression analysis, increasing age, increasing body mass index, and non-Hispanic black race/ethnicity were independently associated with increased rates of hypertension. Overall, in 1999-2000, 68.9% were aware of their hypertension (nonsignificant decline of -0.3%; 95% CI, -4.2% to 3.6%), 58.4% were treated (increase of 6.0%; 95% Cl, 1.2%-10.8%), and hypertension was controlled in 31.0% (increase of 6.4%; 95% Cl, 1.6%-11.2%). Women, Mexican Americans, and those aged 60 years or older had significantly lower rates of control compared with men, younger individuals, and non-Hispanic whites. Conclusions Contrary to earlier reports, hypertension prevalence is increasing in the United States. Hypertension control rates, although improving, continue to be low. Programs targeting hypertension prevention and treatment are of utmost importance.	Univ S Carolina, Palmetto Hlth Alliance, Dept Med, Div Geriatr, Columbia, SC 29203 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Epidemiol, Milwaukee, WI 53226 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical College of Wisconsin; Medical College of Wisconsin	Hajjar, I (corresponding author), Univ S Carolina, Palmetto Hlth Alliance, Dept Med, Div Geriatr, 9 Med Pk,Suite 230, Columbia, SC 29203 USA.	ihab.hajjar@palmettohealth.org						[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], VITAL HLTH STAT; [Anonymous], 1996, ANAL REPORTING GUIDE; AYLA C, 2002, MMWR-MORBID MORTAL W, V51, P456; Baines LA, 2001, DIABETES, V50, P843; Barker WH, 1998, HYPERTENSION, V31, P552, DOI 10.1161/01.HYP.31.1.552; BERGLUND PA, 2002, P 27 ANN SAS US GROU; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Goff DC, 2001, ANN EPIDEMIOL, V11, P271, DOI 10.1016/S1047-2797(00)00224-6; Hansson L, 1999, BLOOD PRESSURE, V8, P196; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; Kannel W B, 1995, Hypertens Res, V18, P181, DOI 10.1291/hypres.18.181; KANNEL WB, 1993, J CARDIOVASC PHARM, V21, pS27, DOI 10.1097/00005344-199321002-00006; Klein RJ., 2001, HLTH PEOPLE 2010 STA, DOI DOI 10.1037/E583772012-001; Kotchen JM, 1998, AM J PUBLIC HEALTH, V88, P1696, DOI 10.2105/AJPH.88.11.1696; Lloyd-Jones DM, 2000, HYPERTENSION, V36, P594, DOI 10.1161/01.HYP.36.4.594; Lloyd-Jones DM, 2002, HYPERTENSION, V40, P640, DOI 10.1161/01.HYP.0000035855.44620.DA; *NAT AC AG SOC, 2000, HYP COMM COND OLD AM; *NAT HLTH NUTR EX, 1989, CYCL 2 BLOOD PRESS Q; Neal B, 2000, LANCET, V356, P1955; *NHANES, 2002, BLOOD PRESS SECT PHY; Rust K., 1985, J OFF STAT, V1, P381; Rust K F, 1996, Stat Methods Med Res, V5, P283, DOI 10.1177/096228029600500305; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; Vargas CM, 1997, PREV MED, V26, P678, DOI 10.1006/pmed.1997.0190; Wassertheil-Smoller S, 2000, HYPERTENSION, V36, P780, DOI 10.1161/01.HYP.36.5.780; *WEST INC, 1996, NAT HLTH NUTR EX SUR; 1992, VITAL HLTH STAT, V2, P1; 1997, ARCH INTERN MED, V157, P2413; 1995, HLTH PEOPLE 2000 MID	36	1689	1832	1	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					199	206		10.1001/jama.290.2.199	http://dx.doi.org/10.1001/jama.290.2.199			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851274	Bronze			2022-12-28	WOS:000183989800024
J	Schuppan, D; Esslinger, B; Dieterich, W				Schuppan, D; Esslinger, B; Dieterich, W			Innate immunity and coeliac disease	LANCET			English	Editorial Material							GLUTEN; GLIADIN; SPRUE		Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany.							Ciclitira PJ, 2001, GASTROENTEROLOGY, V120, P1526, DOI 10.1053/gast.2001.24056; Liu JJ, 2002, AM J HUM GENET, V70, P51, DOI 10.1086/338453; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Schuppan D, 2002, SCIENCE, V297, P2218, DOI 10.1126/science.1077572; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Tuckova L, 2002, J LEUKOCYTE BIOL, V71, P625; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; Wills AJ, 2002, CURR OPIN NEUROL, V15, P519, DOI 10.1097/00019052-200210000-00001	10	29	29	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					3	4		10.1016/S0140-6736(03)13843-3	http://dx.doi.org/10.1016/S0140-6736(03)13843-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853189				2022-12-28	WOS:000184056900003
J	Haberer, J; Trivedi, NN; Kohlwes, J; Tierney, L				Haberer, J; Trivedi, NN; Kohlwes, J; Tierney, L			A gut feeling	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHRONIC ISCHEMIC GASTRITIS; MESENTERIC ISCHEMIA; CT ANGIOGRAPHY; REVASCULARIZATION		Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA	Stanford University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Haberer, J (corresponding author), Stanford Univ, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	haberer@healthpolicy.stanford.edu	Haberer, Jessica/AAH-7976-2019	Haberer, Jessica/0000-0001-5845-3190				BABU SC, 1993, AM J SURG, V166, P227, DOI 10.1016/S0002-9610(05)81061-X; Bakker RC, 1997, MAYO CLIN PROC, V72, P546, DOI 10.4065/72.6.546; Bouras EP, 2001, MAYO CLIN PROC, V76, P923; Brandt LJ, 2002, SLEISENGER FORDTRANS, V2, P2321; Dunphy JE, 1936, AM J MED SCI, V192, P109, DOI 10.1097/00000441-193607000-00014; Hojgaard L, 1987, GASTROENTEROLOGY, V92, P226, DOI 10.1016/0016-5085(87)90864-X; Horton KM, 2002, GASTROINTEST ENDOSC, V55, pS37, DOI 10.1067/mge.2002.124745; Horton KM, 2001, RADIOGRAPHICS, V21, P1463, DOI 10.1148/radiographics.21.6.g01nv091463; Kim TS, 1998, J VASC INTERV RADIOL, V9, P553, DOI 10.1016/S1051-0443(98)70320-3; MCAFEE MK, 1992, AM J SURG, V164, P220, DOI 10.1016/S0002-9610(05)81074-8; Meaney JFM, 1997, J MAGN RESON IMAGING, V7, P171, DOI 10.1002/jmri.1880070126; Moawad J, 1997, SURG CLIN N AM, V77, P357, DOI 10.1016/S0039-6109(05)70554-5; Taourel PG, 1996, RADIOLOGY, V199, P632, DOI 10.1148/radiology.199.3.8637978; VANDAMME H, 1992, J CARDIOVASC SURG, V33, P451	14	10	11	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					73	78		10.1056/NEJMcps030332	http://dx.doi.org/10.1056/NEJMcps030332			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840095				2022-12-28	WOS:000183896100012
J	Markowitz, AJ; Rabow, MW				Markowitz, AJ; Rabow, MW			Alzheimer disease: "It's okay, mama, if you want to go, it's okay"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Hurley AC, 2002, JAMA-J AM MED ASSOC, V288, P2324, DOI 10.1001/jama.288.18.2324	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					105	105		10.1001/jama.290.1.105	http://dx.doi.org/10.1001/jama.290.1.105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837718				2022-12-28	WOS:000183868600026
J	Masoudi, FA; Wang, YF; Inzucchi, SE; Setaro, JF; Havranek, EP; Foody, JM; Krumholz, HM				Masoudi, FA; Wang, YF; Inzucchi, SE; Setaro, JF; Havranek, EP; Foody, JM; Krumholz, HM			Metformin and thiazolidinedione use in medicare patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LACTIC-ACIDOSIS; THERAPY; CONTRAINDICATIONS	Context According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these anti hyperglycemic drugs in diabetic patients with heart failure. Objective To determine the proportions of patients hospitalized with heart failure and concomitant diabetes treated with metformin or thiazolidinediones. Design Serial cross-sectional measurements using data from retrospective medical record abstraction. Setting Nongovernmental acute care hospitals in the United States. Patients Two nationally representative samples of Medicare beneficiaries hospitalized with the primary diagnosis of heart failure and concomitant diabetes between April 1998 and March 1999 and between July 2000 and June 2001. Main Outcome Measures The prescription of either metformin or a thiazolidinedione at hospital discharge. Results In the 1998-1999 sample (n=12505), 7.1% of patients were discharged with a prescription for metformin, 7.2% with a prescription for a thiazolidinedione, and 13.5% with a prescription for either drug. In the 2000-2001 sample (n=13158), metformin use increased to 11.2%, thiazolidinedione use to 16.1%, And use of either drug to 24.4% (P<.001 for all comparisons). Similar increases were seen among patients of all age groups, all races, and both sexes. Conclusions The use of metformin and thiazolidinediones is common and has increased rapidly in Medicare beneficiaries with diabetes and heart failure in direct contrast with explicit warnings against this practice by the Food and Drug Administration. Further studies to establish the safety and effectiveness of this practice are needed to ensure optimal care of patients with diabetes and heart failure.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, Endocrinol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Geriatr Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med,Div Cardiol, Denver, CO USA; Colorado Fdn Med Care, Aurora, CO USA	Yale University; Yale University; Yale University; Yale University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 333 Cedar St,Room I-456 SHM,POB 208088, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	Inzucchi, Silvio/ABF-4121-2021; Masoudi, Frederick/Q-7467-2019; , Harlan/AAI-2875-2020		NCI NIH HHS [500-02-CO 01] Funding Source: Medline; NIA NIH HHS [K08-AG01011] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG001011] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; *BRIST MYERS SQUIB, GLUC GLUC XR PRESCR; CAMPBELL IW, 1985, HORM METAB RES, V15, P105; Emslie-Smith AM, 2001, DIABETIC MED, V18, P483, DOI 10.1046/j.1464-5491.2001.00509.x; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; *GLAX PHARM, 2002, AV PRESCR INF; Goff DC, 2000, ARCH INTERN MED, V160, P197, DOI 10.1001/archinte.160.2.197; Holstein A, 1999, DIABETIC MED, V16, P692, DOI 10.1046/j.1464-5491.1999.00115.x; Horlen C, 2002, JAMA-J AM MED ASSOC, V287, P2504, DOI 10.1001/jama.287.19.2504-a; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; INZUCCHI SE, 2002, PRACT DIABETOL, V21, P7; LUFT D, 1978, DIABETOLOGIA, V14, P75, DOI 10.1007/BF01263444; *MED EC CO INC, 1998, PHYS DESK REF; *MED EC CO INC, 1999, PHYS DESK REF; Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415; Parulkar AA, 2001, ANN INTERN MED, V134, P61, DOI 10.7326/0003-4819-134-1-200101020-00014; SALPETER S, 2002, COCHRANE DB SYST REV, V2, P2967; Stang M, 1999, DIABETES CARE, V22, P925, DOI 10.2337/diacare.22.6.925; *TAK PHARM, 2002, ACT PRESCR INF; Tang WHW, 2003, J AM COLL CARDIOL, V41, P1394, DOI 10.1016/S0735-1097(03)00159-1; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; *US FDA, SUMM ACT AV; WIHOLM BE, 1993, EUR J CLIN PHARMACOL, V44, P589, DOI 10.1007/BF02440866	23	96	97	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					81	85		10.1001/jama.290.1.81	http://dx.doi.org/10.1001/jama.290.1.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837715	Bronze			2022-12-28	WOS:000183868600023
J	Levi, DM; Tzakis, AG; Kato, T; Madariaga, J; Mittal, NK; Nery, J; Nishida, S; Ruiz, P				Levi, DM; Tzakis, AG; Kato, T; Madariaga, J; Mittal, NK; Nery, J; Nishida, S; Ruiz, P			Transplantation of the abdominal wall	LANCET			English	Article							MULTIVISCERAL TRANSPLANTATION; INTESTINAL TRANSPLANTATION; CAMPATH-1H; DONOR	Background Closure of the abdomen in patients undergoing intestinal transplantation can be extremely difficult, if not impossible. We describe our initial experience with abdominal wall allotransplantation to facilitate abdominal closure. Methods We undertook nine cadaveric abdominal wall composite allograft transplants in eight patients. The graft's blood supply was based on the inferior epigastric. vessels left in continuity with the donor femoral and iliac vessels. Skin biopsies were undertaken randomly and when rejection was suspected. Vessel patency was monitored by doppler ultrasound. Findings Six patients have survived, five of whom have intact, viable abdominal wall grafts. Two patients have had a clinically mild episode of acute rejection of the skin of the abdominal wall that resolved with corticosteroid therapy. No clinically apparent graft-versus-host disease has been noted. Interpretation Transplantation of an abdominal wall composite allograft can facilitate reconstruction and closure of the abdominal compartment in intestinal transplant recipients with complex abdominal wall defects.	Univ Miami, Jackson Mem Med Ctr, Dept Surg, Div Transplantat, Miami, FL USA; Univ Miami, Jackson Mem Med Ctr, Dept Pathol, Miami, FL USA	University of Miami; University of Miami	Levi, DM (corresponding author), Univ Miami, Sch Med, Daughtry Family Dept Surg, POB 015809, Miami, FL 33101 USA.							Abu-Elmagd K, 2000, ANN SURG, V232, P680, DOI 10.1097/00000658-200011000-00010; Alexandrides IJ, 2000, PLAST RECONSTR SURG, V106, P805, DOI 10.1097/00006534-200009040-00008; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; Hettiaratchy S, 2001, LANCET, V357, P494, DOI 10.1016/S0140-6736(00)04037-X; Jones JW, 2000, NEW ENGL J MED, V343, P468, DOI 10.1056/NEJM200008173430704; Kato T, 2002, WORLD J SURG, V26, P226; Nishida S, 2002, J GASTROINTEST SURG, V6, P233, DOI 10.1016/S1091-255X(01)00073-7; Nishida S, 2002, TRANSPL P, V34, P1889, DOI 10.1016/S0041-1345(02)03111-1; STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343; Tzakis AG, 2002, TRANSPL P, V34, P937, DOI 10.1016/S0041-1345(02)02679-9	10	242	257	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2173	2176		10.1016/S0140-6736(03)13769-5	http://dx.doi.org/10.1016/S0140-6736(03)13769-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842369				2022-12-28	WOS:000183815600008
J	Klausner, RD; Fauci, AS; Corey, L; Nabel, GJ; Gayle, H; Berkley, S; Haynes, BF; Baltimore, D; Collins, C; Douglas, RG; Esparza, J; Francis, DP; Ganguly, NK; Gerberding, JL; Johnston, MI; Kazatchkine, MD; McMichael, AJ; Makgoba, MW; Pantaleo, G; Piot, P; Shao, YM; Tramont, E; Varmus, H; Wasserheit, JN				Klausner, RD; Fauci, AS; Corey, L; Nabel, GJ; Gayle, H; Berkley, S; Haynes, BF; Baltimore, D; Collins, C; Douglas, RG; Esparza, J; Francis, DP; Ganguly, NK; Gerberding, JL; Johnston, MI; Kazatchkine, MD; McMichael, AJ; Makgoba, MW; Pantaleo, G; Piot, P; Shao, YM; Tramont, E; Varmus, H; Wasserheit, JN			The need for a global HIV vaccine enterprise	SCIENCE			English	Editorial Material									Bill & Melinda Gates Fdn, Seattle, WA 98102 USA; NIAID, Div AIDS, NIH, Vaccine & Prevent Res Program, Bethesda, MD 20892 USA; NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, HIV Vaccine Trials Network, Program Infect Dis, Seattle, WA 98109 USA; Univ Washington, Dept Lab Med, Seattle, WA 98109 USA; Int AIDS Vaccine Initiat, New York, NY 10038 USA; Duke Univ, Sch Med, Durham, NC 27710 USA; CALTECH, Pasadena, CA 91125 USA; AIDS Vaccine Advocacy Coalit, New York, NY 10011 USA; Sequella Global TB Fdn, Rockville, MD 20850 USA; WHO, UNAIDS, Joint UN Programme HIV AIDS, HIV Vaccine Initiat, Geneva 27, Switzerland; VaxGen Inc, Brisbane, CA 94005 USA; Indian Council Med Res, New Delhi 110029, India; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; ANRS, F-75013 Paris, France; Univ Oxford, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Natal, ZA-4041 Durban, South Africa; Univ Lausanne, CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Bill & Melinda Gates Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; International AIDS Vaccine Initiative; Duke University; California Institute of Technology; UNAIDS; World Health Organization; Indian Council of Medical Research (ICMR); Centers for Disease Control & Prevention - USA; University of Oxford; University of Kwazulu Natal; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Memorial Sloan Kettering Cancer Center	Klausner, RD (corresponding author), Bill & Melinda Gates Fdn, Seattle, WA 98102 USA.		Pantaleo, Giuseppe/K-6163-2016; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436				FRANCIS DW, COMMUNICATION; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X	2	156	167	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2036	2039		10.1126/science.1086916	http://dx.doi.org/10.1126/science.1086916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829768				2022-12-28	WOS:000183774900028
J	Montgomery, DR; Manga, M				Montgomery, DR; Manga, M			Streamflow and water well responses to earthquakes	SCIENCE			English	Review							CLOSELY CLUSTERED WELLS; LEVEL CHANGES; GROUNDWATER LEVEL; LOMA-PRIETA; SEARCH; CALIFORNIA; PARKFIELD; AQUIFER; AUGUST; RIVER		Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA	University of Washington; University of Washington Seattle; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Montgomery, DR (corresponding author), Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA.		Manga, Michael/D-3847-2013	Manga, Michael/0000-0003-3286-4682				ATWATER BF, 1992, J GEOPHYS RES-SOL EA, V97, P1901, DOI 10.1029/91JB02346; BODVARSSON G, 1970, J GEOPHYS RES, V75, P2711, DOI 10.1029/JB075i014p02711; BOWER DR, 1978, CAN J EARTH SCI, V15, P331, DOI 10.1139/e78-039; BRIGGS RC, 1955, CALIFORNIA DIVISION, V171, P81; BRIGGS RO, 1991, WATER RESOUR BULL, V27, P991; Brodsky EE, 2000, GEOPHYS RES LETT, V27, P2741, DOI 10.1029/2000GL011534; BRODSKY EE, IN PRESS J GEOPHYS R; Chia YP, 2001, B SEISMOL SOC AM, V91, P1062, DOI 10.1785/0120000726; COOPER HH, 1965, J GEOPHYS RES, V70, P3915, DOI 10.1029/JZ070i016p03915; DOBROVOLSKY IP, 1979, PURE APPL GEOPHYS, V117, P1025, DOI 10.1007/BF00876083; FLEEGER GM, 1999, 994170 WRIR US GEOL; Grecksch G, 1999, GEOPHYS J INT, V138, P470, DOI 10.1046/j.1365-246X.1999.00894.x; Gudmundsson A, 2000, GEOPHYS RES LETT, V27, P2993, DOI 10.1029/1999GL011266; Hayford JF., 1908, CALIFORNIA EARTHQUAK, P114; IGARASHI G, 1991, J GEOPHYS RES-SOLID, V96, P4269, DOI 10.1029/90JB02637; KAWABE I, 1988, GEOPHYS RES LETT, V15, P1235, DOI 10.1029/GL015i011p01235; KING CY, 1994, APPL GEOCHEM, V9, P83, DOI 10.1016/0883-2927(94)90055-8; King CY, 1999, J GEOPHYS RES-SOL EA, V104, P13073, DOI 10.1029/1999JB900080; King CY, 2000, GEOPHYS J INT, V143, P469, DOI 10.1046/j.1365-246X.2000.01272.x; Kunugi T, 2000, J GEOPHYS RES-SOL EA, V105, P7805, DOI 10.1029/2000JB900020; Lee M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015116; Leonardi V, 1998, GEODIN ACTA, V11, P85, DOI 10.1016/S0985-3111(98)80007-7; Manga M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016618; Manga M, 2001, GEOPHYS RES LETT, V28, P2133, DOI 10.1029/2000GL012481; Masterlark TL, 1999, B SEISMOL SOC AM, V89, P1439; MATSUMOTO N, 1992, GEOPHYS RES LETT, V19, P1193, DOI 10.1029/92GL01042; MCPHERSON RC, 1992, CALIF GEOL, V45, P31; Montgomery DR, 2003, EARTH PLANET SC LETT, V209, P19, DOI 10.1016/S0012-821X(03)00074-8; MUIRWOOD R, 1993, J GEOPHYS RES-SOL EA, V98, P22035, DOI 10.1029/93JB02219; Nur A., 1974, GEOLOGY, V2, P217, DOI DOI 10.1130/0091-7613(1974)2<217:MJESCO>2.0.CO;2; Ohno M, 1997, GEOPHYS RES LETT, V24, P691, DOI 10.1029/97GL00471; PAPADOPOULOS GA, 1993, B SEISMOL SOC AM, V83, P925; Quilty EG, 1997, B SEISMOL SOC AM, V87, P310; Quilty EG, 1995, 95813 US GEOL SURV; Roeloffs E, 1996, ADV GEOPHYS, V37, P135, DOI 10.1016/S0065-2687(08)60270-8; Roeloffs E, 1997, PURE APPL GEOPHYS, V149, P21, DOI 10.1007/BF00945160; Roeloffs EA, 1998, J GEOPHYS RES-SOL EA, V103, P869, DOI 10.1029/97JB02335; ROELOFFS EA, 1995, 9542 US GEOL SURV; ROJSTACZER S, 1992, GEOLOGY, V20, P211, DOI 10.1130/0091-7613(1992)020<0211:PCAWLE>2.3.CO;2; ROJSTACZER S, 1995, NATURE, V373, P237, DOI 10.1038/373237a0; Sato T, 2000, GEOPHYS RES LETT, V27, P1219, DOI 10.1029/1999GL011187; SIBSON RH, 1981, AM GEOPHYS UNION M E, V4, P593; Silver PG, 1996, SCIENCE, V273, P77, DOI 10.1126/science.273.5271.77; VORHIS RC, 1967, 544C US GEOL SURV; Waag CJ, 1985, EARTHQ SPECTRA, V2, P151; WAKITA H, 1975, SCIENCE, V189, P553, DOI 10.1126/science.189.4202.553; WALLER R, 1966, 544A US GEOL SURV; WALLER R, 1966, 544B US GEOL SURV; WHITEHEAD RL, 1984, PURE APPL GEOPHYS, V122, P280, DOI 10.1007/BF00874599; Wood S.H., 1985, EARTHQ SPECTRA, V2, P127, DOI [10.1193/1.1585305, DOI 10.1193/1.1585305]; Woodcock D., 1996, OREGON OREG GEOL, V58, P27	51	218	239	5	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2047	2049		10.1126/science.1082980	http://dx.doi.org/10.1126/science.1082980			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829774	Green Submitted			2022-12-28	WOS:000183774900034
J	Paratcha, G; Ledda, F; Ibanez, CF				Paratcha, G; Ledda, F; Ibanez, CF			The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family Ligands	CELL			English	Article							MICE LACKING GDNF; C-RET PROTOONCOGENE; TYROSINE KINASE; N-CAM; SYNAPTIC PLASTICITY; FGF RECEPTOR; NERVOUS-SYSTEM; LIPID RAFTS; NEURONAL SURVIVAL; AXONAL GROWTH	Intercellular communication involves either direct cell-cell contact or release and uptake of diffusible signals, two strategies mediated by distinct and largely non-overlapping sets of molecules. Here, we show that the neural cell adhesion molecule NCAM can function as a signaling receptor for members of the GDNF ligand family. Association of NCAM with GFRalpha1, a GPI-anchored receptor for GDNF, downregulates NCAM-mediated cell adhesion and promotes high-affinity binding of GDNF to p140(NCAM), resulting in rapid activation of cytoplasmic protein tyrosine kinases Fyn and FAK in cells lacking RET, a known GDNF signaling receptor. GDNF stimulates Schwann cell migration and axonal growth in hippocampal and cortical neurons via binding to NCAM and activation of Fyn, but independently of RET. These results uncover an unexpected intersection between short- and long-range mechanisms of intercellular communication and reveal a pathway for GDNF signaling that does not require the RET receptor.	Karolinska Inst, Div Mol Neurobiol, Dept Neurosci, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Div Mol Neurobiol, Dept Neurosci, Retzius Vag 8,A2-2, S-17177 Stockholm, Sweden.			Paratcha, Gustavo/0000-0002-0804-4433				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chao CC, 2003, NEUROBIOL AGING, V24, P105, DOI 10.1016/S0197-4580(02)00047-7; Chazal G, 2000, J NEUROSCI, V20, P1446; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; DOHERTY P, 1995, J NEUROBIOL, V26, P437, DOI 10.1002/neu.480260315; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; Holst BD, 1998, P NATL ACAD SCI USA, V95, P2597, DOI 10.1073/pnas.95.5.2597; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; KLINZ SG, 1995, J NEUROCHEM, V65, P84; Kokaia Z, 1999, EUR J NEUROSCI, V11, P1202, DOI 10.1046/j.1460-9568.1999.00513.x; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nanobashvili A, 2000, P NATL ACAD SCI USA, V97, P12312, DOI 10.1073/pnas.97.22.12312; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Polo-Parada L, 2001, NEURON, V32, P815, DOI 10.1016/S0896-6273(01)00521-9; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Ronn LCB, 2000, INT J DEV NEUROSCI, V18, P193, DOI 10.1016/S0736-5748(99)00088-X; Saffell JL, 1995, MOL CELL NEUROSCI, V6, P521, DOI 10.1006/mcne.1995.0004; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Stork O, 1997, EUR J NEUROSCI, V9, P1117, DOI 10.1111/j.1460-9568.1997.tb01464.x; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Trupp M, 1997, J NEUROSCI, V17, P3554; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Yu T, 1998, J NEUROSCI, V18, P4684	50	449	481	1	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					867	879		10.1016/S0092-8674(03)00435-5	http://dx.doi.org/10.1016/S0092-8674(03)00435-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837245	Bronze			2022-12-28	WOS:000183817900011
J	Missler, M; Zhang, WQ; Rohlmann, A; Kattenstroth, G; Hammer, RE; Gottmann, K; Sudhof, TC				Missler, M; Zhang, WQ; Rohlmann, A; Kattenstroth, G; Hammer, RE; Gottmann, K; Sudhof, TC			alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis	NATURE			English	Article							CALCIUM CHANNELS; TRANSMITTER RELEASE; MICE LACKING; NEOCORTICAL NEURONS; LATROTOXIN RECEPTOR; GABAERGIC SYNAPSES; NERVE-TERMINALS; PYRAMIDAL CELLS; RAT NEOCORTEX; BRAIN	Synapses are specialized intercellular junctions in which cell adhesion molecules connect the presynaptic machinery for neurotransmitter release to the postsynaptic machinery for receptor signalling. Neurotransmitter release requires the presynaptic co-assembly of Ca2+ channels with the secretory apparatus, but little is known about how synaptic components are organized. alpha-Neurexins, a family of > 1,000 presynaptic cell-surface proteins encoded by three genes, link the pre- and postsynaptic compartments of synapses by binding extracellularly to postsynaptic cell adhesion molecules and intracellularly to presynaptic PDZ domain proteins. Using triple-knockout mice, we show that alpha-neurexins are not required for synapse formation, but are essential for Ca2+-triggered neurotransmitter release. Neurotransmitter release is impaired because synaptic Ca2+ channel function is markedly reduced, although the number of cell-surface Ca2+ channels appears normal. These data suggest that alpha-neurexins organize presynaptic terminals by functionally coupling Ca2+ channels to the presynaptic machinery.	Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Ctr Basic Neurosci, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Gottingen, Zentrum Physiol & Pathophysiol, D-37073 Gottingen, Germany; Ruhr Univ Bochum, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Gottingen; Ruhr University Bochum	Missler, M (corresponding author), Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA.			Missler, Markus/0000-0001-8008-984X; Rohlmann, Astrid/0000-0003-0869-6893; Hammer, Robert E./0000-0001-5487-7551				Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Ben-Ari Y, 2001, TRENDS NEUROSCI, V24, P353, DOI 10.1016/S0166-2236(00)01813-0; Bergsman JB, 2000, J NEUROSCI, V20, P4368, DOI 10.1523/JNEUROSCI.20-12-04368.2000; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borst JGG, 1996, NATURE, V383, P431, DOI 10.1038/383431a0; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Hata Y, 1996, J NEUROSCI, V16, P2488; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Ino M, 2001, P NATL ACAD SCI USA, V98, P5323, DOI 10.1073/pnas.081089398; Iwasaki S, 2000, J NEUROSCI, V20, P59, DOI 10.1523/JNEUROSCI.20-01-00059.2000; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Katz B., 1969, RELEASE NEURAL TRANS; Koester HJ, 2000, J PHYSIOL-LONDON, V529, P625, DOI 10.1111/j.1469-7793.2000.00625.x; Levi S, 2002, J NEUROSCI, V22, P4274, DOI 10.1523/JNEUROSCI.22-11-04274.2002; Ludwig A, 1997, J NEUROSCI, V17, P1339; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Mohrmann R, 1999, J NEUROSCI, V19, P10004; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Muth JN, 2001, TRENDS PHARMACOL SCI, V22, P526, DOI 10.1016/S0165-6147(00)01797-1; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; Plitzko D, 2001, EUR J NEUROSCI, V14, P1412, DOI 10.1046/j.0953-816x.2001.01740.x; Rico B, 2002, NAT NEUROSCI, V5, P225, DOI 10.1038/nn808; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Rozov A, 2001, J PHYSIOL-LONDON, V531, P807, DOI 10.1111/j.1469-7793.2001.0807h.x; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Sakmann B., 1995, SINGLE CHANNEL RECOR; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Singer JH, 1996, J NEUROPHYSIOL, V76, P799, DOI 10.1152/jn.1996.76.2.799; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Xu-Friedman MA, 2001, J NEUROSCI, V21, P6666, DOI 10.1523/JNEUROSCI.21-17-06666.2001; Zhang W, 1999, EUR J NEUROSCI, V11, P2332, DOI 10.1046/j.1460-9568.1999.00655.x	50	480	494	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					939	948		10.1038/nature01755	http://dx.doi.org/10.1038/nature01755			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827191				2022-12-28	WOS:000183753900039
J	Harrap, SB				Harrap, SB			Where are all the blood-pressure genes?	LANCET			English	Review							COMPLEX HUMAN-DISEASES; WIDE LINKAGE ANALYSIS; GENOME SCAN; SUSCEPTIBILITY; DISEQUILIBRIUM; HYPERTENSION; PATTERNS; FAMILY; TRAITS	Context The potential for discovery of underlying genetic causes for common conditions, such as hypertension, is a major justification for the human genome project. Hopes have been raised that personalised molecular prognostic and therapeutic strategies will result from genomic studies. Starting point The largest and most recent searches of the genome (Mark Caulfield and colleagues, Lancet 2003; 361: 2118-23; Michael Province and colleagues, Am J Hypertens 2003; 16: 144-47) have found limited evidence of genes that determine hypertension, and even less evidence for the existence of causative DNA variants (alleles) within these genes. Previous genomic studies did not reach a consensus on the likely location of blood-pressure genes. The difficulty in identifying genetic causes for common conditions might be because the causative alleles are numerous, with small individual impact, and are distributed unevenly between populations. Where next? Without comprehensive and reliable description of the alleles associated with hypertension, using genetics for diagnosis remains tenuous. However, the discovery of a single allele proven to be associated with control of blood pressure could lead to the discovery of relevant and hovel physiological targets for the prevention and treatment of hypertension.	Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia	University of Melbourne	Harrap, SB (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.			Harrap, Stephen/0000-0003-2907-6714				Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069; Bashyam MD, 2003, J HUM GENET, V48, P55, DOI 10.1007/s100380300007; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Caulfield M, 2003, LANCET, V361, P2118, DOI 10.1016/S0140-6736(03)13722-1; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Cooper RS, 2002, HYPERTENSION, V40, P629, DOI 10.1161/01.HYP.0000035708.02789.39; Cui JSS, 2003, HYPERTENSION, V41, P207, DOI 10.1161/01.HYP.0000044938.94050.E3; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Harrap SB, 2000, AM J EPIDEMIOL, V152, P704, DOI 10.1093/aje/152.8.704; Harrap SB, 2002, PHYSIOL GENOMICS, V8, P99, DOI 10.1152/physiolgenomics.00069.2001; HARRAP SB, 1986, HYPERTENSION, V8, P572, DOI 10.1161/01.HYP.8.7.572; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kaplan N, 2001, GENET EPIDEMIOL, V20, P432, DOI 10.1002/gepi.1012; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Perola M, 2000, J HYPERTENS, V18, P1579, DOI 10.1097/00004872-200018110-00008; Phillips PC, 1999, TRENDS GENET, V15, P6, DOI 10.1016/S0168-9525(98)01622-9; Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272; Province MA, 2003, AM J HYPERTENS, V16, P144, DOI 10.1016/S0895-7061(02)03248-X; Ranade K, 2003, AM J HYPERTENS, V16, P158, DOI 10.1016/S0895-7061(02)03245-4; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Rice T, 2000, CIRCULATION, V102, P1956, DOI 10.1161/01.CIR.102.16.1956; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Thiel BA, 2003, AM J HYPERTENS, V16, P151, DOI 10.1016/S0895-7061(02)03246-6; WATTERSON GA, 1977, THEOR POPUL BIOL, V11, P141, DOI 10.1016/0040-5809(77)90023-5; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866; Xu XP, 1999, AM J HUM GENET, V64, P1694, DOI 10.1086/302405; Zhu DL, 2001, J HYPERTENS, V19, P55, DOI 10.1097/00004872-200101000-00008	30	56	65	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2149	2151		10.1016/S0140-6736(03)13694-X	http://dx.doi.org/10.1016/S0140-6736(03)13694-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826450				2022-12-28	WOS:000183654200025
J	Pisani, E; Garnett, GP; Brown, T; Stover, J; Grassly, NC; Hankins, C; Walker, N; Ghys, PD				Pisani, E; Garnett, GP; Brown, T; Stover, J; Grassly, NC; Hankins, C; Walker, N; Ghys, PD			Back to basics in HIV prevention: focus on exposure	BRITISH MEDICAL JOURNAL			English	Article							COUNTRIES	Despite worldwide efforts to prevent HIV infection, the number of people affected continues to rise. The authors of this article argue that a commonsense approach based on simple country by country analyses could improve the situation.	UNAIDS, Joint United Nations Programme HIV AIDS, CH-1211 Geneva, Switzerland; Family Hlth Int, Bangkok, Thailand; Univ London Imperial Coll Sci Technol & Med, UNAIDS Reference Grp, London, England; East West Ctr Thai Red Cross Soc Collaborat, Bangkok, Thailand; Futures Grp Inc, Glastonbury, CT USA	UNAIDS; Imperial College London	Ghys, PD (corresponding author), UNAIDS, Joint United Nations Programme HIV AIDS, 20 Ave Appia, CH-1211 Geneva, Switzerland.		Grassly, Nicholas C/C-6381-2008; Garnett, Geoffrey P/A-9312-2008	Grassly, Nicholas C/0000-0001-6067-4507; Hankins, Catherine/0000-0002-1642-8592; Pisani, Elizabeth/0000-0002-3674-631X				Ainsworth M, 2000, LANCET, V356, P55, DOI 10.1016/S0140-6736(00)02440-5; BARNETT T, 2002, AIDS 21ST CENTURY DI; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; GHEE AE, 2002, 14 INT AIDS C BARC J; *GLOB HIV PREV WOR, 2002, GLOB MOB HIV PREV BL; GORBACH P, 2002, BSS 5 SEXUAL BEHAV U; Jha P, 2001, SCIENCE, V292, P224, DOI 10.1126/science.1058187; *JOINT UN PROGR HI, 2002, REP GLOB HIV AIDS EP; Joint United Nations Program on HIV/AIDS and World Health Organization, 2000, GUID 2 GEN HIV SURV; Joint United Nations Programme on HIV/AIDS, 2002, AIDS EP UPD DEC 2002; KITABU MZ, 8 INT C AIDS AMST; LENG HB, 2002, LOW PREVALENCE SEXUA; LENG HB, 2002, HIV SENTINEL SURVEIL; *MIN HLTH REP IND, IN PRESS EST HIV IND; National Council for Population and Development (Kenya) Kenya. Central Bureau of Statistics. Macro International, 1999, KENY DEM HLTH SURV 1; *REP IND DIR COMM, 2002, BEH SURV POP RISK HI; *REP IND DIR COMM, 2002, NAT EST HIV INF 2002; RHODES T, 2002, BEHAV RISK FACTORS H; SOTO RJ, 2002, 14 INT AIDS C BARC J	19	83	85	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2003	326	7403					1384	1387		10.1136/bmj.326.7403.1384	http://dx.doi.org/10.1136/bmj.326.7403.1384			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694CN	12816830	Green Published			2022-12-28	WOS:000183756400028
J	Bigelow, MS; Lepeshkin, NN; Boyd, RW				Bigelow, MS; Lepeshkin, NN; Boyd, RW			Superluminal and slow light propagation in a room-temperature solid	SCIENCE			English	Article							ELECTROMAGNETICALLY INDUCED TRANSPARENCY; PULSE-PROPAGATION; ABSORPTION-LINE; GROUP-VELOCITY; ATOMIC VAPOR; ALEXANDRITE; STORAGE; SPEED; GAS	We have observed both superluminal and ultraslow light propagation in an alexandrite crystal at room temperature. Group velocities as slow as 91 meters per second to as fast as - 800 meters per second were measured and attributed to the influence of coherent population oscillations involving chromium ions in either mirror or inversion sites within the crystal lattice. Namely, ions in mirror sites are inversely saturable and cause superluminal light propagation, whereas ions in inversion sites experience conventional saturable absorption and produce slow light. This technique for producing large group indices is considerably easier than the existing methods to implement and is therefore suitable for diverse applications.	Univ Rochester, Inst Opt, Rochester, NY 14627 USA	University of Rochester	Bigelow, MS (corresponding author), Univ Rochester, Inst Opt, Rochester, NY 14627 USA.	mbigs@optics.rochester.edu						AKULSHIN AM, 1999, PHYS REV LETT, V81, P2190; Bigelow MS, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.113903; BOYD R, 2002, PROGR OPTICS, V43; Brillouin L., 1960, WAVE PROPAGATION GRO; Budker D, 1999, PHYS REV LETT, V83, P1767, DOI 10.1103/PhysRevLett.83.1767; CHU S, 1982, PHYS REV LETT, V48, P738, DOI 10.1103/PhysRevLett.48.738; FARRELL EF, 1963, AM MINERAL, V48, P804; HARRIS SE, 1990, PHYS REV LETT, V64, P1107, DOI 10.1103/PhysRevLett.64.1107; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; HILLMAN LW, 1983, OPT COMMUN, V45, P416, DOI 10.1016/0030-4018(83)90303-6; KASAPI A, 1995, PHYS REV LETT, V74, P2447, DOI 10.1103/PhysRevLett.74.2447; Kash MM, 1999, PHYS REV LETT, V82, P5229, DOI 10.1103/PhysRevLett.82.5229; Kuzmich A, 2001, PHYS REV LETT, V86, P3925, DOI 10.1103/PhysRevLett.86.3925; Landau LD., 1984, ELECTRODYNAMICS CONT; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; MALCUIT MS, 1984, J OPT SOC AM B, V1, P73, DOI 10.1364/JOSAB.1.000073; Milonni PW, 2002, J PHYS B-AT MOL OPT, V35, pR31, DOI 10.1088/0953-4075/35/6/201; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; POWELL RC, 1985, PHYS REV B, V32, P2788, DOI 10.1103/PhysRevB.32.2788; SEGARD B, 1985, PHYS LETT A, V109, P213, DOI 10.1016/0375-9601(85)90305-6; SHAND ML, 1981, J APPL PHYS, V52, P953, DOI 10.1063/1.328784; Sommerfeld A, 1907, Z PHYS, V8, P841; STEINBERG AM, 1994, PHYS REV A, V49, P2071, DOI 10.1103/PhysRevA.49.2071; TEWARI SP, 1986, PHYS REV LETT, V56, P1811, DOI 10.1103/PhysRevLett.56.1811; Turukhin AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.023602; Wang LJ, 2000, NATURE, V406, P277, DOI 10.1038/35018520	26	678	716	3	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					200	202		10.1126/science.1084429	http://dx.doi.org/10.1126/science.1084429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855803				2022-12-28	WOS:000184056200038
J	Bodenheimer, T; Grumbach, K				Bodenheimer, T; Grumbach, K			Electronic technology - A spark to revitalize primary care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH INFORMATION; CHRONIC ILLNESS; E-MAIL; INTERNET; PHYSICIANS; MEDICINE; WEB; COMMUNICATION; INTERVENTION; PATIENT	The computer revolution has enormous potential to improve primary care in the areas of medical records, communication between physicians and patients, information sharing among health care providers, and rapid access to reliable medical information for both physicians and patients. A number of barriers must be overcome before computerization is widely embraced in primary care: e-health often takes too much time and is too expensive; the quality of Web-based medical information is inadequate; software programs may not interact with one another; patient privacy must be protected; public and private insurers rarely pay for electronic communication with patients; and the computer could interfere with the patient-physician relationship. Studies have shown that some computerized systems, such as reminder prompts and physician performance feedback, may improve physician performance and patient outcomes, but if these systems are too time-consuming, physicians may not use them. If primary care practices are to benefit from the electronic revolution, they must redesign their clinical processes to ensure that e-health facilitates rather than hinders the work of physicians.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Bldg 80-83,1001 Potrero Ave, San Francisco, CA 94110 USA.		Grumbach, Kevin/L-9222-2016					Angelo SJ, 2002, JAMA-J AM MED ASSOC, V287, P1227, DOI 10.1001/jama.287.10.1227; Aubert BA, 2001, SOC SCI MED, V53, P879, DOI 10.1016/S0277-9536(00)00388-9; Baker A M, 2001, Jt Comm J Qual Improv, V27, P179; Baker L, 2003, JAMA-J AM MED ASSOC, V289, P2400, DOI 10.1001/jama.289.18.2400; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2003, J AM MED INFORM ASSN, V10, P1, DOI 10.1197/jamia.M1097; BAZZOLI F, 2000, INTERNET HLTH CA JUL, P54; Biermann JS, 1999, CANCER, V86, P381, DOI 10.1002/(SICI)1097-0142(19990801)86:3<381::AID-CNCR4>3.3.CO;2-7; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Brodie M, 2000, HEALTH AFFAIR, V19, P255, DOI 10.1377/hlthaff.19.6.255; Chambliss ML, 2001, J FAM PRACTICE, V50, P1063; CHIN T, 2002, AM MED NEWS     0225, V27, P30; CHIN T, 2003, AM MED NEWS     0310, P35; CHIN T, 2002, AM MED NEWS     0920, P34; CHIN T, 2003, AM MED NEWS     0217, P1; CROSS MA, 2001, INTERNET HLTH CA MAY, P34; DAHLBERG PK, 2000, INTERNET HLTH CA JUL, P32; Demakis JG, 2000, JAMA-J AM MED ASSOC, V284, P1411, DOI 10.1001/jama.284.11.1411; Dick RS, 1997, COMPUTER BASED PATIE; Ebell MH, 2001, FAM MED, V33, P311; Eysenbach G, 2002, JAMA-J AM MED ASSOC, V287, P2691, DOI 10.1001/jama.287.20.2691; Fischer S, 2003, J AM MED INFORM ASSN, V10, P139, DOI 10.1197/jamia.M1180; Goldsmith J, 2000, HEALTH AFFAIR, V19, P42, DOI 10.1377/hlthaff.19.6.42; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Hersh WR, 1998, JAMA-J AM MED ASSOC, V280, P1347, DOI 10.1001/jama.280.15.1347; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kassirer JP, 2000, HEALTH AFFAIR, V19, P115, DOI 10.1377/hlthaff.19.6.115; KATZ SJ, IN PRESS J GEN INTER; Kleinke JD, 2000, HEALTH AFFAIR, V19, P57, DOI 10.1377/hlthaff.19.6.57; Lindberg DAB, 2001, JAMA-J AM MED ASSOC, V285, P806, DOI 10.1001/jama.285.6.806; LIPPMAN H, 2000, HIPPOCRATES      AUG, P39; LOWES R, 2001, MED EC          0409, P30; MACDONALD K, 2002, ACHIEVING TANGIBLE I; McDonald CJ, 1998, JAMA-J AM MED ASSOC, V280, P1325, DOI 10.1001/jama.280.15.1325; McKay HG, 2001, DIABETES CARE, V24, P1328, DOI 10.2337/diacare.24.8.1328; Mitchell E, 2001, BMJ-BRIT MED J, V322, P279, DOI 10.1136/bmj.322.7281.279; Mohr DN, 2003, J AM MED INFORM ASSN, V10, P85, DOI 10.1197/jamia.M1130; Moyer CA, 2002, AM J MANAG CARE, V8, P427; Moyer CA, 1999, AM J MANAG CARE, V5, P1513; OBRIEN MAT, 1998, COCHRANE LIB; Papshev D, 2001, AM J MANAG CARE, V7, P725; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Rajendran PR, 2001, JAMA-J AM MED ASSOC, V285, P804, DOI 10.1001/jama.285.6.804-a; SCHERGER JE, 2000, HIPPOCRATES      AUG, P8; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Solberg L I, 2000, Jt Comm J Qual Improv, V26, P525; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Winker MA, 2000, JAMA-J AM MED ASSOC, V283, P1600, DOI 10.1001/jama.283.12.1600	49	160	162	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					259	264		10.1001/jama.290.2.259	http://dx.doi.org/10.1001/jama.290.2.259			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	698GH	12851283				2022-12-28	WOS:000183989800033
J	Poole-Wilson, PA; Swedberg, K; Cleland, JGF; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, E; Metra, M; Remme, WJ; Torp-Pedersen, C; Scherhag, A; Skene, A				Poole-Wilson, PA; Swedberg, K; Cleland, JGF; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, E; Metra, M; Remme, WJ; Torp-Pedersen, C; Scherhag, A; Skene, A		COMET Investigators	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol, European Trial (COMET): randomised controlled trial	LANCET			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; INTERVENTION TRIAL; MERIT-HF; BETA-BLOCKERS; MORTALITY; BISOPROLOL; MORBIDITY; BLOCKADE; DESIGN; CR/XL	Background beta blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome. Methods In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily). Patients were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary endpoints were all-cause mortality and the composite endpoint of all-cause mortality or all-cause admission. Analysis was done by intention to treat. Findings The mean study duration was 58 months (SD 6). The mean ejection fraction was 0.26 (0.07) and the mean age 62 years (11). The all-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.93], p=0.0017). The reduction of all-cause mortality was consistent across predefined subgroups. The composite endpoint of mortality or all-cause admission occurred in 1116 (74%) of 1511 on carvedilol and in 1160 (76%) of 1518 on metoprolol (0.94 [0.86-1.02], p=0.122). Incidence of side-effects and drug withdrawals did not differ by much between the two study groups. Interpretation Our results suggest that carvedilol extends survival compared with metoprolol.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London SW3 6LY, England; Sahlgrenska Univ Hosp Ostra, Dept Med, Gothenburg, Sweden; Univ Hull, Dept Cardiol, Kingston Upon Hull, Yorks, England; Osped Cattinara, Dept Cardiol, Trieste, Italy; Univ Hosp, Med Klin 1, Aachen, Germany; Hop La Pitie Salpetriere, Dept Cardiol, Paris, France; SOCAR Res SA, Nyon, Switzerland; F Hoffmann La Roche & Co Ltd, Rotterdam, Netherlands; Univ Brescia, Cattedra Cardiol, I-25121 Brescia, Italy; Sticares Cardiovasc Res Fdn, Rhoon, Netherlands; Bispebjerg Univ Hosp, Dept Cardiol, Copenhagen, Denmark; Nottingham Clin Res Grp, Nottingham, England	Imperial College London; Sahlgrenska University Hospital; University of Hull; RWTH Aachen University; RWTH Aachen University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Roche Holding; University of Brescia; University of Copenhagen; Bispebjerg Hospital	Poole-Wilson, PA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London SW3 6LY, England.		Metra, marco/E-7101-2010; Swedberg, Karl/B-2475-2008; Torp-Pedersen, Christian/E-5931-2013; Di Lenarda, Andrea/AAC-2377-2022; Cleland, John G./AAZ-4185-2020	Di Lenarda, Andrea/0000-0001-8482-4872; Cleland, John G./0000-0002-1471-7016; Metra, Marco/0000-0001-6691-8568				BOLGER AP, INT J CARDIOL; Cowie MR, 1997, EUR HEART J, V18, P208; Di Lenarda A, 1999, J AM COLL CARDIOL, V33, P1926, DOI 10.1016/S0735-1097(99)00134-5; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Freemantle N, 2003, JAMA-J AM MED ASSOC, V289, P2554, DOI 10.1001/jama.289.19.2554; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gilbert EM, 1996, CIRCULATION, V94, P2817, DOI 10.1161/01.CIR.94.11.2817; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; Jacob S, 1996, J HYPERTENS, V14, P489; Lechat P, 1999, LANCET, V353, P9; Lechat P, 2001, CIRCULATION, V103, P1428, DOI 10.1161/01.CIR.103.10.1428; Lubsen J, 2000, LANCET, V356, P1757, DOI 10.1016/S0140-6736(00)03215-3; MacMahon S, 1997, LANCET, V349, P375; Metra M, 2000, CIRCULATION, V102, P546; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Packer M, 2001, AM HEART J, V141, P899, DOI 10.1067/mhj.2001.115584; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Poole-Wilson PA, 2002, EUR J HEART FAIL, V4, P321, DOI 10.1016/S1388-9842(02)00025-9; Remme WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/euhj.2001.2783; Rossig L, 2000, J AM COLL CARDIOL, V36, P2081, DOI 10.1016/S0735-1097(00)01002-0; SANDBERG A, 1988, EUR J CLIN PHARMACOL, V33, P9; Sanderson JE, 1999, J AM COLL CARDIOL, V34, P1522, DOI 10.1016/S0735-1097(99)00367-8; Shibata MC, 2001, EUR J HEART FAIL, V3, P351, DOI 10.1016/S1388-9842(01)00144-1; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Wikstrand J, 2002, J AM COLL CARDIOL, V40, P491, DOI 10.1016/S0735-1097(02)01970-8; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92	29	1288	1391	0	75	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					7	13		10.1016/S0140-6736(03)13800-7	http://dx.doi.org/10.1016/S0140-6736(03)13800-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853193				2022-12-28	WOS:000184056900007
J	Johansson, LC; Norberg, RA				Johansson, LC; Norberg, RA			Delta-wing function of webbed feet gives hydrodynamic lift for swimming propulsion in birds	NATURE			English	Article							LEADING-EDGE; FLIGHT	Most foot-propelled swimming birds sweep their webbed feet backwards in a curved path that lies in a plane aligned with the swimming direction. When the foot passes the most outward position, near the beginning of the power stroke, a tangent to the foot trajectory is parallel with the line of swimming and the foot web is perpendicular to it. But later in the stroke the foot takes an increasingly transverse direction, swinging towards the longitudinal axis of the body. Here we show that, early in the power stroke, propulsion is achieved mostly by hydrodynamic drag on the foot, whereas there is a gradual transition into lift-based propulsion later in the stroke. At the shift to lift mode, the attached vortices of the drag-based phase turn into a starting vortex, shed at the trailing edge, and into spiralling leading-edge vortices along the sides of the foot. Because of their delta shape, webbed feet can generate propulsive forces continuously through two successive modes, from drag at the beginning of the stroke, all the way through the transition to predominantly lift later in the stroke.	Univ Gothenburg, Dept Zool, SE-40530 Gothenburg, Sweden; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	University of Gothenburg; Harvard University	Norberg, RA (corresponding author), Univ Gothenburg, Dept Zool, Box 463, SE-40530 Gothenburg, Sweden.		Johansson, Christoffer/B-2189-2013	Johansson, Christoffer/0000-0002-1851-3635				Blake R. W., 1981, S ZOOL SOC LONDON, V48, P29; Braun J., 1985, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V169, P307; Ellington CP, 1996, NATURE, V384, P626, DOI 10.1038/384626a0; Johansson LC, 2000, NATURE, V407, P582, DOI 10.1038/35036689; Johansson LC, 2001, J EXP BIOL, V204, P1687; Katz J., 1991, LOW SPEED AERODYNAMI; Lee M., 1990, APPL MECH REV, V43, P209, DOI [10.1115/1.3119169, DOI 10.1115/1.3119169]; NORBERG RA, 1994, P ROY SOC B-BIOL SCI, V257, P227, DOI 10.1098/rspb.1994.0119; THOMAS ALR, 1993, PHILOS T ROY SOC B, V340, P361, DOI 10.1098/rstb.1993.0079; WALKER JA, 1997, QUICKSAND QUICK SMOO	10	42	43	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					65	68		10.1038/nature01695	http://dx.doi.org/10.1038/nature01695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840759				2022-12-28	WOS:000183912800040
J	Mitchell, SL; Teno, JM; Roy, J; Kabumoto, G; Mor, V				Mitchell, SL; Teno, JM; Roy, J; Kabumoto, G; Mor, V			Clinical and organizational factors associated with feeding tube use among nursing home residents with advanced cognitive impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCED DEMENTIA; PREFERENCES; DIRECTIVES; ATTITUDES; FACILITY; RISK	Context Empiric data and expert opinion suggest that use of feeding tubes is not beneficial for older persons with advanced dementia. Previous research has shown a 10-fold variation in this practice across the United States. Objective To identify the facility and resident characteristics associated with feeding tube use among US nursing homes residents with severe cognitive impairment. Design, Setting, and Participants Cross-sectional study of all residents with advanced cognitive impairment who had Minimum Data Set assessments within 60 days of April 1, 1999, (N = 186835) and who resided in Medicare- or Medicaid-certified US nursing homes. Main Outcomes Measures Facility and resident characteristics described in the 1999 On-line Survey Certification of Automated Records and the 1999 Minimum Data Set. Multivariate analysis using generalized estimating equations determined the facility and resident factors independently associated with feeding tube use. Results Thirty-four percent of residents with advanced cognitive impairment had feeding tubes (N = 63 101). Resident characteristics associated with a greater likelihood of feeding tube use included younger age, nonwhite race, male sex, divorced marital status, lack of advance directives, a recent decline in functional status, and no diagnosis of Alzheimer disease. Controlling for these patient factors, residents living in facilities that were for profit (adjusted odds ratio (OR], 1.09; 95% confidence interval [Cl], 1.06-1.12); located in an urban area (OR, 1.14; 95% Cl, 1.11-1.16); having more than 100 beds (OR, 1.04; 95% Cl, 1.01-1.07); and lacking a special dementia care unit (OR, 1.11; 95% Cl, 1.07-1.15) had a higher likelihood of having a feeding tube. Additionally, feeding tube use was more likely among residents living in facilities that had a smaller proportion of residents with do-not-resuscitate orders, had a higher prevalence of non-white residents, and lacked a nurse practitioner or physician assistant on staff. Conclusions More than one third of severely cognitively impaired residents in US nursing homes have feeding tubes. Feeding tube use is independently associated with both the residents' clinical characteristics and the nursing homes' fiscal, organizational, and demographic features.	Beth Israel Deaconess Med Ctr, Hebrew Rehabil Ctr Aged, Res & Training Inst, Dept Med, Boston, MA 02131 USA; Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA; Brown Univ, Sch Med, Dept Community Hlth, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Brown University	Mitchell, SL (corresponding author), Beth Israel Deaconess Med Ctr, Hebrew Rehabil Ctr Aged, Res & Training Inst, Dept Med, 1200 Ctr St, Boston, MA 02131 USA.				NATIONAL INSTITUTE ON AGING [K23AG020054, R37AG011624] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11624, K23AG20054-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahronheim JC, 2001, J AM GERIATR SOC, V49, P148, DOI 10.1046/j.1532-5415.2001.49035.x; BATCHELOR AJ, 1992, J AM GERIATR SOC, V40, P679, DOI 10.1111/j.1532-5415.1992.tb01959.x; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; FRIES BE, 1994, MED CARE, V32, P668, DOI 10.1097/00005650-199407000-00002; Gessert CE, 2000, J AM GERIATR SOC, V48, P1593, DOI 10.1111/j.1532-5415.2000.tb03869.x; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; GRADY D, 2000, NY TIMES        0120, pA13; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Intrator O, 1999, MED CARE, V37, P228, DOI 10.1097/00005650-199903000-00003; Kayser-Jones J, 1999, J AM GERIATR SOC, V47, P1187, DOI 10.1111/j.1532-5415.1999.tb05198.x; Kiely DK, 2001, J AM GERIATR SOC, V49, P1346, DOI 10.1046/j.1532-5415.2001.49263.x; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; Meier DE, 2002, NEW ENGL J MED, V346, P1087, DOI 10.1056/NEJM200204043461413; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Mitchell S L, 2001, J Am Med Dir Assoc, V2, P10, DOI 10.1097/00130535-200101000-00003; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 2003, J AM GERIATR SOC, V51, P75, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell SL, 2003, J AM GERIATR SOC, V51, P129, DOI 10.1034/j.1601-5215.2002.51021.x; Mitchell Susan L, 2003, J Am Med Dir Assoc, V4, P27, DOI 10.1097/00130535-200301000-00005; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG; Teno JM, 2002, JAMA-J AM MED ASSOC, V287, P3211, DOI 10.1001/jama.287.24.3211; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	26	236	240	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					73	80		10.1001/jama.290.1.73	http://dx.doi.org/10.1001/jama.290.1.73			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696CR	12837714	Bronze			2022-12-28	WOS:000183868600022
J	Wald, NJ; Law, MR				Wald, NJ; Law, MR			A strategy to reduce cardiovascular disease by more than 80%	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; RISK-FACTOR; HOMOCYSTEINE; CHOLESTEROL; STROKE	Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels. Design We quantified the efficacy and adverse effects of the proposed formulation from published meta-analyses of randomised trials and cohort studies and a meta-analysis of 15 trials of low dose (50-125 mg/day) aspirin. Outcome measures Proportional reduction in ischaemic heart disease (IHD) events and strokes; life years gained; and prevalence of adverse effects. Results The formulation which met our objectives was: a statin (for example, atorvastatin (daily dose 10 mg) or simvastatin (40 mg); three blood pressure lowering drugs (for example, a thiazide, a P blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; folic acid (0.8 mg); and aspirin (75 mg). We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%). One third of people taking this pill from age 55 would benefit, gaining on average about I I years of life free from an IHD event or stroke. Summing the adverse effects of the components observed in randomised trials shows that the Polypill would cause symptoms in 8-15% of people (depending on the precise formulation). Conclusion The Polypill strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than an), other single intervention.	Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.	n.j.wald@qmul.ac.uk	Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; *BRIT MED ASS, 2002, 44 BMA RPS; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 2002, ARCH INTERN MED, V162, P2405, DOI 10.1001/archinte.162.21.2405; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; LAW MR, IN PRESS HLTH TECHNO; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; Wald NJ, 1999, BMJ-BRIT MED J, V319, P1562, DOI 10.1136/bmj.319.7224.1562; WALD NJ, 2000, Patent No. 000879162000; 2001, J MED SCREEN, V8, P220	25	1045	1115	3	67	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2003	326	7404					1419	1423		10.1136/bmj.326.7404.1419	http://dx.doi.org/10.1136/bmj.326.7404.1419			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829553	Green Published, Bronze			2022-12-28	WOS:000183931800015
J	Kitagawa, H; Fujiki, R; Yoshimura, K; Mezaki, Y; Uematsu, Y; Matsui, D; Ogawa, S; Unno, K; Okubo, M; Tokita, A; Nakagawa, T; Ito, T; Ishimi, Y; Nagasawa, H; Matsumoto, T; Yanagisawa, J; Kato, S				Kitagawa, H; Fujiki, R; Yoshimura, K; Mezaki, Y; Uematsu, Y; Matsui, D; Ogawa, S; Unno, K; Okubo, M; Tokita, A; Nakagawa, T; Ito, T; Ishimi, Y; Nagasawa, H; Matsumoto, T; Yanagisawa, J; Kato, S			RETRACTED: The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome (Retracted article. See vol. 149, pg. 245, 2012)	CELL			English	Article; Retracted Publication							ESTROGEN-RECEPTOR; DNA-REPLICATION; TRANSCRIPTION; GENE; ISWI; ACTIVATION; IDENTIFICATION; ACETYLATION; SUPERFAMILY; REQUIREMENT	We identified a human multiprotein complex (WINAC) that directly interacts with the vitamin D receptor (VDR) through the Williams syndrome transcription factor (WSTF), WINAC has ATP-dependent chromatin-remodeling activity and contains both SWI/SNF components and DNA replication-related factors. The latter might explain a WINAC requirement for normal S phase progression. WINAC mediates the recruitment of unliganded VDR to VDR target sites in promoters, while subsequent binding of coregulators requires ligand binding. This recruitment order exemplifies that an interaction of a sequence-specific regulator with a chromatin-remodeling complex can organize nucleosomal arrays at specific local sites in order to make promoters accessible for coregulators. Furthermore, overexpression of WSTF could restore the impaired recruitment of VDR to vitamin D regulated promoters in fibroblasts from Williams syndrome patients. This suggests that WINAC dysfunction contributes to Williams syndrome, which could therefore be considered, at least in part, a chromatin-remodeling factor disease.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 7708503, Japan; Juntendo Univ, Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138431, Japan; Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Dept Appl Biol Chem, Tokyo 1130032, Japan; SORST, Japan Sci & Technol, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Tokushima University; Juntendo University; Nagasaki University; University of Tokyo; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp						Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fyodorov DV, 2002, MOL CELL BIOL, V22, P6344, DOI 10.1128/MCB.22.18.6344-6353.2002; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; GARABEDIAN M, 1985, NEW ENGL J MED, V312, P948, DOI 10.1056/NEJM198504113121503; Glass CK, 2000, GENE DEV, V14, P121; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hoogenraad CC, 2002, NAT GENET, V32, P116, DOI 10.1038/ng954; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Kitagawa H, 2002, MOL CELL BIOL, V22, P3698, DOI 10.1128/MCB.22.11.3698-3706.2002; Lazzaro MA, 2001, J NEUROCHEM, V77, P1145, DOI 10.1046/j.1471-4159.2001.00324.x; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Loyola A, 2001, GENE DEV, V15, P2837; Lu XJ, 1998, GENOMICS, V54, P241, DOI 10.1006/geno.1998.5578; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ohba R, 1996, MOL CELL BIOL, V16, P5754; ONATE SA, 1995, SCIENCE, V270, P1354; Peoples RJ, 1998, CYTOGENET CELL GENET, V82, P238, DOI 10.1159/000015110; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; TAYLOR AB, 1982, NEW ENGL J MED, V306, P972, DOI 10.1056/NEJM198204223061607; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	47	206	215	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					905	917		10.1016/S0092-8674(03)00436-7	http://dx.doi.org/10.1016/S0092-8674(03)00436-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837248	Bronze			2022-12-28	WOS:000183817900014
J	Lowe, CJ; Wu, M; Salic, A; Evans, L; Lander, E; Stange-Thomann, N; Gruber, CE; Gerhart, J; Kirschner, M				Lowe, CJ; Wu, M; Salic, A; Evans, L; Lander, E; Stange-Thomann, N; Gruber, CE; Gerhart, J; Kirschner, M			Anteroposterior patterning in hemichordates and the origins of the chordate nervous system	CELL			English	Article							HOMEOBOX GENES; DEVELOPMENTAL EXPRESSION; ANIMAL PHYLOGENY; NEURAL PLATE; HOX CLUSTER; SEA-URCHIN; BODY PLAN; DROSOPHILA; EVOLUTION; BRAIN	The chordate central nervous system has been hypothesized to originate from either a dorsal centralized, or a ventral centralized, or a noncentralized nervous system of a deuterostome ancestor. In an effort to resolve these issues, we examined the hemichordate Saccoglossus kowalevskii and studied the expression of orthologs of genes that are involved in patterning the chordate central nervous system. All 22 orthologs studied are expressed in the ectoderm in an anteroposterior arrangement nearly identical to that found in chordates. Domain topography is conserved between hemichordates and chordates despite the fact that hemichordates have a diffuse nerve net, whereas chordates have a centralized system. We propose that the deuterostome ancestor may have had a diffuse nervous system, which was later centralized during the evolution of the chordate lineage.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; MIT, Ctr Genome Res, Whitehead Inst, Cambridge, MA 02142 USA; Express Genom Inc, Frederick, MD 21701 USA	University of California System; University of California Berkeley; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Lowe, CJ (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	clowe@uclink4.berkeley.edu	Salic, Adrian/GXG-1611-2022	Lowe, Christopher/0000-0002-7789-8643	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042724] Funding Source: NIH RePORTER; NICHD NIH HHS [1-R01-HD42724] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; Arenas-Mena C, 2000, DEVELOPMENT, V127, P4631; Arendt D, 1996, BIOESSAYS, V18, P255, DOI 10.1002/bies.950180314; BALSER EJ, 1990, ACTA ZOOL-STOCKHOLM, V71, P235, DOI 10.1111/j.1463-6395.1990.tb01082.x; Bateson W., 1886, Q J MICROSC SCI, V26, P511; Bateson W, 1884, Q J MICROSC SCI, V24, P208; Bateson W, 1885, Q J MICROSC SCI, V25, P81; Bateson W., 1886, Q J MICROSC SCI, V26, P535; Brusca R.C., 1990, INVERTEBRATES; BULLOCK TH, 1945, Q J MICROSC SCI, V86, P55; Bullock TH, 1965, STRUCTURE FUNCTION N, P1567; BURDONJONES C, 1952, PHILOS T ROY SOC B, V236, P553, DOI 10.1098/rstb.1952.0010; Cameron CB, 1996, CAN J ZOOL, V74, P15, DOI 10.1139/z96-003; Cameron CB, 2000, P NATL ACAD SCI USA, V97, P4469, DOI 10.1073/pnas.97.9.4469; Carpenter EM, 2002, DEV NEUROSCI-BASEL, V24, P24, DOI 10.1159/000064943; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; COLWIN AL, 1950, J EXP ZOOL, V115, P263, DOI 10.1002/jez.1401150204; COLWIN AL, 1953, J MORPHOL, V92, P401, DOI 10.1002/jmor.1050920302; COLWIN LH, 1962, BIOL BULL, V123, P493; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; GARSTANG W, 1894, ZOOL ANT, V17, P122; GARSTANG WALTER, 1928, QUART JOUR MICROS SCI, V72, P51; Gee H., 1996, BACKBONE VIEWS ORIGI; Geoffroy Saint-Hilaire E., 1822, MEM HIST NAT, V9, P89; Glavic A, 2002, DEVELOPMENT, V129, P1609; Gomez-Skarmeta JL, 2002, CURR OPIN GENET DEV, V12, P403, DOI 10.1016/S0959-437X(02)00317-9; Hirth F, 2003, DEVELOPMENT, V130, P2365, DOI 10.1242/dev.00438; Jan Yuh Nung, 1993, P1207; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; KARR TL, 1989, DEVELOPMENT, V105, P605; KIM YJ, 1993, J NEUROSCI, V13, P1045; KNIGHTJONES EW, 1952, PHILOS T ROY SOC B, V236, P315, DOI 10.1098/rstb.1952.0004; KRUMLAUF R, 1993, J NEUROBIOL, V24, P1328, DOI 10.1002/neu.480241006; LACALLI TC, 1994, AM ZOOL, V34, P533; Lilly B, 1999, MECH DEVELOP, V88, P195, DOI 10.1016/S0925-4773(99)00189-6; LOWE CJ, IN PRESS METHODS CEL; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mendez AT, 2000, MAR BIOTECHNOL, V2, P231, DOI 10.1007/s101269900027; Morgan T, 1894, J MORPHOL, V9, P1, DOI DOI 10.1002/JMOR.1050090102; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Nielsen C, 1999, DEV GENES EVOL, V209, P198, DOI 10.1007/s004270050244; Nubler-Jung K, 1999, J ZOOL SYST EVOL RES, V37, P93; Ogasawara M, 1999, DEVELOPMENT, V126, P2539; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Papillon D, 2003, DEV GENES EVOL, V213, P142, DOI 10.1007/s00427-003-0306-z; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; Peterson KJ, 2001, EVOL DEV, V3, P170, DOI 10.1046/j.1525-142x.2001.003003170.x; Popodi E, 1996, MOL BIOL EVOL, V13, P1078, DOI 10.1093/oxfordjournals.molbev.a025670; Raikova OI, 2000, ZOOMORPHOLOGY, V120, P107, DOI 10.1007/s004350000028; Reichert H, 2001, PHILOS T R SOC B, V356, P1533, DOI 10.1098/rstb.2001.0972; Reuter M, 1998, TISSUE CELL, V30, P57, DOI 10.1016/S0040-8166(98)80006-2; Rubenstein JLR, 1998, ANNU REV NEUROSCI, V21, P445, DOI 10.1146/annurev.neuro.21.1.445; Rubenstein JLR, 1997, MOL CELLULAR APPROAC, P356; Ruiz-Trillo I, 2002, P NATL ACAD SCI USA, V99, P11246, DOI 10.1073/pnas.172390199; Salic AN, 1997, DEVELOPMENT, V124, P4739; Sasai Y, 2001, INT J DEV BIOL, V45, P321; SCHMIDTOTT U, 1992, DEVELOPMENT, V116, P111; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Shu DG, 2003, NATURE, V421, P526, DOI 10.1038/nature01264; SIMEONE A, 1994, NEURON, V13, P83, DOI 10.1016/0896-6273(94)90461-8; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Suda Y, 1999, DEVELOPMENT, V126, P743; Sussel L, 1999, DEVELOPMENT, V126, P3359; Takacs CM, 2002, EVOL DEV, V4, P405, DOI 10.1046/j.1525-142X.2002.02029.x; Tallafuss A, 2002, GENE, V287, P23, DOI 10.1016/S0378-1119(01)00829-0	67	355	362	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					853	865		10.1016/S0092-8674(03)00469-0	http://dx.doi.org/10.1016/S0092-8674(03)00469-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837244	Bronze			2022-12-28	WOS:000183817900010
J	Tyree, MT				Tyree, MT			The ascent of water	NATURE			English	Article									US Forest Serv, USDA, NE Expt Stn, Burlington, VT 05402 USA	United States Department of Agriculture (USDA); United States Forest Service	Tyree, MT (corresponding author), US Forest Serv, USDA, NE Expt Stn, POB 968, Burlington, VT 05402 USA.							Tyree MT, 2003, TREES-STRUCT FUNCT, V17, P95, DOI 10.1007/s00468-002-0227-x; Tyree MT, 2002, XYLEM STRUCTURE ASCE; Wei CF, 1999, PLANT PHYSIOL, V121, P1191, DOI 10.1104/pp.121.4.1191	3	107	115	5	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					923	923		10.1038/423923a	http://dx.doi.org/10.1038/423923a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827177	Bronze			2022-12-28	WOS:000183753900026
J	Halsell, JS; Riddle, JR; Atwood, JE; Gardner, P; Shope, R; Poland, GA; Gray, GC; Ostroff, S; Eckart, RE; Hospenthal, DR; Gibson, RL; Grabenstein, JD; Arness, MK; Tornberg, DN				Halsell, JS; Riddle, JR; Atwood, JE; Gardner, P; Shope, R; Poland, GA; Gray, GC; Ostroff, S; Eckart, RE; Hospenthal, DR; Gibson, RL; Grabenstein, JD; Arness, MK; Tornberg, DN		Dept Def Smallpox Vaccination Clin	Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; MYOCARDITIS; PERICARDITIS; SURVEILLANCE	Context In the United States, the annual incidence of myocarditis is estimated at 1 to 10 per 100000 population. As many as 1% to 5% of patients with acute viral infections involve the myocardium. Although many viruses have been reported to cause myopencarditis, it has been a rare or unrecognized event after vaccination with the currently used strain of vaccinia virus (New York City Board of Health). Objective To describe a series of probable cases of myopericarditis following smallpox vaccination among US military service members reported since the reintroduction of vaccinia vaccine. Design, Setting, Participants Surveillance case definitions are presented. The cases were identified either through sentinel reporting to US military headquarters surveillance using the Defense Medical Surveillance System or reports to the Vaccine Adverse Event Reporting System using International Classification of Diseases, Ninth Revision. The cases occurred among individuals vaccinated from mid-December 2002 to March 14, 2003. Main Outcome Measure Elevated serum levels of creatine kinase (MB isoenzyme), troponin 1, and troponin T, usually in the presence of ST-segment elevation on electrocardiogram and wall motion abnormalities on echocardiogram. Results Among 230734 primary, vaccinees, 18 cases of probable myopericarditis after smallpox vaccination were reported (an incidence of 7.8 per 100000 over 30 days). No cases of myopericarditis following smallpox vaccination were reported among 95 622 vaccinees who were previously vaccinated. All cases were white men aged 21 years to 33 years (mean age, 26.5 years), who presented with acute myopericarditis 7 to 19 days following vaccination. A causal relationship is supported by the close temporal clustering (7-19 days; mean, 10.5 days following vaccination), wide geographic and temporal distribution, occurrence in only primary vaccinees, and lack of evidence for alternative etiologies or other diseases associated with myopericarditis. Additional supporting evidence is the observation that the observed rate of myopericarditis among primary vaccinees is 3.6-fold (95% confidence interval, 3.33-4.11) higher than the expected rate among personnel who were not vaccinated. The background incidence of myopericarditis did not show statistical significance when stratified by age (20-34 years: 2.18 expected cases per 100000; 95% confidence interval [CI], 1.90-2.34), race (whites: 1.82 per 100000; 95% Cl, 1.50-2.01), and sex (males: 2.28 per 100000; 95% Cl, 2.04-2.54). Conclusion Among US military personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12819 primary vaccinees. Myopericarditis should be considered an expected adverse event associated with smallpox vaccination. Clinicians should consider myopericarditis in the differential diagnosis of patients presenting with chest pain 4 to 30 days following smallpox vaccination and be aware of the implications as well as the need to report this potential adverse advent.	Armed Forces Epidemiol Board, Falls Church, VA 22041 USA		Riddle, JR (corresponding author), Armed Forces Epidemiol Board, Skyline 6,Suite 682,5111 Leesburg Pike, Falls Church, VA 22041 USA.	James.Riddle@otsg.amedd.army.mil	Gray, Gregory C./ABF-1298-2020; Grabenstein, John/Y-7322-2019	Gray, Gregory/0000-0002-4628-5908				AHLBORG B, 1966, ACTA MED SCAND, VS, P127; BENGTSSON ELIAS, 1966, ACTA MED SCAND SUPPL, V464, P113; BENGTSSON ELLAS, 1957, CARDIOLOGIA, V30, P1, DOI 10.1159/000165631; CANGEMI VF, 1958, NEW ENGL J MED, V258, P1257, DOI 10.1056/NEJM195806192582507; *CDCP, TEMP DEF REC HEART P; *CDCP, INT SMALLP FACT SHEE; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P278; DOLGOPOL VB, 1955, ARCH NEURO PSYCHIATR, V73, P216, DOI 10.1001/archneurpsyc.1955.02330080094018; DONADON W, 1974, MINERVA CARDIOANGIOL, V22, P642; Drucker N A, 1997, Adv Pediatr, V44, P141; FEERY BJ, 1977, MED J AUSTRALIA, V2, P180, DOI 10.5694/j.1326-5377.1977.tb114544.x; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; FINLAYJONES LR, 1964, NEW ENGL J MED, V270, P41, DOI 10.1056/NEJM196401022700108; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; HALLETT P, 1969, MED J AUSTRALIA, V1, P898, DOI 10.5694/j.1326-5377.1969.tb49779.x; HEIKKILA J, 1982, BRIT HEART J, V47, P381; HELLE EPJ, 1978, ANN CLIN RES, V10, P280; *INF MED CLIN GREN, 1974, PEDIATRIE, V29, P179; Jezek Z, 1988, HUMAN MONKEYPOX; KARJALAINEN J, 1983, ACTA MED SCAND, V213, P65; Karjalainen J, 1999, EUR HEART J, V20, P1120, DOI 10.1053/euhj.1998.1444; Klein RM, 1998, AM HEART J, V136, P389, DOI 10.1016/S0002-8703(98)70211-X; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; MACADAM D, 1962, BRIT MED J, V2, P1099; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MATHIEU L, 1953, ARCH MAL COEUR VAISS, V48, P802; MATTHEWS AW, 1974, BRIT HEART J, V36, P1043; MEAD J, 1966, J AM GERIATR SOC, V14, P754, DOI 10.1111/j.1532-5415.1966.tb02902.x; NEFF JM, 1967, NEW ENGL J MED, V276, P125, DOI 10.1056/NEJM196701192760301; NEFF JM, 1967, PEDIATRICS, V39, P916; PHILLIPS M, 1986, JAMA-J AM MED ASSOC, V256, P2696, DOI 10.1001/jama.256.19.2696; PRICE M. A., 1968, Papua New Guinea Medical Journal, V11, P30; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; SOLE MJ, 1993, J AM COLL CARDIOL, V22, pA99, DOI 10.1016/0735-1097(93)90470-L; Towbin J A, 2001, Adolesc Med, V12, P47; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; World Health Organisation, 1977, INT CLASS DIS 9 REV; WYNNE J, 2001, CARDIOMYOPATHIES MYO, P1783; 2003, MORB MORTAL WKLY REP, V52, P492	40	202	212	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3283	3289		10.1001/jama.289.24.3283	http://dx.doi.org/10.1001/jama.289.24.3283			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693EX	12824210	Bronze			2022-12-28	WOS:000183704600022
J	Fu, Q; Saltsburg, H; Flytzani-Stephanopoulos, M				Fu, Q; Saltsburg, H; Flytzani-Stephanopoulos, M			Active nonmetallic Au and Pt species on ceria-based water-gas shift catalysts	SCIENCE			English	Article							OXIDE COMPOSITE CATALYSTS; CARBON-MONOXIDE; TOTAL OXIDATION; OXYGEN; METHANE	Traditional analysis of reactions catalyzed by supported metals involves the structure of the metallic particles. However, we report here that for the class of nanostructured gold - or platinum-cerium oxide catalysts, which are active for the water-gas shift reaction, metal nanoparticles do not participate in the reaction. Nonmetallic gold or platinum species strongly associated with surface cerium-oxygen groups are responsible for the activity.	Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02155 USA	Tufts University	Flytzani-Stephanopoulos, M (corresponding author), Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02155 USA.	maria.flytzani-stephanopoulos@tufts.edu						Bondzie VA, 1999, CATAL LETT, V63, P143, DOI 10.1023/A:1019012903936; Bunluesin T, 1998, APPL CATAL B-ENVIRON, V15, P107, DOI 10.1016/S0926-3373(97)00040-4; Chiang YM, 1997, J ELECTROCERAM, V1, P7, DOI 10.1023/A:1009934829870; Fu Q, 2003, CHEM ENG J, V93, P41, DOI 10.1016/S1385-8947(02)00107-9; Fu Q, 2001, CATAL LETT, V77, P87, DOI 10.1023/A:1012666128812; Gandhi H. S., 1976, SAE TECH PAP SER, V55; HARDACRE C, 1994, J PHYS CHEM-US, V98, P10901, DOI 10.1021/j100093a036; HEDLEY N, 1968, CHEM CYANIDATION; Henry CR, 1998, SURF SCI REP, V31, P235; Kaspar J., 2000, HDB PHYS CHEM RARE E, P159; LI C, 1990, J CATAL, V123, P436, DOI 10.1016/0021-9517(90)90140-F; Li Y, 2000, APPL CATAL B-ENVIRON, V27, P179, DOI 10.1016/S0926-3373(00)00147-8; LIU W, 1995, J CATAL, V153, P317, DOI 10.1006/jcat.1995.1133; LIU W, 1995, J CATAL, V153, P304, DOI 10.1006/jcat.1995.1132; Long RQ, 1997, J RAMAN SPECTROSC, V28, P29, DOI 10.1002/(SICI)1097-4555(199701)28:1<29::AID-JRS59>3.0.CO;2-G; MCBRIDE JR, 1994, J APPL PHYS, V76, P2435, DOI 10.1063/1.357593; Murrell L. L., 1991, CATALYSIS AUTOMOTIVE, VII, P275; Radnik R, 2003, PHYS CHEM CHEM PHYS, V5, P172, DOI 10.1039/b207290d; Shelef M, 2002, CATALY SCI, V2, P343, DOI 10.1142/9781860949654_0010; Swartz SL, 2001, FUEL CELL B, V30, P7; Trovarelli A, 1996, CATAL REV, V38, P439, DOI 10.1080/01614949608006464; TULLER HL, 1979, J ELECTROCHEM SOC, V126, P209, DOI 10.1149/1.2129007; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Zalc JM, 2002, J CATAL, V206, P169, DOI 10.1006/jcat.2001.3465	24	2472	2528	44	1602	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2003	301	5635					935	938		10.1126/science.1085721	http://dx.doi.org/10.1126/science.1085721			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12843399				2022-12-28	WOS:000184755900029
J	Yamamoto, M; Sato, S; Hemmi, H; Hoshino, K; Kaisho, T; Sanjo, H; Takeuchi, O; Sugiyama, M; Okabe, M; Takeda, K; Akira, S				Yamamoto, M; Sato, S; Hemmi, H; Hoshino, K; Kaisho, T; Sanjo, H; Takeuchi, O; Sugiyama, M; Okabe, M; Takeda, K; Akira, S			Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway	SCIENCE			English	Article								Stimulation of Toll-like receptors (TLRs) triggers activation of a common MyD88-dependent signaling pathway as well as a MyD88-independent pathway that is unique to TLR3 and TLR4 signaling pathways leading to interferon (IFN)-beta production. Here we disrupted the gene encoding a Toll/IL-1 receptor (TIR) domain- containing adaptor, TRIF. TRIF-deficient mice were defective in both TLR3- and TLR4-mediated expression of IFN-beta and activation of IRF-3. Furthermore, inflammatory cytokine production in response to the TLR4 ligand, but not to other TLR ligands, was severely impaired in TRIF-deficient macrophages. Mice deficient in both MyD88 and TRIF showed complete loss of nuclear factor kappa B activation in response to TLR4 stimulation. These findings demonstrate that TRIF is essential for TLR3- and TLR4-mediated signaling pathways facilitating mammalian antiviral host defense.	Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Suita, Osaka 5650871, Japan; Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Kanagawa 2300045, Japan	Osaka University; Japan Science & Technology Agency (JST); RIKEN	Akira, S (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Host Def, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.		Takeuchi, Osamu/D-6007-2011; Hoshino, Katsuaki/L-9162-2014; Takeda, Kiyoshi/C-9331-2009; Akira, Shizuo/C-3134-2009; Takeuchi, Osamu/AAG-9359-2019; Kaisho, Tsuneyasu/B-4130-2012; Hoshino, Katsuaki/AAE-2830-2022; Okabe, Masaru/B-6917-2015	Hoshino, Katsuaki/0000-0003-0493-4815; Takeuchi, Osamu/0000-0002-1260-6232; Hoshino, Katsuaki/0000-0003-0493-4815; Sato, Shintaro/0000-0001-5156-3354; Okabe, Masaru/0000-0002-0803-9044				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hoshino K, 2002, INT IMMUNOL, V14, P1225, DOI 10.1093/intimm/dxf089; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Nomura F, 2000, GENES CELLS, V5, P191; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TAKEUCHI O, UNPUB; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668	21	2393	2512	6	226	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 1	2003	301	5633					640	643		10.1126/science.1087262	http://dx.doi.org/10.1126/science.1087262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	706UN	12855817				2022-12-28	WOS:000184473600038
J	Neuner, JM; Hamel, MB; Phillips, RS; Bona, K; Aronson, MD				Neuner, JM; Hamel, MB; Phillips, RS; Bona, K; Aronson, MD			Diagnosis and management of adults with pharyngitis - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	24th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 02-05, 2001	SAN DIEGO, CA	Soc Gen Internal Med			GROUP-A STREPTOCOCCI; ACUTE RHEUMATIC-FEVER; BETA-HEMOLYTIC STREPTOCOCCI; APPROPRIATE ANTIBIOTIC USE; RESPIRATORY-TRACT INFECTIONS; MANAGING SORE THROAT; OPTICAL IMMUNOASSAY; DECISION-ANALYSIS; GENERAL-PRACTICE; RAPID DETECTION	Background: Rheumatic fever has become uncommon in the United States while rapid diagnostic test technology for streptococcal antigens has improved. However, little is known about the effectiveness or cost-effectiveness of various strategies for managing pharyngitis caused by group A beta-hemolytic streptococcus (GAS) in U.S. adults. Objective: To examine the cost-effectiveness of several diagnostic and management strategies for patients with suspected GAS pharyngitis. Design: Cost-effectiveness analysis. Data Sources: Published literature, including systematic reviews where possible. When costs were not available in the literature, we estimated them from our institution and Medicare charges. Target Population: Adults in the general U.S. population. Time Horizon: 1 year. Perspective: Societal. Interventions: Five strategies for the management of adult patients with pharyngitis: 1) observation without testing or treatment, 2) empirical treatment with penicillin, 3) throat culture using a two-plate selective culture technique, 4) optical immunoassay (OIA) followed by culture to confirm negative OIA test results, or 5) OIA alone. Outcome Measures: Cost per lost quality-adjusted life-days (converted to life-years where appropriate) and incremental cost-effectiveness. Results of Base-Case Analysis: Empirical treatment was the least effective strategy at a GAS pharyngitis prevalence of 10% (resulting in 0.41 lost quality-adjusted life-day). Although the other four strategies had similar effectiveness (all resulted in about 0.27 lost quality-adjusted life-day), culture was the least expensive strategy. Results of Sensitivity Analyses: Results were sensitive to the prevalence of GAS pharyngitis: OIA followed by culture was most effective when GAS pharyngitis prevalence was greater than 20%. Observation was least expensive when prevalence was less than 6%, and empirical treatment was least expensive when prevalence was greater than 71%. The effectiveness of strategies was also very sensitive to the probability of anaphylaxis: When the probability of anaphylaxis was about half the baseline probability, OIA/culture was most effective; when the probability was 1.6 times that of baseline, observation was most effective. Only at an OIA cost less than half of baseline did the OIA alone strategy become less expensive than culture. Results were not sensitive to other variations in probabilities or costs of diagnosis or treatment of GAS pharyngitis. Conclusions: Observation, culture, and two rapid antigen test strategies for diagnostic testing and treatment of suspected GAS pharyngitis in adults have very similar effectiveness and costs, although culture is the least expensive and most effective strategy when the GAS pharyngitis prevalence is 10%. Empirical treatment was not the most effective or least expensive strategy at any prevalence of GAS pharyngitis in adults, although it may be reasonable for individual patients at very high risk for GAS pharyngitis as assessed by a clinical decision rule.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Harvard University; Beth Israel Deaconess Medical Center; Medical College of Wisconsin	Aronson, MD (corresponding author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Rose Bldg,Room 118, Boston, MA 02215 USA.							ANHALT JP, 1992, J CLIN MICROBIOL, V30, P2135, DOI 10.1128/JCM.30.8.2135-2138.1992; BAKER DM, 1995, DIAGN MICR INFEC DIS, V21, P61, DOI 10.1016/0732-8893(95)00023-4; BELLON J, 1991, J CLIN MICROBIOL, V29, P2084, DOI 10.1128/JCM.29.9.2084-2085.1991; Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768; BRINK WR, 1951, AM J MED, V10, P300, DOI 10.1016/0002-9343(51)90274-4; BRUMFITT W, 1957, LANCET, V1, P8; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; CATANZARO FJ, 1954, AM J MED, V17, P749, DOI 10.1016/0002-9343(54)90219-3; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; CENTOR RM, 1986, J GEN INTERN MED, V1, P248, DOI 10.1007/BF02596194; CENTOR RM, 1986, ANN INTERN MED, V105, P892, DOI 10.7326/0003-4819-105-6-892; CHAMOVITZ R, 1954, NEW ENGL J MED, V251, P466, DOI 10.1056/NEJM195409162511203; Cooper RJ, 2001, ANN INTERN MED, V134, P509, DOI 10.7326/0003-4819-134-6-200103200-00019; CRAWFORD G, 1979, ANN INTERN MED, V90, P293, DOI 10.7326/0003-4819-90-3-293; Dagnelie CF, 1996, BRIT J GEN PRACT, V46, P589; DAJANI A, 1995, PEDIATRICS, V96, P758; DALY JA, 1994, J CLIN MICROBIOL, V32, P531, DOI 10.1128/JCM.32.2.531-532.1994; DELMAR C, 1992, MED J AUSTRALIA, V156, P644, DOI 10.5694/j.1326-5377.1992.tb121463.x; DELMAR CB, 2002, COCHRANE DATABASE SY, P2; DEMEYERE M, 1992, EUR J CLIN PHARMACOL, V43, P581, DOI 10.1007/BF02284954; DENNY FW, 1950, JAMA-J AM MED ASSOC, V143, P151, DOI 10.1001/jama.1950.02910370001001; DENNY FW, 1953, PEDIATRICS, V11, P7; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; Dobbs F, 1996, BRIT J GEN PRACT, V46, P461; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Ebell MH, 2000, JAMA-J AM MED ASSOC, V284, P2912, DOI 10.1001/jama.284.22.2912; FEINSTEIN AR, 1964, ANN INTERN MED, V60, P87, DOI 10.7326/0003-4819-60-2-87; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FRIES SM, 1995, J PEDIATR-US, V126, P933, DOI 10.1016/S0022-3476(95)70213-X; Gerber MA, 1997, JAMA-J AM MED ASSOC, V277, P899, DOI 10.1001/jama.277.11.899; GERBER MA, 1989, PEDIATR INFECT DIS J, V8, P820, DOI 10.1097/00006454-198911000-00032; Gold MR, 1996, COST EFFECTIVENESS H; Goldman L., 2000, CECIL TXB MED; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GOSLINGS WR, 1963, NEW ENGL J MED, V268, P687, DOI 10.1056/NEJM196303282681301; GRAHAM L, 1986, J CLIN MICROBIOL, V24, P644, DOI 10.1128/JCM.24.4.644-646.1986; Gunnarsson RK, 1997, SCAND J PRIM HEALTH, V15, P149, DOI 10.3109/02813439709018506; HARBECK RJ, 1993, J CLIN MICROBIOL, V31, P839, DOI 10.1128/JCM.31.4.839-844.1993; HEITER BJ, 1995, J CLIN MICROBIOL, V33, P1408, DOI 10.1128/JCM.33.5.1408-1410.1995; HERMAN JM, 1984, J FAM PRACTICE, V19, P767; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HILLNER BE, 1987, J GEN INTERN MED, V2, P244, DOI 10.1007/BF02596449; HOFFMANN S, 1990, DIAGN MICR INFEC DIS, V13, P209, DOI 10.1016/0732-8893(90)90061-Y; Hoffmann Steen, 1992, Scandinavian Journal of Primary Health Care, V10, P295, DOI 10.3109/02813439209014077; HOLMBERG SD, 1983, JAMA-J AM MED ASSOC, V250, P2307, DOI 10.1001/jama.250.17.2307; HORDER J, 1954, Practitioner, V173, P177; HUOVINEN P, 1989, ANN INTERN MED, V110, P612, DOI 10.7326/0003-4819-110-8-612; Kaltwasser G, 1997, PEDIATR INFECT DIS J, V16, P748, DOI 10.1097/00006454-199708000-00004; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KELLOGG JA, 1986, JAMA-J AM MED ASSOC, V255, P2638, DOI 10.1001/jama.255.19.2638; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; KIRSCHNER CG, 1994, CPT 95; KIRSCHNER CG, 1997, PHYSICIANS CURRENT P; KJAKOVIC M, 1993, NZ MED J, V106, P381; KOMAROFF AL, 1986, J GEN INTERN MED, V1, P1, DOI 10.1007/BF02596317; Kuhn S, 1999, DIAGN MICR INFEC DIS, V34, P275, DOI 10.1016/S0732-8893(99)00027-9; LAUER BA, 1983, J CLIN MICROBIOL, V17, P338, DOI 10.1128/JCM.17.2.338-340.1983; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Little P, 1999, BRIT MED J, V319, P736, DOI 10.1136/bmj.319.7212.736; MANDELL GL, 1995, GOODMAN GILMANS PHAR, P272; Martin JM, 2002, NEW ENGL J MED, V346, P1200, DOI 10.1056/NEJMoa013169; McIsaac WJ, 1998, CAN MED ASSOC J, V158, P75; *MED EC, 2000, DRUG TOP RED BOOK; MELAND E, 1993, SCAND J INFECT DIS, V25, P177, DOI 10.3109/00365549309008482; MOYER NP, 1990, J CLIN MICROBIOL, V28, P1661, DOI 10.1128/JCM.28.7.1661-1663.1990; Petersen K, 1997, J GEN INTERN MED, V12, P95, DOI 10.1046/j.1525-1497.1997.00013.x; Pitetti RD, 1998, PEDIATR EMERG CARE, V14, P396, DOI 10.1097/00006565-199812000-00004; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; RODDEY OF, 1995, JAMA-J AM MED ASSOC, V274, P1863, DOI 10.1001/jama.274.23.1863; SANFORD JP, 1984, PHARYNGITIS MANAGEME, P251; SAVOIA D, 1994, MICROBIOS, V77, P253; SCHAPPERT SM, 1998, AMBULATORY CARE VISI; Schlager TA, 1996, ARCH PEDIAT ADOL MED, V150, P245, DOI 10.1001/archpedi.1996.02170280015002; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SIEGEL AC, 1961, NEW ENGL J MED, V265, P559, DOI 10.1056/NEJM196109212651201; SMITH JM, 1995, LAB MED, V26, P408, DOI 10.1093/labmed/26.6.408; Snow V, 2001, ANN INTERN MED, V134, P506, DOI 10.7326/0003-4819-134-6-200103200-00018; Steinhoff MC, 1997, LANCET, V350, P918, DOI 10.1016/S0140-6736(97)03317-5; STOLLERMAN GH, 1982, ADV INTERNAL MED, V27, P373; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; TSEVAT J, 1995, J AM COLL CARDIOL, V26, P914, DOI 10.1016/0735-1097(95)00284-1; TSEVAT J, 1991, J PEDIATR-US, V118, P546, DOI 10.1016/S0022-3476(05)83375-X; Tsevat J, 1999, ARCH PEDIAT ADOL MED, V153, P681, DOI 10.1001/archpedi.153.7.681; VALKENBURG HA, 1971, J INFECT DIS, V124, P348, DOI 10.1093/infdis/124.4.348; VEASY LG, 1994, J PEDIATR-US, V124, P9, DOI 10.1016/S0022-3476(94)70247-0; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WALSH BT, 1975, ARCH INTERN MED, V135, P1493, DOI 10.1001/archinte.135.11.1493; WANNAMAKER LW, 1951, AM J MED, V10, P673, DOI 10.1016/0002-9343(51)90336-1; Webb KH, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e2; WEGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695, DOI 10.1001/jama.267.5.695; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WIGTON RS, 1986, ARCH INTERN MED, V146, P81, DOI 10.1001/archinte.146.1.81; Zwart S, 2000, BRIT MED J, V320, P150, DOI 10.1136/bmj.320.7228.150	96	66	69	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					113	122		10.7326/0003-4819-139-2-200307150-00011	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	701HX	12859161				2022-12-28	WOS:000184163100005
J	Yiu, MWC; Ooi, GC; Yuen, KY; Tsang, KWT; Lam, WK; Chan, FL				Yiu, MWC; Ooi, GC; Yuen, KY; Tsang, KWT; Lam, WK; Chan, FL			High resolution CT of Well's disease	LANCET			English	Editorial Material									Univ Hong Kong, Queen Mary Hosp, Dept Radiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Diagnost Radiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Yiu, MWC (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Radiol, Hong Kong, Hong Kong, Peoples R China.		Yuen, Kwok Yung/C-4465-2009	Yuen, Kwok-yung/0000-0002-2083-1552					0	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 12	2003	362	9378					117	117		10.1016/S0140-6736(03)13862-7	http://dx.doi.org/10.1016/S0140-6736(03)13862-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867111				2022-12-28	WOS:000184089200010
J	Sadler, JE				Sadler, JE			A menage a trois in two configurations	SCIENCE			English	Editorial Material							GLYCOPROTEIN IB-ALPHA; VON-WILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; THROMBIN; BINDING; PLATELETS; DOMAIN; COMPLEX; SITE		Washington Univ, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X				BODE W, 1992, PROTEIN SCI, V1, P426; Celikel R, 2003, SCIENCE, V301, P218, DOI 10.1126/science.1084183; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; Dumas JJ, 2003, SCIENCE, V301, P222, DOI 10.1126/science.1083917; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JANDROTPERRUS M, 1991, THROMB HAEMOSTASIS, V66, P300; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200	16	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					177	179		10.1126/science.1087734	http://dx.doi.org/10.1126/science.1087734			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855796				2022-12-28	WOS:000184056200028
J	Spiegel, PB; Qassim, M				Spiegel, PB; Qassim, M			Forgotten refugees and other displaced populations	LANCET			English	Editorial Material									UNHCR, CH-1211 Geneva, Switzerland; UNHCR, Nairobi, Kenya		Spiegel, PB (corresponding author), UNHCR, CH-1211 Geneva, Switzerland.		Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				*COMM AG SOC ENQ, 2003, NAT REF SURV QUAL FI; *ECHO, ASS IR POP; GROOT F, 2002, REFUGEES URBAN AREAS, P1; *HUM RIGHTS WATCH, BHUT REF REND STAT L; Salama P, 1999, BRIT MED J, V319, P1569, DOI 10.1136/bmj.319.7224.1569; *STEER COMM HUM RE, 1998, SPHER PROJ HUM CHAR; *UNHCR, 2003, GLOB APP STRAT PROGR; *UNHCR, 2002, HLTH INF SYST BHUT R; *UNHCR WFP, 2002, ANTHR MICR NUTR SURV; *US COMM REF, AFGH HUM AID REF; *USAID, MAN RIV COUNTR GUIN; *USAID, FACT SHEET HUM REC A; *USAID, ASS IR; WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; AFROL NEWS SAHARAWI; COMMISSION ADOPTS EU; AFGHANISTAN CRISIS C	17	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					72	74		10.1016/S0140-6736(03)13812-3	http://dx.doi.org/10.1016/S0140-6736(03)13812-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853202				2022-12-28	WOS:000184056900027
J	Mello, MM; Studdert, DM; Brennan, TA				Mello, MM; Studdert, DM; Brennan, TA			The rise of litigation in human subjects research	ANNALS OF INTERNAL MEDICINE			English	Article							PUNITIVE DAMAGES	Owing to widespread public concern about the adequacy of protections for human research subjects and recent instances of serious injury to subjects at several major research institutions, lawsuits against investigators, institutional review boards, and academic institutions are becoming increasingly common. Several claim-promoting conditions are ripe to promote the further growth of this litigation and raise the stakes for research institutions. While this litigation may serve a valuable compensation function for injured subjects, it will also have profound effects on institutional review boards, leading to a more legalistic, mechanistic approach to ethical review that does not further the interests of human subjects or scientific progress.	Harvard Univ, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Mello, MM (corresponding author), Harvard Univ, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.		Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537; Mello, Michelle/0000-0003-2877-4270				Anderlik MR, 2001, J LAW MED ETHICS, V29, P220; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; BRENNAN TA, 1991, JUST DOCTORING MED E; Cerminara KL, 1998, AM J LAW MED, V24, P7; De Ville Kenneth, 2002, Account Res, V9, P17; DEMBNER A, 2001, BOSTON GLOBE    0218, pA1; Eisenberg T, 2002, CORNELL LAW REV, V87, P743; Gillis Justin, 2002, Washington Post, pA14; HEATH D, 2002, SEATTLE TIMES   0809, pA1; Hensler D. R., 2000, CLASS ACTION DILEMMA; Jones JH., 1981, BAD BLOOD TUSKEGEE S; Kopelman LM, 2002, J LAW MED ETHICS, V30, P38, DOI 10.1111/j.1748-720X.2002.tb00718.x; Mello MM, 2001, J HEALTH POLIT POLIC, V26, P429, DOI 10.1215/03616878-26-2-429; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1; *OFF HUM RES PROT, 2002, DRAFT INT GUID FIN R; *OFF INSP GEN, 2000, PUBL OFF INSP GEN; *OFF INSP GEN, 1998, PUBL OFF INSP GEN I; Parmet WE, 2000, ANNU REV PUBL HEALTH, V21, P437, DOI 10.1146/annurev.publhealth.21.1.437; Rustad ML, 1998, WISC LAW REV, P15; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; STOLBERG SG, 2000, NY TIMES        0525, pA20; STOLBERG SG, 1999, NY TIMES MAGAZI 1128, P6; Studdert DM, 2000, NEW ENGL J MED, V342, P280, DOI 10.1056/NEJM200001273420411; WHITE E, 2002, MED RES LAW POLICY R, V1, P95; 2002, REUTERS HLTH IN 0327	25	64	64	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					40	45		10.7326/0003-4819-139-1-200307010-00011	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	695GR	12834317				2022-12-28	WOS:000183823200006
J	Miles, MA; Feliciangeli, MD; de Arias, AR				Miles, MA; Feliciangeli, MD; de Arias, AR			Science, medicine, and the future - American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GENETIC EXCHANGE; CRUZI; IDENTIFICATION; LINEAGES; BRAZIL		Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; Univ Carabobo, BIOMED, Secc Entomol Med, Maracay, Venezuela; Inst Invest Ciencias Salud, Vector Control Programmes, Asuncion, Paraguay	University of London; London School of Hygiene & Tropical Medicine; Research Institute for Health Sciences (IICS)	Miles, MA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	michael.miles@lshtm.ac.uk		Rojas de Arias, Antonieta/0000-0002-6207-1870				Bingle LEH, 2001, MICROBIOL-SGM, V147, P3231, DOI 10.1099/00221287-147-12-3231; Brisse S, 2000, INT J PARASITOL, V30, P35, DOI 10.1016/S0020-7519(99)00168-X; Carcavallo RV, 1998, ATLAS CHAGASDISEASE; CHAPMAN MD, 1984, J PROTOZOOL, V31, P482, DOI 10.1111/j.1550-7408.1984.tb02999.x; Coura JR, 2002, TRENDS PARASITOL, V18, P171, DOI 10.1016/S1471-4922(01)02200-0; Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074-02762002000500002; Feliciangeli MD, 2003, TRENDS PARASITOL, V19, P44, DOI 10.1016/S1471-4922(02)00013-2; Feliciangeli MD, 2002, TROP MED INT HEALTH, V7, P280, DOI 10.1046/j.1365-3156.2002.00853.x; Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; Machado CA, 2001, P NATL ACAD SCI USA, V98, P7396, DOI 10.1073/pnas.121187198; MILES MA, 1977, T ROY SOC TROP MED H, V71, P217, DOI 10.1016/0035-9203(77)90012-8; MILES MA, 1981, LANCET, V1, P1338; MILES MA, 1997, TOPLEY WILSONS MICRO, V5, P283; Monteiro FA, 2001, TRENDS PARASITOL, V17, P344, DOI 10.1016/S1471-4922(01)01921-3; *PAN AM HLTH ORG, 1994, SCI PUBL, V547; Rohlf FJ., 2002, MORPHOLOGY SHAPE PHY; Schofield CJ, 1999, ADV PARASIT, V42, P1, DOI 10.1016/S0065-308X(08)60147-5; Schofield CJ, 2001, INT J PARASITOL, V31, P615, DOI 10.1016/S0020-7519(01)00162-X; Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012; *WHO, 2002, TECHN REP SER WHO, V905	21	109	116	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2003	326	7404					1444	1448		10.1136/bmj.326.7404.1444	http://dx.doi.org/10.1136/bmj.326.7404.1444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829559	Green Published, Green Accepted			2022-12-28	WOS:000183931800021
J	Veenhoven, R; Bogaert, D; Uiterwaal, C; Brouwer, C; Kiezebrink, H; Bruin, J; IJzerman, E; Hermans, P; de Groot, R; Zegers, B; Kuis, W; Rijkers, G; Schilder, A; Sanders, E				Veenhoven, R; Bogaert, D; Uiterwaal, C; Brouwer, C; Kiezebrink, H; Bruin, J; IJzerman, E; Hermans, P; de Groot, R; Zegers, B; Kuis, W; Rijkers, G; Schilder, A; Sanders, E			Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study	LANCET			English	Article							DAY-CARE-CENTERS; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; PRONE CHILDREN; INFECTIONS; RESPONSES; PREVENTION; EFFICACY; HISTORY; LIFE	Background Pneumococcal conjugate vaccine prevents recurrent acute otitis media (AOM) in infants immunised at 2, 4, 6, and 12-15 months of age. We aimed to find out whether this vaccine also prevents AOM in older children who have had previous episodes of AOM. Methods In this double-blind, randomised study, we enrolled 383 patients aged 1-7 years who had had two or more episodes of AOM in the year before entry. Randomisation was stratified in four groups according to age (12-24 months vs 25-84 months) and the number of previous AOM episodes (two or three episodes vs four or more episodes). Children received either 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine, or hepatitis A or B vaccines. They were followed up for 18 months for recurrence of AOM. We also cultured samples of middle-ear fluid and nasopharyngeal swabs to assess association of pneumococcal serotypes with AOM after vaccination. Findings We noted no reduction of AOM episodes in the pneumococcal vaccine group compared with controls (intention-to-treat analysis: rate ratio 1-25, 95% CI 0.99-1.57). Although nasopharyngeal carriage of pneumococci of serotypes included in the conjugate-vaccine was greatly reduced after pneumococcal vaccinations, immediate and complete replacement by non-vaccine pneumococcal serotypes took place. Interpretation These data do not lend support to the use of pneumococcal conjugate vaccine to prevent otitis media in previously unvaccinated toddlers and children with a history of recurrent AOM.	Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol, NL-3508 AB Utrecht, Netherlands; Spaarne Hosp, Dept Paediat, Haarlem, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Reg Publ Hlth Lab, Haarlem, Netherlands; Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Otorhinolaryngol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Lab Paediat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Spaarne Hospital; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Sanders, E (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol, POB 85090, NL-3508 AB Utrecht, Netherlands.	eam.sanders@planet.nl	Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019; de Groot, R./H-8039-2014; Hermans, Peter P.W.M./F-4655-2010	Rijkers, Ger/0000-0001-6948-6123; Bogaert, Debby/0000-0003-2651-7000				Abramson JS, 2000, PEDIATRICS, V106, P362; ALHO OP, 1990, AM J EPIDEMIOL, V132, P1164, DOI 10.1093/oxfordjournals.aje.a115759; Alho OP, 1996, J FAM PRACTICE, V43, P258; Appelman CLM, 1990, HUISARTS WET, V33, P242; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Breukels MA, 1999, J INFECT DIS, V179, P1152, DOI 10.1086/314705; Dagan R, 2000, PEDIATR INFECT DIS J, V19, P95, DOI 10.1097/00006454-200002000-00002; Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525; DOUGLAS RM, 1984, J INFECT DIS, V149, P861, DOI 10.1093/infdis/149.6.861; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Faden H, 1997, J INFECT DIS, V175, P1440, DOI 10.1086/516477; GIEBINK GS, 1989, PEDIATR INFECT DIS J, V8, pS18; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; HERROD HG, 1989, J CLIN IMMUNOL, V9, P429, DOI 10.1007/BF00917109; KALM O, 1986, ACTA OTO-LARYNGOL, V101, P467, DOI 10.3109/00016488609108633; Kilpi T, 2001, PEDIATR INFECT DIS J, V20, P654, DOI 10.1097/00006454-200107000-00004; KILPI T, 2002, 3 INT S PNEUM PNEUM, P110; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; KOCH A, 2001, JAMA-J AM MED ASSOC, V285, P1348; Lipsitch M, 2000, VACCINE, V18, P2895, DOI 10.1016/S0264-410X(00)00046-3; Maly RC, 1999, J FAM PRACTICE, V48, P356; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; OBrien KL, 1996, PEDIATR INFECT DIS J, V15, P425, DOI 10.1097/00006454-199605000-00009; PRELLNER K, 1990, ANN OTO RHINOL LARYN, V99, P628, DOI 10.1177/000348949009900808; ROSEN C, 1984, ACTA OTO-LARYNGOL, V98, P524, DOI 10.3109/00016488409107593; SANDERS LAM, 1995, PEDIATR RES, V37, P812, DOI 10.1203/00006450-199506000-00023; SANDERS LAM, 1994, J INFECT DIS, V170, P854, DOI 10.1093/infdis/170.4.854; Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3; Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048	30	239	255	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2189	2195		10.1016/S0140-6736(03)13772-5	http://dx.doi.org/10.1016/S0140-6736(03)13772-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842372				2022-12-28	WOS:000183815600011
J	Waggoner, SE				Waggoner, SE			Cervical cancer	LANCET			English	Review							SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS TYPE-16; LYMPH-NODE METASTASES; GYNECOLOGIC-ONCOLOGY-GROUP; PELVIC RADIATION-THERAPY; EARLY INVASIVE-CARCINOMA; QUALITY-OF-LIFE; BULKY STAGE-IB; RADICAL HYSTERECTOMY; UTERINE CERVIX	Cervical cancer is a serious health problem, with nearly 500 000 women developing the disease each year worldwide. Most cases occur in less developed countries where no effective screening systems are available. Risk factors include exposure to human papillomavirus, smoking, and immune-system dysfunction. Most women with early-stage tumours can be cured, although long-term morbidity from treatment is common. Results of randomised clinical trials have shown that for women with locally advanced cancers, chemoradiotherapy should be regarded as the standard of care; however, the applicability of this treatment to women in less developed countries remains largely untested. Many women with localised (stage IB) tumours even now receive various combinations of surgery and radiotherapy, despite unresolved concern about the morbidity of this approach compared with definitive radiotherapy or radical surgery. Treatment of recurrent cervical cancer remains largely ineffective. Quality of life should be taken into account in treatment of women with primary and recurrent cervical cancer.	Univ Hosp Cleveland, Gynecol Oncol Sect, Cleveland, OH 44106 USA	University Hospitals of Cleveland	Waggoner, SE (corresponding author), Univ Hosp Cleveland, Gynecol Oncol Sect, 11100 Euclid Ave, Cleveland, OH 44106 USA.	steven.waggoner@uhhs.com						AYHAN A, 1991, J SURG ONCOL, V48, P207, DOI 10.1002/jso.2930480314; Benedet J, 1998, J EPIDEMIOL BIOSTAT, V3, P5; Berumen J, 2001, JNCI-J NATL CANCER I, V93, P1325, DOI 10.1093/jnci/93.17.1325; BLOSS JD, 1995, GYNECOL ONCOL, V59, P105, DOI 10.1006/gyno.1995.1275; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BOYCE J, 1981, GYNECOL ONCOL, V12, P154, DOI 10.1016/0090-8258(81)90145-1; Brader KR, 1998, J CLIN ONCOL, V16, P1879, DOI 10.1200/JCO.1998.16.5.1879; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; COLEMAN RL, 1994, GYNECOL ONCOL, V55, P29, DOI 10.1006/gyno.1994.1242; Covens A, 1999, GYNECOL ONCOL, V74, P423, DOI 10.1006/gyno.1999.5466; Covens A, 1999, CANCER, V86, P2273, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2273::AID-CNCR15>3.0.CO;2-C; Creasman WT, 1999, GYNECOL ONCOL, V74, P163, DOI 10.1006/gyno.1999.5514; Creasman WT, 1998, AM J OBSTET GYNECOL, V178, P62, DOI 10.1016/S0002-9378(98)70628-3; Daly SF, 1998, AM J OBSTET GYNECOL, V179, P399, DOI 10.1016/S0002-9378(98)70371-0; Dargent D, 2000, CANCER, V88, P1877, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1877::AID-CNCR17>3.3.CO;2-N; DELGADO G, 1990, GYNECOL ONCOL, V38, P352, DOI 10.1016/0090-8258(90)90072-S; DELGADO G, 1997, OBSTET GYNECOL SURV, V33, P173; Fotiou S, 1997, INT J GYNECOL CANCER, V7, P117, DOI 10.1046/j.1525-1438.1997.00430.x; GAUTHIER P, 1985, OBSTET GYNECOL, V66, P569; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Greimel E, 2002, GYNECOL ONCOL, V85, P140, DOI 10.1006/gyno.2002.6586; Grigsby PW, 2001, J CLIN ONCOL, V19, P3745, DOI 10.1200/JCO.2001.19.17.3745; Grisaru D, 2001, CANCER, V92, P2999, DOI 10.1002/1097-0142(20011215)92:12<2999::AID-CNCR10145>3.0.CO;2-1; HACKER NF, 1995, INT J GYNECOL CANCER, V5, P250, DOI 10.1046/j.1525-1438.1995.05040250.x; HAIE C, 1988, RADIOTHER ONCOL, V11, P101, DOI 10.1016/0167-8140(88)90245-9; HOMESLEY HD, 1980, SURG GYNECOL OBSTET, V150, P529; HOPKINS MP, 1991, AM J OBSTET GYNECOL, V164, P1520, DOI 10.1016/0002-9378(91)91431-U; Hoskins WJ, 1997, PRINCIPLES PRACTICE; Ijaz T, 1998, GYNECOL ONCOL, V70, P241, DOI 10.1006/gyno.1998.5093; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JOHNSON TL, 1992, MODERN PATHOL, V5, P35; JONES WB, 1993, GYNECOL ONCOL, V51, P26, DOI 10.1006/gyno.1993.1241; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; KEYS HM, 1997, TREATMENT PATIENTS S; Kim PY, 1998, GYNECOL ONCOL, V69, P243, DOI 10.1006/gyno.1998.5012; KINNEY WK, 1989, GYNECOL ONCOL, V34, P258, DOI 10.1016/0090-8258(89)90156-X; Kjellberg L, 2000, BRIT J CANCER, V82, P1332, DOI 10.1054/bjoc.1999.1100; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Landoni F, 2001, GYNECOL ONCOL, V80, P3, DOI 10.1006/gyno.2000.6010; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; MAGRINA JF, 1995, GYNECOL ONCOL, V59, P277; MAIMAN M, 1991, CANCER, V71, P402; Melikian AA, 1999, CANCER LETT, V146, P127, DOI 10.1016/S0304-3835(99)00203-7; MENDENHALL WM, 1991, INT J RADIAT ONCOL, V21, P899, DOI 10.1016/0360-3016(91)90727-L; MONK BJ, 1994, GYNECOL ONCOL, V54, P4, DOI 10.1006/gyno.1994.1157; Moore David H., 2001, Gynecologic Oncology, V80, P276; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; MORROW CP, 1980, GYNECOL ONCOL, V10, P105, DOI 10.1016/0090-8258(80)90071-2; Mundt AJ, 2001, GYNECOL ONCOL, V82, P456, DOI 10.1006/gyno.2001.6250; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; NOLLER KL, 1972, MAYO CLIN PROC, V47, P629; OQUINN AG, 1980, GYNECOL ONCOL, V9, P68, DOI 10.1016/0090-8258(80)90010-4; PARK RC, 1993, CANCER, V71, P1446; PARKIN DM, 1997, SCI PUBLICATIONS IAR, V143; PENALVER MA, 1989, GYNECOL ONCOL, V34, P274, DOI 10.1016/0090-8258(89)90159-5; PEREZ CA, 1985, INT J RADIAT ONCOL, V11, P1903, DOI 10.1016/0360-3016(85)90270-6; Perez CA, 1998, INT J RADIAT ONCOL, V41, P307, DOI 10.1016/S0360-3016(98)00067-4; PEREZ CA, 1984, CANCER, V54, P235, DOI 10.1002/1097-0142(19840715)54:2<235::AID-CNCR2820540210>3.0.CO;2-H; PEREZ CA, 1995, INT J RADIAT ONCOL, V32, P1275, DOI 10.1016/0360-3016(95)00220-S; Petereit DG, 1999, INT J RADIAT ONCOL, V45, P1267, DOI 10.1016/S0360-3016(99)00262-X; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Portelance L, 2001, INT J RADIAT ONCOL, V51, P261, DOI 10.1016/S0360-3016(01)01664-9; POTISH RA, 1989, INT J RADIAT ONCOL, V17, P979, DOI 10.1016/0360-3016(89)90145-4; POTTER ME, 1990, GYNECOL ONCOL, V37, P78, DOI 10.1016/0090-8258(90)90312-9; Prokopczyk B, 1997, J NATL CANCER I, V89, P868, DOI 10.1093/jnci/89.12.868; Roman LD, 1998, GYNECOL ONCOL, V68, P220, DOI 10.1006/gyno.1998.4943; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Rose PG, 1999, J CLIN ONCOL, V17, P2676, DOI 10.1200/JCO.1999.17.9.2676; ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387; RUTLEDGE FN, 1976, CANCER, V38, P596, DOI 10.1002/1097-0142(197607)38:1<596::AID-CNCR2820380184>3.0.CO;2-C; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schorge JO, 2000, GYNECOL ONCOL, V78, P217, DOI 10.1006/gyno.2000.5857; Schover LR, 2000, GYNECOL ONCOL, V76, P3, DOI 10.1006/gyno.1999.5692; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; SHINGLETON HM, 1989, OBSTET GYNECOL, V73, P1027; SLATTERY ML, 1989, JAMA-J AM MED ASSOC, V261, P1593, DOI 10.1001/jama.261.11.1593; Stoppler MC, 1996, J VIROL, V70, P6987; Sung HY, 2000, CANCER, V88, P2283, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2283::AID-CNCR12>3.3.CO;2-4; TANAKA Y, 1984, ACTA RADIOL ONCOL, V23, P455, DOI 10.3109/02841868409136048; Thomas G, 2001, SEMIN ONCOL, V28, P60, DOI 10.1053/sonc.2001.25400; Tsai CS, 1999, GYNECOL ONCOL, V75, P328, DOI 10.1006/gyno.1999.5527; Tseng CJ, 1997, AM J OBSTET GYNECOL, V176, P1009, DOI 10.1016/S0002-9378(97)70394-6; Wagenaar HC, 2001, GYNECOL ONCOL, V82, P474, DOI 10.1006/gyno.2001.6267; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Whitney CW, 1999, J CLIN ONCOL, V17, P1339, DOI 10.1200/JCO.1999.17.5.1339; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X	90	705	773	2	72	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2217	2225		10.1016/S0140-6736(03)13778-6	http://dx.doi.org/10.1016/S0140-6736(03)13778-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842378				2022-12-28	WOS:000183815600026
J	Martin, OY; Hosken, DJ				Martin, OY; Hosken, DJ			The evolution of reproductive isolation through sexual conflict	NATURE			English	Article							FLY SEPSIS-CYNIPSEA; SERIALLY BOTTLENECKED LINES; RAPID EVOLUTION; SPECIATION; SELECTION; BEHAVIOR; COSTS; SIZE	Classical population-genetics theory suggests that reproductive isolation will evolve fastest in small isolated populations(1). In contrast, recent theory suggests that divergence should occur fastest in larger allopatric populations(2). The rationale behind this is that sexual conflict, potentially the strongest driver of speciation, is greater in larger, higher-density populations. This idea is highly controversial(3) and has little experimental support(4,5). Here we show, using replicate fly populations with varying levels of sexual conflict, that larger, more dense populations with more sexual conflict diverged to a greater degree than small populations with relaxed conflict. This result strongly suggests that speciation can occur rapidly in large populations through increased sexual conflict.	Univ Zurich, Museum Zool, CH-8057 Zurich, Switzerland	University of Zurich	Martin, OY (corresponding author), Univ Zurich, Museum Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		MARTIN, OLIVER Y/A-4534-2009	MARTIN, OLIVER Y/0000-0002-8601-7131				Andres JA, 2003, J EVOLUTION BIOL, V16, P219, DOI 10.1046/j.1420-9101.2003.00525.x; Arnqvist G, 2000, P NATL ACAD SCI USA, V97, P10460, DOI 10.1073/pnas.97.19.10460; Blanckenhorn WU, 2002, BEHAV ECOL, V13, P353, DOI 10.1093/beheco/13.3.353; Blanckenhorn WU, 2000, ETHOLOGY, V106, P577, DOI 10.1046/j.1439-0310.2000.00573.x; Cooper TF, 2003, P NATL ACAD SCI USA, V100, P1072, DOI 10.1073/pnas.0334340100; Ding A, 2002, EVOL ECOL RES, V4, P259; Gage MJG, 2002, P ROY SOC B-BIOL SCI, V269, P2309, DOI 10.1098/rspb.2002.2154; Gavrilets S, 2000, NATURE, V403, P886, DOI 10.1038/35002564; Hosken DJ, 2003, J EVOLUTION BIOL, V16, P485, DOI 10.1046/j.1420-9101.2003.00537.x; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; Martin OY, 2003, EVOL ECOL RES, V5, P119; Martin OY, 2002, ANIM BEHAV, V63, P541, DOI 10.1006/anbe.2001.1929; MEFFERT LM, 1992, EVOLUTION, V46, P1399, DOI 10.1111/j.1558-5646.1992.tb01132.x; MEFFERT LM, 1991, EVOLUTION, V45, P293, DOI 10.1111/j.1558-5646.1991.tb04404.x; Muhlhauser C, 2002, BEHAV ECOL, V13, P359, DOI 10.1093/beheco/13.3.359; Parker G.A., 1979, P123; PARKER GA, 1972, BEHAVIOUR, V41, P242, DOI 10.1163/156853972X00031; PARKER GA, 1972, BEHAVIOUR, V41, P172, DOI 10.1163/156853972X00257; Price T, 1998, PHILOS T R SOC B, V353, P251, DOI 10.1098/rstb.1998.0207; Rice WR, 2000, P NATL ACAD SCI USA, V97, P12953, DOI 10.1073/pnas.97.24.12953; Rice WR, 1998, ENDLESS FORMS, P261; Rice WR, 1997, BEHAV ECOL SOCIOBIOL, V41, P1, DOI 10.1007/s002650050357; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; SHARP PM, 1984, GENETICS, V106, P601; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Tregenza T, 2000, NATURE, V407, P149, DOI 10.1038/35025138; WARD PI, 1992, FUNCT ECOL, V6, P649, DOI 10.2307/2389959	28	195	202	0	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					979	982		10.1038/nature01752	http://dx.doi.org/10.1038/nature01752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827200				2022-12-28	WOS:000183753900048
J	Murakami, Y; Yoo, JH; Shindo, D; Atou, T; Kikuchi, M				Murakami, Y; Yoo, JH; Shindo, D; Atou, T; Kikuchi, M			Magnetization distribution in the mixed-phase state of hole-doped manganites	NATURE			English	Article							ANTIFERROMAGNETIC METALLIC STATE; FERROMAGNETIC PHASE; MAGNETORESISTANCE; RESISTIVITY; TRANSITION	The effect of 'colossal magnetoresistance' (CMR) in hole-doped manganites - an abnormal decrease of resistivity when a magnetic field is applied(1) - has attracted significant interest from researchers in the past decade. But the underlying mechanism for the CMR phenomenon is not yet fully understood. It has become clear that a phase-separated state(2-6), where magnetic and nonmagnetic phases coexist, is important, but the detailed magnetic microstructure of this mixed-phase state is so far unclear. Here we use electron microscopy to study the magnetic microstructure and development of ferromagnetic domains in the mixed-phase state of La1-xSrxMnO3 (x = 0.54, 0.56). Our measurements show that, in the absence of a magnetic field, the magnetic flux is closed within ferromagnetic regions, indicating a negligible magnetic interaction between separated ferromagnetic domains. However, we also find that the domains start to combine with only very small changes in temperature. We propose that the delicate nature of the magnetic microstructure in the mixed-phase state of hole-doped manganites is responsible for the CMR effect, in which significant conduction paths form between the ferromagnetic domains upon application of a magnetic field.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan; Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; Tohoku Fukushi Univ, Kansei Fukushi Res Ctr, Sendai, Miyagi 9818522, Japan	Tohoku University; Tohoku University	Murakami, Y (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Sendai, Miyagi 9808577, Japan.	murakami@tagen.tohoku.ac.jp	Atou, Toshiyuki/F-2849-2014; Shindo, Daisuke/I-3865-2012					Akimoto T, 1998, PHYS REV B, V57, pR5594, DOI 10.1103/PhysRevB.57.R5594; ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675; DEGENNES PG, 1960, PHYS REV, V118, P141, DOI 10.1103/PhysRev.118.141; Fath M, 1999, SCIENCE, V285, P1540, DOI 10.1126/science.285.5433.1540; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; Kikuchi K, 1999, J SOLID STATE CHEM, V146, P1, DOI 10.1006/jssc.1999.8218; Loudon JC, 2002, NATURE, V420, P797, DOI 10.1038/nature01299; Lu QY, 1997, SCIENCE, V276, P2006, DOI 10.1126/science.276.5321.2006; Mayr M, 2001, PHYS REV LETT, V86, P135, DOI 10.1103/PhysRevLett.86.135; Moreo A, 1999, SCIENCE, V283, P2034, DOI 10.1126/science.283.5410.2034; Moreo A, 2000, PHYS REV LETT, V84, P5568, DOI 10.1103/PhysRevLett.84.5568; Mori S, 1998, PHYS REV LETT, V81, P3972, DOI 10.1103/PhysRevLett.81.3972; Moritomo Y, 1998, PHYS REV B, V58, P5544, DOI 10.1103/PhysRevB.58.5544; REZ D, 1994, ACTA CRYSTALLOGR A, V50, P481, DOI 10.1107/S0108767393013200; Shindo D, 2002, ANAL ELECT MICROSCOP; Tonomura A., 1999, ELECT HOLOGRAPHY, Vsecond; Uehara M, 1999, NATURE, V399, P560, DOI 10.1038/21142; URUSHIBARA A, 1995, PHYS REV B, V51, P14103, DOI 10.1103/PhysRevB.51.14103; Zhang LW, 2002, SCIENCE, V298, P805, DOI 10.1126/science.1077346	19	90	92	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2003	423	6943					965	968		10.1038/nature01715	http://dx.doi.org/10.1038/nature01715			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827195				2022-12-28	WOS:000183753900043
J	Redl, FX; Cho, KS; Murray, CB; O'Brien, S				Redl, FX; Cho, KS; Murray, CB; O'Brien, S			Three-dimensional binary superlattices of magnetic nanocrystals and semiconductor quantum dots	NATURE			English	Article							SELF-ORGANIZATION; COLLOIDAL SYNTHESIS; GOLD; SILVER; NANOPARTICLES; PARTICLES; FILMS	Recent advances in strategies for synthesizing nanoparticles such as semiconductor quantum dots(1), magnets and noble-metal clusters(2) - have enabled the precise control of composition, size, shape(3), crystal structure(4), and surface chemistry. The distinct properties of the resulting nanometre-scale building blocks can be harnessed in assemblies with new collective properties(2,5,6), which can be further engineered by controlling interparticle spacing and by material processing. Our study is motivated by the emerging concept of metamaterials(7) - materials with properties arising from the controlled interaction of the different nanocrystals in an assembly. Previous multi-component nanocrystal assemblies have usually resulted in amorphous or short-range-ordered materials(8,9) because of non-directional forces or insufficient mobility during assembly(10-14). Here we report the self-assembly of PbSe semiconductor quantum dots and Fe2O3 magnetic nanocrystals into precisely ordered three-dimensional superlattices. The use of specific size ratios directs the assembly of the magnetic and semiconducting nanoparticles into AB(13) or AB(2) superlattices with potentially tunable optical and magnetic properties. This synthesis concept could ultimately enable the fine-tuning of material responses to magnetic, electrical, optical and mechanical stimuli(6).	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA; Univ New Orleans, Adv Mat Res Inst, New Orleans, LA 70148 USA	International Business Machines (IBM); Columbia University; University of Louisiana System; University of New Orleans	Murray, CB (corresponding author), IBM Corp, Thomas J Watson Res Ctr, 1101 Kitchawan Rd,Route 134, Yorktown Hts, NY 10598 USA.		O'Brien, Stephen/D-7682-2013; OBrien, Stephen/O-8814-2019	O'Brien, Stephen/0000-0001-7531-8900; OBrien, Stephen/0000-0001-7531-8900				BENTZON MD, 1989, PHILOS MAG B, V60, P169, DOI 10.1080/13642818908211188; Brust M, 2002, COLLOID SURFACE A, V202, P175, DOI 10.1016/S0927-7757(01)01087-1; Collier CP, 1998, ANNU REV PHYS CHEM, V49, P371, DOI 10.1146/annurev.physchem.49.1.371; CORNELL RM, 1999, IRON OXIDES; ELDRIDGE MD, 1993, NATURE, V365, P35, DOI 10.1038/365035a0; Fullam S, 2002, CHEM MATER, V14, P3643, DOI 10.1021/cm011182e; Galow TH, 2000, ADV MATER, V12, P576; Gomez S, 2001, CHEM COMMUN, P1474, DOI 10.1039/b103781c; HACHISU S, 1987, PHYSICS COMPLEX SUPE, P221; Hao EC, 1998, J MATER CHEM, V8, P1327, DOI 10.1039/a802655f; Hunt N, 2000, PHYS REV E, V62, P900, DOI 10.1103/PhysRevE.62.900; Hyeon T, 2001, J AM CHEM SOC, V123, P12798, DOI 10.1021/ja016812s; Kolny J, 2002, NANO LETT, V2, P361, DOI 10.1021/nl0156843; Korgel BA, 1998, J PHYS CHEM B, V102, P8379, DOI 10.1021/jp981598o; Korgel BA, 1998, PHYS REV LETT, V80, P3531, DOI 10.1103/PhysRevLett.80.3531; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Murray CB, 2001, IBM J RES DEV, V45, P47, DOI 10.1147/rd.451.0047; Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545; MURRAY MJ, 1980, PHILOS MAG A, V42, P721, DOI 10.1080/01418618008239380; OHARA PC, 1995, PHYS REV LETT, V75, P3466, DOI 10.1103/PhysRevLett.75.3466; SANDERS JV, 1980, PHILOS MAG A, V42, P705, DOI 10.1080/01418618008239379; Shevchenko EV, 2002, J AM CHEM SOC, V124, P11480, DOI 10.1021/ja025976l; SHMAKOV AN, 1995, J APPL CRYSTALLOGR, V28, P141, DOI 10.1107/S0021889894010113; Sun SH, 1999, J APPL PHYS, V85, P4325, DOI 10.1063/1.370357; Trindade T, 2001, CHEM MATER, V13, P3843, DOI 10.1021/cm000843p; Walser RM, 2001, PROC SPIE, V4467, P1, DOI 10.1117/12.432921; Wang ZL, 1999, MATER CHARACT, V42, P101, DOI 10.1016/S1044-5803(98)00050-3; Zanchet D, 1999, PHYS REV LETT, V82, P5277, DOI 10.1103/PhysRevLett.82.5277; Zeng H, 2002, NATURE, V420, P395, DOI 10.1038/nature01208	29	724	744	7	444	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					968	971		10.1038/nature01702	http://dx.doi.org/10.1038/nature01702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827196				2022-12-28	WOS:000183753900044
J	Margot, JL; Brown, ME				Margot, JL; Brown, ME			A low-density M-type asteroid in the main belt	SCIENCE			English	Article							TELESCOPE; SYSTEM; MASS	The orbital parameters of a satellite revolving around 22 Kalliope indicate that the bulk density of this main-belt asteroid is 2.37 +/- 0.4 grams per cubic centimeter. M-type asteroids such as Kalliope are thought to be the disrupted metallic cores of differentiated bodies. The low density indicates that Kalliope cannot be predominantly composed of metal and may be composed of chondritic material with similar to30% porosity. The satellite orbit is circular, suggesting that Kalliope and its satellite have different internal structures and tidal dissipation rates. The satellite may be an aggregate of impact ejecta from an earlier collision with Kalliope.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Margot, JL (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.		Margot, Jean-Luc/A-6154-2012	Margot, Jean-Luc/0000-0001-9798-1797; Brown, Michael E./0000-0002-8255-0545				BOWELL E, 1979, ASTEROIDS, P1108; Britt D. T., 2002, ASTEROIDS 3, VIII, P485; Burns JA, 2002, SCIENCE, V297, P942, DOI 10.1126/science.1072078; BUS SJ, 2002, ASTEROIDS, V3, P169; CLOUTIS EA, 1990, J GEOPHYS RES-SOLID, V95, P281, DOI 10.1029/JB095iB01p00281; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Gaffey M.J., 2002, ASTEROIDS, VIII, P183; GAFFEY MJ, 1976, J GEOPHYS RES, V81, P905, DOI 10.1029/JB081i005p00905; GOLDREICH P, 1966, ICARUS, V5, P375, DOI 10.1016/0019-1035(66)90051-0; GOLDREICH P, 1963, MON NOT R ASTRON SOC, V126, P257, DOI 10.1093/mnras/126.3.257; GRADIE J, 1982, SCIENCE, V216, P1405, DOI 10.1126/science.216.4553.1405; GREENBERG R, 1981, ASTRON J, V86, P912, DOI 10.1086/112968; HARDERSEN PS, 2002, LUNAR PLANET I C, V33, P1148; Hayward TL, 2001, PUBL ASTRON SOC PAC, V113, P105, DOI 10.1086/317969; HE HL, 1994, INT J ROCK MECH MIN, V31, P525; Heintz WD, 1998, ASTROPHYS J SUPPL S, V117, P587, DOI 10.1086/313127; Hilton J. L., 2002, ASTEROIDS, V103; KAULA WM, 1964, REV GEOPHYS, V2, P661, DOI 10.1029/RG002i004p00661; Lagerkvist CI, 1996, EARTH MOON PLANETS, V72, P219, DOI 10.1007/BF00117521; MAGNUSSON P, 1990, ICARUS, V85, P229, DOI 10.1016/0019-1035(90)90113-N; MAGNUSSON P, 1994, ASTEROIDS COMETS MET, P1471; Magri C, 2001, METEORIT PLANET SCI, V36, P1697, DOI 10.1111/j.1945-5100.2001.tb01857.x; MAGRI C, COMMUNICATION; Margot JL, 2002, NATURE, V416, P694, DOI 10.1038/416694a; Margot JL, 2002, SCIENCE, V296, P1445, DOI 10.1126/science.1072094; MARGOT JL, 2001, 7703 IAU; McLean IS, 1998, P SOC PHOTO-OPT INS, V3354, P566, DOI 10.1117/12.317283; Merline W.J., 2002, ASTEROIDS, VIII, P289; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; OSTRO SJ, 1991, SCIENCE, V252, P1399, DOI 10.1126/science.252.5011.1399; Rivkin AS, 2000, ICARUS, V145, P351, DOI 10.1006/icar.2000.6354; SCHMADEL LD, 1999, DICT MINOR PLANET NA; Tedesco EF, 2002, ASTRON J, V123, P1056, DOI 10.1086/338320; Tholen DJ, 1997, ICARUS, V125, P245, DOI 10.1006/icar.1996.5494; Veillet C, 2002, NATURE, V416, P711, DOI 10.1038/416711a; Viateau B, 2000, ASTRON ASTROPHYS, V354, P725; Wizinowich P, 2000, P SOC PHOTO-OPT INS, V4007, P2, DOI 10.1117/12.390368; Yeomans DK, 1997, SCIENCE, V278, P2106, DOI 10.1126/science.278.5346.2106	38	48	48	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1939	1942		10.1126/science.1085844	http://dx.doi.org/10.1126/science.1085844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817147				2022-12-28	WOS:000183619400044
J	Zuger, A				Zuger, A			Behind the research: A big study yields big questions	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10027 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Zuger, A (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10027 USA.								0	11	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					213	214		10.1056/NEJMp038121	http://dx.doi.org/10.1056/NEJMp038121			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867605				2022-12-28	WOS:000184165700004
J	LaCroix, AZ; Cauley, JA; Pettinger, M; Hsia, J; Bauer, DC; McGowan, J; Chen, Z; Lewis, CE; McNeeley, SG; Passaro, MD; Jackson, RD				LaCroix, AZ; Cauley, JA; Pettinger, M; Hsia, J; Bauer, DC; McGowan, J; Chen, Z; Lewis, CE; McNeeley, SG; Passaro, MD; Jackson, RD			Statin use, clinical fracture, and bone density in postmenopausal women: Results from the women's health initiative observational study	ANNALS OF INTERNAL MEDICINE			English	Article							HMG-COA REDUCTASE; MINERAL DENSITY; RISK; INHIBITORS; PRAVASTATIN; LOVASTATIN; FREQUENCY; MASS	Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to stimulate bone formation in laboratory studies, both in vitro and in vivo. While early epidemiologic studies showed lower risk for hip fracture among statin users than nonusers, subsequent studies have produced mixed results. Objective: To examine the association of statin use with incidence of hip, lower arm or wrist, and other clinical fractures and with baseline levels of bone density. Design: Prospective study. Setting: women's Health Initiative Observational Study conducted in 40 clinical centers in the United States. Participants: 93 716 postmenopausal women ages 50 to 79 years. Measurements: Rates of hip, lower arm or wrist, and other clinical fractures were compared among 7846 statin users and 85 870 nonusers over a median follow-up of 3.9 years. In 6442 women enrolled at three clinical centers, baseline levels of total hip, posterior-anterior spine, and total-body bone density measured by using dual-energy x-ray absorptiometry were compared according to statin use. Results: Age-adjusted rates of hip, lower arm or wrist, and other clinical fractures were similar between statin users and nonusers regardless of duration of statin use. The multivadate-adjusted hazard ratios for current statin use were 1.22 (95% CI, 0.83 to 1.81) for hip fracture, 1.04 (CI, 0.85 to 1.27) for lower arm or wrist fracture, and 1.11 (CI, 1.00 to 1.22) for other clinical fracture. Bone density levels did not statistically differ between statin users and nonusers at any skeletal site after adjustment for age, ethnicity, body mass index, and other factors. Conclusion: Statin use did not improve fracture risk or bone density in the Women's Health Initiative Observational Study. The cumulative evidence does not warrant use of statins to prevent or treat osteoporosis.	Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98109 USA; Univ Pittsburgh, Pittsburgh, PA USA; George Washington Univ, Washington, DC USA; Medlant Res Inst, Washington, DC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Natl Inst Arthrit & Musculoskeletal Dis, NIH, Bethesda, MD USA; Univ Arizona, Tucson, AZ USA; Univ Alabama Birmingham, Birmingham, AL USA; Wayne State Univ, Detroit, MI USA; Ohio State Univ, Columbus, OH 43210 USA	Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; George Washington University; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Arizona; University of Alabama System; University of Alabama Birmingham; Wayne State University; University System of Ohio; Ohio State University	LaCroix, AZ (corresponding author), Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, 1100 Fairview Ave N,MP-1002,POB 19024, Seattle, WA 98109 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Bauer DC, 1999, J BONE MINER RES, V14, pS179; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140-6736(00)02408-9; Garrett IR, 2000, J BONE MINER RES, V15, pS225; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Kristal AR, 1997, AM J EPIDEMIOL, V146, P856, DOI 10.1093/oxfordjournals.aje.a009203; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; MUNDY GR, 2001, IBMS BONE KEY, P1; Pasco JA, 2002, ARCH INTERN MED, V162, P537, DOI 10.1001/archinte.162.5.537; PEDERSEN TR, 1994, LANCET, V344, P1383; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; Reid IR, 2001, LANCET, V357, P509, DOI 10.1016/S0140-6736(00)04042-3; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850; Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watanabe S, 2000, J BONE MINER RES, V15, pS194	22	133	142	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					97	104		10.7326/0003-4819-139-2-200307150-00009	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859159				2022-12-28	WOS:000184163100003
J	Deblock, R; Onac, E; Gurevich, L; Kouwenhoven, LP				Deblock, R; Onac, E; Gurevich, L; Kouwenhoven, LP			Detection of quantum noise from an electrically driven two-level system	SCIENCE			English	Article							SINGLE-COOPER-PAIR; MESOSCOPIC CONDUCTORS; SHOT-NOISE; FLUCTUATIONS; STATES	The electrical noise of mesoscopic devices can be strongly influenced by the quantum motion of electrons. To probe this effect, we have measured the current fluctuations at high frequency ( 5 to 90 gigahertz) using a superconductor-insulatorsuperconductor tunnel junction as an on-chip spectrum analyzer. By coupling this frequency-resolved noise detector to a quantum device, we can measure the high-frequency, nonsymmetrized noise as demonstrated for a Josephson junction. The same scheme is used to detect the current fluctuations arising from coherent charge oscillations in a two-level system, a superconducting charge qubit. A narrow band peak is observed in the spectral noise density at the frequency of the coherent charge oscillations.	Delft Univ Technol, Dept Nanosci, NL-2600 GA Delft, Netherlands; Delft Univ Technol, ERATO Mesoscop Correlat Project, NL-2600 GA Delft, Netherlands	Delft University of Technology; Delft University of Technology	Deblock, R (corresponding author), Univ Paris 11, CNRS, Phys Solides Lab, Batiment 510, F-91405 Orsay, France.	deblock@ps.u-psud.fr; leo@qt.tn.tudelft.nl	Gurevich, Leonid/AAC-8551-2020; Gurevich, Leonid A/R-4984-2016	Gurevich, Leonid/0000-0002-5777-2541; Gurevich, Leonid A/0000-0002-5777-2541; Deblock, Richard/0000-0001-9750-3373				Aguado R, 2000, PHYS REV LETT, V84, P1986, DOI 10.1103/PhysRevLett.84.1986; Blanter YM, 2000, PHYS REP, V336, P1, DOI 10.1016/S0370-1573(99)00123-4; Bouchiat V, 1998, PHYS SCRIPTA, VT76, P165, DOI 10.1238/Physica.Topical.076a00165; Choi MS, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.045105; Clerk AA, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.176804; Durkan C, 2002, APPL PHYS LETT, V80, P458, DOI 10.1063/1.1434301; FEYNMAN RP, 1965, LECT PHYSICS, V3; Gavish U, 2000, PHYS REV B, V62, pR10637, DOI 10.1103/PhysRevB.62.R10637; INGOLD GL, 1992, NATO ADV SCI I B-PHY, V294, P21; KOCH RH, 1981, PHYS REV LETT, V47, P1216, DOI 10.1103/PhysRevLett.47.1216; KOROTKOV AN, 1994, PHYS REV B, V49, P7548, DOI 10.1103/PhysRevB.49.7548; Lesovik GB, 1997, JETP LETT+, V65, P295, DOI 10.1134/1.567363; Martin I, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.018301; Nakamura Y, 1997, PHYS REV LETT, V79, P2328, DOI 10.1103/PhysRevLett.79.2328; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Ruskov R, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.075303; Schoelkopf RJ, 1997, PHYS REV LETT, V78, P3370, DOI 10.1103/PhysRevLett.78.3370; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; TUCKER JR, 1985, REV MOD PHYS, V57, P1055, DOI 10.1103/RevModPhys.57.1055	19	159	160	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					203	206		10.1126/science.1084175	http://dx.doi.org/10.1126/science.1084175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855804	Green Submitted			2022-12-28	WOS:000184056200039
J	McGrath, J; Somlo, S; Makova, S; Tian, X; Brueckner, M				McGrath, J; Somlo, S; Makova, S; Tian, X; Brueckner, M			Two populations of node monocilia initiate left-right asymmetry in the mouse	CELL			English	Article							POLYCYSTIC KIDNEY-DISEASE; PRIMARY CILIARY DYSKINESIA; RIGHT AXIS DETERMINATION; SITUS-INVERSUS; PRIMARY CILIUM; KINESIN-II; GENE; MICE; MUTATIONS; EXPRESSION	The vertebrate body plan has conserved handed left-right (LR) asymmetry that is manifested in the heart, lungs, and gut. Leftward flow of extracellular fluid at the node (nodal flow) is critical for normal LR axis determination in the mouse. Nodal flow is generated by motile node cell monocilia and requires the axonemal dynein, left-right dynein (lrd). In the absence of lrd, LR determination becomes random. The cation channel polycystin-2 is also required to establish LR asymmetry. We show that lrd localizes to a centrally located subset of node monocilia, while polycystin-2 is found in all node monocilia. Asymmetric calcium signaling appears at the left margin of the node coincident with nodal flow. These observations suggest that LR asymmetry is established by an entirely ciliary mechanism: motile, lrd-containing monocilia generate nodal flow, and nonmotile polycystin-2 containing cilia sense nodal flow initiating an asymmetric calcium signal at the left border of the node.	Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, Cardiol Sect, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Brueckner, M (corresponding author), Yale Univ, Sch Med, Dept Comparat Med, 333 Cedar St, New Haven, CT 06520 USA.	martina.brueckner@yale.edu			NIDDK NIH HHS [DK54053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bartoloni L, 2002, P NATL ACAD SCI USA, V99, P10282, DOI 10.1073/pnas.152337699; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BROWN NA, 1990, DEVELOPMENT, V109, P1; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Essner JJ, 2002, NATURE, V418, P37, DOI 10.1038/418037a; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Guichard C, 2001, AM J HUM GENET, V68, P1030, DOI 10.1086/319511; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hummel K. P., 1959, Journal of Heredity, V50, P9; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Levin M, 1999, DEVELOPMENT, V126, P4703; Levin M, 2002, CELL, V111, P77, DOI 10.1016/S0092-8674(02)00939-X; Levin M, 1998, DEV BIOL, V203, P90, DOI 10.1006/dbio.1998.9024; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 2001, DEVELOPMENT, V128, P1831; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mochizuki T, 1998, NATURE, V395, P177, DOI 10.1038/26006; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; Olbrich H, 2002, NAT GENET, V30, P143, DOI 10.1038/ng817; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Pennarun G, 1999, AM J HUM GENET, V65, P1508, DOI 10.1086/302683; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Poole CA, 1997, CELL BIOL INT, V21, P483, DOI 10.1006/cbir.1997.0177; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; Supp DM, 1999, DEVELOPMENT, V126, P5495; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Watanabe D, 2003, DEVELOPMENT, V130, P1725, DOI 10.1242/dev.00407; Wilhelmi H, 1921, ARCH ENTWICKLUNG ORG, V48, P517, DOI 10.1007/BF02554577; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 2002, HUM MOL GENET, V11, P1845, DOI 10.1093/hmg/11.16.1845; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	50	570	595	1	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					61	73		10.1016/S0092-8674(03)00511-7	http://dx.doi.org/10.1016/S0092-8674(03)00511-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859898	Bronze			2022-12-28	WOS:000184219900006
J	De Jesus, H				De Jesus, H			Images in clinical medicine: A quarter-century of fibrous dysplasia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Hosp Funchal, P-9000 Funchal, Madeira, Portugal		De Jesus, H (corresponding author), Ctr Hosp Funchal, P-9000 Funchal, Madeira, Portugal.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					E2	E2		10.1056/ENEJMicm990639	http://dx.doi.org/10.1056/ENEJMicm990639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853600				2022-12-28	WOS:000184024400010
J	Hillier, LW; Fulton, RS; Fulton, LA; Graves, TA; Pepin, KH; Wagner-McPherson, C; Layman, D; Maas, J; Jaeger, S; Walker, R; Wylie, K; Sekhon, M; Becker, MC; O'Laughlin, MD; Schaller, ME; Fewell, GA; Delehaunty, KD; Miner, TL; Nash, WE; Cordes, M; Du, H; Sun, H; Edwards, J; Bradshaw-Cordum, H; Ali, J; Andrews, S; Isak, A; VanBrunt, A; Nguyen, C; Du, FY; Lamar, B; Courtney, L; Kalicki, J; Ozersky, P; Bielicki, L; Scott, K; Holmes, A; Harkins, R; Harris, A; Strong, CM; Hou, SF; Tomlinson, C; Dauphin-Kohlberg, S; Kozlowicz-Reilly, A; Leonard, S; Rohlfing, T; Rock, SM; Tin-Wollam, AM; Abbott, A; Minx, P; Maupin, R; Strowmatt, C; Latreille, P; Miller, N; Johnson, D; Murray, J; Woessner, JP; Wendl, MC; Yang, SP; Schultz, BR; Wallis, JW; Spieth, J; Bieri, TA; Nelson, JO; Berkowicz, N; Wohldmann, PE; Cook, LL; Hickenbotham, MT; Eldred, J; Williams, D; Bedell, JA; Mardis, ER; Clifton, SW; Chissoe, SL; Marra, MA; Raymond, C; Haugen, E; Gillett, W; Zhou, Y; James, R; Phelps, K; Iadanoto, S; Bubb, K; Simms, E; Levy, R; Clendenning, J; Kaul, R; Kent, WJ; Furey, TS; Baertsch, RA; Brent, MR; Keibler, E; Flicek, P; Bork, P; Suyama, M; Bailey, JA; Portnoy, ME; Torrents, D; Chinwalla, AT; Gish, WR; Eddy, SR; McPherson, JD; Olson, MV; Eichler, EE; Green, ED; Waterston, RH; Wilson, RK				Hillier, LW; Fulton, RS; Fulton, LA; Graves, TA; Pepin, KH; Wagner-McPherson, C; Layman, D; Maas, J; Jaeger, S; Walker, R; Wylie, K; Sekhon, M; Becker, MC; O'Laughlin, MD; Schaller, ME; Fewell, GA; Delehaunty, KD; Miner, TL; Nash, WE; Cordes, M; Du, H; Sun, H; Edwards, J; Bradshaw-Cordum, H; Ali, J; Andrews, S; Isak, A; VanBrunt, A; Nguyen, C; Du, FY; Lamar, B; Courtney, L; Kalicki, J; Ozersky, P; Bielicki, L; Scott, K; Holmes, A; Harkins, R; Harris, A; Strong, CM; Hou, SF; Tomlinson, C; Dauphin-Kohlberg, S; Kozlowicz-Reilly, A; Leonard, S; Rohlfing, T; Rock, SM; Tin-Wollam, AM; Abbott, A; Minx, P; Maupin, R; Strowmatt, C; Latreille, P; Miller, N; Johnson, D; Murray, J; Woessner, JP; Wendl, MC; Yang, SP; Schultz, BR; Wallis, JW; Spieth, J; Bieri, TA; Nelson, JO; Berkowicz, N; Wohldmann, PE; Cook, LL; Hickenbotham, MT; Eldred, J; Williams, D; Bedell, JA; Mardis, ER; Clifton, SW; Chissoe, SL; Marra, MA; Raymond, C; Haugen, E; Gillett, W; Zhou, Y; James, R; Phelps, K; Iadanoto, S; Bubb, K; Simms, E; Levy, R; Clendenning, J; Kaul, R; Kent, WJ; Furey, TS; Baertsch, RA; Brent, MR; Keibler, E; Flicek, P; Bork, P; Suyama, M; Bailey, JA; Portnoy, ME; Torrents, D; Chinwalla, AT; Gish, WR; Eddy, SR; McPherson, JD; Olson, MV; Eichler, EE; Green, ED; Waterston, RH; Wilson, RK			The DNA sequence of human chromosome 7	NATURE			English	Article							HUMAN-CHROMOSOME 7; HUMAN-GENOME; GENE; MAP; IDENTIFICATION; DUPLICATION; INTEGRATION; ANNOTATION; EVOLUTION	Human chromosome 7 has historically received prominent attention in the human genetics community, primarily related to the search for the cystic fibrosis gene and the frequent cytogenetic changes associated with various forms of cancer. Here we present more than 153 million base pairs representing 99.4% of the euchromatic sequence of chromosome 7, the first metacentric chromosome completed so far. The sequence has excellent concordance with previously established physical and genetic maps, and it exhibits an unusual amount of segmentally duplicated sequence (8.2%), with marked differences between the two arms. Our initial analyses have identified 1,150 protein-coding genes, 605 of which have been confirmed by complementary DNA sequences, and an additional 941 pseudogenes. Of genes confirmed by transcript sequences, some are polymorphic for mutations that disrupt the reading frame.	Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Univ Washington, Genome Ctr, Seattle, WA 98195 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Washington Univ, Dept Comp Sci, St Louis, MO 63130 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Case Western Reserve Univ, Sch Med, Ctr Computat Genome, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); University of Washington; University of Washington Seattle; University of California System; University of California Santa Cruz; Washington University (WUSTL); European Molecular Biology Laboratory (EMBL); Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Wilson, RK (corresponding author), Washington Univ, Sch Med, Genome Sequencing Ctr, Campus Box 8501,4444 Forest Pk Ave, St Louis, MO 63108 USA.	rwilson@watson.wustl.edu	McPherson, John D/D-2633-2017; Brent, Michael/AAK-3702-2020; Mardis, Elaine/W-2202-2019; Sekhon, Mandeep/L-4665-2018; Wendl, Michael C/A-2741-2008; Marra, Marco A/B-5987-2008; Bork, Peer/F-1813-2013; Wilson, Richard K./AAF-4139-2019; Torrents, David/G-5785-2015	McPherson, John D/0000-0001-8049-9347; Brent, Michael/0000-0002-8689-0299; Sekhon, Mandeep/0000-0002-9993-6938; Marra, Marco A/0000-0001-7146-7175; Bork, Peer/0000-0002-2627-833X; Wilson, Richard K./0000-0002-1992-1358; Schultz, Brian/0000-0003-4964-976X; Furey, Terry/0000-0001-5546-9672; Kaul, Rajinder/0000-0002-7895-9284; Haugen, Eric/0000-0001-7444-8981; Flicek, Paul/0000-0002-3897-7955; Chinwalla, Asif/0000-0001-7831-3996; Eddy, Sean/0000-0001-6676-4706; Suyama, Mikita/0000-0001-9526-3193; Torrents, David/0000-0002-6086-9037				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Ashburner M, 2001, GENOME RES, V11, P1425; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; Bouffard GG, 1997, GENOME RES, V7, P673, DOI 10.1101/gr.7.7.673; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Collins JE, 2003, GENOME RES, V13, P27, DOI 10.1101/gr.695703; Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a; DeSilva U, 1999, GENOME RES, V9, P428; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Eddy SR, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-18; Eichler EE, 1999, GENOME RES, V9, P1048, DOI 10.1101/gr.9.11.1048; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Felsenfeld A, 1999, GENOME RES, V9, P1; Flicek P, 2003, GENOME RES, V13, P46, DOI 10.1101/gr.830003; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Horvath JE, 2001, HUM MOL GENET, V10, P2215, DOI 10.1093/hmg/10.20.2215; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; *HUM GEN MAPP CONS, 2001, NATURE, V409, P934; Korenberg JR, 2000, J COGNITIVE NEUROSCI, V12, P89, DOI 10.1162/089892900562002; Korf I, 2001, Bioinformatics, V17 Suppl 1, pS140; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MARAIA RJ, 1994, NUCLEIC ACIDS RES, V22, P3045, DOI 10.1093/nar/22.15.3045; Mefford HC, 2002, NAT REV GENET, V3, P91, DOI 10.1038/nrg727; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mulder Nicola J, 2002, Brief Bioinform, V3, P225; Nadezhdin EV, 2001, MOL GENET GENOMICS, V265, P820; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; Ohta T, 1995, J MOL EVOL, V41, P717, DOI 10.1007/BF00173150; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Riethman HC, 2001, NATURE, V409, P948, DOI 10.1038/35057180; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SOLOVYEV VV, 2001, STAT APPROACHES EUKA; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wheelan SJ, 2001, GENOME RES, V11, P1952, DOI 10.1101/gr.195301; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	49	198	992	1	28	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					157	U2		10.1038/nature01782	http://dx.doi.org/10.1038/nature01782			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853948	Bronze			2022-12-28	WOS:000184032700033
J	Sicardy, B; Widemann, T; Lellouch, E; Veillet, C; Cuillandre, JC; Colas, F; Roques, F; Beisker, W; Kretlow, M; Lagrange, AM; Gendron, E; Lacombe, F; Lecacheux, J; Birnbaum, C; Fienga, A; Leyrat, C; Maury, A; Raynaud, E; Renner, S; Schultheis, M; Brooks, K; Delsanti, A; Hainaut, OR; Gilmozzi, R; Lidman, C; Spyromilio, J; Rapaport, M; Rosenzweig, P; Naranjo, O; Porras, L; Diaz, F; Calderon, H; Carrillo, S; Carvajal, A; Recalde, E; Cavero, LG; Montalvo, C; Barria, D; Campos, R; Duffard, R; Levato, H				Sicardy, B; Widemann, T; Lellouch, E; Veillet, C; Cuillandre, JC; Colas, F; Roques, F; Beisker, W; Kretlow, M; Lagrange, AM; Gendron, E; Lacombe, F; Lecacheux, J; Birnbaum, C; Fienga, A; Leyrat, C; Maury, A; Raynaud, E; Renner, S; Schultheis, M; Brooks, K; Delsanti, A; Hainaut, OR; Gilmozzi, R; Lidman, C; Spyromilio, J; Rapaport, M; Rosenzweig, P; Naranjo, O; Porras, L; Diaz, F; Calderon, H; Carrillo, S; Carvajal, A; Recalde, E; Cavero, LG; Montalvo, C; Barria, D; Campos, R; Duffard, R; Levato, H			Large changes in Pluto's atmosphere as revealed by recent stellar occultations	NATURE			English	Article							SURFACE	Pluto's tenuous nitrogen atmosphere was first detected by the imprint left on the light curve of a star that was occulted by the planet in 1985 (ref. 1), and studied more extensively during a second occultation event in 1988 (refs 2 - 6). These events are, however, quite rare and Pluto's atmosphere remains poorly understood, as in particular the planet has not yet been visited by a spacecraft. Here we report data from the first occultations by Pluto since 1988. We find that, during the intervening 14 years, there seems to have been a doubling of the atmospheric pressure, a probable seasonal effect on Pluto.	Observ Paris, LESIA, F-92195 Meudon, France; Univ Paris 06, F-75005 Paris, France; Canada France Hawaii Telescope Corp, Waimea, HI 96743 USA; Observ Paris, IMCCE, F-75014 Paris, France; Int Occulat Timing Assoc, Eruopean Sect, D-30459 Hannover, Germany; Observ Grenoble, F-38041 Grenoble, France; Cite Sci & Ind, F-75930 Paris, France; Gene Shoemaker Observ, San Pedro De Atacama, Chile; Inst Astrophys Paris, F-75014 Paris, France; European So Observ, Santiago 19, Chile; Observ Aquitain Sci Univ, F-33270 Floirac, France; Univ Los Andes, Fac Ciencias, Merida 5101, Venezuela; Cumbaya, Quito 1722, Ecuador; Asociac Eta Carinae, Lima 1, Peru; Univ Catolica Norte, Observ Cerro Armazones, Antofagasta 1280, Chile; Lab Nacl Astrofis, BR-37504364 Itajuba, Brazil; Observ Nacl, BR-20921400 Rio De Janeiro, Brazil; Complejo Astron, San Juan, Argentina	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; UDICE-French Research Universities; Sorbonne Universite; Canada France Hawaii Telescope; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Sorbonne Universite; European Southern Observatory; University of Los Andes Venezuela; Universidad Catolica del Norte	Sicardy, B (corresponding author), Observ Paris, LESIA, F-92195 Meudon, France.	bruno.sicardy@obspm.fr	Barria, Daniela/GRN-8314-2022; Hainaut, Olivier R./AAY-7006-2021; Barría, Daniela/AAZ-3278-2020; Duffard, Rene/A-2233-2009; Veillet, Christian/P-5301-2018	Duffard, Rene/0000-0001-5963-5850; Veillet, Christian/0000-0003-0272-0418; Barria, Daniela/0000-0003-4754-4673; Kretlow, Mike/0000-0001-8858-3420; Lidman, Chris/0000-0003-1731-0497; DELSANTI, Audrey/0000-0002-1413-2288; Cuillandre, Jean-Charles/0000-0002-3263-8645				BROSCH N, 1995, MON NOT R ASTRON SOC, V276, P571, DOI 10.1093/mnras/276.2.571; ELLIOT JL, 1989, ICARUS, V77, P148, DOI 10.1016/0019-1035(89)90014-6; Elliot JL, 2003, NATURE, V424, P165, DOI 10.1038/nature01762; ELLIOT JL, 1992, ASTRON J, V103, P991, DOI 10.1086/116121; Grundy WM, 2001, ICARUS, V153, P248, DOI 10.1006/icar.2001.6684; Hansen CJ, 1996, ICARUS, V120, P247, DOI 10.1006/icar.1996.0049; HUBBARD WB, 1988, NATURE, V336, P452, DOI 10.1038/336452a0; Lellouch E, 2000, ICARUS, V147, P220, DOI 10.1006/icar.2000.6441; McDonald SW, 2000, ASTRON J, V120, P1599, DOI 10.1086/301543; McDonald SW, 2000, ASTRON J, V119, P1999, DOI 10.1086/301312; MILLIS RL, 1993, ICARUS, V105, P282, DOI 10.1006/icar.1993.1126; Null GW, 1996, ASTRON J, V111, P1368, DOI 10.1086/117883; Sicardy B, 1999, ICARUS, V142, P357, DOI 10.1006/icar.1999.6219; Spencer J.R., 1997, PLUTO CHARON, P435; STANSBERRY JA, 1994, ICARUS, V111, P503, DOI 10.1006/icar.1994.1160; Strobel DF, 1996, ICARUS, V120, P266, DOI 10.1006/icar.1996.0050; Yelle R.V., 1997, PLUTO CHARON PART 4, P347; YELLE RV, 1989, NATURE, V339, P288, DOI 10.1038/339288a0	18	85	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					168	170		10.1038/nature01766	http://dx.doi.org/10.1038/nature01766			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853950				2022-12-28	WOS:000184032700035
J	Souter, VL; Kapur, RP; Nyholt, DR; Skogerboe, K; Myerson, D; Ton, CC; Opheim, KE; Easterling, TR; Shields, LE; Montgomery, GW; Glass, IA				Souter, VL; Kapur, RP; Nyholt, DR; Skogerboe, K; Myerson, D; Ton, CC; Opheim, KE; Easterling, TR; Shields, LE; Montgomery, GW; Glass, IA			Brief report: A report of dizygous monochorionic twins	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACYTOPLASMIC SPERM INJECTION; BINOVULAR ZONA-PELLUCIDA; WEINBERG RULE; FERTILIZATION; EMBRYO; HERMAPHRODITE; PREGNANCIES; CHIMERISM; ZYGOSITY		Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat & Med Med Genet, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Dept Labs, Seattle, WA 98105 USA; Queensland Inst Med Res, Genet Epidemiol Lab, Brisbane, Qld 4006, Australia; Seattle Univ, Dept Chem, Seattle, WA 98122 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Genelex, Redmond, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; QIMR Berghofer Medical Research Institute; Seattle University; Fred Hutchinson Cancer Center	Souter, VL (corresponding author), Good Samaritan Reg Med Ctr, Dept Obstet & Gynecol, 1111 E McDowell Rd, Phoenix, AZ 85006 USA.	vsouter@u.washington.edu	Montgomery, Grant W/B-7148-2008; Nyholt, Dale Robert/J-3174-2017	Montgomery, Grant W/0000-0002-4140-8139; Nyholt, Dale Robert/0000-0001-7159-3040; Souter, Vivienne/0000-0002-7140-0584; Myerson, David/0000-0002-2628-940X	NCI NIH HHS [CA15074, CA18029] Funding Source: Medline; NHLBI NIH HHS [HL36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742; ALIKANI M, 1994, HUM REPROD, V9, P1318, DOI 10.1093/oxfordjournals.humrep.a138701; Blickstein I, 1999, NEW ENGL J MED, V340, P738, DOI 10.1056/NEJM199903043400916; Carroll SGM, 2002, BJOG-INT J OBSTET GY, V109, P182; DEROM C, 1987, LANCET, V1, P1236; DEROM C, 1987, LANCET, V2, P170; Dommergues M, 2002, CURR OPIN OBSTET GYN, V14, P169, DOI 10.1097/00001703-200204000-00011; Ewen KR, 2000, AM J HUM GENET, V67, P727, DOI 10.1086/303048; Giltay JC, 1998, AM J HUM GENET, V62, P937, DOI 10.1086/301796; Golubovsky M, 2002, TWIN RES, V5, P75; HUSBY H, 1991, ACTA GENET MED GEMEL, V40, P147, DOI 10.1017/S0001566000002579; Keith L, 1997, J REPROD MED, V42, P699; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; NYLANDER PP, 1970, OBSTET GYNECOL, V36, P621; Peramo B, 1999, FERTIL STERIL, V72, P1116, DOI 10.1016/S0015-0282(99)00412-4; Repas-Humpe LM, 1999, ANN HEMATOL, V78, P431, DOI 10.1007/s002770050543; Safran A, 1998, HUM REPROD, V13, P2575, DOI 10.1093/humrep/13.9.2575; Strain L, 1998, NEW ENGL J MED, V338, P166, DOI 10.1056/NEJM199801153380305; TARKOWSKI AK, 1982, J EMBRYOL EXP MORPH, V71, P215; TAYLOR AS, 1994, HUM REPROD, V9, P2389, DOI 10.1093/oxfordjournals.humrep.a138457; TIPPETT P, 1983, VOX SANG, V44, P333, DOI 10.1111/j.1423-0410.1983.tb03657.x; vanDijk BA, 1996, AM J MED GENET, V61, P264, DOI 10.1002/(SICI)1096-8628(19960122)61:3<264::AID-AJMG11>3.0.CO;2-R; Vicdan K, 1999, J ASSIST REPROD GEN, V16, P355, DOI 10.1023/A:1020537812619; VLIETINCK R, 1988, ACTA GENET MED GEMEL, V37, P137, DOI 10.1017/S0001566000004049	25	101	107	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					154	158		10.1056/NEJMoa030050	http://dx.doi.org/10.1056/NEJMoa030050			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853588	Green Published			2022-12-28	WOS:000184024400008
J	Balescu, R				Balescu, R			Ilya Prigogine (1917-2003) - Obituary	NATURE			English	Biographical-Item											Balescu, R (corresponding author), 86 Ave A Huysmans, B-1050 Brussels, Belgium.							PRIGOGINE IR, PUBLICATION LIST	1	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					30	30		10.1038/424030a	http://dx.doi.org/10.1038/424030a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840746	Bronze			2022-12-28	WOS:000183912800028
J	Tallman, MS; Gray, R; Robert, NJ; LeMaistre, CF; Osborne, CK; Vaughan, WP; Gradishar, WJ; Pisansky, TM; Fetting, J; Paietta, E; Lazarus, HM				Tallman, MS; Gray, R; Robert, NJ; LeMaistre, CF; Osborne, CK; Vaughan, WP; Gradishar, WJ; Pisansky, TM; Fetting, J; Paietta, E; Lazarus, HM			Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; BONE-MARROW; MYELODYSPLASTIC SYNDROME; RANDOMIZED-TRIAL; AXILLARY NODES; THERAPY; SUPPORT; CYCLOPHOSPHAMIDE; METHOTREXATE; RESCUE	BACKGROUND: The prognosis for women with primary breast cancer and 10 or more involved axillary lymph nodes is poor. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse. METHODS: We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation. RESULTS: Among the 511 eligible patients, there was no significant difference in disease-free survival, overall survival, or the time to recurrence between those who received CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation. Among 417 patients fulfilling strict eligibility criteria, the time to recurrence was longer for patients who underwent stem-cell transplantation than for those who received CAF alone. In the transplantation group, nine patients died of transplantation-related complications and a myelodysplastic syndrome or acute myeloid leukemia developed in nine. CONCLUSIONS: The addition of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation to six cycles of adjuvant chemotherapy with CAF may reduce the risk of relapse but does not improve the outcome among patients with primary breast cancer and at least 10 involved axillary lymph nodes. Conventional-dose adjuvant chemotherapy remains the standard of care for such patients.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Inova Fairfax Hosp, Falls Church, VA USA; Texas Transplant Inst, San Antonio, TX USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Univ Alabama Birmingham, Birmingham, AL USA; Mayo Clin, Div Radiat Oncol, Rochester, MN USA; Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; New York Med Coll, Our Lady Mercy Canc Ctr, Bronx, NY USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Harvard University; Dana-Farber Cancer Institute; Inova Fairfax Hospital; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; University of Alabama System; University of Alabama Birmingham; Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; New York Medical College; Case Western Reserve University	Tallman, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, 676 N St Clair St,Suite 850, Chicago, IL 60611 USA.	m-tallman@northwestern.edu			NATIONAL CANCER INSTITUTE [U10CA023318, U10CA016116, U10CA021115, U10CA066636, U10CA013650, U10CA032102, U10CA017145] Funding Source: NIH RePORTER; NCI NIH HHS [CA66636, CA32102, CA28926, CA23318, CA21115, CA17145, CA16116, CA13650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abruzzese E, 1999, BLOOD, V94, P1814; Ando M, 1999, JPN J CLIN ONCOL, V29, P28, DOI 10.1093/jjco/29.1.28; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BONADONNA G, 1985, J CLIN ONCOL, V3, P259, DOI 10.1200/JCO.1985.3.2.259; BULL JM, 1978, CANCER, V41, P1649, DOI 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J; BUZZONI R, 1991, J CLIN ONCOL, V9, P2134, DOI 10.1200/JCO.1991.9.12.2134; Chaplain G, 2000, J CLIN ONCOL, V18, P2836, DOI 10.1200/JCO.2000.18.15.2836; COX DR, 1972, J R STAT SOC B, V34, P187; CROWN JP, 2002, P AN M AM SOC CLIN, V21, pA42; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1994, NEW ENGL J MED, V330, P1458; GarciaCarbonero R, 1997, J CLIN ONCOL, V15, P3178, DOI 10.1200/JCO.1997.15.10.3178; Gianni AM, 1997, J CLIN ONCOL, V15, P2312, DOI 10.1200/JCO.1997.15.6.2312; Gradishar WJ, 1996, ANN INTERN MED, V125, P599, DOI 10.7326/0003-4819-125-7-199610010-00010; Hortobagyi GN, 2000, JNCI-J NATL CANCER I, V92, P225, DOI 10.1093/jnci/92.3.225; JONES SE, 1987, AM J CLIN ONCOL-CANC, V10, P387, DOI 10.1097/00000421-198710000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; Kleinman MB, 1999, BONE MARROW TRANSPL, V23, P1297, DOI 10.1038/sj.bmt.1701794; Laughlin MJ, 1998, J CLIN ONCOL, V16, P1008, DOI 10.1200/JCO.1998.16.3.1008; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Metayer C, 2003, BLOOD, V101, P2015, DOI 10.1182/blood-2002-04-1261; Nichols G, 2002, LEUKEMIA, V16, P1673, DOI 10.1038/sj.leu.2402631; Pedersen-Bjergaard J, 2000, BLOOD, V95, P3273, DOI 10.1182/blood.V95.11.3273.011k15_3273_3279; PEDERSENBJERGAA.J, 2000, BLOOD, V96, P1680; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 2001, P AN M AM SOC CLIN, V20, pA21; ROCHE HH, 2001, P AN M AM SOC CLIN, V20, pA26; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; Rodenhuis S, 2003, NEW ENGL J MED, V349, P7, DOI 10.1056/NEJMoa022794; ROMANUNFER S, 1995, BONE MARROW TRANSPL, V16, P163; ROSS AA, 1993, BLOOD, V82, P2605; *SCAND BREAST CANC, 1999, P AN M AM SOC CLIN, V18, pA2; Schulze R, 1997, BONE MARROW TRANSPL, V19, P1223, DOI 10.1038/sj.bmt.1700817; Somlo G, 1997, J CLIN ONCOL, V15, P2882, DOI 10.1200/JCO.1997.15.8.2882; TALLMAN MS, 1995, J CLIN ONCOL, V13, P1557, DOI 10.1200/JCO.1995.13.7.1557; Tomas JF, 1997, BONE MARROW TRANSPL, V19, P331, DOI 10.1038/sj.bmt.1700658	37	134	140	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					17	26		10.1056/NEJMoa030684	http://dx.doi.org/10.1056/NEJMoa030684			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840088				2022-12-28	WOS:000183896100004
J	Gupta, S; Bent, S; Kohlwes, J				Gupta, S; Bent, S; Kohlwes, J			Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C - A systematic review and critical analysis	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC LIVER-DISEASE; CHRONIC VIRAL-HEPATITIS; VIRUS-RELATED CIRRHOSIS; DYSPLASTIC NODULES; UNITED-STATES; TRANSPLANT PATIENTS; CLINICAL-EVALUATION; POSITIVE PATIENTS; TUMOR-MARKERS; SURVEILLANCE	Background: Patients with hepatitis C virus (HCV) are at increased risk for hepatocellular carcinoma. Although serum a-fetoprotein (AFP) is often used to detect hepatocellular carcinoma in HCV-infected individuals, its utility is unclear. Purpose: To define the test characteristics of AFP for the diagnosis of hepatocellular carcinoma in patients with HCV. Data Sources: MEDLINE search from 1966 to December 2002 for English- and non-English-language articles examining the test characteristics of AFP for identifying hepatocellular carcinoma. Study Selection: Articles were included if they reported the sensitivity and specificity of AFP for detecting hepatocellular carcinoma in patients with HCV. Articles were excluded if the cause of hepatitis was ambiguous or if 50% or more of the study patients did not have HCV. Data Extraction: Relevant articles were evaluated for quality of evidence; test characteristics were abstracted and calculated. Data Synthesis: Five studies met all inclusion criteria and were analyzed. The overall quality of evidence was limited; only one study universally applied an acceptable gold standard test, and three of five studies used a case-control design that potentially overestimates diagnostic accuracy. By using the most commonly reported cutoff value of a positive test result for hepatocellular carcinoma (AFP level > 20 mug/L), the ranges of test characteristics were as follows: sensitivity, 41% to 65%; specificity, 80% to 94%; positive likelihood ratios, 3.1 to 6.8; and negative likelihood ratios, 0.4 to 0.6. Conclusions: The paucity of high-quality data calls for more rigorous study of AFP and other diagnostic tests for detecting hepatocellular carcinoma in HCV-infected patients with an accepted gold standard applied to the entire cohort. Even if the "best-case" estimates of AFP sensitivity and specificity are accurate, AFP has limited utility for detecting hepatocellular carcinoma.	Vet Affairs Med Ctr, Dept Med 111, Vet Affairs PRIME Program, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Kohlwes, J (corresponding author), Vet Affairs Med Ctr, Dept Med 111, Vet Affairs PRIME Program, 4150 Clement St, San Francisco, CA 94121 USA.	samirguptaresearch@yahoo.com						Bennett GL, 2002, AM J ROENTGENOL, V179, P75, DOI 10.2214/ajr.179.1.1790075; Cedrone A, 2000, HEPATO-GASTROENTEROL, V47, P1654; Chalasani N, 1999, AM J GASTROENTEROL, V94, P2224; Chalasani N, 1999, AM J GASTROENTEROL, V94, P2988, DOI 10.1016/S0002-9270(99)00504-3; Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1; COTTONE M, 1994, J HEPATOL, V21, P1029, DOI 10.1016/S0168-8278(05)80613-0; CURLEY S, 2002, UPTODATE; CURLEY SA, 1995, ANN SURG, V222, P375, DOI 10.1097/00000658-199509000-00014; Degos F, 2000, GUT, V47, P131, DOI 10.1136/gut.47.1.131; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Furui J, 1995, HEPATO-GASTROENTEROL, V42, P445; Gambarin-Gelwan M, 2000, AM J GASTROENTEROL, V95, P1535; Giannini E, 2000, HEPATO-GASTROENTEROL, V47, P1395; Guyatt G., 2015, USERS GUIDES MED LIT; Hu KQ, 1999, HEPATOLOGY, V29, P1311, DOI 10.1002/hep.510290424; Ishii M, 2000, AM J GASTROENTEROL, V95, P1036; Izzo F, 1997, J Chemother, V9, P151; Izzo F, 1998, ANN SURG, V227, P513, DOI 10.1097/00000658-199804000-00011; Izzo F, 1999, ANN SURG ONCOL, V6, P178, DOI 10.1007/s10434-999-0178-1; Johnson PJ, 2002, AM J GASTROENTEROL, V97, P225; Kim CK, 2001, J ULTRAS MED, V20, P99; Larcos G, 1998, AM J ROENTGENOL, V171, P433, DOI 10.2214/ajr.171.2.9694470; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Lim JH, 2000, AM J ROENTGENOL, V175, P693, DOI 10.2214/ajr.175.3.1750693; Lin DY, 2001, J GASTROEN HEPATOL, V16, P715, DOI 10.1046/j.1440-1746.2001.02511.x; Manghisi G, 1998, HEPATOLOGY, V28, P751; Nguyen MH, 2002, HEPATOLOGY, V36, P410, DOI 10.1053/jhep.2002.34744; PATERON D, 1994, J HEPATOL, V20, P65, DOI 10.1016/S0168-8278(05)80468-4; *PDQ CANC INF SUMM, 2002, SCREEN DET HEP CANC; Peng YC, 1999, HEPATO-GASTROENTEROL, V46, P3208; Perrone F, 2000, HEPATOLOGY, V31, P840; Peterson MS, 2000, RADIOLOGY, V217, P743, DOI 10.1148/radiology.217.3.r00dc28743; Sherman M, 2001, J HEPATOL, V34, P603, DOI 10.1016/S0168-8278(01)00025-3; SHIINA S, 2002, RADIOFREQUENCY ABLAT; Songsivilai S, 1995, ASIAN PAC J ALLERGY, V13, P167; TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625; Tong MJ, 2001, J GASTROEN HEPATOL, V16, P553, DOI 10.1046/j.1440-1746.2001.02470.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Tradati F, 1998, BLOOD, V91, P1173; Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2; TSAI JF, 1994, BRIT J CANCER, V69, P1157, DOI 10.1038/bjc.1994.227; Tsai JF, 1997, BRIT J CANCER, V75, P1460, DOI 10.1038/bjc.1997.250; TSAI JF, 1995, BRIT J CANCER, V72, P442, DOI 10.1038/bjc.1995.352; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Yuen MF, 2000, HEPATOLOGY, V31, P330, DOI 10.1002/hep.510310211	45	269	287	2	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2003	139	1					46	50		10.7326/0003-4819-139-1-200307010-00012	http://dx.doi.org/10.7326/0003-4819-139-1-200307010-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695GR	12834318				2022-12-28	WOS:000183823200007
J	Ducas, J; Grech, ED				Ducas, J; Grech, ED			ABC of interventional cardiology - Percutaneous coronary intervention: cardiogenic shock	BRITISH MEDICAL JOURNAL			English	Review							REVASCULARIZATION		Hlth Sci Ctr, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB, Canada; Univ Manitoba, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Ducas, J (corresponding author), Hlth Sci Ctr, Winnipeg, MB, Canada.			Ducas, John/0000-0001-5953-3352				Berger PB, 1997, CIRCULATION, V96, P122; GOLBERG RJ, 1999, NEW ENGL J MED, V340, P1162; Hasdai D, 2000, LANCET, V356, P749, DOI 10.1016/S0140-6736(00)02640-4; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; White HD, 2000, EUR HEART J, V21, P1897, DOI 10.1053/euhj.2000.2141	5	7	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2003	326	7404					1450	1452		10.1136/bmj.326.7404.1450	http://dx.doi.org/10.1136/bmj.326.7404.1450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829561	Green Published			2022-12-28	WOS:000183931800023
J	Wilson, S; Johnston, A; Robson, J; Poulter, N; Collier, D; Feder, G; Caulfield, MJ				Wilson, S; Johnston, A; Robson, J; Poulter, N; Collier, D; Feder, G; Caulfield, MJ			Comparison of methods to identify individuals at increased risk of coronary disease from the general population	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK; PRIMARY PREVENTION; HEART-DISEASE; FRAMINGHAM; MORTALITY	Objectives To evaluate the guidelines on measurement of cholesterol in the national service framework for coronary heart disease and to compare alternative strategies for identifying people at high risk of coronary disease in the general population. Design Comparison of methods (national service framework criteria, Sheffield tables, age threshold of 50 years, estimated risk assessment using fixed cholesterol values) for identifying people with a 10 year coronary event risk of 15% or greater. Setting Health survey for England 1998. Subjects 6307 people aged between 30 and 74 years with no history of myocardial infarction, stroke, or angina. Main outcome measures Proportion of the total population selected for measurement of cholesterol and proportion of people at 15% or greater risk identified. Results The national service framework guidelines selected 43.4% (95% confidence interval 42.2% to 44.6%) of the study population for cholesterol measurement and identified 81.2% (80.2% to 82.2%) of those at 15% or greater risk. The Sheffield tables selected 73.1% (72.0% to 74.2%) for cholesterol measurement and identified 99.91% (99.83% to 99.99%) of those at 15% or greater risk. An age threshold of 50 years selected 46.3% (45.1% to 47.5%) for cholesterol measurement and identified 92.8% (92.1% to 93.4%) of those at 15% or greater risk. Estimated risk assessments using fixed cholesterol values selected 17.8% (16.8% to 18.7%) for cholesterol measurement and identified 75.9% (74.8% to 76.9%) of those at 15% or greater risk. Conclusion Measuring the cholesterol concentration of everyone aged 50 years and over is a simple and efficient method of identifying people at high risk of coronary disease in the general population.	Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Barts & London Queen Marys Sch Med & Dent, Inst Community Hlth Sci, London E1 4NS, England; Univ London Imperial Coll Sci Technol & Med, Cardiovasc Studies Unit, London W2 1PG, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London	Wilson, S (corresponding author), Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.	s.l.wilson@qmul.ac.uk	Robson, John/H-3904-2014	Robson, John/0000-0001-6889-0415; Johnston, Atholl/0000-0001-5787-2270; Feder, Gene/0000-0002-7890-3926; Caulfield, Mark/0000-0001-9295-3594				Altman D.G., 1991, PRACTICAL STAT MED R; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; *DEP HLTH, 2000, NAT SERV FRAM COR HE; ERENS B, 1999, HLTH SURVEY ENGLAND, V1; Erens B., 2000, HLTH SURVEY ENGLAND; Erens B, 1999, HLTH SURVEY ENGLAND, V2; Gregory J., 1990, DIETARY NUTR SURVEY; Haq IU, 1999, HEART, V81, P40, DOI 10.1136/hrt.81.1.40; Karter AJ, 1998, WESTERN J MED, V169, P139; Knuiman MW, 1997, J EPIDEMIOL COMMUN H, V51, P515, DOI 10.1136/jech.51.5.515; *NHS CTR REV DISS, 1998, EFF HLTH CARE, V14, P1; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Robson J, 2000, BRIT MED J, V320, P702, DOI 10.1136/bmj.320.7236.702; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Wallis EJ, 2000, BMJ-BRIT MED J, V320, P671, DOI 10.1136/bmj.320.7236.671; Wilson S, 2003, J CARDIOVASC RISK, V10, P137, DOI 10.1097/00043798-200304000-00009; Wood D, 1998, HEART, V80, pS1	17	10	10	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2003	326	7404					1436	1438B		10.1136/bmj.326.7404.1436	http://dx.doi.org/10.1136/bmj.326.7404.1436			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697FP	12829557	Green Published, Bronze			2022-12-28	WOS:000183931800019
J	Fukushima, T; Kosaka, A; Ishimura, Y; Yamamoto, T; Takigawa, T; Ishii, N; Aida, T				Fukushima, T; Kosaka, A; Ishimura, Y; Yamamoto, T; Takigawa, T; Ishii, N; Aida, T			Molecular ordering of organic molten salts triggered by single-walled carbon nanotubes	SCIENCE			English	Article							IONIC LIQUIDS; FUNCTIONALIZATION; DESIGN	When mixed with imidazolium ion-based room-temperature ionic liquid, pristine single-walled carbon nanotubes formed gels after being ground. The heavily entangled nanotube bundles were found to untangle within the gel to form much finer bundles. Phase transition and rheological properties suggest that the gels are formed by physical cross-linking of the nanotube bundles, mediated by local molecular ordering of the ionic liquids rather than by entanglement of the nanotubes. The gels were thermally stable and did not shrivel, even under reduced pressure resulting from the nonvolatility of the ionic liquids, but they would readily undergo a gel-to-solid transition on absorbent materials. The use of a polymerizable ionic liquid as the gelling medium allows for the fabrication of a highly electroconductive polymer/ nanotube composite material, which showed a substantial enhancement in dynamic hardness.	Japan Sci & Technol Corp, Natl Museum Emerging Sci & Innovat, ERATO, Koto Ku, Tokyo 1350064, Japan; Kyoto Univ, Dept Chem Mat, Sakyo Ku, Kyoto 6068501, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	Japan Science & Technology Agency (JST); Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Aida, T (corresponding author), Japan Sci & Technol Corp, Natl Museum Emerging Sci & Innovat, ERATO, Koto Ku, 2-41 Aomi, Tokyo 1350064, Japan.	fukushima@nanospace.miraikan.jst.go.jp; aida@macro.t.u-tokyo.ac.jp	Fukushima, Takanori/D-2474-2015; Ishii, Noriyuki/E-5661-2011; Aida, Takuzo/I-9117-2012	Fukushima, Takanori/0000-0001-5586-9238; Ishii, Noriyuki/0000-0002-4120-6203; 				Ajayan PM, 2000, ADV MATER, V12, P750, DOI 10.1002/(SICI)1521-4095(200005)12:10<750::AID-ADMA750>3.0.CO;2-6; Bandyopadhyaya R, 2002, NANO LETT, V2, P25, DOI 10.1021/nl010065f; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Chen J, 2002, J AM CHEM SOC, V124, P9034, DOI 10.1021/ja026104m; Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b; DOI M, 1986, THEORY POLYMER DYNAM, P78101; Dresselhaus M. S., 2001, CARBON NANOTUBES SYN; FULLER J, 1994, J CHEM SOC CHEM COMM, P299, DOI 10.1039/c39940000299; Hamon MA, 2001, J AM CHEM SOC, V123, P11292, DOI 10.1021/ja0109702; Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N; Huddleston JG, 2001, GREEN CHEM, V3, P156, DOI 10.1039/b103275p; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Mamedov AA, 2002, NAT MATER, V1, P190, DOI 10.1038/nmat747; Nagasawa S, 2000, CHEM PHYS LETT, V328, P374, DOI 10.1016/S0009-2614(00)00960-X; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Star A, 2002, ANGEW CHEM INT EDIT, V41, P2508, DOI 10.1002/1521-3773(20020715)41:14<2508::AID-ANIE2508>3.0.CO;2-A; Steuerman DW, 2002, J PHYS CHEM B, V106, P3124, DOI 10.1021/jp014326l; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Wasserscheid P, 2000, ANGEW CHEM INT EDIT, V39, P3772, DOI 10.1002/1521-3773(20001103)39:21<3772::AID-ANIE3772>3.0.CO;2-5; Weiner S, 1997, J MATER CHEM, V7, P689, DOI 10.1039/a604512j; Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t; WILKES JS, 1992, J CHEM SOC CHEM COMM, P965, DOI 10.1039/c39920000965; Yudasaka M, 1999, J PHYS CHEM B, V103, P3576, DOI 10.1021/jp990072g	24	1187	1238	15	523	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2003	300	5628					2072	2074		10.1126/science.1082289	http://dx.doi.org/10.1126/science.1082289			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829776				2022-12-28	WOS:000183774900039
J	Corrigan, CP; Williams-Jones, B				Corrigan, CP; Williams-Jones, B			Consent is not enough - putting incompetent patients first in clinical trials	LANCET			English	Editorial Material									Univ Cambridge, Fac Social & Polit Sci, Ctr Family Res, Cambridge CB2 3RF, England; Univ Cambridge, Cambridge Genet Knowledge Pk, Cambridge CB2 3RF, England	University of Cambridge; University of Cambridge	Corrigan, CP (corresponding author), Univ Cambridge, Fac Social & Polit Sci, Ctr Family Res, Cambridge CB2 3RF, England.		Williams-Jones, Bryn/E-2108-2013	Williams-Jones, Bryn/0000-0001-6771-3919; Corrigan, Oonagh/0000-0002-7301-2200				Kent G, 1997, J MED ETHICS, V23, P186, DOI 10.1136/jme.23.3.186; MCDONALD M, 2000, GOVERNANCE HLTH RES, P363; *US FDA, 2003, TEST HUM	3	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2096	2097		10.1016/S0140-6736(03)13728-2	http://dx.doi.org/10.1016/S0140-6736(03)13728-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	692GY	12826428				2022-12-28	WOS:000183654200004
J	Begelman, MC				Begelman, MC			Evidence for black holes	SCIENCE			English	Review							ADVECTION-DOMINATED ACCRETION; QUASI-PERIODIC OSCILLATIONS; MASS; EXTRACTION; ENERGY; MCG-6-30-15; TURBULENCE; GROWTH; LIMITS; ORBIT	Black holes are common objects in the universe. Each galaxy contains large numbers - perhaps millions - of stellar- mass black holes, each the remnant of a massive star. In addition, nearly every galaxy contains a supermassive black hole at its center, with a mass ranging from millions to billions of solar masses. This review discusses the demographics of black holes, the ways in which they interact with their environment, factors that may regulate their formation and growth, and progress toward determining whether these objects really warp spacetime as predicted by the general theory of relativity.	Univ Colorado, Joint Inst Lab Astrophys, UCB 440, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Begelman, MC (corresponding author), Univ Colorado, Joint Inst Lab Astrophys, UCB 440, Boulder, CO 80309 USA.	mitch@jila.colorado.edu		BEGELMAN, MITCHELL/0000-0003-0936-8488				Agol E, 2000, ASTROPHYS J, V528, P161, DOI 10.1086/308177; Baganoff FK, 2001, NATURE, V413, P45, DOI 10.1038/35092510; Balbus SA, 1998, REV MOD PHYS, V70, P1, DOI 10.1103/RevModPhys.70.1; BEGELMAN MC, 1980, NATURE, V287, P307, DOI 10.1038/287307a0; Begelman MC, 2002, ASTROPHYS J, V568, pL97, DOI 10.1086/340457; BEGELMAN MC, IN PRESS COEVOLUTION; Bennett DP, 2002, ASTROPHYS J, V579, P639, DOI 10.1086/342225; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Blandford RD, 1999, ASTR SOC P, V182, P87; Blandford RD, 1999, MON NOT R ASTRON SOC, V303, pL1, DOI 10.1046/j.1365-8711.1999.02358.x; Brown EF, 1998, ASTROPHYS J, V504, pL95, DOI 10.1086/311578; Charles P, 2001, ESO ASTROPHY SYMP, P27, DOI 10.1007/10720995_3; Colbert EJM, 1999, ASTROPHYS J, V519, P89, DOI 10.1086/307356; di Matteo T, 2001, ASTROPHYS J, V547, P731, DOI 10.1086/318405; EISENHAUER F, UNPUB; ELZANT A, IN PRESS ASTROPHYS J; Fabian AC, 2002, MON NOT R ASTRON SOC, V335, pL1, DOI 10.1046/j.1365-8711.2002.05740.x; Fabian AC, 1999, MON NOT R ASTRON SOC, V308, pL39, DOI 10.1046/j.1365-8711.1999.03017.x; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; Fryer CL, 1999, ASTROPHYS J, V522, P413, DOI 10.1086/307647; GARCIA MR, 2001, APJ, V553, P47; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; GHEZ AM, IN PRESS ASTROPHYS J; Hartle J.B., 2003, GRAVITY INTRO EINSTE; Hawley JF, 2002, ASTROPHYS J, V573, P738, DOI 10.1086/340765; ICHIMARU S, 1977, ASTROPHYS J, V214, P840, DOI 10.1086/155314; JUNOR W, 1995, ASTRON J, V109, P500, DOI 10.1086/117295; King AR, 2001, ASTROPHYS J, V552, pL109, DOI 10.1086/320343; KORMENDY J, 2001, P 20 TEX S REL ASTR, P363; Krolik J. H., 1999, ACTIVE GALACTIC NUCL; Lattimer JM, 2001, ASTROPHYS J, V550, P426, DOI 10.1086/319702; Mao S, 2002, MON NOT R ASTRON SOC, V329, P349, DOI 10.1046/j.1365-8711.2002.04986.x; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; Meier DL, 2001, SCIENCE, V291, P84, DOI 10.1126/science.291.5501.84; Miller JM, 2002, ASTROPHYS J, V570, pL69, DOI 10.1086/341099; Miller JM, 2003, ASTROPHYS J, V585, pL37, DOI 10.1086/368373; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; Moderski R, 1998, MON NOT R ASTRON SOC, V301, P142, DOI 10.1046/j.1365-8711.1998.02009.x; Narayan R, 2000, ASTROPHYS J, V539, P798, DOI 10.1086/309268; NARAYAN R, 1995, ASTROPHYS J, V452, P710, DOI 10.1086/176343; Piran T, 1999, PHYS REP, V314, P575, DOI 10.1016/S0370-1573(98)00127-6; PROGA D, IN PRESS ASTROPHYS J; Quataert E, 1999, ASTROPHYS J, V520, P248, DOI 10.1086/307423; REES MJ, 1988, NATURE, V333, P523, DOI 10.1038/333523a0; REES MJ, 1982, NATURE, V295, P17, DOI 10.1038/295017a0; Remillard RA, 2002, ASTROPHYS J, V580, P1030, DOI 10.1086/343791; Reynolds CS, 1997, ASTROPHYS J, V488, P109, DOI 10.1086/304703; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; Thorne Kip S., 1994, BLACK HOLES TIME WAR; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; VANDERMAREL RP, IN PRESS COEVOLUTION; Wilms J, 2001, MON NOT R ASTRON SOC, V328, pL27, DOI 10.1046/j.1365-8711.2001.05066.x; WILSON AS, 1995, ASTROPHYS J, V438, P62, DOI 10.1086/175054; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x	58	47	47	2	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1898	1903		10.1126/science.1085334	http://dx.doi.org/10.1126/science.1085334			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817138				2022-12-28	WOS:000183619400033
J	Ribic, CM; Sargent, DJ; Moore, MJ; Thibodeau, SN; French, AJ; Goldberg, RM; Hamilton, SR; Laurent-Puig, P; Gryfe, R; Shepherd, LE; Tu, D; Redston, M; Gallinger, S				Ribic, CM; Sargent, DJ; Moore, MJ; Thibodeau, SN; French, AJ; Goldberg, RM; Hamilton, SR; Laurent-Puig, P; Gryfe, R; Shepherd, LE; Tu, D; Redston, M; Gallinger, S			Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; REPLICATION ERRORS; RANDOMIZED TRIAL; YOUNG-PATIENTS; FOLINIC ACID; STAGE B2; CARCINOMA; SURVIVAL	Background: Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors. We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer. Methods: Tumor specimens were collected from patients with colon cancer who were enrolled in randomized trials of fluorouracil-based adjuvant chemotherapy. Microsatellite instability was assessed with the use of mononucleotide and dinucleotide markers. Results: Of 570 tissue specimens, 95 (16.7 percent) exhibited high-frequency microsatellite instability. Among 287 patients who did not receive adjuvant therapy, those with tumors displaying high-frequency microsatellite instability had a better five-year rate of overall survival than patients with tumors exhibiting microsatellite stability or low-frequency instability (hazard ratio for death, 0.31 [95 percent confidence interval, 0.14 to 0.72]; P=0.004). Among patients who received adjuvant chemotherapy, high-frequency microsatellite instability was not correlated with increased overall survival (hazard ratio for death, 1.07 [95 percent confidence interval, 0.62 to 1.86]; P=0.80). The benefit of treatment differed significantly according to the microsatellite-instability status (P=0.01). Adjuvant chemotherapy improved overall survival among patients with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability, according to a multivariate analysis adjusted for stage and grade (hazard ratio for death, 0.72 [95 percent confidence interval, 0.53 to 0.99]; P=0.04). By contrast, there was no benefit of adjuvant chemotherapy in the group with high-frequency microsatellite instability. Conclusions: Fluorouracil-based adjuvant chemotherapy benefited patients with stage II or stage III colon cancer with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability but not those with tumors exhibiting high-frequency microsatellite instability.	Univ Toronto, Ctr Canc Genet, Samuel Lunenfeld Res Inst, Toronto, ON, Canada; Univ Toronto, Princess Margaret Hosp, Dept Med & Surg, Toronto, ON, Canada; Univ Toronto, Mt Sinai Hosp, Dept Surg, Toronto, ON M5G 1X5, Canada; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Queens Univ, Clin Trials Grp, Natl Canc Inst Canada, Kingston, ON, Canada; Eastern Cooperat Oncol Grp, Brookline, MA USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Federat Francophone Cancerol Digest, Paris, France; Brigham & Womens Hosp, Boston, MA 02115 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic; Queens University - Canada; Canadian Cancer Trials Group; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Brigham & Women's Hospital	Gallinger, S (corresponding author), Mt Sinai Hosp, 600 Univ Ave,Suite 1225, Toronto, ON M5G 1X5, Canada.		Gallinger, Steven/E-4575-2013; Gryfe, Robert/AAF-1870-2021; Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013; Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013	Goldberg, Richard/0000-0003-3713-6895; Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; Sargent, Daniel/0000-0002-2684-4741	NATIONAL CANCER INSTITUTE [U10CA021115, U10CA025224, P50CA062924, U01CA060100, U10CA023318] Funding Source: NIH RePORTER; NCI NIH HHS [CA25224, CA62924, U10 CA023318, CA60100, CA21115, U10 CA021115, CA23318, U10 CA025224, P50 CA062924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; American Joint Committee on Cancer, 1992, MAN STAG CANC; Anthoney DA, 1996, CANCER RES, V56, P1374; BEART RW, 1990, ARCH SURG-CHICAGO, V125, P897; Boland CR, 1998, CANCER RES, V58, P5248; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Bras-Goncalves RA, 2000, BRIT J CANCER, V82, P913, DOI 10.1054/bjoc.1999.1019; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; Claij N, 1999, EXP CELL RES, V246, P1, DOI 10.1006/excr.1998.4299; COX DR, 1972, J R STAT SOC B, V34, P187; Dietmaier W, 1997, CANCER RES, V57, P4749; Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3; Elsaleh H, 2000, LANCET, V355, P1745, DOI 10.1016/S0140-6736(00)02261-3; Elsaleh H, 2000, ONCOLOGY-BASEL, V58, P52, DOI 10.1159/000012079; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Fielding LP, 1995, ARCH PATHOL LAB MED, V119, P1115; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1994, CELL, V77, P167; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KIM HG, 1994, AM J PATHOL, V145, P148; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LABIANCA R, 1995, LANCET, V345, P939; Laiho P, 2002, CANCER RES, V62, P1166; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LOTHE RA, 1993, CANCER RES, V53, P5849; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; MAKELA JT, 1995, ARCH SURG-CHICAGO, V130, P1062; Meyers M, 2001, CANCER RES, V61, P5193; MILLER BA, 1996, NIH PUBLICATION NCI; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; NAUTA R, 1989, ARCH SURG-CHICAGO, V124, P180; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Obrand DI, 1997, DIS COLON RECTUM, V40, P15, DOI 10.1007/BF02055676; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rosty C, 2001, INT J CANCER, V95, P162, DOI 10.1002/1097-0215(20010520)95:3<162::AID-IJC1028>3.0.CO;2-J; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; STRAND M, 1994, NATURE, V368, P569, DOI 10.1038/368569a0; TEMPERO M, 1994, NEW ENGL J MED, V331, P267, DOI 10.1056/NEJM199407283310410; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Wright CM, 2000, BRIT J SURG, V87, P1197, DOI 10.1046/j.1365-2168.2000.01508.x; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	56	1609	1676	4	50	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					247	257		10.1056/NEJMoa022289	http://dx.doi.org/10.1056/NEJMoa022289			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12867608	Green Accepted			2022-12-28	WOS:000184165700008
J	Jacklin, PB; Roberts, JA; Wallace, P; Haines, A; Harrison, R; Barber, JA; Thompson, SG; Lewis, L; Currell, R; Parker, S; Wainwright, P				Jacklin, PB; Roberts, JA; Wallace, P; Haines, A; Harrison, R; Barber, JA; Thompson, SG; Lewis, L; Currell, R; Parker, S; Wainwright, P		Virtual Outreach Project Grp	Virtual outreach: economic evaluation of joint teleconsultations for patients referred by their general practitioner for a specialist opinion	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIALS; PRIMARY-CARE; FOLLOW-UP; COST DATA; CONSULTATIONS; SATISFACTION; TELEMEDICINE; SYSTEM; HEALTH	Objectives To test the hypotheses that, compared with conventional outpatient consultations, joint teleconsultation (virtual outreach) would incur no increased costs to the NHS, reduce costs to patients, and reduce absences from work by patients and their carers. Design Cost consequences study alongside randomised controlled trial. Setting Two hospitals in London and Shrewsbury and 29 general practices in inner London and Wales. Participants 3170 patients identified; 2094 eligible for inclusion and willing to participate. 1051 randomised to virtual outreach and 1043 to standard outpatient appointments. Main outcome measures NHS costs, patient costs, health status (SF-12), time spent attending index consultation, patient satisfaction. Results Overall six month costs were greater for the virtual outreach consultations (pound724 per patient) than for conventional outpatient appointments (pound625): difference in means pound99 ($162; is not an element of138) (95% confidence interval pound10 to pound187, P=0.03). if the analysis is restricted to resource items deemed "attributable" to the index consultation, six month costs were still greater for virtual outreach: difference in means pound108 (pound73 to pound142, P < 0.0001). In both analyses the index consultation accounted for the excess cost. Savings to patients in terms of costs and time occurred in both centres: difference in mean total patient cost 8 pound (5 pound to 10 pound, P < 0.0001). Loss of productive time was less in the virtual outreach group: difference in mean cost pound11 (pound10 to pound12, P < 0.0001). Condusion The main hypothesis that virtual outreach would be cost neutral is rejected, but the hypotheses that costs to patients and losses in productivity would be lower are supported.	London Sch Hyg & Trop Med, Dept Publ Hlth Policy, London WC1 7HT, England; London Sch Hyg & Trop Med, Deans Off, London WC1 7HT, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Univ Coll Hosp Res & Dev Directorate, London NW1 2LT, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Univ Coll Swansea, Sch Hlth Sci, Swansea SA2 8PP, W Glam, Wales	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; MRC Biostatistics Unit; University of Cambridge; Swansea University	Jacklin, PB (corresponding author), London Sch Hyg & Trop Med, Dept Publ Hlth Policy, London WC1 7HT, England.	paul.jacklin@lshtm.ac.uk		Barber, Julie/0000-0001-5762-762X; Haines, Andy/0000-0002-8053-4605; Parker, Stuart/0000-0002-8675-6276				*AUT ASS, PETR CAR RUNN COSTS; Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Bashshur R L, 1995, Telemed J, V1, P19, DOI 10.1089/tmj.1.1995.1.19; Bergmo T S, 1996, J Telemed Telecare, V2, P136, DOI 10.1258/1357633961929952; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; BROMWICH M, 1976, EC CAPITAL BUDGETING; Burns T, 1999, LANCET, V353, P2185, DOI 10.1016/S0140-6736(98)12191-8; *DEP HLTH, 2000, REF COSTS 2000; Donaldson C, 2002, EVIDENCE BASED HLTH; Doolittle GC, 1998, J TELEMED TELECARE, V4, P84, DOI 10.1258/1357633981932000; Drummond MF, 2015, METHODS EC EVALUATIO; GRACE JF, 1986, FAM PRACT, V3, P143, DOI 10.1093/fampra/3.3.143; *HM TREAS, 1997, APPR EV CENTR GOV; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; MARSH GN, 1982, BRIT MED J, V284, P1176, DOI 10.1136/bmj.284.6323.1176; Marshall MN, 1998, BRIT J GEN PRACT, V48, P1379; McIntosh E, 1997, J Telemed Telecare, V3, P132, DOI 10.1258/1357633971931039; Netten A.P., 2000, UNIT COSTS HLTH SOCI; NHS Executive, 1998, INF HLTH INF STRAT M; Nitzkin J L, 1997, Telemed J, V3, P141, DOI 10.1089/tmj.1.1997.3.141; *OFF NAT STAT, 2001, NEW EARN SURV; Parkerson GR, 1996, FAM PRACT, V13, P303, DOI 10.1093/fampra/13.3.303; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; ROLAND M, 1992, HOSP REFERRALS, P62; *ROYAL COLL GEN PR, 1992, 56 ROYAL COLL GEN PR; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5; Vlek JFM, 2003, BRIT J GEN PRACT, V53, P108; Wallace P, 2002, LANCET, V359, P1961, DOI 10.1016/S0140-6736(02)08828-1; WALLACE P, 1992, REFERRAL MED AUTPATI; Wallace Paul, 2002, BMC Fam Pract, V3, P1, DOI 10.1186/1471-2296-3-1; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; Whitten P, 1998, J TELEMED TELECARE, V4, P152, DOI 10.1258/1357633981932136; Whitten PS, 2002, BRIT MED J, V324, P1434, DOI 10.1136/bmj.324.7351.1434; Wootton R, 2000, BRIT MED J, V320, P1252, DOI 10.1136/bmj.320.7244.1252	36	62	63	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 12	2003	327	7406					84	88A		10.1136/bmj.327.7406.84	http://dx.doi.org/10.1136/bmj.327.7406.84			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702NF	12855528	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000184229400021
J	Thulborn, T				Thulborn, T			Comment on "Ascent of dinosaurs linked to an iridium anomaly at the Triassic-Jurassic boundary"	SCIENCE			English	Editorial Material									Monash Univ, Sch Geosci, Clayton, Vic 3800, Australia; Univ Queensland, Dept Zool & Entomol, Vertebrate Palaeontol Lab, St Lucia, Qld 4072, Australia	Monash University; University of Queensland	Thulborn, T (corresponding author), Monash Univ, Sch Geosci, Box 28E, Clayton, Vic 3800, Australia.							Anderson JM, 1998, PALAEONTOLOGY, V41, P387; BARTHOLOMAI ALAN, 1966, AUSTRALIAN NATUR HIST, V15, P147; Hill D., 1965, TRIASSIC FOSSILS QUE; Molnar Ralph E., 1991, P605; Olsen PE, 2002, SCIENCE, V296, P1305, DOI 10.1126/science.1065522; Paul G., 1988, PREDATORY DINOSAURS; Raath M. A., 1996, Memoirs of the Queensland Museum, V39, P703; RAATH M A, 1990, Palaeontologia Africana, V27, P89; Staines H. R. E., 1964, Australian Journal of Science, V27, P55; Thulborn T., 1990, DINOSAUR TRACKS; Thulborn T., 2000, GAIA, P301; YOUNG GC, 1996, AUSTR PHANEROZOIC TI	12	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855792				2022-12-28	WOS:000184056200022
J	Alavi, A; Hood, JD; Frausto, R; Stupack, DG; Cheresh, DA				Alavi, A; Hood, JD; Frausto, R; Stupack, DG; Cheresh, DA			Role of Raf in vascular protection from distinct apoptotic stimuli	SCIENCE			English	Article							KINASE-ACTIVITY; B-RAF; PROTEIN; SRC; PHOSPHORYLATION; REQUIREMENT; PATHWAYS; SERINE	Raf kinases have been linked to endothelial cell survival. Here, we show that basic fibroblast growth factor ( bFGF) and vascular endothelial growth factor ( VEGF) differentially activate Raf, resulting in protection from distinct pathways of apoptosis in human endothelial cells and chick embryo vasculature. bFGF activated Raf-1 via p21-activated protein kinase-1 (PAK-1) phosphorylation of serines 338 and 339, resulting in Raf-1 mitochondrial translocation and endothelial cell protection from the intrinsic pathway of apoptosis, independent of the mitogen-activated protein kinase kinase-1 (MEK1). In contrast, VEGF activated Raf-1 via Src kinase, leading to phosphorylation of tyrosines 340 and 341 and MEK1-dependent protection from extrinsic-mediated apoptosis. These findings implicate Raf-1 as a pivotal regulator of endothelial cell survival during angiogenesis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cheresh@scripps.edu	; Frausto, Ricardo/AAE-3146-2021	Alavi, Alireza/0000-0002-5502-2616; Frausto, Ricardo/0000-0003-3064-6745	NCI NIH HHS [CA75924, CA50286, P01 CA78045, CA45726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078045, R37CA050286, R01CA050286, R01CA045726, T32CA075924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	22	275	299	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					94	96		10.1126/science.1082015	http://dx.doi.org/10.1126/science.1082015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843393				2022-12-28	WOS:000183914700040
J	Hoffmann, AA; Hallas, RJ; Dean, JA; Schiffer, M				Hoffmann, AA; Hallas, RJ; Dean, JA; Schiffer, M			Low potential for climatic stress adaptation in a rainforest Drosophila species	SCIENCE			English	Article							OPPOSITE LATITUDINAL CLINES; DESICCATION RESISTANCE; CORRELATED RESPONSES; LABORATORY CULTURE; GENETIC-VARIATION; LIFE-HISTORY; MELANOGASTER; TOLERANCE; SELECTION; POPULATIONS	The ability of sensitive rainforest species to evolve in response to climate change is largely unknown. We show that the Australian tropical rainforest fly Drosophila birchii exhibits clinal variation in desiccation resistance, but the most resistant population lacks the ability to evolve further resistance even after intense selection for over 30 generations. Parent-offspring comparisons indicate low heritable variation for this trait but high levels of genetic variation for morphology. D. birchii also exhibits abundant genetic variation at microsatellite loci. The low potential for resistance evolution highlights the importance of assessing evolutionary potential in targeted ecological traits and species from threatened habitats.	La Trobe Univ, Ctr Environm Stress & Adaptat Res, Bundoora, Vic 3086, Australia	La Trobe University	Hoffmann, AA (corresponding author), La Trobe Univ, Ctr Environm Stress & Adaptat Res, Bundoora, Vic 3086, Australia.		Hoffmann, Ary/C-2961-2011; Hoffmann, Ary/R-2972-2019; Schiffer, Michele/AAN-1478-2020	Hoffmann, Ary/0000-0001-9497-7645; Schiffer, Michele/0000-0002-5203-2480				Addo-Bediako A, 2001, J INSECT PHYSIOL, V47, P1377, DOI 10.1016/S0022-1910(01)00128-7; AYALA FJ, 1965, EVOLUTION, V19, P538, DOI 10.1111/j.1558-5646.1965.tb03329.x; Baer CF, 2000, EVOLUTION, V54, P238, DOI 10.1111/j.0014-3820.2000.tb00024.x; BLOWS MW, 1993, EVOLUTION, V47, P1255, DOI 10.1111/j.1558-5646.1993.tb02151.x; Bradshaw WE, 2001, P NATL ACAD SCI USA, V98, P14509, DOI 10.1073/pnas.241391498; Crandall KA, 2000, TRENDS ECOL EVOL, V15, P290, DOI 10.1016/S0169-5347(00)01876-0; Frankham R., 2010, INTRO CONSERVATION G, V2, DOI [10.1017/CBO9780511809002, 10.1017/CBO9780511808999]; Gibbs AG, 1997, J EXP BIOL, V200, P1821; Harshman LG, 2000, TRENDS ECOL EVOL, V15, P32, DOI 10.1016/S0169-5347(99)01756-5; Hercus MJ, 1999, GENETICS, V151, P1493; HOFFMANN AA, 1993, J EVOLUTION BIOL, V6, P643, DOI 10.1046/j.1420-9101.1993.6050643.x; Hoffmann AA, 2001, EVOLUTION, V55, P436, DOI 10.1111/j.0014-3820.2001.tb01305.x; HOFFMANN AA, 1989, BIOL J LINN SOC, V37, P117, DOI 10.1111/j.1095-8312.1989.tb02098.x; Hoffmann AA, 2000, ADAPTIVE GENETIC VARIATION IN THE WILD, P200; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; Jenkins NL, 2001, AUST J ENTOMOL, V40, P41, DOI 10.1046/j.1440-6055.2001.00197.x; Karan D, 1998, ECOL ENTOMOL, V23, P391, DOI 10.1046/j.1365-2311.1998.00157.x; Karan D, 1998, EVOLUTION, V52, P825, DOI 10.1111/j.1558-5646.1998.tb03706.x; Lewontin RC, 1974, GENETIC BASIS EVOLUT; Lovejoy T.E., 1986, P257; PARSONS PA, 1982, EVOL BIOL, V14, P297; Partridge L, 1999, P ROY SOC B-BIOL SCI, V266, P255, DOI 10.1098/rspb.1999.0630; Reed DH, 2001, EVOLUTION, V55, P1095, DOI 10.1111/j.0014-3820.2001.tb00629.x; Roff D.A., 1997, EVOLUTIONARY QUANTIT; Sgro CM, 2000, AM NAT, V156, P341, DOI 10.1086/303394; Warren MS, 2001, NATURE, V414, P65, DOI 10.1038/35102054	26	267	271	2	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					100	102		10.1126/science.1084296	http://dx.doi.org/10.1126/science.1084296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843394				2022-12-28	WOS:000183914700042
J	Chopra, SS				Chopra, SS			Industry funding of clinical trials: Benefit or bias?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-INTEREST; QUALITY; DRUGS; DISCONTINUATION; INNOVATION		Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Vanderbilt University	Chopra, SS (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.							World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boyd EA, 2000, JAMA-J AM MED ASSOC, V284, P2209, DOI 10.1001/jama.284.17.2209; Boyd K, 2001, BRIT MED J, V322, P605; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; Cho MK, 1996, ANN INTERN MED, V124, P485, DOI 10.7326/0003-4819-124-5-199603010-00004; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Davidoff F, 2001, JAMA-J AM MED ASSOC, V286, P1232, DOI 10.1001/jama.286.10.1232; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; Evans S, 2001, BMJ-BRIT MED J, V322, P569, DOI 10.1136/bmj.322.7286.569; Findlay SD, 2001, PHARMACOECONOMICS, V19, P109, DOI 10.2165/00019053-200119020-00001; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72; Johns MME, 2003, JAMA-J AM MED ASSOC, V289, P741, DOI 10.1001/jama.289.6.741; Lievre M, 2001, BRIT MED J, V322, P603, DOI 10.1136/bmj.322.7286.603; Montaner JSG, 2001, LANCET, V358, P1893, DOI 10.1016/S0140-6736(01)06891-X; Moses HI, 2002, NEW ENGL J MED, V347, P1371, DOI 10.1056/NEJMsb021319; Nathan DG, 2002, NEW ENGL J MED, V347, P1368, DOI 10.1056/NEJMsb020394; Niiler E, 2000, NAT BIOTECHNOL, V18, P1235, DOI 10.1038/82325; Psaty BM, 2003, JAMA-J AM MED ASSOC, V289, P2128, DOI 10.1001/jama.289.16.2128; Rao JN, 2002, BRIT MED J, V325, P36, DOI 10.1136/bmj.325.7354.36; Relman AS, 2002, NEW REPUBLIC, V227, P27; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Vogel G, 1997, SCIENCE, V276, P525	30	62	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					113	114		10.1001/jama.290.1.113	http://dx.doi.org/10.1001/jama.290.1.113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837722				2022-12-28	WOS:000183868600030
J	Black, RE; Morris, SS; Bryce, J				Black, RE; Morris, SS; Bryce, J			Where and why are 10 million children dying every year?	LANCET			English	Article							MORTALITY; DEATHS; MALNUTRITION; INFECTION; DIARRHEA; RISK	More than 10 million children die each year, most from preventable causes and almost all in poor countries. Six countries account for 50% of worldwide deaths in children younger than 5 years, and 42 countries for 90%. The causes of death differ substantially from one country to another, highlighting the need to expand understanding of child health epidemiology at a country level rather than in geopolitical regions. Other key issues include the importance of undernutrition as an underlying cause of child deaths associated with infectious diseases, the effects of multiple concurrent illnesses, and recognition. that pneumonia and diarrhoea remain the diseases that are most often associated with child deaths. A better understanding of child health epidemiology could contribute to more effective approaches to saving children's lives.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; London School of Hygiene & Tropical Medicine	Black, RE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	rblack@jhsph.edu		Black, Robert/0000-0001-9926-7984; Morris, Saul/0000-0002-9372-7342				African Population and Health Research Center, 2002, POP HLTH DYN NAIR IN; Ahmad OB, 2000, B WORLD HEALTH ORGAN, V78, P1175; ANKER M, 2001, STANDARD VERBAL AUTO; Arifeen S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e67; Baqui AH, 2001, ACTA PAEDIATR, V90, P682, DOI 10.1080/080352501750258775; BAQUI AH, 1998, B WORLD HEALTH ORGAN, V76, P154; Barreto I C, 2000, Rev Panam Salud Publica, V7, P303, DOI 10.1590/S1020-49892000000500003; Becker S, 1996, DEMOGRAPHY, V33, P329, DOI 10.2307/2061765; CAULFIELD L, IN PRESS COMP QUANTI; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; EZZATI M, IN PRESS LANCET; FISHMAN S, IN PRESS COMP QUANTI; Hill K ., 1998, TRENDS CHILD MORTALI; *INT I POP SCI ORC, 2000, 2000 NAT FAM HLTH SU; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; Kalter HD, 1997, B WORLD HEALTH ORGAN, V75, P65; Kolstad PR, 1997, B WORLD HEALTH ORGAN, V75, P77; Lopez ADAO, 2001, 40 GPE WHO; MATHERS CSC, GLOBAL BURDEN DIS 20; MORRIS SS, IN PRESS INT J EPIDE; Mosley WH, 1984, POPUL DEV REV, V10, P25, DOI 10.2307/2807954; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; RICE AL, IN PRESS COMP QUANTI; Scrimshaw NS, 1997, AM J CLIN NUTR, V66, P464; SCUMACHER R, 2002, MORTALITY STUDY GUIN; SETTYVENUGOPAL V, 2002, POPULATION REPORTS L, V13; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; *UN POP DIV, 2001, WORLD POP PROSP 2000; *UNAIDS, 2002, GLOB REP HIV AIDS EP; *UNICEF, 2002, STAT WORLDS CHILDR 2; *UNICEF, 2001, PROGR WORLD SUMM CHI; *UNICEF, CHILD MORT STAT; United Nations, 2001, REPORT SECRETARY GEN; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; WHO, 2002, RED RISKS PROM HLTH; Yassin KM, 2000, SOC SCI MED, V51, P185, DOI 10.1016/S0277-9536(99)00459-1; Yoon PW, 1997, AM J CLIN NUTR, V65, P1070, DOI 10.1093/ajcn/65.4.1070	38	2736	2822	4	96	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2226	2234		10.1016/S0140-6736(03)13779-8	http://dx.doi.org/10.1016/S0140-6736(03)13779-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842379				2022-12-28	WOS:000183815600027
J	Mou, Z; Fan, WH; Dong, XN				Mou, Z; Fan, WH; Dong, XN			Inducers of plant systemic acquired resistance regulate NPR1 function through redox changes	CELL			English	Article							SALICYLIC-ACID; GLUTATHIONE HOMEOSTASIS; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DISEASE-RESISTANCE; NITRIC-OXIDE; ARABIDOPSIS; GENE; INDUCTION; ACTIVATION	NPR1 is an essential regulator of plant systemic acquired resistance (SAR), which confers immunity to a broad-spectrum of pathogens. SAR induction results in accumulation of the signal molecule salicylic acid (SA), which induces defense gene expression via activation of NPR1. We found that in an uninduced state, NPR1 is present as an oligomer formed through intermolecular disulfide bonds. Upon SAR induction, a biphasic change in cellular reduction potential occurs, resulting in reduction of NPR1 to a monomeric form. Monomeric NPR1 accumulates in the nucleus and activates gene expression. Inhibition of NPR1 reduction prevents defense gene expression, whereas mutation of Cys82 or Cys216 in NPR1 leads to constitutive monomerization, nuclear localization of the mutant proteins, and defense gene expression. These data provide a missing link between accumulation of SA and activation of NPR1 in the SAR signaling pathway.	Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA	Duke University	Dong, XN (corresponding author), Duke Univ, Dept Biol, Dev Cell & Mol Biol Grp, POB 91000, Durham, NC 27708 USA.	xdong@duke.edu						Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Bent AF, 2000, PLANT PHYSIOL, V124, P1540, DOI 10.1104/pp.124.4.1540; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Chamnongpol S, 1998, P NATL ACAD SCI USA, V95, P5818, DOI 10.1073/pnas.95.10.5818; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; Chern MS, 2001, PLANT J, V27, P101, DOI 10.1046/j.1365-313x.2001.01070.x; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; Garlick AP, 2002, PLANTA, V216, P265, DOI 10.1007/s00425-002-0842-1; Glazebrook J, 1996, GENETICS, V143, P973; Gupte SA, 2002, J PHARMACOL EXP THER, V301, P299, DOI 10.1124/jpet.301.1.299; Hothersall JS, 1998, FEBS LETT, V434, P97, DOI 10.1016/S0014-5793(98)00959-4; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kinkema M, 2000, PLANT CELL, V12, P2339, DOI 10.1105/tpc.12.12.2339; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kvaratskhelia M, 1997, J BIOL CHEM, V272, P20998, DOI 10.1074/jbc.272.34.20998; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; Murphy DM, 2002, J BIOL CHEM, V277, P6162, DOI 10.1074/jbc.M110105200; Noctor G, 2002, J EXP BOT, V53, P1283, DOI 10.1093/jexbot/53.372.1283; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; RAO MV, 1995, PHOTOCHEM PHOTOBIOL, V61, P71, DOI 10.1111/j.1751-1097.1995.tb09245.x; Rao MV, 1999, PLANT J, V17, P603, DOI 10.1046/j.1365-313X.1999.00400.x; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shah J, 1997, MOL PLANT MICROBE IN, V10, P69, DOI 10.1094/MPMI.1997.10.1.69; Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235; Vanacker H, 2000, PLANT PHYSIOL, V123, P1289, DOI 10.1104/pp.123.4.1289; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206; Wu GS, 1997, PLANT PHYSIOL, V115, P427, DOI 10.1104/pp.115.2.427; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	44	1008	1090	10	184	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 27	2003	113	7					935	944		10.1016/S0092-8674(03)00429-X	http://dx.doi.org/10.1016/S0092-8674(03)00429-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837250	Bronze			2022-12-28	WOS:000183817900016
J	Larsen, EC; Connolly, SA; Rosenberg, AE				Larsen, EC; Connolly, SA; Rosenberg, AE			A nine-year-old girl with hepatosplenomegaly and pain in the thigh - Gaucher's disease, type I.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; ENZYME REPLACEMENT THERAPY; CLINICAL-FEATURES; BONE; ABNORMALITIES; LYMPHOMA; CHILDREN; PATIENT		Dartmouth Hitchcock Med Ctr, Div Pediat Hematol Oncol, Lebanon, NH 03766 USA; Dartmouth Coll Sch Med, Dept Pediat, Lebanon, NH USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Dartmouth College; Dartmouth College; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Larsen, EC (corresponding author), Dartmouth Hitchcock Med Ctr, Div Pediat Hematol Oncol, Lebanon, NH 03766 USA.							BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BELL RS, 1986, J BONE JOINT SURG AM, V68A, P1380, DOI 10.2106/00004623-198668090-00011; Beutler E., 2001, METABOLIC MOL BASES, VIII, P3635; Bohm P, 2001, CANCER, V91, P457; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; Charrow J, 1998, ARCH INTERN MED, V158, P1754, DOI 10.1001/archinte.158.16.1754; Charrow J, 2000, ARCH INTERN MED, V160, P2835, DOI 10.1001/archinte.160.18.2835; Cohen IJ, 1996, ARCH DIS CHILD, V75, P218, DOI 10.1136/adc.75.3.218; Coventry S, 1999, PEDIATR DEVEL PATHOL, V2, P478, DOI 10.1007/s100249900152; Cox TM, 1997, BAILLIERE CLIN HAEM, V10, P657, DOI 10.1016/S0950-3536(97)80033-9; Cox TM, 2001, J INHERIT METAB DIS, V24, P106; Dolen EG, 1997, PEDIATR RADIOL, V27, P514, DOI 10.1007/s002470050170; Gillis S, 1999, AM J HEMATOL, V61, P103, DOI 10.1002/(SICI)1096-8652(199906)61:2<103::AID-AJH5>3.3.CO;2-M; Harris CM, 1999, NEUROPEDIATRICS, V30, P289, DOI 10.1055/s-2007-973507; Hollak CEM, 1997, BRIT J HAEMATOL, V96, P470; KATZ K, 1991, J BONE JOINT SURG AM, V73A, P513, DOI 10.2106/00004623-199173040-00006; Katz K, 1996, J BONE JOINT SURG AM, V78A, P14, DOI 10.2106/00004623-199601000-00003; KATZ K, 1991, J BONE JOINT SURG AM, V73, P791; KILPATRICK SE, 1995, CANCER, V76, P2471, DOI 10.1002/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z; Ladisch Stephan, 1997, P615; Mankin HJ, 2001, J BONE JOINT SURG AM, V83A, P748, DOI 10.2106/00004623-200105000-00016; Margolin Judith F., 1997, P409; McCabe ERB, 1996, JAMA-J AM MED ASSOC, V275, P548, DOI 10.1001/jama.1996.03530310054033; MILLER ST, 1983, CANCER, V52, P2285, DOI 10.1002/1097-0142(19831215)52:12<2285::AID-CNCR2820521222>3.0.CO;2-K; ROSENTHAL DI, 1995, PEDIATRICS, V96, P629; SHIRAN A, 1993, CANCER, V72, P219, DOI 10.1002/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; SIDRANSKY E, 1993, JAMA-J AM MED ASSOC, V269, P1154, DOI 10.1001/jama.269.9.1154; STOWENS DW, 1985, MEDICINE, V64, P310, DOI 10.1097/00005792-198509000-00003; ZEVIN S, 1993, Q J MED, V86, P565	31	5	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2669	2677		10.1056/NEJMcpc030014	http://dx.doi.org/10.1056/NEJMcpc030014			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826642				2022-12-28	WOS:000183726400011
J	Guha-Sapir, D; van Panhuis, WG				Guha-Sapir, D; van Panhuis, WG			The importance of conflict-related mortality in civilian populations	LANCET			English	Article							RESIDENT POPULATIONS; MALNUTRITION; AFGHANISTAN; REFUGEES; HEALTH; RATES	Civil conflict affects the health of individuals in many countries, and draws a substantial amount of international humanitarian aid. The most widely used indicator of the effect of conflict is the rate of civilian death during conflict. We aimed to assess mortality estimates from conflicts in Sudan, Somalia, the Democratic Republic of Congo, and Afghanistan by calculating the relative risk of death during and after conflict compared with that in preconflict peacetime. Katale, in the Democratic Republic of Congo, had the highest relative risk of death during conflict (11.2 [9.1-13.8] and 103.3 [94.7-112.6], for children younger than 5 years and the whole population, respectively). Our results suggest that high rates of civilian mortality are determined more by the pre-existing fragility of the affected population than the intensity of the conflict. In many instances, a high rate of civilian deaths during conflict shows that international development aid before the conflict was grossly inadequate.	Catholic Univ Louvain, Sch Publ Hlth, WHO, Collaborating Ctr Res Epidemiol Disasters, B-1200 Brussels, Belgium	Universite Catholique Louvain; World Health Organization	Guha-Sapir, D (corresponding author), Catholic Univ Louvain, Sch Publ Hlth, WHO, Collaborating Ctr Res Epidemiol Disasters, B-1200 Brussels, Belgium.	sapir@epid.ucl.ac.be	Van Panhuis, Willem/S-5495-2019	Van Panhuis, Willem/0000-0002-7278-9982				Assefa F, 2001, JAMA-J AM MED ASSOC, V286, P2723, DOI 10.1001/jama.286.21.2723; GESSNER BD, 1994, JAMA-J AM MED ASSOC, V272, P382, DOI 10.1001/jama.272.5.382; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; SHEARS P, 1987, BMJ-BRIT MED J, V295, P314, DOI 10.1136/bmj.295.6593.314	5	18	19	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	2003	361	9375					2126	2128		10.1016/S0140-6736(03)13691-4	http://dx.doi.org/10.1016/S0140-6736(03)13691-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826439				2022-12-28	WOS:000183654200015
J	Kirshner, RP				Kirshner, RP			Throwing light on dark energy	SCIENCE			English	Review							IA SUPERNOVAE; ACCELERATING UNIVERSE; COSMOLOGICAL CONSTANT; HUBBLE DIAGRAM; CONSEQUENCES; PARAMETERS; DISCOVERY; DENSITY; LAMBDA; OMEGA	Supernova observations show that the expansion of the universe has been speeding up. This unexpected acceleration is ascribed to a dark energy that pervades space. Supernova data, combined with other observations, indicate that the universe is about 14 billion years old and is composed of about 30% matter and 70% dark energy. New observational programs can trace the history of cosmic expansion more precisely and over a larger span of time than has been done to date to learn whether the dark energy is a modern version of Einstein's cosmological constant or another form of dark energy that changes with time. Either conclusion is an enigma that points to gaps in our fundamental understanding of gravity.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 01238 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Kirshner, RP (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 01238 USA.	kirshner@cfa.harvard.edu						Blakeslee JP, 2003, ASTROPHYS J, V589, P693, DOI 10.1086/374797; Burgasser A.J., 2002, THESIS HARVARD U; CALWELL RR, 1998, PHYS REV LETT, V80, P1582; CARROLL S, EFI200127; CARROLL S, 2003, EFI200301; CARROLL SM, 2001, COSMOLOGICAL CONSTAN; Coil AL, 2000, ASTROPHYS J, V544, pL111, DOI 10.1086/317311; EDDINGTON AS, 1987, EXPANDING UNIVERSE; Einstein A, 1932, P NATL ACAD SCI USA, V18, P213, DOI 10.1073/pnas.18.3.213; FALL SM, SCI HUBBLE SPACE TEL; Filippenko AV, 1997, ANNU REV ASTRON ASTR, V35, P309, DOI 10.1146/annurev.astro.35.1.309; Filippenko AV, 2001, ASTR SOC P, V246, P121; Freedman WL, 2001, ASTROPHYS J, V553, P47, DOI 10.1086/320638; Gamow G., 1970, MY WORLD LINE INFORM, P44; Garnavich PM, 1998, ASTROPHYS J, V493, pL53, DOI 10.1086/311140; Garnavich PM, 1998, ASTROPHYS J, V509, P74, DOI 10.1086/306495; Gilliland RL, 1999, ASTROPHYS J, V521, P30, DOI 10.1086/307549; Guth Alan, 1997, INFLATIONARY UNIVERS; Hoflich P, 1998, ASTROPHYS J, V495, P617, DOI 10.1086/305327; Kirshner Robert P., 2002, EXTRAVAGANT UNIVERSE; KRAGH H, 1996, COSMOLOGY CONTROVERS, P54; NOMOTO K, 1984, ASTROPHYS J, V279, pL23, DOI 10.1086/184247; PADMANABHAN T, IN PRESS PHYS REP; PADMANABHAN T, 2002, THEORETICIANS ANAL S; Parodi BR, 2000, ASTROPHYS J, V540, P634, DOI 10.1086/309385; PEEBLES PJE, 1988, ASTROPHYS J, V325, pL17, DOI 10.1086/185100; Percival WJ, 2001, MON NOT R ASTRON SOC, V327, P1297, DOI 10.1046/j.1365-8711.2001.04827.x; Perlmutter S, 1997, ASTROPHYS J, V483, P565, DOI 10.1086/304265; Perlmutter S, 2003, PHYS TODAY, V56, P53, DOI 10.1063/1.1580050; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; RATRA B, 1988, PHYS REV D, V37, P3406, DOI 10.1103/PhysRevD.37.3406; Riess AG, 2001, ASTROPHYS J, V560, P49, DOI 10.1086/322348; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; Riess AG, 1996, ASTROPHYS J, V473, P88, DOI 10.1086/178129; RIESS AG, IN PRESS ASTROPHYS J; Sullivan M, 2003, MON NOT R ASTRON SOC, V340, P1057, DOI 10.1046/j.1365-8711.2003.06312.x; TIMMES FX, IN PRESS ASTROPHYS J; TONRY J, IN PRESS ASTROPHYS J; Turner MS, 2002, ASTROPHYS J, V569, P18, DOI 10.1086/338580; Turner MS, 2003, PHYS TODAY, V56, P10, DOI 10.1063/1.1620807; Weller J, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.103512; WETTERICH C, 1988, NUCL PHYS B, V302, P668, DOI 10.1016/0550-3213(88)90193-9; WHELAN J, 1973, ASTROPHYS J, V186, P1007, DOI 10.1086/152565; Wilson G, 2002, ASTRON J, V124, P1258, DOI 10.1086/341818; WOODVASEY WM, 2002, B AM ASTRON SOC, V201, P5608; WRIGHT N, 2003, COSMOLOGY TUTORIAL; ZELDOVICH YB, 1968, SOV PHYS USPEKHI, V11, P381, DOI 10.1070/PU1968v011n03ABEH003927; ZELDOVICH YB, 1967, JETP LETT-USSR, V6, P316; [No title captured]	54	33	34	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2003	300	5627					1914	1918		10.1126/science.1086879	http://dx.doi.org/10.1126/science.1086879			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817141	Green Submitted			2022-12-28	WOS:000183619400036
J	Schotte, F; Lim, MH; Jackson, TA; Smirnov, AV; Soman, J; Olson, JS; Phillips, GN; Wulff, M; Anfinrud, PA				Schotte, F; Lim, MH; Jackson, TA; Smirnov, AV; Soman, J; Olson, JS; Phillips, GN; Wulff, M; Anfinrud, PA			Watching a protein as it functions with 150-ps time-resolved X-ray crystallography	SCIENCE			English	Article							LIGAND-BINDING; CARBONMONOXY-MYOGLOBIN; CONFORMATIONAL RELAXATION; CRYSTAL-STRUCTURE; PHOTODISSOCIATION; DYNAMICS; CO; INTERMEDIATE; CAVITIES; MOTIONS	We report picosecond time-resolved x-ray diffraction from the myoglobin (Mb) mutant in which Leu(29) is replaced by Phe (L29F mutant). The frame-by-frame structural evolution, resolved to 1.8 angstroms, allows one to literally "watch" the protein as it executes its function. Time-resolved mid-infrared spectroscopy of flash-photolyzed L29F MbCO revealed a short-lived CO intermediate whose 140-ps lifetime is shorter than that found in wild-type protein by a factor of 1000. The electron density maps of the protein unveil transient conformational changes far more dramatic than the structural differences between the carboxy and deoxy states and depict the correlated side-chain motion responsible for rapidly sweeping CO away from its primary docking site.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Pusan Natl Univ, Dept Chem, Pusan 609735, South Korea; Harvard Univ, Sch Med, Boston, MA 02115 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pusan National University; Harvard University; Harvard Medical School; Rice University; University of Wisconsin System; University of Wisconsin Madison; European Synchrotron Radiation Facility (ESRF)	Schotte, F (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.		Smirnov, Alexey/AAB-2521-2020	Smirnov, Alexey/0000-0001-5361-8232; Olson, John/0000-0002-0760-5403	NHLBI NIH HHS [HL47020] Funding Source: Medline; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029031, ZIADK029031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Cho A, 2002, SCIENCE, V296, P1008, DOI 10.1126/science.296.5570.1008; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; FRAUENFELDER H, 1991, BER BUNSEN PHYS CHEM, V95, P272, DOI 10.1002/bbpc.19910950310; Goodno GD, 1999, J PHYS CHEM A, V103, P10630, DOI 10.1021/jp993559y; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Vitkup D, 1997, NAT STRUCT BIOL, V4, P202, DOI 10.1038/nsb0397-202; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Ye X, 2002, J AM CHEM SOC, V124, P5914, DOI 10.1021/ja017359n	22	649	658	3	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1944	1947		10.1126/science.1078797	http://dx.doi.org/10.1126/science.1078797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817148				2022-12-28	WOS:000183619400046
J	Laskin, A; Gaspar, DJ; Wang, WH; Hunt, SW; Cowin, JP; Colson, SD; Finlayson-Pitts, BJ				Laskin, A; Gaspar, DJ; Wang, WH; Hunt, SW; Cowin, JP; Colson, SD; Finlayson-Pitts, BJ			Reactions at interfaces as a source of sulfate formation in sea-salt particles	SCIENCE			English	Article							MARINE BOUNDARY-LAYER; ATMOSPHERIC SULFUR; CHLORIDE DEPLETION; DIMETHYL SULFIDE; AIR-POLLUTION; AEROSOL; CHEMISTRY; MECHANISM; OZONE; H2SO4	Understanding the formation of sulfate particles in the troposphere is critical because of their health effects and their direct and indirect effects on radiative forcing, and hence on climate. Laboratory studies of the chemical and physical changes in sodium chloride, the major component of sea-salt particles, show that sodium hydroxide is generated upon reaction of deliquesced sodium chloride particles with gas-phase hydroxide. The increase in alkalinity will lead to an increase in the uptake and oxidation of sulfur dioxide to sulfate in sea-salt particles. This chemistry is missing from current models but is consistent with a number of previously unexplained field study observations.	Pacific NW Natl Lab, Richland, WA 99352 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of California System; University of California Irvine	Laskin, A (corresponding author), Pacific NW Natl Lab, POB 999,MSIN K8-88, Richland, WA 99352 USA.	alexander.laskin@pnl.gov; bj.finlay@uci.edu	Laskin, Alexander/I-2574-2012; Gaspar, Dan/H-6166-2011	Laskin, Alexander/0000-0002-7836-8417; Hunt, Sherri/0000-0001-5701-0865; Gaspar, Daniel/0000-0002-8089-810X; Finlayson-Pitts, Barbara/0000-0003-4650-168X				ARMSTRONG JT, 1991, ELECTRON PROBE QUANTITATION, P261; Ayers GP, 1999, J ATMOS CHEM, V33, P299, DOI 10.1023/A:1006120205159; Barrie LA, 2001, TELLUS B, V53, P615, DOI 10.1034/j.1600-0889.2001.530507.x; BERRESHEIM H, 1993, J GEOPHYS RES-ATMOS, V98, P12701, DOI 10.1029/93JD00815; Berresheim H, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000229; CHAMEIDES WL, 1992, J GEOPHYS RES-ATMOS, V97, P20565, DOI 10.1029/92JD01923; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; Cooper PL, 1996, J PHYS CHEM-US, V100, P2249, DOI 10.1021/jp952142z; De Bruyn WJ, 1998, J GEOPHYS RES-ATMOS, V103, P16703, DOI 10.1029/98JD00971; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; EISELE FL, 1993, J GEOPHYS RES-ATMOS, V98, P9001, DOI 10.1029/93JD00031; GONG SL, IN PRESS J GEOPHYS R; HOFFMANN MR, 1986, ATMOS ENVIRON, V20, P1145, DOI 10.1016/0004-6981(86)90147-2; HOIGNE J, 1985, WATER RES, V19, P993, DOI 10.1016/0043-1354(85)90368-9; HOUGHTON JT, 2001, IPCC REPORT; IKEGAMI M, 1994, TELLUS B, V46, P142, DOI 10.1034/j.1600-0889.1994.t01-1-00006.x; Jefferson A, 1997, J GEOPHYS RES-ATMOS, V102, P19021, DOI 10.1029/97JD01152; Jungwirth P, 2001, J PHYS CHEM B, V105, P10468, DOI 10.1021/jp012750g; Jungwirth P, 2002, J PHYS CHEM B, V106, P6361, DOI 10.1021/jp020242g; Kasibhatla P, 1997, J GEOPHYS RES-ATMOS, V102, P3737, DOI 10.1029/96JD03084; Keene WC, 1998, J AEROSOL SCI, V29, P339, DOI 10.1016/S0021-8502(97)10011-8; Keene WC, 1990, GLOBAL BIOGEOCHEM CY, V4, P407, DOI 10.1029/GB004i004p00407; Kerminen VM, 1998, J AEROSOL SCI, V29, P929, DOI 10.1016/S0021-8502(98)00002-0; KIM Y, 1995, J GEOPHYS RES-ATMOS, V100, P23027, DOI 10.1029/95JD00558; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; KREY J, 1972, Z PHYS CHEM NEUE FOL, V81, P252, DOI 10.1524/zpch.1972.81.5_6.252; Laskin A, 2003, AEROSOL SCI TECH, V37, P246, DOI 10.1080/02786820300945; Laskin A, 2002, ENVIRON SCI TECHNOL, V36, P4948, DOI 10.1021/es020551k; Laskin A, 2001, ANAL CHEM, V73, P1023, DOI 10.1021/ac0009604; Lohmann U, 2001, TELLUS B, V53, P646, DOI 10.1034/j.1600-0889.2001.530508.x; MINZ FR, 2002, ULLMANNS ENCY IND CH; ODowd CD, 1997, ATMOS ENVIRON, V31, P73, DOI 10.1016/S1352-2310(96)00106-9; Oum KW, 1998, SCIENCE, V279, P74, DOI 10.1126/science.279.5347.74; Pitts Jr J. N., 2000, CHEM UPPER LOWER ATM; Roelofs GJ, 2001, TELLUS B, V53, P673, DOI 10.1034/j.1600-0889.2001.530509.x; ROESELOVA M, UNPUB; Rosenfeld D, 2002, SCIENCE, V297, P1667, DOI 10.1126/science.1073869; Sievering H, 1990, GLOBAL BIOGEOCHEM CY, V4, P395, DOI 10.1029/GB004i004p00395; SIEVERING H, 1992, NATURE, V360, P571, DOI 10.1038/360571a0; Spicer CW, 1996, J GEOPHYS RES-ATMOS, V101, P29137, DOI 10.1029/96JD00099; van den Berg A, 2000, J GEOPHYS RES-ATMOS, V105, P11671, DOI 10.1029/1999JD901073; Vogt R, 1996, NATURE, V383, P327, DOI 10.1038/383327a0; Yao XH, 2003, ATMOS ENVIRON, V37, P743, DOI 10.1016/S1352-2310(02)00955-X; Yao XH, 2001, ENVIRON SCI TECHNOL, V35, P600, DOI 10.1021/es000964q	45	238	247	6	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	2003	301	5631					340	344		10.1126/science.1085374	http://dx.doi.org/10.1126/science.1085374			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702CG	12843398				2022-12-28	WOS:000184207300035
J	Diebold, SS; Montoya, M; Unger, H; Alexopoulou, L; Roy, P; Haswell, LE; Al-Shamkhani, A; Flavell, R; Borrow, P; Sousa, CRE				Diebold, SS; Montoya, M; Unger, H; Alexopoulou, L; Roy, P; Haswell, LE; Al-Shamkhani, A; Flavell, R; Borrow, P; Sousa, CRE			Viral infection switches non-plasmacytoid dendritic cells into high interferon producers	NATURE			English	Article								Type I interferons (IFN-I) are important cytokines linking innate and adaptive immunity(1). Plasmacytoid dendritic cells make high levels of IFN-I in response to viral infection and are thought to be the major source of the cytokines in vivo(2). Here, we show that conventional non-plasmacytoid dendritic cells taken from mice infected with a dendritic-cell-tropic strain of lymphocytic choriomeningitis virus make similarly high levels of IFN-I on subsequent culture. Similarly, non-plasmacytoid dendritic cells secrete high levels of IFN-I in response to double-stranded RNA (dsRNA), a major viral signature(3), when the latter is introduced into the cytoplasm to mimic direct viral infection. This response is partially dependent on the cytosolic dsRNA-binding enzyme protein kinase R-4 and does not require signalling through toll-like receptor (TLR) 3, a surface receptor for dsRNA(5). Furthermore, we show that sequestration of dsRNA by viral NS1 (refs 6,7) explains the inability of conventional dendritic cells to produce IFN-I on infection with influenza. Our results suggest that multiple dendritic cell types, not just plasmacytoid cells, can act as specialized interferon-producing cells in certain viral infections, and reveal the existence of a TLR-independent pathway for dendritic cell activation that can be the target of viral interference.	Canc Res UK, London Res Inst, Immunobiol Lab, London WC2A 3PX, England; Edward Jenner Inst Vaccine Res, Compton RG20 7NN, Berks, England; Univ Vet Med, Inst Virol, A-1210 Vienna, Austria; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; London Sch Hyg & Trop Med, London WC1A 7HT, England; Southampton Gen Hosp, Sch Med, Canc Sci Div, Tenovus Res Lab, Southampton SO16 6YD, Hants, England	Cancer Research UK; University of Veterinary Medicine Vienna; Yale University; Howard Hughes Medical Institute; University of London; London School of Hygiene & Tropical Medicine; University of Southampton	Sousa, CRE (corresponding author), Canc Res UK, London Res Inst, Immunobiol Lab, London WC2A 3PX, England.		Reis e Sousa, Caetano/ABD-7322-2021; Montoya, Maria/G-3430-2015; Reis e Sousa, Caetano/O-1657-2014; Alexopoulou, Lena/A-5041-2017	Reis e Sousa, Caetano/0000-0001-7392-2119; Montoya, Maria/0000-0002-5703-7360; Reis e Sousa, Caetano/0000-0001-7392-2119; Alexopoulou, Lena/0000-0003-4619-697X; Roy, Polly/0000-0001-6535-6911; Borrow, Persephone/0000-0002-3877-9780; Haswell, Linsey/0000-0002-5663-8834				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Bruno L, 2001, EUR J IMMUNOL, V31, P3403, DOI 10.1002/1521-4141(200111)31:11<3403::AID-IMMU3403>3.0.CO;2-T; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; Cousens LP, 1997, P NATL ACAD SCI USA, V94, P634, DOI 10.1073/pnas.94.2.634; Dalod M, 2002, J EXP MED, V195, P517, DOI 10.1084/jem.20011672; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Edwards AD, 2002, J IMMUNOL, V169, P3652, DOI 10.4049/jimmunol.169.7.3652; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; O'Keeffe M, 2002, J EXP MED, V196, P1307, DOI 10.1084/jem.20021031; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	30	472	501	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 17	2003	424	6946					324	328		10.1038/nature01783	http://dx.doi.org/10.1038/nature01783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	701RZ	12819664				2022-12-28	WOS:000184183900045
J	Martinez-Picado, J; Negredo, E; Ruiz, L; Shintani, A; Fumaz, CR; Zala, C; Domingo, P; Vilaro, J; Llibre, JM; Viciana, P; Hertogs, K; Boucher, C; D'Aquila, RT; Clotet, B				Martinez-Picado, J; Negredo, E; Ruiz, L; Shintani, A; Fumaz, CR; Zala, C; Domingo, P; Vilaro, J; Llibre, JM; Viciana, P; Hertogs, K; Boucher, C; D'Aquila, RT; Clotet, B		SWATCH Study Team	Alternation of antiretroviral drug regimens for HIV infection - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; STRUCTURED TREATMENT INTERRUPTION; HIV-1-INFECTED PATIENTS; SIMULTANEOUS ZIDOVUDINE; DIDANOSINE THERAPY; PROTEASE; ADHERENCE; INDINAVIR; SUPPRESSION; RESISTANCE	Background: Mathematical modeling has suggested that alternating antiretrovirall regimens while patients' viral load remains suppressed would minimize HIV resistance mutations. Objective: To compare alternation of antiretroviral regimens with the current standard of switching regimens after viral load rebound. Design: Randomized, multicenter, open-label, pilot trial. Setting: 15 outpatient HIV clinics in Spain and Argentina. Patients: 161 HIV-1-infected, antiretroviral-nalve persons. Intervention: Patients were assigned to continuously receive stavudine, didanosine, and efavirenz (standard of care, regimen A) or zidovudine, lamivudine, and nelfinavir (standard of care, regimen B) until virologic failure, or to alternate between those two regimens every 3 months while viral load was suppressed (regimen Q. Measurements: Time to virologic failure, percentage of patients with undetectable plasma viremia over 48 weeks, CD4 and CD8 cell counts, adverse events, emergence of drug resistance, drug adherence, and quality of life. Results: Patients receiving standard-of-care regimens A and B did not differ. Virologic failure over 48 weeks was delayed in the alternating therapy group compared with the pooled standard-of-cafe group (incidence rate, 1.2 events/1000 person-weeks [95% CI, 0.3 to 3.6 events/1000 person-weeks] vs. 4.8 events/1000 person-weeks [CI, 2.9 to 7.4 events/1000 person-weeks]; P = 0.01). Genotypic drug resistance emerged in 79% of patients in the standard-of-care group who experienced on-therapy treatment failure. Patients in the standard-of-care and alternating therapy groups had similar CD4 cell counts, frequency of adverse events, reported drug adherence, and quality of life. Conclusions: Virologic outcome was better with alternating therapy than with the current standard of care, while adverse events and adherence were similar. The strategy of alternating therapy merits further investigation.	Hosp Badalona Germans Trias & Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain; Hosp Badalona Germans Trias & Pujol, Lluita SIDA Fdn, Barcelona 08916, Spain; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Huesped Fdn, Buenos Aires, DF, Argentina; Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain; Hosp Vic, Vic, Spain; Hosp St Jaume Calella, Calella, Spain; Hosp Virgen Rocio, Seville, Spain; Tibotec Virco, Mechelen, Belgium; Univ Utrecht, Utrecht, Netherlands	Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Hospital Germans Trias i Pujol; Vanderbilt University; Hospital of Santa Creu i Sant Pau; Virgen del Rocio University Hospital; Johnson & Johnson; Utrecht University	Martinez-Picado, J (corresponding author), Hosp Badalona Germans Trias & Pujol, IrsiCaixa Fdn, Carretera Canyet S-N, Barcelona 08916, Spain.	javiermp@ns.hugtip.scs.es	Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Martinez-Picado, Javier/G-5507-2012; IBIS, VIH/O-8856-2015; Torres, OH/D-2215-2012	Domingo, Pere/0000-0003-1138-5770; Martinez-Picado, Javier/0000-0002-4916-2129; Torres, OH/0000-0002-0305-8211; Negredo, Eugenia/0000-0001-5298-1734	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029193] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29193] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; D'Amato RM, 1998, ANTIVIR THER, V3, P147; Deeks S G, 1997, AIDS Clin Rev, P145; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Fumaz CR, 2002, J ACQ IMMUN DEF SYND, V29, P244, DOI 10.1097/00042560-200203010-00004; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 2001, AIDS, V15, P1671, DOI 10.1097/00002030-200109070-00010; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; KOJIMA E, 1995, J INFECT DIS, V171, P1152, DOI 10.1093/infdis/171.5.1152; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Norton L, 1997, SEMIN ONCOL, V24, P3; Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; ROBBINS G, 2002, P 14 INT AIDS C S BA, P26; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; SHAFER R, 2002, P 14 INT AIDS C S BA, P27; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; STASZEWSKI S, 2002, P 14 INT AIDS C S BA, P25; Tuldra A, 2000, J ACQ IMMUN DEF SYND, V25, P221, DOI 10.1097/00126334-200011010-00003; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; 1999, AIDS, V13, P2209	33	36	37	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2003	139	2					81	89		10.7326/0003-4819-139-2-200307150-00007	http://dx.doi.org/10.7326/0003-4819-139-2-200307150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701HX	12859157				2022-12-28	WOS:000184163100001
J	Bolton, G				Bolton, G			Medicine, the arts, and the humanities	LANCET			English	Editorial Material									Kings Coll London, Sch Humanities, London WC2R 2LS, England	University of London; King's College London	Bolton, G (corresponding author), Kings Coll London, Sch Humanities, London WC2R 2LS, England.	gillie.bolton@kcl.ac.uk						Brody H., 2003, STORIES SICKNESS; Calman K, 1996, LANCET, V347, P1499, DOI 10.1016/S0140-6736(96)90665-0; CARTER MA, 2001, J MED HUMANIT, V22, P173, DOI DOI 10.1023/A:1016653500071; Charon R., 2002, STORIES MATTER ROLE; *COUNC SCI TECHN, IM UND REP ARTS HUM; *CTR MED HUM, 2003, C NEW YORK CIT OCT 1; DOWNIE RS, 2003, J MED ETHICS MED HUM, V29, P37; Einstein A., 2002, TIMES HIGHER ED 1220, pviii; EVANS HM, 2003, J MED ETHICS MED HUM, V29, P1; EVANS M, 2000, PHILOS MEETS MED, P105; Friedman LD, 2002, ACAD MED, V77, P320, DOI 10.1097/00001888-200204000-00011; Pattison S, 2003, Med Humanit, V29, P33, DOI 10.1136/mh.29.1.33	12	21	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					93	94		10.1016/S0140-6736(03)13894-9	http://dx.doi.org/10.1016/S0140-6736(03)13894-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	699ZY	12867106				2022-12-28	WOS:000184089200005
J	Bryce, J; el Arifeen, S; Pariyo, G; Lanata, CF; Gwatkin, D; Habicht, JP				Bryce, J; el Arifeen, S; Pariyo, G; Lanata, CF; Gwatkin, D; Habicht, JP		Multi-Country Evaluation IMCI Stud	Reducing child mortality: can public health deliver?	LANCET			English	Article							INTEGRATED MANAGEMENT; CARE; PROGRAM; QUALITY; ILLNESS; BENIN	This is the third paper in the series on child survival. The second paper in the series, published last week, concluded that in the 42 countries with 90% of child deaths worldwide in 2000, 63% of these deaths could have been prevented through full implementation of a few known and effective interventions. Levels of coverage with these interventions are still unacceptably low in most low-income and middle-income countries. Worse still, coverage for some interventions, such as immunisations and attended delivery, are stagnant or even failing in several of the poorest countries. This paper highlights the importance of separating biological or behavioural interventions from the delivery systems required to put them in place, and the need to tailor delivery strategies to the stage of health-system development. We review recent initiatives in child health and discuss essential aspects of delivery systems, including: need for data at the subnational level to support health planning; regular monitoring of provision and use of health services, and of intervention coverage; and the need to achieve high and equitable coverage with selected interventions. Community-based initiatives can extend the delivery of interventions in areas where health services are hard to access, but strengthening national health systems should be the long-term aim. The millennium development goal for child survival can be achieved, but only if strategies for delivery interventions are greatly improved and scaled-up.	WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Makerere Univ, Inst Publ Hlth, Kampala, Uganda; Inst Invest Nutr, Lima, Peru; World Bank, Washington, DC 20433 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of Geneva; World Health Organization; International Centre for Diarrhoeal Disease Research (ICDDR); Makerere University; The World Bank; Cornell University	Bryce, J (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland.	brycej@who.int	Pariyo, George W/K-2335-2017	Pariyo, George W/0000-0002-4411-2309; Arifeen, Shams/0000-0002-5372-5932				Ahmad OB, 2000, B WORLD HEALTH ORGAN, V78, P1175; [Anonymous], TUB MAL; *B M GAT FDN, GRAND CHALL GLOB HLT; Baltazar JC, 2002, B WORLD HEALTH ORGAN, V80, P637; *BELL STUD GROUP C, IN PRESS LANCET; BHUIYA A, 2001, CHALLENGING INEQUITI, P227; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; *BRAZ MIN HLTH NAT, EP SURV; BRYCE JB, IN PRESS AM J PUBLIC; Dadzie Yankum, 2003, Filaria J, V2, P2, DOI 10.1186/1475-2883-2-2; DESAVIGNY D, 2002, 2 TANZ ESS HLTH INT; Gauri V, 2002, WORLD DEV, V30, P2109, DOI 10.1016/S0305-750X(02)00151-1; Giusti D, 1997, HEALTH POLICY PLANN, V12, P193, DOI 10.1093/heapol/12.3.193; GOUWS E, IMPROVING CORRECT US; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; GUTIERREZ G, 1994, SALUD PUBLICA MEXICO, V36, P127; Gwatkin DR, 2001, INT J EPIDEMIOL, V30, P720, DOI 10.1093/ije/30.4.720; HABICHT JP, 1979, SOC SCI MED-MED ANTH, V13, P67, DOI 10.1016/0160-7987(79)90019-X; JONES G, IN PRESS LANCET; Knippenberg R, 1997, INT J HEALTH PLAN M, V12, pS9, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S9::AID-HPM471>3.3.CO;2-U; Lambrechts T, 1999, B WORLD HEALTH ORGAN, V77, P582; LANATA CF, 2002, MEJORANDO CALIDAD AT; LevyBruhl D, 1997, INT J HEALTH PLAN M, V12, pS49, DOI 10.1002/(SICI)1099-1751(199706)12:1+<S49::AID-HPM466>3.3.CO;2-G; MILLS A, 2002, IMPROVING HLTH OUTCO; *MIN SAL, 2001, EXP PCMI; *NAT CONTR DIARRH, 1988, LANCET, V2, P145; Nicholas D D, 1991, Qual Assur Health Care, V3, P147; Omaswa F, 1997, B WORLD HEALTH ORGAN, V75, P155; *PATH, 2002, HEALTHT UPD; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4; *TANZ IMCI MULT CO, IN PRESS HLTH POLICY; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; UNICEF, DEL CAR; *UNICEF, MEASL TRENDS DEC; *UNICEF, 2001, PROGR WORLD SUMM CHI; *UNICEF, ROUT IMM TRENDS DEC; United Nations Children's Fund (UNICEF), MULT IND CLUST SURV; *US NIH, DIS CONTR PRIOR PROG; Victora CG, 1996, HEALTH POLICY PLANN, V11, P132, DOI 10.1093/heapol/11.2.132; VICTORA CG, COCOVERAGE CHILD SUR; VICTORA CG, IN PRESS LANCET; *WHO, 2002, WHOFCHCAH0216; *WHO, 2003, WHOCDSMAL20031093; *WHO DEP CHILD AD, IMCI IMPL MON; *WORK GROUP RUR ME, 1973, DEL PRIM CAR MED AUX; World Health Organization, WORLD HLTH REP 2002; World Health Organization, WORLD HLTH REP 2000	48	245	254	1	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					159	164		10.1016/S0140-6736(03)13870-6	http://dx.doi.org/10.1016/S0140-6736(03)13870-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	699ZY	12867119				2022-12-28	WOS:000184089200026
J	White, PM; Wardlaw, J				White, PM; Wardlaw, J			Unruptured intracranial aneurysms: prospective data have arrived	LANCET			English	Editorial Material							RISK		Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	White, PM (corresponding author), Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.	pmw@skull.dcn.ed.ac.uk	Hernandez, María/GYU-3543-2022; Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642; White, Philip/0000-0001-6007-6013				Ausman JI, 2002, SURG NEUROL, V58, P287, DOI 10.1016/S0090-3019(02)00891-1; Berenstein A, 1999, NEW ENGL J MED, V340, P1439; Connolly ES, 1999, NEW ENGL J MED, V340, P1440; *D COOP STUD INV, 2001, NEURORADIOLOGY, V43, P415; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Stieg PE, 1999, NEW ENGL J MED, V340, P1441; Tsutsumi K, 1999, STROKE, V30, P1181, DOI 10.1161/01.STR.30.6.1181; Wardlaw JM, 2000, BRAIN, V123, P205, DOI 10.1093/brain/123.2.205; White PM, 2001, RADIOLOGY, V219, P739, DOI 10.1148/radiology.219.3.r01ma16739; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	12	24	26	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					90	91		10.1016/S0140-6736(03)13891-3	http://dx.doi.org/10.1016/S0140-6736(03)13891-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867103				2022-12-28	WOS:000184089200002
J	Atkinson, RC; Beachy, RN; Conway, G; Cordova, FA; Fox, MA; Holbrook, KA; Klessig, DF; McCormick, RL; McPherson, PM; Rawlings, HR; Rapson, R; Vanderhoef, LN; Wiley, JD; Young, CE				Atkinson, RC; Beachy, RN; Conway, G; Cordova, FA; Fox, MA; Holbrook, KA; Klessig, DF; McCormick, RL; McPherson, PM; Rawlings, HR; Rapson, R; Vanderhoef, LN; Wiley, JD; Young, CE			Public sector collaboration for agricultural IP management	SCIENCE			English	Editorial Material									Univ Calif, Oakland, CA 94607 USA; Donald Danforth Plant Sci Ctr, St Louis, MO USA; Rockefeller Fdn, New York, NY 10018 USA; Univ Calif Riverside, Riverside, CA 92521 USA; N Carolina State Univ, Raleigh, NC 27695 USA; Ohio State Univ, Columbus, OH 43210 USA; Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Rutgers State Univ, New Brunswick, NJ 08901 USA; Michigan State Univ, E Lansing, MI 48824 USA; Cornell Univ, Ithaca, NY 14853 USA; McKnight Fdn, Minneapolis, MN 55401 USA; Univ Calif Davis, Davis, CA 95616 USA; Univ Wisconsin, Madison, WI 53706 USA	University of California System; University of California Berkeley; Donald Danforth Plant Science Center; University of California System; University of California Riverside; University of North Carolina; North Carolina State University; Ohio State University; Cornell University; Boyce Thompson Institute for Plant Research; Rutgers State University New Brunswick; Michigan State University; Cornell University; University of California System; University of California Davis; University of Wisconsin System; University of Wisconsin Madison	Atkinson, RC (corresponding author), Univ Calif, Oakland, CA 94607 USA.							Beachy RN, 2003, SCIENCE, V299, P473, DOI 10.1126/science.299.5606.473; Conway G, 1999, NATURE, V402, pC55, DOI [10.1038/35011545, 10.1038/990141]; GRAFF G, UNPUB; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Huang JK, 2002, SCIENCE, V295, P674, DOI 10.1126/science.1067226; KRYDER RD, 2000, 20 ISAAA; Mowery DC, 2001, RES POLICY, V30, P99, DOI 10.1016/S0048-7333(99)00100-6; PAULSON L, COMMUNICATION; Phipps RH, 2002, J ANIM FEED SCI, V11, P1; RUFF M, COMMUNICATION; Wright B. D., 1998, California Agriculture, V52, P8, DOI 10.3733/ca.v052n06p8	11	72	74	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					174	175		10.1126/science.1085553	http://dx.doi.org/10.1126/science.1085553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	699KN	12855794	Green Submitted			2022-12-28	WOS:000184056200026
J	Mariani, R; Chen, D; Schrofelbauer, B; Navarro, F; Konig, R; Bollman, B; Munk, C; Nymark-McMahon, H; Landau, NR				Mariani, R; Chen, D; Schrofelbauer, B; Navarro, F; Konig, R; Bollman, B; Munk, C; Nymark-McMahon, H; Landau, NR			Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; B MESSENGER-RNA; TYPE-1 VIF; EDITING ENZYME; DNA; HYPERMUTATION; PROTEIN; REPLICATION; EXPRESSION; GENE	The HIV-1 accessory protein Vif (virion infectivity factor) is required for the production of infectious virions by CD4(+) lymphocytes. Vif facilitates particle infectivity by blocking the inhibitory activity of APOBEC3G (CEM15), a virion-encapsidated cellular protein that deaminates minus-strand reverse transcript cytosines to uracils. We report that HIV-1 Vif forms a complex with human APOBEC3G that prevents its virion encapsidation. HIV-1 Vif did not efficiently form a complex with mouse APOBEC3G. Vif dramatically reduced the amount of human APOBEC3G encapsidated in HIV-1 virions but did not prevent encapsidation of mouse or AGM APOBEC3G. As a result, these enzymes are potent inhibitors of wild-type HIV-1 replication. The species-specificity of this interaction may play a role in restricting HIV-1 infection to humans. Together these findings suggest that therapeutic intervention that either induced APOBEC3G or blocked its interaction with Vif could be clinically beneficial.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Landau, NR (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	landau@salk.edu	König, Renate/AAB-8918-2019	König, Renate/0000-0003-4882-9179	NIDA NIH HHS [DA014494] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BORMAN AM, 1995, VIROLOGY, V208, P601, DOI 10.1006/viro.1995.1191; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Desrosiers RC, 1998, J VIROL, V72, P1431, DOI 10.1128/JVI.72.2.1431-1437.1998; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FOLEY GE, 1965, CANCER RES, V25, P1254; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; JUTILA MA, 1994, J IMMUNOL, V153, P3917; Keppler OT, 2002, J EXP MED, V195, P719, DOI 10.1084/jem.20011549; Keppler OT, 2001, J VIROL, V75, P8063, DOI 10.1128/JVI.75.17.8063-8073.2001; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; MANGEAT B, 2003, IN PRESS NATURE; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760; Onishi M, 1996, EXP HEMATOL, V24, P324; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Soares MA, 1997, VIROLOGY, V228, P394, DOI 10.1006/viro.1996.8387; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vartanian JP, 2002, J GEN VIROL, V83, P801, DOI 10.1099/0022-1317-83-4-801; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199; ZHANG H, 2003, IN PRESS NATURE	52	748	797	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	2003	114	1					21	31		10.1016/S0092-8674(03)00515-4	http://dx.doi.org/10.1016/S0092-8674(03)00515-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	702JC	12859895	Bronze			2022-12-28	WOS:000184219900003
J	Papp, B; Pal, C; Hurst, LD				Papp, B; Pal, C; Hurst, LD			Dosage sensitivity and the evolution of gene families in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; GENOME; ORGANIZATION; DATABASE; DOMINANCE; CELLS	According to what we term the balance hypothesis, an imbalance in the concentration of the subcomponents of a protein - protein complex can be deleterious(1). If so, there are two consequences: first, both underexpression and overexpression of protein complex subunits should lower fitness, and second, the accuracy of transcriptional co-regulation of subunits should reflect the deleterious consequences of imbalance. Here we show that all these predictions are upheld in yeast ( Saccharomyces cerevisiae). This supports the hypothesis(2,3) that dominance is a by-product of physiology and metabolism rather than the result of selection to mask the deleterious effects of mutations. Beyond this, single-gene duplication of protein subunits is expected to be harmful, as this, too, leads to imbalance. As then expected, we find that members of large gene families are rarely involved in complexes. The balance hypothesis therefore provides a single theoretical framework for understanding components both of dominance and of gene family size.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Eotvos Lorand Univ, Dept Plant Taxon & Ecol, H-1117 Budapest, Hungary	University of Bath; Eotvos Lorand University	Hurst, LD (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	bssldh@bath.ac.uk	Hurst, Laurence/F-9215-2010	Hurst, Laurence/0000-0002-1002-1054; Papp, Balazs/0000-0003-3093-8852				Abruzzi KC, 2002, MOL CELL BIOL, V22, P138, DOI 10.1128/MCB.22.1.138-147.2002; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bray D, 1997, P NATL ACAD SCI USA, V94, P13493, DOI 10.1073/pnas.94.25.13493; Carroll S.B., 2001, DNA DIVERSITY; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fisher R.A., 1930, GENETICAL THEORY NAT; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; HODGKIN J, 1993, TRENDS GENET, V9, P1, DOI 10.1016/0168-9525(93)90050-R; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; KACSER H, 1981, GENETICS, V97, P639; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; Li BJ, 1996, P NATL ACAD SCI USA, V93, P1596, DOI 10.1073/pnas.93.4.1596; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Sokal RR, 1995, BIOMETRY; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL; Veitia RA, 2002, BIOESSAYS, V24, P175, DOI 10.1002/bies.10023; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; WRIGHT S, 1934, AM NAT, V68, P25; Wu X, 2001, MOL GENET GENOMICS, V265, P622, DOI 10.1007/s004380100455; YUAN J, 1995, BLOOD, V86, P3945, DOI 10.1182/blood.V86.10.3945.bloodjournal86103945	30	617	623	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					194	197		10.1038/nature01771	http://dx.doi.org/10.1038/nature01771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853957				2022-12-28	WOS:000184032700042
J	Solomon, R; Donnenfeld, ED				Solomon, R; Donnenfeld, ED			Recent advances and future frontiers in treating age-related cataracts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SALISBURY EYE EVALUATION; INTRAOCULAR LENSES; POSTOPERATIVE OUTCOMES; CAPSULAR OPACIFICATION; UNPRESERVED LIDOCAINE; RACIAL-DIFFERENCES; SURGERY; SILICONE; RISK; PHACOEMULSIFICATION		Ophthalm Consultants Long Isl, Rockville Ctr, New York, NY USA; Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA	Manhattan Eye Ear & Throat Hospital	Solomon, R (corresponding author), 217 E 70th St,1204, New York, NY 10021 USA.							Apple DJ, 1996, SURV OPHTHALMOL, V40, P279, DOI 10.1016/S0039-6257(96)82003-0; BASS EB, 1995, ARCH OPHTHALMOL-CHIC, V113, P1248, DOI 10.1001/archopht.1995.01100100036025; Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249; Castells X, 1998, INT OPHTHALMOL, V22, P363, DOI 10.1023/A:1006484411524; Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DODICK JM, 1994, INT OPHTHALMOL CLIN, V34, P201, DOI 10.1097/00004397-199403420-00014; Donnenfeld ED, 2003, J CATARACT REFR SURG, V29, P1097, DOI 10.1016/S0886-3350(02)01917-X; *FDN AM AC OPHTH, 2000, LENS CAT 11; Fine IH, 2002, J CATARACT REFR SURG, V28, P1054, DOI 10.1016/S0886-3350(02)01399-8; Fine IH, 1998, OPHTHALMIC SURG LAS, V29, P822; FISHER SJ, 1985, GERIATRIC CLIN N AM, V1, P339; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; Gills JP, 1997, J CATARACT REFR SURG, V23, P545, DOI 10.1016/S0886-3350(97)80211-8; GILVARRY A, 1982, T OPHTHAL SOC UK, V102, P502; Hammond CJ, 2000, NEW ENGL J MED, V342, P1786, DOI 10.1056/NEJM200006153422404; Hollick EJ, 2000, AM J OPHTHALMOL, V129, P577, DOI 10.1016/S0002-9394(99)00447-X; JAFFEE NS, 1997, CATARACT SURG ITS CO; Javitt JC, 2000, OPHTHALMOLOGY, V107, P2040, DOI 10.1016/S0161-6420(00)00368-7; Jick SS, 2001, EPIDEMIOLOGY, V12, P229, DOI 10.1097/00001648-200103000-00016; KADOR PF, 1983, OPHTHALMOLOGY, V90, P352; KELMAN CD, 1967, AM J OPHTHALMOL, V64, P23, DOI 10.1016/0002-9394(67)93340-5; Koch PS, 1997, J CATARACT REFR SURG, V23, P551, DOI 10.1016/S0886-3350(97)80212-X; KOCH PS, 1997, SIMPLIFYING PHACOEMU; Kraff M C, 1982, J Am Intraocul Implant Soc, V8, P38; Kruger AJ, 2000, J CATARACT REFR SURG, V26, P566, DOI 10.1016/S0886-3350(00)00323-0; Leaming DV, 2002, J CATARACT REFR SURG, V28, P1681, DOI 10.1016/S0886-3350(02)01432-3; Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9; Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097; MCLEMORE CS, 1965, ARCH OPHTHALMOL-CHIC, V74, P443; Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819; MUNOZ B, 1993, ARCH OPHTHALMOL-CHIC, V111, P110, DOI 10.1001/archopht.1993.01090010114036; NANEVICZ TM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1825; Olson RJ, 1998, OPHTHALMIC SURG LAS, V29, P55; Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841; Patel BCK, 1996, OPHTHALMOLOGY, V103, P1196, DOI 10.1016/S0161-6420(96)30522-8; Schein OD, 2000, NEW ENGL J MED, V342, P168, DOI 10.1056/NEJM200001203420304; SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9; Schmidbauer JM, 2001, INT OPHTHALMOL CLIN, V41, P109, DOI 10.1097/00004397-200107000-00010; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; Soscia W, 2002, J CATARACT REFR SURG, V28, P1044, DOI 10.1016/S0886-3350(02)01276-2; STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026; STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131; Steinert RF, 1999, OPHTHALMOLOGY, V106, P1243, DOI 10.1016/S0161-6420(99)00704-6; Sugar A, 1999, J CATARACT REFR SURG, V25, P688, DOI 10.1016/S0886-3350(99)00021-8; TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1312, DOI 10.1001/archopht.1995.01100100100038; Vargas LG, 2001, INT OPHTHALMOL CLIN, V41, P1, DOI 10.1097/00004397-200107000-00003; West SK, 1998, AM J EPIDEMIOL, V148, P1033; Yorston D, 2000, SURV OPHTHALMOL, V45, pS1, DOI 10.1016/S0039-6257(00)00183-1	49	20	21	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 9	2003	290	2					248	251		10.1001/jama.290.2.248	http://dx.doi.org/10.1001/jama.290.2.248			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698GH	12851280				2022-12-28	WOS:000183989800030
J	Mocroft, A; Ledergerber, B; Katlama, C; Kirk, O; Reiss, P; Monforte, AD; Knsyz, B; Dietrich, M; Phillips, AN; Lundgren, JD				Mocroft, A; Ledergerber, B; Katlama, C; Kirk, O; Reiss, P; Monforte, AD; Knsyz, B; Dietrich, M; Phillips, AN; Lundgren, JD		EuroSIDA Study Grp	Decline in the AIDS and death rates in the EuroSIDA study: an observational study	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-INFECTED PATIENTS; CLINICAL PROGRESSION; VIROLOGICAL FAILURE; HIV-INFECTION; CELL COUNTS; EUROPE; RECOMMENDATIONS; INDIVIDUALS; PREDICTORS	Background Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1-mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe. Methods We analysed data for 9803 patients in 70 European HIV centres including ones in Israel and Argentina. Incidence rates of AIDS or death were calculated for overall and most recent CD4 count in 6-monthly periods and in three treatment eras (pre-HAART, 1994-1995; early-HAART, 1996-1997; and late-HAART, 1998-2002). Findings The incidence of AIDS or death fell after September, 1998, by 8% per 6-month period (rate ratio 0.92, 95% CI 0.88-0.95, p<0.0001). When AIDS and death were analysed separately, the incidence of all deaths during the late-HAART era was significantly lower than that during the early-HAART era in patients whose latest CD4 count was 20 cells/mu L or less (0.43, 0.35-0.53, p<0.0001), but at higher CD4 counts, did not differ between early-HAART and late-HAART. Incidence of AIDS was about 50% lower in late-HAART than in early-HAART, irrespective of latest CD4 count (p<0.0001). In multivariate Cox's models, with early-HAART as the reference, there was an increased risk of AIDS (relative hazard 1.39; 95% CI 1.16-1.67, p=0.0004) and all deaths (1.29; 1.08-1.56, p=0.0065) in the pre-HAART era, and a reduced risk of AIDS (0.62; 0.50-0.77, p<0.0001) and all deaths (0.66; 0.53-0.82, p=0.0002) in the late-HAART era. Interpretation The initial drop in mortality and morbidity after the introduction of HAART has been sustained. Potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.	UCL Royal Free & UCL Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England; UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Univ Hosp, Zurich, Switzerland; Hop La Pitie Salpetriere, Paris, France; Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Osped L Sacco, Milan, Italy; Univ Wroclaw, Dept Infect Dis, PL-50138 Wroclaw, Poland; Bernhard Nocht Inst Trop Med, Hamburg, Germany	University of London; University College London; University of London; University College London; University of Zurich; University Zurich Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Copenhagen; University of Amsterdam; Academic Medical Center Amsterdam; University of Milan; Luigi Sacco Hospital; University of Wroclaw; Bernhard Nocht Institut fur Tropenmedizin	Mocroft, A (corresponding author), UCL Royal Free & UCL Med Sch, Royal Free Ctr HIV Med, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	a.mocroft@pcps.ucl.ac.uk	Mocroft, Amanda/C-1527-2008; VALLET, Yannick/F-9979-2011; Ledergerber, Bruno/B-5656-2009; Phillips, Andrew N/B-4427-2008; kirk, ole/ABB-4746-2021; Lundgren, Jens/AAE-6876-2019; Mocroft, Amanda/G-8748-2011	Ledergerber, Bruno/0000-0002-6881-4401; Phillips, Andrew N/0000-0003-2384-4807; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Benson CA, 2002, J INFECT DIS, V185, P599, DOI 10.1086/339014; *BHIVA, 2001, HIV MED, V2, P276; Coakley EPG, 2000, AIDS, V14, P1147, DOI 10.1097/00002030-200006160-00011; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Flandre P, 2002, AIDS, V16, P561, DOI 10.1097/00002030-200203080-00007; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Miller V, 2002, J INFECT DIS, V186, P189, DOI 10.1086/341466; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Sterling TR, 2001, AIDS, V15, P2251, DOI 10.1097/00002030-200111230-00006; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	29	980	1011	1	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2003	362	9377					22	29		10.1016/S0140-6736(03)13802-0	http://dx.doi.org/10.1016/S0140-6736(03)13802-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853195				2022-12-28	WOS:000184056900009
J	Iverson, NR; Cohen, D; Hooyer, TS; Fischer, UH; Jackson, M; Moore, PL; Lappegard, G; Kohler, J				Iverson, NR; Cohen, D; Hooyer, TS; Fischer, UH; Jackson, M; Moore, PL; Lappegard, G; Kohler, J			Effects of basal debris on glacier flow	SCIENCE			English	Article							ICE STREAM B; SOFT BED; MECHANICS; PRESSURE; SHEET	Glacier movement is resisted partially by debris, either within glaciers or under glaciers in water-saturated layers. In experiments beneath a thick, sliding glacier, ice containing 2 to 11% debris exerted shear traction of 60 to 200 kilopascals on a smooth rock bed, comparable to the total shear traction beneath glaciers and contrary to the usual assumption that debris-bed friction is negligible. Imposed pore-water pressure that was 60 to 100% of the normal stress in a subglacial debris layer reduced shear traction on the debris sufficiently to halt its deformation and cause slip of ice over the debris. Slip resistance was thus less than debris shearing resistance.	Iowa State Univ, Dept Geol & Atmospher Sci, Ames, IA 50011 USA; Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Wisconsin Geol & Nat Hist Survey, Madison, WI 53705 USA; ETH Zentrum, Hydraul Hydrol & Glaciol Lab, CH-8092 Zurich, Switzerland; Norwegian Water Resources & Energy Directorate, N-0301 Oslo, Norway; Univ Oslo, Dept Geog, N-0316 Oslo, Norway; Norwegian Polar Res Inst, Polar Environm Ctr, N-9296 Tromso, Norway	Iowa State University; Yale University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Norwegian Water Resources & Energy Directorate; University of Oslo; Norwegian Polar Institute	Iverson, NR (corresponding author), Iowa State Univ, Dept Geol & Atmospher Sci, Ames, IA 50011 USA.	niverson@iastate.edu	Jackson, Miriam/M-1898-2018; Cohen, Denis/P-2015-2016	Jackson, Miriam/0000-0003-3719-6716; Cohen, Denis/0000-0002-8262-9798; Kohler, Jack/0000-0003-1963-054X				[Anonymous], J GLACIOL; Boulton G.S., 1975, ICE AGES ANCIENT MOD, P7; BOULTON GS, 1987, J GEOPHYS RES-SOLID, V92, P9059, DOI 10.1029/JB092iB09p09059; BROWN NE, 1987, J GEOPHYS RES-SOLID, V92, P8985, DOI 10.1029/JB092iB09p08985; Budd W., 1979, J GLACIOL, V23, P157, DOI [DOI 10.3198/1979JOG23-89-157-170, 10.3189/S0022143000029804]; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Clark PU, 1996, GEOLOGY, V24, P679, DOI 10.1130/0091-7613(1996)024<0679:NROASB>2.3.CO;2; Clarke GKC, 1999, GEOPH MONOG SERIES, V112, P243; Cohen D, 2000, J GLACIOL, V46, P599, DOI 10.3189/172756500781832747; DRAKE LD, 1973, PROC R SOC LON SER-A, V332, P51, DOI 10.1098/rspa.1973.0013; Fischer UH, 1997, ANN GLACIOL, V24, P390, DOI 10.3189/S0260305500012490; Fowler AC, 2001, J GLACIOL, V47, P527, DOI 10.3189/172756501781831792; Hallet B., 1981, ANN GLACIOL, V2, p23?28, DOI [10.3189/172756481794352487, DOI 10.3189/172756481794352487]; Iverson NR, 1999, J GLACIOL, V45, P41, DOI 10.3189/S0022143000003026; Iverson NR, 1999, J GLACIOL, V45, P31, DOI 10.3189/S0022143000003014; Kamb B., 2001, ANTARCT RES SER, V77, DOI DOI 10.1029/AR077P0157; Lambe T.W., 1969, SOIL MECH; MACAYEAL DR, 1992, NATURE, V359, P29, DOI 10.1038/359029a0; Patterson W.S.B, 1994, PHYS GLACIERS, Vthird, P496; SHOEMAKER EM, 1988, J GLACIOL, V34, P259; Tulaczyk S, 2000, J GEOPHYS RES-SOL EA, V105, P463, DOI 10.1029/1999JB900329; Tulaczyk S, 2000, J GEOPHYS RES-SOL EA, V105, P483, DOI 10.1029/1999JB900328	22	76	78	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					81	84		10.1126/science.1083086	http://dx.doi.org/10.1126/science.1083086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843389				2022-12-28	WOS:000183914700036
J	Langford, CA				Langford, CA			Treatment of ANCA-associated vasculitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIAID, Immunol Dis Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Langford, CA (corresponding author), NIAID, Immunol Dis Sect, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.								0	25	29	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					3	4		10.1056/NEJMp030047	http://dx.doi.org/10.1056/NEJMp030047			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840085				2022-12-28	WOS:000183896100001
J	Mora, JR; Bono, MR; Manjunath, N; Weninger, W; Cavanagh, LL; Rosemblatt, M; von Andrian, UH				Mora, JR; Bono, MR; Manjunath, N; Weninger, W; Cavanagh, LL; Rosemblatt, M; von Andrian, UH			Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells	NATURE			English	Article							CHEMOKINE RECEPTOR; IN-VIVO; LYMPHOCYTE; TISSUE; DIFFERENTIATION; LOCALIZATION; MIGRATION; INTEGRINS; EFFECTOR; ACQUISITION	Whereas naive T cells migrate only to secondary lymphoid organs(1,2), activation by antigen confers to T cells the ability to home to non-lymphoid sites(3,4). Activated effector/memory T cells migrate preferentially to tissues that are connected to the secondary lymphoid organs where antigen was first encountered(5-7). Thus, oral antigens induce effector/memory cells that express essential receptors for intestinal homing, namely the integrin alpha4beta7 and CCR9, the receptor for the gut-associated chemokine TECK/CCL25 (refs 6, 8, 9). Here we show that this imprinting of gut tropism is mediated by dendritic cells from Peyer's patches. Stimulation of CD8-expressing T cells by dendritic cells from Peyer's patches, peripheral lymph nodes and spleen induced equivalent activation markers and effector activity in T cells, but only Peyer's patch dendritic cells induced high levels of alpha4beta7, responsiveness to TECK and the ability to home to the small intestine. These findings establish that Peyer's patch dendritic cells imprint gut-homing specificity on T cells, and thus license effector/memory cells to access anatomical sites most likely to contain their cognate antigen.	Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Chile, Fdn Ciencias Vida, Fac Ciencias, Lab Inmunol, Santiago 6842301, Chile; Millennium Inst Fundamental & Appl Biol, Santiago 6842301, Chile	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Universidad de Chile	von Andrian, UH (corresponding author), Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.	uva@cbr.med.harvard.edu	Bono, Maria/G-7461-2014; von Andrian, Ulrich H/A-5775-2008	Weninger, Wolfgang/0000-0003-3133-8699				ANDREW DP, 1994, J IMMUNOL, V153, P3847; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Carramolino L, 2001, BLOOD, V97, P850, DOI 10.1182/blood.V97.4.850; Davenport MP, 2000, IMMUNOL TODAY, V21, P315, DOI 10.1016/S0167-5699(00)01644-3; GUYGRAND D, 1978, J EXP MED, V148, P1661, DOI 10.1084/jem.148.6.1661; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Kantele A, 1999, J IMMUNOL, V162, P5173; Kelsall BL, 2002, NAT IMMUNOL, V3, P699, DOI 10.1038/ni0802-699; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Manjunath N, 1999, P NATL ACAD SCI USA, V96, P13932, DOI 10.1073/pnas.96.24.13932; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Maurice MM, 2001, P NATL ACAD SCI USA, V98, P7437, DOI 10.1073/pnas.141143298; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; Schott E, 2002, EUR J IMMUNOL, V32, P3425, DOI 10.1002/1521-4141(2002012)32:12<3425::AID-IMMU3425>3.0.CO;2-Q; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; Svensson M, 2002, J CLIN INVEST, V110, P1113, DOI 10.1172/JCI200215988; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Weninger W, 2002, IMMUNOL REV, V186, P221, DOI 10.1034/j.1600-065X.2002.18618.x; Xie HJ, 1999, J EXP MED, V189, P1765, DOI 10.1084/jem.189.11.1765; Zaballos A, 1999, J IMMUNOL, V162, P5671; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241	30	839	870	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					88	93		10.1038/nature01726	http://dx.doi.org/10.1038/nature01726			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840763				2022-12-28	WOS:000183912800046
J	Pham, P; Bransteitter, R; Petruska, J; Goodman, MF				Pham, P; Bransteitter, R; Petruska, J; Goodman, MF			Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation	NATURE			English	Article							IMMUNOGLOBULIN GENES; POLYMERASE-ETA; RECOMBINATION; MECHANISMS; MUTATIONS; FIDELITY; SEQUENCE; REGION; REPAIR	Activation-induced cytidine deaminase (AID) is a protein required for B cells to undergo class switch recombination and somatic hypermutation (SHM)-two processes essential for producing high-affinity antibodies(1). Purified AID catalyses the deamination of C to U on single-stranded (ss) DNA(2-4). Here, we show in vitro that AID-catalysed C deaminations occur preferentially on 5' WRC sequences in accord with SHM spectra observed in vivo. Although about 98% of DNA clones suffer no mutations, most of the remaining mutated clones have 10-70 C to T transitions per clone. Therefore, AID carries out multiple C deaminations on individual DNA strands, rather than jumping from one strand to another. The avid binding of AID to ssDNA could result from its large net positive charge (+11) at pH 7.0, owing to a basic amino-terminal domain enriched in arginine and lysine. Furthermore, AID exhibits a 15-fold preference for C deamination on the non-transcribed DNA strand exposed by RNA polymerase than the transcribed strand protected as a RNA-DNA hybrid. These deamination results on ssDNA bear relevance to three characteristic features of SHM: preferential mutation at C sites within WRC hotspot sequences, the broad clonal mutagenic heterogeneity of antibody variable regions targeted for mutation(5,6), and the requirement for active transcription to obtain mutagenesis(7),(8).	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@usc.edu						Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Dorner T, 1998, IMMUNOL REV, V162, P161, DOI 10.1111/j.1600-065X.1998.tb01439.x; GEARHART PJ, 1983, P NATL ACAD SCI-BIOL, V80, P3439, DOI 10.1073/pnas.80.11.3439; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Kinoshita K, 2000, CURR OPIN IMMUNOL, V12, P195, DOI 10.1016/S0952-7915(99)00072-2; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Liu YJ, 1996, IMMUNITY, V4, P603, DOI 10.1016/S1074-7613(00)80486-0; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; Martin A, 2002, NAT REV IMMUNOL, V2, P605, DOI 10.1038/nri858; Michael N, 2002, IMMUNITY, V16, P123, DOI 10.1016/S1074-7613(02)00261-3; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302	27	508	525	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					103	107		10.1038/nature01760	http://dx.doi.org/10.1038/nature01760			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12819663				2022-12-28	WOS:000183912800049
J	Stalenhoef, AF				Stalenhoef, AF			Phytosterolemia and xanthomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Med Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Stalenhoef, AF (corresponding author), Univ Med Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands.		Stalenhoef, A.F.H./H-8094-2014						0	4	5	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2003	349	1					51	51		10.1056/NEJMicm000052	http://dx.doi.org/10.1056/NEJMicm000052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PW	12840092				2022-12-28	WOS:000183896100008
J	Sharp, D				Sharp, D			Anyone for GM decaff?	LANCET			English	Editorial Material							COFFEE; CAFFEINE		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							Ashihara H, 2001, TRENDS PLANT SCI, V6, P407, DOI 10.1016/S1360-1385(01)02055-6; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; Michaud DS, 2001, CANCER EPIDEM BIOMAR, V10, P429; Ogita S, 2003, NATURE, V423, P823, DOI 10.1038/423823a; Shlonsky AK, 2003, ANN EPIDEMIOL, V13, P273, DOI 10.1016/S1047-2797(02)00414-3	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	2003	361	9376					2172	2172		10.1016/S0140-6736(03)13786-5	http://dx.doi.org/10.1016/S0140-6736(03)13786-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842367				2022-12-28	WOS:000183815600006
J	Aaron, SD; Vandemheen, KL; Hebert, P; Dales, R; Stiell, IG; Ahuja, J; Dickinson, G; Brison, R; Rowe, BH; Dreyer, J; Yetisir, E; Cass, D; Wells, G				Aaron, SD; Vandemheen, KL; Hebert, P; Dales, R; Stiell, IG; Ahuja, J; Dickinson, G; Brison, R; Rowe, BH; Dreyer, J; Yetisir, E; Cass, D; Wells, G			Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL RE-ADMISSION; QUALITY-OF-LIFE; SHORT-TERM; EXACERBATIONS; COPD; DYSPNEA; RECOVERY; THERAPY; RELAPSE; VISITS	BACKGROUND: In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations of chronic obstructive pulmonary disease (COPD). METHODS: We enrolled 147 patients who were being discharged from the emergency department after an exacerbation of COPD and randomly assigned them to 10 days of treatment with 40 mg of oral prednisone once daily or identical-appearing placebo. All patients received oral antibiotics for 10 days, plus inhaled bronchodilators. The primary end point was relapse, defined as an unscheduled visit to a physician's office or a return to the emergency department because of worsening dyspnea, within 30 days after randomization. RESULTS: The overall rate of relapse at 30 days was lower in the prednisone group than in the placebo group (27 percent vs. 43 percent, P=0.05), and the time to relapse was prolonged in those taking prednisone (P=0.04). After 10 days of therapy, patients in the prednisone group had greater improvements in forced expiratory volume in one second than did patients in the placebo group (mean [+/-SD] increase from base line, 34+/-42 percent vs. 15+/-31 percent; P=0.007). Patients in the prednisone group also had significant improvements in dyspnea, as measured by the transitional dyspnea index (P=0.04) and by the dyspnea domain of the Chronic Respiratory Disease Index Questionnaire (P=0.02), but not in health-related quality of life (P=0.14). CONCLUSIONS: Outpatient treatment with oral prednisone offers a small advantage over placebo in treating patients who are discharged from the emergency department with an exacerbation of COPD.	Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Univ Alberta, Div Emergency Med, Edmonton, AB, Canada; London Hlth Sci Ctr, Dept Emergency Med, London, ON, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada; University of Alberta; London Health Sciences Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Aaron, SD (corresponding author), Ottawa Gen Hosp, Div Resp Med, Gen Campus,Rm 1812F,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	saaron@ottawahospital.on.ca		Aaron, Shawn/0000-0002-4762-3542; Stiell, Ian/0000-0002-2583-6408				Aaron SD, 2002, CHEST, V121, P688, DOI 10.1378/chest.121.3.688; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; Henzen C, 2000, LANCET, V355, P542, DOI 10.1016/S0140-6736(99)06290-X; Lau ACW, 2001, RESP MED, V95, P876, DOI 10.1053/rmed.2001.1180; MAHLER DA, 1984, CHEST, V85, P751, DOI 10.1378/chest.85.6.751; McEvoy CE, 1998, AM J RESP CRIT CARE, V157, P704, DOI 10.1164/ajrccm.157.3.9703080; McEvoy CE, 1997, CHEST, V111, P732, DOI 10.1378/chest.111.3.732; Miravitlles M, 2002, CHEST, V121, P1449, DOI 10.1378/chest.121.5.1449; MURATA GH, 1992, ARCH INTERN MED, V152, P73, DOI 10.1001/archinte.152.1.73; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Osman LM, 1997, THORAX, V52, P67; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pearson MG, 1997, THORAX, V52, pS1; Redelmeier DA, 1996, CHEST, V109, P1163, DOI 10.1378/chest.109.5.1163; Rowe BH, 2001, COCHRANE DB SYST REV, V1; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Sin DD, 2002, AM J MED, V112, P120, DOI 10.1016/S0002-9343(01)01079-8; STEHR DE, 1991, ANN EMERG MED, V20, P1113, DOI 10.1016/S0196-0644(05)81386-1; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; WOODBAKER R, 2001, COCHRANE DB SYST REV, V2	23	215	228	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2618	2625		10.1056/NEJMoa023161	http://dx.doi.org/10.1056/NEJMoa023161			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826636				2022-12-28	WOS:000183726400005
J	Hu, FB				Hu, FB			The Mediterranean diet and mortality - Olive oil and beyond	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; PREVENTION		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.		Hu, Frank/C-1919-2013					De Lorgeril M., 1995, LANCET, V345, P738; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Kafatos A, 1997, AM J CLIN NUTR, V65, P1882, DOI 10.1093/ajcn/65.6.1882; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S	6	157	161	0	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	2003	348	26					2595	2596		10.1056/NEJMp030069	http://dx.doi.org/10.1056/NEJMp030069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	693PN	12826632				2022-12-28	WOS:000183726400001
J	Kaye, SB				Kaye, SB			Chemotherapy for recurrent ovarian cancer	LANCET			English	Editorial Material							1ST-LINE		Royal Marsden Hosp, Canc Res UK Dept Med Oncol, Sutton SM2 5PT, Surrey, England	Cancer Research UK; Royal Marsden NHS Foundation Trust	Kaye, SB (corresponding author), Royal Marsden Hosp, Canc Res UK Dept Med Oncol, Downs Rd, Sutton SM2 5PT, Surrey, England.							GONZALEZMARTIN A, 2003, P ASCO, V22, P451; GORE ME, 1990, GYNECOL ONCOL, V36, P207, DOI 10.1016/0090-8258(90)90174-J; Kaye SB, 2002, BRIT J CANCER, V87, P813, DOI 10.1038/sj.bjc.6600568; Parmar MKB, 2002, LANCET, V360, P505; Sandercock J, 2002, BRIT J CANCER, V87, P815, DOI 10.1038/sj.bjc.6600567; VANDERBURG ME, 2002, BRIT J CANCER, V7, P19; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72	7	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2094	2095		10.1016/S0140-6736(03)13726-9	http://dx.doi.org/10.1016/S0140-6736(03)13726-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826426				2022-12-28	WOS:000183654200002
J	Cirak, F; Cisternas, JE; Cuitino, AM; Ertl, G; Holmes, P; Kevrekidis, IG; Ortiz, M; Rotermund, HH; Schunack, M; Wolff, J				Cirak, F; Cisternas, JE; Cuitino, AM; Ertl, G; Holmes, P; Kevrekidis, IG; Ortiz, M; Rotermund, HH; Schunack, M; Wolff, J			Oscillatory thermomechanical instability of an ultrathin catalyst	SCIENCE			English	Article							ADSORPTION; SURFACES; STRAIN; CO	Because of the small thermal capacity of ultrathin (similar to 200 nanometers) metal single crystals, it is possible to explore the coupling of catalytic and thermal action at low pressures. We analyzed a chemothermomechanical instability in this regime, in which catalytic reaction kinetics interact with heat transfer and mechanical buckling to create oscillations. These interacting components are separated and explored through experimentation, mathematical modeling, and scientific computation, and an explanation of the phenomenon emerges from their synthesis.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; Rutgers State Univ, Dept Mech & Aerosp Engn, Piscataway, NJ 08854 USA; Princeton Univ, Program Appl & Computat Math, Princeton, NJ 08544 USA	Max Planck Society; Fritz Haber Institute of the Max Planck Society; California Institute of Technology; Princeton University; Princeton University; Rutgers State University New Brunswick; Princeton University	Rotermund, HH (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.		Cisternas, Jaime E/C-1761-2013	Cisternas, Jaime E/0000-0002-2955-1821; Cuitino, Alberto/0000-0002-5180-9147				ALSARRAF N, 1992, NATURE, V360, P243, DOI 10.1038/360243a0; Cirak F, 2000, INT J NUMER METH ENG, V47, P2039, DOI 10.1002/(SICI)1097-0207(20000430)47:12<2039::AID-NME872>3.0.CO;2-1; Cirak F, 2001, INT J NUMER METH ENG, V51, P813, DOI 10.1002/nme.182.abs; Cisternas J, 2003, PHYSICA D, V177, P71, DOI 10.1016/S0167-2789(02)00750-9; Cisternas J, 2003, J CHEM PHYS, V118, P3312, DOI 10.1063/1.1531070; EISWIRTH M, 1995, PHYSICA D, V84, P40, DOI 10.1016/0167-2789(95)00011-R; Gioia G, 1997, ADV APPL MECH, V33, P119, DOI 10.1016/S0065-2156(08)70386-7; Gioia G, 2002, P ROY SOC A-MATH PHY, V458, P1223, DOI 10.1098/rspa.2001.0921; Gsell M, 1998, SCIENCE, V280, P717, DOI 10.1126/science.280.5364.717; KRISCHER K, 1992, J CHEM PHYS, V96, P9161, DOI 10.1063/1.462226; Mavrikakis M, 1998, PHYS REV LETT, V81, P2819, DOI 10.1103/PhysRevLett.81.2819; MORGENSTERN D, 1959, ARCH RATION MECH AN, V4, P145, DOI 10.1007/BF00281383; Nowacki W, 1962, THERMOELASTICITY; ORTIZ M, 1994, J MECH PHYS SOLIDS, V42, P531, DOI 10.1016/0022-5096(94)90030-2; ROTERMUND HH, 1995, SCIENCE, V270, P608, DOI 10.1126/science.270.5236.608; Rotermund HH, 1998, CURR OPIN SOLID ST M, V3, P354, DOI 10.1016/S1359-0286(98)80044-2; Xu Y, 2001, SURF SCI, V494, P131, DOI 10.1016/S0039-6028(01)01464-9	17	34	35	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1932	1936		10.1126/science.1083909	http://dx.doi.org/10.1126/science.1083909			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817145				2022-12-28	WOS:000183619400042
J	Excoffier, L; Hamilton, G				Excoffier, L; Hamilton, G			Comment on "Genetic structure of human populations"	SCIENCE			English	Editorial Material							SUBDIVISION; DIVERSITY		Univ Bern, Inst Zool, Computat & Mol Populat Genet Lab, CH-3012 Bern, Switzerland	University of Bern	Excoffier, L (corresponding author), Univ Bern, Inst Zool, Computat & Mol Populat Genet Lab, Batzerstr 6, CH-3012 Bern, Switzerland.		Hamilton, Grant/G-2552-2010; Excoffier, Laurent/D-3498-2013	Hamilton, Grant/0000-0001-8445-0575; Excoffier, Laurent/0000-0002-7507-6494				Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Flint J, 1999, HUM GENET, V105, P567, DOI 10.1007/s004390051147; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Michalakis Y, 1996, GENETICS, V142, P1061; Romualdi C, 2002, GENOME RES, V12, P602, DOI 10.1101/gr.214902; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rousset F, 1996, GENETICS, V142, P1357; Schlotterer C, 2002, CURR OPIN GENET DEV, V12, P683, DOI 10.1016/S0959-437X(02)00349-0; SLATKIN M, 1995, GENETICS, V139, P457	9	41	47	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817127				2022-12-28	WOS:000183619400018
J	Thompson, IM; Goodman, PJ; Tangen, CM; Lucia, MS; Miller, GJ; Ford, LG; Lieber, MM; Cespedes, RD; Atkins, JN; Lippman, SM; Carlin, SM; Ryan, A; Szczepanek, CM; Crowley, JJ; Coltman, CA				Thompson, IM; Goodman, PJ; Tangen, CM; Lucia, MS; Miller, GJ; Ford, LG; Lieber, MM; Cespedes, RD; Atkins, JN; Lippman, SM; Carlin, SM; Ryan, A; Szczepanek, CM; Crowley, JJ; Coltman, CA			The influence of finasteride on the development of prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN RECEPTOR GENE; RADICAL PROSTATECTOMY; PREVENTION TRIAL; THERAPY; RISK; HYPERPLASIA; FEATURES; ANTIGEN; VOLUME; BIOPSY	Background: Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5alpha<LF>-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. Methods: In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study. Results: Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P<0.001). Tumors of Gleason grade 7, 8, 9, or 10 were more common in the finasteride group (280 of 757 tumors [37.0 percent], or 6.4 percent of the 4368 men included in the final analysis) than in the placebo group (237 of 1068 tumors [22.2 percent], P<0.001 for the comparison between groups; or 5.1 percent of the 4692 men included in the final analysis, P=0.005 for the comparison between groups). Sexual side effects were more common in finasteride-treated men, whereas urinary symptoms were more common in men receiving placebo. Conclusions: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.	SW Oncol Grp, Operat Off, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; NCI, Bethesda, MD 20892 USA; Mayo Clin, Rochester, MN USA; Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA; SE Med Oncol Ctr, Goldsboro, NC USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Grand Rapids Community Clin Oncol Program, Grand Rapids, MI USA; SW Oncol Grp, Ctr Stat, San Antonio, TX 78245 USA; Univ Colorado, Denver, CO 80202 USA	Southwest Oncology Group; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; United States Department of Defense; United States Air Force; University of Texas System; UTMD Anderson Cancer Center; Southwest Oncology Group; University of Colorado System; University of Colorado Denver	Thompson, IM (corresponding author), SW Oncol Grp, Operat Off, 14980 Omicron Dr, San Antonio, TX 78245 USA.				NATIONAL CANCER INSTITUTE [U10CA035178, U10CA045808, U10CA037429] Funding Source: NIH RePORTER; NCI NIH HHS [CA35178, CA45808, CA37429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; *AM CANC SOC, 2003, CANC FACTS FIG 2003; Andriole GL, 1998, UROLOGY, V52, P195, DOI 10.1016/S0090-4295(98)00184-8; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Barry MJ, 1992, J UROLOGY, V148, P1564, DOI DOI 10.1016/S0022-5347(17)36966-5; Basillote JB, 2003, UROLOGY, V61, P167, DOI 10.1016/S0090-4295(02)02103-9; Bostwick D G, 1998, Anat Pathol, V3, P1; Civantos F, 1996, Semin Urol Oncol, V14, P22; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; EPSTEIN JI, 2002, CAMPBELLS UROLOGY, V4, P3025; FEIGL P, 1995, CONTROL CLIN TRIALS, V16, P150, DOI 10.1016/0197-2456(94)00XXX-M; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Gescher AJ, 2003, LANCET ONCOL, V4, P72, DOI 10.1016/S1470-2045(03)00976-8; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P8272; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177; Hsing Ann W., 2002, Prostate, V52, P213, DOI 10.1002/pros.10108; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; ISHIKAWA S, 1989, J UROLOGY, V141, P1139, DOI 10.1016/S0022-5347(17)41193-1; Karakiewicz PI, 1997, UROLOGY, V49, P55, DOI 10.1016/S0090-4295(96)00360-3; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; Lippman SM, 2002, CLIN CANCER RES, V8, P305; Lippman SM, 2002, CANCER RES, V62, P5119; McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901; Pauler DK, 2002, CONTROL CLIN TRIALS, V23, P675, DOI 10.1016/S0197-2456(02)00231-3; Prehn RT, 1999, CANCER RES, V59, P4161; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; Schatzl G, 2003, J UROLOGY, V169, P1312, DOI 10.1097/01.ju.0000056900.26628.16; SMITH DM, 1994, CANCER, V73, P1472, DOI 10.1002/1097-0142(19940301)73:5<1472::AID-CNCR2820730525>3.0.CO;2-M; Yang XJ, 1999, UROLOGY, V53, P696, DOI 10.1016/S0090-4295(98)00579-2	30	1945	2020	0	81	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					215	224		10.1056/NEJMoa030660	http://dx.doi.org/10.1056/NEJMoa030660			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701KA	12824459				2022-12-28	WOS:000184165700005
J	Wiebers, D; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Thielen, K; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Naleway, A; Yoo, B; Sorensen, B; Wiebers, DO; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Thielen, K; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Wiebers, DO; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Naleway, A; Drake, CG; Ferguson, GG; Kurtzke, J; Andreoli, A; Edner, G; Sengupta, R; Castel, JP; Molyneux, A; Marler, JR				Wiebers, D; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Thielen, K; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Naleway, A; Yoo, B; Sorensen, B; Wiebers, DO; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Thielen, K; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Wiebers, DO; Whisnant, JP; Huston, J; Meissner, I; Brown, RD; Piepgras, DG; Forbes, GS; Nichols, D; O'Fallon, WM; Peacock, J; Jaeger, L; Kassell, NF; Kongable-Beckman, GL; Torner, JC; Naleway, A; Drake, CG; Ferguson, GG; Kurtzke, J; Andreoli, A; Edner, G; Sengupta, R; Castel, JP; Molyneux, A; Marler, JR		Int Study Unruptured Intracranial	Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment	LANCET			English	Article							MANAGEMENT	Background The management of unruptured intracranial aneurysms is controversial. Investigators from the International Study of Unruptured Intracranial Aneurysms aimed to assess the natural history of unruptured intracranial aneurysms and to measure the risk associated with their repair. Methods Centres in the USA, Canada, and Europe enrolled patients for prospective assessment of unruptured aneurysms. Investigators recorded the natural history in patients who did not have surgery, and assessed morbidity and mortality associated with repair of unruptured aneurysms by either open surgery or endovascular procedures. Findings 4060 patients were assessed-1692 did not have aneurysmal repair, 1917 had open surgery, and 451 had endovascular procedures. 5-year cumulative rupture rates for patients who did not have a history of subarachnoid haemorrhage with aneurysms located in internal carotid artery, anterior communicating or anterior cerebral artery, or middle cerebral artery were 0%, 2.6%, 14.5%, and 40% for aneurysms less than 7 mm, 7-12 mm, 13-24 mm, and 25 mm or greater, respectively, compared with rates of 2.5%, 14.5%, 18.4%, and 50%, respectively, for the same size categories involving posterior circulation and posterior communicating artery aneurysms. These rates were often equalled or exceeded by the risks associated with surgical or endovascular repair of comparable lesions. Patients' age was a strong predictor of surgical outcome, and the size and location of an aneurysm predict both surgical and endovascular outcomes. Interpretation. Many factors are involved in management of patients with unruptured intracranial aneurysms. Site, size, and group specific risks of the natural history should be compared with site, size, and age-specific risks of repair for each patient.	Mayo Clin & Mayo Fdn, ISUIA Coordinating Ctr, Rochester, MN 55905 USA; Univ Virginia, Charlottesville, VA USA; Univ Iowa, Iowa City, IA USA; NINDS, Bethesda, MD 20892 USA	Mayo Clinic; University of Virginia; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Wiebers, D (corresponding author), Mayo Clin & Mayo Fdn, ISUIA Coordinating Ctr, 200 1st St SW, Rochester, MN 55905 USA.	wiebers.david@mayo.edu			NINDS NIH HHS [R01-NS-28492] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028492] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bederson JB, 2000, STROKE, V31, P2742, DOI 10.1161/01.STR.31.11.2742; Berenstein A, 1999, NEW ENGL J MED, V340, P1439; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Broderick JP, 2000, ANN NEUROL, V48, P5, DOI 10.1002/1531-8249(200007)48:1<5::AID-ANA1>3.0.CO;2-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes G, 1996, AM J NEURORADIOL, V17, P1407; *ISUIA INV, INT STUD UNR INTR AN; Johnston SC, 1999, NEUROLOGY, V52, P1799, DOI 10.1212/WNL.52.9.1799; Juvela S, 2008, J NEUROSURG, V108, P1052, DOI 10.3171/JNS/2008/108/5/1052; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531; RANKIN J, 1957, Scott Med J, V2, P200; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	15	2415	2554	9	121	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					103	110		10.1016/S0140-6736(03)13860-3	http://dx.doi.org/10.1016/S0140-6736(03)13860-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867109				2022-12-28	WOS:000184089200008
J	Bergthorsson, U; Adams, KL; Thomason, B; Palmer, JD				Bergthorsson, U; Adams, KL; Thomason, B; Palmer, JD			Widespread horizontal transfer of mitochondrial genes in flowering plants	NATURE			English	Article							PHYLOGENETIC ANALYSES; LATERAL TRANSFER; EVOLUTION; NUCLEUS; PROKARYOTES; ANGIOSPERMS; INVASION; DIVERSE; RATES	Horizontal gene transfer - the exchange of genes across mating barriers - is recognized as a major force in bacterial evolution(1,2). However, in eukaryotes it is prevalent only in certain phagotrophic protists and limited largely to the ancient acquisition of bacterial genes(3-5). Although the human genome was initially reported(6) to contain over 100 genes acquired during vertebrate evolution from bacteria, this claim was immediately and repeatedly rebutted(7,8). Moreover, horizontal transfer is unknown within the evolution of animals, plants and fungi except in the special context of mobile genetic elements(9-12). Here we show, however, that standard mitochondrial genes, encoding ribosomal and respiratory proteins, are subject to evolutionarily frequent horizontal transfer between distantly related flowering plants. These transfers have created a variety of genomic outcomes, including gene duplication, recapture of genes lost through transfer to the nucleus, and chimaeric, half-monocot, half-dicot genes. These results imply the existence of mechanisms for the delivery of DNA between unrelated plants, indicate that horizontal transfer is also a force in plant nuclear genomes, and are discussed in the contexts of plant molecular phylogeny and genetically modified plants.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Iowa State Univ, Dept Bot, Ames, IA 50011 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Indiana University System; Indiana University Bloomington; Iowa State University; University of Michigan System; University of Michigan	Palmer, JD (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	jpalmer@bio.indiana.edu	Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220				Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Adams KL, 2000, NATURE, V408, P354, DOI 10.1038/35042567; Adams KL, 2002, P NATL ACAD SCI USA, V99, P9905, DOI 10.1073/pnas.042694899; Andersson JO, 2003, CURR BIOL, V13, P94, DOI 10.1016/S0960-9822(03)00003-4; Archibald JM, 2003, P NATL ACAD SCI USA, V100, P7678, DOI 10.1073/pnas.1230951100; Barkman TJ, 2000, P NATL ACAD SCI USA, V97, P13166, DOI 10.1073/pnas.220427497; BLANCHARD JL, 1995, J MOL EVOL, V41, P397, DOI 10.1007/BF00160310; Cho Y, 1998, P NATL ACAD SCI USA, V95, P14244, DOI 10.1073/pnas.95.24.14244; Eickbush T.H., 2002, MOBILE DNA-UK, V2, P1111, DOI [10.1128/9781555817954.ch49, DOI 10.1128/9781555817954.CH49]; Feschotte C, 2002, P NATL ACAD SCI USA, V99, P280, DOI 10.1073/pnas.022626699; Goddard MR, 1999, P NATL ACAD SCI USA, V96, P13880, DOI 10.1073/pnas.96.24.13880; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Intrieri MC, 2001, MOL PHYLOGENET EVOL, V20, P100, DOI 10.1006/mpev.2001.0927; Kadowaki KI, 1996, EMBO J, V15, P6652, DOI 10.1002/j.1460-2075.1996.tb01055.x; Koonin EV, 2001, ANNU REV MICROBIOL, V55, P709, DOI 10.1146/annurev.micro.55.1.709; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laroche J, 1997, P NATL ACAD SCI USA, V94, P5722, DOI 10.1073/pnas.94.11.5722; Nixon JEJ, 2002, EUKARYOT CELL, V1, P181, DOI 10.1128/EC.1.2.181-190.2002; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Robertson Hugh M., 2002, P1093; Salzberg SL, 2001, SCIENCE, V292, P1903, DOI 10.1126/science.1061036; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; SMITH JM, 1992, J MOL EVOL, V34, P126; Stanhope MJ, 2001, NATURE, V411, P940, DOI 10.1038/35082058; Stupar RM, 2001, P NATL ACAD SCI USA, V98, P5099, DOI 10.1073/pnas.091110398; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054; Zardoya R, 2002, P NATL ACAD SCI USA, V99, P14893, DOI 10.1073/pnas.192573799	30	322	344	5	94	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 10	2003	424	6945					197	201		10.1038/nature01743	http://dx.doi.org/10.1038/nature01743			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699AA	12853958	Green Published			2022-12-28	WOS:000184032700043
J	Weyand, CM; Goronzy, JJ				Weyand, CM; Goronzy, JJ			Mechanisms of disease: Medium- and large-vessel vasculitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GIANT-CELL ARTERITIS; POSITRON-EMISSION-TOMOGRAPHY; INTERFERON-GAMMA-RECEPTOR; BACILLE CALMETTE-GUERIN; POLYMYALGIA-RHEUMATICA; TEMPORAL ARTERITIS; TAKAYASUS-ARTERITIS; CORTICOSTEROID TREATMENT; DENDRITIC CELLS; MYCOBACTERIAL INFECTION		Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Immunol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Weyand, CM (corresponding author), Mayo Clin, Dept Med, Rochester, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NEI NIH HHS [R01 EY11916] Funding Source: Medline; NHLBI NIH HHS [R01 HL63919] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011916] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063919] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHKAR AA, 1994, ANN INTERN MED, V120, P987, DOI 10.7326/0003-4819-120-12-199406150-00003; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Atalay MK, 2001, CURR OPIN RHEUMATOL, V13, P41, DOI 10.1097/00002281-200101000-00007; BALDURSSON O, 1994, ARTHRITIS RHEUM-US, V37, P1007, DOI 10.1002/art.1780370705; BJORNSSON J, 2002, INFLAMMATORY DIS BLO, P255; Blain H, 2002, J GERONTOL A-BIOL, V57, pM241, DOI 10.1093/gerona/57.4.M241; Blockmans D, 1999, RHEUMATOLOGY, V38, P444, DOI 10.1093/rheumatology/38.5.444; Blockmans D, 2000, AM J MED, V108, P246, DOI 10.1016/S0002-9343(99)00424-6; Borkowski A, 2002, AM J PATHOL, V161, P115, DOI 10.1016/S0002-9440(10)64163-6; Brack A, 1997, MOL MED, V3, P530, DOI 10.1007/BF03401699; Brack A, 1999, ARTHRITIS RHEUM, V42, P311, DOI 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F; Brack A, 1997, J CLIN INVEST, V99, P2842, DOI 10.1172/JCI119477; Caux C, 2002, TRANSPLANTATION, V73, pS7, DOI 10.1097/00007890-200201151-00005; CID MC, 1989, ARTHRITIS RHEUM, V32, P884; Cid MC, 2000, ARTHRITIS RHEUM-US, V43, P184, DOI 10.1002/1529-0131(200001)43:1<184::AID-ANR23>3.0.CO;2-N; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Cyster JG, 2000, CURR BIOL, V10, pR30, DOI 10.1016/S0960-9822(99)00253-5; de Jong R, 1998, SCIENCE, V280, P1435; Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duhaut P, 1999, J RHEUMATOL, V26, P361; Elling H, 2000, CLIN EXP RHEUMATOL, V18, pS12; Elling P, 1996, J RHEUMATOL, V23, P112; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; EVANS JM, 1995, ARTHRITIS RHEUM, V38, P290; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Ghanchi FD, 1997, SURV OPHTHALMOL, V42, P99, DOI 10.1016/S0039-6257(97)00052-0; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; Gravanis MB, 2000, INT J CARDIOL, V75, pS21, DOI 10.1016/S0167-5273(00)00184-4; GRUNEWALD J, 1994, ARTHRITIS RHEUM-US, V37, P1221, DOI 10.1002/art.1780370817; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; HALL S, 1985, MEDICINE, V64, P89, DOI 10.1097/00005792-198503000-00002; Hayreh SS, 1997, CLIN NEUROSCI, V4, P251; Helweg-Larsen J, 2002, RHEUMATOLOGY, V41, P445, DOI 10.1093/rheumatology/41.4.445; Huang Fang-Ping, 2001, Current Molecular Medicine (Hilversum), V1, P457, DOI 10.2174/1566524013363573; Hunder GG, 2002, CLEV CLIN J MED, V69, P79, DOI 10.3949/ccjm.69.Suppl_2.SII79; Johnston SL, 2002, J CLIN PATHOL, V55, P481, DOI 10.1136/jcp.55.7.481; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Kaiser M, 1999, AM J PATHOL, V155, P765, DOI 10.1016/S0002-9440(10)65175-9; Kaiser M, 1998, ARTHRITIS RHEUM, V41, P623, DOI 10.1002/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KERR GS, 1995, RHEUM DIS CLIN N AM, V21, P1041; Krupa WM, 2002, AM J PATHOL, V161, P1815, DOI 10.1016/S0002-9440(10)64458-6; Lammas DA, 2002, INT J EXP PATHOL, V83, P1, DOI 10.1046/j.1365-2613.2002.00216.x; Lavignac C, 1996, REV MED INTERNE, V17, P814, DOI 10.1016/0248-8663(96)82684-1; Liozon E, 2001, AM J MED, V111, P211, DOI 10.1016/S0002-9343(01)00770-7; MartinezTaboada V, 1996, J MOL MED-JMM, V74, P695, DOI 10.1007/s001090050074; McFadzean R M, 1998, Curr Opin Ophthalmol, V9, P10; Mitchell BM, 2001, INVEST OPHTH VIS SCI, V42, P2572; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Numano F, 2000, LANCET, V356, P1023, DOI 10.1016/S0140-6736(00)02701-X; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Ray-Chaudhuri N, 2002, BRIT J OPHTHALMOL, V86, P530, DOI 10.1136/bjo.86.5.530; Regan MJ, 2002, ARTHRITIS RHEUM-US, V46, P1056, DOI 10.1002/art.517; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Rittner HL, 1999, CIRC RES, V84, P1050, DOI 10.1161/01.RES.84.9.1050; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Schmidt WA, 2000, CLIN EXP RHEUMATOL, V18, pS40; Seko Y, 1996, CIRCULATION, V93, P1788, DOI 10.1161/01.CIR.93.10.1788; SEKO Y, 1994, J CLIN INVEST, V93, P750, DOI 10.1172/JCI117029; Smetana GW, 2002, JAMA-J AM MED ASSOC, V287, P92, DOI 10.1001/jama.287.1.92; Sneller MC, 2002, CLEV CLIN J MED, V69, P40, DOI 10.3949/ccjm.69.Suppl_2.SII40; Stanson AW, 2000, CLIN EXP RHEUMATOL, V18, pS43; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Turlakow A, 2001, ARCH INTERN MED, V161, P1003, DOI 10.1001/archinte.161.7.1003; WAGNER AD, 1994, J CLIN INVEST, V94, P1134, DOI 10.1172/JCI117428; Wagner AD, 1996, AM J PATHOL, V148, P1925; WAWRYK SO, 1991, J CLIN PATHOL, V44, P497, DOI 10.1136/jcp.44.6.497; Weyand CM, 1997, ARTHRITIS RHEUM, V40, P19, DOI 10.1002/art.1780400105; WEYAND CM, 1992, J CLIN INVEST, V90, P2355, DOI 10.1172/JCI116125; Weyand CM, 1999, ARCH INTERN MED, V159, P577, DOI 10.1001/archinte.159.6.577; Weyand CM, 1996, J CLIN INVEST, V98, P1642, DOI 10.1172/JCI118959; Weyand CM, 2002, CLEV CLIN J MED, V69, P28; WEYAND CM, 1994, ANN INTERN MED, V121, P484, DOI 10.7326/0003-4819-121-7-199410010-00003; Weyand CM, 2002, ARTHRITIS RHEUM, V46, P457, DOI 10.1002/art.10071; Weyand CM, 1999, ARTHRITIS RHEUM-US, V42, P844, DOI 10.1002/1529-0131(199905)42:5<844::AID-ANR2>3.0.CO;2-M; WEYAND CM, 1994, ARTHRITIS RHEUM, V37, P514, DOI 10.1002/art.1780370411; WEYAND CM, 1994, J EXP MED, V179, P951, DOI 10.1084/jem.179.3.951; Weyand CM, 2000, J RHEUMATOL, V27, P517; Weyand CM, 2000, ARTHRITIS RHEUM, V43, P1041, DOI 10.1002/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7; WEYAND CM, 1995, RHEUM DIS CLIN N AM, V21, P1027; WEYAND CM, 2002, INFLAMMATORY DIS BLO, P1; WEYAND CM, 2002, INFLAMMATORY DIS BLO, P413; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914	86	491	523	0	21	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2003	349	2					160	169		10.1056/NEJMra022694	http://dx.doi.org/10.1056/NEJMra022694			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	698XH	12853590				2022-12-28	WOS:000184024400011
J	Raymond, PA; Cole, JJ				Raymond, PA; Cole, JJ			Increase in the export of alkalinity from North America's largest river	SCIENCE			English	Article							WEATHERING RATES; CARBON; CHEMISTRY; EROSION; STREAMFLOW; NITROGEN; TRENDS; IMPACT; FLUX	Chemical weathering and the subsequent export of carbonate alkalinity (HCO3- + CO3-2) from soils to rivers account for significant amounts of terrestrially sequestered atmospheric CO2. We show here that during the past half-century, the export of this alkalinity has increased dramatically from North America's largest river, the Mississippi. This increased export is in part the result of increased flow resulting from higher rainfall in the Mississippi basin. Subcatchment data from the Mississippi suggest that the increase in the export of alkalinity is also linked to amount and type of land cover. These observations have important implications for the potential management of carbon sequestration in the United States.	Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA	Yale University; Cary Institute of Ecosystem Studies	Raymond, PA (corresponding author), Yale Univ, Sch Forestry & Environm Studies, 205 Prospect St, New Haven, CT 06511 USA.	peter.raymond@yale.edu	Raymond, Peter A/C-4087-2009; Cole, Jonathan Jay/G-4566-2011	Raymond, Peter A/0000-0002-8564-7860; Cole, Jonathan Jay/0000-0003-4633-7402				Baldwin CK, 1999, WATER RESOUR RES, V35, P1143, DOI 10.1029/1998WR900070; Banfield JF, 1999, P NATL ACAD SCI USA, V96, P3404, DOI 10.1073/pnas.96.7.3404; BERNER RA, 1984, AM J SCI, V284, P1183, DOI 10.2475/ajs.284.10.1183; Cochran MF, 1996, CHEM GEOL, V132, P71; Dai A, 1997, J CLIMATE, V10, P2943, DOI 10.1175/1520-0442(1997)010<2943:SOGLPV>2.0.CO;2; Dijkstra FA, 2003, BIOGEOCHEMISTRY, V62, P253, DOI 10.1023/A:1021132132199; Frankignoulle M, 1998, SCIENCE, V282, P434, DOI 10.1126/science.282.5388.434; Gaillardet J, 1999, CHEM GEOL, V159, P3, DOI 10.1016/S0009-2541(99)00031-5; Goolsby DA, 2001, HYDROL PROCESS, V15, P1209, DOI 10.1002/hyp.210; Hicke JA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013578; HODELL DA, 1991, GEOLOGY, V19, P24, DOI 10.1130/0091-7613(1991)019<0024:VITSIC>2.3.CO;2; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; HOWARTH RW, 1991, ECOL APPL, V1, P27, DOI 10.2307/1941845; Johnson LB, 1997, FRESHWATER BIOL, V37, P193, DOI 10.1046/j.1365-2427.1997.d01-539.x; Jones DL, 1998, PLANT SOIL, V205, P25, DOI 10.1023/A:1004356007312; Jongmans AG, 1997, NATURE, V389, P682, DOI 10.1038/39493; LASAGA AC, 1994, GEOCHIM COSMOCHIM AC, V58, P2361, DOI 10.1016/0016-7037(94)90016-7; Lins HF, 1999, GEOPHYS RES LETT, V26, P227, DOI 10.1029/1998GL900291; Liu Z, 2000, ENVIRON GEOL, V39, P1053, DOI 10.1007/s002549900072; LYNCH JA, 1995, ATMOS ENVIRON, V29, P1231, DOI 10.1016/1352-2310(94)00371-Q; Markewitz D, 2001, NATURE, V410, P802, DOI 10.1038/35071052; MEYBECK M, 1987, AM J SCI, V287, P401, DOI 10.2475/ajs.287.5.401; Millot R, 2002, EARTH PLANET SC LETT, V196, P83, DOI 10.1016/S0012-821X(01)00599-4; Morgan J.J., 1996, AQUATIC CHEM, V3; Moulton KL, 2000, AM J SCI, V300, P539, DOI 10.2475/ajs.300.7.539; Nemani R, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014867; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; RAYMO ME, 1988, GEOLOGY, V16, P649, DOI 10.1130/0091-7613(1988)016<0649:IOLCMB>2.3.CO;2; Richey JE, 2002, NATURE, V416, P617, DOI 10.1038/416617a; Rothman DH, 2002, P NATL ACAD SCI USA, V99, P4167, DOI 10.1073/pnas.022055499; Rothman DH, 2001, P NATL ACAD SCI USA, V98, P4305, DOI 10.1073/pnas.071047798; Schlesinger WH, 2000, BIOGEOCHEMISTRY, V48, P7, DOI 10.1023/A:1006247623877; SCHWARTZMAN DW, 1989, NATURE, V340, P457, DOI 10.1038/340457a0; Semhi K, 2000, APPL GEOCHEM, V15, P865, DOI 10.1016/S0883-2927(99)00076-1; SKIBA U, 1992, ATMOS ENVIRON A-GEN, V26, P2477, DOI 10.1016/0960-1686(92)90100-Y; Smith SV, 2001, GLOBAL BIOGEOCHEM CY, V15, P697, DOI 10.1029/2000GB001341; Strakhov N.M., 1967, PRINCIPLES LITHOGENE, V1; SUNDQUIST ET, 1993, SCIENCE, V259, P934, DOI 10.1126/science.259.5097.934; SUNDQUIST ET, 1991, QUATERNARY SCI REV, V10, P283, DOI 10.1016/0277-3791(91)90026-Q; TURNER RE, 1994, NATURE, V368, P619, DOI 10.1038/368619a0; WHITE AF, 1995, GEOCHIM COSMOCHIM AC, V59, P1729, DOI 10.1016/0016-7037(95)00078-E; White AF, 1999, GEOCHIM COSMOCHIM AC, V63, P3277, DOI 10.1016/S0016-7037(99)00250-1	42	257	273	4	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					88	91		10.1126/science.1083788	http://dx.doi.org/10.1126/science.1083788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843391				2022-12-28	WOS:000183914700038
J	Critchley, JA; Capewell, S				Critchley, JA; Capewell, S			Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED TRIAL; MALE BRITISH DOCTORS; STOPPING SMOKING; CIGARETTE-SMOKING; BYPASS-SURGERY; FOLLOW-UP; PRIMARY PREVENTION; CARDIAC EVENTS; CASE-FATALITY	Context As more interventions become available for the treatment of coronary heart disease (CHD), policy makers and health practitioners need to understand the benefits of each intervention, to better determine where to focus resources. This is particularly true when a patient with CHD quits smoking. Objective To conduct a systematic review to determine the magnitude of risk reduction achieved by smoking cessation in patients with CHD. Data Sources Nine electronic databases were searched from start of database to April 2003, supplemented by cross-checking references, contact with experts, and with large international cohort studies (identified by the Prospective Studies Collaboration). Study Selection Prospective cohort studies of patients who were diagnosed with CHD were included if they reported all-cause mortality and had at least 2 years of follow-up. Smoking status had to be measured after CHD diagnosis to ascertain quitting. Data Extraction Two reviewers independently assessed studies to determine eligibility, quality assessment of studies, and results, and independently carried out data extraction using a prepiloted, standardized form. Data Synthesis From the literature search, 665 publications were screened and 20 studies were included. Results showed a 36% reduction in crude relative risk (RR) of mortality for patients with CHD who quit compared with those who continued smoking (RR, 0.64; 95% confidence interval [CI], 0.58-0.71). Results from individual studies did not vary greatly despite many differences in patient characteristics, such as age, sex, type of CHD, and the years in which studies took place. Adjusted risk estimates did not differ substantially from crude estimates. Many studies did not adequately address quality issues, such as control of confounding, and misclassification of smoking status. However, restriction to 6 higher-quality studies had little effect on the estimate (RR, 0.71; 95% Cl, 0.65-0.77). Few studies included large numbers of elderly persons, women, ethnic minorities, or patients from developing countries. Conclusions Quitting smoking is associated with a substantial reduction in risk of all-cause mortality among patients with CHD. This risk reduction appears to be consistent regardless of age, sex, index cardiac event, country, and year of study commencement.	Univ Liverpool, Dept Publ Hlth, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Critchley, JA (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	juliac@liverpool.ac.uk		Critchley, Julia/0000-0002-5248-4188				ABERG A, 1983, BRIT HEART J, V49, P416, DOI 10.1136/hrt.49.5.416; *AM AC FAM PHYS, FAM PRACT MAN OCT 19; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BAUGHMAN KL, 1982, ARCH INTERN MED, V142, P875, DOI 10.1001/archinte.142.5.875; Bednarzewski J, 1984, Wiad Lek, V37, P569; BENSHLOMO Y, 1994, AM J PUBLIC HEALTH, V84, P1235, DOI 10.2105/AJPH.84.8.1235; BLAIR A, 1995, REGUL TOXICOL PHARM, V22, P189, DOI 10.1006/rtph.1995.1084; BURR ML, 1992, EUR HEART J, V13, P166, DOI 10.1093/oxfordjournals.eurheartj.a060141; Capewell S, 2000, EUR HEART J, V21, P1833, DOI 10.1053/euhj.2000.2318; *COCHR COLL, 2000, REV MAN 4 1; COOK DG, 1986, LANCET, V2, P1376; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; DEEKS J, 1999, STAT METH PROGR MET; DOBSON AJ, 1991, J CLIN EPIDEMIOL, V44, P1247, DOI 10.1016/0895-4356(91)90157-5; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Dornelas EA, 2000, PREV MED, V30, P261, DOI 10.1006/pmed.2000.0644; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Egger M, 1998, BRIT MED J, V316, P140; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; FRIEDENREICH CM, 1993, EPIDEMIOLOGY, V4, P295, DOI 10.1097/00001648-199307000-00004; GORDON T, 1974, LANCET, V2, P1345; GRAND A, 1992, ANN CARDIOL ANGEIOL, V41, P55; Greenwood DC, 1995, J EPIDEMIOL COMMUN H, V49, P583, DOI 10.1136/jech.49.6.583; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; Gupta R, 1993, Indian Heart J, V45, P125; Hajek P, 2002, BMJ-BRIT MED J, V324, P87, DOI 10.1136/bmj.324.7329.87; HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502; Hasdai D, 1997, NEW ENGL J MED, V336, P755, DOI 10.1056/NEJM199703133361103; HEDBACK B, 1993, EUR HEART J, V14, P831, DOI 10.1093/eurheartj/14.6.831; HERLITZ J, 1995, CARDIOLOGY, V86, P496, DOI 10.1159/000176929; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; HUBERT HB, 1982, AM J EPIDEMIOL, V115, P231, DOI 10.1093/oxfordjournals.aje.a113295; Iso H, 1999, J CARDIOVASC RISK, V6, P315; JOHANSSON S, 1985, AM J EPIDEMIOL, V121, P823, DOI 10.1093/oxfordjournals.aje.a114053; Jousilahti P, 1999, J CARDIOVASC RISK, V6, P293; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Naidoo B, 2000, TOB CONTROL, V9, P397, DOI 10.1136/tc.9.4.397; NEGRI E, 1994, J EPIDEMIOL COMMUN H, V48, P129, DOI 10.1136/jech.48.2.129; *OFF SMOK HLTH, 1990, HLTH BEN SMOK CESS R; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PERKINS J, 1985, POSTGRAD MED J, V61, P295, DOI 10.1136/pgmj.61.714.295; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; REID DD, 1976, LANCET, V2, P979; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; SALONEN JT, 1980, BRIT HEART J, V43, P463, DOI 10.1136/hrt.43.4.463; SATO I, 1992, JPN CIRC J, V56, P217, DOI 10.1253/jcj.56.217; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; Skaar KL, 1997, BEHAV MED, V23, P5, DOI 10.1080/08964289709596362; SPARROW D, 1978, J CHRON DIS, V31, P425, DOI 10.1016/0021-9681(78)90006-1; *STAT CORP, 2000, STAT VERS 6 STAT SOF; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; van Domburg RT, 2000, J AM COLL CARDIOL, V36, P878, DOI 10.1016/S0735-1097(00)00810-X; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WILHELMSSON C, 1975, LANCET, V1, P416; WOODWARD M, 1992, EUR HEART J, V13, P160, DOI 10.1093/oxfordjournals.eurheartj.a060140	63	683	731	1	49	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2003	290	1					86	97		10.1001/jama.290.1.86	http://dx.doi.org/10.1001/jama.290.1.86			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696CR	12837716				2022-12-28	WOS:000183868600024
J	Venis, S				Venis, S			Child survival	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Venis, S (corresponding author), The Lancet, London NW1 7BY, England.							2003, LANCET, V361, P1	1	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 28	2003	361	9376					2172	2172		10.1016/S0140-6736(03)13787-7	http://dx.doi.org/10.1016/S0140-6736(03)13787-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	695DJ	12842368				2022-12-28	WOS:000183815600007
J	Maiato, H; Fairley, EAL; Rieder, CL; Swedlow, JR; Sunkel, CE; Earnshaw, WC				Maiato, H; Fairley, EAL; Rieder, CL; Swedlow, JR; Sunkel, CE; Earnshaw, WC			Human CLASP1 is an outer kinetochore component that regulates spindle microtubule dynamics	CELL			English	Article							KINESIN-RELATED PROTEIN; NEWT LUNG-CELLS; MITOTIC SPINDLE; CENP-E; IN-VITRO; CHROMOSOME ALIGNMENT; INSTABILITY; ATTACHMENT; MITOSIS; INVITRO	One of the most intriguing aspects of mitosis is the ability of kinetochores to hold onto plus ends of microtubules that are actively gaining or losing tubulin subunits. Here, we show that CLASP1, a microtubule-associated protein, localizes preferentially near the plus ends of growing spindle microtubules and is also a component of a kinetochore region that we term the outer corona. A truncated form of CLASP1 lacking the kinetochore binding domain behaves as a dominant negative, leading to the formation of radial arrays of microtubule bundles that are highly resistant to depolymerization. Microinjection of CLASP1-specific antibodies suppresses microtubule dynamics at kinetochores and throughout the spindle, resulting in the formation of monopolar asters with chromosomes buried in the interior. Incubation with microtubule-stabilizing drugs rescues the kinetochore association with microtubule plus ends at the periphery of the asters. Our data suggest that CLASP1 is required at kinetochores for attached microtubules to exhibit normal dynamic behavior.	Univ Edinburgh, Inst Cell & Mol Biol, Chromosome Struct Grp, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Porto, Inst Biol Mol & Celular, Genet Mol Lab, P-4150180 Oporto, Portugal; Wadsworth Ctr, Lab Cell Regulat, Div Mol Med, Albany, NY 12201 USA; Univ Dundee, Div Gene Regulat & Express, MSI, WTB Complex, Dundee DD1 5EH, Scotland; Univ Porto, Inst Ciencias Biomed Abel Alazar, P-4099003 Oporto, Portugal	University of Edinburgh; Universidade do Porto; Wadsworth Center; University of Dundee; Universidade do Porto	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Chromosome Struct Grp, Wellcome Trust Ctr Cell Biol, Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		Earnshaw, William/AAY-7438-2020; Sunkel, Claudio E/J-3352-2013; Maiato, Helder/J-9466-2013	Sunkel, Claudio E/0000-0002-2963-9380; Maiato, Helder/0000-0002-6200-9997; Earnshaw, William/0000-0002-7191-0621; Swedlow, Jason/0000-0002-2198-1958	NIGMS NIH HHS [GM 40198, R37 GM040198, R37 GM040198-20] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040198, R01GM040198] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; AIZAWA H, 1991, J BIOL CHEM, V266, P9841; Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Cheeseman IM, 2001, J CELL BIOL, V152, P197, DOI 10.1083/jcb.152.1.197; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Dujardin D, 1998, J CELL BIOL, V141, P849, DOI 10.1083/jcb.141.4.849; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; Inoue YH, 2000, J CELL BIOL, V149, P153, DOI 10.1083/jcb.149.1.153; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Janke C, 2002, EMBO J, V21, P181, DOI 10.1093/emboj/21.1.181; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; JORDAN MA, 1992, J CELL SCI, V102, P401; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LaFountain JR, 2001, MOL BIOL CELL, V12, P4054, DOI 10.1091/mbc.12.12.4054; Lemos CL, 2000, EMBO J, V19, P3668, DOI 10.1093/emboj/19.14.3668; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; Maiato H, 2002, J CELL BIOL, V157, P749, DOI 10.1083/jcb.200201101; Mastronarde D. N., 1997, Molecular Biology of the Cell, V8, p171A; McEwen BF, 1998, CHROMOSOMA, V107, P366, DOI 10.1007/s004120050320; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; PASQUALONE D, 1994, J CELL BIOL, V127, P849; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; Rieder CL, 1999, METHOD CELL BIOL, V61, P297; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Tirnauer JS, 2002, MOL BIOL CELL, V13, P4308, DOI 10.1091/mbc.e02-04-0236; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; Yin HW, 2002, MOL BIOL CELL, V13, P1881, DOI 10.1091/mbc.01-09-0458	56	164	169	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 27	2003	113	7					891	904		10.1016/S0092-8674(03)00465-3	http://dx.doi.org/10.1016/S0092-8674(03)00465-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	695EJ	12837247	Bronze, Green Submitted			2022-12-28	WOS:000183817900013
J	Molloy, JE; Veigel, C				Molloy, JE; Veigel, C			Myosin motors walk the walk	SCIENCE			English	Editorial Material							F-ACTIN		Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research	Molloy, JE (corresponding author), Natl Inst Med Res, Div Phys Biochem, Mill Hill, London NW7 1AA, England.			Molloy, Justin/0000-0002-8307-2450				Ali MY, 2002, NAT STRUCT BIOL, V9, P464, DOI 10.1038/nsb803; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; VELGEL C, 2002, NATURE CELL BIOL, V4, P59; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	14	28	29	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 27	2003	300	5628					2045	2046		10.1126/science.1087148	http://dx.doi.org/10.1126/science.1087148			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694KZ	12829773				2022-12-28	WOS:000183774900033
J	Morris, MC; Kaiser, P; Rudyak, S; Baskerville, C; Watson, MH; Reed, SI				Morris, MC; Kaiser, P; Rudyak, S; Baskerville, C; Watson, MH; Reed, SI			Cks1-dependent proteasome recruitment and activation of CDC20 transcription in budding yeast	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEOLYSIS; PROTEIN-KINASE; M-PHASE; GENE; ELONGATION; COMPLEX; PDS1; CLB2	Cks proteins are small evolutionarily conserved proteins that interact genetically and physically with cyclin-dependent kinases. However, in spite of a large body of genetic, biochemical and structural research, no compelling unifying model of their functions has emerged(1,2). Here we show, by investigating the essential role of Cks1 in Saccharomyces cerevisiae, that the protein is primarily involved in promoting mitosis by modulating the transcriptional activation of the APC/C protein-ubiquitin ligase activator Cdc20. Cks1 is required for both the periodic dissociation of Cdc28 kinase from the CDC20 promoter and the periodic association of the proteasome with the promoter. We propose that the essential role of Cks1 is to recruit the proteasome to, and/or dissociate the Cdc28 kinase from, the CDC20 promoter, thus facilitating transcription by remodelling transcriptional complexes or chromatin associated with the CDC20 gene.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		MORRIS, May C/J-5940-2016; Rudyak, Stanislav/U-1781-2017; MORRIS, May/ABB-2629-2021	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; COLLART MA, 1993, CURRENT PROTOCOLS MO, V2; ENDICOTT JA, 1995, STRUCTURE, V3, P321, DOI 10.1016/S0969-2126(01)00162-9; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; HILT W, 1993, J BIOL CHEM, V268, P3479; Jensen S, 2001, J CELL BIOL, V152, P27, DOI 10.1083/jcb.152.1.27; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; MAHER M, 1995, MOL CELL BIOL, V15, P3129; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	23	103	107	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2003	423	6943					1009	1013		10.1038/nature01720	http://dx.doi.org/10.1038/nature01720			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694BL	12827207				2022-12-28	WOS:000183753900055
J	Oyama, N; Chan, I; Neill, SM; Hamada, T; South, AP; Wessagowit, V; Wojnarowska, F; D'Cruz, D; Hughes, GJ; Black, MM; McGrath, JA				Oyama, N; Chan, I; Neill, SM; Hamada, T; South, AP; Wessagowit, V; Wojnarowska, F; D'Cruz, D; Hughes, GJ; Black, MM; McGrath, JA			Autoantibodies to extracellular matrix protein 1 in lichen sclerosus	LANCET			English	Article							BENIGN EPIDERMOLYSIS-BULLOSA; HUMAN KERATINOCYTES; LIPOID PROTEINOSIS; PEMPHIGOID ANTIGEN; SKIN DISEASES; GENE ECM1; MUTATIONS; EXPRESSION; ATROPHICUS; HEMIDESMOSOMES	Background Lichen sclerosus is a common acquired inflammatory disorder of skin and mucous membranes. The aetiology is unknown, although HLA-subtype susceptibility and high rates of other autoimmune disorders suggest that autoantibodies to specific mucocutaneous antigens are involved. The clinicopathological similarities between lichen sclerosus and lipoid proteinosis, which results from mutations in extracellular matrix protein 1 (ECM1), suggest this protein as an autoantigen. Methods We analysed serum autoantibody profiles in 171 individuals (86 with lichen sclerosus, 85 healthy controls) by immunoblotting of extracts from normal human skin and lipoid proteinosis skin (lacking ECM1). We generated a full-length glutathione-S-transferase fusion protein for ECM1 to confirm specific immunoreactivity. We affinity-purified serum from patients with lichen sclerosus and did indirect immunofluorescence microscopy on normal skin with or without preabsorption with recombinant ECM1. Findings By immunoblotting, IgG autoantibodies were found in 20 (67% [95% Cl 45-84]) of 30 lichen sclerosus serum samples. The highest titre was 1 in 20. The bands were not detected in ECM1-deficient substrate. These samples, and those from 56 other patients with lichen sclerosus, showed immunoreactivity to the recombinant ECM1 protein (64 of 86 positive; 74% [65-84]). Only six (7% [2-13]) of 85 control serum samples were positive. Affinity-purified IgG from serum of patients with lichen sclerosus labelled skin similarly to a polyclonal antibody to ECM1. The positive staining was blocked by preabsorption with excess recombinant ECM1 protein. Interpretation These findings provide evidence for a specific humoral immune response to ECM1 in lichen sclerosus and offer insight into disease diagnosis, monitoring, and approaches to treatment.	St Thomas Hosp, St Johns Inst Dermatol, Div Skin Sci,Genet Skin Dis Grp, Guys Kings & St Thomas Sch Med, London SE1 7EH, England; St Thomas Hosp, St Johns Inst Dermatol, Div Skin Sci,Dept Immunofluorescence, Guys Kings & St Thomas Sch Med, London SE1 7EH, England; Churchill Hosp, Dept Dermatol, Oxford, England; St Thomas Hosp, Rayne Inst, Dept Immunol, Lupus Res Unit, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	McGrath, JA (corresponding author), St Thomas Hosp, St Johns Inst Dermatol, Div Skin Sci,Genet Skin Dis Grp, Guys Kings & St Thomas Sch Med, London SE1 7EH, England.	john.mcgrath@kcl.ac.uk	McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	Oyama, Noritaka/0000-0003-4934-5205; McGrath, John/0000-0002-3708-9964				Azurdia RM, 1999, BRIT J DERMATOL, V140, P79; BERNARD P, 1992, J INVEST DERMATOL, V99, P174, DOI 10.1111/1523-1747.ep12616797; Bhogal BS., 1990, MANAGEMENT BLISTERIN, P15; BUSHKELL LL, 1981, ACTA DERM-VENEREOL, V61, P157; Chan LS, 2002, ARCH DERMATOL, V138, P370, DOI 10.1001/archderm.138.3.370; DOMLOGEHULTSCH N, 1994, ARCH DERMATOL, V130, P1521, DOI 10.1001/archderm.130.12.1521; Hamada T, 2003, J INVEST DERMATOL, V120, P345, DOI 10.1046/j.1523-1747.2003.12073.x; Hamada T, 2002, HUM MOL GENET, V11, P833, DOI 10.1093/hmg/11.7.833; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; HARRINGTON CI, 1981, BRIT J DERMATOL, V104, P563, DOI 10.1111/j.1365-2133.1981.tb08172.x; IRVINE HG, 1913, JAMA-J AM MED ASSOC, V61, P396; Jonkman MF, 1999, J DERMATOL SCI, V20, P103, DOI 10.1016/S0923-1811(99)00017-1; MACFARLANE AW, 1989, CLIN EXP DERMATOL, V14, P245, DOI 10.1111/j.1365-2230.1989.tb00944.x; MCGRATH JA, 1995, J INVEST DERMATOL, V104, P467, DOI 10.1111/1523-1747.ep12605904; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; MEFFERT JJ, 1995, J AM ACAD DERMATOL, V32, P393, DOI 10.1016/0190-9622(95)90060-8; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Ohata Y, 1995, CLIN EXP DERMATOL, V20, P454, DOI 10.1111/j.1365-2230.1995.tb01376.x; Oyama N, 1999, J INVEST DERMATOL, V113, P600, DOI 10.1046/j.1523-1747.1999.00734.x; Powell J, 2000, BRIT J DERMATOL, V142, P481, DOI 10.1046/j.1365-2133.2000.03360.x; Powell JJ, 1999, LANCET, V353, P1777, DOI 10.1016/S0140-6736(98)08228-2; SAHN EE, 1994, PEDIATR DERMATOL, V11, P160, DOI 10.1111/j.1525-1470.1994.tb00572.x; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; Smits P, 2000, J INVEST DERMATOL, V114, P718, DOI 10.1046/j.1523-1747.2000.00916.x; Tasker GL, 2003, CLIN EXP DERMATOL, V28, P128, DOI 10.1046/j.1365-2230.2003.01211.x; THOMAS RHM, 1986, BRIT J DERMATOL, V114, P377, DOI 10.1111/j.1365-2133.1986.tb02831.x; THOMAS RHM, 1998, BRIT J DERMATOL, V118, P41; Wallace H J, 1971, Trans St Johns Hosp Dermatol Soc, V57, P9; Yancey KB, 2000, JAMA-J AM MED ASSOC, V284, P350, DOI 10.1001/jama.284.3.350; Zillikens D, 1999, J DERMATOL SCI, V20, P134, DOI 10.1016/S0923-1811(99)00019-5	30	191	208	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	2003	362	9378					118	123		10.1016/S0140-6736(03)13863-9	http://dx.doi.org/10.1016/S0140-6736(03)13863-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699ZY	12867112				2022-12-28	WOS:000184089200011
J	Ohbayashi, M; Ohki, K; Miyashita, Y				Ohbayashi, M; Ohki, K; Miyashita, Y			Conversion of working memory to motor sequence in the monkey premotor cortex	SCIENCE			English	Article							PREFRONTAL CORTEX; FRONTAL-CORTEX; DECISIONS; SELECTION; MOVEMENT; PRIMATE; AREAS	To plan a serial order behavior, we hold serial sensory information in our minds and convert it to a movement program. We trained monkeys to memorize a sequence of positional cues and to reproduce it by making saccades in either the original or reverse order. The order was determined in the middle of a trial on the basis of an instruction stimulus. Triggered by the instruction stimulus, single neurons in the dorsal premotor cortex became transiently active only when the order needed to be determined. These transient neurons, together with nearby sustained neurons that hold information on cue or movement sequences, appear to mediate the generation of a motor program from the maintained information.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Ohbayashi, M (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ohbayashi-tky@umin.ac.jp; yasushi_miyashita@m.u-tokyo.ac.jp	Miyashita, Yasushi/B-7171-2019; Ohbayashi, Machiko/A-6910-2018	Miyashita, Yasushi/0000-0003-3496-8637; Ohbayashi, Machiko/0000-0003-2563-9049				BARONE P, 1989, EXP BRAIN RES, V78, P447; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; Boussaoud D, 1996, BEHAV BRAIN RES, V72, P1; DIPELLEGRINO G, 1993, J NEUROSCI, V13, P1227; Georgopoulos AP, 2000, CURR OPIN NEUROBIOL, V10, P238, DOI 10.1016/S0959-4388(00)00072-6; Gold JI, 2001, TRENDS COGN SCI, V5, P10, DOI 10.1016/S1364-6613(00)01567-9; Grafton ST, 1998, J NEUROPHYSIOL, V79, P1092, DOI 10.1152/jn.1998.79.2.1092; HALSBAND U, 1985, BEHAV BRAIN RES, V18, P269, DOI 10.1016/0166-4328(85)90035-X; Hoshi E, 2000, NATURE, V408, P466, DOI 10.1038/35044075; Lashley K., 1951, CEREBRAL MECH BEHAV, P112, DOI DOI 10.1093/RFS/HHQ153; Leon MI, 1998, NEURON, V21, P669, DOI 10.1016/S0896-6273(00)80584-X; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; LUPPINO G, 1990, EXP BRAIN RES, V82, P214; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Miller GA, 1960, PLANS STRUCTURE BEHA; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; Owen AM, 1998, P NATL ACAD SCI USA, V95, P7721, DOI 10.1073/pnas.95.13.7721; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1986, J NEUROSCI, V6, P2054; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; Schall JD, 2001, NAT REV NEUROSCI, V2, P33, DOI 10.1038/35049054; Simon SR, 2002, J NEUROPHYSIOL, V88, P2047, DOI 10.1152/jn.2002.88.4.2047; Stern CE, 2000, NEUROIMAGE, V11, P392, DOI 10.1006/nimg.2000.0569; Tanji J, 2001, CURR OPIN NEUROBIOL, V11, P164, DOI 10.1016/S0959-4388(00)00192-6; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245	27	111	113	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2003	301	5630					233	236		10.1126/science.1084884	http://dx.doi.org/10.1126/science.1084884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	699KN	12855814				2022-12-28	WOS:000184056200049
J	Bridgewater, B; Grayson, AD; Jackson, M; Brooks, N; Grotte, GJ; Keenan, DJM; Millner, R; Fabri, BM; Jones, M				Bridgewater, B; Grayson, AD; Jackson, M; Brooks, N; Grotte, GJ; Keenan, DJM; Millner, R; Fabri, BM; Jones, M		North West Quality Improvement P	Surgeon specific mortality in. adult cardiac surgery: comparison between crude and risk stratified data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OPERATIVE RISK; EUROPEAN SYSTEM; BYPASS-SURGERY; VALIDATION; EUROSCORE; VOLUME	Objective As a result of recent failures in clinical governance the government has made a commitment to bring individual surgeons' mortality data into the public domain. We have analysed a database to compare crude mortality after coronary artery bypass surgery with outcomes that were stratified by risk. Design Retrospective analysis of prospectively collected data. Setting All NHS centres in the geographical north west of England that undertake cardiac surgery in adults. Participants All patients undergoing isolated bypass graft surgery for the first time between April 1999 and March 2002. Main outcome measures Surgeon specific postoperative mortality and predicted mortality by EuroSCORE. Results 8572 patients were operated on by 23 surgeons. Overall mortality was 1.7%. Observed mortality between surgeons ranged from 0% to 3.7%; predicted mortality ranged from 2% to 3.7%. Eighty five per cent (7286) of the patients had a EuroSCORE of 5 or less; 49% of the deaths were in this lower risk group. A large proportion of the variability in predicted mortality between surgeons was due to a small but differing number of high risk patients. Conclusions It is possible to collect risk stratified data on all patients undergoing coronary bypass surgery. For most the predicted mortality is low. The small proportion of high risk patients is responsible for most of the differences in predicted mortality between surgeons. Crude comparisons of death rates can be misleading and may encourage surgeons to practise risk averse behaviour. We recommend a comparison of death rates that is stratified by risk and based on low risk cases as the national benchmark for assessing consultant specific performance.	Univ S Manchester Hosp, Manchester M23 9LT, Lancs, England; Ctr Cardiothorac, Liverpool L14 3PE, Merseyside, England; Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; Blackpool Victoria Hosp, Blackpool FY3 HNR, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester	Bridgewater, B (corresponding author), Univ S Manchester Hosp, Manchester M23 9LT, Lancs, England.	ben.bridgewater@smuht.nwest.nhs.uk		Grayson, Antony/0000-0003-2940-0828				Bridgewater B, 1998, HEART, V79, P350, DOI 10.1136/hrt.79.4.350; Dyer O, 2003, BRIT MED J, V326, P1053, DOI 10.1136/bmj.326.7398.1053-a; Fine LG, 2003, BRIT MED J, V326, P25, DOI 10.1136/bmj.326.7379.25; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; Hannan EL, 1999, NEW ENGL J MED, V340, P1677, DOI 10.1056/NEJM199905273402112; Keogh B, 2002, NATL ADULT CARDIAC S; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7; Nashef SAM, 2002, EUR J CARDIO-THORAC, V22, P101, DOI 10.1016/S1010-7940(02)00208-7; *NEW YORK STAT DEP, 2002, COR ART BYP SURG NEW; PARSONNET V, 1979, CIRCULATION, P3; Roques F, 2003, EUR HEART J, V24, P881, DOI 10.1016/S0195-668X(02)00799-6; Roques F, 2000, EUR J CARDIO-THORAC, V18, P27, DOI 10.1016/S1010-7940(00)00417-6; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; SPEIGELHALTER DJ, 2002, BRIT MED J, V324, P261; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; WESTABY S, 2002, BR J CARDIOL ACUTE I, V9, pAIC5; Wynne-Jones K, 2000, HEART, V84, P71, DOI 10.1136/heart.84.1.71; NW REGIONAL QUALITY	22	93	97	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2003	327	7405					13	17		10.1136/bmj.327.7405.13	http://dx.doi.org/10.1136/bmj.327.7405.13			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842949	Green Published, Bronze			2022-12-28	WOS:000184062700014
J	James, A				James, A			Lancet International Fellowships 2004	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		James, A (corresponding author), Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 5	2003	362	9377					6	6		10.1016/S0140-6736(03)13846-9	http://dx.doi.org/10.1016/S0140-6736(03)13846-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699KW	12853192				2022-12-28	WOS:000184056900006
J	Poller, L; Keown, M; Chauhan, N; van den Besselaar, AMHP; Tripodi, A; Shiach, C; Jespersen, J				Poller, L; Keown, M; Chauhan, N; van den Besselaar, AMHP; Tripodi, A; Shiach, C; Jespersen, J			Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EUROPEAN CONCERTED ACTION; SENSITIVITY INDEX CALIBRATION; PROTHROMBIN TIME; OF-CARE; ANTICOAGULATION ECAA; SELF-MANAGEMENT; MONITOR; THROMBOPLASTIN; COAGUCHEK; MULTICENTER	Objective To find out how accurately two point of care test systems-CoaguChek Mini and TAS PT-NC (RapidPointCoag)-display international normalised ratios (INRs). Design Comparison of the INRs from the two systems with a "true" INR on a conventional manual test from the same sample of blood. Setting 10 European Concerted Action on Anticoagulation centres. Participants 600 patients on long term dosage of warfarin. Main outcome measures Comparable results between the different methods. Results The mean displayed INR differed by 21.3% between the two point of care test monitoring systems. The INR on one system was 15.2% higher, on average, than the true INR, but on the other system the INR was 7.1% lower. The percentage difference between the mean displayed INR and the true INR at individual centres varied considerably with both systems. Conclusions Improved international sensitivity index calibration of point of care test monitors by their manufacturers is needed, and better methods of quality control of individual instruments by their users are also needed.	Univ Manchester, Sch Biol Sci, European Concerted Act Anticoagulat Cent Facil, Manchester M13 9PT, Lancs, England; Leiden Univ, Med Ctr, Haemostasis & Thrombosis Res Ctr, Leiden, Netherlands; Univ Milan, IRCCS Maggiore Hosp, Haemophilia & Thrombosis Ctr, Milan, Italy; Manchester Royal Infirm, Dept Haematol, Manchester M13 9WL, Lancs, England; Univ So Dentmark, Dept Thrombosis Res, Esbjerg, Denmark; Ribe Cty Hosp, Dept Clin Chem, DK-6700 Esbjerg, Denmark	University of Manchester; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Manchester	Poller, L (corresponding author), Univ Manchester, Sch Biol Sci, European Concerted Act Anticoagulat Cent Facil, Manchester M13 9PT, Lancs, England.	ecaa@man.ac.uk		Jespersen, Jorgen/0000-0002-3059-2356				Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Ansell J, 2001, CHEST, V119, p22S, DOI 10.1378/chest.119.1_suppl.22S; Bussey HI, 1997, PHARMACOTHERAPY, V17, P861; Cachia PG, 1998, J CLIN PATHOL, V51, P68, DOI 10.1136/jcp.51.1.68; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; Connolly ST, 2000, BRIT MED J, V320, P1219, DOI 10.1136/bmj.320.7244.1219; Cromheecke ME, 2000, LANCET, V356, P97, DOI 10.1016/S0140-6736(00)02470-3; Fitzmaurice DA, 2002, J CLIN PATHOL, V55, P845, DOI 10.1136/jcp.55.11.845; KAATZ SS, 1995, ARCH INTERN MED, V155, P1861, DOI 10.1001/archinte.155.17.1861; LUCAS FV, 1987, AM J CLIN PATHOL, V88, P442, DOI 10.1093/ajcp/88.4.442; MCCURDY SA, 1992, ARCH INTERN MED, V152, P589, DOI 10.1001/archinte.152.3.589; Poller L, 2003, J THROMB HAEMOST, V1, P766, DOI 10.1046/j.1538-7836.2003.00120.x; Poller L, 2002, THROMB HAEMOSTASIS, V88, P992; Poller L, 2002, THROMB RES, V107, P61, DOI 10.1016/S0049-3848(02)00179-2; Poller L, 2002, BRIT J HAEMATOL, V116, P844, DOI 10.1046/j.0007-1048.2002.03361.x; Poller L, 2002, CLIN CHEM, V48, P255; Poller L, 2002, CLIN CHEM, V48, P1672; POLLER L, 2003, IN PRESS CLIN CHEM; Shiach CR, 2002, BRIT J HAEMATOL, V119, P370, DOI 10.1046/j.1365-2141.2002.03888.x; Tripodi A, 1998, THROMB HAEMOSTASIS, V79, P439; TRIPODI A, 1993, THROMB HAEMOSTASIS, V70, P921; TRIPODI A, 1995, THROMB HAEMOSTASIS, V74, P1368; van den Besselaar A. M. H. P., 1999, WHO TECH REP SER, V889, P64; van den Besselar AMHP, 2000, THROMB HAEMOSTASIS, V84, P410; VANDENBESSELAAR AMHP, 1993, THROMB HAEMOSTASIS, V70, P794	26	41	42	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2003	327	7405					30	32A		10.1136/bmj.327.7405.30	http://dx.doi.org/10.1136/bmj.327.7405.30			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	699NK	12842954	Green Published, Bronze			2022-12-28	WOS:000184062700024
J	Kasparian, J; Rodriguez, M; Mejean, G; Yu, J; Salmon, E; Wille, H; Bourayou, R; Frey, S; Andre, YB; Mysyrowicz, A; Sauerbrey, R; Wolf, JP; Woste, L				Kasparian, J; Rodriguez, M; Mejean, G; Yu, J; Salmon, E; Wille, H; Bourayou, R; Frey, S; Andre, YB; Mysyrowicz, A; Sauerbrey, R; Wolf, JP; Woste, L			White-light filaments for atmospheric analysis	SCIENCE			English	Review							ULTRASHORT LASER-PULSES; DYNAMIC SPATIAL REPLENISHMENT; FEMTOSECOND-TERAWATT LASER; CONICAL EMISSION; AIR; DISCHARGES; PROPAGATION; GENERATION	Most long-path remote spectroscopic studies of the atmosphere rely on ambient light or narrow-band lasers. High-power femtosecond laser pulses have been found to propagate in the atmosphere as dynamically self-guided. laments that emit in a continuum from the ultraviolet to the infrared. This white light exhibits a directional behavior with enhanced backward scattering and was detected from an altitude of more than 20 kilometers. This light source opens the way to white-light and nonlinear light detection and ranging applications for atmospheric trace-gas remote sensing or remote identification of aerosols. Air ionization inside the. laments also opens promising perspectives for laser-induced condensation and lightning control. The mobile femtosecond-terawatt laser system, Teramobile, has been constructed to study these applications.	Univ Lyon 1, Spectrometrie Ion & Mol Lab, Teramobile Project, CNRS,UMR 5579, F-69622 Villeurbanne, France; Free Univ Berlin, Inst Expt Phys, Teramobile Project, D-14195 Berlin, Germany; Inst Opt & Quantenelekt, Teramobile Project, D-07743 Jena, Germany; ENSTA, Ecole Polytech, Ctr Yvette, Lab Opt Appl,Teramobile Project,CNRS,UMR 7639, F-91761 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Institut Polytechnique de Paris	Kasparian, J (corresponding author), Univ Lyon 1, Spectrometrie Ion & Mol Lab, Teramobile Project, CNRS,UMR 5579, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.		Kasparian, Jerome/K-4700-2013; Wolf, Jean-Pierre/B-8315-2012; Mysyrowicz, Andre/ABD-5993-2020	Kasparian, Jerome/0000-0003-2398-3882; Wolf, Jean-Pierre/0000-0003-3729-958X; 				Akozbek N, 2000, PHYS REV E, V61, P4540, DOI 10.1103/PhysRevE.61.4540; Akozbek N, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.143901; Akozbek N, 2001, OPT COMMUN, V191, P353, DOI 10.1016/S0030-4018(01)01113-0; Boutou V, 2002, APPL PHYS B-LASERS O, V75, P145, DOI 10.1007/s00340-002-0970-0; BRAUN A, 1995, OPT LETT, V20, P73, DOI 10.1364/OL.20.000073; Brixner T, 2001, NATURE, V414, P57, DOI 10.1038/35102037; Brodeur A, 1997, OPT LETT, V22, P304, DOI 10.1364/OL.22.000304; Couairon A, 2002, J OPT SOC AM B, V19, P1117, DOI 10.1364/JOSAB.19.001117; Gaeta AL, 2003, SCIENCE, V301, P54, DOI 10.1126/science.1083629; Kasparian J, 2000, APPL PHYS B-LASERS O, V71, P877, DOI 10.1007/s003400000463; Kasparian J, 2000, OPT LETT, V25, P1397, DOI 10.1364/OL.25.001397; KOOPMAN DW, 1971, J APPL PHYS, V42, P1883, DOI 10.1063/1.1660462; Kosareva OG, 1997, OPT LETT, V22, P1332, DOI 10.1364/OL.22.001332; Lange HR, 1998, PHYS REV LETT, V81, P1611, DOI 10.1103/PhysRevLett.81.1611; MEJEAN G, IN PRESS APPL PHYS B; MEJEAN G, UNPUB; MEYERS RA, 2000, ENCY ANAL CHEM, V3; MIKI M, 1993, J PHYS D APPL PHYS, V26, P1244, DOI 10.1088/0022-3727/26/8/014; Mlejnek M, 1999, PHYS REV LETT, V83, P2938, DOI 10.1103/PhysRevLett.83.2938; Mlejnek M, 1998, OPT LETT, V23, P382, DOI 10.1364/OL.23.000382; Mlejnek M, 1999, OPT EXPRESS, V4, P223, DOI 10.1364/OE.4.000223; Nibbering ETJ, 1996, OPT LETT, V21, P62, DOI 10.1364/OL.21.000062; Pepin H, 2001, PHYS PLASMAS, V8, P2532, DOI 10.1063/1.1342230; Rairoux P, 2000, APPL PHYS B-LASERS O, V71, P573, DOI 10.1007/s003400000375; Rodriguez M, 2002, OPT LETT, V27, P772, DOI 10.1364/OL.27.000772; Schillinger H, 1999, APPL PHYS B-LASERS O, V68, P753, DOI 10.1007/s003400050699; Shen Y. R., 1984, PRINCIPLES NONLINEAR; Sprangle P, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046418; Stein B, 1999, J GEOPHYS RES-ATMOS, V104, P23983, DOI 10.1029/1999JD900064; STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8; Tzortzakis S, 2000, OPT COMMUN, V181, P123, DOI 10.1016/S0030-4018(00)00734-3; Wille H, 2002, EUR PHYS J-APPL PHYS, V20, P183, DOI 10.1051/epjap:2002090; Yu J, 2001, OPT LETT, V26, P533, DOI 10.1364/OL.26.000533; ZHAO XM, 1995, IEEE J QUANTUM ELECT, V31, P599, DOI 10.1109/3.364418	35	784	835	7	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2003	301	5629					61	64		10.1126/science.1085020	http://dx.doi.org/10.1126/science.1085020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696YG	12843384				2022-12-28	WOS:000183914700030
J	Yandulov, DV; Schrock, RR				Yandulov, DV; Schrock, RR			Catalytic reduction of dinitrogen to ammonia at a single molybdenum center	SCIENCE			English	Article							NITROGEN-FIXATION; IRON PROTEIN; MOFE-PROTEIN; COMPLEXES; CHEMISTRY; TUNGSTEN; MECHANISM; MODELS	Dinitrogen (N-2) was reduced to ammonia at room temperature and 1 atmosphere with molybdenum catalysts that contain tetradentate [HIPTN3N](3-) triamidoamine ligands {such as [HIPTN3N]Mo(N-2), where [HIPTN3N](3-) is[{3,5-(2,4,6-i-Pr3C6H2)(2)C6H3NCH2CH2}(3)N](3-)} in heptane. Slow addition of the proton source [{2,6-lutidinium}{BAr'(4)}, where Ar' is 3,5-(CF3)(2)C6H3] and reductant (decamethyl chromocene) was critical for achieving high efficiency (similar to66% in four turnovers). Numerous x-ray studies, along with isolation and characterization of six proposed intermediates in the catalytic reaction under noncatalytic conditions, suggest that N-2 was reduced at a sterically protected, single molybdenum center that cycled from Mo(III) through Mo(VI) states.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Schrock, RR (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	rrs@mit.edu	Yandulov, Dmitry/GXG-1415-2022	Yandulov, Dmitry/0000-0003-2272-9030	NIGMS NIH HHS [GM 31978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN AD, 1965, CHEM COMMUN, P621, DOI 10.1039/c19650000621; Barriere F, 2003, COORDIN CHEM REV, V236, P71, DOI 10.1016/S0010-8545(02)00183-2; BAZHENOVA TA, 1995, COORDIN CHEM REV, V144, P69, DOI 10.1016/0010-8545(95)01139-G; BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHANEY AL, 1962, CLIN CHEM, V8, P130; CHATT J, 1978, CHEM REV, V78, P589, DOI 10.1021/cr60316a001; CHEN J, 1993, ANGEW CHEM INT EDIT, V32, P1592; Connelly NG, 1996, CHEM REV, V96, P877, DOI 10.1021/cr940053x; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; DICKSON CR, 1978, J AM CHEM SOC, V100, P8007, DOI 10.1021/ja00493a039; DZIEGIELEWSKI JO, 1990, POLYHEDRON, V9, P645, DOI 10.1016/S0277-5387(00)80270-3; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; Eady RR, 2001, J INORG BIOCHEM, V86, P42; Einsle O, 2002, SCIENCE, V297, P1696, DOI 10.1126/science.1073877; Fryzuk MD, 2000, COORDIN CHEM REV, V200, P379, DOI 10.1016/S0010-8545(00)00264-2; Greco GE, 2001, INORG CHEM, V40, P3861, DOI 10.1021/ic001123n; Greco GE, 2001, INORG CHEM, V40, P3850, DOI 10.1021/ic001122v; HENDERSON RA, 1983, ADV INORG CHEM RAD, V27, P197, DOI 10.1016/S0898-8838(08)60108-7; HIDAI M, 1995, CHEM REV, V95, P1115, DOI 10.1021/cr00036a008; Hidai M, 1999, COORDIN CHEM REV, V185-6, P99, DOI 10.1016/S0010-8545(98)00250-1; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KOMORI K, 1989, J AM CHEM SOC, V111, P1939, DOI 10.1021/ja00187a092; Pickett CJ, 1996, J BIOL INORG CHEM, V1, P601, DOI 10.1007/s007750050099; PICKETT CJ, 1985, NATURE, V317, P652, DOI 10.1038/317652a0; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Rees DC, 1993, ADV INORG CHEM, V40, P89; Richards RL, 1996, COORDIN CHEM REV, V154, P83, DOI 10.1016/0010-8545(96)01186-1; ROBBINS JL, 1982, J AM CHEM SOC, V104, P1882, DOI 10.1021/ja00371a017; Schrock RR, 1997, PURE APPL CHEM, V69, P2197, DOI 10.1351/pac199769102197; SHILOV AE, 1987, J MOL CATAL, V41, P221, DOI 10.1016/0304-5102(87)80030-5; TANAKA K, 1982, CHEM LETT, P1203, DOI 10.1246/cl.1982.1203; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; Yandulov DV, 2002, J AM CHEM SOC, V124, P6252, DOI 10.1021/ja020186x; Yandulov DV, 2003, INORG CHEM, V42, P796, DOI 10.1021/ic020505l; YANDULOV DV, UNPUB	39	1028	1041	21	582	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	2003	301	5629					76	78		10.1126/science.1085326	http://dx.doi.org/10.1126/science.1085326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	696YG	12843387				2022-12-28	WOS:000183914700034
J	Chakrabarty, D; Morgan, EH; Muno, MP; Galloway, DK; Wijnands, R; van der Klis, M; Markwardt, CB				Chakrabarty, D; Morgan, EH; Muno, MP; Galloway, DK; Wijnands, R; van der Klis, M; Markwardt, CB			Nuclear-powered millisecond pulsars and the maximum spin frequency of neutron stars	NATURE			English	Article							X-RAY-BURSTS; GRAVITATIONAL-RADIATION; BINARY; DISCOVERY; OSCILLATIONS; SYSTEM	Millisecond pulsars are neutron stars that are thought to have been spun-up by mass accretion from a stellar companion(1). It is not known whether there is a natural brake for this process, or if it continues until the centrifugal breakup limit is reached at submillisecond periods. Many neutron stars that are accreting mass from a companion star exhibit thermonuclear X-ray bursts that last tens of seconds, caused by unstable nuclear burning on their surfaces(2). Millisecond-period brightness oscillations during bursts from ten neutron stars (as distinct from other rapid X-ray variability that is also observed(3,4)) are thought to measure the stellar spin(2,5), but direct proof of a rotational origin has been lacking. Here we report the detection of burst oscillations at the known spin frequency of an accreting millisecond pulsar, and we show that these oscillations always have the same rotational phase. This firmly establishes burst oscillations as nuclear-powered pulsations tracing the spin of accreting neutron stars, corroborating earlier evidence(5,6). The distribution of spin frequencies of the 11 nuclear-powered pulsars cuts off well below the breakup frequency for most neutron-star models, supporting theoretical predictions that gravitational radiation losses can limit accretion torques in spinning up millisecond pulsars(7-9).	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Univ Amsterdam, Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; NASA, High Energy Astrophys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of California System; University of California Santa Barbara; University of St Andrews; University of Amsterdam; University of Amsterdam; University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Chakrabarty, D (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	deepto@space.mit.edu		Galloway, Duncan/0000-0002-6558-5121; Wijnands, Rudi/0000-0002-3516-2152				ALPAR MA, 1982, NATURE, V300, P728, DOI 10.1038/300728a0; Andersson N, 1999, ASTROPHYS J, V516, P307, DOI 10.1086/307082; BACKER DC, 1982, NATURE, V300, P615, DOI 10.1038/300615a0; Bildsten L, 1998, ASTROPHYS J, V501, pL89, DOI 10.1086/311440; BILDSTEN L, 2002, IN PRESS RADIO PULSA; CAMILO F, 1994, ASTROPHYS J, V421, pL15, DOI 10.1086/187176; Chakrabarty D, 1998, NATURE, V394, P346, DOI 10.1038/28561; COOK GB, 1994, ASTROPHYS J, V424, P823, DOI 10.1086/173934; COOK GB, 1994, ASTROPHYS J, V423, pL117, DOI 10.1086/187250; Cumming A, 2000, ASTROPHYS J, V544, P453, DOI 10.1086/317191; Galloway DK, 2002, ASTROPHYS J, V576, pL137, DOI 10.1086/343841; Galloway DK, 2001, ASTROPHYS J, V549, pL85, DOI 10.1086/319134; Haensel P, 1999, ASTRON ASTROPHYS, V344, P151; in't Zand JJM, 2001, ASTRON ASTROPHYS, V372, P916, DOI 10.1051/0004-6361:20010546; MARKWARDT CB, 2003, 8080 IAU; Muno MP, 2002, ASTROPHYS J, V580, P1048, DOI 10.1086/343793; Spitkovsky A, 2002, ASTROPHYS J, V566, P1018, DOI 10.1086/338040; Strohmayer TE, 1997, ASTROPHYS J, V486, P355, DOI 10.1086/304522; Strohmayer TE, 1996, ASTROPHYS J, V469, pL9, DOI 10.1086/310261; Strohmayer TE, 2002, ASTROPHYS J, V577, P337, DOI 10.1086/342152; STROHMAYER TE, 2003, IN PRESS COMPACT STE; van der Klis M, 2000, ANNU REV ASTRON ASTR, V38, P717, DOI 10.1146/annurev.astro.38.1.717; WAGONER RV, 1984, ASTROPHYS J, V278, P345, DOI 10.1086/161798; Wijnands R, 1998, NATURE, V394, P344, DOI 10.1038/28557; Wijnands R, 2001, ASTROPHYS J, V549, pL71, DOI 10.1086/319128; WIJNANDS R, IN PRESS NATURE; Zand JJMI, 1998, ASTRON ASTROPHYS, V331, pL25	30	328	331	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2003	424	6944					42	44		10.1038/nature01732	http://dx.doi.org/10.1038/nature01732			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840751	Green Submitted			2022-12-28	WOS:000183912800032
J	Wang, YX; Yun, WB; Jacobsen, C				Wang, YX; Yun, WB; Jacobsen, C			Achromatic Fresnel optics for wideband extreme-ultraviolet and X-ray imaging	NATURE			English	Article							ENGINEERING TEST STAND; ZONE PLATES; LENSES; LITHOGRAPHY; REFLECTION; COMPOUND	Advances in extreme-ultraviolet (EUV) and X-ray optics are providing powerful new capabilities in high-resolution imaging and trace-element analysis of microscopic specimens(1), and the potential for fabricating devices of smaller critical dimensions in next-generation integrated circuit lithography(2). However, achieving the highest resolution with such optics usually requires the illuminating EUV or X-ray beam to be highly monochromatic. It would therefore be highly desirable to have large-field-of-view, sub-100-nm resolution optics that are achromatic to a significant degree, allowing more light to be utilized from broader bandwidth sources such as laser-produced plasmas. Here we report an achromatic Fresnel optical system for EUV or X-ray radiation that combines a Fresnel zone plate with a refractive lens with opposite chromatic aberration. We use the large anomalous dispersion property of the refractive lens material near an absorption edge to make its fabrication practical. The resulting structure can deliver a resolution comparable to that of the Fresnel zone plates that have achieved the highest resolution (25 nm; ref. 3) in the entire electromagnetic spectrum, but with an improvement of two or more orders of magnitude in spectral bandwidth.	Xradia Inc, Concord, CA 94520 USA; SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Yun, WB (corresponding author), Xradia Inc, 4075A Sprig Dr, Concord, CA 94520 USA.		Jacobsen, Chris Johnson/E-2827-2015	Jacobsen, Chris Johnson/0000-0001-8562-0353				BAEZ AV, 1960, NATURE, V186, P958, DOI 10.1038/186958a0; Chapman HN, 2001, J VAC SCI TECHNOL B, V19, P2389, DOI 10.1116/1.1414017; Dambach S, 1998, PHYS REV LETT, V80, P5473, DOI 10.1103/PhysRevLett.80.5473; Dobson SL, 1997, APPL OPTICS, V36, P4744, DOI 10.1364/AO.36.004744; EINSTEIN A, 1918, VERH DTSCH PHYS GES, V20, P86; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENKE BL, 1993, ATOM DATA NUCL DATA, V54, P181, DOI 10.1006/adnd.1993.1013; Hignette O, 2001, P SOC PHOTO-OPT INS, V4499, P105, DOI 10.1117/12.450227; Hirai Y, 2002, J VAC SCI TECHNOL B, V20, P2867, DOI 10.1116/1.1515305; Jackson J., 1975, CLASSICAL ELECTRODYN; KIRKPATRICK P, 1948, J OPT SOC AM, V38, P766, DOI 10.1364/JOSA.38.000766; Lengeler B, 2002, J SYNCHROTRON RADIAT, V9, P119, DOI 10.1107/S0909049502003436; Liu RS, 2001, SOLID STATE COMMUN, V118, P367, DOI 10.1016/S0038-1098(01)00121-1; MEYERILSE W, 2000, XRAY MICROSCOPY; MICHETTE A, 2000, P SOC PHOTO-OPT INS, V4145, P303; Michette A. G., 1986, OPTICAL SYSTEMS SOFT; Naulleau P, 2002, J VAC SCI TECHNOL B, V20, P2829, DOI 10.1116/1.1524976; Peuker M, 2001, APPL PHYS LETT, V78, P2208, DOI 10.1063/1.1361285; Roentgen W.C., 1895, SITZUNGSBER PHYS MED, V9, P132; Rontgen WC, 1896, NATURE, V53, P274; Snigirev A, 1996, NATURE, V384, P49, DOI 10.1038/384049a0; SPILLER E, 1972, APPL PHYS LETT, V20, P365, DOI 10.1063/1.1654189; STERN MB, 1992, J VAC SCI TECHNOL B, V10, P2520, DOI 10.1116/1.586050; vanBuuren TWH, 1997, ABSTR PAP AM CHEM S, V213, P313; Walsby ED, 2002, J VAC SCI TECHNOL B, V20, P2780, DOI 10.1116/1.1518021; YANG BX, 1993, NUCL INSTRUM METH A, V328, P578, DOI 10.1016/0168-9002(93)90678-B; YOUNG M, 1972, J OPT SOC AM, V62, P972, DOI 10.1364/JOSA.62.000972	27	131	145	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2003	424	6944					50	53		10.1038/nature01756	http://dx.doi.org/10.1038/nature01756			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	696XL	12840754				2022-12-28	WOS:000183912800035
J	Anderson, P; Doyle, LW				Anderson, P; Doyle, LW		Victorian Infant Collaborative Stu	Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COGNITIVE-ABILITIES; PARENTING STRESS; GESTATIONAL-AGE; INFANTS; BRAIN; IMPACT; LESS; ADOLESCENTS; ATTAINMENT; DISORDERS	Context The outcome into school age of regional cohorts of children born in the 1990s with birth weights less than 1000 g (extremely low birth weight, ELBW) or earlier than 28 weeks' gestation (very preterm) is not known. Objective To determine the cognitive, educational, and behavioral outcome of ELBW or very preterm infants born in the 1990s compared with normal birth weight (NBW) controls. Design Regional cohort study. Setting Victoria, Australia. Participants The ELBW or very preterm cohort was composed of 298 consecutive survivors born during 1991-1992. The NBW cohort was composed of 262 randomly selected children with birth weights of more than 2499 g. Main Outcome Measures Cognitive ability, educational progress, and behavioral problems. Results The follow-up rates from birth to 8 years of age for survivors were 92.3% (275/298) for the ELBW or very preterm cohort and 85.1% (223/262) for the NBW cohort. The ELBW or very preterm children scored significantly below NBW controls on full-scale IQ (mean difference, -9.4; 95% confidence interval [CI], -12.1 to -6.7; P<.001) and indices of verbal comprehension (mean difference, -6.8; 95% Cl, -9.5 to -4.2; P<001), perceptual organization (mean difference, -9.9; 95% Cl, -12.7 to -7.2; P<001), freedom from distractibility (mean difference, -8.1; 95% Cl, -10.8 to -5.5; P<001), and processing speed (mean difference, -6.7; 95% Cl, -9.4 to -4.0; P<001). The ELBW or very preterm children performed significantly worse than the NBW cohort on tests of reading (mean difference, -6.7; 95% Cl, -9.5 to -3.9; P<001), spelling (mean difference, -5.6; 95% Cl, -8.0 to -3.3; P<.001), and arithmetic (mean difference, -8.8; 95% Cl, -11.3 to -6.2; P<.001). Attentional difficulties, internalizing behavior problems, and immature adaptive skills were more prevalent in the ELBW or very preterm cohort. Conclusion School-aged ELBW or very preterm children born in the 1990s continue to display cognitive, educational, and behavioral impairments.	Royal Womens Hosp, Dept Obstet & Gynaecol, Carlton, Vic 3053, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia	Murdoch Children's Research Institute; University of Melbourne	Doyle, LW (corresponding author), Royal Womens Hosp, Dept Obstet & Gynaecol, 132 Grattan St, Carlton, Vic 3053, Australia.	lwd@unimelb.edu.au	Anderson, Peter J/B-6839-2015; Doyle, Lex/AAJ-5205-2021; Anderson, Peter John/O-5302-2019	Anderson, Peter J/0000-0001-7430-868X; Doyle, Lex/0000-0002-7667-7312; Anderson, Peter John/0000-0001-7430-868X				[Anonymous], 1997, Arch Dis Child Fetal Neonatal Ed, V77, pF91; AYLWARD GP, 1992, J DEV BEHAV PEDIATR, V13, P222; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Botting N, 1998, DEV MED CHILD NEUROL, V40, P652; Botting N, 1997, J CHILD PSYCHOL PSYC, V38, P931, DOI 10.1111/j.1469-7610.1997.tb01612.x; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; Doyle LW, 1997, J PAEDIATR CHILD H, V33, P161; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; Emsley HCA, 1998, ARCH DIS CHILD-FETAL, V78, pF99, DOI 10.1136/fn.78.2.F99; FERRARA TB, 1994, J PEDIATR-US, V124, P119, DOI 10.1016/S0022-3476(94)70266-7; Grantham-McGregor SM, 1998, J PEDIATR-US, V132, P661, DOI 10.1016/S0022-3476(98)70357-9; Gross SJ, 2001, J PEDIATR-US, V138, P169, DOI 10.1067/mpd.2001.111945; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Hack M, 1996, PEDIATRICS, V98, P931; HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514; Hall A, 1995, DEV MED CHILD NEUROL, V37, P1037; HAMMILL DD, 1994, COMPREHENSIVE SCALE; Hille ETM, 2001, LANCET, V357, P1641, DOI 10.1016/S0140-6736(00)04818-2; Horbar JD, 2002, PEDIATRICS, V110, P143, DOI 10.1542/peds.110.1.143; Inder TE, 1999, ANN NEUROL, V46, P755, DOI 10.1002/1531-8249(199911)46:5<755::AID-ANA11>3.0.CO;2-0; Isaacs EB, 2000, PEDIATR RES, V47, P713, DOI 10.1203/00006450-200006000-00006; LEVYSHIFF R, 1994, J PEDIATR PSYCHOL, V19, P63, DOI 10.1093/jpepsy/19.1.63; Maalouf EF, 1999, J PEDIATR-US, V135, P351, DOI 10.1016/S0022-3476(99)70133-2; Nosarti C, 2002, BRAIN, V125, P1616, DOI 10.1093/brain/awf157; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Prifitera A., 1998, WISC 3 CLIN USE INTE, P1, DOI DOI 10.1016/B978-012564930-8/50002-4; Resnick MB, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e74; Reynolds C. R., 1992, BEHAV ASSESSMENT SYS; Rickards AL, 2001, J DEV BEHAV PEDIATR, V22, P11, DOI 10.1097/00004703-200102000-00002; Robson AL, 1997, J PEDIATR PSYCHOL, V22, P297, DOI 10.1093/jpepsy/22.3.297; Rose SA, 1996, CHILD DEV, V67, P2005, DOI 10.1111/j.1467-8624.1996.tb01840.x; Saigal S, 2000, J PEDIATR-US, V137, P701, DOI 10.1067/mpd.2000.109001; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Saigal S, 2000, PEDIATRICS, V105, P325, DOI 10.1542/peds.105.2.325; Singer LT, 1999, JAMA-J AM MED ASSOC, V281, P799, DOI 10.1001/jama.281.9.799; Skranes JS, 1998, PEDIATR RADIOL, V28, P471, DOI 10.1007/s002470050387; SOMMERFELT K, 1993, ACTA PAEDIATR, V82, P723, DOI 10.1111/j.1651-2227.1993.tb12546.x; Stewart AL, 1999, LANCET, V353, P1653, DOI 10.1016/S0140-6736(98)07130-X; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2000, CHILD NEUROPSYCHOL, V6, P49, DOI 10.1076/0929-7049(200003)6:1;1-B;FT049; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; TAYLOR HG, 1995, J PEDIATR PSYCHOL, V20, P703, DOI 10.1093/jpepsy/20.6.703; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wilkinson GS., 2006, WRAT 4 WIDE RANGE AC; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	46	661	674	1	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	2003	289	24					3264	3272		10.1001/jama.289.24.3264	http://dx.doi.org/10.1001/jama.289.24.3264			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	693EX	12824207	Bronze			2022-12-28	WOS:000183704600019
J	Bhargava, A; Bigombe, B				Bhargava, A; Bigombe, B			Public policies and the orphans of AIDS in Africa	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEXUAL-BEHAVIOR; GENDER	International help to care for Africa's orphans is essential not only for their immediate welfare but also to protect the long term prosperity of these countries. A researcher in child health and former Ugandan government peace minister assess how to make the best use of resources.	Univ Houston, Dept Econ, Houston, TX 77204 USA; World Bank, Washington, DC 20433 USA	University of Houston System; University of Houston; The World Bank	Bhargava, A (corresponding author), Univ Houston, Dept Econ, Houston, TX 77204 USA.	bhargava@uh.edu						Bhagava A, 2001, J HEALTH ECON, V20, P423, DOI 10.1016/S0167-6296(01)00073-X; Bhargava A, 2003, J ECONOMETRICS, V112, P225, DOI 10.1016/S0304-4076(02)00162-8; Bhargava A, 2000, AM J PHYS ANTHROPOL, V111, P89, DOI 10.1002/(SICI)1096-8644(200001)111:1&lt;89::AID-AJPA6&gt;3.0.CO;2-X; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; DEININGER K, 2001, DOES COST SCH AFFECT; FALKNER F, 1994, EUR J CLIN NUTR, V48, pS15; Kinsman J, 2001, HEALTH EDUC RES, V16, P85, DOI 10.1093/her/16.1.85; Machel JZ, 2001, REPROD HEALTH MATTER, V9, P82, DOI 10.1016/S0968-8080(01)90011-4; *MACR, 1999, DEM HLTH SURV DEM HL; *MACR, 2000, DEM HLTH SURV DEM HL; MARCHAT JM, 2001, RESULTS NIGERIA FIRM; Meekers D, 2000, INT J STD AIDS, V11, P21, DOI 10.1258/0956462001914850; Ndubani P, 2001, HEALTH POLICY PLANN, V16, P107, DOI 10.1093/heapol/16.1.107; NZOIKA C, 2001, REPROD HEALTH MATTER, V9, P108; Spira R, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e56; TERMINASSIAN T, 2001, DEBT RELIEF HIPCS FI; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; World Bank, 2001, WORLD DEV IND; *WORLD BANK MET, 2001, ED TRAIN MAD	19	36	36	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2003	326	7403					1387	1389		10.1136/bmj.326.7403.1387	http://dx.doi.org/10.1136/bmj.326.7403.1387			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	694CN	12816831	Green Published			2022-12-28	WOS:000183756400029
J	Hughes, R; Goldkorn, A; Masoli, M; Weatherall, M; Burgess, C; Beasley, R				Hughes, R; Goldkorn, A; Masoli, M; Weatherall, M; Burgess, C; Beasley, R			Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial	LANCET			English	Article							INHALED MAGNESIUM; BRONCHIAL-ASTHMA; CLINICAL-TRIAL; SMOOTH-MUSCLE; SULFATE; INHALATION; ALBUTEROL; HISTAMINE; MODERATE; THERAPY	Background Intravenous magnesium can cause bronchodilation in treatment of severe asthma, however its effect by the nebulised route is uncertain. We aimed to assess the effectiveness of isotonic magnesium sulphate as an adjuvant to nebulised salbutamol in severe attacks of asthma. Methods We enrolled 52 patients with severe exacerbations of asthma presenting to the emergency departments at two hospitals in New Zealand. A severe exacerbation was defined as a forced expiratory volume at 1 s (FEV1) of less than 50% predicted 30 min after initial administration of 2.5 mg salbutamol via nebulisation. In this randomised double-blind placebo-controlled trial patients received 2.5 mg nebulised salbutamol mixed with either 2.5 mL isotonic magnesium sulphate or isotonic saline on three occasions at 30 min intervals. The primary outcome measure was FEV1 at 90 min. Analysis was per protocol. Findings At 90 min the mean FEV1 in the magnesium group was 1.96 L (95% CI 1.68-2.24) and in the saline group 1.55 L (1.24-1.87). The difference in the mean FEV1 between the magnesium and saline groups was 0.37 L (0.13-0.61, p=0.003). Interpretation Use of isotonic magnesium as an adjuvant to nebulised salbutamol results in an enhanced bronchodilator response in treatment of severe asthma.	Med Res Inst New Zealand, Wellington, New Zealand; Green Lane Hosp, Auckland 3, New Zealand; Univ Otago, Wellington Sch Med & Hlth Sci, Dunedin, New Zealand; Univ Southampton, Southampton, Hants, England	Medical Research Institute Of New Zealand; University of Otago; University of Southampton	Beasley, R (corresponding author), Med Res Inst New Zealand, POB 10055, Wellington, New Zealand.	richard.beasley@mrinz.ac.nz	Weatherall, Mark/Y-6824-2019; Beasley, Richard/AAH-3908-2019	Weatherall, Mark/0000-0002-0051-9107; Beasley, Richard/0000-0003-0337-406X				Bessmertny O, 2002, ANN EMERG MED, V39, P585, DOI 10.1067/mem.2002.123300; BLOCH H, 1995, CHEST, V107, P1576, DOI 10.1378/chest.107.6.1576; BOULET LP, 1987, THORAX, V42, P953, DOI 10.1136/thx.42.12.953; *BRIT THOR SOC, 2003, THORAX S1, V58, pI1; Cairns CB, 1996, ACAD EMERG MED, V3, P1093, DOI 10.1111/j.1553-2712.1996.tb03366.x; Ciarallo L, 2000, ARCH PEDIAT ADOL MED, V154, P979, DOI 10.1001/archpedi.154.10.979; DANGELO EKG, 1992, J CLIN INVEST, V89, P1988, DOI 10.1172/JCI115807; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; Devi P R, 1997, Indian Pediatr, V34, P389; Emelyanov A, 1999, EUR RESPIR J, V13, P38, DOI 10.1183/09031936.99.13103899; Emerman CL, 1999, CHEST, V115, P92, DOI 10.1378/chest.115.1.92; Hill J, 1997, CLIN EXP ALLERGY, V27, P546, DOI 10.1046/j.1365-2222.1997.490854.x; Hill J, 1995, BRIT J CLIN PHARMACO, V40, P539, DOI 10.1111/j.1365-2125.1995.tb05798.x; Mangat HS, 1998, EUR RESPIR J, V12, P341, DOI 10.1183/09031936.98.12020341; Meral A, 1996, TURKISH J PEDIATR, V38, P169; NADLER JL, 1987, HYPERTENSION, V9, P379, DOI 10.1161/01.HYP.9.4.379; Nannini LJ, 2000, AM J MED, V108, P193, DOI 10.1016/S0002-9343(99)00463-5; *NIH, 2002, GLOB IN ASTHM GLOB S; OKAYAMA H, 1987, JAMA-J AM MED ASSOC, V257, P1076, DOI 10.1001/jama.257.8.1076; ROLLA G, 1987, MAGNESIUM, V6, P201; ROLLA G, 1988, DRUG EXP CLIN RES, V14, P609; Rolla Giovanni, 1994, Magnesium Research, V7, P129; ROWE B, 2000, COCHRANE LIB; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SILVERMAN R, 1996, ACAD EMERG MED, V3, P467; Silverman RA, 2002, CHEST, V122, P489, DOI 10.1378/chest.122.2.489; SKOBELOFF EM, 1989, JAMA-J AM MED ASSOC, V262, P1210, DOI 10.1001/jama.262.9.1210; SPIVEY WH, 1990, ANN EMERG MED, V19, P1107, DOI 10.1016/S0196-0644(05)81513-6; Trendelenburg F., 1912, ARCH EXP PHARM THER, V19, P79	29	77	81	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	2003	361	9375					2114	2117		10.1016/S0140-6736(03)13721-X	http://dx.doi.org/10.1016/S0140-6736(03)13721-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826434				2022-12-28	WOS:000183654200010
J	Moynihan, R				Moynihan, R			Making medical journalism healthier	LANCET			English	Editorial Material							COVERAGE; PRESS; NEWS				Moynihan, R (corresponding author), 1312,21st St Apt 4 NW, Washington, DC 20036 USA.		Moynihan, Ray/ABC-3010-2020					Cassels A, 2003, CAN MED ASSOC J, V168, P1133; Collier J, 2002, LANCET, V360, P1405, DOI 10.1016/S0140-6736(02)11394-8; Hoye Sigurd, 2002, Tidsskr Nor Laegeforen, V122, P1671; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; Moynihan R, 2003, BMJ-BRIT MED J, V326, P1189, DOI 10.1136/bmj.326.7400.1189; Moynihan R, 2003, BRIT MED J, V326, P1094; Moynihan R., TIPSHEET REPORTING D; *NIH, 2003, WORKSH MED MED OFF M; OXMAN AD, 1993, J CLIN EPIDEMIOL, V46, P987, DOI 10.1016/0895-4356(93)90166-X; Schwartz LM, 2003, J GEN INTERN MED, V18, P153, DOI 10.1046/j.1525-1497.2003.21216.x; Schwartz LM, 2002, JAMA-J AM MED ASSOC, V287, P2859, DOI 10.1001/jama.287.21.2859; Sweet M, 2001, BRIT MED J, V323, P1258; Woloshin S, 2002, JAMA-J AM MED ASSOC, V287, P2856, DOI 10.1001/jama.287.21.2856	13	13	13	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 21	2003	361	9375					2097	2098		10.1016/S0140-6736(03)13729-4	http://dx.doi.org/10.1016/S0140-6736(03)13729-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	692GY	12826429				2022-12-28	WOS:000183654200005
J	Dickinson, JL; Koenig, WD				Dickinson, JL; Koenig, WD			Desperately seeking similarity	SCIENCE			English	Editorial Material							STRATEGIES; EVOLUTION; RELATIVES		Univ Calif Berkeley, Hastings Reservat & Museum Vertebrate Zool, Berkeley, CA 93924 USA	University of California System; University of California Berkeley	Dickinson, JL (corresponding author), Univ Calif Berkeley, Hastings Reservat & Museum Vertebrate Zool, Berkeley, CA 93924 USA.		Koenig, Walter D/A-5509-2009	Koenig, Walter/0000-0001-6207-1427				Baglione V, 2003, SCIENCE, V300, P1947, DOI 10.1126/science.1082429; Baglione V, 2002, ANIM BEHAV, V64, P887, DOI 10.1006/anbe.2002.2007; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Cockburn A, 1998, ANNU REV ECOL SYST, V29, P141, DOI 10.1146/annurev.ecolsys.29.1.141; EMLEN ST, 1995, P NATL ACAD SCI USA, V92, P8092, DOI 10.1073/pnas.92.18.8092; Goodnight KF, 1999, MOL ECOL, V8, P1231, DOI 10.1046/j.1365-294x.1999.00664.x; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Petrie M, 1999, NATURE, V401, P155, DOI 10.1038/43651; Russell AF, 2001, P ROY SOC B-BIOL SCI, V268, P2169, DOI 10.1098/rspb.2001.1790; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Sinervo B, 2003, SCIENCE, V300, P1949, DOI 10.1126/science.1083109; West SA, 2002, SCIENCE, V296, P72, DOI 10.1126/science.1065507; Zamudio KR, 2000, P NATL ACAD SCI USA, V97, P14427, DOI 10.1073/pnas.011544998	14	6	8	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2003	300	5627					1887	1889		10.1126/science.1085692	http://dx.doi.org/10.1126/science.1085692			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691RN	12817132				2022-12-28	WOS:000183619400027
